data_2lmp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lmp _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 . . . . . 0 CA--C 1.527 0.087 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.573 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.573 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.445 HD21 ' CB ' ' A' ' 30' ' ' ALA . 72.4 m-80 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.445 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.431 HD12 HG21 ' A' ' 32' ' ' ILE . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.428 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.875 0.369 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 6.3 p80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.423 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.491 ' O ' ' CG2' ' C' ' 39' ' ' VAL . 57.4 t . . . . . 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.592 ' CG2' ' NE2' ' C' ' 14' ' ' HIS . 2.0 p . . . . . 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' O ' ' F' ' 40' ' ' VAL . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.766 HE22 ' H ' ' F' ' 37' ' ' GLY . 88.1 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.433 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.559 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.503 ' O ' ' N ' ' C' ' 29' ' ' GLY . 12.9 m120 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.401 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.423 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' B' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.62 ' CE1' ' H ' ' E' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.578 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.409 HD22 ' H ' ' C' ' 34' ' ' LEU . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t . . . . . 0 N--CA 1.466 0.357 0 CA-C-O 120.754 0.311 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.642 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' F' ' 29' ' ' GLY . 4.7 t-20 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' F' ' 29' ' ' GLY . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.415 HD12 HG23 ' E' ' 32' ' ' ILE . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.405 ' O ' ' CG1' ' E' ' 36' ' ' VAL . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.452 ' N ' ' CG1' ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.642 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.469 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 . . . . . 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 CA--C 1.529 0.152 0 N-CA-C 113.412 0.893 . . . . 0.0 113.412 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' R' ' 38' ' ' GLY . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.578 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.766 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.509 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.409 HE22 HG12 ' J' ' 36' ' ' VAL . 40.7 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 . . . . . 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 CA--C 1.547 0.832 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.513 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.884 0.373 . . . . 0.0 110.962 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.604 HE22 ' CG1' ' K' ' 36' ' ' VAL . 50.3 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.457 HD11 ' N ' ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' I' ' 26' ' ' SER . 88.4 m-20 . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.406 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.5 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 44.7 t . . . . . 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 120.611 0.243 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 67.4 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.685 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.685 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' I' ' 28' ' ' LYS . 1.1 t-20 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.68 ' N ' ' ND2' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.43 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.495 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 38' ' ' GLY . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.431 ' O ' ' OD1' ' K' ' 27' ' ' ASN . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.618 ' O ' ' ND2' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.512 ' O ' ' O ' ' J' ' 37' ' ' GLY . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.533 ' H ' ' CG2' ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.579 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.604 ' CG1' HE22 ' H' ' 15' ' ' GLN . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' J' ' 38' ' ' GLY . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.534 ' N ' ' OXT' ' L' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 23' ' ' ASP . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.506 ' CG1' ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . 0.412 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.576 ' ND1' ' NE2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . 0.42 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t . . . . . 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.513 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.505 ' CG1' ' N ' ' N' ' 13' ' ' HIS . 67.2 t . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.696 ' CD2' ' H ' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.576 ' NE2' ' ND1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.625 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.412 ' O ' ' CD1' ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.561 ' C ' ' H ' ' O' ' 26' ' ' SER . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.462 ' H ' HG11 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.625 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.658 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' Q' ' 13' ' ' HIS . 34.8 m-70 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' P' ' 13' ' ' HIS . 32.1 m80 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.424 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . 0.417 HD11 HE21 ' Q' ' 15' ' ' GLN . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.49 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.531 ' O ' ' NE2' ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.658 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' P' ' 13' ' ' HIS . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.424 ' NE2' ' OE1' ' P' ' 15' ' ' GLN . 33.9 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . 0.423 ' C ' ' CD2' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.51 ' CB ' ' HZ3' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.412 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.551 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.551 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . 0.413 HD13 HG21 ' Q' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . 0.408 HD13 HG21 ' Q' ' 32' ' ' ILE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.497 ' CG1' ' O ' ' Q' ' 36' ' ' VAL . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.459 ' N ' ' CG1' ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.707 0.289 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.481 ' O ' ' NE2' ' A' ' 14' ' ' HIS . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.469 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.402 HD11 HG23 ' A' ' 32' ' ' ILE . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 . . . . . 0 N--CA 1.461 0.092 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.663 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.703 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . 0.56 ' HZ3' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.419 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . 0.56 ' CG2' ' HZ3' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.66 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.66 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.404 ' H ' HD13 ' C' ' 34' ' ' LEU . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.521 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.467 ' O ' ' CD1' ' H' ' 31' ' ' ILE . 13.5 t . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.475 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.415 ' N ' ' OG ' ' B' ' 26' ' ' SER . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.459 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.404 HD13 ' H ' ' B' ' 34' ' ' LEU . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.527 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.521 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.545 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.519 ' N ' ' OE1' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 28.9 m170 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.627 ' HE2' ' CG ' ' E' ' 16' ' ' LYS . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.524 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.524 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.458 ' H ' HG11 ' D' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.475 ' ND2' ' O ' ' C' ' 26' ' ' SER . 3.4 m120 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.446 HG21 HD11 ' D' ' 32' ' ' ILE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.4 ' CD2' ' N ' ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.703 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' C' ' 38' ' ' GLY . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.435 ' O ' ' CD2' ' E' ' 13' ' ' HIS . 55.1 t . . . . . 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' E' ' 12' ' ' VAL . 18.0 m80 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.644 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 70.1 m80 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.627 ' CG ' ' HE2' ' D' ' 14' ' ' HIS . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.495 ' CG1' ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.502 HG21 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.432 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.644 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.569 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 46.4 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.502 ' H ' HG21 ' E' ' 31' ' ' ILE . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.448 ' CG1' ' NE2' ' D' ' 15' ' ' GLN . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' E' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.42 HG23 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.553 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.533 0 N-CA-C 114.727 1.38 . . . . 0.0 114.727 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.46 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.452 0.168 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.42 ' H ' HG23 ' G' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.506 ' C ' ' ND1' ' H' ' 14' ' ' HIS . 2.5 t60 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.553 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . 0.49 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.569 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 . . . . . 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.109 0 CA-C-O 119.108 -0.829 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.497 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p . . . . . 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.895 0.379 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.588 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.569 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.435 ' OD1' ' N ' ' I' ' 27' ' ' ASN . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.545 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.559 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.418 ' CE1' ' HZ3' ' Q' ' 28' ' ' LYS . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.672 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 1.0 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.672 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' J' ' 17' ' ' LEU . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.575 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.575 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.418 HD13 ' N ' ' J' ' 35' ' ' MET . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.418 ' N ' HD13 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.559 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.424 ' CG1' ' CD2' ' H' ' 13' ' ' HIS . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.598 ' CG1' ' HE2' ' K' ' 14' ' ' HIS . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.518 ' O ' ' CD2' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.638 ' ND1' ' CG ' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.429 ' HG3' ' H ' ' J' ' 15' ' ' GLN . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.421 ' O ' ' O ' ' K' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.664 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.664 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 62.5 m-20 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.532 ' CD1' ' O ' ' E' ' 38' ' ' GLY . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.489 ' O ' ' CB ' ' L' ' 34' ' ' LEU . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.452 ' O ' ' O ' ' K' ' 37' ' ' GLY . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 10.4 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.638 ' CG ' ' ND1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.406 ' C ' ' CG2' ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.462 HG12 ' H ' ' L' ' 25' ' ' GLY . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.489 ' CB ' ' O ' ' K' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.5 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . 0.488 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 53.8 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . 0.445 HD13 HE21 ' M' ' 15' ' ' GLN . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 36.6 t . . . . . 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . 0.497 ' CD1' ' H ' ' H' ' 39' ' ' VAL . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.434 ' CG2' ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.434 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.593 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . 0.586 ' N ' ' CD2' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.488 ' CG1' ' NE2' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.422 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.416 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.463 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.463 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.662 0.267 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.679 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 2.1 t-20 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.494 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.422 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.679 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.423 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' P' ' 38' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' Q' ' 14' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' O ' ' Q' ' 13' ' ' HIS . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.559 ' CG2' ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.559 ' H ' ' CG2' ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . 0.408 HG22 HD11 ' R' ' 31' ' ' ILE . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . 0.413 HD11 HG21 ' R' ' 32' ' ' ILE . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.812 0.339 . . . . 0.0 110.319 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 70.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.44 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.45 ' CD1' ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t . . . . . 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.487 ' CG ' ' HZ2' ' K' ' 28' ' ' LYS . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.3 m80 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.478 HD21 ' N ' ' B' ' 17' ' ' LEU . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.401 HD11 ' H ' ' B' ' 35' ' ' MET . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.401 ' H ' HD11 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 83.5 t . . . . . 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.743 0.306 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.563 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 8.6 p-80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.675 HE22 ' N ' ' F' ' 37' ' ' GLY . 86.8 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.653 ' N ' ' CD2' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.421 HG23 HD12 ' C' ' 31' ' ' ILE . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 28.6 p-80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.68 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.452 ' HZ2' ' CD2' ' D' ' 14' ' ' HIS . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.525 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.408 HG23 HD11 ' D' ' 31' ' ' ILE . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.487 ' CG1' ' N ' ' D' ' 40' ' ' VAL . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.506 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 49.2 t . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.473 ' N ' ' CG1' ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.525 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.437 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' D' ' 27' ' ' ASN . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 12.9 m120 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.539 ' HZ3' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.444 ' O ' ' N ' ' F' ' 37' ' ' GLY . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.513 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 . . . . . 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.444 HG22 HD11 ' F' ' 32' ' ' ILE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.461 ' C ' ' CD2' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' F' ' 37' ' ' GLY . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.675 ' N ' HE22 ' C' ' 15' ' ' GLN . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.522 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.415 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.55 ' CD2' ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.55 ' H ' ' CD2' ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.403 ' O ' ' CD1' ' M' ' 31' ' ' ILE . 42.6 t . . . . . 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.814 0.34 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.701 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.701 ' H ' ' CG ' ' H' ' 14' ' ' HIS . 55.9 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.413 ' HB3' ' CE2' ' H' ' 19' ' ' PHE . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.413 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.181 0 CA-C-O 119.877 -0.402 . . . . 0.0 113.356 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' I' ' 40' ' ' VAL . 81.0 t . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.462 0.173 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.762 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.762 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.453 ' CG1' ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.401 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.483 ' N ' ' CG1' ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.536 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.899 HD22 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.899 ' H ' HD22 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.529 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.416 HD21 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.413 ' CG1' ' NE2' ' H' ' 15' ' ' GLN . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.428 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 43.6 t-80 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . 0.41 ' C ' ' CD2' ' K' ' 17' ' ' LEU . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.583 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.583 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.536 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.424 HD11 HG23 ' K' ' 32' ' ' ILE . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' L' ' 35' ' ' MET . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.503 ' N ' ' O ' ' K' ' 37' ' ' GLY . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.44 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.404 HD11 HG23 ' L' ' 32' ' ' ILE . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.442 ' O ' ' O ' ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.458 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.459 ' O ' ' CG1' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 87.5 t . . . . . 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.253 0 CA-C-O 121.252 0.548 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.51 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 120.938 0.399 . . . . 0.0 110.56 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 33.4 m-70 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.567 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.567 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.575 ' CG2' ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.575 ' H ' ' CG2' ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' N' ' 29' ' ' GLY . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' N' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.51 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.45 ' H ' ' CD1' ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p . . . . . 0 N--CA 1.468 0.437 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' N' ' 13' ' ' HIS . 21.9 m-70 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.469 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.469 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.493 ' CG1' ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.674 ' N ' ' HZ1' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.409 HG21 HD11 ' O' ' 31' ' ' ILE . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.431 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.431 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.474 ' CG1' ' CD2' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.443 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . 0.421 ' CD1' ' N ' ' P' ' 17' ' ' LEU . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.707 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.674 ' HZ1' ' N ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.46 ' O ' ' CG1' ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.474 ' CD2' ' CG1' ' P' ' 12' ' ' VAL . 5.1 m-70 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.517 HD22 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.707 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . 0.483 ' CD2' ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . 0.483 ' N ' ' CD2' ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.636 ' CG1' ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.636 ' H ' ' CG1' ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.7 m120 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.517 ' C ' HD22 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.559 ' O ' ' O ' ' R' ' 37' ' ' GLY . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.539 ' C ' ' HZ3' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.493 ' CA ' ' HZ3' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.993 0.425 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.526 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.425 HG23 HD13 ' A' ' 32' ' ' ILE . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.42 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.42 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 CA--C 1.528 0.117 0 CA-C-O 120.855 0.36 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.542 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 21.4 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' B' ' 23' ' ' ASP . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t . . . . . 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 121.016 0.436 . . . . 0.0 110.512 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.457 ' CE1' ' OXT' ' E' ' 40' ' ' VAL . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.551 ' OE1' ' NE2' ' D' ' 15' ' ' GLN . 4.3 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.467 ' CB ' ' OD1' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.801 HD21 ' H ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.411 HG21 HD13 ' C' ' 31' ' ' ILE . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' D' ' 34' ' ' LEU . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' D' ' 36' ' ' VAL . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' C' ' 40' ' ' VAL . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.566 ' CG ' ' HE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.566 ' HE2' ' CG ' ' D' ' 11' ' ' GLU . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.551 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 57.0 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.421 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.53 ' O ' ' O ' ' D' ' 23' ' ' ASP . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.41 ' O ' ' CG2' ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.436 ' CD2' ' O ' ' C' ' 34' ' ' LEU . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.54 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.61 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.511 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.442 ' N ' ' OG ' ' E' ' 26' ' ' SER . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.446 ' N ' ' CA ' ' F' ' 38' ' ' GLY . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.457 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m . . . . . 0 N--CA 1.467 0.381 0 N-CA-C 110.419 -0.215 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.48 ' CD2' ' H ' ' F' ' 13' ' ' HIS . 10.6 p80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.61 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' E' ' 23' ' ' ASP . 37.1 tt0 . . . . . 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.434 HG22 HD13 ' F' ' 31' ' ' ILE . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.429 HG21 HD12 ' F' ' 32' ' ' ILE . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.426 ' OXT' ' O ' ' F' ' 39' ' ' VAL . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.499 HE22 ' CA ' ' I' ' 37' ' ' GLY . 39.0 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 75.8 tt0 . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.63 0.253 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 49.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 . . . . . 0 N--CA 1.465 0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' G' ' 13' ' ' HIS . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 14.2 tp60 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.536 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' CD2' ' I' ' 19' ' ' PHE . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' H' ' 23' ' ' ASP . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 . . . . . 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.553 2.458 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.431 ' H ' HD21 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' G' ' 38' ' ' GLY . 97.7 t . . . . . 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 120.985 0.422 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.79 HE22 ' H ' ' L' ' 37' ' ' GLY . 9.5 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.478 ' CG ' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.478 ' N ' ' CG ' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.431 HD21 ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' J' ' 36' ' ' VAL . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.499 ' CA ' HE22 ' G' ' 15' ' ' GLN . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.419 ' HE2' HE22 ' J' ' 15' ' ' GLN . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 1.2 mp0 -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.458 ' H ' ' HG ' ' K' ' 26' ' ' SER . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.458 ' CD1' ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' I' ' 36' ' ' VAL . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 10.5 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.46 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.46 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.458 ' HG ' ' H ' ' J' ' 25' ' ' GLY . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' L' ' 35' ' ' MET . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 8.6 m120 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.79 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . 0.494 ' C ' ' CD2' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.494 ' CD2' ' C ' ' M' ' 13' ' ' HIS . 3.4 m-70 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.385 0 N-CA-C 116.633 2.086 . . . . 0.0 116.633 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 35' ' ' MET . . . . . 0.427 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.615 ' CB ' ' H ' ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.426 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.426 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.755 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.429 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.404 ' O ' ' O ' ' N' ' 38' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.428 ' CD2' ' N ' ' O' ' 13' ' ' HIS . 4.5 m-70 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.615 ' H ' ' CB ' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.755 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.4 HG22 HD12 ' O' ' 31' ' ' ILE . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.412 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.47 0.528 0 CA-C-O 120.752 0.311 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.606 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.606 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.587 ' H ' ' HG ' ' O' ' 26' ' ' SER . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . 0.4 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 35' ' ' MET . . . . . 0.4 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.467 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.427 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 75.2 m80 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.461 ' CD ' HE21 ' R' ' 15' ' ' GLN . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.418 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.467 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' Q' ' 40' ' ' VAL . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.432 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.483 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.461 HE21 ' CD ' ' Q' ' 15' ' ' GLN . 86.1 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . 0.41 HG23 HD12 ' R' ' 32' ' ' ILE . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.652 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.652 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.599 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.599 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 38' ' ' GLY . 6.5 p . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.534 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.435 ' HB3' ' CZ ' ' B' ' 19' ' ' PHE . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.654 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.512 ' C ' ' HG ' ' B' ' 26' ' ' SER . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.512 ' HG ' ' C ' ' B' ' 25' ' ' GLY . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.488 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.488 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.672 ' CD2' ' HZ1' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.8 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' C' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.654 ' H ' ' HB3' ' B' ' 23' ' ' ASP . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.482 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.556 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.556 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.501 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.501 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.479 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' E' ' 36' ' ' VAL . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.405 ' O ' ' CG1' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.671 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 28.7 m80 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.437 ' O ' ' OD2' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.4 HD13 ' CD1' ' C' ' 19' ' ' PHE . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.525 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.017 0.437 . . . . 0.0 111.443 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.454 ' CD2' ' H ' ' F' ' 13' ' ' HIS . 6.6 p80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.403 HG23 HD13 ' F' ' 32' ' ' ILE . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.606 ' O ' ' CD2' ' G' ' 14' ' ' HIS . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 . . . . . 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 120.715 0.293 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.76 HE22 ' H ' ' K' ' 37' ' ' GLY . 99.1 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.524 ' CG ' ' H ' ' H' ' 23' ' ' ASP . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.524 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p . . . . . 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.466 0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.556 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 12.9 m120 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.652 ' HZ1' ' NZ ' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . 0.4 ' H ' ' H ' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . 0.4 ' H ' ' H ' ' J' ' 9' ' ' GLY . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.473 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.473 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.652 ' NZ ' ' HZ1' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.506 ' CD2' ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.506 ' N ' ' CD2' ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.488 ' CG2' HE22 ' G' ' 15' ' ' GLN . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.672 ' HZ1' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.76 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.406 ' O ' ' NZ ' ' Q' ' 28' ' ' LYS . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.408 ' C ' ' CD2' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.64 ' CG2' ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.64 ' H ' ' CG2' ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.542 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' E' ' 38' ' ' GLY . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . 0.538 HE21 ' CD1' ' M' ' 17' ' ' LEU . 38.6 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . 0.538 ' CD1' HE21 ' M' ' 15' ' ' GLN . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.475 ' N ' ' CG1' ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.543 ' OE1' ' NE2' ' O' ' 15' ' ' GLN . 2.9 mt-30 -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.402 HG22 HD12 ' N' ' 32' ' ' ILE . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.473 ' O ' ' CG2' ' N' ' 12' ' ' VAL . 15.7 m . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.539 ' CG ' ' CG1' ' Q' ' 40' ' ' VAL . 88.5 m-70 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.543 ' NE2' ' OE1' ' N' ' 15' ' ' GLN . 51.9 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.402 ' N ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' P' ' 27' ' ' ASN . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 40' ' ' VAL . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.557 ' HE2' HE21 ' P' ' 15' ' ' GLN . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.557 HE21 ' HE2' ' P' ' 13' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . 0.599 ' CD1' ' N ' ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.543 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.603 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.557 ' CG1' ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.557 ' N ' ' CG1' ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.543 ' C ' HE22 ' N' ' 15' ' ' GLN . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . 0.422 ' C ' ' CD2' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.442 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.614 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.614 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . 0.437 ' H ' ' HB2' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . 0.5 ' CD2' ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . 0.5 ' N ' ' CD2' ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' O' ' 15' ' ' GLN . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.484 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.484 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 46.8 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 51.3 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.428 ' H ' HG21 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.619 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.655 HE21 ' NE2' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.467 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.48 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.655 ' NE2' HE21 ' C' ' 15' ' ' GLN . 49.9 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.417 ' CD1' ' N ' ' D' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.504 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.467 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 58.2 m-80 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.437 HG23 HD13 ' D' ' 31' ' ' ILE . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' D' ' 37' ' ' GLY . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 45.3 m-70 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.551 ' O ' ' N ' ' F' ' 20' ' ' PHE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.55 ' HB1' ' H ' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.474 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.418 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.495 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.444 ' O ' ' O ' ' F' ' 39' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.57 ' CD2' ' N ' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.57 ' N ' ' CD2' ' F' ' 20' ' ' PHE . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 . . . . . 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.575 0.226 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.474 ' N ' ' HB3' ' E' ' 28' ' ' LYS . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.444 ' O ' ' O ' ' E' ' 40' ' ' VAL . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.45 ' CG2' ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.595 ' NZ ' ' HZ3' ' H' ' 16' ' ' LYS . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE2' ' H' ' 22' ' ' GLU . 67.0 tt0 . . . . . 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.426 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.426 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 . . . . . 0 N--CA 1.462 0.153 0 CA-C-O 120.976 0.417 . . . . 0.0 111.67 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' NE2' ' I' ' 15' ' ' GLN . 45.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.595 ' HZ3' ' NZ ' ' G' ' 16' ' ' LYS . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.505 ' CD1' HE21 ' H' ' 15' ' ' GLN . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' I' ' 22' ' ' GLU . 1.6 m-20 . . . . . 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p . . . . . 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.579 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.548 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.579 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' NE2' ' H' ' 15' ' ' GLN . 26.1 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.452 ' CB ' ' NZ ' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.409 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.405 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' J' ' 34' ' ' LEU . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.448 ' N ' ' CG1' ' J' ' 39' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 5.6 m80 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' OE1' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.546 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.447 ' CD2' ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 4.0 p80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.467 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.546 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.401 ' HB2' ' CD2' ' L' ' 34' ' ' LEU . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 39' ' ' VAL . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' L' ' 13' ' ' HIS . 2.7 p . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' K' ' 13' ' ' HIS . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' K' ' 28' ' ' LYS . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.401 ' CD2' ' HB2' ' K' ' 34' ' ' LEU . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 43.0 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.476 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.403 HD12 HG22 ' N' ' 32' ' ' ILE . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.517 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.402 HG13 ' H ' ' P' ' 12' ' ' VAL . 30.9 m . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 120.707 0.289 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.531 ' HG ' ' H ' ' N' ' 27' ' ' ASN . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.535 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.513 ' O ' ' CG1' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.428 ' CG2' ' C ' ' P' ' 40' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.402 ' H ' HG13 ' O' ' 12' ' ' VAL . 2.3 p . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 3.0 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.524 ' CG ' HD22 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.535 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' P' ' 37' ' ' GLY . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.428 ' C ' ' CG2' ' O' ' 40' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.478 ' N ' ' CG1' ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.469 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.406 ' CG2' ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.55 ' OD1' ' N ' ' Q' ' 28' ' ' LYS . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.439 ' CG1' ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.494 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' O ' ' OXT' ' Q' ' 40' ' ' VAL . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.565 ' NE2' ' H ' ' R' ' 15' ' ' GLN . 0.9 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.414 ' OD1' ' OG ' ' Q' ' 26' ' ' SER . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . 0.567 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.492 ' C ' HE22 ' P' ' 15' ' ' GLN . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.494 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' CE1' ' A' ' 13' ' ' HIS . 82.0 tt0 . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 120.86 0.362 . . . . 0.0 110.5 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.681 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 45.3 m170 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 16.5 t-20 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.409 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p . . . . . 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.783 0.325 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.464 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.681 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.473 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.473 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' A' ' 27' ' ' ASN . 99.3 m-20 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.405 HG21 HD13 ' B' ' 31' ' ' ILE . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.402 HD11 HG23 ' B' ' 32' ' ' ILE . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.67 HE22 ' H ' ' F' ' 37' ' ' GLY . 75.7 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.516 ' O ' ' ND2' ' D' ' 27' ' ' ASN . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.425 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.425 ' N ' ' O ' ' C' ' 37' ' ' GLY . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.419 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.537 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.55 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' E' ' 28' ' ' LYS . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.413 ' H ' ' HB3' ' D' ' 27' ' ' ASN . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' CE1' ' F' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.643 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' E' ' 28' ' ' LYS . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.42 HG21 HD11 ' E' ' 31' ' ' ILE . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.502 ' N ' ' O ' ' F' ' 40' ' ' VAL . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.577 ' CE1' ' ND1' ' E' ' 13' ' ' HIS . 5.6 t-160 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.643 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.436 ' O ' ' CD2' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.496 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.406 HD11 HG23 ' F' ' 31' ' ' ILE . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.67 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' F' ' 40' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.416 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.492 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.401 ' CD ' ' OE1' ' H' ' 22' ' ' GLU . 82.5 tt0 . . . . . 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.395 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.753 0.311 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.507 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.525 ' CD2' ' CE1' ' I' ' 13' ' ' HIS . 85.1 m-70 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 . . . . . 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 1.752 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.479 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' J' ' 11' ' ' GLU . 78.8 mm-40 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.53 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.525 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 2.3 m-70 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.644 HE21 ' CG1' ' K' ' 36' ' ' VAL . 0.8 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.451 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.479 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.474 ' CG2' ' O ' ' K' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.534 HE22 ' NE2' ' I' ' 15' ' ' GLN . 7.9 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.407 HG12 ' H ' ' J' ' 25' ' ' GLY . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' I' ' 23' ' ' ASP . 6.6 m120 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.405 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.421 ' O ' ' CG1' ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.435 ' CG2' ' ND1' ' H' ' 13' ' ' HIS . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' K' ' 15' ' ' GLN . 0.0 OUTLIER -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.695 ' NZ ' ' HZ3' ' L' ' 16' ' ' LYS . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.476 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.475 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.74 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.74 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.644 ' CG1' HE21 ' I' ' 15' ' ' GLN . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.495 ' O ' ' CE ' ' Q' ' 28' ' ' LYS . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 19.3 t-160 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . 0.695 ' HZ3' ' NZ ' ' K' ' 16' ' ' LYS . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.476 ' CB ' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . 0.707 HE21 HE21 ' N' ' 15' ' ' GLN . 6.5 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' HZ2' ' O' ' 28' ' ' LYS . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.441 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . 0.441 ' H ' ' HG2' ' M' ' 22' ' ' GLU . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.439 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.707 HE21 HE21 ' M' ' 15' ' ' GLN . 42.1 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . 0.521 ' C ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.589 ' CG2' ' H ' ' P' ' 12' ' ' VAL . 38.2 t . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.563 ' H ' ' CG1' ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.414 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.414 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.729 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.729 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.659 ' NZ ' ' N ' ' N' ' 22' ' ' GLU . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.589 ' H ' ' CG2' ' O' ' 12' ' ' VAL . 6.5 t . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.57 0.224 . . . . 0.0 111.532 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.589 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.522 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.577 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.425 ' CB ' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' Q' ' 19' ' ' PHE . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.522 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.472 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . 0.508 ' CD2' ' N ' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' R' ' 35' ' ' MET . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.535 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.589 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.542 HE22 ' C ' ' C' ' 36' ' ' VAL . 88.1 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.607 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.607 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.584 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.584 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.69 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' H ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.618 ' H ' ' CD2' ' B' ' 14' ' ' HIS . 33.8 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . 0.46 ' C ' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.665 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.665 ' CG1' ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.425 ' O ' ' CG2' ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.69 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HD12 ' H' ' 31' ' ' ILE . 8.2 m . . . . . 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.467 0.39 0 N-CA-C 110.595 -0.15 . . . . 0.0 110.595 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.581 ' CD1' ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.483 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.5 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.43 ' N ' ' CD2' ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.542 ' C ' HE22 ' A' ' 15' ' ' GLN . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 9.6 p-80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.506 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.506 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.553 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.43 ' CD2' ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' D' ' 37' ' ' GLY . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.584 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.458 ' CB ' ' HZ1' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.458 ' HZ1' ' CB ' ' E' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.477 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.483 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' F' ' 13' ' ' HIS . 2.6 p . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' E' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.584 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 . . . . . 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.088 0.47 . . . . 0.0 111.896 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.477 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.661 HE21 ' CD1' ' G' ' 17' ' ' LEU . 51.5 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.661 ' CD1' HE21 ' G' ' 15' ' ' GLN . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 . . . . . 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.404 HD11 HG21 ' G' ' 32' ' ' ILE . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.548 ' N ' ' OE1' ' H' ' 11' ' ' GLU . 56.8 mp0 . . . . . 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 6.6 t60 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.449 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.505 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 . . . . . 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.537 1.411 0 CA-C-O 119.329 -0.706 . . . . 0.0 114.747 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.401 HD12 ' H ' ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.449 HD12 HG21 ' H' ' 32' ' ' ILE . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.439 ' H ' HD21 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t . . . . . 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 . . . . . 0 N--CA 1.458 -0.065 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.521 HE22 ' H ' ' L' ' 37' ' ' GLY . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.482 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.549 ' CB ' ' HZ3' ' J' ' 28' ' ' LYS . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.505 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' J' ' 23' ' ' ASP . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.521 ' C ' ' HG ' ' I' ' 26' ' ' SER . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.521 ' HG ' ' C ' ' I' ' 25' ' ' GLY . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.57 HD22 ' C ' ' J' ' 29' ' ' GLY . 25.9 p30 -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.439 HD21 ' H ' ' H' ' 34' ' ' LEU . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.436 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' H' ' 38' ' ' GLY . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.7 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.519 ' N ' ' HG ' ' K' ' 26' ' ' SER . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.654 ' N ' ' HG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.549 ' HZ3' ' CB ' ' I' ' 21' ' ' ALA . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.57 ' C ' HD22 ' I' ' 27' ' ' ASN . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.434 HD13 ' H ' ' I' ' 34' ' ' LEU . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.436 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 40' ' ' VAL . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.605 ' CD ' ' HE2' ' J' ' 14' ' ' HIS . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.65 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.65 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.654 ' HG ' ' N ' ' J' ' 26' ' ' SER . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.507 ' O ' ' CA ' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.443 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 0.4 OUTLIER -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.578 ' CE1' ' NZ ' ' L' ' 16' ' ' LYS . 3.9 p80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . 0.578 ' NZ ' ' CE1' ' L' ' 14' ' ' HIS . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.507 ' CA ' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.425 HG22 HD13 ' L' ' 32' ' ' ILE . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.521 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.431 ' OXT' ' OD1' ' Q' ' 27' ' ' ASN . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 96.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.679 HE22 ' CA ' ' P' ' 37' ' ' GLY . 7.8 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.453 ' C ' ' O ' ' N' ' 22' ' ' GLU . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.547 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.547 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t . . . . . 0 CA--C 1.536 0.419 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.671 HE22 ' CG2' ' Q' ' 36' ' ' VAL . 64.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.4 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.475 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.475 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.412 ' H ' ' C ' ' O' ' 24' ' ' VAL . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 9.2 m120 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . 0.431 ' N ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' O' ' 33' ' ' GLY . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.423 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' O ' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.431 ' O ' ' OG ' ' Q' ' 26' ' ' SER . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.42 ' H ' ' C ' ' P' ' 24' ' ' VAL . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . 0.462 HD13 HG21 ' P' ' 32' ' ' ILE . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.679 ' CA ' HE22 ' N' ' 15' ' ' GLN . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' O' ' 38' ' ' GLY . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.513 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 1.9 t60 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.477 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' CD1' ' N ' ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.482 ' O ' ' CB ' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.456 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.627 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.627 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.431 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.671 ' CG2' HE22 ' O' ' 15' ' ' GLN . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 83.6 t60 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.462 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 47.9 t30 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.415 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.476 ' HZ1' ' HE2' ' A' ' 14' ' ' HIS . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.481 HG11 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.481 ' H ' HG11 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.496 ' H ' ' CD1' ' G' ' 31' ' ' ILE . 6.1 t . . . . . 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.5 mp0 . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.576 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.576 ' HE2' ' CG1' ' B' ' 12' ' ' VAL . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.415 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.455 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.476 ' H ' HG11 ' A' ' 39' ' ' VAL . 27.3 m . . . . . 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.451 ' HB3' ' CZ ' ' C' ' 19' ' ' PHE . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.455 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.577 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.577 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.479 ' H ' HG13 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.435 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.436 ' CG1' ' CD2' ' E' ' 13' ' ' HIS . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 24.9 p-80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.674 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.674 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.658 ' N ' ' ND2' ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.405 HD11 HG23 ' D' ' 32' ' ' ILE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.435 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 5.9 m-70 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.416 ' CB ' ' HE2' ' D' ' 14' ' ' HIS . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.484 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.484 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.423 HG23 HD11 ' E' ' 32' ' ' ILE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' E' ' 37' ' ' GLY . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.479 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 . . . . . 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.402 HG23 HD13 ' F' ' 31' ' ' ILE . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' HZ2' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.674 ' HZ2' ' CE1' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.471 ' O ' ' O ' ' H' ' 22' ' ' GLU . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.496 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.53 ' HB ' ' H ' ' H' ' 39' ' ' VAL . 4.0 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.879 0.371 . . . . 0.0 110.472 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.405 ' H ' HD21 ' I' ' 34' ' ' LEU . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.53 ' H ' ' HB ' ' G' ' 39' ' ' VAL . 1.4 p . . . . . 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 36.1 t60 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.523 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.444 ' HA ' ' HZ3' ' I' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.659 ' N ' ' HZ2' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.453 HG11 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.569 ' O ' ' ND2' ' J' ' 27' ' ' ASN . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.437 ' CA ' HD21 ' J' ' 27' ' ' ASN . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.659 ' HZ2' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.475 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' H' ' 33' ' ' GLY . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.5 ' CD1' ' CZ ' ' G' ' 19' ' ' PHE . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.43 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.421 ' O ' ' C ' ' I' ' 40' ' ' VAL . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.406 ' O ' ' OD1' ' K' ' 27' ' ' ASN . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.495 ' CG ' HD22 ' K' ' 27' ' ' ASN . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.683 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.683 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.548 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.453 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.405 ' CD1' ' CG2' ' J' ' 32' ' ' ILE . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.467 ' CG2' ' OE1' ' G' ' 15' ' ' GLN . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.502 ' OD2' ' CG2' ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.44 ' H ' ' HB3' ' J' ' 23' ' ' ASP . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.404 ' H ' HG11 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.495 HD22 ' CG ' ' J' ' 23' ' ' ASP . 1.1 m-80 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.548 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' L' ' 34' ' ' LEU . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.498 ' C ' ' HE2' ' K' ' 14' ' ' HIS . 2.6 t . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.802 0.334 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.549 ' CG1' ' H ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.549 ' H ' ' CG1' ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' K' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.474 ' O ' ' CG1' ' L' ' 36' ' ' VAL . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.463 ' OXT' ' CG1' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' M' ' 20' ' ' PHE . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.427 HG23 HD12 ' M' ' 31' ' ' ILE . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t . . . . . 0 N--CA 1.468 0.454 0 N-CA-C 110.855 -0.054 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.622 ' N ' ' CD2' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.616 ' CB ' HD22 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' P' ' 13' ' ' HIS . 32.8 m . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.539 ' N ' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.403 ' OE1' ' CG ' ' P' ' 15' ' ' GLN . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.616 HD22 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p . . . . . 0 CA--C 1.536 0.413 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.55 ' HE2' ' CG1' ' Q' ' 40' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.643 ' ND1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.459 ' NE2' ' O ' ' R' ' 36' ' ' VAL . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.404 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.485 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.41 ' O ' ' OXT' ' P' ' 40' ' ' VAL . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.466 ' ND1' ' O ' ' P' ' 13' ' ' HIS . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.643 ' CD2' ' ND1' ' P' ' 14' ' ' HIS . 3.3 p-80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . 0.405 ' CB ' ' O ' ' P' ' 15' ' ' GLN . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' CD1' ' C ' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.499 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.499 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . 0.413 ' CB ' ' O ' ' P' ' 34' ' ' LEU . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.55 ' CG1' ' HE2' ' P' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' H ' ' R' ' 15' ' ' GLN . 85.9 t60 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.566 ' H ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . 0.416 HG22 HD12 ' R' ' 31' ' ' ILE . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . 0.578 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.503 0.192 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.578 ' CD1' HE21 ' B' ' 15' ' ' GLN . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.432 ' C ' ' H ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.432 ' H ' ' C ' ' A' ' 22' ' ' GLU . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 32' ' ' ILE . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.421 ' CG1' ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.421 ' N ' ' CG1' ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 . . . . . 0 N--CA 1.461 0.085 0 CA-C-O 120.802 0.334 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.51 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 26.7 t60 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 60.5 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.446 ' CE ' ' SD ' ' C' ' 35' ' ' MET . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.421 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t . . . . . 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 N--CA 1.466 0.374 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.463 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.569 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.484 ' N ' ' CE1' ' B' ' 14' ' ' HIS . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.409 ' N ' HD11 ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.411 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.589 ' ND2' ' H ' ' C' ' 28' ' ' LYS . 8.9 t-20 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.589 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.432 HG22 HD13 ' C' ' 32' ' ' ILE . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.426 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.445 ' CG2' ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.445 ' N ' ' CG2' ' C' ' 39' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.574 ' CG1' ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.574 ' H ' ' CG1' ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' D' ' 12' ' ' VAL . 7.8 m80 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 54.3 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' D' ' 23' ' ' ASP . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.422 ' H ' HG11 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.545 ' HG ' ' H ' ' C' ' 28' ' ' LYS . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.427 HG23 HD13 ' D' ' 32' ' ' ILE . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' OE1' ' B' ' 15' ' ' GLN . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.467 ' O ' ' OXT' ' D' ' 40' ' ' VAL . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.51 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.502 ' O ' ' CG1' ' D' ' 12' ' ' VAL . 59.1 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.646 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.646 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.478 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.42 HG23 HD12 ' E' ' 31' ' ' ILE . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.412 HG23 HD12 ' E' ' 32' ' ' ILE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.462 HD11 ' N ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.462 ' N ' HD11 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m . . . . . 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.496 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt . . . . . 0 CA--C 1.531 0.242 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.419 HG23 HD12 ' F' ' 32' ' ' ILE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.425 ' O ' ' CG2' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.426 ' OE1' ' CG1' ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.415 ' CE ' ' HE2' ' G' ' 14' ' ' HIS . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.478 ' OE1' ' CE1' ' H' ' 20' ' ' PHE . 33.9 tt0 . . . . . 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.599 0 CA-C-O 123.733 1.73 . . . . 0.0 115.358 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.456 ' O ' ' CG2' ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.609 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' I' ' 24' ' ' VAL . 10.8 t0 . . . . . 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' G' ' 38' ' ' GLY . 4.9 t . . . . . 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 C--O 1.231 0.114 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.595 ' HE2' ' CE1' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.508 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' J' ' 23' ' ' ASP . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' H' ' 23' ' ' ASP . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.418 ' O ' ' HA2' ' H' ' 33' ' ' GLY . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.426 ' CG1' ' OE1' ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.41 ' N ' ' CG2' ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.42 ' O ' ' O ' ' K' ' 13' ' ' HIS . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.595 ' CE1' ' HE2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' CA ' ' L' ' 37' ' ' GLY . 84.9 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.509 ' CD1' ' N ' ' J' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 66.5 m-20 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.453 HG22 ' H ' ' K' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' K' ' 35' ' ' MET . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.51 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' L' ' 26' ' ' SER . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.412 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.4 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.453 ' H ' HG22 ' J' ' 31' ' ' ILE . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.404 HD11 HG21 ' K' ' 32' ' ' ILE . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' L' ' 35' ' ' MET . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 120.654 0.264 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.421 ' C ' ' H ' ' L' ' 26' ' ' SER . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.465 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.4 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.505 ' N ' ' CD2' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.577 ' CA ' ' NE2' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.491 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 m80 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.61 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . 0.412 HD13 HG23 ' M' ' 32' ' ' ILE . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 1.0 OUTLIER . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.742 ' H ' ' HZ1' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.61 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . 0.754 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.515 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.527 ' O ' ' NE2' ' N' ' 14' ' ' HIS . 3.2 t . . . . . 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.457 ' ND1' ' C ' ' O' ' 13' ' ' HIS . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.736 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.539 ' O ' ' CB ' ' N' ' 26' ' ' SER . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.742 ' HZ1' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.655 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . 0.497 ' O ' ' HA2' ' N' ' 33' ' ' GLY . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.515 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' P' ' 39' ' ' VAL . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m . . . . . 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.736 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.486 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.486 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.655 HD22 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.754 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . 0.424 HD12 ' H ' ' P' ' 35' ' ' MET . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 35' ' ' MET . . . . . 0.424 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.521 ' CG1' ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.521 ' N ' ' CG1' ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.502 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . 0.418 ' O ' ' O ' ' R' ' 33' ' ' GLY . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' R' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.466 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.475 ' C ' ' HZ1' ' E' ' 28' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -110.17 139.44 45.32 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.844 0.354 . . . . 0.0 110.685 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 -70.64 143.04 51.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.985 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.573 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.573 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.445 HD21 ' CB ' ' A' ' 30' ' ' ALA . 72.4 m-80 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.445 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.431 HD12 HG21 ' A' ' 32' ' ' ILE . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.428 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.712 ' H ' ' H ' ' B' ' 40' ' ' VAL . 59.3 t -144.34 161.42 14.97 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.401 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 57.3 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.497 -179.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -111.92 140.49 46.54 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.914 0.388 . . . . 0.0 110.848 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -74.35 148.8 40.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.783 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 6.3 p80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.423 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.491 ' O ' ' CG2' ' C' ' 39' ' ' VAL . 57.4 t -134.73 118.94 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.712 ' H ' ' H ' ' A' ' 39' ' ' VAL . 11.8 p . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.415 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -107.31 134.79 49.86 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.735 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.434 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 47.1 tp10 -136.25 116.64 13.67 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.592 ' CG2' ' NE2' ' C' ' 14' ' ' HIS . 2.0 p -132.25 119.12 38.77 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' O ' ' F' ' 40' ' ' VAL . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.766 HE22 ' H ' ' F' ' 37' ' ' GLY . 88.1 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.433 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.559 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.503 ' O ' ' N ' ' C' ' 29' ' ' GLY . 12.9 m120 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.401 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.423 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' B' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.62 ' CE1' ' H ' ' E' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.578 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.409 HD22 ' H ' ' C' ' 34' ' ' LEU . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -115.31 139.82 49.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.665 0.269 . . . . 0.0 110.357 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -142.03 146.04 35.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.916 0.389 . . . . 0.0 110.763 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.38 103.13 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.414 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.642 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' F' ' 29' ' ' GLY . 4.7 t-20 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' F' ' 29' ' ' GLY . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.415 HD12 HG23 ' E' ' 32' ' ' ILE . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.405 ' O ' ' CG1' ' E' ' 36' ' ' VAL . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.452 ' N ' ' CG1' ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -109.39 137.33 47.41 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.771 0.319 . . . . 0.0 110.497 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.502 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.4 mp0 -78.67 160.56 27.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.39 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t -108.58 94.29 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.642 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.469 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -98.73 141.16 31.89 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 23' ' ' ASP . 91.8 m-20 59.96 46.71 10.69 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.648 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.509 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 29.3 t -72.8 177.65 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.509 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . 102.07 -32.83 7.07 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -178.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 35.1 m -81.34 -129.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.415 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 98.8 m-20 -99.8 160.85 14.0 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.695 0.76 . . . . 0.0 112.795 -177.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -43.84 -40.05 4.23 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 114.466 -1.243 . . . . 0.0 113.412 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' R' ' 38' ' ' GLY . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.578 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.766 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.509 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.409 HE22 HG12 ' J' ' 36' ' ' VAL . 40.7 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -142.87 176.03 9.38 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.423 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.7 t0 -71.65 48.92 0.16 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.92 -178.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.613 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 33.1 t -143.89 -178.95 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.459 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.613 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . 68.14 -39.2 0.26 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.442 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.465 ' H ' ' C ' ' G' ' 24' ' ' VAL . 36.4 m -67.52 111.22 4.01 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 122.653 -0.322 . . . . 0.0 111.318 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 p-10 -149.09 161.59 41.65 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.825 0.822 . . . . 0.0 112.68 178.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.71 ' H ' ' NZ ' ' H' ' 28' ' ' LYS . 99.1 mttt 29.77 40.62 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 114.135 -1.393 . . . . 0.0 113.293 178.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.43 78.42 0.53 Allowed Glycine 0 N--CA 1.476 1.344 0 C-N-CA 120.087 -1.054 . . . . 0.0 111.534 179.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -81.5 64.44 6.22 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 119.439 1.619 . . . . 0.0 113.863 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.513 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t -96.82 130.56 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.521 179.701 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.74 137.33 46.85 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.735 0.302 . . . . 0.0 110.373 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 -85.5 138.98 31.84 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.962 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.604 HE22 ' CG1' ' K' ' 36' ' ' VAL . 50.3 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.457 HD11 ' N ' ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.537 ' O ' ' O ' ' H' ' 24' ' ' VAL . 88.4 m-20 -131.04 51.8 2.11 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' H' ' 23' ' ' ASP . 8.5 t -64.93 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 101.966 -3.346 . . . . 0.0 101.966 168.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 157.13 -36.95 0.56 Allowed Glycine 0 N--CA 1.465 0.592 0 C-N-CA 117.252 -2.404 . . . . 0.0 118.532 170.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 42.7 t -66.53 111.6 3.68 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 122.752 3.276 . . . . 0.0 107.81 177.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' H' ' 29' ' ' GLY . 40.2 t30 -149.28 142.13 24.69 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 118.215 -1.394 . . . . 0.0 112.161 172.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.71 ' NZ ' ' H ' ' G' ' 28' ' ' LYS . 98.5 mttt -11.97 -44.68 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 115.474 1.657 . . . . 0.0 115.474 172.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 141.62 62.9 0.03 OUTLIER Glycine 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 -176.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.406 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.5 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 44.7 t -156.6 156.0 4.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 87.4 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.555 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.513 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 96.5 m-85 -106.35 134.78 48.96 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.687 0.279 . . . . 0.0 110.283 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 -138.69 150.67 46.45 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.529 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 67.4 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.685 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.685 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' I' ' 28' ' ' LYS . 1.1 t-20 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.68 ' N ' ' ND2' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.43 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.495 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 38' ' ' GLY . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.513 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.431 ' O ' ' OD1' ' K' ' 27' ' ' ASN . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.618 ' O ' ' ND2' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.512 ' O ' ' O ' ' J' ' 37' ' ' GLY . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.533 ' H ' ' CG2' ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.437 ' O ' ' OE1' ' L' ' 11' ' ' GLU . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.579 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.604 ' CG1' HE22 ' H' ' 15' ' ' GLN . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' J' ' 38' ' ' GLY . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.534 ' N ' ' OXT' ' L' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -117.26 142.12 47.45 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.949 0.404 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.437 ' OE1' ' O ' ' K' ' 11' ' ' GLU . 69.6 mm-40 -82.64 131.69 35.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.771 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -125.75 123.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 23' ' ' ASP . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.506 ' CG1' ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . 0.412 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.576 ' ND1' ' NE2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . 0.42 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t -60.62 141.89 16.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.07 29.44 0.59 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t 63.03 -120.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -111.34 169.87 8.5 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.285 0.564 . . . . 0.0 111.168 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -38.74 -39.84 0.55 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.209 -0.905 . . . . 0.0 112.84 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.44 65.17 0.24 Allowed Glycine 0 CA--C 1.535 1.327 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.871 -177.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.46 135.52 35.12 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.513 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -106.23 131.39 53.52 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -141.38 163.09 33.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.031 0.443 . . . . 0.0 110.503 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.505 ' CG1' ' N ' ' N' ' 13' ' ' HIS . 67.2 t -132.23 167.46 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.9 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.696 ' CD2' ' H ' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.576 ' NE2' ' ND1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.625 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.412 ' O ' ' CD1' ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . 0.427 ' H ' ' H ' ' O' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . 0.427 ' H ' ' H ' ' O' ' 9' ' ' GLY . 96.9 m-85 -113.38 136.92 52.24 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.735 0.302 . . . . 0.0 110.45 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -113.32 117.77 32.74 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.65 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m -137.4 161.11 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.561 ' C ' ' H ' ' O' ' 26' ' ' SER . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.462 ' H ' HG11 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.625 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.658 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -110.04 138.95 45.71 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 56.8 mp0 -137.65 144.57 41.92 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.048 0.452 . . . . 0.0 111.007 -179.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.48 128.84 75.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' Q' ' 13' ' ' HIS . 34.8 m-70 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' P' ' 13' ' ' HIS . 32.1 m80 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.424 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . 0.417 HD11 HE21 ' Q' ' 15' ' ' GLN . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.49 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.531 ' O ' ' NE2' ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.658 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' P' ' 13' ' ' HIS . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.424 ' NE2' ' OE1' ' P' ' 15' ' ' GLN . 33.9 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . 0.423 ' C ' ' CD2' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.51 ' CB ' ' HZ3' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.412 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.551 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.551 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . 0.413 HD13 HG21 ' Q' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . 0.408 HD13 HG21 ' Q' ' 32' ' ' ILE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.497 ' CG1' ' O ' ' Q' ' 36' ' ' VAL . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.459 ' N ' ' CG1' ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -93.06 135.04 34.59 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.618 0.247 . . . . 0.0 110.395 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -72.52 140.86 48.42 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.257 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.481 ' O ' ' NE2' ' A' ' 14' ' ' HIS . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.469 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.402 HD11 HG23 ' A' ' 32' ' ' ILE . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.445 ' O ' ' OXT' ' B' ' 40' ' ' VAL . 4.3 t -149.63 166.5 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.338 -179.423 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.2 136.24 47.36 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -144.78 152.75 40.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.389 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.663 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.703 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . 0.56 ' HZ3' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.419 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . 0.56 ' CG2' ' HZ3' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.66 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.66 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.404 ' H ' HD13 ' C' ' 34' ' ' LEU . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.521 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.467 ' O ' ' CD1' ' H' ' 31' ' ' ILE . 13.5 t -56.21 131.7 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.445 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 16.4 m . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.825 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.405 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -107.17 136.6 46.73 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.673 0.273 . . . . 0.0 110.375 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -136.69 155.65 49.59 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 110.65 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -133.2 161.57 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.475 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.415 ' N ' ' OG ' ' B' ' 26' ' ' SER . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.459 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.404 HD13 ' H ' ' B' ' 34' ' ' LEU . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.527 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.521 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.545 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.519 ' N ' ' OE1' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 28.9 m170 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.627 ' HE2' ' CG ' ' E' ' 16' ' ' LYS . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.524 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.559 ' OD2' ' ND2' ' F' ' 27' ' ' ASN . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.524 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.458 ' H ' HG11 ' D' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.475 ' ND2' ' O ' ' C' ' 26' ' ' SER . 3.4 m120 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.446 HG21 HD11 ' D' ' 32' ' ' ILE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.4 ' CD2' ' N ' ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.703 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' C' ' 38' ' ' GLY . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.19 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -116.04 141.66 47.84 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -138.55 150.15 46.05 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.663 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.435 ' O ' ' CD2' ' E' ' 13' ' ' HIS . 55.1 t -123.78 134.01 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' E' ' 12' ' ' VAL . 18.0 m80 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.644 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 70.1 m80 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.627 ' CG ' ' HE2' ' D' ' 14' ' ' HIS . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.465 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.495 ' CG1' ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.502 HG21 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 77.1 t80 -71.3 135.05 47.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.692 0.282 . . . . 0.0 110.509 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.485 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 96.9 mt-10 -72.26 152.39 42.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.522 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -114.27 129.39 70.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.432 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.644 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.569 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 46.4 mp0 -93.35 132.4 37.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 56.99 59.87 3.27 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.33 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.626 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 12.0 t 71.76 -170.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.626 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -81.76 -35.45 22.08 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 119.977 -1.106 . . . . 0.0 111.033 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 30.8 t -81.44 119.87 24.28 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.559 ' ND2' ' OD2' ' D' ' 23' ' ' ASP . 51.4 m-80 -88.91 155.83 19.28 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.264 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -47.01 47.31 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 177.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.502 ' H ' HG21 ' E' ' 31' ' ' ILE . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.448 ' CG1' ' NE2' ' D' ' 15' ' ' GLN . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' E' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.42 HG23 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.553 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' G' ' 24' ' ' VAL . 98.3 mt-10 -137.86 -178.41 5.24 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.451 ' C ' ' O ' ' G' ' 22' ' ' GLU . 67.9 t0 4.71 60.53 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.299 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.518 ' N ' ' O ' ' G' ' 22' ' ' GLU . 11.8 t -70.95 123.33 24.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.351 178.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.82 -34.24 4.42 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.174 -1.571 . . . . 0.0 109.174 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' G' ' 27' ' ' ASN . 56.2 p -151.04 123.91 8.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.666 HD22 ' N ' ' H' ' 29' ' ' GLY . 25.4 t-20 -41.68 150.8 0.1 Allowed 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.864 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -74.71 -50.33 17.91 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.654 -179.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.31 50.35 3.23 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.039 -0.867 . . . . 0.0 110.965 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.61 137.79 49.81 Favored 'General case' 0 C--N 1.349 0.559 0 CA-C-N 119.041 1.421 . . . . 0.0 114.727 -176.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.46 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t -91.86 135.06 28.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.039 -0.981 . . . . 0.0 111.4 179.839 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -112.75 139.76 48.09 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.681 0.276 . . . . 0.0 110.604 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -87.5 130.54 34.67 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.816 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.42 ' H ' HG23 ' G' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.506 ' C ' ' ND1' ' H' ' 14' ' ' HIS . 2.5 t60 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.553 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.516 ' CB ' ' HZ2' ' H' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.569 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 -157.15 47.64 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.45 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.7 OUTLIER -62.59 -166.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 120.435 -0.506 . . . . 0.0 109.93 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.45 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -91.31 27.67 9.11 Favored Glycine 0 N--CA 1.468 0.818 0 CA-C-N 116.733 -0.212 . . . . 0.0 113.243 -173.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.466 ' O ' ' O ' ' H' ' 27' ' ' ASN . 60.5 p -153.44 120.45 5.74 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.49 ' C ' HD21 ' G' ' 27' ' ' ASN . 99.8 m-20 -40.74 167.01 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.817 -177.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.516 ' HZ2' ' CB ' ' H' ' 21' ' ' ALA . 98.7 mttt -79.46 -49.31 12.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.14 -178.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.666 ' N ' HD22 ' G' ' 27' ' ' ASN . . . 90.16 53.17 2.4 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 119.282 -1.437 . . . . 0.0 112.3 179.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.497 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p -69.46 131.0 34.4 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 95.2 t . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.772 -179.751 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.466 ' CE2' ' O ' ' I' ' 11' ' ' GLU . 87.8 t80 -71.86 135.02 46.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.921 0.391 . . . . 0.0 110.471 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 -78.35 156.91 29.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.782 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.588 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.569 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.435 ' OD1' ' N ' ' I' ' 27' ' ' ASN . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.545 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.559 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.418 ' CE1' ' HZ3' ' Q' ' 28' ' ' LYS . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.672 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 1.0 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.672 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' J' ' 17' ' ' LEU . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.575 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.575 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.418 HD13 ' N ' ' J' ' 35' ' ' MET . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.418 ' N ' HD13 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.559 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.424 ' CG1' ' CD2' ' H' ' 13' ' ' HIS . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' L' ' 11' ' ' GLU . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.598 ' CG1' ' HE2' ' K' ' 14' ' ' HIS . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.518 ' O ' ' CD2' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.638 ' ND1' ' CG ' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.429 ' HG3' ' H ' ' J' ' 15' ' ' GLN . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.421 ' O ' ' O ' ' K' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.664 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.664 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 62.5 m-20 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.532 ' CD1' ' O ' ' E' ' 38' ' ' GLY . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.489 ' O ' ' CB ' ' L' ' 34' ' ' LEU . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.452 ' O ' ' O ' ' K' ' 37' ' ' GLY . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -110.46 134.95 51.86 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.694 0.283 . . . . 0.0 110.45 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' K' ' 11' ' ' GLU . 97.4 mt-10 -80.93 119.52 23.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.615 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 10.4 p -141.04 164.65 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.73 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.638 ' CG ' ' ND1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.406 ' C ' ' CG2' ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.462 HG12 ' H ' ' L' ' 25' ' ' GLY . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.489 ' CB ' ' O ' ' K' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . 0.509 ' CD2' ' O ' ' N' ' 10' ' ' TYR . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.5 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . 0.488 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 53.8 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . 0.445 HD13 HE21 ' M' ' 15' ' ' GLN . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.615 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 36.6 t -148.16 178.55 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.615 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . 63.56 28.63 72.77 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.771 -0.649 . . . . 0.0 113.158 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 90.0 p -108.15 -120.26 0.26 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 117.806 0.803 . . . . 0.0 110.046 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -80.17 171.18 15.43 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.921 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -54.73 -38.85 67.61 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.682 0.753 . . . . 0.0 110.847 177.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.96 1.48 Allowed Glycine 0 CA--C 1.543 1.836 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.394 -177.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.51 -160.0 1.11 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 -178.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . 0.509 ' O ' ' CD2' ' M' ' 10' ' ' TYR . 99.4 m-85 -103.95 129.75 51.52 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -156.22 143.88 19.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.058 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t -125.22 92.71 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . 0.497 ' CD1' ' H ' ' H' ' 39' ' ' VAL . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.11 147.68 35.56 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 120.849 0.356 . . . . 0.0 110.789 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . 0.463 ' OE1' ' N ' ' O' ' 11' ' ' GLU . 57.0 mp0 -71.14 136.31 48.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.133 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m -134.14 160.04 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.434 ' CG2' ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.434 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.593 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . 0.586 ' N ' ' CD2' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.488 ' CG1' ' NE2' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.422 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.416 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.463 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.463 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -113.69 141.04 47.73 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.733 0.302 . . . . 0.0 110.41 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -126.88 147.0 50.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.888 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -124.08 134.36 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.679 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 2.1 t-20 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.494 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.422 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.679 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.423 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' P' ' 38' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' Q' ' 14' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' O ' ' Q' ' 13' ' ' HIS . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.559 ' CG2' ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.559 ' H ' ' CG2' ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . 0.408 HG22 HD11 ' R' ' 31' ' ' ILE . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . 0.413 HD11 HG21 ' R' ' 32' ' ' ILE . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.6 p90 -149.98 159.87 44.06 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.788 0.328 . . . . 0.0 110.67 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -138.45 154.13 48.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.319 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 70.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.45 ' CD1' ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t -29.28 151.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.867 -1.064 . . . . 0.0 110.742 179.471 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -111.39 134.01 53.28 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.555 0.216 . . . . 0.0 110.555 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.487 ' CG ' ' HZ2' ' K' ' 28' ' ' LYS . 79.5 mm-40 -139.61 157.2 46.19 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.3 m80 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.478 HD21 ' N ' ' B' ' 17' ' ' LEU . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.401 HD11 ' H ' ' B' ' 35' ' ' MET . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.401 ' H ' HD11 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 83.5 t -65.65 134.67 29.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 34.5 m . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.142 -0.933 . . . . 0.0 110.1 179.813 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.483 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -104.29 133.33 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.957 0.408 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.2 131.93 56.35 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.983 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -132.4 157.97 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.382 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.563 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 8.6 p-80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.675 HE22 ' N ' ' F' ' 37' ' ' GLY . 86.8 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.653 ' N ' ' CD2' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.421 HG23 HD12 ' C' ' 31' ' ' ILE . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 28.6 p-80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.68 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.452 ' HZ2' ' CD2' ' D' ' 14' ' ' HIS . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.525 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.408 HG23 HD11 ' D' ' 31' ' ' ILE . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.487 ' CG1' ' N ' ' D' ' 40' ' ' VAL . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.419 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -75.01 133.27 41.7 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -73.28 147.67 44.32 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.355 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.506 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 49.2 t -134.79 164.88 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.782 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.473 ' N ' ' CG1' ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.525 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.479 ' OD2' ' O ' ' F' ' 26' ' ' SER . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.437 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' D' ' 27' ' ' ASN . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 12.9 m120 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.539 ' HZ3' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.444 ' O ' ' N ' ' F' ' 37' ' ' GLY . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.46 134.39 48.65 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.569 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -111.29 139.92 46.29 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.315 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.05 99.79 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.513 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -60.01 139.6 57.33 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 65.6 t0 -70.43 46.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.603 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 97.2 t -80.64 -179.81 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.603 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -71.16 -32.5 65.59 Favored Glycine 0 CA--C 1.529 0.969 0 C-N-CA 121.001 -0.619 . . . . 0.0 113.019 -178.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.61 ' O ' ' O ' ' F' ' 27' ' ' ASN . 97.1 p -151.54 124.71 8.74 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 118.624 1.212 . . . . 0.0 113.425 -179.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.61 ' O ' ' O ' ' F' ' 26' ' ' SER . 37.8 t30 -41.29 -149.92 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.796 1.239 . . . . 0.0 113.053 177.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.554 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 95.6 mttt 82.61 50.03 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.451 -1.25 . . . . 0.0 112.976 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.444 HG22 HD11 ' F' ' 32' ' ' ILE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.461 ' C ' ' CD2' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' F' ' 37' ' ' GLY . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.675 ' N ' HE22 ' C' ' 15' ' ' GLN . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.522 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.415 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -142.85 -174.57 4.21 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.449 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 65.3 t0 -59.45 46.33 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 113.972 -1.467 . . . . 0.0 114.581 -178.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.539 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 57.4 t -80.38 179.61 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 118.12 -1.432 . . . . 0.0 107.713 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.539 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -71.39 -33.79 64.12 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.249 -179.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.488 ' O ' ' O ' ' G' ' 27' ' ' ASN . 34.9 t -153.14 122.45 6.66 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 117.424 0.612 . . . . 0.0 111.734 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.57 ' ND2' ' H ' ' H' ' 25' ' ' GLY . 6.8 m120 -40.67 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.346 -0.542 . . . . 0.0 109.926 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.479 ' N ' HD22 ' H' ' 27' ' ' ASN . 88.4 tttt -80.13 -47.4 14.83 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.721 ' H ' ' ND2' ' H' ' 27' ' ' ASN . . . 81.61 59.32 2.38 Favored Glycine 0 CA--C 1.543 1.789 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 125.53 53.52 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 -175.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.55 ' CD2' ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.55 ' H ' ' CD2' ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.67 ' H ' ' H ' ' H' ' 40' ' ' VAL . 42.6 t -147.28 139.26 18.68 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.794 -179.323 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.402 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.51 133.47 51.14 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.417 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -154.94 125.76 7.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.668 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.701 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.701 ' H ' ' CG ' ' H' ' 14' ' ' HIS . 55.9 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.413 ' HB3' ' CE2' ' H' ' 19' ' ' PHE . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.413 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 -62.52 -59.99 4.17 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 t -84.86 172.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.713 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.57 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . 94.67 -34.43 4.75 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 3.8 m -80.68 120.62 24.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 112.881 -1.66 . . . . 0.0 111.05 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.721 ' ND2' ' H ' ' G' ' 29' ' ' GLY . 8.4 m-80 -88.29 161.93 16.89 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.327 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -44.19 -39.82 4.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.417 -177.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.96 64.8 0.25 Allowed Glycine 0 CA--C 1.533 1.181 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.356 -178.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' I' ' 40' ' ' VAL . 81.0 t -134.64 125.49 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.67 ' H ' ' H ' ' G' ' 39' ' ' VAL . 6.1 p . . . . . 0 C--O 1.218 -0.561 0 CA-C-O 117.805 -1.093 . . . . 0.0 110.828 -178.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.12 133.29 51.95 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.939 0.399 . . . . 0.0 110.571 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.07 115.82 27.42 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.817 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.762 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.762 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.453 ' CG1' ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.401 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.483 ' N ' ' CG1' ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.536 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.899 HD22 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.899 ' H ' HD22 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.529 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.416 HD21 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.413 ' CG1' ' NE2' ' H' ' 15' ' ' GLN . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.428 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 43.6 t-80 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . 0.41 ' C ' ' CD2' ' K' ' 17' ' ' LEU . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.583 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.583 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.536 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.424 HD11 HG23 ' K' ' 32' ' ' ILE . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' L' ' 35' ' ' MET . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.503 ' N ' ' O ' ' K' ' 37' ' ' GLY . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -80.29 136.7 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 110.553 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.37 126.81 30.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.098 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -129.9 132.53 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.44 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.404 HD11 HG23 ' L' ' 32' ' ' ILE . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.442 ' O ' ' O ' ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.458 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.459 ' O ' ' CG1' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.622 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 87.5 t -78.12 -177.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.622 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -90.0 24.59 14.99 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.426 ' H ' ' C ' ' M' ' 24' ' ' VAL . 67.8 m -112.58 126.39 55.3 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 113.878 -1.161 . . . . 0.0 109.243 179.439 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 66.9 t30 62.42 155.87 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.942 0.401 . . . . 0.0 110.473 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.76 -49.41 58.94 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -177.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . 0.539 ' O ' ' ND2' ' N' ' 27' ' ' ASN . . . 90.21 50.8 2.92 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.76 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.51 -147.97 0.35 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 117.475 0.638 . . . . 0.0 110.989 -177.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.51 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -114.21 137.51 51.67 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' N' ' 11' ' ' GLU . 56.6 mp0 -112.76 144.31 42.51 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.557 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m -134.52 160.52 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.56 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 33.4 m-70 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.567 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.567 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.575 ' CG2' ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.575 ' H ' ' CG2' ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' M' ' 29' ' ' GLY . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' N' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.51 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.45 ' H ' ' CD1' ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -110.89 131.1 55.33 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.655 0.264 . . . . 0.0 110.876 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -146.99 153.08 39.63 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.36 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p -136.46 148.57 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.322 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' N' ' 13' ' ' HIS . 21.9 m-70 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.469 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.469 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.493 ' CG1' ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.674 ' N ' ' HZ1' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.409 HG21 HD11 ' O' ' 31' ' ' ILE . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.431 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.431 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.16 130.06 55.49 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -143.86 158.62 43.57 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.274 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.474 ' CG1' ' CD2' ' Q' ' 13' ' ' HIS . 47.5 t -126.34 130.88 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.443 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . 0.421 ' CD1' ' N ' ' P' ' 17' ' ' LEU . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.707 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.674 ' HZ1' ' N ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.46 ' O ' ' CG1' ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.474 ' CD2' ' CG1' ' P' ' 12' ' ' VAL . 5.1 m-70 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.517 HD22 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.707 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . 0.483 ' CD2' ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . 0.483 ' N ' ' CD2' ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.636 ' CG1' ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.636 ' H ' ' CG1' ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.7 m120 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.517 ' C ' HD22 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.559 ' O ' ' O ' ' R' ' 37' ' ' GLY . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.539 ' C ' ' HZ3' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.493 ' CA ' ' HZ3' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -149.12 156.76 42.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.728 0.299 . . . . 0.0 110.431 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -154.74 146.53 23.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.963 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.526 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.425 HG23 HD13 ' A' ' 32' ' ' ILE . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.42 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.42 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 40' ' ' VAL . 61.8 t -85.09 163.07 2.8 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.413 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 89.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.668 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -77.85 129.95 36.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -158.08 130.12 6.95 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.364 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.542 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 21.4 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' B' ' 23' ' ' ASP . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -85.04 129.09 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.468 0.464 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.567 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -85.07 135.9 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.793 0.33 . . . . 0.0 110.311 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -135.82 141.64 44.73 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.18 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m -136.27 160.47 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.512 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.457 ' CE1' ' OXT' ' E' ' 40' ' ' VAL . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.551 ' OE1' ' NE2' ' D' ' 15' ' ' GLN . 4.3 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.467 ' CB ' ' OD1' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.801 HD21 ' H ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.411 HG21 HD13 ' C' ' 31' ' ' ILE . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' D' ' 34' ' ' LEU . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' D' ' 36' ' ' VAL . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' C' ' 40' ' ' VAL . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.566 ' CG ' ' HE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.566 ' HE2' ' CG ' ' D' ' 11' ' ' GLU . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.551 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 57.0 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.421 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.53 ' O ' ' O ' ' D' ' 23' ' ' ASP . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.41 ' O ' ' CG2' ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.436 ' CD2' ' O ' ' C' ' 34' ' ' LEU . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.54 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -111.83 134.97 53.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.687 0.279 . . . . 0.0 110.418 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -112.0 132.16 54.96 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.464 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -120.15 120.1 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.61 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.511 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.442 ' N ' ' OG ' ' E' ' 26' ' ' SER . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.446 ' N ' ' CA ' ' F' ' 38' ' ' GLY . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.457 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -106.77 135.21 48.71 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.485 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -73.3 147.9 44.06 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.185 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m -136.27 167.85 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.419 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.48 ' CD2' ' H ' ' F' ' 13' ' ' HIS . 10.6 p80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.61 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.627 ' CG ' ' H ' ' F' ' 23' ' ' ASP . 37.1 tt0 -71.67 -173.42 0.95 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.627 ' H ' ' CG ' ' F' ' 22' ' ' GLU . 53.5 p30 -62.52 51.88 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.559 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 7.5 t -60.58 -131.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.559 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . 113.08 27.93 3.53 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 40.7 t -140.23 112.67 7.88 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.914 0.387 . . . . 0.0 110.494 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -64.15 179.16 0.58 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.637 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt 63.92 39.62 7.99 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.434 HG22 HD13 ' F' ' 31' ' ' ILE . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.429 HG21 HD12 ' F' ' 32' ' ' ILE . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.426 ' OXT' ' O ' ' F' ' 39' ' ' VAL . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . 0.59 ' CE1' ' N ' ' H' ' 9' ' ' GLY . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.499 HE22 ' CA ' ' I' ' 37' ' ' GLY . 39.0 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.404 ' HG2' ' N ' ' G' ' 23' ' ' ASP . 75.8 tt0 -159.48 176.9 11.53 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.404 ' N ' ' HG2' ' G' ' 22' ' ' GLU . 65.6 t0 -46.53 -59.66 2.85 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.789 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.6 m -101.44 174.95 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 176.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 69.29 26.98 74.13 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.866 178.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' G' ' 27' ' ' ASN . 6.1 t -153.21 120.62 5.9 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.724 -0.391 . . . . 0.0 112.021 -176.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.559 ' O ' ' O ' ' G' ' 26' ' ' SER . 67.2 t30 -41.98 -179.33 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.261 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.499 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 63.0 mttp -72.58 -41.14 66.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.229 -0.589 . . . . 0.0 111.824 -178.118 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.0 66.86 0.86 Allowed Glycine 0 CA--C 1.536 1.374 0 C-N-CA 119.527 -1.321 . . . . 0.0 112.145 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.27 -150.77 0.46 Allowed 'General case' 0 C--O 1.234 0.265 0 CA-C-N 117.422 0.611 . . . . 0.0 110.47 -177.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 49.4 t -45.11 145.05 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' H' ' 40' ' ' VAL . 16.5 m . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.06 -0.972 . . . . 0.0 111.039 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . 0.59 ' N ' ' CE1' ' G' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -106.94 132.15 53.21 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.765 0.316 . . . . 0.0 110.238 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -133.92 128.12 33.88 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.589 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' G' ' 13' ' ' HIS . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 14.2 tp60 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.536 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' CD2' ' I' ' 19' ' ' PHE . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.47 ' O ' ' N ' ' H' ' 24' ' ' VAL . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 23.78 45.9 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' H' ' 22' ' ' GLU . 2.4 m -75.77 179.42 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 CA-C-N 114.202 -1.363 . . . . 0.0 114.453 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' I' ' 27' ' ' ASN . . . 103.96 -37.22 3.87 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 111.196 -2.729 . . . . 0.0 117.784 169.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.408 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 43.4 m -66.02 111.39 3.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 121.684 2.742 . . . . 0.0 110.058 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.712 ' O ' ' N ' ' H' ' 29' ' ' GLY . 86.0 m-20 -149.77 142.98 25.1 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.154 -0.619 . . . . 0.0 110.796 173.311 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' H' ' 27' ' ' ASN . 98.8 mttt -9.81 -45.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 172.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.712 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 168.21 61.04 0.03 OUTLIER Glycine 0 CA--C 1.553 2.458 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.566 -175.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.431 ' H ' HD21 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' G' ' 38' ' ' GLY . 97.7 t -55.18 159.78 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' G' ' 40' ' ' VAL . 3.9 t . . . . . 0 C--O 1.218 -0.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.65 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.28 132.57 52.17 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.861 0.363 . . . . 0.0 110.427 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -139.17 132.17 29.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.79 HE22 ' H ' ' L' ' 37' ' ' GLY . 9.5 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.478 ' CG ' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.478 ' N ' ' CG ' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.431 HD21 ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' J' ' 36' ' ' VAL . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.499 ' CA ' HE22 ' G' ' 15' ' ' GLN . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.459 ' O ' ' CG2' ' H' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.419 ' HE2' HE22 ' J' ' 15' ' ' GLN . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 1.2 mp0 -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.458 ' H ' ' HG ' ' K' ' 26' ' ' SER . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.458 ' CD1' ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' I' ' 36' ' ' VAL . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 10.5 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.46 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.46 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.458 ' HG ' ' H ' ' J' ' 25' ' ' GLY . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' L' ' 35' ' ' MET . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.64 132.51 51.69 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.83 0.348 . . . . 0.0 110.125 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -84.93 117.7 24.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.785 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -128.64 129.08 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.017 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 8.6 m120 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.79 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . 0.494 ' C ' ' CD2' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.494 ' CD2' ' C ' ' M' ' 13' ' ' HIS . 3.4 m-70 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -84.83 150.09 4.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 38.68 5.35 Favored Glycine 0 CA--C 1.532 1.102 0 CA-C-N 114.061 -1.427 . . . . 0.0 115.78 175.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 61.98 111.58 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 116.688 2.107 . . . . 0.0 116.688 170.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.464 ' O ' ' C ' ' M' ' 28' ' ' LYS . 64.9 t30 -128.81 159.73 34.81 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 105.901 -1.888 . . . . 0.0 105.901 172.561 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.464 ' C ' ' O ' ' M' ' 27' ' ' ASN . 98.9 mttt -31.09 -40.2 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 113.207 0.817 . . . . 0.0 113.207 -175.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . 0.462 ' O ' ' CB ' ' M' ' 30' ' ' ALA . . . 82.55 66.98 1.51 Allowed Glycine 0 CA--C 1.538 1.51 0 CA-C-O 117.006 -1.997 . . . . 0.0 110.51 176.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' M' ' 29' ' ' GLY . . . 179.91 179.77 0.51 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 122.995 3.398 . . . . 0.0 116.633 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 35' ' ' MET . . . . . 0.427 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -106.42 133.83 50.5 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -143.73 111.98 6.31 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.932 0.396 . . . . 0.0 110.571 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t -124.29 131.43 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.667 179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.615 ' CB ' ' H ' ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.426 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.426 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.755 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.429 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.404 ' O ' ' O ' ' N' ' 38' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -107.88 136.23 47.95 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.722 0.296 . . . . 0.0 110.39 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -139.47 120.25 14.34 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m -139.38 160.26 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.428 ' CD2' ' N ' ' O' ' 13' ' ' HIS . 4.5 m-70 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.615 ' H ' ' CB ' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.755 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.4 HG22 HD12 ' O' ' 31' ' ' ILE . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.412 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.17 137.14 46.66 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' CE1' ' P' ' 13' ' ' HIS . 83.7 tt0 -116.66 125.65 52.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.22 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.48 133.27 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.816 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.425 ' CE1' ' OE2' ' P' ' 11' ' ' GLU . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.606 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.606 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.587 ' H ' ' HG ' ' O' ' 26' ' ' SER . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . 0.4 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 35' ' ' MET . . . . . 0.4 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.467 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.427 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 75.2 m80 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.461 ' CD ' HE21 ' R' ' 15' ' ' GLN . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.418 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.467 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' Q' ' 40' ' ' VAL . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.432 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.483 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.461 HE21 ' CD ' ' Q' ' 15' ' ' GLN . 86.1 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . 0.41 HG23 HD12 ' R' ' 32' ' ' ILE . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -74.62 126.34 30.61 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -158.34 141.59 15.01 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.652 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.652 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.599 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.599 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 38' ' ' GLY . 6.5 p -32.68 159.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.445 ' N ' ' CG2' ' A' ' 39' ' ' VAL . 26.6 m . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.69 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.99 139.66 32.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.834 0.35 . . . . 0.0 110.667 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -146.0 143.87 29.74 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.534 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.435 ' HB3' ' CZ ' ' B' ' 19' ' ' PHE . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.654 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.512 ' C ' ' HG ' ' B' ' 26' ' ' SER . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.512 ' HG ' ' C ' ' B' ' 25' ' ' GLY . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.488 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.488 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.48 154.98 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 117.855 -1.069 . . . . 0.0 110.444 178.763 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -109.74 131.06 55.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.93 0.395 . . . . 0.0 110.772 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -144.1 146.65 32.94 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.248 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t -119.64 129.52 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.672 ' CD2' ' HZ1' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.8 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' C' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.654 ' H ' ' HB3' ' B' ' 23' ' ' ASP . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.482 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.556 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.556 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.501 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.501 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.479 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' E' ' 36' ' ' VAL . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.405 ' O ' ' CG1' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . 0.448 ' H ' ' H ' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . 0.448 ' H ' ' H ' ' E' ' 9' ' ' GLY . 94.0 m-85 -106.05 133.37 50.86 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.637 0.256 . . . . 0.0 110.37 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -73.63 142.65 46.5 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -112.15 97.72 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.671 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 28.7 m80 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.437 ' O ' ' OD2' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.4 HD13 ' CD1' ' C' ' 19' ' ' PHE . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.525 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.86 131.77 54.68 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.808 0.337 . . . . 0.0 110.372 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -76.71 145.1 38.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.754 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m -137.82 169.45 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.443 -179.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.454 ' CD2' ' H ' ' F' ' 13' ' ' HIS . 6.6 p80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -106.23 136.97 45.0 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 54.9 60.76 3.29 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.891 177.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 10.2 m -66.05 124.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.21 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.18 -31.96 3.91 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 16.0 p -179.01 -117.36 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.981 0.39 . . . . 0.0 111.374 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -54.54 -179.81 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.5 0.667 . . . . 0.0 112.643 -178.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -67.79 -41.05 83.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.735 -1.12 . . . . 0.0 112.378 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.403 HG23 HD13 ' F' ' 32' ' ' ILE . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.606 ' O ' ' CD2' ' G' ' 14' ' ' HIS . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.468 ' C ' ' H ' ' G' ' 24' ' ' VAL . 21.7 pt-20 -157.57 -150.5 0.27 Allowed 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.4 t0 -70.0 46.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.412 . . . . 0.0 110.652 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.468 ' H ' ' C ' ' G' ' 22' ' ' GLU . 10.6 m -71.46 -168.54 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.17 28.47 15.56 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' H' ' 29' ' ' GLY . 35.4 t -80.77 113.83 19.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.493 -0.854 . . . . 0.0 109.373 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -92.03 -176.15 4.31 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.878 -178.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -48.74 -40.35 28.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.338 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.28 63.19 0.28 Allowed Glycine 0 CA--C 1.536 1.384 0 CA-C-O 119.519 -0.6 . . . . 0.0 114.201 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -107.1 101.15 10.58 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p -160.17 150.65 5.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.309 179.487 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -103.63 132.87 49.5 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -74.12 118.49 17.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.55 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.76 HE22 ' H ' ' K' ' 37' ' ' GLY . 99.1 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.4 ' CA ' ' NZ ' ' H' ' 28' ' ' LYS . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.676 ' H ' ' HZ2' ' H' ' 28' ' ' LYS . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.524 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 -117.01 46.95 1.57 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 31.2 m -73.81 176.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.407 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.21 27.3 7.7 Favored Glycine 0 N--CA 1.471 0.991 0 N-CA-C 114.131 0.412 . . . . 0.0 114.131 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.449 ' O ' ' C ' ' H' ' 27' ' ' ASN . 42.8 t -153.78 120.86 5.71 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 117.823 0.811 . . . . 0.0 109.08 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 47.8 m-80 -41.33 150.26 0.09 Allowed 'General case' 0 CA--C 1.52 -0.209 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.619 -178.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.676 ' HZ2' ' H ' ' H' ' 22' ' ' GLU . 90.4 mttt -75.78 -50.57 14.85 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 119.452 -0.899 . . . . 0.0 112.024 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.44 ' O ' ' OG ' ' G' ' 26' ' ' SER . . . 89.07 50.32 3.29 Favored Glycine 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 178.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p -156.78 146.71 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.299 -179.922 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.531 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 94.7 m-85 -108.14 136.34 47.97 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.774 0.321 . . . . 0.0 110.43 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -113.44 126.52 55.43 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.571 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.556 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 12.9 m120 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.652 ' HZ1' ' NZ ' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.4 ' H ' ' H ' ' J' ' 9' ' ' GLY . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.473 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.473 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.652 ' NZ ' ' HZ1' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.506 ' CD2' ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.506 ' N ' ' CD2' ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.488 ' CG2' HE22 ' G' ' 15' ' ' GLN . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.672 ' HZ1' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.76 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.406 ' O ' ' NZ ' ' Q' ' 28' ' ' LYS . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -100.02 133.44 44.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 110.547 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -110.0 122.24 47.1 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.42 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 t -126.77 127.22 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.408 ' C ' ' CD2' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.64 ' CG2' ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.64 ' H ' ' CG2' ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.542 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' E' ' 38' ' ' GLY . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . 0.438 ' O ' ' OE2' ' N' ' 11' ' ' GLU . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . 0.538 HE21 ' CD1' ' M' ' 17' ' ' LEU . 38.6 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . 0.538 ' CD1' HE21 ' M' ' 15' ' ' GLN . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m -84.15 172.16 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.73 -34.42 4.77 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.405 ' C ' ' OD1' ' N' ' 27' ' ' ASN . 2.0 m -80.47 120.19 24.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.602 -0.799 . . . . 0.0 111.189 -179.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.447 ' O ' ' OD1' ' N' ' 27' ' ' ASN . 97.3 m-20 -90.26 164.27 14.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.835 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -42.78 -38.01 1.97 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.56 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.59 74.85 0.07 OUTLIER Glycine 0 CA--C 1.531 1.083 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.568 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.7 109.05 15.75 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -178.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.475 ' N ' ' CG1' ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -107.84 132.15 53.74 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.758 0.313 . . . . 0.0 110.705 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' M' ' 12' ' ' VAL . 81.7 tt0 -74.69 135.48 41.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.286 -0.416 . . . . 0.0 109.971 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m -137.19 159.18 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.543 ' OE1' ' NE2' ' O' ' 15' ' ' GLN . 2.9 mt-30 -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.447 ' OD1' ' O ' ' M' ' 27' ' ' ASN . 3.3 m120 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.402 HG22 HD12 ' N' ' 32' ' ' ILE . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.09 137.92 51.69 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.846 0.355 . . . . 0.0 110.539 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.74 148.68 22.31 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.29 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.473 ' O ' ' CG2' ' N' ' 12' ' ' VAL . 15.7 m -120.54 132.49 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.539 ' CG ' ' CG1' ' Q' ' 40' ' ' VAL . 88.5 m-70 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.543 ' NE2' ' OE1' ' N' ' 15' ' ' GLN . 51.9 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.402 ' N ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' P' ' 27' ' ' ASN . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 40' ' ' VAL . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . 0.413 ' H ' ' H ' ' P' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . 0.413 ' H ' ' H ' ' P' ' 9' ' ' GLY . 95.9 m-85 -83.62 139.98 32.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.982 0.42 . . . . 0.0 110.76 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -140.14 165.37 27.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.785 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p -106.68 114.54 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.557 ' HE2' HE21 ' P' ' 15' ' ' GLN . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.557 HE21 ' HE2' ' P' ' 13' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . 0.599 ' CD1' ' N ' ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.543 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.603 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.557 ' CG1' ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.557 ' N ' ' CG1' ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.543 ' C ' HE22 ' N' ' 15' ' ' GLN . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . 0.422 ' C ' ' CD2' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.442 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.614 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.614 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . 0.437 ' H ' ' HB2' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . 0.5 ' CD2' ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . 0.5 ' N ' ' CD2' ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' O' ' 15' ' ' GLN . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.484 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.484 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -114.69 136.28 53.24 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.72 0.295 . . . . 0.0 110.307 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -141.63 142.96 33.41 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 46.8 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 51.3 t -133.05 133.8 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.432 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 66.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.568 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -107.62 139.92 41.43 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.669 0.271 . . . . 0.0 110.468 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -70.54 130.98 43.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.428 ' H ' HG21 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 25.1 t -133.96 131.45 56.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 90.3 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.455 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . 0.531 ' CD1' ' O ' ' D' ' 9' ' ' GLY . 95.8 m-85 -101.68 132.42 47.38 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.01 145.65 38.05 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 121.077 0.465 . . . . 0.0 111.351 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -120.97 129.41 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.619 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.655 HE21 ' NE2' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.467 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.48 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' E' ' 11' ' ' GLU . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.655 ' NE2' HE21 ' C' ' 15' ' ' GLN . 49.9 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.417 ' CD1' ' N ' ' D' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.504 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.467 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 58.2 m-80 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.437 HG23 HD13 ' D' ' 31' ' ' ILE . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' D' ' 37' ' ' GLY . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -108.09 135.29 49.69 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 120.742 0.306 . . . . 0.0 110.224 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' D' ' 11' ' ' GLU . 80.2 mm-40 -85.33 118.59 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.419 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -122.64 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 45.3 m-70 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.551 ' O ' ' N ' ' F' ' 20' ' ' PHE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.55 ' HB1' ' H ' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.474 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.418 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.495 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.444 ' O ' ' O ' ' F' ' 39' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.41 135.37 54.17 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.841 0.353 . . . . 0.0 110.423 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -136.92 158.04 45.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.446 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t -106.6 109.33 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.57 ' CD2' ' N ' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.57 ' N ' ' CD2' ' F' ' 20' ' ' PHE . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 133.87 -174.15 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -120.94 54.89 1.07 Allowed 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 176.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 p -66.59 134.83 29.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 114.964 -1.016 . . . . 0.0 111.746 -178.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.93 -31.66 2.04 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 108.501 -1.839 . . . . 0.0 108.501 177.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.3 t -81.26 -129.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.628 -0.786 . . . . 0.0 110.012 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -99.91 161.02 13.87 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.27 -40.38 3.45 Favored 'General case' 0 C--O 1.232 0.156 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.985 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.474 ' N ' ' HB3' ' E' ' 28' ' ' LYS . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.444 ' O ' ' O ' ' E' ' 40' ' ' VAL . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.45 ' CG2' ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.595 ' NZ ' ' HZ3' ' H' ' 16' ' ' LYS . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.436 ' O ' ' ND2' ' H' ' 27' ' ' ASN . 67.0 tt0 -143.82 167.17 22.94 Favored 'General case' 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -73.52 49.59 0.29 Allowed 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 119.029 -1.068 . . . . 0.0 111.372 -179.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.573 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 95.1 t -156.36 178.74 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.573 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . 61.39 28.92 70.23 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 120.774 -0.727 . . . . 0.0 113.449 177.139 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 43.7 t -154.15 111.37 3.41 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 118.42 1.11 . . . . 0.0 112.122 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.54 ' C ' ' HZ3' ' H' ' 28' ' ' LYS . 98.8 m-20 -53.22 172.49 0.06 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.067 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.401 ' N ' ' HZ2' ' H' ' 28' ' ' LYS . 66.0 tttm -60.46 -39.22 86.79 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.35 0.595 . . . . 0.0 110.555 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -104.55 70.23 0.25 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-N 115.034 -0.985 . . . . 0.0 112.404 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.61 85.34 2.91 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 -177.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.426 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.426 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.47 ' CG2' ' N ' ' G' ' 40' ' ' VAL . 2.7 p -137.09 161.06 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.47 ' N ' ' CG2' ' G' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.019 -0.991 . . . . 0.0 111.0 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -82.81 138.24 34.05 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.923 0.392 . . . . 0.0 110.36 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 -94.54 146.32 24.19 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.67 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' NE2' ' I' ' 15' ' ' GLN . 45.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.595 ' HZ3' ' NZ ' ' G' ' 16' ' ' LYS . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.505 ' CD1' HE21 ' H' ' 15' ' ' GLN . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' I' ' 22' ' ' GLU . 1.6 m-20 -149.88 51.29 0.92 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 t -100.15 -141.06 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -174.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.569 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -71.07 -34.14 64.94 Favored Glycine 0 N--CA 1.461 0.308 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.955 -172.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.569 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 12.0 t 139.59 113.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 174.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' G' ' 22' ' ' GLU . 28.3 t-20 -57.01 170.57 0.43 Allowed 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.878 -1.51 . . . . 0.0 108.938 175.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.54 ' HZ3' ' C ' ' G' ' 27' ' ' ASN . 98.6 mttt -58.97 -41.36 87.33 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.353 178.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.6 62.27 0.5 Allowed Glycine 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -177.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p -6.23 122.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.457 -179.78 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.344 -1.503 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -130.79 140.61 50.3 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.3 109.11 19.29 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.579 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.548 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.579 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' NE2' ' H' ' 15' ' ' GLN . 26.1 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.452 ' CB ' ' NZ ' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.409 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.405 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' J' ' 34' ' ' LEU . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.448 ' N ' ' CG1' ' J' ' 39' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 5.6 m80 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' OE1' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.546 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.447 ' CD2' ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 4.0 p80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.467 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.546 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.401 ' HB2' ' CD2' ' L' ' 34' ' ' LEU . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 39' ' ' VAL . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -149.49 159.51 44.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.706 0.289 . . . . 0.0 110.296 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 57.6 mp0 -139.99 157.61 45.39 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.93 0.395 . . . . 0.0 110.493 -179.728 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' L' ' 13' ' ' HIS . 2.7 p -140.53 166.2 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.916 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' K' ' 13' ' ' HIS . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' K' ' 28' ' ' LYS . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.401 ' CD2' ' HB2' ' K' ' 34' ' ' LEU . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 43.0 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 3.9 m -71.24 -168.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.94 28.13 17.08 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' N' ' 28' ' ' LYS . 29.2 t -81.09 114.93 20.27 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.66 -179.15 5.97 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.052 0.93 . . . . 0.0 113.033 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -55.77 -39.17 70.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.867 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.21 68.47 0.44 Allowed Glycine 0 CA--C 1.534 1.262 0 C-N-CA 121.076 -0.583 . . . . 0.0 113.636 -176.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.8 106.8 11.62 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 178.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.476 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -111.61 134.98 52.81 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.73 0.3 . . . . 0.0 110.264 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -138.85 109.98 6.85 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 121.075 0.464 . . . . 0.0 110.774 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -126.96 132.01 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.115 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.458 ' O ' ' OG ' ' M' ' 26' ' ' SER . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.403 HD12 HG22 ' N' ' 32' ' ' ILE . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.517 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' P' ' 9' ' ' GLY . 53.2 p90 -148.76 162.3 40.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.74 0.305 . . . . 0.0 110.282 179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -138.69 111.76 7.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.122 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.402 HG13 ' H ' ' P' ' 12' ' ' VAL . 30.9 m -127.74 135.47 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.837 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.531 ' HG ' ' H ' ' N' ' 27' ' ' ASN . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.535 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.513 ' O ' ' CG1' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.428 ' CG2' ' C ' ' P' ' 40' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' O' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.93 151.07 43.98 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -77.51 110.02 11.94 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.378 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.402 ' H ' HG13 ' O' ' 12' ' ' VAL . 2.3 p -141.04 136.96 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 3.0 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.524 ' CG ' HD22 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.535 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' P' ' 37' ' ' GLY . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.428 ' C ' ' CG2' ' O' ' 40' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.478 ' N ' ' CG1' ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.469 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.406 ' CG2' ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.55 ' OD1' ' N ' ' Q' ' 28' ' ' LYS . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.439 ' CG1' ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.494 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' O ' ' OXT' ' Q' ' 40' ' ' VAL . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.565 ' NE2' ' H ' ' R' ' 15' ' ' GLN . 0.9 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.414 ' OD1' ' OG ' ' Q' ' 26' ' ' SER . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . 0.567 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.492 ' C ' HE22 ' P' ' 15' ' ' GLN . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.494 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -110.52 136.25 49.94 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' CE1' ' A' ' 13' ' ' HIS . 82.0 tt0 -111.32 113.62 26.22 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.5 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.681 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 45.3 m170 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 16.5 t-20 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.409 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p -51.85 147.89 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.838 -1.077 . . . . 0.0 110.609 179.862 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -102.74 133.73 47.3 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -79.89 131.49 35.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.67 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.464 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.681 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.473 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.473 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' A' ' 27' ' ' ASN . 99.3 m-20 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.405 HG21 HD13 ' B' ' 31' ' ' ILE . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.402 HD11 HG23 ' B' ' 32' ' ' ILE . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.6 t -50.2 134.28 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.224 -0.279 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.652 178.929 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -115.66 139.1 50.44 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.799 0.333 . . . . 0.0 110.57 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -87.22 117.15 25.78 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t -124.14 129.56 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.67 HE22 ' H ' ' F' ' 37' ' ' GLY . 75.7 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.516 ' O ' ' ND2' ' D' ' 27' ' ' ASN . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.425 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.425 ' N ' ' O ' ' C' ' 37' ' ' GLY . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.419 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.537 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.55 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' E' ' 28' ' ' LYS . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.413 ' H ' ' HB3' ' D' ' 27' ' ' ASN . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -105.73 134.2 49.24 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.909 0.385 . . . . 0.0 110.629 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.38 131.79 25.23 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.9 123.95 72.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' CE1' ' F' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.643 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' E' ' 28' ' ' LYS . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.42 HG21 HD11 ' E' ' 31' ' ' ILE . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.502 ' N ' ' O ' ' F' ' 40' ' ' VAL . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.461 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -107.32 134.88 49.74 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.11 141.56 48.67 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -117.35 119.17 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.577 ' CE1' ' ND1' ' E' ' 13' ' ' HIS . 5.6 t-160 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.643 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -113.5 152.58 30.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 43.6 t0 66.64 50.38 1.2 Allowed 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 120.766 -0.373 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -55.73 160.46 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 130.39 -36.92 2.22 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -176.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.0 m -79.94 118.05 21.33 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.552 ' O ' ' N ' ' F' ' 29' ' ' GLY . 81.9 m-20 -91.99 -161.31 0.81 Allowed 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.817 -176.581 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -47.99 48.63 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 -177.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.406 HD11 HG23 ' F' ' 31' ' ' ILE . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.67 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' F' ' 40' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.416 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.492 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.444 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 82.5 tt0 -156.66 114.34 3.21 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.454 ' O ' ' OD2' ' G' ' 23' ' ' ASP . 2.5 p-10 47.54 47.62 17.36 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 111.542 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.498 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 16.9 t -52.91 -175.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.498 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . 165.0 19.73 0.02 OUTLIER Glycine 0 CA--C 1.534 1.24 0 C-N-CA 119.316 -1.421 . . . . 0.0 113.568 -179.024 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.428 ' O ' ' O ' ' G' ' 27' ' ' ASN . 35.1 t -102.23 120.67 40.86 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 118.229 1.014 . . . . 0.0 112.132 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' CE ' ' H' ' 28' ' ' LYS . 11.6 m120 53.47 151.68 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.16 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.41 -48.26 35.32 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.632 0.729 . . . . 0.0 111.948 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.95 58.11 0.4 Allowed Glycine 0 N--CA 1.476 1.351 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.842 -177.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.37 109.53 17.37 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 -175.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m -58.91 172.63 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.47 0.526 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.432 -179.898 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.32 132.21 52.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.898 0.38 . . . . 0.0 110.414 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -141.21 104.45 4.63 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.557 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.507 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.525 ' CD2' ' CE1' ' I' ' 13' ' ' HIS . 85.1 m-70 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 -74.69 46.41 0.28 Allowed 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 m -80.36 -179.37 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -70.87 -28.77 70.11 Favored Glycine 0 N--CA 1.466 0.673 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -175.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 0.2 OUTLIER 160.79 125.84 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.807 0.813 . . . . 0.0 112.23 175.086 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -49.23 158.13 0.4 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.32 176.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' O ' ' G' ' 27' ' ' ASN . 26.9 tttp -70.26 -48.1 58.38 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 174.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.33 59.81 0.5 Allowed Glycine 0 CA--C 1.542 1.752 0 CA-C-N 114.305 -1.316 . . . . 0.0 112.386 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.479 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 p -167.02 140.62 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.319 -179.692 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -112.97 136.23 52.87 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.968 0.413 . . . . 0.0 110.074 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' J' ' 11' ' ' GLU . 78.8 mm-40 -71.03 162.87 28.69 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.53 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.525 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 2.3 m-70 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.644 HE21 ' CG1' ' K' ' 36' ' ' VAL . 0.8 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.451 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.479 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.474 ' CG2' ' O ' ' K' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.534 HE22 ' NE2' ' I' ' 15' ' ' GLN . 7.9 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.407 HG12 ' H ' ' J' ' 25' ' ' GLY . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' I' ' 23' ' ' ASP . 6.6 m120 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.405 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.421 ' O ' ' CG1' ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.435 ' CG2' ' ND1' ' H' ' 13' ' ' HIS . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' K' ' 15' ' ' GLN . 0.0 OUTLIER -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.695 ' NZ ' ' HZ3' ' L' ' 16' ' ' LYS . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.476 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.475 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.74 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.74 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.644 ' CG1' HE21 ' I' ' 15' ' ' GLN . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.495 ' O ' ' CE ' ' Q' ' 28' ' ' LYS . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -105.81 134.0 49.63 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.838 0.351 . . . . 0.0 110.581 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.32 127.1 56.03 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.088 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.06 127.95 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 19.3 t-160 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . 0.695 ' HZ3' ' NZ ' ' K' ' 16' ' ' LYS . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.476 ' CB ' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . 0.707 HE21 HE21 ' N' ' 15' ' ' GLN . 6.5 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' HZ2' ' O' ' 28' ' ' LYS . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.441 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . 0.441 ' H ' ' HG2' ' M' ' 22' ' ' GLU . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t -73.34 160.45 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.93 -35.1 5.06 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 177.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.505 ' HG ' ' ND2' ' N' ' 27' ' ' ASN . 3.7 t -80.35 118.96 22.45 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.334 -0.433 . . . . 0.0 111.818 -178.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.47 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 98.3 m-20 -90.37 -179.26 5.57 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.809 178.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.58 -37.66 18.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.397 179.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.49 76.3 0.07 OUTLIER Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -177.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.24 108.82 14.16 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 -176.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.48 141.22 45.33 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 120.762 0.315 . . . . 0.0 110.347 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -115.86 136.43 53.05 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.129 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -120.93 128.85 76.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.439 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.707 HE21 HE21 ' M' ' 15' ' ' GLN . 42.1 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . 0.521 ' C ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.505 ' ND2' ' HG ' ' M' ' 26' ' ' SER . 14.6 m120 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -149.14 152.5 36.22 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.878 0.37 . . . . 0.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -162.29 143.67 10.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.137 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.589 ' CG2' ' H ' ' P' ' 12' ' ' VAL . 38.2 t -137.32 176.94 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.013 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.563 ' H ' ' CG1' ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.414 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.414 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.729 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.729 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.659 ' NZ ' ' N ' ' N' ' 22' ' ' GLU . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.054 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -109.57 133.01 53.61 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.617 0.246 . . . . 0.0 110.827 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -140.71 142.73 34.82 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.718 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.589 ' H ' ' CG2' ' O' ' 12' ' ' VAL . 6.5 t -141.34 92.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.532 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.589 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.522 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.577 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.425 ' CB ' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' Q' ' 19' ' ' PHE . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.522 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.472 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' OD1' ' N ' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' R' ' 35' ' ' MET . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.589 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.92 136.38 45.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.767 0.318 . . . . 0.0 110.539 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -99.97 121.36 41.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.542 HE22 ' C ' ' C' ' 36' ' ' VAL . 88.1 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.607 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.607 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.584 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.584 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.69 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -138.18 152.38 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.843 179.663 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -115.03 136.6 52.95 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.764 0.316 . . . . 0.0 110.312 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -134.35 127.75 32.3 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.674 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' H ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.618 ' H ' ' CD2' ' B' ' 14' ' ' HIS . 33.8 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . 0.46 ' C ' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.665 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.665 ' CG1' ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.425 ' O ' ' CG2' ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.69 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HD12 ' H' ' 31' ' ' ILE . 8.2 m -65.15 133.5 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.446 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 54.0 p90 -151.25 162.71 40.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.889 0.376 . . . . 0.0 110.498 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -134.78 150.0 50.48 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.279 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -126.34 138.21 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.595 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.581 ' CD1' ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.483 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.5 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.43 ' N ' ' CD2' ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.542 ' C ' HE22 ' A' ' 15' ' ' GLN . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 9.6 p-80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.506 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.506 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.553 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.43 ' CD2' ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' D' ' 37' ' ' GLY . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -106.79 134.38 50.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 120.847 0.356 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' D' ' 11' ' ' GLU . 98.2 mt-10 -86.09 114.45 22.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.333 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m -131.45 162.44 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.584 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.458 ' CB ' ' HZ1' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.458 ' HZ1' ' CB ' ' E' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.477 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.483 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -112.55 136.15 52.43 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -110.2 113.88 26.91 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.882 0.373 . . . . 0.0 110.65 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' F' ' 13' ' ' HIS . 2.6 p -141.69 163.59 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.89 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' E' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.584 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' F' ' 23' ' ' ASP . 94.1 mt-10 -95.26 117.65 30.64 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' F' ' 22' ' ' GLU . 14.4 t0 89.33 48.45 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.268 0.556 . . . . 0.0 109.581 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 6.4 m -72.04 161.5 4.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.129 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.13 -33.09 6.05 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.366 -0.693 . . . . 0.0 111.366 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.533 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 26.4 t -81.12 -129.42 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 117.58 0.69 . . . . 0.0 110.48 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.533 ' N ' ' OG ' ' F' ' 26' ' ' SER . 63.3 t30 -100.19 160.6 14.2 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -44.29 -40.37 5.2 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.896 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.477 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . 0.454 ' CD2' ' O ' ' H' ' 10' ' ' TYR . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.661 HE21 ' CD1' ' G' ' 17' ' ' LEU . 51.5 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.661 ' CD1' HE21 ' G' ' 15' ' ' GLN . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.445 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 4.1 pt-20 -167.65 104.93 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' G' ' 22' ' ' GLU . 63.5 m-20 -160.71 46.81 0.22 Allowed 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -175.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.52 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 51.3 t -82.42 173.7 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.284 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.52 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . 91.21 -33.35 4.76 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 36.7 t -151.69 123.64 8.09 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.511 ' OD1' ' N ' ' H' ' 27' ' ' ASN . 16.3 t30 -41.52 150.95 0.09 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.837 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.434 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 88.8 tttt -75.22 -50.5 15.97 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.502 177.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.37 50.32 3.22 Favored Glycine 0 CA--C 1.545 1.931 0 CA-C-O 118.417 -1.213 . . . . 0.0 111.596 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -130.64 105.28 7.71 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.404 HD11 HG21 ' G' ' 32' ' ' ILE . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.434 ' O ' ' C ' ' G' ' 40' ' ' VAL . 7.9 p -136.12 137.78 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' G' ' 39' ' ' VAL . 27.5 m . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.72 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . 0.454 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 94.1 m-85 -107.62 138.33 44.05 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.696 0.284 . . . . 0.0 110.428 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.548 ' N ' ' OE1' ' H' ' 11' ' ' GLU . 56.8 mp0 -134.08 146.9 50.73 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 6.6 t60 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.449 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.505 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 42.86 50.16 5.17 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' N ' ' H' ' 25' ' ' GLY . 42.9 t -49.73 164.56 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.343 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' OD1' ' H' ' 27' ' ' ASN . . . -174.8 21.58 0.06 OUTLIER Glycine 0 C--O 1.224 -0.496 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.284 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 33.4 t -68.66 115.7 8.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.511 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 3.4 m120 -118.33 -158.76 0.73 Allowed 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 121.63 0.729 . . . . 0.0 112.612 -178.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 61.2 tttt 29.51 40.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.205 -1.361 . . . . 0.0 112.34 -178.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . 111.31 73.96 0.72 Allowed Glycine 0 CA--C 1.537 1.411 0 C-N-CA 120.29 -0.957 . . . . 0.0 114.747 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.401 HD12 ' H ' ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.449 HD12 HG21 ' H' ' 32' ' ' ILE . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.439 ' H ' HD21 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t -111.17 135.8 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.44 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 70.0 t . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 118.106 -0.949 . . . . 0.0 110.132 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . 0.441 ' O ' ' CD2' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -108.3 131.99 54.15 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.787 0.327 . . . . 0.0 110.834 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -74.3 119.11 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.989 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.521 HE22 ' H ' ' L' ' 37' ' ' GLY . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.482 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.549 ' CB ' ' HZ3' ' J' ' 28' ' ' LYS . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.505 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' J' ' 23' ' ' ASP . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.521 ' C ' ' HG ' ' I' ' 26' ' ' SER . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.521 ' HG ' ' C ' ' I' ' 25' ' ' GLY . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.57 HD22 ' C ' ' J' ' 29' ' ' GLY . 25.9 p30 -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.439 HD21 ' H ' ' H' ' 34' ' ' LEU . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.436 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' H' ' 40' ' ' VAL . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.44 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.7 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.519 ' N ' ' HG ' ' K' ' 26' ' ' SER . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.654 ' N ' ' HG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.549 ' HZ3' ' CB ' ' I' ' 21' ' ' ALA . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.57 ' C ' HD22 ' I' ' 27' ' ' ASN . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.434 HD13 ' H ' ' I' ' 34' ' ' LEU . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.436 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 40' ' ' VAL . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.605 ' CD ' ' HE2' ' J' ' 14' ' ' HIS . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.65 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.65 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.654 ' HG ' ' N ' ' J' ' 26' ' ' SER . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.507 ' O ' ' CA ' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . 0.433 ' CE2' ' O ' ' L' ' 11' ' ' GLU . 92.6 t80 -70.08 138.02 51.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.865 0.364 . . . . 0.0 110.773 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.433 ' O ' ' CE2' ' L' ' 10' ' ' TYR . 83.8 tt0 -70.34 123.73 22.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.376 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.09 108.98 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.443 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 0.4 OUTLIER -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.578 ' CE1' ' NZ ' ' L' ' 16' ' ' LYS . 3.9 p80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . 0.578 ' NZ ' ' CE1' ' L' ' 14' ' ' HIS . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.507 ' CA ' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.425 HG22 HD13 ' L' ' 32' ' ' ILE . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.521 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.431 ' OXT' ' OD1' ' Q' ' 27' ' ' ASN . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' M' ' 25' ' ' GLY . 96.8 t -49.15 164.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' M' ' 24' ' ' VAL . . . -174.45 19.52 0.05 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 41.7 m -80.54 -130.23 0.02 OUTLIER 'General case' 0 C--O 1.232 0.135 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.43 HD22 ' CA ' ' M' ' 30' ' ' ALA . 17.0 p-10 -100.59 162.41 12.94 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.343 0.592 . . . . 0.0 110.879 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' N' ' 27' ' ' ASN . 64.3 mttp -40.0 -37.99 0.66 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.11 -0.95 . . . . 0.0 113.067 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.94 76.17 0.07 OUTLIER Glycine 0 N--CA 1.471 1.001 0 C-N-CA 120.423 -0.894 . . . . 0.0 112.743 -176.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . 0.43 ' CA ' HD22 ' M' ' 27' ' ' ASN . . . -80.1 142.74 34.57 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 -177.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -111.4 136.29 50.75 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -107.04 109.38 21.24 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.865 0.364 . . . . 0.0 110.815 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t -134.3 125.46 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.679 HE22 ' CA ' ' P' ' 37' ' ' GLY . 7.8 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.453 ' C ' ' O ' ' N' ' 22' ' ' GLU . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.547 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.547 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.432 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -108.24 135.02 50.25 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.854 0.359 . . . . 0.0 110.43 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -117.85 126.03 51.63 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.276 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t -125.37 128.31 72.54 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.843 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.671 HE22 ' CG2' ' Q' ' 36' ' ' VAL . 64.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.4 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.475 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.475 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.412 ' H ' ' C ' ' O' ' 24' ' ' VAL . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 9.2 m120 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . 0.431 ' N ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' O' ' 33' ' ' GLY . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' O' ' 40' ' ' VAL . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.423 ' N ' ' CG2' ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -110.72 132.49 54.15 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.947 0.403 . . . . 0.0 110.788 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.45 122.48 15.65 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.014 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -126.26 128.12 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' O ' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.431 ' O ' ' OG ' ' Q' ' 26' ' ' SER . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.42 ' H ' ' C ' ' P' ' 24' ' ' VAL . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . 0.462 HD13 HG21 ' P' ' 32' ' ' ILE . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.679 ' CA ' HE22 ' N' ' 15' ' ' GLN . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' O' ' 38' ' ' GLY . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.513 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 1.9 t60 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.477 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' CD1' ' N ' ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.482 ' O ' ' CB ' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.456 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.627 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.627 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.431 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.671 ' CG2' HE22 ' O' ' 15' ' ' GLN . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 83.6 t60 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.462 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 47.9 t30 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.438 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -147.87 158.83 44.23 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.76 0.314 . . . . 0.0 110.344 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -157.83 133.46 9.08 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.415 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.476 ' HZ1' ' HE2' ' A' ' 14' ' ' HIS . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.481 HG11 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.481 ' H ' HG11 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.496 ' H ' ' CD1' ' G' ' 31' ' ' ILE . 6.1 t -94.73 126.41 47.16 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 44.6 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.43 -179.297 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.68 132.78 52.27 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.566 0.222 . . . . 0.0 110.433 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.5 mp0 -130.06 126.25 37.18 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.144 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.576 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.576 ' HE2' ' CG1' ' B' ' 12' ' ' VAL . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.415 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.455 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.476 ' H ' HG11 ' A' ' 39' ' ' VAL . 27.3 m -132.28 128.4 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.436 -179.885 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.074 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -107.28 134.28 50.6 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.873 0.368 . . . . 0.0 110.23 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -134.08 131.74 39.14 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.269 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -131.44 134.58 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.451 ' HB3' ' CZ ' ' C' ' 19' ' ' PHE . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.455 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.577 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.577 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.479 ' H ' HG13 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.435 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.436 ' CG1' ' CD2' ' E' ' 13' ' ' HIS . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 24.9 p-80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.674 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.674 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.658 ' N ' ' ND2' ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.405 HD11 HG23 ' D' ' 32' ' ' ILE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.435 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -107.28 134.64 50.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.623 0.249 . . . . 0.0 110.763 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -75.07 157.7 34.35 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.139 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -116.3 127.48 73.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.82 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 5.9 m-70 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.416 ' CB ' ' HE2' ' D' ' 14' ' ' HIS . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.484 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.484 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.423 HG23 HD11 ' E' ' 32' ' ' ILE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' E' ' 37' ' ' GLY . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.59 133.77 49.78 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.889 0.376 . . . . 0.0 110.282 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -122.4 116.92 24.85 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.959 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m -136.2 159.8 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.623 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.479 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.435 ' C ' ' H ' ' F' ' 24' ' ' VAL . 93.1 mt-10 -69.02 161.2 29.48 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -68.31 46.22 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.508 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 41.9 t -80.57 -179.87 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.508 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -71.39 -34.13 63.94 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 118.571 -1.776 . . . . 0.0 111.22 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.427 ' O ' ' C ' ' F' ' 27' ' ' ASN . 39.1 t -162.22 120.27 2.18 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 119.014 -1.075 . . . . 0.0 113.118 175.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' F' ' 26' ' ' SER . 14.9 m-20 -24.34 149.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.686 174.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -175.85 -48.58 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 120.12 -0.632 . . . . 0.0 112.139 173.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.402 HG23 HD13 ' F' ' 31' ' ' ILE . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' HZ2' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.674 ' HZ2' ' CE1' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.471 ' O ' ' O ' ' H' ' 22' ' ' GLU . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 179.0 157.15 0.51 Allowed 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.26 56.38 7.02 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.027 179.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 85.7 t -65.04 133.42 30.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.64 0.733 . . . . 0.0 110.907 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.34 -29.42 2.74 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.966 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' G' ' 27' ' ' ASN . 22.1 t -160.41 139.5 10.64 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -177.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.436 ' C ' ' O ' ' G' ' 26' ' ' SER . 24.5 t-20 -23.57 142.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 122.03 0.919 . . . . 0.0 113.085 -176.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -127.99 -30.95 2.42 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.455 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.429 ' HA3' ' H ' ' H' ' 29' ' ' GLY . . . -70.27 96.78 0.56 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.019 -0.61 . . . . 0.0 111.947 -177.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.74 178.36 8.95 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.496 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.53 ' HB ' ' H ' ' H' ' 39' ' ' VAL . 4.0 t -84.31 127.07 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.222 -0.363 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.835 -179.371 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -108.49 135.71 49.31 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.901 0.381 . . . . 0.0 110.459 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.67 164.88 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.472 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.82 49.25 2.15 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 m -71.05 160.85 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 118.28 -1.368 . . . . 0.0 109.697 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.57 ' H ' ' CB ' ' I' ' 26' ' ' SER . . . 109.97 -28.43 10.52 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 105.776 -2.93 . . . . 0.0 105.776 -174.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.459 ' OG ' ' OG ' ' I' ' 26' ' ' SER . 0.7 OUTLIER 74.46 119.49 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.144 -1.528 . . . . 0.0 112.124 178.583 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -83.34 162.36 21.11 Favored 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 177.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.28 -39.74 22.63 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.429 ' H ' ' HA3' ' G' ' 29' ' ' GLY . . . 170.89 67.06 0.04 OUTLIER Glycine 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 -178.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.405 ' H ' HD21 ' I' ' 34' ' ' LEU . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.53 ' H ' ' HB ' ' G' ' 39' ' ' VAL . 1.4 p -156.87 171.59 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.441 ' H ' HG22 ' H' ' 39' ' ' VAL . 31.2 t . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.43 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.506 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -106.48 133.99 50.31 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 120.914 0.388 . . . . 0.0 110.358 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -148.27 146.31 28.56 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 36.1 t60 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.523 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.444 ' HA ' ' HZ3' ' I' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.659 ' N ' ' HZ2' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.453 HG11 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.569 ' O ' ' ND2' ' J' ' 27' ' ' ASN . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.57 ' CB ' ' H ' ' H' ' 25' ' ' GLY . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.659 ' HZ2' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.475 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' H' ' 33' ' ' GLY . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.5 ' CD1' ' CZ ' ' G' ' 19' ' ' PHE . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.43 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.421 ' O ' ' C ' ' I' ' 40' ' ' VAL . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.406 ' O ' ' OD1' ' K' ' 27' ' ' ASN . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.495 ' CG ' HD22 ' K' ' 27' ' ' ASN . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.683 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.683 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.548 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.453 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.405 ' CD1' ' CG2' ' J' ' 32' ' ' ILE . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.467 ' CG2' ' OE1' ' G' ' 15' ' ' GLN . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.502 ' OD2' ' CG2' ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.44 ' H ' ' HB3' ' J' ' 23' ' ' ASP . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.404 ' H ' HG11 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.495 HD22 ' CG ' ' J' ' 23' ' ' ASP . 1.1 m-80 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.548 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' L' ' 34' ' ' LEU . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -82.8 138.8 33.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.836 0.351 . . . . 0.0 110.74 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -153.31 132.8 12.91 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.159 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.498 ' C ' ' HE2' ' K' ' 14' ' ' HIS . 2.6 t -110.66 101.88 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.46 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.549 ' CG1' ' H ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.549 ' H ' ' CG1' ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' K' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.474 ' O ' ' CG1' ' L' ' 36' ' ' VAL . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.463 ' OXT' ' CG1' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.549 ' O ' ' NZ ' ' M' ' 28' ' ' LYS . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.28 153.67 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.82 -21.37 0.25 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-N 116.106 -0.497 . . . . 0.0 112.054 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 29.8 p -151.15 169.35 22.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.124 0.462 . . . . 0.0 111.162 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -31.36 134.76 0.07 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.673 -177.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' M' ' 20' ' ' PHE . 88.3 tttt 179.92 -50.48 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.881 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' N' ' 29' ' ' GLY . . . -71.14 58.41 1.08 Allowed Glycine 0 CA--C 1.538 1.53 0 CA-C-N 113.675 -1.602 . . . . 0.0 113.929 -178.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.13 -169.43 3.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 117.31 0.555 . . . . 0.0 109.691 -179.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.427 HG23 HD12 ' M' ' 31' ' ' ILE . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 45.8 p90 -146.26 154.82 42.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.981 0.42 . . . . 0.0 110.217 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.36 152.82 44.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.339 -179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t -127.0 132.85 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.855 -179.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.622 ' N ' ' CD2' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.616 ' CB ' HD22 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -89.65 136.2 33.17 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.873 0.368 . . . . 0.0 110.537 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 89.4 mt-10 -134.95 143.97 47.18 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' P' ' 13' ' ' HIS . 32.8 m -138.85 166.41 22.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 -179.052 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.539 ' N ' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.403 ' OE1' ' CG ' ' P' ' 15' ' ' GLN . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.616 HD22 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.2 135.2 49.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.411 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -72.59 130.81 41.44 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.106 0.479 . . . . 0.0 110.663 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p -138.98 161.53 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.53 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.55 ' HE2' ' CG1' ' Q' ' 40' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.643 ' ND1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.459 ' NE2' ' O ' ' R' ' 36' ' ' VAL . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.404 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.485 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.41 ' O ' ' OXT' ' P' ' 40' ' ' VAL . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.466 ' ND1' ' O ' ' P' ' 13' ' ' HIS . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.643 ' CD2' ' ND1' ' P' ' 14' ' ' HIS . 3.3 p-80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . 0.405 ' CB ' ' O ' ' P' ' 15' ' ' GLN . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' CD1' ' C ' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.499 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.499 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . 0.413 ' CB ' ' O ' ' P' ' 34' ' ' LEU . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.55 ' CG1' ' HE2' ' P' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' H ' ' R' ' 15' ' ' GLN . 85.9 t60 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.566 ' H ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . 0.416 HG22 HD12 ' R' ' 31' ' ' ILE . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . 0.578 ' N ' ' CD2' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -113.9 137.85 51.11 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.889 0.376 . . . . 0.0 110.42 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -73.76 128.4 35.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.492 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.578 ' CD1' HE21 ' B' ' 15' ' ' GLN . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.432 ' C ' ' H ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.432 ' H ' ' C ' ' A' ' 22' ' ' GLU . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 32' ' ' ILE . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.421 ' CG1' ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.421 ' N ' ' CG1' ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.435 ' CG2' ' N ' ' A' ' 40' ' ' VAL . 2.8 p -126.3 160.57 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.435 ' N ' ' CG2' ' A' ' 39' ' ' VAL . 13.5 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.998 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -84.08 139.44 32.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 110.564 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.33 125.08 27.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.369 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.51 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 26.7 t60 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 60.5 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.446 ' CE ' ' SD ' ' C' ' 35' ' ' MET . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.421 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t -135.5 139.71 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.453 ' OXT' ' O ' ' C' ' 40' ' ' VAL . 86.7 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.301 178.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -105.78 132.74 51.53 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.748 0.309 . . . . 0.0 110.66 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 141.39 49.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.494 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -121.85 130.65 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.231 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.463 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.569 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.484 ' N ' ' CE1' ' B' ' 14' ' ' HIS . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.409 ' N ' HD11 ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.411 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.589 ' ND2' ' H ' ' C' ' 28' ' ' LYS . 8.9 t-20 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.589 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.432 HG22 HD13 ' C' ' 32' ' ' ILE . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.426 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.445 ' CG2' ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.453 ' O ' ' OXT' ' B' ' 40' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.574 ' CG1' ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.574 ' H ' ' CG1' ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' D' ' 12' ' ' VAL . 7.8 m80 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 54.3 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' D' ' 23' ' ' ASP . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.422 ' H ' HG11 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.545 ' HG ' ' H ' ' C' ' 28' ' ' LYS . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.427 HG23 HD13 ' D' ' 32' ' ' ILE . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' OE1' ' B' ' 15' ' ' GLN . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.467 ' O ' ' OXT' ' D' ' 40' ' ' VAL . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.51 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . 0.428 ' H ' ' H ' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . 0.428 ' H ' ' H ' ' E' ' 9' ' ' GLY . 97.8 m-85 -105.38 134.41 48.54 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.738 0.304 . . . . 0.0 110.474 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -122.2 132.59 54.52 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.253 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.502 ' O ' ' CG1' ' D' ' 12' ' ' VAL . 59.1 t -117.23 129.93 72.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.646 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.646 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.478 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.42 HG23 HD12 ' E' ' 31' ' ' ILE . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.412 HG23 HD12 ' E' ' 32' ' ' ILE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.462 HD11 ' N ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.462 ' N ' HD11 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -108.56 133.87 52.1 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.876 0.37 . . . . 0.0 110.504 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -80.38 158.17 26.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.095 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m -109.8 105.75 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.496 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 80.1 tt0 -128.9 131.42 47.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.517 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 2.6 p-10 50.2 46.42 24.83 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.945 -0.571 . . . . 0.0 112.156 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -85.25 -171.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.456 0.646 . . . . 0.0 109.569 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.93 -31.35 3.69 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.078 -0.964 . . . . 0.0 111.112 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' F' ' 27' ' ' ASN . 71.1 p -142.23 -129.66 0.09 Allowed 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 121.077 0.465 . . . . 0.0 111.374 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' F' ' 23' ' ' ASP . 70.1 m-80 53.37 151.86 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.036 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt -71.77 46.17 0.12 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.886 -1.052 . . . . 0.0 112.388 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.419 HG23 HD12 ' F' ' 32' ' ' ILE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.425 ' O ' ' CG2' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.426 ' OE1' ' CG1' ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.415 ' CE ' ' HE2' ' G' ' 14' ' ' HIS . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.626 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 33.9 tt0 -170.38 179.81 3.28 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.626 ' H ' ' CG ' ' G' ' 22' ' ' GLU . 66.1 t0 -59.14 47.13 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 114.576 -1.193 . . . . 0.0 113.492 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 31.9 m -83.36 -161.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.8 -35.52 24.8 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 118.637 -1.744 . . . . 0.0 111.344 -177.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.447 ' O ' ' O ' ' G' ' 27' ' ' ASN . 44.1 t -157.47 114.08 2.95 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.763 175.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.447 ' O ' ' O ' ' G' ' 26' ' ' SER . 78.8 m-20 -47.73 179.67 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -77.86 -47.9 17.7 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 118.275 -1.37 . . . . 0.0 108.543 176.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.499 ' CA ' ' HZ3' ' H' ' 28' ' ' LYS . . . 80.66 51.84 4.68 Favored Glycine 0 CA--C 1.54 1.647 0 CA-C-O 117.843 -1.532 . . . . 0.0 115.646 174.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' G' ' 29' ' ' GLY . . . 180.0 -178.42 0.42 Allowed 'General case' 0 C--O 1.24 0.599 0 CA-C-N 121.71 2.755 . . . . 0.0 115.358 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m -116.47 161.03 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 78.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.279 179.396 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.41 133.46 51.89 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -89.84 101.56 14.26 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.456 ' O ' ' CG2' ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.609 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' I' ' 24' ' ' VAL . 10.8 t0 -152.69 55.12 0.79 Allowed 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.573 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 8.0 p -91.43 -124.17 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -175.37 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.573 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . -75.31 -39.84 35.21 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 116.974 -2.536 . . . . 0.0 112.385 -175.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.6 p -156.9 111.89 2.81 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 119.521 1.66 . . . . 0.0 112.264 174.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.529 ' OD1' ' ND2' ' I' ' 27' ' ' ASN . 13.3 m-80 -49.36 162.4 0.14 Allowed 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.499 ' HZ3' ' CA ' ' G' ' 29' ' ' GLY . 25.9 tptp -70.56 -47.48 60.09 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 119.124 -1.03 . . . . 0.0 109.785 176.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.49 58.89 0.84 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.401 ' O ' ' O ' ' G' ' 38' ' ' GLY . 4.9 t -71.02 133.32 32.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.514 -179.554 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.01 137.56 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.777 0.322 . . . . 0.0 110.583 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -87.57 118.23 26.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.431 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.595 ' HE2' ' CE1' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.508 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' J' ' 23' ' ' ASP . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' H' ' 23' ' ' ASP . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.418 ' O ' ' HA2' ' H' ' 33' ' ' GLY . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.426 ' CG1' ' OE1' ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.41 ' N ' ' CG2' ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.42 ' O ' ' O ' ' K' ' 13' ' ' HIS . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.595 ' CE1' ' HE2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' CA ' ' L' ' 37' ' ' GLY . 84.9 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.509 ' CD1' ' N ' ' J' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 66.5 m-20 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.453 HG22 ' H ' ' K' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' K' ' 35' ' ' MET . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.51 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' L' ' 26' ' ' SER . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.412 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.4 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.453 ' H ' HG22 ' J' ' 31' ' ' ILE . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.404 HD11 HG21 ' K' ' 32' ' ' ILE . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' L' ' 35' ' ' MET . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.6 m-85 -107.7 138.72 43.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 110.45 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -128.57 145.8 51.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.333 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -135.04 160.29 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.458 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.421 ' C ' ' H ' ' L' ' 26' ' ' SER . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.465 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.4 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.505 ' N ' ' CD2' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.577 ' CA ' ' NE2' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.491 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 m80 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.61 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t -50.3 165.84 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.512 ' N ' ' CG1' ' M' ' 24' ' ' VAL . . . -173.86 19.44 0.05 OUTLIER Glycine 0 CA--C 1.518 0.223 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 30.5 m -80.55 -130.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -100.58 161.76 13.39 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.033 0.444 . . . . 0.0 111.149 179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -41.11 -37.62 0.91 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.925 178.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -132.49 79.03 0.35 Allowed Glycine 0 N--CA 1.472 1.083 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.17 109.93 7.07 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 -176.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . 0.412 HD13 HG23 ' M' ' 32' ' ' ILE . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.467 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -109.83 135.72 50.27 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.879 0.371 . . . . 0.0 110.703 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -141.07 159.21 42.7 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.745 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 1.0 OUTLIER -138.56 168.77 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 -179.796 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.742 ' H ' ' HZ1' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.61 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . 0.754 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.515 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.21 133.46 53.54 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.707 0.289 . . . . 0.0 110.537 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . 0.414 ' HG2' ' HE2' ' N' ' 14' ' ' HIS . 79.1 tt0 -159.09 158.2 32.5 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.527 ' O ' ' NE2' ' N' ' 14' ' ' HIS . 3.2 t -124.01 168.98 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.457 ' ND1' ' C ' ' O' ' 13' ' ' HIS . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.736 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.539 ' O ' ' CB ' ' N' ' 26' ' ' SER . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.742 ' HZ1' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.655 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . 0.497 ' O ' ' HA2' ' N' ' 33' ' ' GLY . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.515 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' P' ' 39' ' ' VAL . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -118.96 139.77 51.12 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.682 0.277 . . . . 0.0 110.327 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 96.8 mt-10 -76.39 116.78 17.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.376 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m -120.37 132.63 69.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.736 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.486 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.486 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.655 HD22 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.754 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . 0.424 HD12 ' H ' ' P' ' 35' ' ' MET . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 35' ' ' MET . . . . . 0.424 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.521 ' CG1' ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.521 ' N ' ' CG1' ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' P' ' 11' ' ' GLU . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.502 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . 0.418 ' O ' ' O ' ' R' ' 33' ' ' GLY . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' R' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.466 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.475 ' C ' ' HZ1' ' E' ' 28' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 . . . . . 0 CA--C 1.527 0.087 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.57 HG13 ' C ' ' B' ' 12' ' ' VAL . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.912 HD11 HG21 ' C' ' 36' ' ' VAL . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.732 ' OD1' HG11 ' B' ' 24' ' ' VAL . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.844 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.408 ' O ' ' C ' ' A' ' 28' ' ' LYS . 36.6 m120 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.442 ' O ' HD12 ' B' ' 34' ' ' LEU . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.432 ' O ' HD13 ' G' ' 31' ' ' ILE . 59.3 t . . . . . 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.875 0.369 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.722 HG21 ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 2.3 p-80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.708 HD21 HG11 ' D' ' 36' ' ' VAL . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.732 HG11 ' OD1' ' A' ' 23' ' ' ASP . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.512 HD12 ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.484 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.903 ' O ' HD13 ' H' ' 31' ' ' ILE . 57.4 t . . . . . 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.722 ' O ' HG21 ' B' ' 12' ' ' VAL . 2.0 p . . . . . 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.499 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.671 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.439 HE22 ' CB ' ' F' ' 36' ' ' VAL . 26.9 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.576 ' C ' HD12 ' C' ' 17' ' ' LEU . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.633 HD21 HG11 ' E' ' 36' ' ' VAL . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.529 ' CZ ' HD23 ' C' ' 17' ' ' LEU . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.58 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.564 ' O ' ' N ' ' C' ' 29' ' ' GLY . 92.7 m-20 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.534 HG23 ' CG2' ' D' ' 31' ' ' ILE . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.67 HG23 HD13 ' C' ' 34' ' ' LEU . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.88 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.88 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 17' ' ' LEU . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.621 ' HA ' HG21 ' D' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.451 ' O ' HG23 ' C' ' 12' ' ' VAL . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.613 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.561 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.638 HG11 ' HG2' ' E' ' 28' ' ' LYS . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.534 ' CG2' HG23 ' C' ' 31' ' ' ILE . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' D' ' 32' ' ' ILE . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.401 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.708 HG11 HD21 ' B' ' 17' ' ' LEU . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.625 HG12 HG23 ' D' ' 40' ' ' VAL . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.625 HG23 HG12 ' D' ' 39' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t . . . . . 0 N--CA 1.466 0.357 0 CA-C-O 120.754 0.311 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' HB3' ' E' ' 21' ' ' ALA . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.515 ' HB3' ' CE1' ' E' ' 19' ' ' PHE . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' F' ' 29' ' ' GLY . 17.3 t30 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.638 ' HG2' HG11 ' D' ' 24' ' ' VAL . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.436 ' O ' HG23 ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.408 ' O ' HD12 ' F' ' 34' ' ' LEU . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.643 HG12 HD11 ' F' ' 34' ' ' LEU . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.535 HG12 ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.535 ' N ' HG12 ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.674 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 . . . . . 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 CA--C 1.529 0.152 0 N-CA-C 113.412 0.893 . . . . 0.0 113.412 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.801 HD12 HG22 ' R' ' 39' ' ' VAL . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.43 HD13 HG21 ' F' ' 32' ' ' ILE . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.643 HD11 HG12 ' E' ' 36' ' ' VAL . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.534 ' N ' HD12 ' F' ' 34' ' ' LEU . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.613 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.424 ' O ' HD13 ' L' ' 31' ' ' ILE . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.47 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 12' ' ' VAL . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 . . . . . 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 CA--C 1.547 0.832 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.432 HD13 ' O ' ' A' ' 39' ' ' VAL . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.535 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.884 0.373 . . . . 0.0 110.962 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' I' ' 12' ' ' VAL . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.492 ' HB2' ' HD1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.575 ' OE1' HG13 ' K' ' 36' ' ' VAL . 8.6 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.465 ' N ' HD12 ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' I' ' 26' ' ' SER . 88.4 m-20 . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.903 HD13 ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.431 HG22 HD11 ' I' ' 34' ' ' LEU . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.571 HD23 ' H ' ' H' ' 35' ' ' MET . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.571 ' H ' HD23 ' H' ' 34' ' ' LEU . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.625 ' H ' ' HA2' ' I' ' 38' ' ' GLY . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.495 HG23 ' O ' ' H' ' 38' ' ' GLY . 44.7 t . . . . . 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 120.611 0.243 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' H' ' 12' ' ' VAL . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.415 ' OE1' HG12 ' K' ' 36' ' ' VAL . 18.1 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.945 HD11 HG11 ' K' ' 36' ' ' VAL . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.535 ' HB2' HG22 ' J' ' 24' ' ' VAL . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 1.028 HG12 ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 1.028 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 4.9 t30 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.53 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.578 ' CD1' HG13 ' C' ' 39' ' ' VAL . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.66 HG23 HD13 ' I' ' 34' ' ' LEU . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.682 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.682 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.47 ' CG2' HD21 ' J' ' 34' ' ' LEU . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.625 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.594 ' CG2' HD12 ' P' ' 31' ' ' ILE . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.585 ' O ' HG13 ' I' ' 40' ' ' VAL . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.598 HD22 HD12 ' I' ' 17' ' ' LEU . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 21' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' L' ' 30' ' ' ALA . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.539 HG23 ' H ' ' J' ' 26' ' ' SER . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.539 ' H ' HG23 ' J' ' 24' ' ' VAL . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.467 ' NZ ' HG22 ' D' ' 40' ' ' VAL . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.468 ' O ' ' OD1' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.561 ' CD1' HG22 ' D' ' 39' ' ' VAL . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.777 HG22 HD11 ' K' ' 34' ' ' LEU . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.665 HD23 ' N ' ' J' ' 35' ' ' MET . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.665 ' N ' HD23 ' J' ' 34' ' ' LEU . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.583 HG22 HD22 ' J' ' 34' ' ' LEU . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.471 ' CG2' HD11 ' P' ' 31' ' ' ILE . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.615 ' H ' HG23 ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.415 HD21 ' CE1' ' L' ' 19' ' ' PHE . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' J' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.413 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.59 HG13 ' N ' ' K' ' 25' ' ' GLY . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.59 ' N ' HG13 ' K' ' 24' ' ' VAL . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.401 ' H ' ' HA ' ' J' ' 28' ' ' LYS . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.462 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.688 HG23 HD13 ' K' ' 34' ' ' LEU . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.836 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.836 HD12 ' C ' ' K' ' 33' ' ' GLY . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.945 HG11 HD11 ' I' ' 17' ' ' LEU . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.457 HG12 HG13 ' K' ' 40' ' ' VAL . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.615 HG23 ' H ' ' J' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.528 HG23 ' O ' ' L' ' 12' ' ' VAL . 6.3 m . . . . . 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.415 ' CE1' HD21 ' K' ' 17' ' ' LEU . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.863 ' O ' HG13 ' L' ' 24' ' ' VAL . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.863 HG13 ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.433 ' HB2' ' OD2' ' J' ' 23' ' ' ASP . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.424 HD13 ' O ' ' F' ' 38' ' ' GLY . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.564 HD12 ' O ' ' K' ' 34' ' ' LEU . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.508 HG13 ' HG ' ' L' ' 34' ' ' LEU . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 13' ' ' HIS . . . . . 0.474 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.62 ' HD1' ' CD2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.452 ' OE1' HD11 ' M' ' 17' ' ' LEU . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.455 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t . . . . . 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' N' ' 13' ' ' HIS . 67.2 t . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.731 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' HD1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.576 HE21 HG22 ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.412 HD11 HG21 ' P' ' 36' ' ' VAL . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.634 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.628 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.512 ' O ' HD12 ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.468 HG22 ' O ' ' N' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.863 HD21 HG21 ' Q' ' 36' ' ' VAL . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.548 ' H ' ' HB2' ' P' ' 22' ' ' GLU . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.624 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.624 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.628 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.527 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.527 HD12 ' O ' ' O' ' 33' ' ' GLY . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.575 ' O ' HG23 ' O' ' 36' ' ' VAL . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.696 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m80 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.424 ' HA ' ' O ' ' Q' ' 14' ' ' HIS . 73.2 m-70 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.422 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.416 ' HB3' ' CZ ' ' P' ' 19' ' ' PHE . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.548 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.594 HD12 ' CG2' ' I' ' 39' ' ' VAL . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.634 HD13 ' CD1' ' N' ' 19' ' ' PHE . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.74 HD23 ' N ' ' P' ' 35' ' ' MET . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.74 ' N ' HD23 ' P' ' 34' ' ' LEU . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.576 HG22 HE21 ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.696 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.427 ' HB2' HE21 ' Q' ' 15' ' ' GLN . 3.6 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.613 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.404 ' CB ' ' NZ ' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.416 HG23 HG23 ' P' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' R' ' 34' ' ' LEU . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.863 HG21 HD21 ' O' ' 17' ' ' LEU . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.623 HG12 ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.623 ' N ' HG12 ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.469 ' HB3' ' CG1' ' R' ' 24' ' ' VAL . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.469 ' CG1' ' HB3' ' R' ' 21' ' ' ALA . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.435 ' O ' HG23 ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' Q' ' 34' ' ' LEU . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.632 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.801 HG22 HD12 ' F' ' 31' ' ' ILE . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.707 0.289 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.582 HG11 ' HA ' ' B' ' 12' ' ' VAL . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 17' ' ' LEU . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.794 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.811 ' O ' HG13 ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.459 ' H ' HG13 ' B' ' 24' ' ' VAL . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.459 ' O ' HG21 ' A' ' 12' ' ' VAL . 9.4 pt-20 . . . . . 0 N--CA 1.461 0.092 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.582 ' HA ' HG11 ' A' ' 12' ' ' VAL . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.679 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.541 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.768 HD11 HG11 ' D' ' 36' ' ' VAL . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.541 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.993 HG12 ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.993 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.599 HD11 HG13 ' N' ' 39' ' ' VAL . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.648 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.467 ' O ' ' CD1' ' H' ' 31' ' ' ILE . 13.5 t . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.496 HG23 ' ND1' ' C' ' 14' ' ' HIS . 16.7 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.528 ' H ' ' CE1' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' HG23 ' C' ' 12' ' ' VAL . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.503 ' OE1' HG13 ' F' ' 36' ' ' VAL . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.476 ' O ' HD23 ' C' ' 17' ' ' LEU . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.782 HD11 HG11 ' E' ' 36' ' ' VAL . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.541 HG22 ' CA ' ' D' ' 25' ' ' GLY . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.455 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.446 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.477 ' O ' ' HB2' ' C' ' 30' ' ' ALA . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' C' ' 29' ' ' GLY . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' C' ' 32' ' ' ILE . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.483 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.416 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.613 ' HB ' HG22 ' D' ' 36' ' ' VAL . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.747 ' O ' HG21 ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.648 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.574 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.519 ' OE1' ' N ' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' H ' ' C' ' 13' ' ' HIS . 5.9 m-70 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.79 HD11 HG11 ' F' ' 36' ' ' VAL . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.541 ' CA ' HG22 ' C' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 10.0 m-20 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.446 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.716 HD11 HG23 ' P' ' 39' ' ' VAL . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.412 HD13 ' CD1' ' B' ' 19' ' ' PHE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.59 ' N ' HD23 ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.768 HG11 HD11 ' B' ' 17' ' ' LEU . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.905 HG13 HD12 ' J' ' 31' ' ' ILE . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.438 ' H ' HG11 ' E' ' 39' ' ' VAL . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t . . . . . 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.426 ' O ' ' CB ' ' F' ' 13' ' ' HIS . 40.6 m-70 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.604 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 49.1 m-70 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.516 ' C ' HD12 ' E' ' 17' ' ' LEU . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.599 HD11 ' OE1' ' D' ' 15' ' ' GLN . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.653 HG12 ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.653 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.642 ' O ' HG13 ' Q' ' 39' ' ' VAL . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.509 HG22 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.484 HD12 ' N ' ' E' ' 35' ' ' MET . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.484 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.782 HG11 HD11 ' C' ' 17' ' ' LEU . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.84 HG21 HD11 ' J' ' 31' ' ' ILE . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.432 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.642 ' C ' HD12 ' F' ' 17' ' ' LEU . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.642 HD12 ' C ' ' F' ' 16' ' ' LYS . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.569 ' OE1' ' N ' ' F' ' 22' ' ' GLU . 46.4 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' R' ' 39' ' ' VAL . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' D' ' 19' ' ' PHE . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.703 HD21 ' CG2' ' F' ' 36' ' ' VAL . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.79 HG11 HD11 ' D' ' 17' ' ' LEU . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.795 HG23 HD12 ' L' ' 31' ' ' ILE . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.533 HG22 ' O ' ' F' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.573 HG21 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.626 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.586 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.6 HD21 HG11 ' I' ' 36' ' ' VAL . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.522 HG13 ' O ' ' G' ' 18' ' ' VAL . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.533 0 N-CA-C 114.727 1.38 . . . . 0.0 114.727 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.409 HG22 HG12 ' H' ' 31' ' ' ILE . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.564 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.452 0.168 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.603 HG23 ' O ' ' H' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.626 ' CE1' ' O ' ' G' ' 13' ' ' HIS . 7.2 t-80 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.586 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.51 HD11 HG13 ' K' ' 36' ' ' VAL . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.463 HG13 ' CG1' ' I' ' 18' ' ' VAL . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.49 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.619 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 . . . . . 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.109 0 CA-C-O 119.108 -0.829 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.564 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.584 ' HA3' HD13 ' N' ' 31' ' ' ILE . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.507 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p . . . . . 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.895 0.379 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.518 ' CG ' HD11 ' I' ' 17' ' ' LEU . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.439 ' C ' HD12 ' I' ' 17' ' ' LEU . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.856 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.463 ' CG1' HG13 ' H' ' 18' ' ' VAL . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.481 ' HB1' ' HE3' ' I' ' 28' ' ' LYS . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.448 ' HA ' ' CB ' ' H' ' 23' ' ' ASP . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.413 ' O ' ' O ' ' I' ' 26' ' ' SER . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.574 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.594 HG23 HD13 ' I' ' 34' ' ' LEU . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.813 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.813 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.6 HG11 HD21 ' G' ' 17' ' ' LEU . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.626 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.411 ' H ' ' CG1' ' I' ' 12' ' ' VAL . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CB ' HG13 ' L' ' 40' ' ' VAL . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' HA ' ' K' ' 15' ' ' GLN . 0.8 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.544 ' H ' ' HG3' ' K' ' 15' ' ' GLN . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.544 ' C ' HD12 ' J' ' 17' ' ' LEU . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.854 HD21 HG21 ' L' ' 36' ' ' VAL . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.906 HG12 ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.906 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.679 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.905 HD12 HG13 ' D' ' 39' ' ' VAL . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.588 ' CG2' HD21 ' K' ' 34' ' ' LEU . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.534 HD12 ' O ' ' I' ' 34' ' ' LEU . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.452 ' H ' HD12 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.626 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.661 ' HD1' ' CE1' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.578 ' HA ' ' CD2' ' J' ' 14' ' ' HIS . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.416 ' CD2' HD13 ' J' ' 17' ' ' LEU . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.431 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.434 ' HB3' HG22 ' L' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 1.038 HG12 ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 1.038 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 26.1 m120 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.665 HD11 HG21 ' F' ' 39' ' ' VAL . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' J' ' 32' ' ' ILE . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.51 HG13 HD11 ' H' ' 17' ' ' LEU . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.548 HG22 ' N ' ' L' ' 13' ' ' HIS . 10.4 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CE1' ' HD1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.474 ' O ' HG23 ' L' ' 24' ' ' VAL . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.592 ' C ' HG23 ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.592 HG23 ' C ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.795 HD12 HG23 ' F' ' 39' ' ' VAL . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.492 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.854 HG21 HD21 ' J' ' 17' ' ' LEU . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.538 ' HB ' HD11 ' R' ' 31' ' ' ILE . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.46 HG13 ' CB ' ' J' ' 13' ' ' HIS . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.509 ' OE1' HG12 ' O' ' 36' ' ' VAL . 7.9 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' N' ' 17' ' ' LEU . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 36.6 t . . . . . 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.408 ' O ' HG23 ' M' ' 39' ' ' VAL . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.49 ' CD2' HD12 ' M' ' 17' ' ' LEU . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.584 HD13 ' HA3' ' H' ' 38' ' ' GLY . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.599 HG13 HD11 ' B' ' 31' ' ' ILE . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.566 HG22 ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.566 ' N ' HG22 ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.464 ' OD1' ' OD2' ' O' ' 23' ' ' ASP . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.697 HD23 ' N ' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.509 HG12 ' OE1' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.546 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.419 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.577 HG22 ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.577 ' N ' HG22 ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.662 0.267 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.728 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.493 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 28.0 t30 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.457 ' C ' ' O ' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.653 HD12 ' H ' ' P' ' 35' ' ' MET . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.653 ' H ' HD12 ' P' ' 34' ' ' LEU . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' N' ' 17' ' ' LEU . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.546 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.716 HG23 HD11 ' D' ' 31' ' ' ILE . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.437 ' H ' HG23 ' P' ' 40' ' ' VAL . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.728 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.569 HD23 ' C ' ' Q' ' 17' ' ' LEU . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.46 ' N ' HD23 ' Q' ' 17' ' ' LEU . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.598 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.541 HG12 ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.541 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.642 HG13 ' O ' ' E' ' 29' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.559 ' N ' HG12 ' Q' ' 39' ' ' VAL . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' R' ' 13' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.596 ' C ' HD12 ' R' ' 17' ' ' LEU . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.596 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.718 HG22 ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.718 ' H ' HG22 ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' L' ' 39' ' ' VAL . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.524 HG22 HD22 ' R' ' 34' ' ' LEU . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.72 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.559 ' HB ' HD11 ' F' ' 31' ' ' ILE . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.812 0.339 . . . . 0.0 110.319 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.496 ' NE2' ' O ' ' C' ' 36' ' ' VAL . 33.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.536 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.536 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.531 HD11 ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.411 ' O ' HD12 ' B' ' 34' ' ' LEU . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t . . . . . 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.564 ' HE1' HG23 ' C' ' 12' ' ' VAL . 7.3 m-70 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.75 ' C ' HD22 ' B' ' 17' ' ' LEU . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.75 HD22 ' C ' ' B' ' 16' ' ' LYS . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.517 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' B' ' 30' ' ' ALA . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' B' ' 29' ' ' GLY . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.411 HD12 ' O ' ' A' ' 34' ' ' LEU . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.408 ' H ' HD12 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.408 HG22 HG11 ' C' ' 39' ' ' VAL . 83.5 t . . . . . 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.564 HG23 ' HE1' ' B' ' 14' ' ' HIS . 34.0 m . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.743 0.306 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.47 ' CB ' ' O ' ' D' ' 14' ' ' HIS . 12.1 p80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.667 ' HB3' HD21 ' C' ' 17' ' ' LEU . 27.0 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' C' ' 17' ' ' LEU . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.933 HD22 ' N ' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' E' ' 32' ' ' ILE . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.52 HG12 ' N ' ' C' ' 25' ' ' GLY . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.491 HD11 ' HB ' ' O' ' 39' ' ' VAL . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.799 HG22 HD11 ' D' ' 34' ' ' LEU . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.498 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.498 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.496 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.475 ' CD2' ' HB3' ' E' ' 13' ' ' HIS . 34.4 p80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.68 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.592 HD12 HD22 ' E' ' 17' ' ' LEU . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.473 ' CD1' HD13 ' F' ' 32' ' ' ILE . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.54 ' H ' ' CD ' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.514 HG12 ' OG ' ' E' ' 26' ' ' SER . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.837 HG23 HD13 ' D' ' 34' ' ' LEU . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.665 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.837 HD13 HG23 ' D' ' 32' ' ' ILE . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.598 HG11 HD21 ' B' ' 17' ' ' LEU . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.663 ' CG2' HD11 ' J' ' 31' ' ' ILE . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.5 HG12 ' N ' ' E' ' 13' ' ' HIS . 49.2 t . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.5 ' N ' HG12 ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.592 HD22 HD12 ' D' ' 17' ' ' LEU . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.54 ' CD ' ' H ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.501 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.501 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.514 ' OG ' HG12 ' D' ' 24' ' ' VAL . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 73.0 m-20 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.61 ' HZ2' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.934 HD11 HG13 ' Q' ' 39' ' ' VAL . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.509 HD13 ' CD2' ' C' ' 19' ' ' PHE . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.644 HD12 ' O ' ' D' ' 34' ' ' LEU . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.446 ' H ' HD12 ' E' ' 34' ' ' LEU . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' C' ' 17' ' ' LEU . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.512 ' ND1' ' N ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.512 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 . . . . . 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.629 HD12 HG11 ' Q' ' 39' ' ' VAL . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.473 HD13 ' CD1' ' D' ' 19' ' ' PHE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.706 HD23 ' O ' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.601 ' HB ' HD21 ' F' ' 34' ' ' LEU . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' E' ' 36' ' ' VAL . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.606 ' HB ' HD11 ' L' ' 31' ' ' ILE . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.463 ' O ' HG13 ' G' ' 12' ' ' VAL . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.466 ' HD1' ' C ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.53 ' O ' HD22 ' G' ' 17' ' ' LEU . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.53 HD22 ' O ' ' G' ' 16' ' ' LYS . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.416 HG23 ' CG2' ' H' ' 31' ' ' ILE . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.691 HD23 ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.691 ' H ' HD23 ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.403 ' O ' ' CD1' ' M' ' 31' ' ' ILE . 42.6 t . . . . . 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.814 0.34 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.409 ' O ' HG23 ' G' ' 12' ' ' VAL . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.665 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.665 ' H ' ' CG ' ' H' ' 14' ' ' HIS . 7.8 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.627 HD12 HD22 ' I' ' 17' ' ' LEU . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.472 ' HZ ' HD13 ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.731 ' HB1' HG13 ' I' ' 24' ' ' VAL . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.181 0 CA-C-O 119.877 -0.402 . . . . 0.0 113.356 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.416 ' CG2' HG23 ' G' ' 31' ' ' ILE . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.645 ' O ' HG11 ' I' ' 39' ' ' VAL . 81.0 t . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.462 0.173 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.627 HD22 HD12 ' H' ' 17' ' ' LEU . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.972 HG12 ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.972 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.404 HG21 HD13 ' I' ' 32' ' ' ILE . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.615 ' O ' HG11 ' J' ' 39' ' ' VAL . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.645 HG11 ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.489 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.647 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.602 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.944 HD21 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' D' ' 39' ' ' VAL . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.944 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.663 HD11 ' CG2' ' D' ' 39' ' ' VAL . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.405 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.55 HD23 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.569 HG11 HD21 ' H' ' 17' ' ' LEU . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.615 HG11 ' O ' ' I' ' 38' ' ' GLY . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.475 HG13 ' ND1' ' H' ' 13' ' ' HIS . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 83.8 t60 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.616 ' O ' ' CD2' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.629 HD23 ' N ' ' K' ' 18' ' ' VAL . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.629 ' N ' HD23 ' K' ' 17' ' ' LEU . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.922 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.922 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.602 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.992 HD22 HG13 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.725 ' N ' HD23 ' K' ' 34' ' ' LEU . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.992 HG13 HD22 ' K' ' 34' ' ' LEU . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.505 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.455 ' O ' HD11 ' Q' ' 31' ' ' ILE . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.56 HG23 HD12 ' Q' ' 31' ' ' ILE . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.44 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.502 HD21 ' NE2' ' K' ' 15' ' ' GLN . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.606 HD11 ' HB ' ' F' ' 39' ' ' VAL . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.479 HD23 ' C ' ' L' ' 34' ' ' LEU . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' HG23 ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.512 ' O ' HG13 ' L' ' 36' ' ' VAL . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.558 HG11 ' HA2' ' Q' ' 29' ' ' GLY . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.562 HG12 ' O ' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' O' ' 36' ' ' VAL . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.552 ' H ' HG21 ' N' ' 24' ' ' VAL . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 87.5 t . . . . . 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.253 0 CA-C-O 121.252 0.548 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.428 HG22 ' N ' ' M' ' 33' ' ' GLY . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 33' ' ' GLY . . . . . 0.428 ' N ' HG22 ' M' ' 32' ' ' ILE . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 120.938 0.399 . . . . 0.0 110.56 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.484 ' CG ' ' CD2' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 51.4 m80 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.684 HD22 HD12 ' M' ' 17' ' ' LEU . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CE2' ' HB3' ' N' ' 17' ' ' LEU . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' O' ' 23' ' ' ASP . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.53 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.53 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.905 HG22 ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.905 ' H ' HG22 ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' N' ' 26' ' ' SER . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.613 HD13 HG11 ' I' ' 39' ' ' VAL . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' O' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.531 ' H ' HD11 ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p . . . . . 0 N--CA 1.468 0.437 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.484 ' CD2' ' CG ' ' N' ' 13' ' ' HIS . 30.8 m80 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.582 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.668 ' H ' ' HZ2' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.786 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.786 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.41 ' SD ' ' HB2' ' P' ' 35' ' ' MET . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' M' ' 17' ' ' LEU . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' C' ' 31' ' ' ILE . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.473 ' N ' HG22 ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 47.5 t . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.465 ' NE2' HG21 ' R' ' 40' ' ' VAL . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.862 HD21 HG11 ' R' ' 36' ' ' VAL . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.666 ' O ' HG23 ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.415 HG23 ' N ' ' P' ' 25' ' ' GLY . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.415 ' N ' HG23 ' P' ' 24' ' ' VAL . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.706 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.668 ' HZ2' ' H ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 33' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.709 HD12 ' O ' ' O' ' 34' ' ' LEU . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.537 ' H ' HD12 ' P' ' 34' ' ' LEU . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.605 HG12 HD21 ' Q' ' 34' ' ' LEU . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' H ' ' Q' ' 38' ' ' GLY . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.511 ' O ' HG12 ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.402 HG12 ' CE1' ' P' ' 13' ' ' HIS . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.443 ' O ' ' O ' ' P' ' 13' ' ' HIS . 59.6 m170 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.529 ' CZ ' ' HB3' ' Q' ' 21' ' ' ALA . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.548 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.615 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.553 HD21 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.706 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.558 ' HA2' HG11 ' L' ' 39' ' ' VAL . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.56 HD12 HG23 ' K' ' 39' ' ' VAL . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.965 HD23 ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.965 ' N ' HD23 ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.803 HG22 HD22 ' Q' ' 34' ' ' LEU . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.934 HG13 HD11 ' E' ' 31' ' ' ILE . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.409 HG13 ' CG ' ' O' ' 13' ' ' HIS . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' R' ' 17' ' ' LEU . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.548 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 81.7 m-20 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.553 ' C ' HD21 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.55 HG23 ' CD1' ' R' ' 34' ' ' LEU . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.55 ' CD1' HG23 ' R' ' 32' ' ' ILE . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.862 HG11 HD21 ' P' ' 17' ' ' LEU . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.61 ' C ' ' HZ2' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.492 ' C ' ' NZ ' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.993 0.425 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 12' ' ' VAL . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.781 ' CD1' HG21 ' C' ' 36' ' ' VAL . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.641 HG12 ' N ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.641 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.427 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.418 ' O ' HG22 ' B' ' 36' ' ' VAL . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 CA--C 1.528 0.117 0 CA-C-O 120.855 0.36 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.554 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 5.7 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.626 HD11 HG21 ' D' ' 36' ' ' VAL . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.436 ' H ' HG22 ' B' ' 24' ' ' VAL . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.46 ' O ' HG21 ' O' ' 39' ' ' VAL . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' N' ' 39' ' ' VAL . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.437 HD12 HG23 ' N' ' 39' ' ' VAL . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.563 HG22 HD11 ' C' ' 34' ' ' LEU . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 34' ' ' LEU . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t . . . . . 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 121.016 0.436 . . . . 0.0 110.512 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.587 ' HB2' ' HD1' ' D' ' 13' ' ' HIS . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.554 ' OE1' ' NE2' ' B' ' 15' ' ' GLN . 1.2 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.681 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.973 HD21 HG11 ' E' ' 36' ' ' VAL . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.518 ' HZ ' HD23 ' C' ' 17' ' ' LEU . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' B' ' 22' ' ' GLU . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.621 ' CB ' ' ND2' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.738 HG22 HG21 ' D' ' 24' ' ' VAL . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.621 ' ND2' ' CB ' ' C' ' 23' ' ' ASP . 2.5 m120 -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.613 HG23 HD13 ' C' ' 34' ' ' LEU . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.819 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.819 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.781 HG21 ' CD1' ' A' ' 17' ' ' LEU . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.894 HG23 HD11 ' I' ' 31' ' ' ILE . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.448 ' N ' HG12 ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' NE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.587 ' HD1' ' HB2' ' C' ' 13' ' ' HIS . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.552 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 11.6 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.612 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.738 HG21 HG22 ' C' ' 24' ' ' VAL . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.46 ' O ' HG22 ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.656 HG22 HD11 ' E' ' 34' ' ' LEU . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.612 ' CD2' HG22 ' C' ' 36' ' ' VAL . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.85 ' CG1' HG12 ' E' ' 36' ' ' VAL . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.706 HG23 HD11 ' J' ' 31' ' ' ILE . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' E' ' 12' ' ' VAL . 16.4 m . . . . . 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.651 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.431 HD12 ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.475 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.466 HD21 HG13 ' R' ' 40' ' ' VAL . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.437 ' CD1' HG23 ' Q' ' 39' ' ' VAL . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.729 HG23 HD13 ' E' ' 34' ' ' LEU . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.686 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.729 HD13 HG23 ' E' ' 32' ' ' ILE . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.973 HG11 HD21 ' C' ' 17' ' ' LEU . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.596 ' O ' HD12 ' L' ' 31' ' ' ILE . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.64 HG23 HD11 ' K' ' 31' ' ' ILE . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.521 HG22 ' O ' ' F' ' 38' ' ' GLY . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m . . . . . 0 N--CA 1.467 0.381 0 N-CA-C 110.419 -0.215 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 30.5 p-80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.651 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.489 ' C ' HD23 ' F' ' 17' ' ' LEU . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' E' ' 23' ' ' ASP . 37.1 tt0 . . . . . 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.403 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.545 HG11 ' HG ' ' D' ' 17' ' ' LEU . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.521 ' O ' HG22 ' E' ' 40' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.451 HG13 ' NE2' ' D' ' 13' ' ' HIS . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.481 HG23 ' O ' ' G' ' 12' ' ' VAL . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.426 ' NE2' HG12 ' I' ' 36' ' ' VAL . 17.9 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.699 HD11 HG11 ' I' ' 36' ' ' VAL . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.6 HG23 ' O ' ' G' ' 18' ' ' VAL . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.569 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 75.8 tt0 . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.63 0.253 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' H' ' 38' ' ' GLY . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.585 HG23 HD13 ' M' ' 31' ' ' ILE . 49.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 . . . . . 0 N--CA 1.465 0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.605 ' CG ' HG13 ' J' ' 40' ' ' VAL . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.636 ' C ' HD12 ' H' ' 17' ' ' LEU . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.776 ' N ' HD12 ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.502 ' CE1' ' HB3' ' H' ' 17' ' ' LEU . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' H' ' 23' ' ' ASP . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 . . . . . 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.553 2.458 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.542 ' HB3' HD22 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' G' ' 38' ' ' GLY . 97.7 t . . . . . 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 120.985 0.422 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.43 HE21 ' HG3' ' J' ' 15' ' ' GLN . 2.3 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.494 ' CD2' HG21 ' K' ' 36' ' ' VAL . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.504 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.504 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.894 HD11 HG23 ' C' ' 39' ' ' VAL . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.903 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.903 HD23 ' O ' ' I' ' 33' ' ' GLY . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.699 HG11 HD11 ' G' ' 17' ' ' LEU . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.52 HG11 HD13 ' N' ' 31' ' ' ILE . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.418 HG22 ' O ' ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CD2' HG11 ' L' ' 40' ' ' VAL . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 21' ' ' ALA . . . . . 0.405 ' HB1' ' OD2' ' J' ' 23' ' ' ASP . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.706 HD11 HG23 ' D' ' 39' ' ' VAL . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.824 HG22 HD11 ' K' ' 34' ' ' LEU . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.874 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.874 HD12 ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.771 HG11 HD21 ' H' ' 17' ' ' LEU . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.665 HG23 HD12 ' P' ' 31' ' ' ILE . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.605 HG13 ' CG ' ' H' ' 13' ' ' HIS . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.401 HG21 HD21 ' Q' ' 27' ' ' ASN . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.431 ' HA ' ' H ' ' J' ' 15' ' ' GLN . 3.1 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.706 HG12 ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.706 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' K' ' 27' ' ' ASN . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.64 HD11 HG23 ' E' ' 39' ' ' VAL . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.581 HG23 HD13 ' K' ' 34' ' ' LEU . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.697 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.824 HD11 HG22 ' J' ' 32' ' ' ILE . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.494 HG21 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.487 ' CG2' HD11 ' P' ' 31' ' ' ILE . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.401 HD23 ' C ' ' L' ' 17' ' ' LEU . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.596 HD12 ' O ' ' E' ' 38' ' ' GLY . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.5 HG23 HD12 ' R' ' 31' ' ' ILE . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' M' ' 14' ' ' HIS . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 13' ' ' HIS . . . . . 0.444 ' C ' ' CG ' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.486 ' CE1' ' HB ' ' M' ' 12' ' ' VAL . 3.0 m80 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.581 ' CD1' HG21 ' O' ' 36' ' ' VAL . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.385 0 N-CA-C 116.633 2.086 . . . . 0.0 116.633 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.585 HD13 HG23 ' G' ' 39' ' ' VAL . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 35' ' ' MET . . . . . 0.47 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.688 ' HB2' ' HD2' ' O' ' 13' ' ' HIS . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.542 HD23 ' HB2' ' M' ' 17' ' ' LEU . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' N' ' 17' ' ' LEU . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.806 ' OD2' HG23 ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.427 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.427 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.879 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.415 ' N ' ' CG ' ' N' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.779 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.52 HD13 HG11 ' I' ' 39' ' ' VAL . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.416 HG21 HD11 ' O' ' 34' ' ' LEU . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.43 HD12 ' O ' ' M' ' 34' ' ' LEU . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.454 HG13 ' HA3' ' B' ' 29' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.688 ' HD2' ' HB2' ' N' ' 13' ' ' HIS . 3.4 m80 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' Q' ' 36' ' ' VAL . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.419 ' CZ ' ' HB3' ' O' ' 17' ' ' LEU . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.806 HG23 ' OD2' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.744 ' N ' HG12 ' O' ' 24' ' ' VAL . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.879 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.779 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.404 HD13 HG21 ' O' ' 32' ' ' ILE . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.561 ' O ' HD12 ' P' ' 34' ' ' LEU . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.639 ' CG2' HG12 ' P' ' 36' ' ' VAL . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.548 HG22 ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.548 ' N ' HG22 ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.47 0.528 0 CA-C-O 120.752 0.311 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.571 HD22 HD12 ' O' ' 17' ' ' LEU . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 18' ' ' VAL . . . . . 0.423 HG13 ' O ' ' P' ' 18' ' ' VAL . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.728 HG12 ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.728 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.508 ' HA3' HG13 ' J' ' 39' ' ' VAL . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.665 HD12 HG23 ' J' ' 39' ' ' VAL . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.703 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.703 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.779 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.544 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.436 HG13 ' O ' ' P' ' 39' ' ' VAL . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.453 ' HB3' ' CE1' ' Q' ' 13' ' ' HIS . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.453 ' CE1' ' HB3' ' Q' ' 11' ' ' GLU . 30.1 m-70 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.47 ' CE1' HG23 ' R' ' 12' ' ' VAL . 89.6 m-70 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.579 HG23 ' O ' ' Q' ' 24' ' ' VAL . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' Q' ' 30' ' ' ALA . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.516 ' HB2' ' O ' ' Q' ' 29' ' ' GLY . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.449 ' CG2' HG21 ' L' ' 39' ' ' VAL . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.682 HD12 ' O ' ' P' ' 34' ' ' LEU . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.522 ' H ' HD12 ' Q' ' 34' ' ' LEU . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.779 HG22 ' CG2' ' P' ' 36' ' ' VAL . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.544 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' E' ' 31' ' ' ILE . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.489 ' O ' HG12 ' Q' ' 40' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.47 HG23 ' CE1' ' Q' ' 14' ' ' HIS . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.483 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 33.8 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB3' ' R' ' 21' ' ' ALA . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.438 ' HB3' ' CE2' ' R' ' 19' ' ' PHE . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.464 ' HA ' HG12 ' Q' ' 24' ' ' VAL . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.5 HD12 HG23 ' L' ' 39' ' ' VAL . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.543 HG11 HD13 ' P' ' 17' ' ' LEU . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.466 HG13 HD21 ' E' ' 27' ' ' ASN . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' O ' ' B' ' 12' ' ' VAL . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.761 ' CE1' ' HZ1' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.761 ' HZ1' ' CE1' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.434 ' HB3' ' CE2' ' A' ' 19' ' ' PHE . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.423 ' HG2' ' N ' ' A' ' 23' ' ' ASP . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.423 ' N ' ' HG2' ' A' ' 22' ' ' GLU . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.82 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.599 HG12 HD12 ' B' ' 31' ' ' ILE . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 38' ' ' GLY . 6.5 p . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 12' ' ' VAL . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.422 ' NE2' HG11 ' D' ' 40' ' ' VAL . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.842 HD11 HG11 ' D' ' 36' ' ' VAL . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.448 ' HB3' ' HZ1' ' D' ' 28' ' ' LYS . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.647 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.421 HG12 ' N ' ' B' ' 25' ' ' GLY . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.427 ' O ' ' O ' ' B' ' 27' ' ' ASN . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' N ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.828 HD13 ' O ' ' N' ' 38' ' ' GLY . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.405 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.441 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.56 ' CD2' ' NZ ' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 11.9 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.685 ' CD2' HD12 ' B' ' 17' ' ' LEU . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.533 ' HB3' ' H ' ' B' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.666 HG12 ' N ' ' C' ' 25' ' ' GLY . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.666 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.534 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.572 HD11 HG23 ' P' ' 39' ' ' VAL . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' C' ' 34' ' ' LEU . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.823 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.823 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.577 ' O ' HD12 ' J' ' 31' ' ' ILE . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.565 HG12 ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.565 ' N ' HG12 ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.587 HD12 ' N ' ' D' ' 17' ' ' LEU . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' D' ' 26' ' ' SER . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.479 ' H ' HG23 ' D' ' 24' ' ' VAL . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.457 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' B' ' 21' ' ' ALA . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.842 HG11 HD11 ' B' ' 17' ' ' LEU . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.551 HG13 ' O ' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.512 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.649 ' CE1' ' O ' ' F' ' 12' ' ' VAL . 23.1 m-70 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.437 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.413 ' H ' HG12 ' R' ' 39' ' ' VAL . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.422 ' O ' ' HB3' ' D' ' 28' ' ' LYS . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' E' ' 34' ' ' LEU . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.558 HG23 HD12 ' K' ' 31' ' ' ILE . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.649 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.017 0.437 . . . . 0.0 111.443 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.456 ' HB3' ' H ' ' E' ' 13' ' ' HIS . 23.0 p-80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.785 HD12 HG22 ' R' ' 39' ' ' VAL . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.525 HG21 HD23 ' D' ' 17' ' ' LEU . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.574 ' HB ' HD11 ' L' ' 31' ' ' ILE . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.512 HG13 ' H ' ' H' ' 12' ' ' VAL . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.641 HE22 HG23 ' J' ' 36' ' ' VAL . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 . . . . . 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.954 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.609 ' O ' HD11 ' M' ' 31' ' ' ILE . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 120.715 0.293 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.621 HG22 HG12 ' I' ' 12' ' ' VAL . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.582 HE22 HG22 ' K' ' 36' ' ' VAL . 25.7 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.711 HD21 HG21 ' J' ' 36' ' ' VAL . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.535 ' CG ' ' H ' ' H' ' 23' ' ' ASP . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.535 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.954 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.442 ' O ' HD23 ' I' ' 34' ' ' LEU . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.554 ' O ' HG23 ' I' ' 39' ' ' VAL . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p . . . . . 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.466 0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.621 HG12 HG22 ' H' ' 12' ' ' VAL . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.585 ' OE1' HD21 ' J' ' 17' ' ' LEU . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.886 HD11 HG21 ' K' ' 36' ' ' VAL . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.442 HG23 ' H ' ' I' ' 24' ' ' VAL . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 89.6 m-20 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.829 ' HZ2' ' HZ3' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.407 HD13 ' O ' ' C' ' 38' ' ' GLY . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.456 HD22 HG13 ' I' ' 36' ' ' VAL . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.573 ' CG2' HD21 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.554 HG23 ' O ' ' H' ' 38' ' ' GLY . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.598 ' OXT' HG13 ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.477 ' H ' HG23 ' I' ' 12' ' ' VAL . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.484 ' CD2' HG21 ' K' ' 40' ' ' VAL . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.555 ' CD ' HD21 ' K' ' 17' ' ' LEU . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.724 ' O ' HD23 ' J' ' 17' ' ' LEU . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.863 HD22 HD12 ' I' ' 17' ' ' LEU . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.829 ' HZ3' ' HZ2' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.577 HD12 ' O ' ' C' ' 38' ' ' GLY . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.958 HD23 ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.958 ' N ' HD23 ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.711 HG21 HD21 ' H' ' 17' ' ' LEU . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.406 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.555 HD21 ' CD ' ' J' ' 15' ' ' GLN . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.454 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.56 ' NZ ' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.558 HD12 HG23 ' E' ' 39' ' ' VAL . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.444 HG21 HD13 ' K' ' 32' ' ' ILE . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.46 ' O ' HD12 ' L' ' 34' ' ' LEU . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.886 HG21 HD11 ' I' ' 17' ' ' LEU . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.49 ' N ' HG22 ' K' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.453 HG12 ' NE2' ' K' ' 14' ' ' HIS . 28.6 t . . . . . 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.406 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.607 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 18' ' ' VAL . . . . . 0.524 ' N ' HD23 ' L' ' 17' ' ' LEU . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.785 HG22 ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.785 ' H ' HG22 ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.529 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.574 HD11 ' HB ' ' F' ' 39' ' ' VAL . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.786 HD11 HG12 ' K' ' 36' ' ' VAL . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.542 ' H ' HD12 ' L' ' 34' ' ' LEU . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.801 HG11 ' CD1' ' J' ' 17' ' ' LEU . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.681 HG22 HD12 ' R' ' 31' ' ' ILE . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.487 HG11 ' N ' ' N' ' 13' ' ' HIS . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 18' ' ' VAL . . . . . 0.415 HG13 ' O ' ' M' ' 18' ' ' VAL . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.609 HD11 ' O ' ' G' ' 38' ' ' GLY . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.609 HG12 ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.609 ' N ' HG12 ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.487 ' N ' HG11 ' M' ' 12' ' ' VAL . 30.8 t-80 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 0.1 OUTLIER -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.737 HD21 HG11 ' P' ' 36' ' ' VAL . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 57.4 m-20 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.41 HD13 HG21 ' N' ' 31' ' ' ILE . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.438 ' H ' ' HB3' ' O' ' 34' ' ' LEU . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.828 ' O ' HD13 ' B' ' 31' ' ' ILE . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.48 ' O ' HG21 ' N' ' 12' ' ' VAL . 15.7 m . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.756 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 78.5 m80 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.53 ' OE1' ' NE2' ' N' ' 15' ' ' GLN . 17.3 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.614 ' N ' HD12 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.71 ' H ' HG11 ' P' ' 24' ' ' VAL . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.54 HG23 HD21 ' O' ' 34' ' ' LEU . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.564 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.793 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.48 HG23 HD12 ' C' ' 31' ' ' ILE . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.47 HG23 ' O ' ' Q' ' 12' ' ' VAL . 1.3 p . . . . . 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.756 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.483 ' H ' ' CD2' ' P' ' 14' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 16' ' ' LYS . . . . . 0.493 ' C ' HD12 ' P' ' 17' ' ' LEU . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.855 ' N ' HD12 ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.618 ' CD1' HD13 ' R' ' 32' ' ' ILE . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.682 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.776 HG13 ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.776 ' N ' HG13 ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.793 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.737 HG11 HD21 ' N' ' 17' ' ' LEU . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.404 ' N ' ' HA2' ' Q' ' 37' ' ' GLY . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.572 HG23 HD11 ' C' ' 31' ' ' ILE . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.483 HG13 ' CE1' ' N' ' 13' ' ' HIS . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.47 ' O ' HG23 ' P' ' 12' ' ' VAL . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.479 ' N ' HD23 ' Q' ' 17' ' ' LEU . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.61 ' CG ' HG22 ' R' ' 24' ' ' VAL . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.817 HG12 ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.817 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.406 ' H ' ' CB ' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' K' ' 39' ' ' VAL . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.984 HD23 ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.984 ' N ' HD23 ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.451 ' CG2' HD11 ' R' ' 34' ' ' LEU . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.404 ' HA2' ' N ' ' P' ' 38' ' ' GLY . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 18' ' ' VAL . . . . . 0.418 ' O ' HG13 ' R' ' 18' ' ' VAL . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.723 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.534 ' N ' HG23 ' R' ' 24' ' ' VAL . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.723 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.681 HD12 HG22 ' L' ' 39' ' ' VAL . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.618 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.451 HD11 ' CG2' ' Q' ' 36' ' ' VAL . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.785 HG22 HD12 ' F' ' 31' ' ' ILE . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.495 ' CG1' ' NE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.827 ' HD1' ' H ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' D' ' 36' ' ' VAL . 6.3 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.448 HD11 HG21 ' C' ' 36' ' ' VAL . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.654 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.49 ' O ' HG23 ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.59 HG12 ' N ' ' A' ' 37' ' ' GLY . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.59 ' N ' HG12 ' A' ' 36' ' ' VAL . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.532 ' O ' HD13 ' H' ' 31' ' ' ILE . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.484 HG23 HD12 ' G' ' 31' ' ' ILE . 51.3 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.827 ' H ' ' HD1' ' A' ' 14' ' ' HIS . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.521 ' C ' HD12 ' B' ' 17' ' ' LEU . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.761 HD21 HG21 ' D' ' 36' ' ' VAL . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.436 HD11 HD12 ' A' ' 31' ' ' ILE . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.732 ' HB2' HD13 ' C' ' 34' ' ' LEU . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.433 HG23 HD11 ' H' ' 31' ' ' ILE . 25.1 t . . . . . 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.646 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.44 ' H ' ' HG3' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.536 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.536 HD12 ' C ' ' C' ' 16' ' ' LYS . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.42 HG13 ' HA ' ' B' ' 18' ' ' VAL . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.576 HD12 ' HB ' ' O' ' 39' ' ' VAL . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.512 ' CG2' HD21 ' D' ' 34' ' ' LEU . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.761 HD12 ' N ' ' C' ' 35' ' ' MET . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.761 ' N ' HD12 ' C' ' 34' ' ' LEU . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' D' ' 38' ' ' GLY . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' I' ' 31' ' ' ILE . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.646 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 7.1 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.849 HD21 HG21 ' F' ' 36' ' ' VAL . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' E' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.552 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 31.6 m120 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.541 ' HA2' HG21 ' P' ' 39' ' ' VAL . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.615 HD11 ' HB ' ' P' ' 39' ' ' VAL . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.518 HG22 HD11 ' E' ' 34' ' ' LEU . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' C' ' 32' ' ' ILE . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.761 HG21 HD21 ' B' ' 17' ' ' LEU . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.477 ' N ' ' O ' ' C' ' 38' ' ' GLY . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.517 ' CG2' HD11 ' J' ' 31' ' ' ILE . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.412 ' O ' HG12 ' D' ' 39' ' ' VAL . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 29.8 m170 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.419 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.611 ' CE2' HD12 ' F' ' 32' ' ' ILE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.692 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.552 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.419 ' O ' ' N ' ' E' ' 29' ' ' GLY . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.5 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.524 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.714 HD11 HG11 ' Q' ' 39' ' ' VAL . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.923 HG23 HD13 ' E' ' 34' ' ' LEU . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.709 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.923 HD13 HG23 ' E' ' 32' ' ' ILE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.511 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.602 HG22 HD12 ' L' ' 31' ' ' ILE . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.487 ' OXT' HG12 ' E' ' 40' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.601 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 . . . . . 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.575 0.226 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.524 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.831 HD11 HG23 ' R' ' 39' ' ' VAL . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.611 HD12 ' CE2' ' E' ' 19' ' ' PHE . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.849 HG21 HD21 ' D' ' 17' ' ' LEU . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.921 HG12 HD11 ' L' ' 31' ' ' ILE . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.637 HG23 ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.498 ' CD1' HG21 ' I' ' 36' ' ' VAL . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE2' ' H' ' 22' ' ' GLU . 67.0 tt0 . . . . . 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.508 HG23 ' O ' ' G' ' 31' ' ' ILE . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.461 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 . . . . . 0 N--CA 1.462 0.153 0 CA-C-O 120.976 0.417 . . . . 0.0 111.67 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.718 HD21 HG11 ' J' ' 36' ' ' VAL . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.46 ' CB ' ' H ' ' I' ' 24' ' ' VAL . 1.6 m-20 . . . . . 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.532 HD13 ' O ' ' A' ' 38' ' ' GLY . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.594 HG22 HD11 ' I' ' 34' ' ' LEU . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p . . . . . 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.6 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.61 ' CD2' HG12 ' K' ' 40' ' ' VAL . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.6 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' OE1' ' J' ' 15' ' ' GLN . 7.8 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' O ' HD23 ' I' ' 17' ' ' LEU . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.497 HD22 HD12 ' H' ' 17' ' ' LEU . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.775 ' HB3' ' HZ1' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.549 ' HG2' HG23 ' I' ' 24' ' ' VAL . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.549 HG23 ' HG2' ' I' ' 22' ' ' GLU . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.553 HD11 ' CG2' ' C' ' 39' ' ' VAL . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.516 HG23 HD13 ' I' ' 34' ' ' LEU . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.831 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.831 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.513 HG23 ' O ' ' I' ' 36' ' ' VAL . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.47 ' O ' HD13 ' O' ' 31' ' ' ILE . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.542 HG12 ' O ' ' I' ' 40' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 10.9 m-70 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.615 ' OE1' ' NE2' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.466 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.546 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.522 HD12 HG23 ' C' ' 39' ' ' VAL . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.737 HG22 HD11 ' K' ' 34' ' ' LEU . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.644 HD23 ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.718 HG11 HD21 ' H' ' 17' ' ' LEU . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.408 ' H ' HG22 ' J' ' 39' ' ' VAL . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.504 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 15.1 p-80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.414 ' HB3' ' H ' ' L' ' 14' ' ' HIS . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.455 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.775 ' HZ1' ' HB3' ' I' ' 21' ' ' ALA . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.515 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.626 HG23 HD13 ' K' ' 34' ' ' LEU . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' K' ' 33' ' ' GLY . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.61 HG12 ' CD2' ' I' ' 13' ' ' HIS . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.557 HG22 ' N ' ' L' ' 13' ' ' HIS . 2.7 p . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.557 ' N ' HG22 ' L' ' 12' ' ' VAL . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.414 ' H ' ' HB3' ' K' ' 14' ' ' HIS . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.432 HG12 ' N ' ' L' ' 25' ' ' GLY . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.437 ' O ' ' CG ' ' K' ' 27' ' ' ASN . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.921 HD11 HG12 ' F' ' 39' ' ' VAL . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.593 HD21 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 6.3 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.667 HD11 HG21 ' O' ' 36' ' ' VAL . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 18' ' ' VAL . . . . . 0.573 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 19' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' O' ' 32' ' ' ILE . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 21' ' ' ALA . . . . . 0.641 ' HB1' ' H ' ' N' ' 28' ' ' LYS . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.44 ' H ' HG22 ' M' ' 24' ' ' VAL . 3.9 m . . . . . 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.772 HD11 HG11 ' P' ' 36' ' ' VAL . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.641 ' H ' ' HB1' ' M' ' 21' ' ' ALA . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.596 HG22 ' CG1' ' O' ' 39' ' ' VAL . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.404 ' HB ' ' HE2' ' O' ' 14' ' ' HIS . 30.9 m . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 120.707 0.289 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.473 ' NE2' ' O ' ' Q' ' 37' ' ' GLY . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.607 ' C ' HD12 ' O' ' 17' ' ' LEU . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.618 ' HG ' HD12 ' N' ' 17' ' ' LEU . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.593 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.47 HD13 ' O ' ' I' ' 38' ' ' GLY . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.441 HD13 ' CD2' ' M' ' 19' ' ' PHE . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' P' ' 33' ' ' GLY . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.694 HG13 ' O ' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.431 ' H ' ' HA2' ' P' ' 37' ' ' GLY . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.596 ' CG1' HG22 ' N' ' 39' ' ' VAL . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.463 ' H ' HG22 ' O' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.46 HG23 ' N ' ' Q' ' 13' ' ' HIS . 2.3 p . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.558 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 2.6 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.495 HD22 HD22 ' O' ' 17' ' ' LEU . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 18' ' ' VAL . . . . . 0.497 HG13 ' O ' ' P' ' 18' ' ' VAL . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.445 ' CD2' HD13 ' R' ' 32' ' ' ILE . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.739 HG22 ' HA ' ' Q' ' 23' ' ' ASP . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.56 ' CG ' HD21 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.593 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' P' ' 34' ' ' LEU . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.493 ' O ' HD12 ' Q' ' 34' ' ' LEU . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.772 HG11 HD11 ' N' ' 17' ' ' LEU . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.416 ' H ' ' CA ' ' O' ' 38' ' ' GLY . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.623 HG23 ' O ' ' Q' ' 39' ' ' VAL . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.536 ' O ' HG22 ' P' ' 39' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.58 HG12 ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.58 ' N ' HG12 ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.558 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.739 ' HA ' HG22 ' P' ' 24' ' ' VAL . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.533 HG22 ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.533 ' N ' HG22 ' Q' ' 24' ' ' VAL . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.56 HD21 ' CG ' ' P' ' 27' ' ' ASN . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.441 HD12 HG23 ' K' ' 39' ' ' VAL . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.493 HD12 ' O ' ' P' ' 34' ' ' LEU . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.616 HG13 ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.714 HG11 HD11 ' E' ' 31' ' ' ILE . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.563 HD23 ' C ' ' R' ' 17' ' ' LEU . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 18' ' ' VAL . . . . . 0.438 ' N ' HD23 ' R' ' 17' ' ' LEU . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.847 HG22 HD22 ' R' ' 34' ' ' LEU . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.847 HD22 HG22 ' R' ' 32' ' ' ILE . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.586 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.831 HG23 HD11 ' F' ' 31' ' ' ILE . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.418 HG22 ' H ' ' R' ' 40' ' ' VAL . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 120.86 0.362 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.579 HG13 ' O ' ' B' ' 12' ' ' VAL . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.717 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 2.2 m-70 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.469 ' CD1' HG11 ' C' ' 36' ' ' VAL . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.562 ' O ' ' O ' ' A' ' 26' ' ' SER . 46.6 t30 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.783 HD13 ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.486 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p . . . . . 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.783 0.325 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.717 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.767 ' NE2' HG23 ' E' ' 36' ' ' VAL . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.601 ' CD1' HG21 ' D' ' 36' ' ' VAL . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.668 HG21 ' H ' ' C' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.643 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.426 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 8.6 m120 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' C' ' 34' ' ' LEU . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.486 ' HA3' ' H ' ' A' ' 38' ' ' GLY . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.683 HG23 HD11 ' H' ' 31' ' ' ILE . 16.6 t . . . . . 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.498 HE22 HG13 ' E' ' 36' ' ' VAL . 33.4 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.458 ' O ' HD23 ' C' ' 17' ' ' LEU . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.684 HD11 HG11 ' E' ' 36' ' ' VAL . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.441 ' HA ' HG13 ' D' ' 18' ' ' VAL . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.642 ' HB1' HG21 ' C' ' 24' ' ' VAL . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.642 HG21 ' HB1' ' C' ' 21' ' ' ALA . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.668 ' H ' HG21 ' B' ' 24' ' ' VAL . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.596 ' HA3' HG13 ' O' ' 39' ' ' VAL . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.464 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.498 HD12 HG23 ' O' ' 39' ' ' VAL . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' B' ' 34' ' ' LEU . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.454 ' H ' HD12 ' C' ' 34' ' ' LEU . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.49 ' O ' HG13 ' C' ' 36' ' ' VAL . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.594 HG12 ' N ' ' C' ' 40' ' ' VAL . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.594 ' N ' HG12 ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.752 ' HE2' HG12 ' E' ' 12' ' ' VAL . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.623 ' NE2' HG22 ' F' ' 36' ' ' VAL . 22.9 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.715 HD11 HG21 ' F' ' 36' ' ' VAL . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 18' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' C' ' 18' ' ' VAL . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.487 ' O ' HG22 ' P' ' 39' ' ' VAL . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.505 HD12 HG22 ' D' ' 36' ' ' VAL . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.601 HG21 ' CD1' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.789 ' O ' HD12 ' K' ' 31' ' ' ILE . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.752 HG12 ' HE2' ' D' ' 14' ' ' HIS . 2.7 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.532 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' D' ' 36' ' ' VAL . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.767 HG23 ' NE2' ' B' ' 15' ' ' GLN . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.904 HG23 HD11 ' K' ' 31' ' ' ILE . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' CG ' ' C' ' 13' ' ' HIS . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.521 HG13 ' O ' ' F' ' 12' ' ' VAL . 9.0 p . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.532 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' F' ' 29' ' ' GLY . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.715 HG21 HD11 ' D' ' 17' ' ' LEU . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.477 ' CG2' HG22 ' E' ' 39' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.424 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.509 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.897 HD11 HG11 ' I' ' 36' ' ' VAL . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.551 HG23 ' O ' ' G' ' 18' ' ' VAL . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.492 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.401 ' CD ' ' OE1' ' H' ' 22' ' ' GLU . 82.5 tt0 . . . . . 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.395 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.753 0.311 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB2' ' I' ' 11' ' ' GLU . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.635 ' CD2' ' CG2' ' J' ' 40' ' ' VAL . 80.7 m80 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.7 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.556 HD12 HD22 ' I' ' 17' ' ' LEU . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.47 ' HB1' ' OD2' ' I' ' 23' ' ' ASP . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 . . . . . 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 1.752 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.683 HD11 HG23 ' B' ' 39' ' ' VAL . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.566 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.46 HG12 ' CD1' ' M' ' 31' ' ' ILE . 12.9 p . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.539 ' HB2' HG22 ' H' ' 12' ' ' VAL . 78.8 mm-40 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.798 HG21 ' C ' ' J' ' 12' ' ' VAL . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' H' ' 13' ' ' HIS . 1.1 m80 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.632 ' CE1' HG23 ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.427 ' OE1' HG12 ' K' ' 36' ' ' VAL . 0.7 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.607 ' C ' HD23 ' I' ' 17' ' ' LEU . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.729 HD11 HG11 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.416 ' HB1' ' NZ ' ' I' ' 28' ' ' LYS . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.47 ' OD2' ' HB1' ' H' ' 21' ' ' ALA . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.453 ' H ' ' CB ' ' J' ' 28' ' ' LYS . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.679 HD13 ' CG2' ' J' ' 31' ' ' ILE . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.406 HG21 HD13 ' I' ' 32' ' ' ILE . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.566 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.897 HG11 HD11 ' G' ' 17' ' ' LEU . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.408 ' HA3' ' H ' ' J' ' 37' ' ' GLY . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.467 HG11 HG23 ' J' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.798 ' C ' HG21 ' I' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.578 ' NE2' HG12 ' L' ' 36' ' ' VAL . 2.5 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.808 ' C ' HD12 ' J' ' 17' ' ' LEU . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.808 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' L' ' 32' ' ' ILE . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 27.9 m-20 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.453 ' CB ' ' H ' ' I' ' 28' ' ' LYS . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.679 ' CG2' HD13 ' I' ' 31' ' ' ILE . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.455 HG22 HD21 ' K' ' 34' ' ' LEU . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.408 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.411 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.635 ' O ' HG13 ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' I' ' 37' ' ' GLY . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.635 ' CG2' ' CD2' ' H' ' 13' ' ' HIS . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.529 HE21 ' HG3' ' L' ' 15' ' ' GLN . 2.8 pm0 -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' K' ' 17' ' ' LEU . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.518 HD12 ' C ' ' K' ' 16' ' ' LYS . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.514 ' HB3' ' CE1' ' K' ' 19' ' ' PHE . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 1.057 HG12 ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 1.057 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.904 HD11 HG23 ' E' ' 39' ' ' VAL . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.455 HD21 HG22 ' J' ' 32' ' ' ILE . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.729 HG11 HD11 ' I' ' 17' ' ' LEU . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.423 HG23 ' CD1' ' Q' ' 31' ' ' ILE . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.515 HG23 ' O ' ' K' ' 40' ' ' VAL . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 1.8 t60 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.529 ' HG3' HE21 ' K' ' 15' ' ' GLN . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.506 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.444 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.43 HG22 HD22 ' L' ' 34' ' ' LEU . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.43 HD22 HG22 ' L' ' 32' ' ' ILE . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.578 HG12 ' NE2' ' J' ' 15' ' ' GLN . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.565 HG23 HD12 ' R' ' 31' ' ' ILE . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 18' ' ' VAL . . . . . 0.564 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.47 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.551 ' N ' HG23 ' N' ' 24' ' ' VAL . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.577 HG23 ' O ' ' M' ' 31' ' ' ILE . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.783 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.463 ' H ' ' HA ' ' O' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.503 HE22 ' HB ' ' P' ' 36' ' ' VAL . 5.9 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 21' ' ' ALA . . . . . 0.674 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.551 HG23 ' N ' ' M' ' 23' ' ' ASP . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.408 ' O ' HD12 ' N' ' 31' ' ' ILE . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.408 HD12 ' O ' ' N' ' 29' ' ' GLY . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.438 ' CD2' HG12 ' N' ' 36' ' ' VAL . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.426 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.533 HG13 ' O ' ' N' ' 36' ' ' VAL . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' O' ' 37' ' ' GLY . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.762 HG12 ' H ' ' O' ' 13' ' ' HIS . 38.2 t . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.762 ' H ' HG12 ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.499 ' NE2' HG13 ' Q' ' 36' ' ' VAL . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.865 HD12 HD22 ' P' ' 17' ' ' LEU . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 1.055 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 1.055 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.674 ' HZ3' ' HA ' ' N' ' 21' ' ' ALA . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.641 HG23 HD13 ' O' ' 34' ' ' LEU . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.742 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.831 ' O ' HD12 ' P' ' 34' ' ' LEU . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.426 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.637 ' CG2' HD11 ' P' ' 34' ' ' LEU . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.436 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.596 HG13 ' HA3' ' C' ' 29' ' ' GLY . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.522 HG23 ' O ' ' O' ' 39' ' ' VAL . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.57 0.224 . . . . 0.0 111.532 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.535 ' CE1' HG11 ' O' ' 12' ' ' VAL . 70.9 m80 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.597 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 16' ' ' LYS . . . . . 0.537 ' O ' HD23 ' P' ' 17' ' ' LEU . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.865 HD22 HD12 ' O' ' 17' ' ' LEU . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.508 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' P' ' 30' ' ' ALA . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.609 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.479 HD12 HG23 ' J' ' 39' ' ' VAL . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.402 HG21 HD13 ' P' ' 32' ' ' ILE . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.831 HD12 ' O ' ' O' ' 34' ' ' LEU . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.595 HG23 HG22 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.487 HG22 ' O ' ' D' ' 29' ' ' GLY . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.408 HD12 ' O ' ' R' ' 16' ' ' LYS . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' Q' ' 21' ' ' ALA . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.461 ' HB3' ' CE1' ' Q' ' 19' ' ' PHE . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.504 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' OD1' ' N ' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.423 ' CD1' HG23 ' K' ' 39' ' ' VAL . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.679 HD23 ' N ' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.824 HG11 HD11 ' O' ' 17' ' ' LEU . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.443 HG23 ' O ' ' R' ' 40' ' ' VAL . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.408 ' O ' HD12 ' Q' ' 17' ' ' LEU . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.565 HD12 HG23 ' L' ' 39' ' ' VAL . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.467 HD11 HG13 ' R' ' 36' ' ' VAL . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.467 HG13 HD11 ' R' ' 34' ' ' LEU . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.522 HG22 ' O ' ' R' ' 40' ' ' VAL . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG13 ' O ' ' B' ' 12' ' ' VAL . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.597 HE22 ' N ' ' D' ' 37' ' ' GLY . 32.0 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.968 HD11 HG11 ' C' ' 36' ' ' VAL . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.593 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.593 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.779 HG12 ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.779 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.74 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.614 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 13.0 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.597 HD21 HG11 ' D' ' 36' ' ' VAL . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.934 ' O ' HG13 ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.934 HG13 ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.448 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.48 ' HA3' HG22 ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' O' ' 39' ' ' VAL . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.74 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' C' ' 38' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.73 HG22 HD11 ' H' ' 31' ' ' ILE . 8.2 m . . . . . 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.467 0.39 0 N-CA-C 110.595 -0.15 . . . . 0.0 110.595 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.599 ' HB3' HD11 ' C' ' 17' ' ' LEU . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.833 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.59 ' OD1' ' HB1' ' B' ' 21' ' ' ALA . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.561 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.521 HG12 HD12 ' D' ' 31' ' ' ILE . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.638 HG22 HD21 ' D' ' 34' ' ' LEU . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.694 ' N ' HD23 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.409 ' N ' HD12 ' C' ' 34' ' ' LEU . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.968 HG11 HD11 ' A' ' 17' ' ' LEU . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' B' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 27.1 p80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.456 ' NE2' HD11 ' D' ' 17' ' ' LEU . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.549 ' CD2' HD13 ' C' ' 17' ' ' LEU . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.552 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.473 ' OE1' ' CG2' ' D' ' 24' ' ' VAL . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.453 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.561 ' H ' ' CG1' ' C' ' 24' ' ' VAL . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' P' ' 39' ' ' VAL . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.405 HG21 HD13 ' D' ' 32' ' ' ILE . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.694 HD23 ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.597 HG11 HD21 ' B' ' 17' ' ' LEU . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.597 ' N ' HE22 ' A' ' 15' ' ' GLN . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.409 ' CB ' ' HZ3' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' F' ' 22' ' ' GLU . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.586 HG22 ' O ' ' F' ' 22' ' ' GLU . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.552 ' HZ3' ' HB3' ' D' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.485 HD11 ' CG2' ' D' ' 36' ' ' VAL . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' C' ' 17' ' ' LEU . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.542 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.6 p . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.542 ' N ' HG22 ' F' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.404 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.586 ' O ' HG22 ' E' ' 24' ' ' VAL . 94.1 mt-10 . . . . . 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.088 0.47 . . . . 0.0 111.896 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.469 ' HB2' ' HD2' ' E' ' 28' ' ' LYS . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.545 HD12 HG21 ' Q' ' 39' ' ' VAL . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.502 ' O ' HD12 ' F' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.537 HG11 ' CD2' ' D' ' 17' ' ' LEU . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.493 HG23 ' O ' ' G' ' 12' ' ' VAL . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 . . . . . 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.454 HD11 ' HA3' ' H' ' 29' ' ' GLY . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.67 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.67 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.548 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.8 mp0 . . . . . 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.439 ' H ' HG12 ' G' ' 12' ' ' VAL . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 31.4 t-80 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.532 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.545 HD21 HG11 ' J' ' 36' ' ' VAL . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.532 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 . . . . . 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.537 1.411 0 CA-C-O 119.329 -0.706 . . . . 0.0 114.747 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.73 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.521 HG22 HD21 ' I' ' 34' ' ' LEU . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.649 ' HB3' HD22 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t . . . . . 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 . . . . . 0 N--CA 1.458 -0.065 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.79 ' OE1' HG23 ' L' ' 36' ' ' VAL . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.674 ' N ' HD12 ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD13 ' K' ' 32' ' ' ILE . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.769 ' OD1' HG13 ' J' ' 24' ' ' VAL . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.673 HG13 ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.673 ' N ' HG13 ' I' ' 24' ' ' VAL . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' C ' HD21 ' I' ' 27' ' ' ASN . 0.4 OUTLIER -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' J' ' 29' ' ' GLY . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.789 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.789 HD23 ' O ' ' I' ' 33' ' ' GLY . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.456 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.87 HG13 HD11 ' O' ' 31' ' ' ILE . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.511 ' O ' ' CB ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.582 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.829 HD21 HG21 ' L' ' 36' ' ' VAL . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.82 HG12 ' OG ' ' K' ' 26' ' ' SER . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.63 ' N ' ' OG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.434 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' I' ' 29' ' ' GLY . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.416 HD11 HG23 ' D' ' 39' ' ' VAL . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.642 ' O ' HD12 ' J' ' 34' ' ' LEU . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.642 HD12 ' O ' ' J' ' 33' ' ' GLY . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.545 HG11 HD21 ' H' ' 17' ' ' LEU . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.456 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' P' ' 31' ' ' ILE . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.82 ' OG ' HG12 ' J' ' 24' ' ' VAL . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.461 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.478 HD13 ' CD2' ' I' ' 19' ' ' PHE . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.514 HD23 ' N ' ' K' ' 35' ' ' MET . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.514 ' N ' HD23 ' K' ' 34' ' ' LEU . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.614 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.443 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 2.5 p-80 -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.402 ' CE1' ' ND1' ' K' ' 14' ' ' HIS . 7.5 p-80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.443 HD12 ' O ' ' K' ' 34' ' ' LEU . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.829 HG21 HD21 ' J' ' 17' ' ' LEU . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.614 HG22 HD12 ' R' ' 31' ' ' ILE . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.449 HG23 ' OXT' ' L' ' 40' ' ' VAL . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.45 ' O ' HG23 ' M' ' 12' ' ' VAL . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.588 HD11 HG11 ' O' ' 36' ' ' VAL . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 96.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.538 ' NE2' HG12 ' P' ' 36' ' ' VAL . 1.1 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.827 HD11 HG11 ' P' ' 36' ' ' VAL . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.718 ' H ' HG21 ' O' ' 24' ' ' VAL . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.521 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.521 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.63 ' CD1' HD12 ' O' ' 31' ' ' ILE . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.408 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t . . . . . 0 CA--C 1.536 0.419 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.458 HE22 HG22 ' Q' ' 36' ' ' VAL . 9.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.42 ' O ' HD23 ' O' ' 17' ' ' LEU . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.56 ' CD1' HG11 ' Q' ' 36' ' ' VAL . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.437 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.718 HG21 ' H ' ' N' ' 23' ' ' ASP . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.444 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 89.9 m-20 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' O' ' 30' ' ' ALA . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' O' ' 29' ' ' GLY . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.87 HD11 HG13 ' I' ' 39' ' ' VAL . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.745 HG23 HD21 ' O' ' 34' ' ' LEU . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.616 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.807 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.408 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.588 HG11 HD11 ' M' ' 17' ' ' LEU . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' B' ' 31' ' ' ILE . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.464 ' N ' HG22 ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.43 HG23 ' H ' ' Q' ' 13' ' ' HIS . 12.7 p . . . . . 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.422 ' CD1' HG21 ' R' ' 36' ' ' VAL . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' P' ' 25' ' ' GLY . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' J' ' 39' ' ' VAL . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.827 HG11 HD11 ' N' ' 17' ' ' LEU . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HA3' ' Q' ' 38' ' ' GLY . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' D' ' 31' ' ' ILE . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' R' ' 15' ' ' GLN . 5.9 t-80 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.426 HE22 ' HA2' ' R' ' 37' ' ' GLY . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.637 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.442 HG22 ' CG1' ' R' ' 18' ' ' VAL . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.498 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.958 HG12 ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.958 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.665 HD12 ' O ' ' P' ' 34' ' ' LEU . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.407 ' H ' HD12 ' Q' ' 34' ' ' LEU . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.634 ' CG1' HG12 ' R' ' 36' ' ' VAL . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.902 HG13 ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.463 ' H ' HG12 ' R' ' 40' ' ' VAL . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 32.1 t-80 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.536 ' HG2' ' CE1' ' Q' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.533 ' HG ' HD13 ' Q' ' 17' ' ' LEU . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 18' ' ' VAL . . . . . 0.442 ' CG1' HG22 ' Q' ' 18' ' ' VAL . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.583 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 12.8 t-20 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 30' ' ' ALA . . . . . 0.583 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.614 HD12 HG22 ' L' ' 39' ' ' VAL . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.488 ' O ' HD12 ' R' ' 34' ' ' LEU . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.634 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.426 ' HA2' HE22 ' Q' ' 15' ' ' GLN . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.902 ' O ' HG13 ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.488 ' N ' HG12 ' R' ' 39' ' ' VAL . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.473 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.479 ' HB2' ' HE3' ' C' ' 28' ' ' LYS . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.419 ' H ' ' CG2' ' A' ' 24' ' ' VAL . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.601 HG12 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.601 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' B' ' 36' ' ' VAL . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 ' O ' ' B' ' 37' ' ' GLY . 6.1 t . . . . . 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.5 mp0 . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.534 ' CG1' ' NE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.702 ' HD1' ' H ' ' C' ' 14' ' ' HIS . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.422 ' O ' HD23 ' B' ' 17' ' ' LEU . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' D' ' 32' ' ' ILE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.438 HG22 ' CG2' ' A' ' 36' ' ' VAL . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.542 ' O ' HG11 ' A' ' 39' ' ' VAL . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' H' ' 31' ' ' ILE . 27.3 m . . . . . 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.702 ' H ' ' HD1' ' B' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' E' ' 36' ' ' VAL . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' E' ' 32' ' ' ILE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.561 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.898 ' H ' HG11 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' HB3' ' B' ' 30' ' ' ALA . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.416 HG23 ' O ' ' C' ' 31' ' ' ILE . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.673 HG23 HD13 ' C' ' 34' ' ' LEU . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.703 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.703 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.432 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.507 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.599 ' CG2' HD11 ' I' ' 31' ' ' ILE . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.663 ' O ' HG22 ' E' ' 12' ' ' VAL . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 34.8 p80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.598 ' CD2' HD12 ' C' ' 17' ' ' LEU . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.898 HG11 ' H ' ' C' ' 24' ' ' VAL . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.785 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.737 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.43 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.737 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.714 ' H ' HD22 ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.622 HD12 HG22 ' P' ' 39' ' ' VAL . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' B' ' 19' ' ' PHE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.57 ' O ' HD12 ' E' ' 34' ' ' LEU . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.564 HG11 HG22 ' E' ' 36' ' ' VAL . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.507 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.489 HG23 HD11 ' J' ' 31' ' ' ILE . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.663 HG22 ' O ' ' D' ' 11' ' ' GLU . 71.1 t . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 61.2 m170 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.429 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' E' ' 17' ' ' LEU . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.456 ' HB1' ' CA ' ' F' ' 29' ' ' GLY . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.522 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.464 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.508 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD1' ' C' ' 19' ' ' PHE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.627 ' HG ' HG23 ' E' ' 36' ' ' VAL . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.439 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.718 HG11 HD11 ' C' ' 17' ' ' LEU . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.479 HG22 HD12 ' L' ' 31' ' ' ILE . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.426 HG13 ' CG ' ' C' ' 13' ' ' HIS . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.441 ' OE1' HG22 ' E' ' 24' ' ' VAL . 93.1 mt-10 . . . . . 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.456 ' CA ' ' HB1' ' E' ' 21' ' ' ALA . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.459 HD11 ' HB ' ' R' ' 39' ' ' VAL . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' D' ' 19' ' ' PHE . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.579 HD12 ' O ' ' E' ' 34' ' ' LEU . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' F' ' 34' ' ' LEU . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.48 HG23 HD11 ' L' ' 31' ' ' ILE . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' D' ' 13' ' ' HIS . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.498 HG11 ' N ' ' H' ' 13' ' ' HIS . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' NZ ' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.632 ' NZ ' ' CD2' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.474 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.842 ' HB1' ' CG ' ' H' ' 23' ' ' ASP . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.533 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.599 ' O ' HG12 ' H' ' 39' ' ' VAL . 4.0 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' H ' ' G' ' 12' ' ' VAL . 96.9 mt-10 . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.879 0.371 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.676 HD12 HD22 ' I' ' 17' ' ' LEU . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.41 ' CZ ' ' HB3' ' H' ' 17' ' ' LEU . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.636 ' HB1' ' HD3' ' I' ' 28' ' ' LYS . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.842 ' CG ' ' HB1' ' G' ' 21' ' ' ALA . 4.7 m-20 . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.846 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.911 ' O ' HG21 ' N' ' 31' ' ' ILE . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.599 HG12 ' O ' ' G' ' 39' ' ' VAL . 1.4 p . . . . . 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.411 ' CE1' HG23 ' J' ' 40' ' ' VAL . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.427 ' CE1' ' O ' ' I' ' 15' ' ' GLN . 61.3 t-80 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.427 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.541 ' C ' HD23 ' I' ' 17' ' ' LEU . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.676 HD22 HD12 ' H' ' 17' ' ' LEU . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.572 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.639 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.437 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.606 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.606 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.48 ' CA ' HD22 ' J' ' 27' ' ' ASN . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.639 ' NZ ' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' C' ' 39' ' ' VAL . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.92 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.92 HD23 ' O ' ' I' ' 33' ' ' GLY . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' J' ' 35' ' ' MET . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.464 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.453 ' O ' HG23 ' J' ' 39' ' ' VAL . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.486 HG22 ' CD1' ' O' ' 31' ' ' ILE . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.66 HD11 HG21 ' L' ' 36' ' ' VAL . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.527 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.838 HG12 ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.838 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.441 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.489 HD11 HG23 ' D' ' 39' ' ' VAL . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.573 ' HB2' HD13 ' K' ' 34' ' ' LEU . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.459 ' HB3' ' SD ' ' I' ' 35' ' ' MET . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.629 HG12 HD11 ' K' ' 34' ' ' LEU . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.417 ' H ' ' CA ' ' K' ' 37' ' ' GLY . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.453 HG23 ' O ' ' I' ' 38' ' ' GLY . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.411 HG23 ' CE1' ' I' ' 13' ' ' HIS . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.465 HD22 HD12 ' J' ' 17' ' ' LEU . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.584 ' OD2' HG23 ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.595 HG12 ' H ' ' K' ' 25' ' ' GLY . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.595 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' O ' ' L' ' 29' ' ' GLY . 9.5 m-20 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.663 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' K' ' 35' ' ' MET . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' K' ' 34' ' ' LEU . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.673 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.417 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.456 HG21 ' O ' ' Q' ' 29' ' ' GLY . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.462 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.6 t . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.802 0.334 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.678 HG12 ' N ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.678 ' N ' HG12 ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.59 ' O ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.48 HD11 HG23 ' F' ' 39' ' ' VAL . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.559 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.66 HG21 HD11 ' J' ' 17' ' ' LEU . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.444 ' HB ' HD11 ' R' ' 31' ' ' ILE . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.53 HG12 ' OXT' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' M' ' 12' ' ' VAL . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.47 ' OE1' HG11 ' N' ' 40' ' ' VAL . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.451 ' N ' ' CD1' ' M' ' 20' ' ' PHE . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t . . . . . 0 N--CA 1.468 0.454 0 N-CA-C 110.855 -0.054 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' N ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.496 HD12 HD22 ' O' ' 17' ' ' LEU . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.449 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.661 ' CB ' HD21 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.911 HG21 ' O ' ' H' ' 38' ' ' GLY . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.641 HG22 HD11 ' O' ' 34' ' ' LEU . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' N' ' 35' ' ' MET . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' N' ' 34' ' ' LEU . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.47 HG11 ' OE1' ' M' ' 15' ' ' GLN . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.475 HG21 ' N ' ' P' ' 13' ' ' HIS . 32.8 m . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.617 ' HB3' ' H ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.527 ' OE1' HD21 ' P' ' 17' ' ' LEU . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.797 ' O ' HD23 ' O' ' 17' ' ' LEU . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.797 HD23 ' O ' ' O' ' 16' ' ' LYS . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.482 HG12 ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.539 ' HA ' ' H ' ' P' ' 28' ' ' LYS . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.661 HD21 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.486 ' CD1' HG22 ' I' ' 39' ' ' VAL . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.566 HG23 HD13 ' O' ' 34' ' ' LEU . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.84 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.84 HD12 ' C ' ' O' ' 33' ' ' GLY . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p . . . . . 0 CA--C 1.536 0.413 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.505 ' N ' HG22 ' P' ' 12' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.777 ' CE1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.745 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.551 HD22 HD12 ' O' ' 17' ' ' LEU . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.404 ' OD1' ' O ' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.443 HG22 ' OD1' ' Q' ' 23' ' ' ASP . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.539 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.4 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.622 HG22 HD12 ' D' ' 31' ' ' ILE . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 9.8 p80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.633 ' C ' HD12 ' Q' ' 17' ' ' LEU . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.745 HD11 ' OE1' ' P' ' 15' ' ' GLN . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.433 HG13 ' O ' ' Q' ' 18' ' ' VAL . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' C ' ' CD1' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.427 ' HB2' ' CZ ' ' Q' ' 19' ' ' PHE . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.557 HG12 ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.557 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.456 ' O ' HG21 ' K' ' 39' ' ' VAL . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . 0.446 HD13 HG21 ' Q' ' 32' ' ' ILE . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.433 HD21 ' CG2' ' Q' ' 32' ' ' ILE . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.413 ' SD ' ' HB3' ' R' ' 35' ' ' MET . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.77 HG11 HD11 ' O' ' 17' ' ' LEU . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.4 ' H ' ' HA2' ' P' ' 38' ' ' GLY . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.438 ' C ' ' NE2' ' O' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.435 HG22 ' N ' ' R' ' 13' ' ' HIS . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 39.1 t-80 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.551 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' R' ' 24' ' ' VAL . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.413 ' O ' ' N ' ' R' ' 24' ' ' VAL . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.632 ' O ' ' HB3' ' R' ' 21' ' ' ALA . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.444 HD11 ' HB ' ' L' ' 39' ' ' VAL . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.469 HG22 HD22 ' R' ' 34' ' ' LEU . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.661 HD23 ' N ' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.413 ' HB3' ' SD ' ' Q' ' 35' ' ' MET . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.459 ' HB ' HD11 ' F' ' 31' ' ' ILE . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.503 0.192 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.606 HD21 HG21 ' C' ' 36' ' ' VAL . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG13 ' HB ' ' B' ' 18' ' ' VAL . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.504 ' CD1' HD13 ' C' ' 32' ' ' ILE . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.426 ' O ' ' N ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 26' ' ' SER . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.482 ' O ' HD12 ' A' ' 31' ' ' ILE . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.53 ' O ' HD12 ' B' ' 34' ' ' LEU . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 . . . . . 0 N--CA 1.461 0.085 0 CA-C-O 120.802 0.334 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.544 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 59.4 t-80 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' CG1' ' D' ' 36' ' ' VAL . 8.6 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.565 HD11 HG11 ' D' ' 36' ' ' VAL . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.452 ' HB ' HG13 ' A' ' 18' ' ' VAL . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' C' ' 29' ' ' GLY . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.591 HD13 HG21 ' O' ' 39' ' ' VAL . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.53 HD12 ' O ' ' A' ' 34' ' ' LEU . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.515 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.449 ' O ' HG12 ' C' ' 39' ' ' VAL . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t . . . . . 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 N--CA 1.466 0.374 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.454 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.55 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.63 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.542 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.463 ' O ' ' O ' ' C' ' 26' ' ' SER . 24.0 t30 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.55 HD12 ' HB ' ' O' ' 39' ' ' VAL . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.586 HG22 HD11 ' D' ' 34' ' ' LEU . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.606 HG21 HD21 ' A' ' 17' ' ' LEU . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.564 ' O ' HD11 ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.59 HG22 ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.59 ' N ' HG22 ' C' ' 39' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.742 HG12 ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.742 ' H ' HG12 ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.434 ' CD2' ' O ' ' D' ' 12' ' ' VAL . 16.6 m-70 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 8.1 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD13 ' C' ' 17' ' ' LEU . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.555 ' O ' HG23 ' D' ' 24' ' ' VAL . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.555 HG23 ' O ' ' D' ' 22' ' ' GLU . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.436 ' H ' HG12 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.422 ' H ' ' H ' ' D' ' 25' ' ' GLY . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.517 HD12 HG23 ' P' ' 39' ' ' VAL . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' D' ' 34' ' ' LEU . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.827 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.827 HD12 ' C ' ' D' ' 33' ' ' GLY . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.62 ' CG1' ' NE2' ' B' ' 15' ' ' GLN . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.598 HG12 HD13 ' J' ' 31' ' ' ILE . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.597 HG12 ' O ' ' D' ' 40' ' ' VAL . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.522 ' O ' HG11 ' D' ' 12' ' ' VAL . 59.1 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD12 ' D' ' 17' ' ' LEU . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.447 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.976 HG12 ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.976 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.456 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.636 ' O ' HD23 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.488 ' N ' HD12 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.597 ' HB ' HD11 ' K' ' 31' ' ' ILE . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' D' ' 40' ' ' VAL . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m . . . . . 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.496 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt . . . . . 0 CA--C 1.531 0.242 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.521 HD11 ' HB ' ' R' ' 39' ' ' VAL . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.487 HD13 ' CD1' ' D' ' 19' ' ' PHE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.636 HD23 ' O ' ' E' ' 34' ' ' LEU . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.649 HG23 ' O ' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.55 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.538 HG11 ' CD2' ' D' ' 13' ' ' HIS . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.639 HG23 ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.6 HE22 HG13 ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.509 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.509 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.478 ' OE1' ' CE1' ' H' ' 20' ' ' PHE . 33.9 tt0 . . . . . 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.599 0 CA-C-O 123.733 1.73 . . . . 0.0 115.358 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.639 ' O ' HG23 ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.534 HD11 HG11 ' J' ' 36' ' ' VAL . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' I' ' 24' ' ' VAL . 10.8 t0 . . . . . 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.442 HD11 ' HA2' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.666 HG12 HD11 ' I' ' 34' ' ' LEU . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.42 ' H ' ' HG ' ' I' ' 34' ' ' LEU . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.538 HG23 HD11 ' N' ' 31' ' ' ILE . 4.9 t . . . . . 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 C--O 1.231 0.114 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.523 HG23 ' O ' ' J' ' 12' ' ' VAL . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.726 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.403 ' HB3' ' HE2' ' K' ' 28' ' ' LYS . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.595 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.595 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.452 HG23 ' N ' ' I' ' 25' ' ' GLY . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.556 ' HB2' ' ND2' ' I' ' 27' ' ' ASN . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.62 HD12 HD11 ' J' ' 31' ' ' ILE . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.414 HG23 HD13 ' I' ' 34' ' ' LEU . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.801 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.801 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.6 HG13 HE22 ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.418 ' N ' HG22 ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.523 ' O ' HG23 ' I' ' 12' ' ' VAL . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' CE1' HG13 ' K' ' 12' ' ' VAL . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.55 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 25.7 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' K' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.5 ' HZ ' HD23 ' J' ' 17' ' ' LEU . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.417 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 15.1 m120 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.62 HD11 HD12 ' I' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.763 HG22 HD21 ' K' ' 34' ' ' LEU . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.582 ' H ' HD23 ' K' ' 34' ' ' LEU . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.534 HG11 HD11 ' H' ' 17' ' ' LEU . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.529 ' O ' HG12 ' K' ' 39' ' ' VAL . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.509 HG23 HD12 ' P' ' 31' ' ' ILE . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.481 HG22 ' OXT' ' J' ' 40' ' ' VAL . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.486 ' O ' HG22 ' J' ' 12' ' ' VAL . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' J' ' 13' ' ' HIS . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.447 ' HB3' ' HE2' ' J' ' 14' ' ' HIS . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' J' ' 17' ' ' LEU . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.518 HG12 ' H ' ' K' ' 25' ' ' GLY . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.518 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.439 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB ' ' E' ' 39' ' ' VAL . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.763 HD21 HG22 ' J' ' 32' ' ' ILE . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.528 HG11 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.529 HG12 ' O ' ' J' ' 38' ' ' GLY . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.47 HG12 ' O ' ' L' ' 40' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 120.654 0.264 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.547 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.55 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.439 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.56 HD23 ' N ' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.807 HG21 HD21 ' J' ' 17' ' ' LEU . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.427 ' CA ' ' OE1' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' K' ' 40' ' ' VAL . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.469 HG23 ' O ' ' M' ' 12' ' ' VAL . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 70.5 m-70 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.403 HE22 HG13 ' O' ' 36' ' ' VAL . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' O' ' 36' ' ' VAL . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.486 ' H ' HG23 ' N' ' 24' ' ' VAL . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.661 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.417 HD13 HG21 ' M' ' 31' ' ' ILE . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.514 HG23 ' N ' ' O' ' 13' ' ' HIS . 1.0 OUTLIER . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' N' ' 19' ' ' PHE . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.89 ' H ' ' HZ3' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.492 HG13 ' O ' ' N' ' 23' ' ' ASP . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.661 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.824 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.538 HD11 HG23 ' H' ' 39' ' ' VAL . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.528 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.474 ' O ' HG22 ' O' ' 39' ' ' VAL . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.524 HG23 HD12 ' B' ' 31' ' ' ILE . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.588 HG12 ' H ' ' O' ' 13' ' ' HIS . 3.2 t . . . . . 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.588 ' H ' HG12 ' O' ' 12' ' ' VAL . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.667 HD12 HD22 ' P' ' 17' ' ' LEU . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.514 HG13 ' CG ' ' O' ' 22' ' ' GLU . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.557 ' HB3' ' H ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.89 ' HZ3' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.683 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.747 HG23 HD21 ' O' ' 34' ' ' LEU . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.603 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.747 HD21 HG23 ' O' ' 32' ' ' ILE . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.447 HG11 ' CD1' ' M' ' 17' ' ' LEU . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.528 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.554 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.591 HG21 HD13 ' B' ' 31' ' ' ILE . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m . . . . . 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.541 ' NE2' HG11 ' O' ' 12' ' ' VAL . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.667 HD22 HD12 ' O' ' 17' ' ' LEU . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.532 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.532 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.987 HG12 ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.987 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.683 HD21 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.824 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.646 ' HB2' ' HA2' ' O' ' 29' ' ' GLY . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.857 HG22 HD11 ' Q' ' 34' ' ' LEU . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.658 HD12 ' O ' ' O' ' 34' ' ' LEU . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.449 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.474 ' HB ' HG13 ' Q' ' 36' ' ' VAL . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.554 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.685 HG12 ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.685 ' N ' HG12 ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.494 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.412 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.44 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.593 ' HA3' ' HB2' ' R' ' 30' ' ' ALA . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' K' ' 39' ' ' VAL . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . 0.676 HG23 HD13 ' Q' ' 34' ' ' LEU . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . 0.763 ' C ' HD12 ' Q' ' 34' ' ' LEU . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.857 HD11 HG22 ' P' ' 32' ' ' ILE . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.556 HG11 HD21 ' O' ' 17' ' ' LEU . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.523 HG12 ' NE2' ' O' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.591 HG12 ' H ' ' R' ' 25' ' ' GLY . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.591 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.526 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 30' ' ' ALA . . . . . 0.593 ' HB2' ' HA3' ' Q' ' 29' ' ' GLY . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.405 HG11 HD13 ' P' ' 17' ' ' LEU . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.521 ' HB ' HD11 ' F' ' 31' ' ' ILE . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.445 ' H ' HG22 ' R' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -110.17 139.44 45.32 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.844 0.354 . . . . 0.0 110.685 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 -70.64 143.04 51.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.985 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.57 HG13 ' C ' ' B' ' 12' ' ' VAL . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.912 HD11 HG21 ' C' ' 36' ' ' VAL . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.732 ' OD1' HG11 ' B' ' 24' ' ' VAL . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.844 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.408 ' O ' ' C ' ' A' ' 28' ' ' LYS . 36.6 m120 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.442 ' O ' HD12 ' B' ' 34' ' ' LEU . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.81 ' H ' ' H ' ' B' ' 40' ' ' VAL . 59.3 t -144.34 161.42 14.97 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.553 ' N ' HG12 ' A' ' 39' ' ' VAL . 57.3 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.497 -179.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -111.92 140.49 46.54 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.914 0.388 . . . . 0.0 110.848 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -74.35 148.8 40.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.783 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.722 HG21 ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 2.3 p-80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.708 HD21 HG11 ' D' ' 36' ' ' VAL . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.732 HG11 ' OD1' ' A' ' 23' ' ' ASP . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.512 HD12 ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.484 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.903 ' O ' HD13 ' H' ' 31' ' ' ILE . 57.4 t -134.73 118.94 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.81 ' H ' ' H ' ' A' ' 39' ' ' VAL . 11.8 p . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.415 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -107.31 134.79 49.86 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.735 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.434 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 47.1 tp10 -136.25 116.64 13.67 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.722 ' O ' HG21 ' B' ' 12' ' ' VAL . 2.0 p -132.25 119.12 38.77 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.499 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.671 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.439 HE22 ' CB ' ' F' ' 36' ' ' VAL . 26.9 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.576 ' C ' HD12 ' C' ' 17' ' ' LEU . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.633 HD21 HG11 ' E' ' 36' ' ' VAL . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.529 ' CZ ' HD23 ' C' ' 17' ' ' LEU . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.58 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.564 ' O ' ' N ' ' C' ' 29' ' ' GLY . 92.7 m-20 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.534 HG23 ' CG2' ' D' ' 31' ' ' ILE . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.67 HG23 HD13 ' C' ' 34' ' ' LEU . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.88 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.88 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 17' ' ' LEU . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.621 ' HA ' HG21 ' D' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.451 ' O ' HG23 ' C' ' 12' ' ' VAL . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.613 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.561 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.638 HG11 ' HG2' ' E' ' 28' ' ' LYS . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.534 ' CG2' HG23 ' C' ' 31' ' ' ILE . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' D' ' 32' ' ' ILE . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.401 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.708 HG11 HD21 ' B' ' 17' ' ' LEU . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.625 HG12 HG23 ' D' ' 40' ' ' VAL . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.625 HG23 HG12 ' D' ' 39' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -115.31 139.82 49.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.665 0.269 . . . . 0.0 110.357 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -142.03 146.04 35.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.916 0.389 . . . . 0.0 110.763 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.38 103.13 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.414 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' HB3' ' E' ' 21' ' ' ALA . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.515 ' HB3' ' CE1' ' E' ' 19' ' ' PHE . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' F' ' 29' ' ' GLY . 17.3 t30 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.638 ' HG2' HG11 ' D' ' 24' ' ' VAL . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.436 ' O ' HG23 ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.408 ' O ' HD12 ' F' ' 34' ' ' LEU . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.643 HG12 HD11 ' F' ' 34' ' ' LEU . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.535 HG12 ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.535 ' N ' HG12 ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -109.39 137.33 47.41 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.771 0.319 . . . . 0.0 110.497 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.502 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.4 mp0 -78.67 160.56 27.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.39 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t -108.58 94.29 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.674 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -98.73 141.16 31.89 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 23' ' ' ASP . 91.8 m-20 59.96 46.71 10.69 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.648 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.698 HG12 ' H ' ' F' ' 25' ' ' GLY . 29.3 t -72.8 177.65 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.698 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 102.07 -32.83 7.07 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -178.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 35.1 m -81.34 -129.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.415 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 98.8 m-20 -99.8 160.85 14.0 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.695 0.76 . . . . 0.0 112.795 -177.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -43.84 -40.05 4.23 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 114.466 -1.243 . . . . 0.0 113.412 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.801 HD12 HG22 ' R' ' 39' ' ' VAL . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.43 HD13 HG21 ' F' ' 32' ' ' ILE . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.643 HD11 HG12 ' E' ' 36' ' ' VAL . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.534 ' N ' HD12 ' F' ' 34' ' ' LEU . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.613 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.424 ' O ' HD13 ' L' ' 31' ' ' ILE . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.47 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 12' ' ' VAL . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -142.87 176.03 9.38 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.423 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.7 t0 -71.65 48.92 0.16 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.92 -178.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.81 HG12 ' H ' ' G' ' 25' ' ' GLY . 33.1 t -143.89 -178.95 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.459 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.81 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 68.14 -39.2 0.26 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.442 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.426 ' H ' ' C ' ' G' ' 24' ' ' VAL . 36.4 m -67.52 111.22 4.01 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 122.653 -0.322 . . . . 0.0 111.318 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 p-10 -149.09 161.59 41.65 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.825 0.822 . . . . 0.0 112.68 178.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.766 ' H ' ' NZ ' ' H' ' 28' ' ' LYS . 99.1 mttt 29.77 40.62 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 114.135 -1.393 . . . . 0.0 113.293 178.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.43 78.42 0.53 Allowed Glycine 0 N--CA 1.476 1.344 0 C-N-CA 120.087 -1.054 . . . . 0.0 111.534 179.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -81.5 64.44 6.22 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 119.439 1.619 . . . . 0.0 113.863 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.432 HD13 ' O ' ' A' ' 39' ' ' VAL . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.535 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t -96.82 130.56 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.521 179.701 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.74 137.33 46.85 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.735 0.302 . . . . 0.0 110.373 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 -85.5 138.98 31.84 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.962 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' I' ' 12' ' ' VAL . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.492 ' HB2' ' HD1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.575 ' OE1' HG13 ' K' ' 36' ' ' VAL . 8.6 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.465 ' N ' HD12 ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.537 ' O ' ' O ' ' H' ' 24' ' ' VAL . 88.4 m-20 -131.04 51.8 2.11 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' H' ' 23' ' ' ASP . 8.5 t -64.93 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 101.966 -3.346 . . . . 0.0 101.966 168.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 157.13 -36.95 0.56 Allowed Glycine 0 N--CA 1.465 0.592 0 C-N-CA 117.252 -2.404 . . . . 0.0 118.532 170.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 42.7 t -66.53 111.6 3.68 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 122.752 3.276 . . . . 0.0 107.81 177.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' H' ' 29' ' ' GLY . 40.2 t30 -149.28 142.13 24.69 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 118.215 -1.394 . . . . 0.0 112.161 172.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.766 ' NZ ' ' H ' ' G' ' 28' ' ' LYS . 98.5 mttt -11.97 -44.68 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 115.474 1.657 . . . . 0.0 115.474 172.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 141.62 62.9 0.03 OUTLIER Glycine 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 -176.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.903 HD13 ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.431 HG22 HD11 ' I' ' 34' ' ' LEU . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.571 HD23 ' H ' ' H' ' 35' ' ' MET . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.571 ' H ' HD23 ' H' ' 34' ' ' LEU . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.625 ' H ' ' HA2' ' I' ' 38' ' ' GLY . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.495 HG23 ' O ' ' H' ' 38' ' ' GLY . 44.7 t -156.6 156.0 4.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 87.4 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.555 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.513 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 96.5 m-85 -106.35 134.78 48.96 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.687 0.279 . . . . 0.0 110.283 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 -138.69 150.67 46.45 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.529 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' H' ' 12' ' ' VAL . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.415 ' OE1' HG12 ' K' ' 36' ' ' VAL . 18.1 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.945 HD11 HG11 ' K' ' 36' ' ' VAL . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.535 ' HB2' HG22 ' J' ' 24' ' ' VAL . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 1.028 HG12 ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 1.028 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 4.9 t30 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.53 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.578 ' CD1' HG13 ' C' ' 39' ' ' VAL . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.66 HG23 HD13 ' I' ' 34' ' ' LEU . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.682 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.682 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.47 ' CG2' HD21 ' J' ' 34' ' ' LEU . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.625 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.594 ' CG2' HD12 ' P' ' 31' ' ' ILE . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.585 ' O ' HG13 ' I' ' 40' ' ' VAL . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.513 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.598 HD22 HD12 ' I' ' 17' ' ' LEU . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' L' ' 30' ' ' ALA . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.539 HG23 ' H ' ' J' ' 26' ' ' SER . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.539 ' H ' HG23 ' J' ' 24' ' ' VAL . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.467 ' NZ ' HG22 ' D' ' 40' ' ' VAL . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.468 ' O ' ' OD1' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.561 ' CD1' HG22 ' D' ' 39' ' ' VAL . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.777 HG22 HD11 ' K' ' 34' ' ' LEU . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.665 HD23 ' N ' ' J' ' 35' ' ' MET . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.665 ' N ' HD23 ' J' ' 34' ' ' LEU . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.583 HG22 HD22 ' J' ' 34' ' ' LEU . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.471 ' CG2' HD11 ' P' ' 31' ' ' ILE . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.615 ' H ' HG23 ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.437 ' O ' ' OE1' ' L' ' 11' ' ' GLU . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.415 HD21 ' CE1' ' L' ' 19' ' ' PHE . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' J' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.413 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.59 HG13 ' N ' ' K' ' 25' ' ' GLY . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.59 ' N ' HG13 ' K' ' 24' ' ' VAL . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.401 ' H ' ' HA ' ' J' ' 28' ' ' LYS . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.462 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.688 HG23 HD13 ' K' ' 34' ' ' LEU . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.836 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.836 HD12 ' C ' ' K' ' 33' ' ' GLY . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.945 HG11 HD11 ' I' ' 17' ' ' LEU . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.457 HG12 HG13 ' K' ' 40' ' ' VAL . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.615 HG23 ' H ' ' J' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -117.26 142.12 47.45 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.949 0.404 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.437 ' OE1' ' O ' ' K' ' 11' ' ' GLU . 69.6 mm-40 -82.64 131.69 35.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.771 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.528 HG23 ' O ' ' L' ' 12' ' ' VAL . 6.3 m -125.75 123.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.415 ' CE1' HD21 ' K' ' 17' ' ' LEU . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.863 ' O ' HG13 ' L' ' 24' ' ' VAL . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.863 HG13 ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.433 ' HB2' ' OD2' ' J' ' 23' ' ' ASP . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.424 HD13 ' O ' ' F' ' 38' ' ' GLY . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.564 HD12 ' O ' ' K' ' 34' ' ' LEU . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.508 HG13 ' HG ' ' L' ' 34' ' ' LEU . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 13' ' ' HIS . . . . . 0.474 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.62 ' HD1' ' CD2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.452 ' OE1' HD11 ' M' ' 17' ' ' LEU . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.455 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t -60.62 141.89 16.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.07 29.44 0.59 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t 63.03 -120.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -111.34 169.87 8.5 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.285 0.564 . . . . 0.0 111.168 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -38.74 -39.84 0.55 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.209 -0.905 . . . . 0.0 112.84 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.44 65.17 0.24 Allowed Glycine 0 CA--C 1.535 1.327 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.871 -177.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.46 135.52 35.12 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -106.23 131.39 53.52 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -141.38 163.09 33.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.031 0.443 . . . . 0.0 110.503 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' N' ' 13' ' ' HIS . 67.2 t -132.23 167.46 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.9 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.731 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' HD1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.576 HE21 HG22 ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.412 HD11 HG21 ' P' ' 36' ' ' VAL . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.634 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.628 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.512 ' O ' HD12 ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.468 HG22 ' O ' ' N' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -113.38 136.92 52.24 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.735 0.302 . . . . 0.0 110.45 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -113.32 117.77 32.74 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.65 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m -137.4 161.11 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.863 HD21 HG21 ' Q' ' 36' ' ' VAL . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.548 ' H ' ' HB2' ' P' ' 22' ' ' GLU . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.624 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.624 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.628 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.527 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.527 HD12 ' O ' ' O' ' 33' ' ' GLY . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.575 ' O ' HG23 ' O' ' 36' ' ' VAL . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.696 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -110.04 138.95 45.71 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 56.8 mp0 -137.65 144.57 41.92 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.048 0.452 . . . . 0.0 111.007 -179.515 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.48 128.84 75.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m80 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.424 ' HA ' ' O ' ' Q' ' 14' ' ' HIS . 73.2 m-70 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.422 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.416 ' HB3' ' CZ ' ' P' ' 19' ' ' PHE . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.548 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.594 HD12 ' CG2' ' I' ' 39' ' ' VAL . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.634 HD13 ' CD1' ' N' ' 19' ' ' PHE . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.74 HD23 ' N ' ' P' ' 35' ' ' MET . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.74 ' N ' HD23 ' P' ' 34' ' ' LEU . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.576 HG22 HE21 ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.696 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.427 ' HB2' HE21 ' Q' ' 15' ' ' GLN . 3.6 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.613 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.404 ' CB ' ' NZ ' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.416 HG23 HG23 ' P' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' R' ' 34' ' ' LEU . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.863 HG21 HD21 ' O' ' 17' ' ' LEU . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.623 HG12 ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.623 ' N ' HG12 ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.469 ' HB3' ' CG1' ' R' ' 24' ' ' VAL . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.469 ' CG1' ' HB3' ' R' ' 21' ' ' ALA . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.435 ' O ' HG23 ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' Q' ' 34' ' ' LEU . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.632 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.801 HG22 HD12 ' F' ' 31' ' ' ILE . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -93.06 135.04 34.59 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.618 0.247 . . . . 0.0 110.395 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -72.52 140.86 48.42 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.257 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.582 HG11 ' HA ' ' B' ' 12' ' ' VAL . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 17' ' ' LEU . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.794 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.811 ' O ' HG13 ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.459 ' H ' HG13 ' B' ' 24' ' ' VAL . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.453 HG12 ' H ' ' A' ' 40' ' ' VAL . 4.3 t -149.63 166.5 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.453 ' H ' HG12 ' A' ' 39' ' ' VAL . 18.9 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.338 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.2 136.24 47.36 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.459 ' O ' HG21 ' A' ' 12' ' ' VAL . 9.4 pt-20 -144.78 152.75 40.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.389 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.582 ' HA ' HG11 ' A' ' 12' ' ' VAL . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.679 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.541 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.768 HD11 HG11 ' D' ' 36' ' ' VAL . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.541 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.993 HG12 ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.993 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.599 HD11 HG13 ' N' ' 39' ' ' VAL . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.648 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.505 ' O ' HG13 ' B' ' 40' ' ' VAL . 13.5 t -56.21 131.7 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.505 HG13 ' O ' ' B' ' 39' ' ' VAL . 16.4 m . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.825 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.405 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -107.17 136.6 46.73 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.673 0.273 . . . . 0.0 110.375 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -136.69 155.65 49.59 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 110.65 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.496 HG23 ' ND1' ' C' ' 14' ' ' HIS . 16.7 m -133.2 161.57 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.528 ' H ' ' CE1' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' HG23 ' C' ' 12' ' ' VAL . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.503 ' OE1' HG13 ' F' ' 36' ' ' VAL . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.476 ' O ' HD23 ' C' ' 17' ' ' LEU . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.782 HD11 HG11 ' E' ' 36' ' ' VAL . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.541 HG22 ' CA ' ' D' ' 25' ' ' GLY . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.455 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.446 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.477 ' O ' ' HB2' ' C' ' 30' ' ' ALA . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' C' ' 29' ' ' GLY . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' C' ' 32' ' ' ILE . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.483 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.416 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.613 ' HB ' HG22 ' D' ' 36' ' ' VAL . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.747 ' O ' HG21 ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.648 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.574 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.519 ' OE1' ' N ' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' H ' ' C' ' 13' ' ' HIS . 5.9 m-70 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.79 HD11 HG11 ' F' ' 36' ' ' VAL . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.541 ' CA ' HG22 ' C' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 10.0 m-20 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.446 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.716 HD11 HG23 ' P' ' 39' ' ' VAL . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.412 HD13 ' CD1' ' B' ' 19' ' ' PHE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.59 ' N ' HD23 ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.768 HG11 HD11 ' B' ' 17' ' ' LEU . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.905 HG13 HD12 ' J' ' 31' ' ' ILE . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.438 ' H ' HG11 ' E' ' 39' ' ' VAL . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.19 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -116.04 141.66 47.84 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.531 ' HB3' ' CE1' ' E' ' 13' ' ' HIS . 96.4 mt-10 -138.55 150.15 46.05 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.663 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.78 134.01 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.531 ' CE1' ' HB3' ' E' ' 11' ' ' GLU . 40.6 m-70 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.604 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 49.1 m-70 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.516 ' C ' HD12 ' E' ' 17' ' ' LEU . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.599 HD11 ' OE1' ' D' ' 15' ' ' GLN . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.602 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.653 HG12 ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.653 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.642 ' O ' HG13 ' Q' ' 39' ' ' VAL . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.509 HG22 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.484 HD12 ' N ' ' E' ' 35' ' ' MET . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.484 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.782 HG11 HD11 ' C' ' 17' ' ' LEU . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.84 HG21 HD11 ' J' ' 31' ' ' ILE . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 10' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 77.1 t80 -71.3 135.05 47.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.692 0.282 . . . . 0.0 110.509 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.485 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 96.9 mt-10 -72.26 152.39 42.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.522 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -114.27 129.39 70.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.432 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.642 ' C ' HD12 ' F' ' 17' ' ' LEU . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.642 HD12 ' C ' ' F' ' 16' ' ' LYS . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.569 ' OE1' ' N ' ' F' ' 22' ' ' GLU . 46.4 mp0 -93.35 132.4 37.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 56.99 59.87 3.27 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.33 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' F' ' 25' ' ' GLY . 12.0 t 71.76 -170.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -81.76 -35.45 22.08 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 119.977 -1.106 . . . . 0.0 111.033 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 30.8 t -81.44 119.87 24.28 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.606 ' O ' ' N ' ' F' ' 29' ' ' GLY . 28.5 m120 -88.91 155.83 19.28 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.264 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -47.01 47.31 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 177.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.606 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' R' ' 39' ' ' VAL . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' D' ' 19' ' ' PHE . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.703 HD21 ' CG2' ' F' ' 36' ' ' VAL . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.79 HG11 HD11 ' D' ' 17' ' ' LEU . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.795 HG23 HD12 ' L' ' 31' ' ' ILE . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.533 HG22 ' O ' ' F' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.573 HG21 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.626 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.586 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.6 HD21 HG11 ' I' ' 36' ' ' VAL . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.522 HG13 ' O ' ' G' ' 18' ' ' VAL . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' G' ' 24' ' ' VAL . 98.3 mt-10 -137.86 -178.41 5.24 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.451 ' C ' ' O ' ' G' ' 22' ' ' GLU . 67.9 t0 4.71 60.53 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.299 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.607 ' H ' HG21 ' H' ' 24' ' ' VAL . 11.8 t -70.95 123.33 24.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.351 178.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.82 -34.24 4.42 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.174 -1.571 . . . . 0.0 109.174 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' G' ' 27' ' ' ASN . 56.2 p -151.04 123.91 8.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.474 ' OD1' ' N ' ' H' ' 29' ' ' GLY . 3.8 t30 -41.68 150.8 0.1 Allowed 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.864 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -74.71 -50.33 17.91 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.654 -179.477 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.449 ' N ' ' ND2' ' G' ' 27' ' ' ASN . . . 89.31 50.35 3.23 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.039 -0.867 . . . . 0.0 110.965 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.61 137.79 49.81 Favored 'General case' 0 C--N 1.349 0.559 0 CA-C-N 119.041 1.421 . . . . 0.0 114.727 -176.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.43 HD11 ' N ' ' A' ' 40' ' ' VAL . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.564 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t -91.86 135.06 28.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.039 -0.981 . . . . 0.0 111.4 179.839 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -112.75 139.76 48.09 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.681 0.276 . . . . 0.0 110.604 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -87.5 130.54 34.67 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.816 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.603 HG23 ' O ' ' H' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.626 ' CE1' ' O ' ' G' ' 13' ' ' HIS . 7.2 t-80 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.586 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.51 HD11 HG13 ' K' ' 36' ' ' VAL . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.463 HG13 ' CG1' ' I' ' 18' ' ' VAL . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.696 ' HB1' ' HZ1' ' H' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.619 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 -157.15 47.64 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.607 HG21 ' H ' ' G' ' 24' ' ' VAL . 0.7 OUTLIER -62.59 -166.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 120.435 -0.506 . . . . 0.0 109.93 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -91.31 27.67 9.11 Favored Glycine 0 N--CA 1.468 0.818 0 CA-C-N 116.733 -0.212 . . . . 0.0 113.243 -173.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.466 ' O ' ' O ' ' H' ' 27' ' ' ASN . 60.5 p -153.44 120.45 5.74 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.466 ' O ' ' O ' ' H' ' 26' ' ' SER . 99.8 m-20 -40.74 167.01 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.817 -177.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.696 ' HZ1' ' HB1' ' H' ' 21' ' ' ALA . 98.7 mttt -79.46 -49.31 12.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.14 -178.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 90.16 53.17 2.4 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 119.282 -1.437 . . . . 0.0 112.3 179.582 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.564 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.584 ' HA3' HD13 ' N' ' 31' ' ' ILE . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.507 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p -69.46 131.0 34.4 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 95.2 t . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.772 -179.751 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.466 ' CE2' ' O ' ' I' ' 11' ' ' GLU . 87.8 t80 -71.86 135.02 46.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.921 0.391 . . . . 0.0 110.471 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 -78.35 156.91 29.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.782 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.518 ' CG ' HD11 ' I' ' 17' ' ' LEU . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.439 ' C ' HD12 ' I' ' 17' ' ' LEU . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.856 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.463 ' CG1' HG13 ' H' ' 18' ' ' VAL . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.481 ' HB1' ' HE3' ' I' ' 28' ' ' LYS . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.448 ' HA ' ' CB ' ' H' ' 23' ' ' ASP . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.413 ' O ' ' O ' ' I' ' 26' ' ' SER . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.574 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.594 HG23 HD13 ' I' ' 34' ' ' LEU . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.813 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.813 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.6 HG11 HD21 ' G' ' 17' ' ' LEU . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.626 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.411 ' H ' ' CG1' ' I' ' 12' ' ' VAL . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CB ' HG13 ' L' ' 40' ' ' VAL . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' HA ' ' K' ' 15' ' ' GLN . 0.8 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.544 ' H ' ' HG3' ' K' ' 15' ' ' GLN . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.544 ' C ' HD12 ' J' ' 17' ' ' LEU . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.854 HD21 HG21 ' L' ' 36' ' ' VAL . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.906 HG12 ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.906 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.679 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.905 HD12 HG13 ' D' ' 39' ' ' VAL . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.588 ' CG2' HD21 ' K' ' 34' ' ' LEU . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.534 HD12 ' O ' ' I' ' 34' ' ' LEU . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.452 ' H ' HD12 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.626 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' L' ' 11' ' ' GLU . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.661 ' HD1' ' CE1' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.578 ' HA ' ' CD2' ' J' ' 14' ' ' HIS . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.416 ' CD2' HD13 ' J' ' 17' ' ' LEU . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.431 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.434 ' HB3' HG22 ' L' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 1.038 HG12 ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 1.038 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 26.1 m120 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.665 HD11 HG21 ' F' ' 39' ' ' VAL . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' J' ' 32' ' ' ILE . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.51 HG13 HD11 ' H' ' 17' ' ' LEU . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -110.46 134.95 51.86 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.694 0.283 . . . . 0.0 110.45 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' K' ' 11' ' ' GLU . 97.4 mt-10 -80.93 119.52 23.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.615 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.548 HG22 ' N ' ' L' ' 13' ' ' HIS . 10.4 p -141.04 164.65 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.73 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CE1' ' HD1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.474 ' O ' HG23 ' L' ' 24' ' ' VAL . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.592 ' C ' HG23 ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.592 HG23 ' C ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.795 HD12 HG23 ' F' ' 39' ' ' VAL . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.492 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.854 HG21 HD21 ' J' ' 17' ' ' LEU . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.538 ' HB ' HD11 ' R' ' 31' ' ' ILE . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.46 HG13 ' CB ' ' J' ' 13' ' ' HIS . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' M' M ' 10' ' ' TYR . . . . . 0.509 ' CD2' ' O ' ' N' ' 10' ' ' TYR . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.509 ' OE1' HG12 ' O' ' 36' ' ' VAL . 7.9 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' N' ' 17' ' ' LEU . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' M' ' 25' ' ' GLY . 36.6 t -148.16 178.55 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 63.56 28.63 72.77 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.771 -0.649 . . . . 0.0 113.158 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 90.0 p -108.15 -120.26 0.26 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 117.806 0.803 . . . . 0.0 110.046 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -80.17 171.18 15.43 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.921 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -54.73 -38.85 67.61 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.682 0.753 . . . . 0.0 110.847 177.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.96 1.48 Allowed Glycine 0 CA--C 1.543 1.836 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.394 -177.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.51 -160.0 1.11 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 -178.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.408 ' O ' HG23 ' M' ' 39' ' ' VAL . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' N' N ' 10' ' ' TYR . . . . . 0.509 ' O ' ' CD2' ' M' ' 10' ' ' TYR . 99.4 m-85 -103.95 129.75 51.52 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 11' ' ' GLU . . . . . 0.411 ' H ' ' HG3' ' O' ' 11' ' ' GLU . 16.8 pt-20 -156.22 143.88 19.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.058 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t -125.22 92.71 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.49 ' CD2' HD12 ' M' ' 17' ' ' LEU . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.584 HD13 ' HA3' ' H' ' 38' ' ' GLY . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.599 HG13 HD11 ' B' ' 31' ' ' ILE . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.11 147.68 35.56 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 120.849 0.356 . . . . 0.0 110.789 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.414 ' OE1' ' N ' ' O' ' 11' ' ' GLU . 57.0 mp0 -71.14 136.31 48.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.133 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m -134.14 160.04 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.566 HG22 ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.566 ' N ' HG22 ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.464 ' OD1' ' OD2' ' O' ' 23' ' ' ASP . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.697 HD23 ' N ' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.509 HG12 ' OE1' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.546 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.419 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.577 HG22 ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.577 ' N ' HG22 ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -113.69 141.04 47.73 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.733 0.302 . . . . 0.0 110.41 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -126.88 147.0 50.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.888 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -124.08 134.36 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.728 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.493 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 28.0 t30 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.457 ' C ' ' O ' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.653 HD12 ' H ' ' P' ' 35' ' ' MET . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.653 ' H ' HD12 ' P' ' 34' ' ' LEU . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' N' ' 17' ' ' LEU . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.546 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.716 HG23 HD11 ' D' ' 31' ' ' ILE . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.437 ' H ' HG23 ' P' ' 40' ' ' VAL . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.728 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.569 HD23 ' C ' ' Q' ' 17' ' ' LEU . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.46 ' N ' HD23 ' Q' ' 17' ' ' LEU . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.598 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.541 HG12 ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.541 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.642 HG13 ' O ' ' E' ' 29' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.559 ' N ' HG12 ' Q' ' 39' ' ' VAL . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' R' ' 13' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.596 ' C ' HD12 ' R' ' 17' ' ' LEU . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.596 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.718 HG22 ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.718 ' H ' HG22 ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' L' ' 39' ' ' VAL . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.524 HG22 HD22 ' R' ' 34' ' ' LEU . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.72 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.559 ' HB ' HD11 ' F' ' 31' ' ' ILE . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.6 p90 -149.98 159.87 44.06 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.788 0.328 . . . . 0.0 110.67 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -138.45 154.13 48.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.319 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.496 ' NE2' ' O ' ' C' ' 36' ' ' VAL . 33.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.536 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.536 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.531 HD11 ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.411 ' O ' HD12 ' B' ' 34' ' ' LEU . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t -29.28 151.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.419 HG23 ' H ' ' A' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.867 -1.064 . . . . 0.0 110.742 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -111.39 134.01 53.28 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.555 0.216 . . . . 0.0 110.555 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -139.61 157.2 46.19 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.564 ' HE1' HG23 ' C' ' 12' ' ' VAL . 7.3 m-70 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.75 ' C ' HD22 ' B' ' 17' ' ' LEU . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.75 HD22 ' C ' ' B' ' 16' ' ' LYS . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.517 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' B' ' 30' ' ' ALA . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' B' ' 29' ' ' GLY . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.411 HD12 ' O ' ' A' ' 34' ' ' LEU . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.408 ' H ' HD12 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.408 HG22 HG11 ' C' ' 39' ' ' VAL . 83.5 t -65.65 134.67 29.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 34.5 m . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.142 -0.933 . . . . 0.0 110.1 179.813 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.483 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -104.29 133.33 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.957 0.408 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.2 131.93 56.35 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.983 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.564 HG23 ' HE1' ' B' ' 14' ' ' HIS . 34.0 m -132.4 157.97 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.382 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.47 ' CB ' ' O ' ' D' ' 14' ' ' HIS . 12.1 p80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.667 ' HB3' HD21 ' C' ' 17' ' ' LEU . 27.0 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' C' ' 17' ' ' LEU . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.933 HD22 ' N ' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' E' ' 32' ' ' ILE . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.52 HG12 ' N ' ' C' ' 25' ' ' GLY . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.491 HD11 ' HB ' ' O' ' 39' ' ' VAL . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.799 HG22 HD11 ' D' ' 34' ' ' LEU . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.498 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.498 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.496 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.475 ' CD2' ' HB3' ' E' ' 13' ' ' HIS . 34.4 p80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.68 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.592 HD12 HD22 ' E' ' 17' ' ' LEU . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.473 ' CD1' HD13 ' F' ' 32' ' ' ILE . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.54 ' H ' ' CD ' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.514 HG12 ' OG ' ' E' ' 26' ' ' SER . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.837 HG23 HD13 ' D' ' 34' ' ' LEU . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.665 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.837 HD13 HG23 ' D' ' 32' ' ' ILE . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.598 HG11 HD21 ' B' ' 17' ' ' LEU . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.663 ' CG2' HD11 ' J' ' 31' ' ' ILE . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.419 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -75.01 133.27 41.7 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -73.28 147.67 44.32 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.355 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.5 HG12 ' N ' ' E' ' 13' ' ' HIS . 49.2 t -134.79 164.88 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.782 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.5 ' N ' HG12 ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.592 HD22 HD12 ' D' ' 17' ' ' LEU . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.54 ' CD ' ' H ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.479 ' OD2' ' O ' ' F' ' 26' ' ' SER . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.501 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.501 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.514 ' OG ' HG12 ' D' ' 24' ' ' VAL . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 73.0 m-20 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.61 ' HZ2' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.934 HD11 HG13 ' Q' ' 39' ' ' VAL . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.509 HD13 ' CD2' ' C' ' 19' ' ' PHE . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.644 HD12 ' O ' ' D' ' 34' ' ' LEU . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.446 ' H ' HD12 ' E' ' 34' ' ' LEU . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' C' ' 17' ' ' LEU . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.46 134.39 48.65 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.569 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -111.29 139.92 46.29 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.315 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.05 99.79 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.512 ' ND1' ' N ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.512 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -60.01 139.6 57.33 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 65.6 t0 -70.43 46.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.697 HG12 ' N ' ' F' ' 25' ' ' GLY . 97.2 t -80.64 -179.81 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.697 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -71.16 -32.5 65.59 Favored Glycine 0 CA--C 1.529 0.969 0 C-N-CA 121.001 -0.619 . . . . 0.0 113.019 -178.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.61 ' O ' ' O ' ' F' ' 27' ' ' ASN . 97.1 p -151.54 124.71 8.74 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 118.624 1.212 . . . . 0.0 113.425 -179.563 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.61 ' O ' ' O ' ' F' ' 26' ' ' SER . 37.8 t30 -41.29 -149.92 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.796 1.239 . . . . 0.0 113.053 177.228 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.54 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 95.6 mttt 82.61 50.03 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.451 -1.25 . . . . 0.0 112.976 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.629 HD12 HG11 ' Q' ' 39' ' ' VAL . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.473 HD13 ' CD1' ' D' ' 19' ' ' PHE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.706 HD23 ' O ' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.601 ' HB ' HD21 ' F' ' 34' ' ' LEU . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' E' ' 36' ' ' VAL . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.606 ' HB ' HD11 ' L' ' 31' ' ' ILE . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.463 ' O ' HG13 ' G' ' 12' ' ' VAL . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.466 ' HD1' ' C ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.53 ' O ' HD22 ' G' ' 17' ' ' LEU . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.53 HD22 ' O ' ' G' ' 16' ' ' LYS . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.427 ' HB1' ' N ' ' H' ' 26' ' ' SER . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -142.85 -174.57 4.21 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.449 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 65.3 t0 -59.45 46.33 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 113.972 -1.467 . . . . 0.0 114.581 -178.42 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.719 HG12 ' H ' ' G' ' 25' ' ' GLY . 57.4 t -80.38 179.61 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 118.12 -1.432 . . . . 0.0 107.713 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.719 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -71.39 -33.79 64.12 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.249 -179.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.488 ' O ' ' O ' ' G' ' 27' ' ' ASN . 34.9 t -153.14 122.45 6.66 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 117.424 0.612 . . . . 0.0 111.734 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.488 ' O ' ' O ' ' G' ' 26' ' ' SER . 9.1 m-80 -40.67 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.346 -0.542 . . . . 0.0 109.926 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -80.13 -47.4 14.83 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.698 ' N ' ' ND2' ' H' ' 27' ' ' ASN . . . 81.61 59.32 2.38 Favored Glycine 0 CA--C 1.543 1.789 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 125.53 53.52 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 -175.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.416 HG23 ' CG2' ' H' ' 31' ' ' ILE . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.691 HD23 ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.691 ' H ' HD23 ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.755 ' H ' ' H ' ' H' ' 40' ' ' VAL . 42.6 t -147.28 139.26 18.68 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.794 -179.323 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.402 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.51 133.47 51.14 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.417 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -154.94 125.76 7.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.668 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.409 ' O ' HG23 ' G' ' 12' ' ' VAL . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.665 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.665 ' H ' ' CG ' ' H' ' 14' ' ' HIS . 7.8 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.627 HD12 HD22 ' I' ' 17' ' ' LEU . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.472 ' HZ ' HD13 ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.731 ' HB1' HG13 ' I' ' 24' ' ' VAL . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 -62.52 -59.99 4.17 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.603 HG12 ' H ' ' H' ' 25' ' ' GLY . 3.8 t -84.86 172.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.713 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.603 ' H ' HG12 ' H' ' 24' ' ' VAL . . . 94.67 -34.43 4.75 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.427 ' N ' ' HB1' ' G' ' 21' ' ' ALA . 3.8 m -80.68 120.62 24.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 112.881 -1.66 . . . . 0.0 111.05 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.698 ' ND2' ' N ' ' G' ' 29' ' ' GLY . 10.6 m120 -88.29 161.93 16.89 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.327 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -44.19 -39.82 4.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.417 -177.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.96 64.8 0.25 Allowed Glycine 0 CA--C 1.533 1.181 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.356 -178.268 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.416 ' CG2' HG23 ' G' ' 31' ' ' ILE . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.645 ' O ' HG11 ' I' ' 39' ' ' VAL . 81.0 t -134.64 125.49 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.755 ' H ' ' H ' ' G' ' 39' ' ' VAL . 6.1 p . . . . . 0 C--O 1.218 -0.561 0 CA-C-O 117.805 -1.093 . . . . 0.0 110.828 -178.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.12 133.29 51.95 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.939 0.399 . . . . 0.0 110.571 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.07 115.82 27.42 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.817 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.627 HD22 HD12 ' H' ' 17' ' ' LEU . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.972 HG12 ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.972 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.404 HG21 HD13 ' I' ' 32' ' ' ILE . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.615 ' O ' HG11 ' J' ' 39' ' ' VAL . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.645 HG11 ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.489 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.647 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.602 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.944 HD21 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' D' ' 39' ' ' VAL . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.944 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.663 HD11 ' CG2' ' D' ' 39' ' ' VAL . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.405 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.55 HD23 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.569 HG11 HD21 ' H' ' 17' ' ' LEU . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.615 HG11 ' O ' ' I' ' 38' ' ' GLY . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.475 HG13 ' ND1' ' H' ' 13' ' ' HIS . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 83.8 t60 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.616 ' O ' ' CD2' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.629 HD23 ' N ' ' K' ' 18' ' ' VAL . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.629 ' N ' HD23 ' K' ' 17' ' ' LEU . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.922 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.922 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.602 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.992 HD22 HG13 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.725 ' N ' HD23 ' K' ' 34' ' ' LEU . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.992 HG13 HD22 ' K' ' 34' ' ' LEU . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.505 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.455 ' O ' HD11 ' Q' ' 31' ' ' ILE . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.56 HG23 HD12 ' Q' ' 31' ' ' ILE . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -80.29 136.7 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 110.553 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.37 126.81 30.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.098 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -129.9 132.53 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.44 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.502 HD21 ' NE2' ' K' ' 15' ' ' GLN . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.606 HD11 ' HB ' ' F' ' 39' ' ' VAL . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.479 HD23 ' C ' ' L' ' 34' ' ' LEU . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' HG23 ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.512 ' O ' HG13 ' L' ' 36' ' ' VAL . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.558 HG11 ' HA2' ' Q' ' 29' ' ' GLY . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.562 HG12 ' O ' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' O' ' 36' ' ' VAL . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.552 ' H ' HG21 ' N' ' 24' ' ' VAL . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.713 HG12 ' N ' ' M' ' 25' ' ' GLY . 87.5 t -78.12 -177.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.713 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -90.0 24.59 14.99 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 67.8 m -112.58 126.39 55.3 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 113.878 -1.161 . . . . 0.0 109.243 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 66.9 t30 62.42 155.87 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.942 0.401 . . . . 0.0 110.473 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.76 -49.41 58.94 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -177.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.539 ' O ' ' ND2' ' N' ' 27' ' ' ASN . . . 90.21 50.8 2.92 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.76 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.51 -147.97 0.35 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 117.475 0.638 . . . . 0.0 110.989 -177.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.428 HG22 ' N ' ' M' ' 33' ' ' GLY . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 33' ' ' GLY . . . . . 0.428 ' N ' HG22 ' M' ' 32' ' ' ILE . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -114.21 137.51 51.67 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 11' ' ' GLU . . . . . 0.523 ' OE1' ' N ' ' N' ' 11' ' ' GLU . 56.6 mp0 -112.76 144.31 42.51 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.557 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m -134.52 160.52 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.56 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.484 ' CG ' ' CD2' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 51.4 m80 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.684 HD22 HD12 ' M' ' 17' ' ' LEU . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CE2' ' HB3' ' N' ' 17' ' ' LEU . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' O' ' 23' ' ' ASP . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.53 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.53 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.905 HG22 ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.905 ' H ' HG22 ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' M' ' 29' ' ' GLY . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.613 HD13 HG11 ' I' ' 39' ' ' VAL . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' O' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.531 ' H ' HD11 ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -110.89 131.1 55.33 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.655 0.264 . . . . 0.0 110.876 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -146.99 153.08 39.63 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.36 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p -136.46 148.57 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.322 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.484 ' CD2' ' CG ' ' N' ' 13' ' ' HIS . 30.8 m80 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.582 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.668 ' H ' ' HZ2' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.786 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.786 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.41 ' SD ' ' HB2' ' P' ' 35' ' ' MET . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' M' ' 17' ' ' LEU . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' C' ' 31' ' ' ILE . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.473 ' N ' HG22 ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.16 130.06 55.49 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -143.86 158.62 43.57 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.274 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 47.5 t -126.34 130.88 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.465 ' NE2' HG21 ' R' ' 40' ' ' VAL . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.862 HD21 HG11 ' R' ' 36' ' ' VAL . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.666 ' O ' HG23 ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.415 HG23 ' N ' ' P' ' 25' ' ' GLY . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.415 ' N ' HG23 ' P' ' 24' ' ' VAL . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.706 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.668 ' HZ2' ' H ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 33' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.709 HD12 ' O ' ' O' ' 34' ' ' LEU . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.537 ' H ' HD12 ' P' ' 34' ' ' LEU . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.605 HG12 HD21 ' Q' ' 34' ' ' LEU . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' H ' ' Q' ' 38' ' ' GLY . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.511 ' O ' HG12 ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.402 HG12 ' CE1' ' P' ' 13' ' ' HIS . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.443 ' O ' ' O ' ' P' ' 13' ' ' HIS . 59.6 m170 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.529 ' CZ ' ' HB3' ' Q' ' 21' ' ' ALA . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.548 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.615 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.553 HD21 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.706 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.558 ' HA2' HG11 ' L' ' 39' ' ' VAL . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.56 HD12 HG23 ' K' ' 39' ' ' VAL . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.965 HD23 ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.965 ' N ' HD23 ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.803 HG22 HD22 ' Q' ' 34' ' ' LEU . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.934 HG13 HD11 ' E' ' 31' ' ' ILE . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.409 HG13 ' CG ' ' O' ' 13' ' ' HIS . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' R' ' 17' ' ' LEU . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.548 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 81.7 m-20 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.553 ' C ' HD21 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.55 HG23 ' CD1' ' R' ' 34' ' ' LEU . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.55 ' CD1' HG23 ' R' ' 32' ' ' ILE . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.862 HG11 HD21 ' P' ' 17' ' ' LEU . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.61 ' C ' ' HZ2' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.492 ' C ' ' NZ ' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -149.12 156.76 42.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.728 0.299 . . . . 0.0 110.431 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -154.74 146.53 23.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.963 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 12' ' ' VAL . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.781 ' CD1' HG21 ' C' ' 36' ' ' VAL . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.641 HG12 ' N ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.641 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.427 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.418 ' O ' HG22 ' B' ' 36' ' ' VAL . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.575 HG12 ' N ' ' A' ' 40' ' ' VAL . 61.8 t -85.09 163.07 2.8 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.575 ' N ' HG12 ' A' ' 39' ' ' VAL . 89.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.668 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -77.85 129.95 36.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -158.08 130.12 6.95 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.364 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.554 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 5.7 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.626 HD11 HG21 ' D' ' 36' ' ' VAL . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.436 ' H ' HG22 ' B' ' 24' ' ' VAL . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.46 ' O ' HG21 ' O' ' 39' ' ' VAL . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' N' ' 39' ' ' VAL . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.437 HD12 HG23 ' N' ' 39' ' ' VAL . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.563 HG22 HD11 ' C' ' 34' ' ' LEU . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 34' ' ' LEU . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -85.04 129.09 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.468 0.464 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.567 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -85.07 135.9 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.793 0.33 . . . . 0.0 110.311 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -135.82 141.64 44.73 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.18 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m -136.27 160.47 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.512 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.587 ' HB2' ' HD1' ' D' ' 13' ' ' HIS . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.554 ' OE1' ' NE2' ' B' ' 15' ' ' GLN . 1.2 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.681 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.973 HD21 HG11 ' E' ' 36' ' ' VAL . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.518 ' HZ ' HD23 ' C' ' 17' ' ' LEU . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' B' ' 22' ' ' GLU . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.621 ' CB ' ' ND2' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.738 HG22 HG21 ' D' ' 24' ' ' VAL . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.621 ' ND2' ' CB ' ' C' ' 23' ' ' ASP . 2.5 m120 -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.613 HG23 HD13 ' C' ' 34' ' ' LEU . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.819 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.819 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.781 HG21 ' CD1' ' A' ' 17' ' ' LEU . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.894 HG23 HD11 ' I' ' 31' ' ' ILE . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.448 ' N ' HG12 ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' NE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.587 ' HD1' ' HB2' ' C' ' 13' ' ' HIS . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.552 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 11.6 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.612 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.738 HG21 HG22 ' C' ' 24' ' ' VAL . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.46 ' O ' HG22 ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.656 HG22 HD11 ' E' ' 34' ' ' LEU . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.612 ' CD2' HG22 ' C' ' 36' ' ' VAL . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.85 ' CG1' HG12 ' E' ' 36' ' ' VAL . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.706 HG23 HD11 ' J' ' 31' ' ' ILE . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -111.83 134.97 53.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.687 0.279 . . . . 0.0 110.418 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -112.0 132.16 54.96 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.464 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' E' ' 12' ' ' VAL . 16.4 m -120.15 120.1 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.651 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.431 HD12 ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.475 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.466 HD21 HG13 ' R' ' 40' ' ' VAL . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.437 ' CD1' HG23 ' Q' ' 39' ' ' VAL . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.729 HG23 HD13 ' E' ' 34' ' ' LEU . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.686 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.729 HD13 HG23 ' E' ' 32' ' ' ILE . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.973 HG11 HD21 ' C' ' 17' ' ' LEU . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.596 ' O ' HD12 ' L' ' 31' ' ' ILE . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.64 HG23 HD11 ' K' ' 31' ' ' ILE . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.521 HG22 ' O ' ' F' ' 38' ' ' GLY . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -106.77 135.21 48.71 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.485 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -73.3 147.9 44.06 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.185 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m -136.27 167.85 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.419 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 30.5 p-80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.651 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.489 ' C ' HD23 ' F' ' 17' ' ' LEU . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.63 ' CG ' ' H ' ' F' ' 23' ' ' ASP . 37.1 tt0 -71.67 -173.42 0.95 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.63 ' H ' ' CG ' ' F' ' 22' ' ' GLU . 53.5 p30 -62.52 51.88 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.657 HG12 ' H ' ' F' ' 25' ' ' GLY . 7.5 t -60.58 -131.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.657 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 113.08 27.93 3.53 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.517 ' H ' HG12 ' F' ' 24' ' ' VAL . 40.7 t -140.23 112.67 7.88 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.914 0.387 . . . . 0.0 110.494 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -64.15 179.16 0.58 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.637 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt 63.92 39.62 7.99 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.403 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.545 HG11 ' HG ' ' D' ' 17' ' ' LEU . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.521 ' O ' HG22 ' E' ' 40' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.451 HG13 ' NE2' ' D' ' 13' ' ' HIS . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.59 ' CE1' ' N ' ' H' ' 9' ' ' GLY . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.481 HG23 ' O ' ' G' ' 12' ' ' VAL . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.426 ' NE2' HG12 ' I' ' 36' ' ' VAL . 17.9 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.699 HD11 HG11 ' I' ' 36' ' ' VAL . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.6 HG23 ' O ' ' G' ' 18' ' ' VAL . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.569 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.442 ' HB3' HG11 ' H' ' 24' ' ' VAL . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' G' ' 23' ' ' ASP . 75.8 tt0 -159.48 176.9 11.53 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.431 ' N ' ' HG2' ' G' ' 22' ' ' GLU . 65.6 t0 -46.53 -59.66 2.85 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.789 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.6 m -101.44 174.95 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 176.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 69.29 26.98 74.13 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.866 178.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' G' ' 27' ' ' ASN . 6.1 t -153.21 120.62 5.9 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.724 -0.391 . . . . 0.0 112.021 -176.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.559 ' O ' ' O ' ' G' ' 26' ' ' SER . 67.2 t30 -41.98 -179.33 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.261 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.478 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 63.0 mttp -72.58 -41.14 66.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.229 -0.589 . . . . 0.0 111.824 -178.118 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.0 66.86 0.86 Allowed Glycine 0 CA--C 1.536 1.374 0 C-N-CA 119.527 -1.321 . . . . 0.0 112.145 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.27 -150.77 0.46 Allowed 'General case' 0 C--O 1.234 0.265 0 CA-C-N 117.422 0.611 . . . . 0.0 110.47 -177.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' H' ' 38' ' ' GLY . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.585 HG23 HD13 ' M' ' 31' ' ' ILE . 49.4 t -45.11 145.05 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' H' ' 40' ' ' VAL . 16.5 m . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.06 -0.972 . . . . 0.0 111.039 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 9' ' ' GLY . . . . . 0.59 ' N ' ' CE1' ' G' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -106.94 132.15 53.21 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.765 0.316 . . . . 0.0 110.238 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -133.92 128.12 33.88 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.589 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.605 ' CG ' HG13 ' J' ' 40' ' ' VAL . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.636 ' C ' HD12 ' H' ' 17' ' ' LEU . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.776 ' N ' HD12 ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.502 ' CE1' ' HB3' ' H' ' 17' ' ' LEU . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.475 ' HB1' ' CG1' ' H' ' 24' ' ' VAL . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.47 ' O ' ' N ' ' H' ' 24' ' ' VAL . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 23.78 45.9 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.475 ' CG1' ' HB1' ' H' ' 21' ' ' ALA . 2.4 m -75.77 179.42 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 CA-C-N 114.202 -1.363 . . . . 0.0 114.453 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' I' ' 27' ' ' ASN . . . 103.96 -37.22 3.87 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 111.196 -2.729 . . . . 0.0 117.784 169.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.408 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 43.4 m -66.02 111.39 3.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 121.684 2.742 . . . . 0.0 110.058 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.712 ' O ' ' N ' ' H' ' 29' ' ' GLY . 86.0 m-20 -149.77 142.98 25.1 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.154 -0.619 . . . . 0.0 110.796 173.311 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' H' ' 27' ' ' ASN . 98.8 mttt -9.81 -45.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 172.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.712 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 168.21 61.04 0.03 OUTLIER Glycine 0 CA--C 1.553 2.458 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.566 -175.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.542 ' HB3' HD22 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.516 HG12 ' N ' ' H' ' 40' ' ' VAL . 97.7 t -55.18 159.78 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' G' ' 40' ' ' VAL . 3.9 t . . . . . 0 C--O 1.218 -0.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.65 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.28 132.57 52.17 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.861 0.363 . . . . 0.0 110.427 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -139.17 132.17 29.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.43 HE21 ' HG3' ' J' ' 15' ' ' GLN . 2.3 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.494 ' CD2' HG21 ' K' ' 36' ' ' VAL . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.504 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.504 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.894 HD11 HG23 ' C' ' 39' ' ' VAL . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.903 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.903 HD23 ' O ' ' I' ' 33' ' ' GLY . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.699 HG11 HD11 ' G' ' 17' ' ' LEU . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.52 HG11 HD13 ' N' ' 31' ' ' ILE . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.459 ' O ' ' CG2' ' H' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CD2' HG11 ' L' ' 40' ' ' VAL . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.405 ' HB1' ' OD2' ' J' ' 23' ' ' ASP . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.706 HD11 HG23 ' D' ' 39' ' ' VAL . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.824 HG22 HD11 ' K' ' 34' ' ' LEU . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.874 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.874 HD12 ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.771 HG11 HD21 ' H' ' 17' ' ' LEU . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.665 HG23 HD12 ' P' ' 31' ' ' ILE . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.605 HG13 ' CG ' ' H' ' 13' ' ' HIS . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.401 HG21 HD21 ' Q' ' 27' ' ' ASN . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.431 ' HA ' ' H ' ' J' ' 15' ' ' GLN . 3.1 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.706 HG12 ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.706 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' K' ' 27' ' ' ASN . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.64 HD11 HG23 ' E' ' 39' ' ' VAL . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.581 HG23 HD13 ' K' ' 34' ' ' LEU . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.697 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.824 HD11 HG22 ' J' ' 32' ' ' ILE . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.494 HG21 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.487 ' CG2' HD11 ' P' ' 31' ' ' ILE . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.64 132.51 51.69 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.83 0.348 . . . . 0.0 110.125 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -84.93 117.7 24.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.785 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -128.64 129.08 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.017 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.401 HD23 ' C ' ' L' ' 17' ' ' LEU . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.596 HD12 ' O ' ' E' ' 38' ' ' GLY . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.5 HG23 HD12 ' R' ' 31' ' ' ILE . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' M' ' 14' ' ' HIS . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 13' ' ' HIS . . . . . 0.444 ' C ' ' CG ' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.486 ' CE1' ' HB ' ' M' ' 12' ' ' VAL . 3.0 m80 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.581 ' CD1' HG21 ' O' ' 36' ' ' VAL . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -84.83 150.09 4.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 38.68 5.35 Favored Glycine 0 CA--C 1.532 1.102 0 CA-C-N 114.061 -1.427 . . . . 0.0 115.78 175.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 61.98 111.58 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 116.688 2.107 . . . . 0.0 116.688 170.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.544 ' H ' ' HD2' ' N' ' 28' ' ' LYS . 64.9 t30 -128.81 159.73 34.81 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 105.901 -1.888 . . . . 0.0 105.901 172.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.464 ' C ' ' O ' ' M' ' 27' ' ' ASN . 98.9 mttt -31.09 -40.2 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 113.207 0.817 . . . . 0.0 113.207 -175.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.655 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 82.55 66.98 1.51 Allowed Glycine 0 CA--C 1.538 1.51 0 CA-C-O 117.006 -1.997 . . . . 0.0 110.51 176.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.91 179.77 0.51 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 122.995 3.398 . . . . 0.0 116.633 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.585 HD13 HG23 ' G' ' 39' ' ' VAL . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 35' ' ' MET . . . . . 0.47 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -106.42 133.83 50.5 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 11' ' ' GLU . . . . . 0.426 ' H ' ' HG2' ' O' ' 11' ' ' GLU . 97.1 mt-10 -143.73 111.98 6.31 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.932 0.396 . . . . 0.0 110.571 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t -124.29 131.43 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.667 179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.688 ' HB2' ' HD2' ' O' ' 13' ' ' HIS . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.542 HD23 ' HB2' ' M' ' 17' ' ' LEU . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' N' ' 17' ' ' LEU . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.806 ' OD2' HG23 ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.427 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.427 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.879 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.544 ' HD2' ' H ' ' M' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.779 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.52 HD13 HG11 ' I' ' 39' ' ' VAL . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.416 HG21 HD11 ' O' ' 34' ' ' LEU . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.43 HD12 ' O ' ' M' ' 34' ' ' LEU . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.454 HG13 ' HA3' ' B' ' 29' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -107.88 136.23 47.95 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.722 0.296 . . . . 0.0 110.39 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.426 ' HG2' ' H ' ' N' ' 11' ' ' GLU . 97.2 mt-10 -139.47 120.25 14.34 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m -139.38 160.26 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.688 ' HD2' ' HB2' ' N' ' 13' ' ' HIS . 3.4 m80 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' Q' ' 36' ' ' VAL . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.419 ' CZ ' ' HB3' ' O' ' 17' ' ' LEU . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.806 HG23 ' OD2' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.744 ' N ' HG12 ' O' ' 24' ' ' VAL . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.879 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.779 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.404 HD13 HG21 ' O' ' 32' ' ' ILE . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.561 ' O ' HD12 ' P' ' 34' ' ' LEU . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.639 ' CG2' HG12 ' P' ' 36' ' ' VAL . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.548 HG22 ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.548 ' N ' HG22 ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.17 137.14 46.66 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' CE1' ' P' ' 13' ' ' HIS . 83.7 tt0 -116.66 125.65 52.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.22 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.48 133.27 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.816 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.425 ' CE1' ' OE2' ' P' ' 11' ' ' GLU . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.571 HD22 HD12 ' O' ' 17' ' ' LEU . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 18' ' ' VAL . . . . . 0.423 HG13 ' O ' ' P' ' 18' ' ' VAL . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.728 HG12 ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.728 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.508 ' HA3' HG13 ' J' ' 39' ' ' VAL . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.665 HD12 HG23 ' J' ' 39' ' ' VAL . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.703 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.703 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.779 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.544 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.436 HG13 ' O ' ' P' ' 39' ' ' VAL . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.453 ' HB3' ' CE1' ' Q' ' 13' ' ' HIS . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.453 ' CE1' ' HB3' ' Q' ' 11' ' ' GLU . 30.1 m-70 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.47 ' CE1' HG23 ' R' ' 12' ' ' VAL . 89.6 m-70 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.579 HG23 ' O ' ' Q' ' 24' ' ' VAL . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' Q' ' 30' ' ' ALA . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.516 ' HB2' ' O ' ' Q' ' 29' ' ' GLY . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.449 ' CG2' HG21 ' L' ' 39' ' ' VAL . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.682 HD12 ' O ' ' P' ' 34' ' ' LEU . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.522 ' H ' HD12 ' Q' ' 34' ' ' LEU . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.779 HG22 ' CG2' ' P' ' 36' ' ' VAL . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.544 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' E' ' 31' ' ' ILE . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.489 ' O ' HG12 ' Q' ' 40' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.47 HG23 ' CE1' ' Q' ' 14' ' ' HIS . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.483 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 33.8 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB3' ' R' ' 21' ' ' ALA . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.438 ' HB3' ' CE2' ' R' ' 19' ' ' PHE . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.464 ' HA ' HG12 ' Q' ' 24' ' ' VAL . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.5 HD12 HG23 ' L' ' 39' ' ' VAL . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.543 HG11 HD13 ' P' ' 17' ' ' LEU . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.466 HG13 HD21 ' E' ' 27' ' ' ASN . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -74.62 126.34 30.61 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -158.34 141.59 15.01 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' O ' ' B' ' 12' ' ' VAL . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.761 ' CE1' ' HZ1' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.761 ' HZ1' ' CE1' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.434 ' HB3' ' CE2' ' A' ' 19' ' ' PHE . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.423 ' HG2' ' N ' ' A' ' 23' ' ' ASP . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.423 ' N ' ' HG2' ' A' ' 22' ' ' GLU . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.82 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.599 HG12 HD12 ' B' ' 31' ' ' ILE . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.531 HG22 ' N ' ' A' ' 40' ' ' VAL . 6.5 p -32.68 159.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.531 ' N ' HG22 ' A' ' 39' ' ' VAL . 26.6 m . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.69 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.99 139.66 32.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.834 0.35 . . . . 0.0 110.667 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -146.0 143.87 29.74 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 12' ' ' VAL . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.422 ' NE2' HG11 ' D' ' 40' ' ' VAL . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.842 HD11 HG11 ' D' ' 36' ' ' VAL . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.448 ' HB3' ' HZ1' ' D' ' 28' ' ' LYS . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.647 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.421 HG12 ' N ' ' B' ' 25' ' ' GLY . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.427 ' O ' ' O ' ' B' ' 27' ' ' ASN . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' N ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.828 HD13 ' O ' ' N' ' 38' ' ' GLY . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.405 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.441 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 40' ' ' VAL . 2.7 p -140.48 154.98 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.527 ' OXT' HG22 ' B' ' 40' ' ' VAL . 14.6 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 117.855 -1.069 . . . . 0.0 110.444 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -109.74 131.06 55.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.93 0.395 . . . . 0.0 110.772 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -144.1 146.65 32.94 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.248 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t -119.64 129.52 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.56 ' CD2' ' NZ ' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 11.9 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.685 ' CD2' HD12 ' B' ' 17' ' ' LEU . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.533 ' HB3' ' H ' ' B' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.666 HG12 ' N ' ' C' ' 25' ' ' GLY . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.666 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.534 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.572 HD11 HG23 ' P' ' 39' ' ' VAL . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' C' ' 34' ' ' LEU . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.823 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.823 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.577 ' O ' HD12 ' J' ' 31' ' ' ILE . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.565 HG12 ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.565 ' N ' HG12 ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.587 HD12 ' N ' ' D' ' 17' ' ' LEU . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' D' ' 26' ' ' SER . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.479 ' H ' HG23 ' D' ' 24' ' ' VAL . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.457 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' B' ' 21' ' ' ALA . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.842 HG11 HD11 ' B' ' 17' ' ' LEU . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.551 HG13 ' O ' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -106.05 133.37 50.86 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.637 0.256 . . . . 0.0 110.37 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -73.63 142.65 46.5 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -112.15 97.72 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.512 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.649 ' CE1' ' O ' ' F' ' 12' ' ' VAL . 23.1 m-70 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.437 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.413 ' H ' HG12 ' R' ' 39' ' ' VAL . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.422 ' O ' ' HB3' ' D' ' 28' ' ' LYS . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' E' ' 34' ' ' LEU . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.558 HG23 HD12 ' K' ' 31' ' ' ILE . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.86 131.77 54.68 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.808 0.337 . . . . 0.0 110.372 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -76.71 145.1 38.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.754 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.649 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m -137.82 169.45 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.443 -179.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.456 ' HB3' ' H ' ' E' ' 13' ' ' HIS . 23.0 p-80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -106.23 136.97 45.0 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 54.9 60.76 3.29 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.891 177.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.493 ' O ' HG23 ' F' ' 24' ' ' VAL . 10.2 m -66.05 124.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.21 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.18 -31.96 3.91 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 16.0 p -179.01 -117.36 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.981 0.39 . . . . 0.0 111.374 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -54.54 -179.81 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.5 0.667 . . . . 0.0 112.643 -178.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -67.79 -41.05 83.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.735 -1.12 . . . . 0.0 112.378 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.785 HD12 HG22 ' R' ' 39' ' ' VAL . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.525 HG21 HD23 ' D' ' 17' ' ' LEU . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.574 ' HB ' HD11 ' L' ' 31' ' ' ILE . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.512 HG13 ' H ' ' H' ' 12' ' ' VAL . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.641 HE22 HG23 ' J' ' 36' ' ' VAL . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.633 ' HB1' ' HD3' ' H' ' 28' ' ' LYS . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.445 ' C ' ' H ' ' G' ' 24' ' ' VAL . 21.7 pt-20 -157.57 -150.5 0.27 Allowed 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.4 t0 -70.0 46.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.412 . . . . 0.0 110.652 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.467 HG23 ' H ' ' G' ' 26' ' ' SER . 10.6 m -71.46 -168.54 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.17 28.47 15.56 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.467 ' H ' HG23 ' G' ' 24' ' ' VAL . 35.4 t -80.77 113.83 19.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.493 -0.854 . . . . 0.0 109.373 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -92.03 -176.15 4.31 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.878 -178.382 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -48.74 -40.35 28.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.338 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.28 63.19 0.28 Allowed Glycine 0 CA--C 1.536 1.384 0 CA-C-O 119.519 -0.6 . . . . 0.0 114.201 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.954 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -107.1 101.15 10.58 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 178.754 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.609 ' O ' HD11 ' M' ' 31' ' ' ILE . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p -160.17 150.65 5.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.309 179.487 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -103.63 132.87 49.5 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -74.12 118.49 17.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.55 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.621 HG22 HG12 ' I' ' 12' ' ' VAL . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.582 HE22 HG22 ' K' ' 36' ' ' VAL . 25.7 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.711 HD21 HG21 ' J' ' 36' ' ' VAL . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.4 ' CA ' ' NZ ' ' H' ' 28' ' ' LYS . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.748 ' H ' ' HZ3' ' H' ' 28' ' ' LYS . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.535 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 -117.01 46.95 1.57 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 31.2 m -73.81 176.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.407 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.21 27.3 7.7 Favored Glycine 0 N--CA 1.471 0.991 0 N-CA-C 114.131 0.412 . . . . 0.0 114.131 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.449 ' O ' ' C ' ' H' ' 27' ' ' ASN . 42.8 t -153.78 120.86 5.71 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 117.823 0.811 . . . . 0.0 109.08 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 47.8 m-80 -41.33 150.26 0.09 Allowed 'General case' 0 CA--C 1.52 -0.209 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.619 -178.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.748 ' HZ3' ' H ' ' H' ' 22' ' ' GLU . 90.4 mttt -75.78 -50.57 14.85 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 119.452 -0.899 . . . . 0.0 112.024 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.954 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 89.07 50.32 3.29 Favored Glycine 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 178.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.442 ' O ' HD23 ' I' ' 34' ' ' LEU . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.554 ' O ' HG23 ' I' ' 39' ' ' VAL . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p -156.78 146.71 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.299 -179.922 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.531 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 94.7 m-85 -108.14 136.34 47.97 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.774 0.321 . . . . 0.0 110.43 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -113.44 126.52 55.43 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.571 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.621 HG12 HG22 ' H' ' 12' ' ' VAL . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.585 ' OE1' HD21 ' J' ' 17' ' ' LEU . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.886 HD11 HG21 ' K' ' 36' ' ' VAL . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.442 HG23 ' H ' ' I' ' 24' ' ' VAL . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 12.9 m120 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.639 ' HZ2' ' HZ3' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.407 HD13 ' O ' ' C' ' 38' ' ' GLY . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.456 HD22 HG13 ' I' ' 36' ' ' VAL . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.573 ' CG2' HD21 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.554 HG23 ' O ' ' H' ' 38' ' ' GLY . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.598 ' OXT' HG13 ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.477 ' H ' HG23 ' I' ' 12' ' ' VAL . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.484 ' CD2' HG21 ' K' ' 40' ' ' VAL . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.555 ' CD ' HD21 ' K' ' 17' ' ' LEU . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.724 ' O ' HD23 ' J' ' 17' ' ' LEU . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.863 HD22 HD12 ' I' ' 17' ' ' LEU . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.639 ' HZ3' ' HZ2' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.577 HD12 ' O ' ' C' ' 38' ' ' GLY . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.958 HD23 ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.958 ' N ' HD23 ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.711 HG21 HD21 ' H' ' 17' ' ' LEU . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.406 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.555 HD21 ' CD ' ' J' ' 15' ' ' GLN . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.454 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.56 ' NZ ' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.558 HD12 HG23 ' E' ' 39' ' ' VAL . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.444 HG21 HD13 ' K' ' 32' ' ' ILE . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.46 ' O ' HD12 ' L' ' 34' ' ' LEU . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.886 HG21 HD11 ' I' ' 17' ' ' LEU . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.49 ' N ' HG22 ' K' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -100.02 133.44 44.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 110.547 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -110.0 122.24 47.1 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.42 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.453 HG12 ' NE2' ' K' ' 14' ' ' HIS . 28.6 t -126.77 127.22 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.406 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.607 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 18' ' ' VAL . . . . . 0.524 ' N ' HD23 ' L' ' 17' ' ' LEU . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.785 HG22 ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.785 ' H ' HG22 ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.529 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.574 HD11 ' HB ' ' F' ' 39' ' ' VAL . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.786 HD11 HG12 ' K' ' 36' ' ' VAL . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.542 ' H ' HD12 ' L' ' 34' ' ' LEU . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.801 HG11 ' CD1' ' J' ' 17' ' ' LEU . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.681 HG22 HD12 ' R' ' 31' ' ' ILE . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.487 HG11 ' N ' ' N' ' 13' ' ' HIS . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 18' ' ' VAL . . . . . 0.415 HG13 ' O ' ' M' ' 18' ' ' VAL . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m -84.15 172.16 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.73 -34.42 4.77 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.405 ' C ' ' OD1' ' N' ' 27' ' ' ASN . 2.0 m -80.47 120.19 24.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.602 -0.799 . . . . 0.0 111.189 -179.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.447 ' O ' ' OD1' ' N' ' 27' ' ' ASN . 97.3 m-20 -90.26 164.27 14.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.835 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -42.78 -38.01 1.97 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.56 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.59 74.85 0.07 OUTLIER Glycine 0 CA--C 1.531 1.083 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.568 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.7 109.05 15.75 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -178.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.609 HD11 ' O ' ' G' ' 38' ' ' GLY . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.609 HG12 ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.609 ' N ' HG12 ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -107.84 132.15 53.74 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.758 0.313 . . . . 0.0 110.705 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 11' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' M' ' 12' ' ' VAL . 81.7 tt0 -74.69 135.48 41.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.286 -0.416 . . . . 0.0 109.971 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m -137.19 159.18 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.487 ' N ' HG11 ' M' ' 12' ' ' VAL . 30.8 t-80 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' OE1' ' O' ' 15' ' ' GLN . 0.1 OUTLIER -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.737 HD21 HG11 ' P' ' 36' ' ' VAL . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.447 ' OD1' ' O ' ' M' ' 27' ' ' ASN . 3.3 m120 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.41 HD13 HG21 ' N' ' 31' ' ' ILE . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.438 ' H ' ' HB3' ' O' ' 34' ' ' LEU . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.828 ' O ' HD13 ' B' ' 31' ' ' ILE . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.09 137.92 51.69 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.846 0.355 . . . . 0.0 110.539 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.74 148.68 22.31 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.29 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.48 ' O ' HG21 ' N' ' 12' ' ' VAL . 15.7 m -120.54 132.49 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.756 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 78.5 m80 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.53 ' OE1' ' NE2' ' N' ' 15' ' ' GLN . 17.3 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.614 ' N ' HD12 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.71 ' H ' HG11 ' P' ' 24' ' ' VAL . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.54 HG23 HD21 ' O' ' 34' ' ' LEU . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.564 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.793 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.48 HG23 HD12 ' C' ' 31' ' ' ILE . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -83.62 139.98 32.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.982 0.42 . . . . 0.0 110.76 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -140.14 165.37 27.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.785 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.47 HG23 ' O ' ' Q' ' 12' ' ' VAL . 1.3 p -106.68 114.54 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.756 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.483 ' H ' ' CD2' ' P' ' 14' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 16' ' ' LYS . . . . . 0.493 ' C ' HD12 ' P' ' 17' ' ' LEU . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.855 ' N ' HD12 ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.618 ' CD1' HD13 ' R' ' 32' ' ' ILE . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.682 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.776 HG13 ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.776 ' N ' HG13 ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.793 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.737 HG11 HD21 ' N' ' 17' ' ' LEU . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.404 ' N ' ' HA2' ' Q' ' 37' ' ' GLY . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.572 HG23 HD11 ' C' ' 31' ' ' ILE . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.483 HG13 ' CE1' ' N' ' 13' ' ' HIS . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.47 ' O ' HG23 ' P' ' 12' ' ' VAL . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.479 ' N ' HD23 ' Q' ' 17' ' ' LEU . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.61 ' CG ' HG22 ' R' ' 24' ' ' VAL . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.817 HG12 ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.817 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.406 ' H ' ' CB ' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' K' ' 39' ' ' VAL . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.984 HD23 ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.984 ' N ' HD23 ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.451 ' CG2' HD11 ' R' ' 34' ' ' LEU . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.404 ' HA2' ' N ' ' P' ' 38' ' ' GLY . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 18' ' ' VAL . . . . . 0.418 ' O ' HG13 ' R' ' 18' ' ' VAL . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.723 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.534 ' N ' HG23 ' R' ' 24' ' ' VAL . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.723 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.681 HD12 HG22 ' L' ' 39' ' ' VAL . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.618 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.451 HD11 ' CG2' ' Q' ' 36' ' ' VAL . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.785 HG22 HD12 ' F' ' 31' ' ' ILE . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -114.69 136.28 53.24 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.72 0.295 . . . . 0.0 110.307 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -141.63 142.96 33.41 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.495 ' CG1' ' NE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.827 ' HD1' ' H ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' D' ' 36' ' ' VAL . 6.3 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.448 HD11 HG21 ' C' ' 36' ' ' VAL . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.654 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.49 ' O ' HG23 ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.59 HG12 ' N ' ' A' ' 37' ' ' GLY . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.59 ' N ' HG12 ' A' ' 36' ' ' VAL . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.532 ' O ' HD13 ' H' ' 31' ' ' ILE . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.484 HG23 HD12 ' G' ' 31' ' ' ILE . 51.3 t -133.05 133.8 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.508 HG12 ' O ' ' A' ' 40' ' ' VAL . 66.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.568 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -107.62 139.92 41.43 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.669 0.271 . . . . 0.0 110.468 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -70.54 130.98 43.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.827 ' H ' ' HD1' ' A' ' 14' ' ' HIS . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.521 ' C ' HD12 ' B' ' 17' ' ' LEU . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.761 HD21 HG21 ' D' ' 36' ' ' VAL . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.436 HD11 HD12 ' A' ' 31' ' ' ILE . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.732 ' HB2' HD13 ' C' ' 34' ' ' LEU . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.433 HG23 HD11 ' H' ' 31' ' ' ILE . 25.1 t -133.96 131.45 56.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 90.3 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.455 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 10' ' ' TYR . . . . . 0.531 ' CD1' ' O ' ' D' ' 9' ' ' GLY . 95.8 m-85 -101.68 132.42 47.38 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.01 145.65 38.05 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 121.077 0.465 . . . . 0.0 111.351 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -120.97 129.41 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.646 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.44 ' H ' ' HG3' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.536 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.536 HD12 ' C ' ' C' ' 16' ' ' LYS . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.42 HG13 ' HA ' ' B' ' 18' ' ' VAL . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.576 HD12 ' HB ' ' O' ' 39' ' ' VAL . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.512 ' CG2' HD21 ' D' ' 34' ' ' LEU . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.761 HD12 ' N ' ' C' ' 35' ' ' MET . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.761 ' N ' HD12 ' C' ' 34' ' ' LEU . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' D' ' 38' ' ' GLY . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' I' ' 31' ' ' ILE . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' E' ' 11' ' ' GLU . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.646 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 7.1 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.849 HD21 HG21 ' F' ' 36' ' ' VAL . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' E' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.552 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 31.6 m120 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.541 ' HA2' HG21 ' P' ' 39' ' ' VAL . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.615 HD11 ' HB ' ' P' ' 39' ' ' VAL . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.518 HG22 HD11 ' E' ' 34' ' ' LEU . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' C' ' 32' ' ' ILE . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.761 HG21 HD21 ' B' ' 17' ' ' LEU . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.477 ' N ' ' O ' ' C' ' 38' ' ' GLY . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.517 ' CG2' HD11 ' J' ' 31' ' ' ILE . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.412 ' O ' HG12 ' D' ' 39' ' ' VAL . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -108.09 135.29 49.69 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 120.742 0.306 . . . . 0.0 110.224 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' D' ' 11' ' ' GLU . 80.2 mm-40 -85.33 118.59 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.419 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -122.64 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 29.8 m170 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.419 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.611 ' CE2' HD12 ' F' ' 32' ' ' ILE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.692 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.552 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.419 ' O ' ' N ' ' E' ' 29' ' ' GLY . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.5 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.524 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.714 HD11 HG11 ' Q' ' 39' ' ' VAL . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.923 HG23 HD13 ' E' ' 34' ' ' LEU . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.709 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.923 HD13 HG23 ' E' ' 32' ' ' ILE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.511 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.602 HG22 HD12 ' L' ' 31' ' ' ILE . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.487 ' OXT' HG12 ' E' ' 40' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.41 135.37 54.17 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.841 0.353 . . . . 0.0 110.423 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -136.92 158.04 45.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.446 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t -106.6 109.33 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.601 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 133.87 -174.15 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -120.94 54.89 1.07 Allowed 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 176.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.406 ' O ' HG13 ' F' ' 24' ' ' VAL . 10.7 p -66.59 134.83 29.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 114.964 -1.016 . . . . 0.0 111.746 -178.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.93 -31.66 2.04 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 108.501 -1.839 . . . . 0.0 108.501 177.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.3 t -81.26 -129.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.628 -0.786 . . . . 0.0 110.012 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -99.91 161.02 13.87 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.27 -40.38 3.45 Favored 'General case' 0 C--O 1.232 0.156 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.985 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.524 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.831 HD11 HG23 ' R' ' 39' ' ' VAL . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.611 HD12 ' CE2' ' E' ' 19' ' ' PHE . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.849 HG21 HD21 ' D' ' 17' ' ' LEU . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.921 HG12 HD11 ' L' ' 31' ' ' ILE . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.637 HG23 ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.498 ' CD1' HG21 ' I' ' 36' ' ' VAL . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.436 ' O ' ' ND2' ' H' ' 27' ' ' ASN . 67.0 tt0 -143.82 167.17 22.94 Favored 'General case' 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -73.52 49.59 0.29 Allowed 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 119.029 -1.068 . . . . 0.0 111.372 -179.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.721 HG12 ' N ' ' G' ' 25' ' ' GLY . 95.1 t -156.36 178.74 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.721 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 61.39 28.92 70.23 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 120.774 -0.727 . . . . 0.0 113.449 177.139 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 43.7 t -154.15 111.37 3.41 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 118.42 1.11 . . . . 0.0 112.122 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.541 ' C ' ' HZ2' ' H' ' 28' ' ' LYS . 98.8 m-20 -53.22 172.49 0.06 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.067 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.404 ' N ' ' HZ3' ' H' ' 28' ' ' LYS . 66.0 tttm -60.46 -39.22 86.79 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.35 0.595 . . . . 0.0 110.555 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -104.55 70.23 0.25 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-N 115.034 -0.985 . . . . 0.0 112.404 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.61 85.34 2.91 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 -177.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.508 HG23 ' O ' ' G' ' 31' ' ' ILE . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.461 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.529 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.7 p -137.09 161.06 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.529 ' N ' HG22 ' G' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.019 -0.991 . . . . 0.0 111.0 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -82.81 138.24 34.05 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.923 0.392 . . . . 0.0 110.36 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 -94.54 146.32 24.19 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.67 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.718 HD21 HG11 ' J' ' 36' ' ' VAL . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.46 ' CB ' ' H ' ' I' ' 24' ' ' VAL . 1.6 m-20 -149.88 51.29 0.92 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.441 HG12 ' H ' ' H' ' 25' ' ' GLY . 2.2 t -100.15 -141.06 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -174.329 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.569 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -71.07 -34.14 64.94 Favored Glycine 0 N--CA 1.461 0.308 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.955 -172.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.569 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 12.0 t 139.59 113.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 174.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' G' ' 22' ' ' GLU . 28.3 t-20 -57.01 170.57 0.43 Allowed 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.878 -1.51 . . . . 0.0 108.938 175.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.541 ' HZ2' ' C ' ' G' ' 27' ' ' ASN . 98.6 mttt -58.97 -41.36 87.33 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.353 178.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.6 62.27 0.5 Allowed Glycine 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -177.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.532 HD13 ' O ' ' A' ' 38' ' ' GLY . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.594 HG22 HD11 ' I' ' 34' ' ' LEU . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p -6.23 122.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.409 ' H ' HG22 ' H' ' 40' ' ' VAL . 8.2 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.457 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.344 -1.503 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -130.79 140.61 50.3 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.3 109.11 19.29 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.6 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.61 ' CD2' HG12 ' K' ' 40' ' ' VAL . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.6 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.615 ' NE2' ' OE1' ' J' ' 15' ' ' GLN . 7.8 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' O ' HD23 ' I' ' 17' ' ' LEU . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.497 HD22 HD12 ' H' ' 17' ' ' LEU . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.775 ' HB3' ' HZ1' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.549 ' HG2' HG23 ' I' ' 24' ' ' VAL . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.549 HG23 ' HG2' ' I' ' 22' ' ' GLU . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.553 HD11 ' CG2' ' C' ' 39' ' ' VAL . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.516 HG23 HD13 ' I' ' 34' ' ' LEU . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.831 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.831 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.513 HG23 ' O ' ' I' ' 36' ' ' VAL . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.47 ' O ' HD13 ' O' ' 31' ' ' ILE . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.542 HG12 ' O ' ' I' ' 40' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 10.9 m-70 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.615 ' OE1' ' NE2' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.466 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.546 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.522 HD12 HG23 ' C' ' 39' ' ' VAL . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.737 HG22 HD11 ' K' ' 34' ' ' LEU . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.644 HD23 ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.718 HG11 HD21 ' H' ' 17' ' ' LEU . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.408 ' H ' HG22 ' J' ' 39' ' ' VAL . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.504 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 15.1 p-80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.414 ' HB3' ' H ' ' L' ' 14' ' ' HIS . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.455 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.775 ' HZ1' ' HB3' ' I' ' 21' ' ' ALA . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.515 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.626 HG23 HD13 ' K' ' 34' ' ' LEU . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' K' ' 33' ' ' GLY . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.61 HG12 ' CD2' ' I' ' 13' ' ' HIS . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -149.49 159.51 44.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.706 0.289 . . . . 0.0 110.296 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.526 ' OE1' ' N ' ' L' ' 11' ' ' GLU . 57.6 mp0 -139.99 157.61 45.39 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.93 0.395 . . . . 0.0 110.493 -179.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.557 HG22 ' N ' ' L' ' 13' ' ' HIS . 2.7 p -140.53 166.2 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.916 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.557 ' N ' HG22 ' L' ' 12' ' ' VAL . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.414 ' H ' ' HB3' ' K' ' 14' ' ' HIS . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.432 HG12 ' N ' ' L' ' 25' ' ' GLY . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.437 ' O ' ' CG ' ' K' ' 27' ' ' ASN . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.921 HD11 HG12 ' F' ' 39' ' ' VAL . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.593 HD21 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 6.3 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.667 HD11 HG21 ' O' ' 36' ' ' VAL . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 18' ' ' VAL . . . . . 0.573 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 19' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' O' ' 32' ' ' ILE . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 21' ' ' ALA . . . . . 0.641 ' HB1' ' H ' ' N' ' 28' ' ' LYS . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.44 ' H ' HG22 ' M' ' 24' ' ' VAL . 3.9 m -71.24 -168.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.94 28.13 17.08 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' N' ' 28' ' ' LYS . 29.2 t -81.09 114.93 20.27 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.66 -179.15 5.97 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.052 0.93 . . . . 0.0 113.033 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -55.77 -39.17 70.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.867 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.21 68.47 0.44 Allowed Glycine 0 CA--C 1.534 1.262 0 C-N-CA 121.076 -0.583 . . . . 0.0 113.636 -176.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.8 106.8 11.62 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 178.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -111.61 134.98 52.81 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.73 0.3 . . . . 0.0 110.264 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -138.85 109.98 6.85 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 121.075 0.464 . . . . 0.0 110.774 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -126.96 132.01 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.115 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.772 HD11 HG11 ' P' ' 36' ' ' VAL . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.641 ' H ' ' HB1' ' M' ' 21' ' ' ALA . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.596 HG22 ' CG1' ' O' ' 39' ' ' VAL . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' O' O ' 10' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' P' ' 9' ' ' GLY . 53.2 p90 -148.76 162.3 40.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.74 0.305 . . . . 0.0 110.282 179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.416 ' H ' ' HG2' ' P' ' 11' ' ' GLU . 98.3 mt-10 -138.69 111.76 7.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.122 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.556 HG12 ' H ' ' P' ' 12' ' ' VAL . 30.9 m -127.74 135.47 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.837 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.473 ' NE2' ' O ' ' Q' ' 37' ' ' GLY . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.607 ' C ' HD12 ' O' ' 17' ' ' LEU . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.618 ' HG ' HD12 ' N' ' 17' ' ' LEU . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.593 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.47 HD13 ' O ' ' I' ' 38' ' ' GLY . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.441 HD13 ' CD2' ' M' ' 19' ' ' PHE . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' P' ' 33' ' ' GLY . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.694 HG13 ' O ' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.431 ' H ' ' HA2' ' P' ' 37' ' ' GLY . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.596 ' CG1' HG22 ' N' ' 39' ' ' VAL . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.463 ' H ' HG22 ' O' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 9' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' O' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.93 151.07 43.98 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.416 ' HG2' ' H ' ' O' ' 11' ' ' GLU . 97.9 mt-10 -77.51 110.02 11.94 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.378 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.556 ' H ' HG12 ' O' ' 12' ' ' VAL . 2.3 p -141.04 136.96 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.558 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 2.6 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.495 HD22 HD22 ' O' ' 17' ' ' LEU . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 18' ' ' VAL . . . . . 0.497 HG13 ' O ' ' P' ' 18' ' ' VAL . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.445 ' CD2' HD13 ' R' ' 32' ' ' ILE . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.739 HG22 ' HA ' ' Q' ' 23' ' ' ASP . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.56 ' CG ' HD21 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.593 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' P' ' 34' ' ' LEU . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.493 ' O ' HD12 ' Q' ' 34' ' ' LEU . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.772 HG11 HD11 ' N' ' 17' ' ' LEU . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.416 ' H ' ' CA ' ' O' ' 38' ' ' GLY . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.623 HG23 ' O ' ' Q' ' 39' ' ' VAL . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.536 ' O ' HG22 ' P' ' 39' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.58 HG12 ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.58 ' N ' HG12 ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.558 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.739 ' HA ' HG22 ' P' ' 24' ' ' VAL . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.533 HG22 ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.533 ' N ' HG22 ' Q' ' 24' ' ' VAL . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.56 HD21 ' CG ' ' P' ' 27' ' ' ASN . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.441 HD12 HG23 ' K' ' 39' ' ' VAL . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.493 HD12 ' O ' ' P' ' 34' ' ' LEU . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.616 HG13 ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.714 HG11 HD11 ' E' ' 31' ' ' ILE . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.563 HD23 ' C ' ' R' ' 17' ' ' LEU . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 18' ' ' VAL . . . . . 0.438 ' N ' HD23 ' R' ' 17' ' ' LEU . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.847 HG22 HD22 ' R' ' 34' ' ' LEU . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.847 HD22 HG22 ' R' ' 32' ' ' ILE . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.586 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.831 HG23 HD11 ' F' ' 31' ' ' ILE . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.418 HG22 ' H ' ' R' ' 40' ' ' VAL . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -110.52 136.25 49.94 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -111.32 113.62 26.22 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.5 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.579 HG13 ' O ' ' B' ' 12' ' ' VAL . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.717 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 2.2 m-70 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.469 ' CD1' HG11 ' C' ' 36' ' ' VAL . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.562 ' O ' ' O ' ' A' ' 26' ' ' SER . 46.6 t30 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.783 HD13 ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.486 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p -51.85 147.89 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.838 -1.077 . . . . 0.0 110.609 179.862 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -102.74 133.73 47.3 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -79.89 131.49 35.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.67 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.717 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.767 ' NE2' HG23 ' E' ' 36' ' ' VAL . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.601 ' CD1' HG21 ' D' ' 36' ' ' VAL . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.668 HG21 ' H ' ' C' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.643 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.426 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 8.6 m120 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' C' ' 34' ' ' LEU . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.444 HG21 HG11 ' B' ' 40' ' ' VAL . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.486 ' HA3' ' H ' ' A' ' 38' ' ' GLY . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.683 HG23 HD11 ' H' ' 31' ' ' ILE . 16.6 t -50.2 134.28 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.514 HG13 ' O ' ' B' ' 39' ' ' VAL . 15.9 m . . . . . 0 C--O 1.224 -0.279 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.652 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -115.66 139.1 50.44 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.799 0.333 . . . . 0.0 110.57 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -87.22 117.15 25.78 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t -124.14 129.56 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.498 HE22 HG13 ' E' ' 36' ' ' VAL . 33.4 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.458 ' O ' HD23 ' C' ' 17' ' ' LEU . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.684 HD11 HG11 ' E' ' 36' ' ' VAL . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.441 ' HA ' HG13 ' D' ' 18' ' ' VAL . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.642 ' HB1' HG21 ' C' ' 24' ' ' VAL . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.642 HG21 ' HB1' ' C' ' 21' ' ' ALA . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.668 ' H ' HG21 ' B' ' 24' ' ' VAL . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.596 ' HA3' HG13 ' O' ' 39' ' ' VAL . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.464 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.498 HD12 HG23 ' O' ' 39' ' ' VAL . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' B' ' 34' ' ' LEU . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.454 ' H ' HD12 ' C' ' 34' ' ' LEU . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.49 ' O ' HG13 ' C' ' 36' ' ' VAL . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.594 HG12 ' N ' ' C' ' 40' ' ' VAL . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.594 ' N ' HG12 ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.752 ' HE2' HG12 ' E' ' 12' ' ' VAL . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.623 ' NE2' HG22 ' F' ' 36' ' ' VAL . 22.9 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.715 HD11 HG21 ' F' ' 36' ' ' VAL . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 18' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' C' ' 18' ' ' VAL . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.487 ' O ' HG22 ' P' ' 39' ' ' VAL . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.505 HD12 HG22 ' D' ' 36' ' ' VAL . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.601 HG21 ' CD1' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.789 ' O ' HD12 ' K' ' 31' ' ' ILE . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -105.73 134.2 49.24 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.909 0.385 . . . . 0.0 110.629 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.38 131.79 25.23 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.752 HG12 ' HE2' ' D' ' 14' ' ' HIS . 2.7 t -118.9 123.95 72.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.532 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' D' ' 36' ' ' VAL . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.767 HG23 ' NE2' ' B' ' 15' ' ' GLN . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.904 HG23 HD11 ' K' ' 31' ' ' ILE . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' CG ' ' C' ' 13' ' ' HIS . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.461 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -107.32 134.88 49.74 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.11 141.56 48.67 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.521 HG13 ' O ' ' F' ' 12' ' ' VAL . 9.0 p -117.35 119.17 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -113.5 152.58 30.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 43.6 t0 66.64 50.38 1.2 Allowed 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 120.766 -0.373 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.436 HG12 ' N ' ' F' ' 25' ' ' GLY . 17.5 t -55.73 160.46 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . 130.39 -36.92 2.22 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -176.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.0 m -79.94 118.05 21.33 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.552 ' O ' ' N ' ' F' ' 29' ' ' GLY . 81.9 m-20 -91.99 -161.31 0.81 Allowed 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.817 -176.581 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -47.99 48.63 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 -177.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' F' ' 29' ' ' GLY . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.715 HG21 HD11 ' D' ' 17' ' ' LEU . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.477 ' CG2' HG22 ' E' ' 39' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.424 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.509 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.524 HE21 HD21 ' G' ' 17' ' ' LEU . 51.4 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.897 HD11 HG11 ' I' ' 36' ' ' VAL . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.551 HG23 ' O ' ' G' ' 18' ' ' VAL . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.492 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.444 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 82.5 tt0 -156.66 114.34 3.21 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.454 ' OD2' ' O ' ' G' ' 23' ' ' ASP . 2.5 p-10 47.54 47.62 17.36 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 111.542 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' G' ' 25' ' ' GLY . 16.9 t -52.91 -175.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 165.0 19.73 0.02 OUTLIER Glycine 0 CA--C 1.534 1.24 0 C-N-CA 119.316 -1.421 . . . . 0.0 113.568 -179.024 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.428 ' O ' ' O ' ' G' ' 27' ' ' ASN . 35.1 t -102.23 120.67 40.86 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 118.229 1.014 . . . . 0.0 112.132 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' CE ' ' H' ' 28' ' ' LYS . 76.7 m-20 53.47 151.68 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.16 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.41 -48.26 35.32 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.632 0.729 . . . . 0.0 111.948 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.95 58.11 0.4 Allowed Glycine 0 N--CA 1.476 1.351 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.842 -177.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.37 109.53 17.37 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 -175.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m -58.91 172.63 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.47 0.526 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.432 -179.898 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.32 132.21 52.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.898 0.38 . . . . 0.0 110.414 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -141.21 104.45 4.63 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.557 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB2' ' I' ' 11' ' ' GLU . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.635 ' CD2' ' CG2' ' J' ' 40' ' ' VAL . 80.7 m80 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.7 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.556 HD12 HD22 ' I' ' 17' ' ' LEU . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.47 ' HB1' ' OD2' ' I' ' 23' ' ' ASP . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 -74.69 46.41 0.28 Allowed 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.41 HG11 ' H ' ' G' ' 23' ' ' ASP . 6.8 m -80.36 -179.37 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -70.87 -28.77 70.11 Favored Glycine 0 N--CA 1.466 0.673 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -175.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 0.2 OUTLIER 160.79 125.84 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.807 0.813 . . . . 0.0 112.23 175.086 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.401 HD22 ' HA ' ' I' ' 28' ' ' LYS . 96.6 m-20 -49.23 158.13 0.4 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.32 176.074 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' O ' ' G' ' 27' ' ' ASN . 26.9 tttp -70.26 -48.1 58.38 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 174.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.33 59.81 0.5 Allowed Glycine 0 CA--C 1.542 1.752 0 CA-C-N 114.305 -1.316 . . . . 0.0 112.386 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.683 HD11 HG23 ' B' ' 39' ' ' VAL . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.566 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.46 HG12 ' CD1' ' M' ' 31' ' ' ILE . 12.9 p -167.02 140.62 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.319 -179.692 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -112.97 136.23 52.87 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.968 0.413 . . . . 0.0 110.074 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.539 ' HB2' HG22 ' H' ' 12' ' ' VAL . 78.8 mm-40 -71.03 162.87 28.69 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.798 HG21 ' C ' ' J' ' 12' ' ' VAL . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' H' ' 13' ' ' HIS . 1.1 m80 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.632 ' CE1' HG23 ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.427 ' OE1' HG12 ' K' ' 36' ' ' VAL . 0.7 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.607 ' C ' HD23 ' I' ' 17' ' ' LEU . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.729 HD11 HG11 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.416 ' HB1' ' NZ ' ' I' ' 28' ' ' LYS . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.47 ' OD2' ' HB1' ' H' ' 21' ' ' ALA . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.453 ' H ' ' CB ' ' J' ' 28' ' ' LYS . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.679 HD13 ' CG2' ' J' ' 31' ' ' ILE . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.406 HG21 HD13 ' I' ' 32' ' ' ILE . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.566 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.897 HG11 HD11 ' G' ' 17' ' ' LEU . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.408 ' HA3' ' H ' ' J' ' 37' ' ' GLY . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.467 HG11 HG23 ' J' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.798 ' C ' HG21 ' I' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.578 ' NE2' HG12 ' L' ' 36' ' ' VAL . 2.5 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.808 ' C ' HD12 ' J' ' 17' ' ' LEU . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.808 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' L' ' 32' ' ' ILE . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 27.9 m-20 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.453 ' CB ' ' H ' ' I' ' 28' ' ' LYS . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.679 ' CG2' HD13 ' I' ' 31' ' ' ILE . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.455 HG22 HD21 ' K' ' 34' ' ' LEU . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.408 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.411 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.635 ' O ' HG13 ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' I' ' 37' ' ' GLY . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.635 ' CG2' ' CD2' ' H' ' 13' ' ' HIS . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.529 HE21 ' HG3' ' L' ' 15' ' ' GLN . 2.8 pm0 -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' K' ' 17' ' ' LEU . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.518 HD12 ' C ' ' K' ' 16' ' ' LYS . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.514 ' HB3' ' CE1' ' K' ' 19' ' ' PHE . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 1.057 HG12 ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 1.057 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.904 HD11 HG23 ' E' ' 39' ' ' VAL . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.455 HD21 HG22 ' J' ' 32' ' ' ILE . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.729 HG11 HD11 ' I' ' 17' ' ' LEU . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.423 HG23 ' CD1' ' Q' ' 31' ' ' ILE . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.515 HG23 ' O ' ' K' ' 40' ' ' VAL . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -105.81 134.0 49.63 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.838 0.351 . . . . 0.0 110.581 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.32 127.1 56.03 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.088 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.06 127.95 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 1.8 t60 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.529 ' HG3' HE21 ' K' ' 15' ' ' GLN . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.506 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.444 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.43 HG22 HD22 ' L' ' 34' ' ' LEU . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.43 HD22 HG22 ' L' ' 32' ' ' ILE . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.578 HG12 ' NE2' ' J' ' 15' ' ' GLN . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.565 HG23 HD12 ' R' ' 31' ' ' ILE . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 18' ' ' VAL . . . . . 0.564 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.47 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.551 ' N ' HG23 ' N' ' 24' ' ' VAL . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t -73.34 160.45 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.93 -35.1 5.06 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 177.637 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t -80.35 118.96 22.45 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.334 -0.433 . . . . 0.0 111.818 -178.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -90.37 -179.26 5.57 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.809 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.58 -37.66 18.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.397 179.265 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.49 76.3 0.07 OUTLIER Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -177.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.24 108.82 14.16 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 -176.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.577 HG23 ' O ' ' M' ' 31' ' ' ILE . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.783 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.48 141.22 45.33 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 120.762 0.315 . . . . 0.0 110.347 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -115.86 136.43 53.05 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.129 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -120.93 128.85 76.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.463 ' H ' ' HA ' ' O' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.503 HE22 ' HB ' ' P' ' 36' ' ' VAL . 5.9 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 21' ' ' ALA . . . . . 0.674 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.551 HG23 ' N ' ' M' ' 23' ' ' ASP . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.408 ' O ' HD12 ' N' ' 31' ' ' ILE . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.408 HD12 ' O ' ' N' ' 29' ' ' GLY . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.438 ' CD2' HG12 ' N' ' 36' ' ' VAL . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.426 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.533 HG13 ' O ' ' N' ' 36' ' ' VAL . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' O' ' 37' ' ' GLY . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -149.14 152.5 36.22 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.878 0.37 . . . . 0.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -162.29 143.67 10.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.137 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.762 HG12 ' H ' ' O' ' 13' ' ' HIS . 38.2 t -137.32 176.94 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.013 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.762 ' H ' HG12 ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.499 ' NE2' HG13 ' Q' ' 36' ' ' VAL . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.865 HD12 HD22 ' P' ' 17' ' ' LEU . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 1.055 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 1.055 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.674 ' HZ3' ' HA ' ' N' ' 21' ' ' ALA . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.641 HG23 HD13 ' O' ' 34' ' ' LEU . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.742 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.831 ' O ' HD12 ' P' ' 34' ' ' LEU . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.426 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.637 ' CG2' HD11 ' P' ' 34' ' ' LEU . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.436 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.596 HG13 ' HA3' ' C' ' 29' ' ' GLY . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.522 HG23 ' O ' ' O' ' 39' ' ' VAL . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.054 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -109.57 133.01 53.61 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.617 0.246 . . . . 0.0 110.827 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -140.71 142.73 34.82 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.718 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.613 ' H ' ' CG2' ' O' ' 12' ' ' VAL . 6.5 t -141.34 92.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.532 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.535 ' CE1' HG11 ' O' ' 12' ' ' VAL . 70.9 m80 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.597 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 16' ' ' LYS . . . . . 0.537 ' O ' HD23 ' P' ' 17' ' ' LEU . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.865 HD22 HD12 ' O' ' 17' ' ' LEU . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.508 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' P' ' 30' ' ' ALA . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.609 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.479 HD12 HG23 ' J' ' 39' ' ' VAL . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.402 HG21 HD13 ' P' ' 32' ' ' ILE . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.831 HD12 ' O ' ' O' ' 34' ' ' LEU . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.595 HG23 HG22 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.487 HG22 ' O ' ' D' ' 29' ' ' GLY . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.408 HD12 ' O ' ' R' ' 16' ' ' LYS . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' Q' ' 21' ' ' ALA . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.461 ' HB3' ' CE1' ' Q' ' 19' ' ' PHE . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.504 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' OD1' ' N ' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.423 ' CD1' HG23 ' K' ' 39' ' ' VAL . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.679 HD23 ' N ' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.824 HG11 HD11 ' O' ' 17' ' ' LEU . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.443 HG23 ' O ' ' R' ' 40' ' ' VAL . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.408 ' O ' HD12 ' Q' ' 17' ' ' LEU . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.565 HD12 HG23 ' L' ' 39' ' ' VAL . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.467 HD11 HG13 ' R' ' 36' ' ' VAL . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.467 HG13 HD11 ' R' ' 34' ' ' LEU . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.522 HG22 ' O ' ' R' ' 40' ' ' VAL . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.92 136.38 45.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.767 0.318 . . . . 0.0 110.539 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -99.97 121.36 41.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG13 ' O ' ' B' ' 12' ' ' VAL . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.597 HE22 ' N ' ' D' ' 37' ' ' GLY . 32.0 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.968 HD11 HG11 ' C' ' 36' ' ' VAL . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.593 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.593 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.779 HG12 ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.779 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.74 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -138.18 152.38 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.843 179.663 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -115.03 136.6 52.95 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.764 0.316 . . . . 0.0 110.312 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -134.35 127.75 32.3 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.674 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.614 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 13.0 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.597 HD21 HG11 ' D' ' 36' ' ' VAL . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.934 ' O ' HG13 ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.934 HG13 ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.448 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.48 ' HA3' HG22 ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' O' ' 39' ' ' VAL . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.74 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' C' ' 38' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.73 HG22 HD11 ' H' ' 31' ' ' ILE . 8.2 m -65.15 133.5 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.446 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 54.0 p90 -151.25 162.71 40.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.889 0.376 . . . . 0.0 110.498 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -134.78 150.0 50.48 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.279 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -126.34 138.21 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.595 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.599 ' HB3' HD11 ' C' ' 17' ' ' LEU . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.833 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.59 ' OD1' ' HB1' ' B' ' 21' ' ' ALA . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.561 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.521 HG12 HD12 ' D' ' 31' ' ' ILE . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.638 HG22 HD21 ' D' ' 34' ' ' LEU . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.694 ' N ' HD23 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.409 ' N ' HD12 ' C' ' 34' ' ' LEU . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.968 HG11 HD11 ' A' ' 17' ' ' LEU . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' B' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 27.1 p80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.456 ' NE2' HD11 ' D' ' 17' ' ' LEU . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.549 ' CD2' HD13 ' C' ' 17' ' ' LEU . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.552 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.473 ' OE1' ' CG2' ' D' ' 24' ' ' VAL . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.453 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.561 ' H ' ' CG1' ' C' ' 24' ' ' VAL . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' P' ' 39' ' ' VAL . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.405 HG21 HD13 ' D' ' 32' ' ' ILE . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.694 HD23 ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.597 HG11 HD21 ' B' ' 17' ' ' LEU . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.597 ' N ' HE22 ' A' ' 15' ' ' GLN . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -106.79 134.38 50.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 120.847 0.356 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' D' ' 11' ' ' GLU . 98.2 mt-10 -86.09 114.45 22.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.333 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m -131.45 162.44 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.409 ' CB ' ' HZ3' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' F' ' 22' ' ' GLU . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.586 HG22 ' O ' ' F' ' 22' ' ' GLU . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.552 ' HZ3' ' HB3' ' D' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.485 HD11 ' CG2' ' D' ' 36' ' ' VAL . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' C' ' 17' ' ' LEU . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -112.55 136.15 52.43 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -110.2 113.88 26.91 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.882 0.373 . . . . 0.0 110.65 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.542 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.6 p -141.69 163.59 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.89 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.542 ' N ' HG22 ' F' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.404 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.586 ' O ' HG22 ' E' ' 24' ' ' VAL . 94.1 mt-10 -95.26 117.65 30.64 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' F' ' 22' ' ' GLU . 14.4 t0 89.33 48.45 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.268 0.556 . . . . 0.0 109.581 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 6.4 m -72.04 161.5 4.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.129 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.13 -33.09 6.05 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.366 -0.693 . . . . 0.0 111.366 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.533 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 26.4 t -81.12 -129.42 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 117.58 0.69 . . . . 0.0 110.48 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.533 ' N ' ' OG ' ' F' ' 26' ' ' SER . 63.3 t30 -100.19 160.6 14.2 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -44.29 -40.37 5.2 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.896 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.469 ' HB2' ' HD2' ' E' ' 28' ' ' LYS . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.545 HD12 HG21 ' Q' ' 39' ' ' VAL . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.502 ' O ' HD12 ' F' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.537 HG11 ' CD2' ' D' ' 17' ' ' LEU . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.454 ' CD2' ' O ' ' H' ' 10' ' ' TYR . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.493 HG23 ' O ' ' G' ' 12' ' ' VAL . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.445 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 4.1 pt-20 -167.65 104.93 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' G' ' 22' ' ' GLU . 63.5 m-20 -160.71 46.81 0.22 Allowed 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -175.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.688 HG12 ' N ' ' G' ' 25' ' ' GLY . 51.3 t -82.42 173.7 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.284 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.688 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 91.21 -33.35 4.76 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 36.7 t -151.69 123.64 8.09 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.511 ' OD1' ' N ' ' H' ' 27' ' ' ASN . 16.3 t30 -41.52 150.95 0.09 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.837 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.434 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 88.8 tttt -75.22 -50.5 15.97 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.502 177.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.37 50.32 3.22 Favored Glycine 0 CA--C 1.545 1.931 0 CA-C-O 118.417 -1.213 . . . . 0.0 111.596 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -130.64 105.28 7.71 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.454 HD11 ' HA3' ' H' ' 29' ' ' GLY . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.67 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.67 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.434 ' O ' ' C ' ' G' ' 40' ' ' VAL . 7.9 p -136.12 137.78 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' G' ' 39' ' ' VAL . 27.5 m . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.72 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 10' ' ' TYR . . . . . 0.454 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 94.1 m-85 -107.62 138.33 44.05 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.696 0.284 . . . . 0.0 110.428 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.548 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.8 mp0 -134.08 146.9 50.73 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.439 ' H ' HG12 ' G' ' 12' ' ' VAL . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 31.4 t-80 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.532 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.545 HD21 HG11 ' J' ' 36' ' ' VAL . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.532 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 42.86 50.16 5.17 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.568 HG12 ' N ' ' H' ' 25' ' ' GLY . 42.9 t -49.73 164.56 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.343 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.568 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -174.8 21.58 0.06 OUTLIER Glycine 0 C--O 1.224 -0.496 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.284 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 33.4 t -68.66 115.7 8.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.511 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 3.4 m120 -118.33 -158.76 0.73 Allowed 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 121.63 0.729 . . . . 0.0 112.612 -178.488 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 61.2 tttt 29.51 40.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.205 -1.361 . . . . 0.0 112.34 -178.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . 111.31 73.96 0.72 Allowed Glycine 0 CA--C 1.537 1.411 0 C-N-CA 120.29 -0.957 . . . . 0.0 114.747 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.73 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.521 HG22 HD21 ' I' ' 34' ' ' LEU . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.649 ' HB3' HD22 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t -111.17 135.8 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.44 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 70.0 t . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 118.106 -0.949 . . . . 0.0 110.132 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 9' ' ' GLY . . . . . 0.441 ' O ' ' CD2' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -108.3 131.99 54.15 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.787 0.327 . . . . 0.0 110.834 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -74.3 119.11 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.989 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.79 ' OE1' HG23 ' L' ' 36' ' ' VAL . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.674 ' N ' HD12 ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD13 ' K' ' 32' ' ' ILE . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.769 ' OD1' HG13 ' J' ' 24' ' ' VAL . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.673 HG13 ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.673 ' N ' HG13 ' I' ' 24' ' ' VAL . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' C ' HD21 ' I' ' 27' ' ' ASN . 0.4 OUTLIER -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' J' ' 29' ' ' GLY . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.789 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.789 HD23 ' O ' ' I' ' 33' ' ' GLY . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.456 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.87 HG13 HD11 ' O' ' 31' ' ' ILE . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.44 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.511 ' O ' ' CB ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.582 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.829 HD21 HG21 ' L' ' 36' ' ' VAL . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.82 HG12 ' OG ' ' K' ' 26' ' ' SER . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.63 ' N ' ' OG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.434 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' I' ' 29' ' ' GLY . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.416 HD11 HG23 ' D' ' 39' ' ' VAL . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.642 ' O ' HD12 ' J' ' 34' ' ' LEU . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.642 HD12 ' O ' ' J' ' 33' ' ' GLY . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.545 HG11 HD21 ' H' ' 17' ' ' LEU . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.456 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' P' ' 31' ' ' ILE . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.434 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.82 ' OG ' HG12 ' J' ' 24' ' ' VAL . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.461 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.478 HD13 ' CD2' ' I' ' 19' ' ' PHE . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.514 HD23 ' N ' ' K' ' 35' ' ' MET . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.514 ' N ' HD23 ' K' ' 34' ' ' LEU . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.614 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 10' ' ' TYR . . . . . 0.433 ' CE2' ' O ' ' L' ' 11' ' ' GLU . 92.6 t80 -70.08 138.02 51.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.865 0.364 . . . . 0.0 110.773 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.433 ' O ' ' CE2' ' L' ' 10' ' ' TYR . 83.8 tt0 -70.34 123.73 22.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.376 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' K' ' 12' ' ' VAL . 2.1 t -114.09 108.98 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.443 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 2.5 p-80 -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.402 ' CE1' ' ND1' ' K' ' 14' ' ' HIS . 7.5 p-80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.443 HD12 ' O ' ' K' ' 34' ' ' LEU . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.829 HG21 HD21 ' J' ' 17' ' ' LEU . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.614 HG22 HD12 ' R' ' 31' ' ' ILE . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.449 HG23 ' OXT' ' L' ' 40' ' ' VAL . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.45 ' O ' HG23 ' M' ' 12' ' ' VAL . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.588 HD11 HG11 ' O' ' 36' ' ' VAL . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.58 HG12 ' N ' ' M' ' 25' ' ' GLY . 96.8 t -49.15 164.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.58 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -174.45 19.52 0.05 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 41.7 m -80.54 -130.23 0.02 OUTLIER 'General case' 0 C--O 1.232 0.135 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.462 HD21 ' CA ' ' M' ' 30' ' ' ALA . 17.0 p-10 -100.59 162.41 12.94 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.343 0.592 . . . . 0.0 110.879 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' N' ' 27' ' ' ASN . 64.3 mttp -40.0 -37.99 0.66 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.11 -0.95 . . . . 0.0 113.067 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.94 76.17 0.07 OUTLIER Glycine 0 N--CA 1.471 1.001 0 C-N-CA 120.423 -0.894 . . . . 0.0 112.743 -176.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.462 ' CA ' HD21 ' M' ' 27' ' ' ASN . . . -80.1 142.74 34.57 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 -177.446 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -111.4 136.29 50.75 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -107.04 109.38 21.24 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.865 0.364 . . . . 0.0 110.815 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t -134.3 125.46 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.538 ' NE2' HG12 ' P' ' 36' ' ' VAL . 1.1 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.827 HD11 HG11 ' P' ' 36' ' ' VAL . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.718 ' H ' HG21 ' O' ' 24' ' ' VAL . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.521 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.521 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.63 ' CD1' HD12 ' O' ' 31' ' ' ILE . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.408 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.432 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -108.24 135.02 50.25 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.854 0.359 . . . . 0.0 110.43 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -117.85 126.03 51.63 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.276 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t -125.37 128.31 72.54 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.843 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.458 HE22 HG22 ' Q' ' 36' ' ' VAL . 9.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.42 ' O ' HD23 ' O' ' 17' ' ' LEU . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.56 ' CD1' HG11 ' Q' ' 36' ' ' VAL . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.437 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.718 HG21 ' H ' ' N' ' 23' ' ' ASP . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.444 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 89.9 m-20 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' O' ' 30' ' ' ALA . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' O' ' 29' ' ' GLY . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.87 HD11 HG13 ' I' ' 39' ' ' VAL . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.745 HG23 HD21 ' O' ' 34' ' ' LEU . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.616 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.807 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.408 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.588 HG11 HD11 ' M' ' 17' ' ' LEU . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' B' ' 31' ' ' ILE . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.464 ' N ' HG22 ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -110.72 132.49 54.15 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.947 0.403 . . . . 0.0 110.788 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.45 122.48 15.65 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.014 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.43 HG23 ' H ' ' Q' ' 13' ' ' HIS . 12.7 p -126.26 128.12 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.422 ' CD1' HG21 ' R' ' 36' ' ' VAL . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' P' ' 25' ' ' GLY . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' J' ' 39' ' ' VAL . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.827 HG11 HD11 ' N' ' 17' ' ' LEU . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HA3' ' Q' ' 38' ' ' GLY . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' D' ' 31' ' ' ILE . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' R' ' 15' ' ' GLN . 5.9 t-80 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.426 HE22 ' HA2' ' R' ' 37' ' ' GLY . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.637 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.442 HG22 ' CG1' ' R' ' 18' ' ' VAL . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.498 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.958 HG12 ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.958 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.665 HD12 ' O ' ' P' ' 34' ' ' LEU . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.407 ' H ' HD12 ' Q' ' 34' ' ' LEU . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.634 ' CG1' HG12 ' R' ' 36' ' ' VAL . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.902 HG13 ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.463 ' H ' HG12 ' R' ' 40' ' ' VAL . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 32.1 t-80 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.536 ' HG2' ' CE1' ' Q' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.533 ' HG ' HD13 ' Q' ' 17' ' ' LEU . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 18' ' ' VAL . . . . . 0.442 ' CG1' HG22 ' Q' ' 18' ' ' VAL . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.583 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 12.8 t-20 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 30' ' ' ALA . . . . . 0.583 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.614 HD12 HG22 ' L' ' 39' ' ' VAL . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.488 ' O ' HD12 ' R' ' 34' ' ' LEU . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.634 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.426 ' HA2' HE22 ' Q' ' 15' ' ' GLN . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.902 ' O ' HG13 ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.488 ' N ' HG12 ' R' ' 39' ' ' VAL . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.438 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -147.87 158.83 44.23 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.76 0.314 . . . . 0.0 110.344 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -157.83 133.46 9.08 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.473 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.479 ' HB2' ' HE3' ' C' ' 28' ' ' LYS . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.419 ' H ' ' CG2' ' A' ' 24' ' ' VAL . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.601 HG12 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.601 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' B' ' 36' ' ' VAL . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 ' O ' ' B' ' 37' ' ' GLY . 6.1 t -94.73 126.41 47.16 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 44.6 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.43 -179.297 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.68 132.78 52.27 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.566 0.222 . . . . 0.0 110.433 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.5 mp0 -130.06 126.25 37.18 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.144 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.534 ' CG1' ' NE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.702 ' HD1' ' H ' ' C' ' 14' ' ' HIS . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.422 ' O ' HD23 ' B' ' 17' ' ' LEU . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' D' ' 32' ' ' ILE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.438 HG22 ' CG2' ' A' ' 36' ' ' VAL . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.542 ' O ' HG11 ' A' ' 39' ' ' VAL . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' H' ' 31' ' ' ILE . 27.3 m -132.28 128.4 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.495 HG13 ' O ' ' B' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.436 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.074 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -107.28 134.28 50.6 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.873 0.368 . . . . 0.0 110.23 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -134.08 131.74 39.14 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.269 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -131.44 134.58 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.702 ' H ' ' HD1' ' B' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' E' ' 36' ' ' VAL . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' E' ' 32' ' ' ILE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.561 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.898 ' H ' HG11 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' HB3' ' B' ' 30' ' ' ALA . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.416 HG23 ' O ' ' C' ' 31' ' ' ILE . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.673 HG23 HD13 ' C' ' 34' ' ' LEU . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.703 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.703 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.432 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.507 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.599 ' CG2' HD11 ' I' ' 31' ' ' ILE . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.663 ' O ' HG22 ' E' ' 12' ' ' VAL . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 34.8 p80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.598 ' CD2' HD12 ' C' ' 17' ' ' LEU . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.898 HG11 ' H ' ' C' ' 24' ' ' VAL . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.785 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.737 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.43 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.737 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.714 ' H ' HD22 ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.622 HD12 HG22 ' P' ' 39' ' ' VAL . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' B' ' 19' ' ' PHE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.57 ' O ' HD12 ' E' ' 34' ' ' LEU . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.564 HG11 HG22 ' E' ' 36' ' ' VAL . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.507 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.489 HG23 HD11 ' J' ' 31' ' ' ILE . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -107.28 134.64 50.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.623 0.249 . . . . 0.0 110.763 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -75.07 157.7 34.35 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.139 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.663 HG22 ' O ' ' D' ' 11' ' ' GLU . 71.1 t -116.3 127.48 73.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.82 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 61.2 m170 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.429 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' E' ' 17' ' ' LEU . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.456 ' HB1' ' CA ' ' F' ' 29' ' ' GLY . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.46 ' HB3' HG21 ' F' ' 24' ' ' VAL . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.522 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.464 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.508 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD1' ' C' ' 19' ' ' PHE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.627 ' HG ' HG23 ' E' ' 36' ' ' VAL . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.439 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.718 HG11 HD11 ' C' ' 17' ' ' LEU . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.479 HG22 HD12 ' L' ' 31' ' ' ILE . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.426 HG13 ' CG ' ' C' ' 13' ' ' HIS . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.59 133.77 49.78 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.889 0.376 . . . . 0.0 110.282 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -122.4 116.92 24.85 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.959 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m -136.2 159.8 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.623 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.441 ' OE1' HG22 ' E' ' 24' ' ' VAL . 93.1 mt-10 -69.02 161.2 29.48 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -68.31 46.22 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.749 HG12 ' H ' ' F' ' 25' ' ' GLY . 41.9 t -80.57 -179.87 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.749 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -71.39 -34.13 63.94 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 118.571 -1.776 . . . . 0.0 111.22 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.427 ' O ' ' C ' ' F' ' 27' ' ' ASN . 39.1 t -162.22 120.27 2.18 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 119.014 -1.075 . . . . 0.0 113.118 175.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' F' ' 26' ' ' SER . 14.9 m-20 -24.34 149.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.686 174.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -175.85 -48.58 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 120.12 -0.632 . . . . 0.0 112.139 173.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.456 ' CA ' ' HB1' ' E' ' 21' ' ' ALA . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.459 HD11 ' HB ' ' R' ' 39' ' ' VAL . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' D' ' 19' ' ' PHE . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.579 HD12 ' O ' ' E' ' 34' ' ' LEU . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' F' ' 34' ' ' LEU . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.48 HG23 HD11 ' L' ' 31' ' ' ILE . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' D' ' 13' ' ' HIS . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.498 HG11 ' N ' ' H' ' 13' ' ' HIS . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' NZ ' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.632 ' NZ ' ' CD2' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.474 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.842 ' HB1' ' CG ' ' H' ' 23' ' ' ASP . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 179.0 157.15 0.51 Allowed 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.26 56.38 7.02 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.027 179.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 85.7 t -65.04 133.42 30.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.64 0.733 . . . . 0.0 110.907 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.34 -29.42 2.74 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.966 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' G' ' 27' ' ' ASN . 22.1 t -160.41 139.5 10.64 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -177.469 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.436 ' C ' ' O ' ' G' ' 26' ' ' SER . 24.5 t-20 -23.57 142.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 122.03 0.919 . . . . 0.0 113.085 -176.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -127.99 -30.95 2.42 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.455 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.468 ' HA3' ' H ' ' H' ' 29' ' ' GLY . . . -70.27 96.78 0.56 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.019 -0.61 . . . . 0.0 111.947 -177.077 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.74 178.36 8.95 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.533 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.599 ' O ' HG12 ' H' ' 39' ' ' VAL . 4.0 t -84.31 127.07 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.222 -0.363 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.835 -179.371 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -108.49 135.71 49.31 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.901 0.381 . . . . 0.0 110.459 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' H ' ' G' ' 12' ' ' VAL . 96.9 mt-10 -81.67 164.88 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.472 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.676 HD12 HD22 ' I' ' 17' ' ' LEU . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.41 ' CZ ' ' HB3' ' H' ' 17' ' ' LEU . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.636 ' HB1' ' HD3' ' I' ' 28' ' ' LYS . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.842 ' CG ' ' HB1' ' G' ' 21' ' ' ALA . 4.7 m-20 -135.82 49.25 2.15 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.452 ' H ' HG22 ' H' ' 24' ' ' VAL . 14.0 m -71.05 160.85 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 118.28 -1.368 . . . . 0.0 109.697 -174.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.662 ' H ' ' CB ' ' I' ' 26' ' ' SER . . . 109.97 -28.43 10.52 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 105.776 -2.93 . . . . 0.0 105.776 -174.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.409 ' OG ' ' OG ' ' I' ' 26' ' ' SER . 0.7 OUTLIER 74.46 119.49 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.144 -1.528 . . . . 0.0 112.124 178.583 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -83.34 162.36 21.11 Favored 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 177.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.28 -39.74 22.63 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 179.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.468 ' H ' ' HA3' ' G' ' 29' ' ' GLY . . . 170.89 67.06 0.04 OUTLIER Glycine 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 -178.352 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.846 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.911 ' O ' HG21 ' N' ' 31' ' ' ILE . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.599 HG12 ' O ' ' G' ' 39' ' ' VAL . 1.4 p -156.87 171.59 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.43 178.128 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.506 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -106.48 133.99 50.31 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 120.914 0.388 . . . . 0.0 110.358 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -148.27 146.31 28.56 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.411 ' CE1' HG23 ' J' ' 40' ' ' VAL . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.427 ' CE1' ' O ' ' I' ' 15' ' ' GLN . 61.3 t-80 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.427 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.541 ' C ' HD23 ' I' ' 17' ' ' LEU . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.676 HD22 HD12 ' H' ' 17' ' ' LEU . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.572 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.639 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.437 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.606 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.606 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.662 ' CB ' ' H ' ' H' ' 25' ' ' GLY . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.639 ' NZ ' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' C' ' 39' ' ' VAL . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.92 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.92 HD23 ' O ' ' I' ' 33' ' ' GLY . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' J' ' 35' ' ' MET . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.464 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.453 ' O ' HG23 ' J' ' 39' ' ' VAL . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.486 HG22 ' CD1' ' O' ' 31' ' ' ILE . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.66 HD11 HG21 ' L' ' 36' ' ' VAL . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.527 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.838 HG12 ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.838 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.441 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.489 HD11 HG23 ' D' ' 39' ' ' VAL . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.573 ' HB2' HD13 ' K' ' 34' ' ' LEU . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.459 ' HB3' ' SD ' ' I' ' 35' ' ' MET . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.629 HG12 HD11 ' K' ' 34' ' ' LEU . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.417 ' H ' ' CA ' ' K' ' 37' ' ' GLY . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.453 HG23 ' O ' ' I' ' 38' ' ' GLY . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.411 HG23 ' CE1' ' I' ' 13' ' ' HIS . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.465 HD22 HD12 ' J' ' 17' ' ' LEU . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.584 ' OD2' HG23 ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.595 HG12 ' H ' ' K' ' 25' ' ' GLY . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.595 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' O ' ' L' ' 29' ' ' GLY . 9.5 m-20 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.663 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' K' ' 35' ' ' MET . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' K' ' 34' ' ' LEU . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.673 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.417 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.456 HG21 ' O ' ' Q' ' 29' ' ' GLY . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -82.8 138.8 33.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.836 0.351 . . . . 0.0 110.74 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -153.31 132.8 12.91 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.159 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.462 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.6 t -110.66 101.88 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.46 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.678 HG12 ' N ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.678 ' N ' HG12 ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.59 ' O ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.48 HD11 HG23 ' F' ' 39' ' ' VAL . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.559 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.66 HG21 HD11 ' J' ' 17' ' ' LEU . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.444 ' HB ' HD11 ' R' ' 31' ' ' ILE . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.53 HG12 ' OXT' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' M' ' 12' ' ' VAL . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.47 ' OE1' HG11 ' N' ' 40' ' ' VAL . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.549 ' O ' ' NZ ' ' M' ' 28' ' ' LYS . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.28 153.67 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.82 -21.37 0.25 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-N 116.106 -0.497 . . . . 0.0 112.054 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 29.8 p -151.15 169.35 22.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.124 0.462 . . . . 0.0 111.162 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -31.36 134.76 0.07 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.673 -177.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' M' ' 20' ' ' PHE . 88.3 tttt 179.92 -50.48 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.881 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' N' ' 29' ' ' GLY . . . -71.14 58.41 1.08 Allowed Glycine 0 CA--C 1.538 1.53 0 CA-C-N 113.675 -1.602 . . . . 0.0 113.929 -178.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.13 -169.43 3.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 117.31 0.555 . . . . 0.0 109.691 -179.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 45.8 p90 -146.26 154.82 42.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.981 0.42 . . . . 0.0 110.217 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.36 152.82 44.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.339 -179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t -127.0 132.85 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.855 -179.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' N ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.496 HD12 HD22 ' O' ' 17' ' ' LEU . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.449 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.661 ' CB ' HD21 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.911 HG21 ' O ' ' H' ' 38' ' ' GLY . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.641 HG22 HD11 ' O' ' 34' ' ' LEU . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' N' ' 35' ' ' MET . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' N' ' 34' ' ' LEU . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.47 HG11 ' OE1' ' M' ' 15' ' ' GLN . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -89.65 136.2 33.17 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.873 0.368 . . . . 0.0 110.537 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 89.4 mt-10 -134.95 143.97 47.18 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.475 HG21 ' N ' ' P' ' 13' ' ' HIS . 32.8 m -138.85 166.41 22.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 -179.052 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.617 ' HB3' ' H ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.527 ' OE1' HD21 ' P' ' 17' ' ' LEU . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.797 ' O ' HD23 ' O' ' 17' ' ' LEU . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.797 HD23 ' O ' ' O' ' 16' ' ' LYS . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.482 HG12 ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.539 ' HA ' ' H ' ' P' ' 28' ' ' LYS . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.661 HD21 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.486 ' CD1' HG22 ' I' ' 39' ' ' VAL . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.566 HG23 HD13 ' O' ' 34' ' ' LEU . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.84 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.84 HD12 ' C ' ' O' ' 33' ' ' GLY . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.2 135.2 49.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.411 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -72.59 130.81 41.44 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.106 0.479 . . . . 0.0 110.663 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p -138.98 161.53 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.53 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.505 ' N ' HG22 ' P' ' 12' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.777 ' CE1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.745 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.551 HD22 HD12 ' O' ' 17' ' ' LEU . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.404 ' OD1' ' O ' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.443 HG22 ' OD1' ' Q' ' 23' ' ' ASP . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.539 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.4 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.622 HG22 HD12 ' D' ' 31' ' ' ILE . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 9.8 p80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.633 ' C ' HD12 ' Q' ' 17' ' ' LEU . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.745 HD11 ' OE1' ' P' ' 15' ' ' GLN . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.433 HG13 ' O ' ' Q' ' 18' ' ' VAL . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' C ' ' CD1' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.427 ' HB2' ' CZ ' ' Q' ' 19' ' ' PHE . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.557 HG12 ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.557 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.456 ' O ' HG21 ' K' ' 39' ' ' VAL . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . 0.446 HD13 HG21 ' Q' ' 32' ' ' ILE . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.433 HD21 ' CG2' ' Q' ' 32' ' ' ILE . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.413 ' SD ' ' HB3' ' R' ' 35' ' ' MET . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.77 HG11 HD11 ' O' ' 17' ' ' LEU . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.4 ' H ' ' HA2' ' P' ' 38' ' ' GLY . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.438 ' C ' ' NE2' ' O' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.435 HG22 ' N ' ' R' ' 13' ' ' HIS . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 39.1 t-80 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.551 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' R' ' 24' ' ' VAL . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.413 ' O ' ' N ' ' R' ' 24' ' ' VAL . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.632 ' O ' ' HB3' ' R' ' 21' ' ' ALA . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.444 HD11 ' HB ' ' L' ' 39' ' ' VAL . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.469 HG22 HD22 ' R' ' 34' ' ' LEU . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.661 HD23 ' N ' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.413 ' HB3' ' SD ' ' Q' ' 35' ' ' MET . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.459 ' HB ' HD11 ' F' ' 31' ' ' ILE . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -113.9 137.85 51.11 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.889 0.376 . . . . 0.0 110.42 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -73.76 128.4 35.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.492 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.606 HD21 HG21 ' C' ' 36' ' ' VAL . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG13 ' HB ' ' B' ' 18' ' ' VAL . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.504 ' CD1' HD13 ' C' ' 32' ' ' ILE . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.426 ' O ' ' N ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 26' ' ' SER . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.482 ' O ' HD12 ' A' ' 31' ' ' ILE . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.53 ' O ' HD12 ' B' ' 34' ' ' LEU . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.8 p -126.3 160.57 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.493 ' N ' HG22 ' A' ' 39' ' ' VAL . 13.5 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.998 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -84.08 139.44 32.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 110.564 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.33 125.08 27.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.369 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.544 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 59.4 t-80 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' CG1' ' D' ' 36' ' ' VAL . 8.6 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.565 HD11 HG11 ' D' ' 36' ' ' VAL . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.452 ' HB ' HG13 ' A' ' 18' ' ' VAL . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' C' ' 29' ' ' GLY . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.591 HD13 HG21 ' O' ' 39' ' ' VAL . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.53 HD12 ' O ' ' A' ' 34' ' ' LEU . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.515 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.449 ' O ' HG12 ' C' ' 39' ' ' VAL . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t -135.5 139.71 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.603 HG12 ' O ' ' B' ' 40' ' ' VAL . 86.7 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.301 178.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -105.78 132.74 51.53 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.748 0.309 . . . . 0.0 110.66 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 141.39 49.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.494 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -121.85 130.65 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.231 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.454 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.55 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.63 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.542 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.463 ' O ' ' O ' ' C' ' 26' ' ' SER . 24.0 t30 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.55 HD12 ' HB ' ' O' ' 39' ' ' VAL . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.586 HG22 HD11 ' D' ' 34' ' ' LEU . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.606 HG21 HD21 ' A' ' 17' ' ' LEU . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.564 ' O ' HD11 ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.59 HG22 ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.59 ' N ' HG22 ' C' ' 39' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.742 HG12 ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.742 ' H ' HG12 ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.434 ' CD2' ' O ' ' D' ' 12' ' ' VAL . 16.6 m-70 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 8.1 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD13 ' C' ' 17' ' ' LEU . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.555 ' O ' HG23 ' D' ' 24' ' ' VAL . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.555 HG23 ' O ' ' D' ' 22' ' ' GLU . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.436 ' H ' HG12 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.422 ' H ' ' H ' ' D' ' 25' ' ' GLY . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.517 HD12 HG23 ' P' ' 39' ' ' VAL . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' D' ' 34' ' ' LEU . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.827 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.827 HD12 ' C ' ' D' ' 33' ' ' GLY . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.62 ' CG1' ' NE2' ' B' ' 15' ' ' GLN . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.598 HG12 HD13 ' J' ' 31' ' ' ILE . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.597 HG12 ' O ' ' D' ' 40' ' ' VAL . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -105.38 134.41 48.54 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.738 0.304 . . . . 0.0 110.474 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -122.2 132.59 54.52 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.253 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.575 ' H ' HG21 ' D' ' 12' ' ' VAL . 59.1 t -117.23 129.93 72.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD12 ' D' ' 17' ' ' LEU . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.447 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.976 HG12 ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.976 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.456 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.636 ' O ' HD23 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.488 ' N ' HD12 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.597 ' HB ' HD11 ' K' ' 31' ' ' ILE . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' D' ' 40' ' ' VAL . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -108.56 133.87 52.1 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.876 0.37 . . . . 0.0 110.504 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -80.38 158.17 26.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.095 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m -109.8 105.75 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.496 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 80.1 tt0 -128.9 131.42 47.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.517 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 2.6 p-10 50.2 46.42 24.83 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.945 -0.571 . . . . 0.0 112.156 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -85.25 -171.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.456 0.646 . . . . 0.0 109.569 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.93 -31.35 3.69 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.078 -0.964 . . . . 0.0 111.112 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' F' ' 27' ' ' ASN . 71.1 p -142.23 -129.66 0.09 Allowed 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 121.077 0.465 . . . . 0.0 111.374 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' F' ' 23' ' ' ASP . 70.1 m-80 53.37 151.86 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.036 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt -71.77 46.17 0.12 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.886 -1.052 . . . . 0.0 112.388 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.521 HD11 ' HB ' ' R' ' 39' ' ' VAL . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.487 HD13 ' CD1' ' D' ' 19' ' ' PHE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.636 HD23 ' O ' ' E' ' 34' ' ' LEU . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.649 HG23 ' O ' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.55 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.538 HG11 ' CD2' ' D' ' 13' ' ' HIS . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.639 HG23 ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.6 HE22 HG13 ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.509 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.509 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.612 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 33.9 tt0 -170.38 179.81 3.28 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.612 ' H ' ' CG ' ' G' ' 22' ' ' GLU . 66.1 t0 -59.14 47.13 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 114.576 -1.193 . . . . 0.0 113.492 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' G' ' 22' ' ' GLU . 31.9 m -83.36 -161.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.8 -35.52 24.8 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 118.637 -1.744 . . . . 0.0 111.344 -177.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.447 ' O ' ' O ' ' G' ' 27' ' ' ASN . 44.1 t -157.47 114.08 2.95 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.763 175.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.447 ' O ' ' O ' ' G' ' 26' ' ' SER . 28.5 m120 -47.73 179.67 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -77.86 -47.9 17.7 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 118.275 -1.37 . . . . 0.0 108.543 176.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.614 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 80.66 51.84 4.68 Favored Glycine 0 CA--C 1.54 1.647 0 CA-C-O 117.843 -1.532 . . . . 0.0 115.646 174.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 180.0 -178.42 0.42 Allowed 'General case' 0 C--O 1.24 0.599 0 CA-C-N 121.71 2.755 . . . . 0.0 115.358 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m -116.47 161.03 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 78.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.279 179.396 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.41 133.46 51.89 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -89.84 101.56 14.26 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.639 ' O ' HG23 ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.534 HD11 HG11 ' J' ' 36' ' ' VAL . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.511 ' HA ' HD21 ' H' ' 27' ' ' ASN . 10.8 t0 -152.69 55.12 0.79 Allowed 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.894 HG13 ' H ' ' H' ' 25' ' ' GLY . 8.0 p -91.43 -124.17 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -175.37 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.894 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -75.31 -39.84 35.21 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 116.974 -2.536 . . . . 0.0 112.385 -175.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.6 p -156.9 111.89 2.81 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 119.521 1.66 . . . . 0.0 112.264 174.086 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.529 ' OD1' ' ND2' ' I' ' 27' ' ' ASN . 13.3 m-80 -49.36 162.4 0.14 Allowed 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -70.56 -47.48 60.09 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 119.124 -1.03 . . . . 0.0 109.785 176.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.49 58.89 0.84 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.442 HD11 ' HA2' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.666 HG12 HD11 ' I' ' 34' ' ' LEU . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.42 ' H ' ' HG ' ' I' ' 34' ' ' LEU . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.538 HG23 HD11 ' N' ' 31' ' ' ILE . 4.9 t -71.02 133.32 32.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.424 HG11 ' NE2' ' G' ' 15' ' ' GLN . 18.1 m . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.514 -179.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.01 137.56 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.777 0.322 . . . . 0.0 110.583 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -87.57 118.23 26.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.431 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.523 HG23 ' O ' ' J' ' 12' ' ' VAL . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.726 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.403 ' HB3' ' HE2' ' K' ' 28' ' ' LYS . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.595 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.595 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.452 HG23 ' N ' ' I' ' 25' ' ' GLY . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.556 ' HB2' ' ND2' ' I' ' 27' ' ' ASN . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.62 HD12 HD11 ' J' ' 31' ' ' ILE . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.414 HG23 HD13 ' I' ' 34' ' ' LEU . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.801 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.801 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.6 HG13 HE22 ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.418 ' N ' HG22 ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.523 ' O ' HG23 ' I' ' 12' ' ' VAL . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' CE1' HG13 ' K' ' 12' ' ' VAL . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.55 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 25.7 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' K' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.5 ' HZ ' HD23 ' J' ' 17' ' ' LEU . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.417 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 66.5 m-20 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.62 HD11 HD12 ' I' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.763 HG22 HD21 ' K' ' 34' ' ' LEU . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.582 ' H ' HD23 ' K' ' 34' ' ' LEU . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.534 HG11 HD11 ' H' ' 17' ' ' LEU . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.529 ' O ' HG12 ' K' ' 39' ' ' VAL . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.509 HG23 HD12 ' P' ' 31' ' ' ILE . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.481 HG22 ' OXT' ' J' ' 40' ' ' VAL . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.486 ' O ' HG22 ' J' ' 12' ' ' VAL . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' J' ' 13' ' ' HIS . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.447 ' HB3' ' HE2' ' J' ' 14' ' ' HIS . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' J' ' 17' ' ' LEU . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.518 HG12 ' H ' ' K' ' 25' ' ' GLY . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.518 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.439 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB ' ' E' ' 39' ' ' VAL . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.763 HD21 HG22 ' J' ' 32' ' ' ILE . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.528 HG11 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.529 HG12 ' O ' ' J' ' 38' ' ' GLY . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.47 HG12 ' O ' ' L' ' 40' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.6 m-85 -107.7 138.72 43.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 110.45 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -128.57 145.8 51.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.333 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -135.04 160.29 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.458 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.547 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.55 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.439 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.56 HD23 ' N ' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.807 HG21 HD21 ' J' ' 17' ' ' LEU . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.427 ' CA ' ' OE1' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' K' ' 40' ' ' VAL . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.469 HG23 ' O ' ' M' ' 12' ' ' VAL . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 70.5 m-70 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.403 HE22 HG13 ' O' ' 36' ' ' VAL . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' O' ' 36' ' ' VAL . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.486 ' H ' HG23 ' N' ' 24' ' ' VAL . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.661 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t -50.3 165.84 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -173.86 19.44 0.05 OUTLIER Glycine 0 CA--C 1.518 0.223 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 30.5 m -80.55 -130.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -100.58 161.76 13.39 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.033 0.444 . . . . 0.0 111.149 179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -41.11 -37.62 0.91 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.925 178.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -132.49 79.03 0.35 Allowed Glycine 0 N--CA 1.472 1.083 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.17 109.93 7.07 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 -176.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.417 HD13 HG21 ' M' ' 31' ' ' ILE . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.467 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -109.83 135.72 50.27 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.879 0.371 . . . . 0.0 110.703 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -141.07 159.21 42.7 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.745 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.514 HG23 ' N ' ' O' ' 13' ' ' HIS . 1.0 OUTLIER -138.56 168.77 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 -179.796 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' N' ' 19' ' ' PHE . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.89 ' H ' ' HZ3' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.492 HG13 ' O ' ' N' ' 23' ' ' ASP . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.661 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.824 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.538 HD11 HG23 ' H' ' 39' ' ' VAL . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.528 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.474 ' O ' HG22 ' O' ' 39' ' ' VAL . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.524 HG23 HD12 ' B' ' 31' ' ' ILE . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.21 133.46 53.54 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.707 0.289 . . . . 0.0 110.537 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.449 ' HG2' ' HE2' ' N' ' 14' ' ' HIS . 79.1 tt0 -159.09 158.2 32.5 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.588 HG12 ' H ' ' O' ' 13' ' ' HIS . 3.2 t -124.01 168.98 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.588 ' H ' HG12 ' O' ' 12' ' ' VAL . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.667 HD12 HD22 ' P' ' 17' ' ' LEU . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.514 HG13 ' CG ' ' O' ' 22' ' ' GLU . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.557 ' HB3' ' H ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.89 ' HZ3' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.683 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.747 HG23 HD21 ' O' ' 34' ' ' LEU . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.603 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.747 HD21 HG23 ' O' ' 32' ' ' ILE . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.447 HG11 ' CD1' ' M' ' 17' ' ' LEU . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.528 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.554 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.591 HG21 HD13 ' B' ' 31' ' ' ILE . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -118.96 139.77 51.12 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.682 0.277 . . . . 0.0 110.327 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 96.8 mt-10 -76.39 116.78 17.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.376 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m -120.37 132.63 69.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.541 ' NE2' HG11 ' O' ' 12' ' ' VAL . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.667 HD22 HD12 ' O' ' 17' ' ' LEU . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.532 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.532 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.987 HG12 ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.987 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.683 HD21 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.824 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.646 ' HB2' ' HA2' ' O' ' 29' ' ' GLY . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.857 HG22 HD11 ' Q' ' 34' ' ' LEU . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.658 HD12 ' O ' ' O' ' 34' ' ' LEU . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.449 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.474 ' HB ' HG13 ' Q' ' 36' ' ' VAL . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.554 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.685 HG12 ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.685 ' N ' HG12 ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' P' ' 11' ' ' GLU . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.494 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.412 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.44 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.593 ' HA3' ' HB2' ' R' ' 30' ' ' ALA . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' K' ' 39' ' ' VAL . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . 0.676 HG23 HD13 ' Q' ' 34' ' ' LEU . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . 0.763 ' C ' HD12 ' Q' ' 34' ' ' LEU . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.857 HD11 HG22 ' P' ' 32' ' ' ILE . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.556 HG11 HD21 ' O' ' 17' ' ' LEU . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.523 HG12 ' NE2' ' O' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.591 HG12 ' H ' ' R' ' 25' ' ' GLY . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.591 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.526 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 30' ' ' ALA . . . . . 0.593 ' HB2' ' HA3' ' Q' ' 29' ' ' GLY . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.405 HG11 HD13 ' P' ' 17' ' ' LEU . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.521 ' HB ' HD11 ' F' ' 31' ' ' ILE . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.445 ' H ' HG22 ' R' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 . . . . . 0 CA--C 1.527 0.087 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.57 HG13 ' C ' ' B' ' 12' ' ' VAL . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.912 HD11 HG21 ' C' ' 36' ' ' VAL . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.732 ' OD1' HG11 ' B' ' 24' ' ' VAL . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.844 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.473 HD22 ' CB ' ' A' ' 30' ' ' ALA . 72.4 m-80 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.473 ' CB ' HD22 ' A' ' 27' ' ' ASN . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.442 ' O ' HD12 ' B' ' 34' ' ' LEU . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.432 ' O ' HD13 ' G' ' 31' ' ' ILE . 59.3 t . . . . . 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.875 0.369 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.722 HG21 ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 6.3 p80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.708 HD21 HG11 ' D' ' 36' ' ' VAL . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.732 HG11 ' OD1' ' A' ' 23' ' ' ASP . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.512 HD12 ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.484 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.903 ' O ' HD13 ' H' ' 31' ' ' ILE . 57.4 t . . . . . 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.722 ' O ' HG21 ' B' ' 12' ' ' VAL . 2.0 p . . . . . 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.499 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.671 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.811 HE22 ' H ' ' F' ' 37' ' ' GLY . 88.1 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.576 ' C ' HD12 ' C' ' 17' ' ' LEU . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.633 HD21 HG11 ' E' ' 36' ' ' VAL . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.529 ' CZ ' HD23 ' C' ' 17' ' ' LEU . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.58 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.564 ' O ' ' N ' ' C' ' 29' ' ' GLY . 12.9 m120 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.534 HG23 ' CG2' ' D' ' 31' ' ' ILE . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.67 HG23 HD13 ' C' ' 34' ' ' LEU . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.88 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.88 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 17' ' ' LEU . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.621 ' HA ' HG21 ' D' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.451 ' O ' HG23 ' C' ' 12' ' ' VAL . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.613 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.561 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.638 HG11 ' HG2' ' E' ' 28' ' ' LYS . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.534 ' CG2' HG23 ' C' ' 31' ' ' ILE . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' D' ' 32' ' ' ILE . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.401 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.708 HG11 HD21 ' B' ' 17' ' ' LEU . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.625 HG12 HG23 ' D' ' 40' ' ' VAL . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.625 HG23 HG12 ' D' ' 39' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t . . . . . 0 N--CA 1.466 0.357 0 CA-C-O 120.754 0.311 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' HB3' ' E' ' 21' ' ' ALA . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.515 ' HB3' ' CE1' ' E' ' 19' ' ' PHE . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.485 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 4.7 t-20 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.638 ' HG2' HG11 ' D' ' 24' ' ' VAL . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.436 ' O ' HG23 ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.408 ' O ' HD12 ' F' ' 34' ' ' LEU . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.643 HG12 HD11 ' F' ' 34' ' ' LEU . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.535 HG12 ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.535 ' N ' HG12 ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.674 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 . . . . . 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 CA--C 1.529 0.152 0 N-CA-C 113.412 0.893 . . . . 0.0 113.412 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.801 HD12 HG22 ' R' ' 39' ' ' VAL . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.43 HD13 HG21 ' F' ' 32' ' ' ILE . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.643 HD11 HG12 ' E' ' 36' ' ' VAL . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.534 ' N ' HD12 ' F' ' 34' ' ' LEU . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.613 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.811 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.424 ' O ' HD13 ' L' ' 31' ' ' ILE . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.47 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 12' ' ' VAL . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.421 HE22 HG13 ' J' ' 36' ' ' VAL . 40.7 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 . . . . . 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 CA--C 1.547 0.832 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.432 HD13 ' O ' ' A' ' 39' ' ' VAL . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.535 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.884 0.373 . . . . 0.0 110.962 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' I' ' 12' ' ' VAL . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.492 ' HB2' ' HD1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.949 HE22 HG13 ' K' ' 36' ' ' VAL . 50.3 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.465 ' N ' HD12 ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' I' ' 26' ' ' SER . 88.4 m-20 . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.903 HD13 ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.431 HG22 HD11 ' I' ' 34' ' ' LEU . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.571 HD23 ' H ' ' H' ' 35' ' ' MET . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.571 ' H ' HD23 ' H' ' 34' ' ' LEU . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.625 ' H ' ' HA2' ' I' ' 38' ' ' GLY . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.495 HG23 ' O ' ' H' ' 38' ' ' GLY . 44.7 t . . . . . 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 120.611 0.243 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' H' ' 12' ' ' VAL . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.569 ' NE2' HG12 ' K' ' 36' ' ' VAL . 67.4 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.945 HD11 HG11 ' K' ' 36' ' ' VAL . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.535 ' HB2' HG22 ' J' ' 24' ' ' VAL . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 1.028 HG12 ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 1.028 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' I' ' 28' ' ' LYS . 1.1 t-20 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.68 ' N ' ' ND2' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.445 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.578 ' CD1' HG13 ' C' ' 39' ' ' VAL . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.66 HG23 HD13 ' I' ' 34' ' ' LEU . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.682 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.682 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.47 ' CG2' HD21 ' J' ' 34' ' ' LEU . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.625 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.594 ' CG2' HD12 ' P' ' 31' ' ' ILE . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.585 ' O ' HG13 ' I' ' 40' ' ' VAL . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.598 HD22 HD12 ' I' ' 17' ' ' LEU . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' L' ' 30' ' ' ALA . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.539 HG23 ' H ' ' J' ' 26' ' ' SER . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.539 ' H ' HG23 ' J' ' 24' ' ' VAL . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.467 ' NZ ' HG22 ' D' ' 40' ' ' VAL . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.618 ' O ' ' ND2' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.561 ' CD1' HG22 ' D' ' 39' ' ' VAL . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.777 HG22 HD11 ' K' ' 34' ' ' LEU . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.665 HD23 ' N ' ' J' ' 35' ' ' MET . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.665 ' N ' HD23 ' J' ' 34' ' ' LEU . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.583 HG22 HD22 ' J' ' 34' ' ' LEU . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.471 ' CG2' HD11 ' P' ' 31' ' ' ILE . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.615 ' H ' HG23 ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.415 HD21 ' CE1' ' L' ' 19' ' ' PHE . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' J' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.413 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.59 HG13 ' N ' ' K' ' 25' ' ' GLY . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.59 ' N ' HG13 ' K' ' 24' ' ' VAL . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.401 ' H ' ' HA ' ' J' ' 28' ' ' LYS . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.462 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.688 HG23 HD13 ' K' ' 34' ' ' LEU . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.836 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.836 HD12 ' C ' ' K' ' 33' ' ' GLY . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.949 HG13 HE22 ' H' ' 15' ' ' GLN . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.457 HG12 HG13 ' K' ' 40' ' ' VAL . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.615 HG23 ' H ' ' J' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.528 HG23 ' O ' ' L' ' 12' ' ' VAL . 6.3 m . . . . . 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.415 ' CE1' HD21 ' K' ' 17' ' ' LEU . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.863 ' O ' HG13 ' L' ' 24' ' ' VAL . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.863 HG13 ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.433 ' HB2' ' OD2' ' J' ' 23' ' ' ASP . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.424 HD13 ' O ' ' F' ' 38' ' ' GLY . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.564 HD12 ' O ' ' K' ' 34' ' ' LEU . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.508 HG13 ' HG ' ' L' ' 34' ' ' LEU . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . 0.474 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.62 ' HD1' ' CD2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.452 ' OE1' HD11 ' M' ' 17' ' ' LEU . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.455 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t . . . . . 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' N' ' 13' ' ' HIS . 67.2 t . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.731 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' HD1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.576 HE21 HG22 ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.412 HD11 HG21 ' P' ' 36' ' ' VAL . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.634 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.628 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.512 ' O ' HD12 ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.468 HG22 ' O ' ' N' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.863 HD21 HG21 ' Q' ' 36' ' ' VAL . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.548 ' H ' ' HB2' ' P' ' 22' ' ' GLU . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.624 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.624 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.628 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.527 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.527 HD12 ' O ' ' O' ' 33' ' ' GLY . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.575 ' O ' HG23 ' O' ' 36' ' ' VAL . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.696 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' Q' ' 13' ' ' HIS . 34.8 m-70 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.424 ' HA ' ' O ' ' Q' ' 14' ' ' HIS . 32.1 m80 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.424 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.551 HD11 ' NE2' ' Q' ' 15' ' ' GLN . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.548 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.594 HD12 ' CG2' ' I' ' 39' ' ' VAL . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.634 HD13 ' CD1' ' N' ' 19' ' ' PHE . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.74 HD23 ' N ' ' P' ' 35' ' ' MET . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.74 ' N ' HD23 ' P' ' 34' ' ' LEU . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.576 HG22 HE21 ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.696 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' P' ' 13' ' ' HIS . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.551 ' NE2' HD11 ' P' ' 17' ' ' LEU . 33.9 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.613 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.404 ' CB ' ' NZ ' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.416 HG23 HG23 ' P' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' R' ' 34' ' ' LEU . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.863 HG21 HD21 ' O' ' 17' ' ' LEU . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.623 HG12 ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.623 ' N ' HG12 ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.469 ' HB3' ' CG1' ' R' ' 24' ' ' VAL . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.469 ' CG1' ' HB3' ' R' ' 21' ' ' ALA . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.435 ' O ' HG23 ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' Q' ' 34' ' ' LEU . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.632 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.801 HG22 HD12 ' F' ' 31' ' ' ILE . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.707 0.289 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.582 HG11 ' HA ' ' B' ' 12' ' ' VAL . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 17' ' ' LEU . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.794 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.811 ' O ' HG13 ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.459 ' H ' HG13 ' B' ' 24' ' ' VAL . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.459 ' O ' HG21 ' A' ' 12' ' ' VAL . 9.4 pt-20 . . . . . 0 N--CA 1.461 0.092 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.582 ' HA ' HG11 ' A' ' 12' ' ' VAL . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.679 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.541 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.768 HD11 HG11 ' D' ' 36' ' ' VAL . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.541 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.993 HG12 ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.993 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.599 HD11 HG13 ' N' ' 39' ' ' VAL . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.648 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.467 ' O ' ' CD1' ' H' ' 31' ' ' ILE . 13.5 t . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.496 HG23 ' ND1' ' C' ' 14' ' ' HIS . 16.7 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' HG23 ' C' ' 12' ' ' VAL . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.503 ' OE1' HG13 ' F' ' 36' ' ' VAL . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.476 ' O ' HD23 ' C' ' 17' ' ' LEU . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.782 HD11 HG11 ' E' ' 36' ' ' VAL . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.541 HG22 ' CA ' ' D' ' 25' ' ' GLY . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.455 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.475 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.446 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.477 ' O ' ' HB2' ' C' ' 30' ' ' ALA . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' C' ' 29' ' ' GLY . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' C' ' 32' ' ' ILE . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.483 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.416 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.613 ' HB ' HG22 ' D' ' 36' ' ' VAL . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.747 ' O ' HG21 ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.648 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.574 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.519 ' OE1' ' N ' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 28.9 m170 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.79 HD11 HG11 ' F' ' 36' ' ' VAL . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.541 ' CA ' HG22 ' C' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.475 ' ND2' ' O ' ' C' ' 26' ' ' SER . 3.4 m120 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.446 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.716 HD11 HG23 ' P' ' 39' ' ' VAL . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.412 HD13 ' CD1' ' B' ' 19' ' ' PHE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.59 ' N ' HD23 ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.768 HG11 HD11 ' B' ' 17' ' ' LEU . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.905 HG13 HD12 ' J' ' 31' ' ' ILE . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.438 ' H ' HG11 ' E' ' 39' ' ' VAL . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.435 ' O ' ' CD2' ' E' ' 13' ' ' HIS . 55.1 t . . . . . 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' E' ' 12' ' ' VAL . 18.0 m80 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.713 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 70.1 m80 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.516 ' C ' HD12 ' E' ' 17' ' ' LEU . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.599 HD11 ' OE1' ' D' ' 15' ' ' GLN . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.653 HG12 ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.653 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.642 ' O ' HG13 ' Q' ' 39' ' ' VAL . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.509 HG22 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.484 HD12 ' N ' ' E' ' 35' ' ' MET . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.484 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.782 HG11 HD11 ' C' ' 17' ' ' LEU . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.84 HG21 HD11 ' J' ' 31' ' ' ILE . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.432 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.713 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.642 ' C ' HD12 ' F' ' 17' ' ' LEU . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.642 HD12 ' C ' ' F' ' 16' ' ' LYS . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.569 ' OE1' ' N ' ' F' ' 22' ' ' GLU . 46.4 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' R' ' 39' ' ' VAL . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' D' ' 19' ' ' PHE . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.703 HD21 ' CG2' ' F' ' 36' ' ' VAL . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.79 HG11 HD11 ' D' ' 17' ' ' LEU . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.795 HG23 HD12 ' L' ' 31' ' ' ILE . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.533 HG22 ' O ' ' F' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.573 HG21 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.586 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.6 HD21 HG11 ' I' ' 36' ' ' VAL . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.522 HG13 ' O ' ' G' ' 18' ' ' VAL . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.533 0 N-CA-C 114.727 1.38 . . . . 0.0 114.727 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.409 HG22 HG12 ' H' ' 31' ' ' ILE . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.564 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.452 0.168 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.603 HG23 ' O ' ' H' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.506 ' C ' ' ND1' ' H' ' 14' ' ' HIS . 2.5 t60 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.586 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.51 HD11 HG13 ' K' ' 36' ' ' VAL . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.463 HG13 ' CG1' ' I' ' 18' ' ' VAL . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.49 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.619 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 . . . . . 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.109 0 CA-C-O 119.108 -0.829 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.564 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.584 ' HA3' HD13 ' N' ' 31' ' ' ILE . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.507 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p . . . . . 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.895 0.379 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.518 ' CG ' HD11 ' I' ' 17' ' ' LEU . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.439 ' C ' HD12 ' I' ' 17' ' ' LEU . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.856 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.463 ' CG1' HG13 ' H' ' 18' ' ' VAL . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.481 ' HB1' ' HE3' ' I' ' 28' ' ' LYS . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.448 ' HA ' ' CB ' ' H' ' 23' ' ' ASP . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.413 ' O ' ' O ' ' I' ' 26' ' ' SER . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.574 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.594 HG23 HD13 ' I' ' 34' ' ' LEU . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.813 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.813 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.6 HG11 HD21 ' G' ' 17' ' ' LEU . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.626 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.411 ' H ' ' CG1' ' I' ' 12' ' ' VAL . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CB ' HG13 ' L' ' 40' ' ' VAL . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.672 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 1.0 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.672 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.544 ' C ' HD12 ' J' ' 17' ' ' LEU . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.854 HD21 HG21 ' L' ' 36' ' ' VAL . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.906 HG12 ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.906 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.679 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.905 HD12 HG13 ' D' ' 39' ' ' VAL . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.588 ' CG2' HD21 ' K' ' 34' ' ' LEU . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.534 HD12 ' O ' ' I' ' 34' ' ' LEU . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.452 ' H ' HD12 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.626 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.424 ' CG1' ' CD2' ' H' ' 13' ' ' HIS . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.661 ' HD1' ' CE1' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.544 ' HG3' ' H ' ' J' ' 15' ' ' GLN . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.416 ' CD2' HD13 ' J' ' 17' ' ' LEU . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.431 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.434 ' HB3' HG22 ' L' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 1.038 HG12 ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 1.038 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 62.5 m-20 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.665 HD11 HG21 ' F' ' 39' ' ' VAL . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' J' ' 32' ' ' ILE . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.51 HG13 HD11 ' H' ' 17' ' ' LEU . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.548 HG22 ' N ' ' L' ' 13' ' ' HIS . 10.4 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CE1' ' HD1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.474 ' O ' HG23 ' L' ' 24' ' ' VAL . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.592 ' C ' HG23 ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.592 HG23 ' C ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.795 HD12 HG23 ' F' ' 39' ' ' VAL . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.492 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.854 HG21 HD21 ' J' ' 17' ' ' LEU . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.538 ' HB ' HD11 ' R' ' 31' ' ' ILE . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.46 HG13 ' CB ' ' J' ' 13' ' ' HIS . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.659 ' NE2' HG12 ' O' ' 36' ' ' VAL . 53.8 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' N' ' 17' ' ' LEU . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 36.6 t . . . . . 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.408 ' O ' HG23 ' M' ' 39' ' ' VAL . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.49 ' CD2' HD12 ' M' ' 17' ' ' LEU . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.584 HD13 ' HA3' ' H' ' 38' ' ' GLY . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.599 HG13 HD11 ' B' ' 31' ' ' ILE . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.566 HG22 ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.566 ' N ' HG22 ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.593 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.697 HD23 ' N ' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.659 HG12 ' NE2' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.546 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.419 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.577 HG22 ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.577 ' N ' HG22 ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.662 0.267 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.728 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.459 ' NE2' HD11 ' P' ' 17' ' ' LEU . 19.9 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.459 HD11 ' NE2' ' P' ' 15' ' ' GLN . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.493 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 2.1 t-20 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.494 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.653 HD12 ' H ' ' P' ' 35' ' ' MET . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.653 ' H ' HD12 ' P' ' 34' ' ' LEU . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' N' ' 17' ' ' LEU . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.546 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.716 HG23 HD11 ' D' ' 31' ' ' ILE . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.437 ' H ' HG23 ' P' ' 40' ' ' VAL . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.728 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.569 HD23 ' C ' ' Q' ' 17' ' ' LEU . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.46 ' N ' HD23 ' Q' ' 17' ' ' LEU . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.598 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.541 HG12 ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.541 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.642 HG13 ' O ' ' E' ' 29' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.559 ' N ' HG12 ' Q' ' 39' ' ' VAL . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' R' ' 13' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.596 ' C ' HD12 ' R' ' 17' ' ' LEU . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.596 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.718 HG22 ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.718 ' H ' HG22 ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' L' ' 39' ' ' VAL . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.524 HG22 HD22 ' R' ' 34' ' ' LEU . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.72 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.559 ' HB ' HD11 ' F' ' 31' ' ' ILE . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.812 0.339 . . . . 0.0 110.319 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 70.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.536 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.536 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.531 HD11 ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.411 ' O ' HD12 ' B' ' 34' ' ' LEU . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t . . . . . 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.3 m80 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.75 ' C ' HD22 ' B' ' 17' ' ' LEU . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.75 HD22 ' C ' ' B' ' 16' ' ' LYS . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.517 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' B' ' 30' ' ' ALA . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' B' ' 29' ' ' GLY . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.411 HD12 ' O ' ' A' ' 34' ' ' LEU . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.408 ' H ' HD12 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.408 HG22 HG11 ' C' ' 39' ' ' VAL . 83.5 t . . . . . 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.743 0.306 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.563 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 8.6 p-80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.707 HE22 ' N ' ' F' ' 37' ' ' GLY . 86.8 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' C' ' 17' ' ' LEU . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.933 HD22 ' N ' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' E' ' 32' ' ' ILE . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.52 HG12 ' N ' ' C' ' 25' ' ' GLY . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.491 HD11 ' HB ' ' O' ' 39' ' ' VAL . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.799 HG22 HD11 ' D' ' 34' ' ' LEU . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.498 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.498 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.42 HG23 HG22 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 28.6 p-80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.68 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.592 HD12 HD22 ' E' ' 17' ' ' LEU . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.473 ' CD1' HD13 ' F' ' 32' ' ' ILE . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.54 ' H ' ' CD ' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.514 HG12 ' OG ' ' E' ' 26' ' ' SER . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.837 HG23 HD13 ' D' ' 34' ' ' LEU . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.665 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.837 HD13 HG23 ' D' ' 32' ' ' ILE . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.598 HG11 HD21 ' B' ' 17' ' ' LEU . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.663 ' CG2' HD11 ' J' ' 31' ' ' ILE . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.5 HG12 ' N ' ' E' ' 13' ' ' HIS . 49.2 t . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.5 ' N ' HG12 ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.592 HD22 HD12 ' D' ' 17' ' ' LEU . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.54 ' CD ' ' H ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.501 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.501 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.514 ' OG ' HG12 ' D' ' 24' ' ' VAL . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 12.9 m120 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.61 ' HZ2' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.934 HD11 HG13 ' Q' ' 39' ' ' VAL . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.509 HD13 ' CD2' ' C' ' 19' ' ' PHE . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.644 HD12 ' O ' ' D' ' 34' ' ' LEU . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.446 ' H ' HD12 ' E' ' 34' ' ' LEU . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' C' ' 17' ' ' LEU . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.512 ' ND1' ' N ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.512 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 . . . . . 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.629 HD12 HG11 ' Q' ' 39' ' ' VAL . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.473 HD13 ' CD1' ' D' ' 19' ' ' PHE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.706 HD23 ' O ' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.601 ' HB ' HD21 ' F' ' 34' ' ' LEU . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.707 ' N ' HE22 ' C' ' 15' ' ' GLN . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.606 ' HB ' HD11 ' L' ' 31' ' ' ILE . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.463 ' O ' HG13 ' G' ' 12' ' ' VAL . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.466 ' HD1' ' C ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.53 ' O ' HD22 ' G' ' 17' ' ' LEU . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.53 HD22 ' O ' ' G' ' 16' ' ' LYS . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.416 HG23 ' CG2' ' H' ' 31' ' ' ILE . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.691 HD23 ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.691 ' H ' HD23 ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.403 ' O ' ' CD1' ' M' ' 31' ' ' ILE . 42.6 t . . . . . 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.814 0.34 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.409 ' O ' HG23 ' G' ' 12' ' ' VAL . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.665 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.688 ' NE2' HG12 ' J' ' 36' ' ' VAL . 55.9 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.627 HD12 HD22 ' I' ' 17' ' ' LEU . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.472 ' HZ ' HD13 ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.731 ' HB1' HG13 ' I' ' 24' ' ' VAL . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.181 0 CA-C-O 119.877 -0.402 . . . . 0.0 113.356 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.416 ' CG2' HG23 ' G' ' 31' ' ' ILE . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.645 ' O ' HG11 ' I' ' 39' ' ' VAL . 81.0 t . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.462 0.173 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.627 HD22 HD12 ' H' ' 17' ' ' LEU . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.972 HG12 ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.972 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.404 HG21 HD13 ' I' ' 32' ' ' ILE . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.615 ' O ' HG11 ' J' ' 39' ' ' VAL . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.645 HG11 ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.489 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.647 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.602 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.944 HD21 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' D' ' 39' ' ' VAL . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.944 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.663 HD11 ' CG2' ' D' ' 39' ' ' VAL . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.405 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.55 HD23 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.688 HG12 ' NE2' ' H' ' 15' ' ' GLN . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.615 HG11 ' O ' ' I' ' 38' ' ' GLY . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.475 HG13 ' ND1' ' H' ' 13' ' ' HIS . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 43.6 t-80 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.629 HD23 ' N ' ' K' ' 18' ' ' VAL . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.629 ' N ' HD23 ' K' ' 17' ' ' LEU . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.922 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.922 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.602 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.992 HD22 HG13 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.725 ' N ' HD23 ' K' ' 34' ' ' LEU . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.992 HG13 HD22 ' K' ' 34' ' ' LEU . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.505 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.455 ' O ' HD11 ' Q' ' 31' ' ' ILE . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.56 HG23 HD12 ' Q' ' 31' ' ' ILE . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.44 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.502 HD21 ' NE2' ' K' ' 15' ' ' GLN . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.606 HD11 ' HB ' ' F' ' 39' ' ' VAL . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.479 HD23 ' C ' ' L' ' 34' ' ' LEU . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' HG23 ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.512 ' O ' HG13 ' L' ' 36' ' ' VAL . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.558 HG11 ' HA2' ' Q' ' 29' ' ' GLY . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.562 HG12 ' O ' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' O' ' 36' ' ' VAL . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.552 ' H ' HG21 ' N' ' 24' ' ' VAL . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 87.5 t . . . . . 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.253 0 CA-C-O 121.252 0.548 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.428 HG22 ' N ' ' M' ' 33' ' ' GLY . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . 0.428 ' N ' HG22 ' M' ' 32' ' ' ILE . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 120.938 0.399 . . . . 0.0 110.56 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 33.4 m-70 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.494 HE22 HG22 ' P' ' 36' ' ' VAL . 57.9 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.684 HD22 HD12 ' M' ' 17' ' ' LEU . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CE2' ' HB3' ' N' ' 17' ' ' LEU . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' O' ' 23' ' ' ASP . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.53 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.53 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.905 HG22 ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.905 ' H ' HG22 ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' N' ' 26' ' ' SER . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.613 HD13 HG11 ' I' ' 39' ' ' VAL . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' O' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.531 ' H ' HD11 ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p . . . . . 0 N--CA 1.468 0.437 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' N' ' 13' ' ' HIS . 21.9 m-70 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.582 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.668 ' H ' ' HZ2' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.786 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.786 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.41 ' SD ' ' HB2' ' P' ' 35' ' ' MET . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' M' ' 17' ' ' LEU . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' C' ' 31' ' ' ILE . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.473 ' N ' HG22 ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.474 ' CG1' ' CD2' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.465 ' NE2' HG21 ' R' ' 40' ' ' VAL . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.862 HD21 HG11 ' R' ' 36' ' ' VAL . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.666 ' O ' HG23 ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.415 HG23 ' N ' ' P' ' 25' ' ' GLY . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.415 ' N ' HG23 ' P' ' 24' ' ' VAL . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.706 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.668 ' HZ2' ' H ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.709 HD12 ' O ' ' O' ' 34' ' ' LEU . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.537 ' H ' HD12 ' P' ' 34' ' ' LEU . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.605 HG12 HD21 ' Q' ' 34' ' ' LEU . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' H ' ' Q' ' 38' ' ' GLY . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.511 ' O ' HG12 ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.402 HG12 ' CE1' ' P' ' 13' ' ' HIS . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.474 ' CD2' ' CG1' ' P' ' 12' ' ' VAL . 5.1 m-70 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.529 ' CZ ' ' HB3' ' Q' ' 21' ' ' ALA . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.548 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.615 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.553 HD21 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.706 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.558 ' HA2' HG11 ' L' ' 39' ' ' VAL . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.56 HD12 HG23 ' K' ' 39' ' ' VAL . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.965 HD23 ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.965 ' N ' HD23 ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.803 HG22 HD22 ' Q' ' 34' ' ' LEU . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.934 HG13 HD11 ' E' ' 31' ' ' ILE . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.409 HG13 ' CG ' ' O' ' 13' ' ' HIS . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' R' ' 17' ' ' LEU . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.548 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.7 m120 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.553 ' C ' HD21 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.55 HG23 ' CD1' ' R' ' 34' ' ' LEU . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.55 ' CD1' HG23 ' R' ' 32' ' ' ILE . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.862 HG11 HD21 ' P' ' 17' ' ' LEU . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.61 ' C ' ' HZ2' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.492 ' C ' ' NZ ' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.993 0.425 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 12' ' ' VAL . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.781 ' CD1' HG21 ' C' ' 36' ' ' VAL . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.641 HG12 ' N ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.641 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.427 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.418 ' O ' HG22 ' B' ' 36' ' ' VAL . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 CA--C 1.528 0.117 0 CA-C-O 120.855 0.36 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.577 HE22 ' N ' ' D' ' 37' ' ' GLY . 21.4 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.626 HD11 HG21 ' D' ' 36' ' ' VAL . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.436 ' H ' HG22 ' B' ' 24' ' ' VAL . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.46 ' O ' HG21 ' O' ' 39' ' ' VAL . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' N' ' 39' ' ' VAL . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.437 HD12 HG23 ' N' ' 39' ' ' VAL . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.563 HG22 HD11 ' C' ' 34' ' ' LEU . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 34' ' ' LEU . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t . . . . . 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 121.016 0.436 . . . . 0.0 110.512 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.587 ' HB2' ' HD1' ' D' ' 13' ' ' HIS . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.551 ' OE1' ' NE2' ' D' ' 15' ' ' GLN . 4.3 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.681 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.973 HD21 HG11 ' E' ' 36' ' ' VAL . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.518 ' HZ ' HD23 ' C' ' 17' ' ' LEU . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' B' ' 22' ' ' GLU . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.467 ' CB ' ' OD1' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.738 HG22 HG21 ' D' ' 24' ' ' VAL . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.844 ' H ' HD22 ' C' ' 27' ' ' ASN . 0.3 OUTLIER -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.613 HG23 HD13 ' C' ' 34' ' ' LEU . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.819 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.819 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.781 HG21 ' CD1' ' A' ' 17' ' ' LEU . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.894 HG23 HD11 ' I' ' 31' ' ' ILE . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.448 ' N ' HG12 ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' NE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.587 ' HD1' ' HB2' ' C' ' 13' ' ' HIS . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.551 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 57.0 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.612 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.738 HG21 HG22 ' C' ' 24' ' ' VAL . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.46 ' O ' HG22 ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.656 HG22 HD11 ' E' ' 34' ' ' LEU . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.612 ' CD2' HG22 ' C' ' 36' ' ' VAL . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.85 ' CG1' HG12 ' E' ' 36' ' ' VAL . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.577 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.706 HG23 HD11 ' J' ' 31' ' ' ILE . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' E' ' 12' ' ' VAL . 16.4 m . . . . . 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.651 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.431 HD12 ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.475 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.466 HD21 HG13 ' R' ' 40' ' ' VAL . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.437 ' CD1' HG23 ' Q' ' 39' ' ' VAL . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.729 HG23 HD13 ' E' ' 34' ' ' LEU . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.686 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.729 HD13 HG23 ' E' ' 32' ' ' ILE . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.973 HG11 HD21 ' C' ' 17' ' ' LEU . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.596 ' O ' HD12 ' L' ' 31' ' ' ILE . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.64 HG23 HD11 ' K' ' 31' ' ' ILE . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.521 HG22 ' O ' ' F' ' 38' ' ' GLY . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m . . . . . 0 N--CA 1.467 0.381 0 N-CA-C 110.419 -0.215 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.569 ' H ' ' CD2' ' F' ' 13' ' ' HIS . 10.6 p80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.651 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.489 ' C ' HD23 ' F' ' 17' ' ' LEU . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' E' ' 23' ' ' ASP . 37.1 tt0 . . . . . 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.403 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.545 HG11 ' HG ' ' D' ' 17' ' ' LEU . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.521 ' O ' HG22 ' E' ' 40' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.451 HG13 ' NE2' ' D' ' 13' ' ' HIS . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.481 HG23 ' O ' ' G' ' 12' ' ' VAL . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.551 HE22 ' CA ' ' I' ' 37' ' ' GLY . 39.0 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.699 HD11 HG11 ' I' ' 36' ' ' VAL . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.6 HG23 ' O ' ' G' ' 18' ' ' VAL . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.569 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 75.8 tt0 . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.63 0.253 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' H' ' 38' ' ' GLY . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.585 HG23 HD13 ' M' ' 31' ' ' ILE . 49.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 . . . . . 0 N--CA 1.465 0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.605 ' CG ' HG13 ' J' ' 40' ' ' VAL . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 14.2 tp60 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.636 ' C ' HD12 ' H' ' 17' ' ' LEU . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.776 ' N ' HD12 ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.502 ' CE1' ' HB3' ' H' ' 17' ' ' LEU . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' H' ' 23' ' ' ASP . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 . . . . . 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.553 2.458 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.542 ' HB3' HD22 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' G' ' 38' ' ' GLY . 97.7 t . . . . . 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 120.985 0.422 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.873 HE22 ' H ' ' L' ' 37' ' ' GLY . 9.5 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.494 ' CD2' HG21 ' K' ' 36' ' ' VAL . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.504 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.504 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.894 HD11 HG23 ' C' ' 39' ' ' VAL . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.903 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.903 HD23 ' O ' ' I' ' 33' ' ' GLY . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.699 HG11 HD11 ' G' ' 17' ' ' LEU . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.551 ' CA ' HE22 ' G' ' 15' ' ' GLN . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.52 HG11 HD13 ' N' ' 31' ' ' ILE . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.418 HG22 ' O ' ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CD2' HG11 ' L' ' 40' ' ' VAL . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 1.2 mp0 -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . 0.405 ' HB1' ' OD2' ' J' ' 23' ' ' ASP . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.706 HD11 HG23 ' D' ' 39' ' ' VAL . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.824 HG22 HD11 ' K' ' 34' ' ' LEU . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.874 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.874 HD12 ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.771 HG11 HD21 ' H' ' 17' ' ' LEU . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.665 HG23 HD12 ' P' ' 31' ' ' ILE . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.605 HG13 ' CG ' ' H' ' 13' ' ' HIS . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.401 HG21 HD21 ' Q' ' 27' ' ' ASN . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.431 ' HA ' ' H ' ' J' ' 15' ' ' GLN . 10.5 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.706 HG12 ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.706 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' K' ' 27' ' ' ASN . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.64 HD11 HG23 ' E' ' 39' ' ' VAL . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.581 HG23 HD13 ' K' ' 34' ' ' LEU . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.697 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.824 HD11 HG22 ' J' ' 32' ' ' ILE . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.494 HG21 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.422 ' HA2' HE21 ' I' ' 15' ' ' GLN . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.487 ' CG2' HD11 ' P' ' 31' ' ' ILE . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.401 HD23 ' C ' ' L' ' 17' ' ' LEU . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 8.6 m120 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.596 HD12 ' O ' ' E' ' 38' ' ' GLY . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.873 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.5 HG23 HD12 ' R' ' 31' ' ' ILE . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . 0.494 ' C ' ' CD2' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.494 ' CD2' ' C ' ' M' ' 13' ' ' HIS . 3.4 m-70 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.581 ' CD1' HG21 ' O' ' 36' ' ' VAL . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.385 0 N-CA-C 116.633 2.086 . . . . 0.0 116.633 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.585 HD13 HG23 ' G' ' 39' ' ' VAL . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . 0.47 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.542 HD23 ' HB2' ' M' ' 17' ' ' LEU . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' N' ' 17' ' ' LEU . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.806 ' OD2' HG23 ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.427 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.427 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.879 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.415 ' N ' ' CG ' ' N' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.779 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.52 HD13 HG11 ' I' ' 39' ' ' VAL . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.416 HG21 HD11 ' O' ' 34' ' ' LEU . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.43 HD12 ' O ' ' M' ' 34' ' ' LEU . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.454 HG13 ' HA3' ' B' ' 29' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.428 ' CD2' ' N ' ' O' ' 13' ' ' HIS . 4.5 m-70 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' Q' ' 36' ' ' VAL . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.419 ' CZ ' ' HB3' ' O' ' 17' ' ' LEU . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.806 HG23 ' OD2' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.744 ' N ' HG12 ' O' ' 24' ' ' VAL . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.879 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.779 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.404 HD13 HG21 ' O' ' 32' ' ' ILE . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.561 ' O ' HD12 ' P' ' 34' ' ' LEU . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.639 ' CG2' HG12 ' P' ' 36' ' ' VAL . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.548 HG22 ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.548 ' N ' HG22 ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.47 0.528 0 CA-C-O 120.752 0.311 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . . . . . . . . . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.571 HD22 HD12 ' O' ' 17' ' ' LEU . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . 0.423 HG13 ' O ' ' P' ' 18' ' ' VAL . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.728 HG12 ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.728 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.508 ' HA3' HG13 ' J' ' 39' ' ' VAL . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.665 HD12 HG23 ' J' ' 39' ' ' VAL . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.703 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.703 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.779 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.544 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.436 HG13 ' O ' ' P' ' 39' ' ' VAL . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.427 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 75.2 m80 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.499 ' CD ' HE21 ' R' ' 15' ' ' GLN . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.579 HG23 ' O ' ' Q' ' 24' ' ' VAL . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' Q' ' 30' ' ' ALA . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . 0.516 ' HB2' ' O ' ' Q' ' 29' ' ' GLY . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.449 ' CG2' HG21 ' L' ' 39' ' ' VAL . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.682 HD12 ' O ' ' P' ' 34' ' ' LEU . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.522 ' H ' HD12 ' Q' ' 34' ' ' LEU . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.779 HG22 ' CG2' ' P' ' 36' ' ' VAL . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.544 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' E' ' 31' ' ' ILE . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.489 ' O ' HG12 ' Q' ' 40' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.483 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.499 HE21 ' CD ' ' Q' ' 15' ' ' GLN . 86.1 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB3' ' R' ' 21' ' ' ALA . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.438 ' HB3' ' CE2' ' R' ' 19' ' ' PHE . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.464 ' HA ' HG12 ' Q' ' 24' ' ' VAL . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.5 HD12 HG23 ' L' ' 39' ' ' VAL . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.543 HG11 HD13 ' P' ' 17' ' ' LEU . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.466 HG13 HD21 ' E' ' 27' ' ' ASN . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' O ' ' B' ' 12' ' ' VAL . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.761 ' CE1' ' HZ1' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.761 ' HZ1' ' CE1' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.434 ' HB3' ' CE2' ' A' ' 19' ' ' PHE . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.423 ' HG2' ' N ' ' A' ' 23' ' ' ASP . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.423 ' N ' ' HG2' ' A' ' 22' ' ' GLU . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.82 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.599 HG12 HD12 ' B' ' 31' ' ' ILE . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 38' ' ' GLY . 6.5 p . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 12' ' ' VAL . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.534 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.842 HD11 HG11 ' D' ' 36' ' ' VAL . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.448 ' HB3' ' HZ1' ' D' ' 28' ' ' LYS . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.647 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.421 HG12 ' N ' ' B' ' 25' ' ' GLY . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.427 ' O ' ' O ' ' B' ' 27' ' ' ASN . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' N ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.828 HD13 ' O ' ' N' ' 38' ' ' GLY . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.405 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.441 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.56 ' CD2' ' NZ ' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.8 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.685 ' CD2' HD12 ' B' ' 17' ' ' LEU . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.533 ' HB3' ' H ' ' B' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.666 HG12 ' N ' ' C' ' 25' ' ' GLY . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.666 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.534 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.572 HD11 HG23 ' P' ' 39' ' ' VAL . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' C' ' 34' ' ' LEU . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.823 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.823 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.577 ' O ' HD12 ' J' ' 31' ' ' ILE . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.565 HG12 ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.565 ' N ' HG12 ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.587 HD12 ' N ' ' D' ' 17' ' ' LEU . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' D' ' 26' ' ' SER . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.479 ' H ' HG23 ' D' ' 24' ' ' VAL . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.457 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' B' ' 21' ' ' ALA . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.842 HG11 HD11 ' B' ' 17' ' ' LEU . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.551 HG13 ' O ' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.456 ' H ' ' HB3' ' F' ' 13' ' ' HIS . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.73 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 28.7 m80 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.437 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.413 ' H ' HG12 ' R' ' 39' ' ' VAL . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.422 ' O ' ' HB3' ' D' ' 28' ' ' LYS . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' E' ' 34' ' ' LEU . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.558 HG23 HD12 ' K' ' 31' ' ' ILE . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.017 0.437 . . . . 0.0 111.443 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.512 ' H ' ' CD2' ' F' ' 13' ' ' HIS . 6.6 p80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.73 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.785 HD12 HG22 ' R' ' 39' ' ' VAL . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.525 HG21 HD23 ' D' ' 17' ' ' LEU . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.574 ' HB ' HD11 ' L' ' 31' ' ' ILE . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.512 HG13 ' H ' ' H' ' 12' ' ' VAL . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.641 HE22 HG23 ' J' ' 36' ' ' VAL . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 . . . . . 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.954 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.609 ' O ' HD11 ' M' ' 31' ' ' ILE . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 120.715 0.293 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.621 HG22 HG12 ' I' ' 12' ' ' VAL . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.845 HE22 ' H ' ' K' ' 37' ' ' GLY . 99.1 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.711 HD21 HG21 ' J' ' 36' ' ' VAL . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.535 ' CG ' ' H ' ' H' ' 23' ' ' ASP . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.535 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.954 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.442 ' O ' HD23 ' I' ' 34' ' ' LEU . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.554 ' O ' HG23 ' I' ' 39' ' ' VAL . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p . . . . . 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.466 0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.621 HG12 HG22 ' H' ' 12' ' ' VAL . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.585 ' OE1' HD21 ' J' ' 17' ' ' LEU . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.886 HD11 HG21 ' K' ' 36' ' ' VAL . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.442 HG23 ' H ' ' I' ' 24' ' ' VAL . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 12.9 m120 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.829 ' HZ2' ' HZ3' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.407 HD13 ' O ' ' C' ' 38' ' ' GLY . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.456 HD22 HG13 ' I' ' 36' ' ' VAL . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.573 ' CG2' HD21 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.554 HG23 ' O ' ' H' ' 38' ' ' GLY . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.598 ' OXT' HG13 ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.477 ' H ' HG23 ' I' ' 12' ' ' VAL . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.484 ' CD2' HG21 ' K' ' 40' ' ' VAL . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.555 ' CD ' HD21 ' K' ' 17' ' ' LEU . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.724 ' O ' HD23 ' J' ' 17' ' ' LEU . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.863 HD22 HD12 ' I' ' 17' ' ' LEU . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.829 ' HZ3' ' HZ2' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.577 HD12 ' O ' ' C' ' 38' ' ' GLY . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.958 HD23 ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.958 ' N ' HD23 ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.711 HG21 HD21 ' H' ' 17' ' ' LEU . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.406 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.555 HD21 ' CD ' ' J' ' 15' ' ' GLN . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.454 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.56 ' NZ ' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.558 HD12 HG23 ' E' ' 39' ' ' VAL . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.444 HG21 HD13 ' K' ' 32' ' ' ILE . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.46 ' O ' HD12 ' L' ' 34' ' ' LEU . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.886 HG21 HD11 ' I' ' 17' ' ' LEU . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.845 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.49 ' N ' HG22 ' K' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.453 HG12 ' NE2' ' K' ' 14' ' ' HIS . 28.6 t . . . . . 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.406 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.607 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . 0.524 ' N ' HD23 ' L' ' 17' ' ' LEU . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.785 HG22 ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.785 ' H ' HG22 ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.529 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.574 HD11 ' HB ' ' F' ' 39' ' ' VAL . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.786 HD11 HG12 ' K' ' 36' ' ' VAL . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.542 ' H ' HD12 ' L' ' 34' ' ' LEU . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.801 HG11 ' CD1' ' J' ' 17' ' ' LEU . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.681 HG22 HD12 ' R' ' 31' ' ' ILE . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.487 HG11 ' N ' ' N' ' 13' ' ' HIS . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.671 HE21 HD11 ' M' ' 17' ' ' LEU . 38.6 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.671 HD11 HE21 ' M' ' 15' ' ' GLN . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . 0.415 HG13 ' O ' ' M' ' 18' ' ' VAL . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.609 HD11 ' O ' ' G' ' 38' ' ' GLY . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.609 HG12 ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.609 ' N ' HG12 ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.487 ' N ' HG11 ' M' ' 12' ' ' VAL . 5.6 t60 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.589 ' NE2' HG12 ' P' ' 36' ' ' VAL . 2.9 mt-30 -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.737 HD21 HG11 ' P' ' 36' ' ' VAL . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.41 HD13 HG21 ' N' ' 31' ' ' ILE . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.438 ' H ' ' HB3' ' O' ' 34' ' ' LEU . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.828 ' O ' HD13 ' B' ' 31' ' ' ILE . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.48 ' O ' HG21 ' N' ' 12' ' ' VAL . 15.7 m . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.756 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 88.5 m-70 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.553 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 51.9 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.614 ' N ' HD12 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.71 ' H ' HG11 ' P' ' 24' ' ' VAL . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.54 HG23 HD21 ' O' ' 34' ' ' LEU . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.564 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.793 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.48 HG23 HD12 ' C' ' 31' ' ' ILE . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.47 HG23 ' O ' ' Q' ' 12' ' ' VAL . 1.3 p . . . . . 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.756 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.483 ' H ' ' CD2' ' P' ' 14' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . 0.493 ' C ' HD12 ' P' ' 17' ' ' LEU . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.855 ' N ' HD12 ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.618 ' CD1' HD13 ' R' ' 32' ' ' ILE . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.682 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.776 HG13 ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.776 ' N ' HG13 ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.793 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.737 HG11 HD21 ' N' ' 17' ' ' LEU . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.405 ' HA3' HE22 ' N' ' 15' ' ' GLN . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.404 ' N ' ' HA2' ' Q' ' 37' ' ' GLY . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.572 HG23 HD11 ' C' ' 31' ' ' ILE . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.434 HG13 ' CD2' ' N' ' 13' ' ' HIS . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.47 ' O ' HG23 ' P' ' 12' ' ' VAL . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.479 ' N ' HD23 ' Q' ' 17' ' ' LEU . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.61 ' CG ' HG22 ' R' ' 24' ' ' VAL . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.817 HG12 ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.817 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . 0.406 ' H ' ' CB ' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' K' ' 39' ' ' VAL . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.984 HD23 ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.984 ' N ' HD23 ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.553 HG12 ' NE2' ' O' ' 15' ' ' GLN . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.404 ' HA2' ' N ' ' P' ' 38' ' ' GLY . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . 0.418 ' O ' HG13 ' R' ' 18' ' ' VAL . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.723 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.534 ' N ' HG23 ' R' ' 24' ' ' VAL . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.723 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.681 HD12 HG22 ' L' ' 39' ' ' VAL . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.618 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.451 HD11 ' CG2' ' Q' ' 36' ' ' VAL . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.785 HG22 HD12 ' F' ' 31' ' ' ILE . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.495 ' CG1' ' NE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.827 ' HD1' ' H ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.534 HE21 HD21 ' A' ' 17' ' ' LEU . 46.8 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.534 HD21 HE21 ' A' ' 15' ' ' GLN . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.654 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.49 ' O ' HG23 ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.59 HG12 ' N ' ' A' ' 37' ' ' GLY . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.59 ' N ' HG12 ' A' ' 36' ' ' VAL . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.532 ' O ' HD13 ' H' ' 31' ' ' ILE . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.484 HG23 HD12 ' G' ' 31' ' ' ILE . 51.3 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.827 ' H ' ' HD1' ' A' ' 14' ' ' HIS . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.521 ' C ' HD12 ' B' ' 17' ' ' LEU . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.761 HD21 HG21 ' D' ' 36' ' ' VAL . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.436 HD11 HD12 ' A' ' 31' ' ' ILE . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.732 ' HB2' HD13 ' C' ' 34' ' ' LEU . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.433 HG23 HD11 ' H' ' 31' ' ' ILE . 25.1 t . . . . . 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.646 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.664 HE21 ' NE2' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.536 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.536 HD12 ' C ' ' C' ' 16' ' ' LYS . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.42 HG13 ' HA ' ' B' ' 18' ' ' VAL . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.467 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.576 HD12 ' HB ' ' O' ' 39' ' ' VAL . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.512 ' CG2' HD21 ' D' ' 34' ' ' LEU . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.761 HD12 ' N ' ' C' ' 35' ' ' MET . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.761 ' N ' HD12 ' C' ' 34' ' ' LEU . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' D' ' 38' ' ' GLY . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' I' ' 31' ' ' ILE . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.646 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.664 ' NE2' HE21 ' C' ' 15' ' ' GLN . 49.9 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.849 HD21 HG21 ' F' ' 36' ' ' VAL . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' E' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.552 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.467 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 58.2 m-80 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.541 ' HA2' HG21 ' P' ' 39' ' ' VAL . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.615 HD11 ' HB ' ' P' ' 39' ' ' VAL . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.518 HG22 HD11 ' E' ' 34' ' ' LEU . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' C' ' 32' ' ' ILE . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.761 HG21 HD21 ' B' ' 17' ' ' LEU . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.477 ' N ' ' O ' ' C' ' 38' ' ' GLY . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.517 ' CG2' HD11 ' J' ' 31' ' ' ILE . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.412 ' O ' HG12 ' D' ' 39' ' ' VAL . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 45.3 m-70 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.419 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.611 ' CE2' HD12 ' F' ' 32' ' ' ILE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.692 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.552 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.419 ' O ' ' N ' ' E' ' 29' ' ' GLY . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.5 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.524 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.714 HD11 HG11 ' Q' ' 39' ' ' VAL . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.923 HG23 HD13 ' E' ' 34' ' ' LEU . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.709 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.923 HD13 HG23 ' E' ' 32' ' ' ILE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.511 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.602 HG22 HD12 ' L' ' 31' ' ' ILE . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.487 ' OXT' HG12 ' E' ' 40' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.601 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 . . . . . 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.575 0.226 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.524 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.831 HD11 HG23 ' R' ' 39' ' ' VAL . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.611 HD12 ' CE2' ' E' ' 19' ' ' PHE . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.849 HG21 HD21 ' D' ' 17' ' ' LEU . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.921 HG12 HD11 ' L' ' 31' ' ' ILE . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.637 HG23 ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.498 ' CD1' HG21 ' I' ' 36' ' ' VAL . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE2' ' H' ' 22' ' ' GLU . 67.0 tt0 . . . . . 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.508 HG23 ' O ' ' G' ' 31' ' ' ILE . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.461 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 . . . . . 0 N--CA 1.462 0.153 0 CA-C-O 120.976 0.417 . . . . 0.0 111.67 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.663 HE21 HD11 ' H' ' 17' ' ' LEU . 45.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.718 HD21 HG11 ' J' ' 36' ' ' VAL . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.46 ' CB ' ' H ' ' I' ' 24' ' ' VAL . 1.6 m-20 . . . . . 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.532 HD13 ' O ' ' A' ' 38' ' ' GLY . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.594 HG22 HD11 ' I' ' 34' ' ' LEU . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p . . . . . 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.6 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.61 ' CD2' HG12 ' K' ' 40' ' ' VAL . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.6 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.627 HE21 ' NE2' ' H' ' 15' ' ' GLN . 26.1 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' O ' HD23 ' I' ' 17' ' ' LEU . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.497 HD22 HD12 ' H' ' 17' ' ' LEU . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.775 ' HB3' ' HZ1' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.549 ' HG2' HG23 ' I' ' 24' ' ' VAL . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.549 HG23 ' HG2' ' I' ' 22' ' ' GLU . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.553 HD11 ' CG2' ' C' ' 39' ' ' VAL . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.516 HG23 HD13 ' I' ' 34' ' ' LEU . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.831 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.831 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.513 HG23 ' O ' ' I' ' 36' ' ' VAL . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.47 ' O ' HD13 ' O' ' 31' ' ' ILE . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.542 HG12 ' O ' ' I' ' 40' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 5.6 m80 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' OE1' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.466 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.546 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.522 HD12 HG23 ' C' ' 39' ' ' VAL . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.737 HG22 HD11 ' K' ' 34' ' ' LEU . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.644 HD23 ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.718 HG11 HD21 ' H' ' 17' ' ' LEU . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.408 ' H ' HG22 ' J' ' 39' ' ' VAL . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.504 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 4.0 p80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.414 ' HB3' ' H ' ' L' ' 14' ' ' HIS . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.455 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.775 ' HZ1' ' HB3' ' I' ' 21' ' ' ALA . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.515 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.626 HG23 HD13 ' K' ' 34' ' ' LEU . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' K' ' 33' ' ' GLY . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.61 HG12 ' CD2' ' I' ' 13' ' ' HIS . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.557 HG22 ' N ' ' L' ' 13' ' ' HIS . 2.7 p . . . . . 0 N--CA 1.466 0.341 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.557 ' N ' HG22 ' L' ' 12' ' ' VAL . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.414 ' H ' ' HB3' ' K' ' 14' ' ' HIS . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.432 HG12 ' N ' ' L' ' 25' ' ' GLY . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.437 ' O ' ' CG ' ' K' ' 27' ' ' ASN . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.921 HD11 HG12 ' F' ' 39' ' ' VAL . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.593 HD21 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 43.0 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.667 HD11 HG21 ' O' ' 36' ' ' VAL . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . 0.573 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' O' ' 32' ' ' ILE . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . 0.641 ' HB1' ' H ' ' N' ' 28' ' ' LYS . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.44 ' H ' HG22 ' M' ' 24' ' ' VAL . 3.9 m . . . . . 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.772 HD11 HG11 ' P' ' 36' ' ' VAL . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.641 ' H ' ' HB1' ' M' ' 21' ' ' ALA . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.596 HG22 ' CG1' ' O' ' 39' ' ' VAL . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.404 ' HB ' ' HE2' ' O' ' 14' ' ' HIS . 30.9 m . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 120.707 0.289 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.607 ' C ' HD12 ' O' ' 17' ' ' LEU . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.618 ' HG ' HD12 ' N' ' 17' ' ' LEU . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.593 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.47 HD13 ' O ' ' I' ' 38' ' ' GLY . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.441 HD13 ' CD2' ' M' ' 19' ' ' PHE . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' P' ' 33' ' ' GLY . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.694 HG13 ' O ' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.431 ' H ' ' HA2' ' P' ' 37' ' ' GLY . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.596 ' CG1' HG22 ' N' ' 39' ' ' VAL . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.463 ' H ' HG22 ' O' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.46 HG23 ' N ' ' Q' ' 13' ' ' HIS . 2.3 p . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.558 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 3.0 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.495 HD22 HD22 ' O' ' 17' ' ' LEU . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . 0.497 HG13 ' O ' ' P' ' 18' ' ' VAL . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.445 ' CD2' HD13 ' R' ' 32' ' ' ILE . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.739 HG22 ' HA ' ' Q' ' 23' ' ' ASP . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.56 ' CG ' HD21 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.593 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' P' ' 34' ' ' LEU . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.493 ' O ' HD12 ' Q' ' 34' ' ' LEU . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.772 HG11 HD11 ' N' ' 17' ' ' LEU . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.416 ' H ' ' CA ' ' O' ' 38' ' ' GLY . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.623 HG23 ' O ' ' Q' ' 39' ' ' VAL . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.536 ' O ' HG22 ' P' ' 39' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.58 HG12 ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.58 ' N ' HG12 ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.558 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.739 ' HA ' HG22 ' P' ' 24' ' ' VAL . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.533 HG22 ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.533 ' N ' HG22 ' Q' ' 24' ' ' VAL . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.56 HD21 ' CG ' ' P' ' 27' ' ' ASN . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.441 HD12 HG23 ' K' ' 39' ' ' VAL . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.493 HD12 ' O ' ' P' ' 34' ' ' LEU . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.616 HG13 ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.714 HG11 HD11 ' E' ' 31' ' ' ILE . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.9 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.563 HD23 ' C ' ' R' ' 17' ' ' LEU . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . 0.438 ' N ' HD23 ' R' ' 17' ' ' LEU . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.847 HG22 HD22 ' R' ' 34' ' ' LEU . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.847 HD22 HG22 ' R' ' 32' ' ' ILE . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.586 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.831 HG23 HD11 ' F' ' 31' ' ' ILE . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.418 HG22 ' H ' ' R' ' 40' ' ' VAL . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' CE1' ' A' ' 13' ' ' HIS . 82.0 tt0 . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 120.86 0.362 . . . . 0.0 110.5 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.579 HG13 ' O ' ' B' ' 12' ' ' VAL . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.717 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 45.3 m170 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.469 ' CD1' HG11 ' C' ' 36' ' ' VAL . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 16.5 t-20 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.783 HD13 ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.486 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p . . . . . 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.783 0.325 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.717 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.767 ' NE2' HG23 ' E' ' 36' ' ' VAL . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.601 ' CD1' HG21 ' D' ' 36' ' ' VAL . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.668 HG21 ' H ' ' C' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.643 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' A' ' 27' ' ' ASN . 99.3 m-20 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' C' ' 34' ' ' LEU . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.486 ' HA3' ' H ' ' A' ' 38' ' ' GLY . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.683 HG23 HD11 ' H' ' 31' ' ' ILE . 16.6 t . . . . . 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.777 HE22 ' H ' ' F' ' 37' ' ' GLY . 75.7 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.458 ' O ' HD23 ' C' ' 17' ' ' LEU . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.684 HD11 HG11 ' E' ' 36' ' ' VAL . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.441 ' HA ' HG13 ' D' ' 18' ' ' VAL . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.642 ' HB1' HG21 ' C' ' 24' ' ' VAL . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.642 HG21 ' HB1' ' C' ' 21' ' ' ALA . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.668 ' H ' HG21 ' B' ' 24' ' ' VAL . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.596 ' HA3' HG13 ' O' ' 39' ' ' VAL . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.464 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.498 HD12 HG23 ' O' ' 39' ' ' VAL . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' B' ' 34' ' ' LEU . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.454 ' H ' HD12 ' C' ' 34' ' ' LEU . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.49 ' O ' HG13 ' C' ' 36' ' ' VAL . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.594 HG12 ' N ' ' C' ' 40' ' ' VAL . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.594 ' N ' HG12 ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.752 ' HE2' HG12 ' E' ' 12' ' ' VAL . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.564 ' CD ' HG22 ' F' ' 36' ' ' VAL . 9.5 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.715 HD11 HG21 ' F' ' 36' ' ' VAL . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' C' ' 18' ' ' VAL . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.487 ' O ' HG22 ' P' ' 39' ' ' VAL . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.505 HD12 HG22 ' D' ' 36' ' ' VAL . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.601 HG21 ' CD1' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.789 ' O ' HD12 ' K' ' 31' ' ' ILE . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.752 HG12 ' HE2' ' D' ' 14' ' ' HIS . 2.7 t . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' CE1' ' F' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.532 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' D' ' 36' ' ' VAL . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.767 HG23 ' NE2' ' B' ' 15' ' ' GLN . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.904 HG23 HD11 ' K' ' 31' ' ' ILE . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' CG ' ' C' ' 13' ' ' HIS . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.521 HG13 ' O ' ' F' ' 12' ' ' VAL . 9.0 p . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.577 ' CE1' ' ND1' ' E' ' 13' ' ' HIS . 5.6 t-160 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.532 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' F' ' 29' ' ' GLY . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.715 HG21 HD11 ' D' ' 17' ' ' LEU . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.777 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.477 ' CG2' HG22 ' E' ' 39' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.424 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.509 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.897 HD11 HG11 ' I' ' 36' ' ' VAL . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.551 HG23 ' O ' ' G' ' 18' ' ' VAL . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.492 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.401 ' CD ' ' OE1' ' H' ' 22' ' ' GLU . 82.5 tt0 . . . . . 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.395 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.753 0.311 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB2' ' I' ' 11' ' ' GLU . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.525 ' CD2' ' CE1' ' I' ' 13' ' ' HIS . 85.1 m-70 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.441 HE22 HG13 ' K' ' 36' ' ' VAL . 21.0 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.556 HD12 HD22 ' I' ' 17' ' ' LEU . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.47 ' HB1' ' OD2' ' I' ' 23' ' ' ASP . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 . . . . . 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 1.752 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.683 HD11 HG23 ' B' ' 39' ' ' VAL . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.566 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.46 HG12 ' CD1' ' M' ' 31' ' ' ILE . 12.9 p . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.539 ' HB2' HG22 ' H' ' 12' ' ' VAL . 78.8 mm-40 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.798 HG21 ' C ' ' J' ' 12' ' ' VAL . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.525 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 2.3 m-70 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.632 ' CE1' HG23 ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.921 HE21 HG12 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.607 ' C ' HD23 ' I' ' 17' ' ' LEU . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.729 HD11 HG11 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.416 ' HB1' ' NZ ' ' I' ' 28' ' ' LYS . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.47 ' OD2' ' HB1' ' H' ' 21' ' ' ALA . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.453 ' H ' ' CB ' ' J' ' 28' ' ' LYS . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.679 HD13 ' CG2' ' J' ' 31' ' ' ILE . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.406 HG21 HD13 ' I' ' 32' ' ' ILE . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.566 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.897 HG11 HD11 ' G' ' 17' ' ' LEU . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.408 ' HA3' ' H ' ' J' ' 37' ' ' GLY . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.467 HG11 HG23 ' J' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.798 ' C ' HG21 ' I' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.58 HE22 ' NE2' ' I' ' 15' ' ' GLN . 7.9 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.808 ' C ' HD12 ' J' ' 17' ' ' LEU . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.808 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' L' ' 32' ' ' ILE . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' I' ' 23' ' ' ASP . 6.6 m120 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.453 ' CB ' ' H ' ' I' ' 28' ' ' LYS . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.679 ' CG2' HD13 ' I' ' 31' ' ' ILE . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.455 HG22 HD21 ' K' ' 34' ' ' LEU . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.408 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.411 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.635 ' O ' HG13 ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' I' ' 37' ' ' GLY . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.467 HG23 HG11 ' I' ' 40' ' ' VAL . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.639 ' N ' HE21 ' K' ' 15' ' ' GLN . 0.0 OUTLIER -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' K' ' 17' ' ' LEU . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.518 HD12 ' C ' ' K' ' 16' ' ' LYS . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.514 ' HB3' ' CE1' ' K' ' 19' ' ' PHE . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 1.057 HG12 ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 1.057 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.904 HD11 HG23 ' E' ' 39' ' ' VAL . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.455 HD21 HG22 ' J' ' 32' ' ' ILE . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.921 HG12 HE21 ' I' ' 15' ' ' GLN . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.423 HG23 ' CD1' ' Q' ' 31' ' ' ILE . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.515 HG23 ' O ' ' K' ' 40' ' ' VAL . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 19.3 t-160 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.506 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.444 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.43 HG22 HD22 ' L' ' 34' ' ' LEU . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.43 HD22 HG22 ' L' ' 32' ' ' ILE . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.427 HG12 ' OE1' ' J' ' 15' ' ' GLN . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.565 HG23 HD12 ' R' ' 31' ' ' ILE . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.746 HE21 HE21 ' N' ' 15' ' ' GLN . 6.5 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.421 HD11 ' NE2' ' M' ' 15' ' ' GLN . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . 0.564 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.47 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.551 ' N ' HG23 ' N' ' 24' ' ' VAL . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.577 HG23 ' O ' ' M' ' 31' ' ' ILE . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.783 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.463 ' H ' ' HA ' ' O' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.746 HE21 HE21 ' M' ' 15' ' ' GLN . 42.1 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . 0.674 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.551 HG23 ' N ' ' M' ' 23' ' ' ASP . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.408 ' O ' HD12 ' N' ' 31' ' ' ILE . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.408 HD12 ' O ' ' N' ' 29' ' ' GLY . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.438 ' CD2' HG12 ' N' ' 36' ' ' VAL . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.426 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.533 HG13 ' O ' ' N' ' 36' ' ' VAL . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' O' ' 37' ' ' GLY . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.762 HG12 ' H ' ' O' ' 13' ' ' HIS . 38.2 t . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.762 ' H ' HG12 ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.499 ' NE2' HG13 ' Q' ' 36' ' ' VAL . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.865 HD12 HD22 ' P' ' 17' ' ' LEU . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 1.055 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 1.055 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.674 ' HZ3' ' HA ' ' N' ' 21' ' ' ALA . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.641 HG23 HD13 ' O' ' 34' ' ' LEU . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.742 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.831 ' O ' HD12 ' P' ' 34' ' ' LEU . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.426 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.637 ' CG2' HD11 ' P' ' 34' ' ' LEU . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.436 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.596 HG13 ' HA3' ' C' ' 29' ' ' GLY . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.522 HG23 ' O ' ' O' ' 39' ' ' VAL . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.57 0.224 . . . . 0.0 111.532 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.514 ' CD2' HG23 ' R' ' 40' ' ' VAL . 87.2 m-70 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.597 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . 0.537 ' O ' HD23 ' P' ' 17' ' ' LEU . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.865 HD22 HD12 ' O' ' 17' ' ' LEU . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.508 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' P' ' 30' ' ' ALA . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.609 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.479 HD12 HG23 ' J' ' 39' ' ' VAL . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.402 HG21 HD13 ' P' ' 32' ' ' ILE . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.831 HD12 ' O ' ' O' ' 34' ' ' LEU . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.595 HG23 HG22 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.487 HG22 ' O ' ' D' ' 29' ' ' GLY . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.408 HD12 ' O ' ' R' ' 16' ' ' LYS . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' Q' ' 21' ' ' ALA . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.461 ' HB3' ' CE1' ' Q' ' 19' ' ' PHE . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.504 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' OD1' ' N ' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.423 ' CD1' HG23 ' K' ' 39' ' ' VAL . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.679 HD23 ' N ' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.824 HG11 HD11 ' O' ' 17' ' ' LEU . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.443 HG23 ' O ' ' R' ' 40' ' ' VAL . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.408 ' O ' HD12 ' Q' ' 17' ' ' LEU . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.565 HD12 HG23 ' L' ' 39' ' ' VAL . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.467 HD11 HG13 ' R' ' 36' ' ' VAL . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.467 HG13 HD11 ' R' ' 34' ' ' LEU . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.522 HG22 ' O ' ' R' ' 40' ' ' VAL . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG13 ' O ' ' B' ' 12' ' ' VAL . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.574 HE22 ' C ' ' C' ' 36' ' ' VAL . 88.1 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.968 HD11 HG11 ' C' ' 36' ' ' VAL . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.593 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.593 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.779 HG12 ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.779 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.74 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.614 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 33.8 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.597 HD21 HG11 ' D' ' 36' ' ' VAL . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.934 ' O ' HG13 ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.934 HG13 ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.448 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.48 ' HA3' HG22 ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' O' ' 39' ' ' VAL . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.74 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' C' ' 38' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.73 HG22 HD11 ' H' ' 31' ' ' ILE . 8.2 m . . . . . 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.467 0.39 0 N-CA-C 110.595 -0.15 . . . . 0.0 110.595 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.599 ' HB3' HD11 ' C' ' 17' ' ' LEU . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.833 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.59 ' OD1' ' HB1' ' B' ' 21' ' ' ALA . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.561 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.521 HG12 HD12 ' D' ' 31' ' ' ILE . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.638 HG22 HD21 ' D' ' 34' ' ' LEU . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.694 ' N ' HD23 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.409 ' N ' HD12 ' C' ' 34' ' ' LEU . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.968 HG11 HD11 ' A' ' 17' ' ' LEU . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' B' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 9.6 p-80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.456 ' NE2' HD11 ' D' ' 17' ' ' LEU . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.549 ' CD2' HD13 ' C' ' 17' ' ' LEU . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.552 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.473 ' OE1' ' CG2' ' D' ' 24' ' ' VAL . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.453 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.561 ' H ' ' CG1' ' C' ' 24' ' ' VAL . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' P' ' 39' ' ' VAL . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.405 HG21 HD13 ' D' ' 32' ' ' ILE . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.694 HD23 ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.597 HG11 HD21 ' B' ' 17' ' ' LEU . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.409 ' CB ' ' HZ3' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' F' ' 22' ' ' GLU . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.586 HG22 ' O ' ' F' ' 22' ' ' GLU . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.552 ' HZ3' ' HB3' ' D' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.485 HD11 ' CG2' ' D' ' 36' ' ' VAL . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' C' ' 17' ' ' LEU . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.542 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.6 p . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.542 ' N ' HG22 ' F' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.404 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.586 ' O ' HG22 ' E' ' 24' ' ' VAL . 94.1 mt-10 . . . . . 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.088 0.47 . . . . 0.0 111.896 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.469 ' HB2' ' HD2' ' E' ' 28' ' ' LYS . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.545 HD12 HG21 ' Q' ' 39' ' ' VAL . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.502 ' O ' HD12 ' F' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.537 HG11 ' CD2' ' D' ' 17' ' ' LEU . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.493 HG23 ' O ' ' G' ' 12' ' ' VAL . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.691 HE21 ' CD1' ' G' ' 17' ' ' LEU . 51.5 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.691 ' CD1' HE21 ' G' ' 15' ' ' GLN . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 . . . . . 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.454 HD11 ' HA3' ' H' ' 29' ' ' GLY . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.67 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.67 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.548 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.8 mp0 . . . . . 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.439 ' H ' HG12 ' G' ' 12' ' ' VAL . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 6.6 t60 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.449 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.545 HD21 HG11 ' J' ' 36' ' ' VAL . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.532 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 . . . . . 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.537 1.411 0 CA-C-O 119.329 -0.706 . . . . 0.0 114.747 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.73 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.521 HG22 HD21 ' I' ' 34' ' ' LEU . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.649 ' HB3' HD22 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t . . . . . 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 . . . . . 0 N--CA 1.458 -0.065 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.79 ' OE1' HG23 ' L' ' 36' ' ' VAL . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.674 ' N ' HD12 ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD13 ' K' ' 32' ' ' ILE . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.769 ' OD1' HG13 ' J' ' 24' ' ' VAL . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.673 HG13 ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.673 ' N ' HG13 ' I' ' 24' ' ' VAL . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.611 HD21 ' C ' ' J' ' 29' ' ' GLY . 25.9 p30 -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' J' ' 29' ' ' GLY . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.789 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.789 HD23 ' O ' ' I' ' 33' ' ' GLY . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.456 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.87 HG13 HD11 ' O' ' 31' ' ' ILE . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.7 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.582 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.829 HD21 HG21 ' L' ' 36' ' ' VAL . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.82 HG12 ' OG ' ' K' ' 26' ' ' SER . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.63 ' N ' ' OG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.431 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.611 ' C ' HD21 ' I' ' 27' ' ' ASN . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.416 HD11 HG23 ' D' ' 39' ' ' VAL . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.642 ' O ' HD12 ' J' ' 34' ' ' LEU . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.642 HD12 ' O ' ' J' ' 33' ' ' GLY . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.545 HG11 HD21 ' H' ' 17' ' ' LEU . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.456 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' P' ' 31' ' ' ILE . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.82 ' OG ' HG12 ' J' ' 24' ' ' VAL . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.461 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.478 HD13 ' CD2' ' I' ' 19' ' ' PHE . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.514 HD23 ' N ' ' K' ' 35' ' ' MET . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.514 ' N ' HD23 ' K' ' 34' ' ' LEU . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.614 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.443 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 0.4 OUTLIER -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.578 ' CE1' ' NZ ' ' L' ' 16' ' ' LYS . 3.9 p80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.578 ' NZ ' ' CE1' ' L' ' 14' ' ' HIS . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.443 HD12 ' O ' ' K' ' 34' ' ' LEU . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.829 HG21 HD21 ' J' ' 17' ' ' LEU . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.614 HG22 HD12 ' R' ' 31' ' ' ILE . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.449 HG23 ' OXT' ' L' ' 40' ' ' VAL . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.45 ' O ' HG23 ' M' ' 12' ' ' VAL . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.588 HD11 HG11 ' O' ' 36' ' ' VAL . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 96.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.727 HE22 ' CA ' ' P' ' 37' ' ' GLY . 7.8 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.827 HD11 HG11 ' P' ' 36' ' ' VAL . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.718 ' H ' HG21 ' O' ' 24' ' ' VAL . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.521 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.521 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.63 ' CD1' HD12 ' O' ' 31' ' ' ILE . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.408 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t . . . . . 0 CA--C 1.536 0.419 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.693 HE22 ' CG2' ' Q' ' 36' ' ' VAL . 64.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.42 ' O ' HD23 ' O' ' 17' ' ' LEU . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.56 ' CD1' HG11 ' Q' ' 36' ' ' VAL . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.437 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.718 HG21 ' H ' ' N' ' 23' ' ' ASP . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.444 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 9.2 m120 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' O' ' 30' ' ' ALA . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' O' ' 29' ' ' GLY . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.87 HD11 HG13 ' I' ' 39' ' ' VAL . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.745 HG23 HD21 ' O' ' 34' ' ' LEU . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.616 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.807 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.408 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.588 HG11 HD11 ' M' ' 17' ' ' LEU . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' B' ' 31' ' ' ILE . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.464 ' N ' HG22 ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.43 HG23 ' H ' ' Q' ' 13' ' ' HIS . 12.7 p . . . . . 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.422 ' CD1' HG21 ' R' ' 36' ' ' VAL . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' P' ' 25' ' ' GLY . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' J' ' 39' ' ' VAL . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.827 HG11 HD11 ' N' ' 17' ' ' LEU . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.727 ' CA ' HE22 ' N' ' 15' ' ' GLN . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HA3' ' Q' ' 38' ' ' GLY . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' D' ' 31' ' ' ILE . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.513 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 1.9 t60 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.489 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.637 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.442 HG22 ' CG1' ' R' ' 18' ' ' VAL . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.498 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.958 HG12 ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.958 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.665 HD12 ' O ' ' P' ' 34' ' ' LEU . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.407 ' H ' HD12 ' Q' ' 34' ' ' LEU . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.693 ' CG2' HE22 ' O' ' 15' ' ' GLN . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.902 HG13 ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.463 ' H ' HG12 ' R' ' 40' ' ' VAL . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 83.6 t60 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.462 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.533 ' HG ' HD13 ' Q' ' 17' ' ' LEU . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . 0.442 ' CG1' HG22 ' Q' ' 18' ' ' VAL . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 47.9 t30 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.614 HD12 HG22 ' L' ' 39' ' ' VAL . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.488 ' O ' HD12 ' R' ' 34' ' ' LEU . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.634 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.426 ' HA2' HE22 ' Q' ' 15' ' ' GLN . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.902 ' O ' HG13 ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.488 ' N ' HG12 ' R' ' 39' ' ' VAL . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.473 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.479 ' HB2' ' HE3' ' C' ' 28' ' ' LYS . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.419 ' H ' ' CG2' ' A' ' 24' ' ' VAL . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.601 HG12 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.601 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' B' ' 36' ' ' VAL . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 ' O ' ' B' ' 37' ' ' GLY . 6.1 t . . . . . 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.5 mp0 . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.534 ' CG1' ' NE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.702 ' HD1' ' H ' ' C' ' 14' ' ' HIS . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.422 ' O ' HD23 ' B' ' 17' ' ' LEU . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' D' ' 32' ' ' ILE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.438 HG22 ' CG2' ' A' ' 36' ' ' VAL . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.542 ' O ' HG11 ' A' ' 39' ' ' VAL . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' H' ' 31' ' ' ILE . 27.3 m . . . . . 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.702 ' H ' ' HD1' ' B' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' E' ' 36' ' ' VAL . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' E' ' 32' ' ' ILE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.561 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.898 ' H ' HG11 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' HB3' ' B' ' 30' ' ' ALA . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.416 HG23 ' O ' ' C' ' 31' ' ' ILE . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.673 HG23 HD13 ' C' ' 34' ' ' LEU . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.703 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.703 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.432 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.507 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.599 ' CG2' HD11 ' I' ' 31' ' ' ILE . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.663 ' O ' HG22 ' E' ' 12' ' ' VAL . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.436 ' CG1' ' CD2' ' E' ' 13' ' ' HIS . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 24.9 p-80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.598 ' CD2' HD12 ' C' ' 17' ' ' LEU . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.898 HG11 ' H ' ' C' ' 24' ' ' VAL . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.785 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.737 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.43 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.737 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.714 ' H ' HD22 ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.622 HD12 HG22 ' P' ' 39' ' ' VAL . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' B' ' 19' ' ' PHE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.57 ' O ' HD12 ' E' ' 34' ' ' LEU . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.564 HG11 HG22 ' E' ' 36' ' ' VAL . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.507 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.489 HG23 HD11 ' J' ' 31' ' ' ILE . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.663 HG22 ' O ' ' D' ' 11' ' ' GLU . 71.1 t . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 5.9 m-70 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.429 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' E' ' 17' ' ' LEU . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.456 ' HB1' ' CA ' ' F' ' 29' ' ' GLY . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.522 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.464 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.508 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD1' ' C' ' 19' ' ' PHE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.627 ' HG ' HG23 ' E' ' 36' ' ' VAL . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.439 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.718 HG11 HD11 ' C' ' 17' ' ' LEU . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.479 HG22 HD12 ' L' ' 31' ' ' ILE . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.426 HG13 ' CG ' ' C' ' 13' ' ' HIS . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.441 ' OE1' HG22 ' E' ' 24' ' ' VAL . 93.1 mt-10 . . . . . 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.456 ' CA ' ' HB1' ' E' ' 21' ' ' ALA . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.459 HD11 ' HB ' ' R' ' 39' ' ' VAL . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' D' ' 19' ' ' PHE . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.579 HD12 ' O ' ' E' ' 34' ' ' LEU . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' F' ' 34' ' ' LEU . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.48 HG23 HD11 ' L' ' 31' ' ' ILE . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' D' ' 13' ' ' HIS . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.498 HG11 ' N ' ' H' ' 13' ' ' HIS . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' NZ ' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.632 ' NZ ' ' CD2' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.474 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.842 ' HB1' ' CG ' ' H' ' 23' ' ' ASP . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.533 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.599 ' O ' HG12 ' H' ' 39' ' ' VAL . 4.0 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' H ' ' G' ' 12' ' ' VAL . 96.9 mt-10 . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.879 0.371 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.555 HE22 HG22 ' J' ' 36' ' ' VAL . 49.2 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.676 HD12 HD22 ' I' ' 17' ' ' LEU . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.41 ' CZ ' ' HB3' ' H' ' 17' ' ' LEU . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.636 ' HB1' ' HD3' ' I' ' 28' ' ' LYS . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.842 ' CG ' ' HB1' ' G' ' 21' ' ' ALA . 4.7 m-20 . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.846 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.911 ' O ' HG21 ' N' ' 31' ' ' ILE . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.599 HG12 ' O ' ' G' ' 39' ' ' VAL . 1.4 p . . . . . 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.411 ' CE1' HG23 ' J' ' 40' ' ' VAL . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 36.1 t60 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.523 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.541 ' C ' HD23 ' I' ' 17' ' ' LEU . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.676 HD22 HD12 ' H' ' 17' ' ' LEU . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.572 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.639 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.437 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.606 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.606 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.48 ' CA ' HD22 ' J' ' 27' ' ' ASN . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.639 ' NZ ' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' C' ' 39' ' ' VAL . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.92 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.92 HD23 ' O ' ' I' ' 33' ' ' GLY . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' J' ' 35' ' ' MET . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.464 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.453 ' O ' HG23 ' J' ' 39' ' ' VAL . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.486 HG22 ' CD1' ' O' ' 31' ' ' ILE . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.66 HD11 HG21 ' L' ' 36' ' ' VAL . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.487 ' HB3' HG23 ' J' ' 24' ' ' VAL . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.533 ' CG ' HD21 ' K' ' 27' ' ' ASN . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.838 HG12 ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.838 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.441 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.489 HD11 HG23 ' D' ' 39' ' ' VAL . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.573 ' HB2' HD13 ' K' ' 34' ' ' LEU . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.459 ' HB3' ' SD ' ' I' ' 35' ' ' MET . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.629 HG12 HD11 ' K' ' 34' ' ' LEU . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.417 ' H ' ' CA ' ' K' ' 37' ' ' GLY . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.453 HG23 ' O ' ' I' ' 38' ' ' GLY . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.411 HG23 ' CE1' ' I' ' 13' ' ' HIS . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.465 HD22 HD12 ' J' ' 17' ' ' LEU . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.584 ' OD2' HG23 ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.595 HG12 ' H ' ' K' ' 25' ' ' GLY . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.595 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.533 HD21 ' CG ' ' J' ' 23' ' ' ASP . 1.1 m-80 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.663 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' K' ' 35' ' ' MET . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' K' ' 34' ' ' LEU . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.673 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.417 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.456 HG21 ' O ' ' Q' ' 29' ' ' GLY . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.462 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.6 t . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 120.802 0.334 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.678 HG12 ' N ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.678 ' N ' HG12 ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.48 HD11 HG23 ' F' ' 39' ' ' VAL . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.559 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.66 HG21 HD11 ' J' ' 17' ' ' LEU . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.444 ' HB ' HD11 ' R' ' 31' ' ' ILE . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.53 HG12 ' OXT' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' M' ' 12' ' ' VAL . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.47 ' OE1' HG11 ' N' ' 40' ' ' VAL . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.451 ' N ' ' CD1' ' M' ' 20' ' ' PHE . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t . . . . . 0 N--CA 1.468 0.454 0 N-CA-C 110.855 -0.054 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' N ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.496 HD12 HD22 ' O' ' 17' ' ' LEU . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.449 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.661 ' CB ' HD21 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.911 HG21 ' O ' ' H' ' 38' ' ' GLY . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.641 HG22 HD11 ' O' ' 34' ' ' LEU . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' N' ' 35' ' ' MET . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' N' ' 34' ' ' LEU . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.47 HG11 ' OE1' ' M' ' 15' ' ' GLN . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.475 HG21 ' N ' ' P' ' 13' ' ' HIS . 32.8 m . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.617 ' HB3' ' H ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.527 ' OE1' HD21 ' P' ' 17' ' ' LEU . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.797 ' O ' HD23 ' O' ' 17' ' ' LEU . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.797 HD23 ' O ' ' O' ' 16' ' ' LYS . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.482 HG12 ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.539 ' HA ' ' H ' ' P' ' 28' ' ' LYS . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.661 HD21 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.486 ' CD1' HG22 ' I' ' 39' ' ' VAL . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.566 HG23 HD13 ' O' ' 34' ' ' LEU . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.84 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.84 HD12 ' C ' ' O' ' 33' ' ' GLY . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p . . . . . 0 CA--C 1.536 0.413 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.505 ' N ' HG22 ' P' ' 12' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.643 ' ND1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.745 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.551 HD22 HD12 ' O' ' 17' ' ' LEU . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.404 ' OD1' ' O ' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.443 HG22 ' OD1' ' Q' ' 23' ' ' ASP . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.539 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.4 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.622 HG22 HD12 ' D' ' 31' ' ' ILE . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.643 ' CD2' ' ND1' ' P' ' 14' ' ' HIS . 3.3 p-80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . 0.633 ' C ' HD12 ' Q' ' 17' ' ' LEU . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.745 HD11 ' OE1' ' P' ' 15' ' ' GLN . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.433 HG13 ' O ' ' Q' ' 18' ' ' VAL . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' C ' ' CD1' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.427 ' HB2' ' CZ ' ' Q' ' 19' ' ' PHE . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.557 HG12 ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.557 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.456 ' O ' HG21 ' K' ' 39' ' ' VAL . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . 0.446 HD13 HG21 ' Q' ' 32' ' ' ILE . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.433 HD21 ' CG2' ' Q' ' 32' ' ' ILE . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.413 ' SD ' ' HB3' ' R' ' 35' ' ' MET . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.77 HG11 HD11 ' O' ' 17' ' ' LEU . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.4 ' H ' ' HA2' ' P' ' 38' ' ' GLY . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.438 ' C ' ' NE2' ' O' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.435 HG22 ' N ' ' R' ' 13' ' ' HIS . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 85.9 t60 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.551 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' R' ' 24' ' ' VAL . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.413 ' O ' ' N ' ' R' ' 24' ' ' VAL . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.632 ' O ' ' HB3' ' R' ' 21' ' ' ALA . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.444 HD11 ' HB ' ' L' ' 39' ' ' VAL . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.469 HG22 HD22 ' R' ' 34' ' ' LEU . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.661 HD23 ' N ' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.413 ' HB3' ' SD ' ' Q' ' 35' ' ' MET . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.459 ' HB ' HD11 ' F' ' 31' ' ' ILE . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.503 0.192 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.606 HD21 HG21 ' C' ' 36' ' ' VAL . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG13 ' HB ' ' B' ' 18' ' ' VAL . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.504 ' CD1' HD13 ' C' ' 32' ' ' ILE . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.426 ' O ' ' N ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 26' ' ' SER . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.482 ' O ' HD12 ' A' ' 31' ' ' ILE . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.53 ' O ' HD12 ' B' ' 34' ' ' LEU . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 . . . . . 0 N--CA 1.461 0.085 0 CA-C-O 120.802 0.334 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 26.7 t60 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 60.5 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.565 HD11 HG11 ' D' ' 36' ' ' VAL . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.452 ' HB ' HG13 ' A' ' 18' ' ' VAL . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' C' ' 29' ' ' GLY . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.591 HD13 HG21 ' O' ' 39' ' ' VAL . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.53 HD12 ' O ' ' A' ' 34' ' ' LEU . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.515 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.449 ' O ' HG12 ' C' ' 39' ' ' VAL . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t . . . . . 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 N--CA 1.466 0.374 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.454 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.55 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.484 ' N ' ' CE1' ' B' ' 14' ' ' HIS . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.63 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.542 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' H ' ' C' ' 28' ' ' LYS . 8.9 t-20 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.553 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.55 HD12 ' HB ' ' O' ' 39' ' ' VAL . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.586 HG22 HD11 ' D' ' 34' ' ' LEU . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.606 HG21 HD21 ' A' ' 17' ' ' LEU . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.564 ' O ' HD11 ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.59 HG22 ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.59 ' N ' HG22 ' C' ' 39' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.742 HG12 ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.742 ' H ' HG12 ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' D' ' 12' ' ' VAL . 7.8 m80 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 54.3 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD13 ' C' ' 17' ' ' LEU . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.555 ' O ' HG23 ' D' ' 24' ' ' VAL . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.555 HG23 ' O ' ' D' ' 22' ' ' GLU . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.436 ' H ' HG12 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.422 ' H ' ' H ' ' D' ' 25' ' ' GLY . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.517 HD12 HG23 ' P' ' 39' ' ' VAL . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' D' ' 34' ' ' LEU . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.827 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.827 HD12 ' C ' ' D' ' 33' ' ' GLY . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' B' ' 17' ' ' LEU . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.598 HG12 HD13 ' J' ' 31' ' ' ILE . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.597 HG12 ' O ' ' D' ' 40' ' ' VAL . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.522 ' O ' HG11 ' D' ' 12' ' ' VAL . 59.1 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD12 ' D' ' 17' ' ' LEU . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.447 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.976 HG12 ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.976 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.456 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.636 ' O ' HD23 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.488 ' N ' HD12 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.597 ' HB ' HD11 ' K' ' 31' ' ' ILE . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' D' ' 40' ' ' VAL . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m . . . . . 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.496 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt . . . . . 0 CA--C 1.531 0.242 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.521 HD11 ' HB ' ' R' ' 39' ' ' VAL . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.487 HD13 ' CD1' ' D' ' 19' ' ' PHE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.636 HD23 ' O ' ' E' ' 34' ' ' LEU . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.649 HG23 ' O ' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.55 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.538 HG11 ' CD2' ' D' ' 13' ' ' HIS . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.639 HG23 ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.6 HE22 HG13 ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.509 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.509 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.478 ' OE1' ' CE1' ' H' ' 20' ' ' PHE . 33.9 tt0 . . . . . 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.599 0 CA-C-O 123.733 1.73 . . . . 0.0 115.358 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.639 ' O ' HG23 ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.534 HD11 HG11 ' J' ' 36' ' ' VAL . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' I' ' 24' ' ' VAL . 10.8 t0 . . . . . 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.442 HD11 ' HA2' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.666 HG12 HD11 ' I' ' 34' ' ' LEU . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.42 ' H ' ' HG ' ' I' ' 34' ' ' LEU . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.538 HG23 HD11 ' N' ' 31' ' ' ILE . 4.9 t . . . . . 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 C--O 1.231 0.114 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.523 HG23 ' O ' ' J' ' 12' ' ' VAL . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.726 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.403 ' HB3' ' HE2' ' K' ' 28' ' ' LYS . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.595 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.595 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.452 HG23 ' N ' ' I' ' 25' ' ' GLY . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.556 ' HB2' ' ND2' ' I' ' 27' ' ' ASN . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.62 HD12 HD11 ' J' ' 31' ' ' ILE . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.414 HG23 HD13 ' I' ' 34' ' ' LEU . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.801 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.801 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.6 HG13 HE22 ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.418 ' N ' HG22 ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.523 ' O ' HG23 ' I' ' 12' ' ' VAL . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' CE1' HG13 ' K' ' 12' ' ' VAL . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' CA ' ' L' ' 37' ' ' GLY . 84.9 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' K' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.5 ' HZ ' HD23 ' J' ' 17' ' ' LEU . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.417 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 66.5 m-20 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.62 HD11 HD12 ' I' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.763 HG22 HD21 ' K' ' 34' ' ' LEU . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.582 ' H ' HD23 ' K' ' 34' ' ' LEU . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.534 HG11 HD11 ' H' ' 17' ' ' LEU . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.529 ' O ' HG12 ' K' ' 39' ' ' VAL . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.509 HG23 HD12 ' P' ' 31' ' ' ILE . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.481 HG22 ' OXT' ' J' ' 40' ' ' VAL . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.486 ' O ' HG22 ' J' ' 12' ' ' VAL . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' J' ' 13' ' ' HIS . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.447 ' HB3' ' HE2' ' J' ' 14' ' ' HIS . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' J' ' 17' ' ' LEU . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.518 HG12 ' H ' ' K' ' 25' ' ' GLY . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.518 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.439 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB ' ' E' ' 39' ' ' VAL . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.763 HD21 HG22 ' J' ' 32' ' ' ILE . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.528 HG11 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.529 HG12 ' O ' ' J' ' 38' ' ' GLY . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.47 HG12 ' O ' ' L' ' 40' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 120.654 0.264 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.547 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.55 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.439 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.56 HD23 ' N ' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.807 HG21 HD21 ' J' ' 17' ' ' LEU . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.577 ' CA ' ' NE2' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' K' ' 40' ' ' VAL . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.469 HG23 ' O ' ' M' ' 12' ' ' VAL . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 m80 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.403 HE22 HG13 ' O' ' 36' ' ' VAL . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' O' ' 36' ' ' VAL . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.486 ' H ' HG23 ' N' ' 24' ' ' VAL . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.661 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.417 HD13 HG21 ' M' ' 31' ' ' ILE . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.514 HG23 ' N ' ' O' ' 13' ' ' HIS . 1.0 OUTLIER . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' N' ' 19' ' ' PHE . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.89 ' H ' ' HZ3' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.492 HG13 ' O ' ' N' ' 23' ' ' ASP . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.661 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.824 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.538 HD11 HG23 ' H' ' 39' ' ' VAL . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.528 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.474 ' O ' HG22 ' O' ' 39' ' ' VAL . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.524 HG23 HD12 ' B' ' 31' ' ' ILE . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.588 HG12 ' H ' ' O' ' 13' ' ' HIS . 3.2 t . . . . . 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.588 ' H ' HG12 ' O' ' 12' ' ' VAL . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.667 HD12 HD22 ' P' ' 17' ' ' LEU . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.514 HG13 ' CG ' ' O' ' 22' ' ' GLU . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.557 ' HB3' ' H ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.89 ' HZ3' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.683 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.747 HG23 HD21 ' O' ' 34' ' ' LEU . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.603 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.747 HD21 HG23 ' O' ' 32' ' ' ILE . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.447 HG11 ' CD1' ' M' ' 17' ' ' LEU . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.528 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.554 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.591 HG21 HD13 ' B' ' 31' ' ' ILE . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m . . . . . 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.541 ' NE2' HG11 ' O' ' 12' ' ' VAL . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.667 HD22 HD12 ' O' ' 17' ' ' LEU . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.532 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.532 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.987 HG12 ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.987 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.683 HD21 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.824 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.646 ' HB2' ' HA2' ' O' ' 29' ' ' GLY . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.857 HG22 HD11 ' Q' ' 34' ' ' LEU . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.658 HD12 ' O ' ' O' ' 34' ' ' LEU . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.449 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.474 ' HB ' HG13 ' Q' ' 36' ' ' VAL . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.554 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.685 HG12 ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.685 ' N ' HG12 ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . 0.494 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.412 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.44 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.593 ' HA3' ' HB2' ' R' ' 30' ' ' ALA . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' K' ' 39' ' ' VAL . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . 0.676 HG23 HD13 ' Q' ' 34' ' ' LEU . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . 0.763 ' C ' HD12 ' Q' ' 34' ' ' LEU . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.857 HD11 HG22 ' P' ' 32' ' ' ILE . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.556 HG11 HD21 ' O' ' 17' ' ' LEU . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.523 HG12 ' NE2' ' O' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.591 HG12 ' H ' ' R' ' 25' ' ' GLY . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.591 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.526 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . 0.593 ' HB2' ' HA3' ' Q' ' 29' ' ' GLY . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.405 HG11 HD13 ' P' ' 17' ' ' LEU . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.521 ' HB ' HD11 ' F' ' 31' ' ' ILE . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.445 ' H ' HG22 ' R' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -110.17 139.44 45.32 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.844 0.354 . . . . 0.0 110.685 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.537 ' O ' ' NE2' ' B' ' 13' ' ' HIS . 40.4 tp10 -70.64 143.04 51.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.985 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.57 HG13 ' C ' ' B' ' 12' ' ' VAL . 79.1 t -115.84 94.92 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.196 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 14.9 t60 -125.51 133.91 52.21 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -176.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' O ' ' B' ' 14' ' ' HIS . 44.2 p-80 -155.36 162.38 40.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.656 177.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -90.09 160.13 16.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.2 mtmt -139.37 131.27 27.69 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.912 HD11 HG21 ' C' ' 36' ' ' VAL . 21.9 mt -115.88 126.47 53.98 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-O 120.633 0.254 . . . . 0.0 110.33 178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 m -119.44 96.92 4.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 176.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -107.74 111.07 23.07 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -120.27 112.32 18.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.106 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.53 107.43 17.47 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 105.56 -2.015 . . . . 0.0 105.56 176.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 86.0 mt-10 -161.04 -158.41 0.58 Allowed 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.732 ' OD1' HG11 ' B' ' 24' ' ' VAL . 94.6 m-20 -75.16 47.39 0.36 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.61 178.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 25' ' ' GLY . 34.4 t -60.96 -178.9 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 119.04 -1.064 . . . . 0.0 109.069 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.844 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.95 27.09 22.2 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.716 -1.047 . . . . 0.0 115.287 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 24.7 m -82.37 -126.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 120.464 2.132 . . . . 0.0 109.409 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.473 HD22 ' CB ' ' A' ' 30' ' ' ALA . 72.4 m-80 -100.57 160.94 13.94 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -40.53 -39.86 1.12 Allowed 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 121.372 0.606 . . . . 0.0 110.992 175.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -175.19 68.0 0.1 OUTLIER Glycine 0 CA--C 1.548 2.138 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.757 -179.069 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.473 ' CB ' HD22 ' A' ' 27' ' ' ASN . . . -88.02 173.48 8.85 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 119.179 1.49 . . . . 0.0 113.863 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.499 ' CD1' ' O ' ' M' ' 39' ' ' VAL . 8.1 pt -119.2 124.38 72.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 112.675 -2.057 . . . . 0.0 107.075 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.6 mt -134.63 143.05 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.06 120.53 1.47 Allowed Glycine 0 CA--C 1.53 0.989 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 178.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.442 ' O ' HD12 ' B' ' 34' ' ' LEU . 1.7 tp -168.82 172.92 7.45 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 119.212 -0.995 . . . . 0.0 112.366 -178.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 28.7 mtm -145.37 155.97 43.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.336 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -128.13 132.28 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.49 112.22 3.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.51 -66.15 1.49 Allowed Glycine 0 CA--C 1.538 1.528 0 C-N-CA 121.332 -0.461 . . . . 0.0 113.042 -178.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.81 ' H ' ' H ' ' B' ' 40' ' ' VAL . 59.3 t -144.34 161.42 14.97 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.581 0 CA-C-N 118.097 0.949 . . . . 0.0 109.107 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.553 ' N ' HG12 ' A' ' 39' ' ' VAL . 57.3 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.497 -179.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -111.92 140.49 46.54 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.914 0.388 . . . . 0.0 110.848 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -74.35 148.8 40.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.783 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.722 HG21 ' O ' ' C' ' 12' ' ' VAL . 27.1 m -141.84 160.98 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.011 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 11' ' ' GLU . 65.1 m-70 -71.07 129.14 38.2 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.728 -179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.545 ' O ' ' CG ' ' A' ' 14' ' ' HIS . 6.3 p80 -155.16 160.08 40.64 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.886 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 64.9 tp60 -90.2 159.21 16.84 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -140.54 107.19 5.34 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.379 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.708 HD21 HG11 ' D' ' 36' ' ' VAL . 91.2 mt -120.46 113.15 19.89 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -116.98 100.02 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.433 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 7.7 m-30 -109.65 108.48 18.91 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 179.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.633 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 25.6 t80 -118.84 127.27 53.36 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.94 118.33 27.59 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 113.075 0.768 . . . . 0.0 113.075 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -139.98 113.26 8.38 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.531 ' CB ' ' O ' ' C' ' 26' ' ' SER . 4.6 m-20 -64.44 -52.22 59.18 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -171.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.732 HG11 ' OD1' ' A' ' 23' ' ' ASP . 2.1 t 73.85 -142.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.227 -0.095 0 C-N-CA 116.702 -1.999 . . . . 0.0 107.714 -179.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -101.63 33.5 6.44 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.419 ' O ' ' OG ' ' C' ' 26' ' ' SER . 23.2 t -89.41 104.32 16.88 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 112.409 -1.895 . . . . 0.0 108.517 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -80.88 -169.53 2.25 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 115.222 1.564 . . . . 0.0 115.222 -174.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -56.15 -39.72 72.74 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 112.347 -2.206 . . . . 0.0 116.427 -174.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 29' ' ' GLY . . . -100.55 67.87 0.5 Allowed Glycine 0 CA--C 1.537 1.449 0 C-N-CA 120.152 -1.023 . . . . 0.0 115.421 -173.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 105.01 10.26 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.512 HD12 ' O ' ' N' ' 39' ' ' VAL . 95.4 mt -131.01 131.37 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.729 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.4 tt -131.82 124.87 54.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.499 0.666 . . . . 0.0 110.96 179.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -123.47 116.63 2.96 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.484 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 58.4 tp -152.08 135.6 16.1 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 119.009 -1.076 . . . . 0.0 112.511 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.544 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 23.3 mtp -127.65 128.22 45.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.752 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.21 121.19 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.324 0.583 . . . . 0.0 110.661 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' B' ' 38' ' ' GLY . . . -91.11 121.85 6.47 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 177.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' B' ' 37' ' ' GLY . . . -38.21 -62.13 1.11 Allowed Glycine 0 CA--C 1.543 1.816 0 C-N-CA 120.303 -0.951 . . . . 0.0 111.925 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.903 ' O ' HD13 ' H' ' 31' ' ' ILE . 57.4 t -134.73 118.94 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 177.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.81 ' H ' ' H ' ' A' ' 39' ' ' VAL . 11.8 p . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.415 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -107.31 134.79 49.86 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.735 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 47.1 tp10 -136.25 116.64 13.67 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.722 ' O ' HG21 ' B' ' 12' ' ' VAL . 2.0 p -132.25 119.12 38.77 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.725 0 CA-C-O 120.785 0.326 . . . . 0.0 111.337 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.499 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 19.7 m80 -117.42 140.61 49.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.671 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 86.2 m-70 -136.88 157.2 47.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.239 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.811 HE22 ' H ' ' F' ' 37' ' ' GLY . 88.1 mt-30 -90.41 159.85 16.36 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.576 ' C ' HD12 ' C' ' 17' ' ' LEU . 58.9 mttp -140.31 100.04 3.8 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.633 HD21 HG11 ' E' ' 36' ' ' VAL . 9.1 mp -116.75 120.09 37.49 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -123.4 99.81 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.529 ' CZ ' HD23 ' C' ' 17' ' ' LEU . 7.1 m-30 -110.39 116.59 31.71 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 65.5 t80 -128.6 131.96 48.16 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.49 127.32 40.59 Favored 'General case' 0 C--O 1.25 1.079 0 N-CA-C 113.442 0.904 . . . . 0.0 113.442 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.58 ' HG3' ' H ' ' C' ' 23' ' ' ASP . 12.8 tp10 -93.38 -169.38 2.12 Favored 'General case' 0 C--N 1.361 1.08 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.966 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' N ' ' D' ' 25' ' ' GLY . 9.6 m-20 -158.67 50.25 0.38 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.1 m -75.63 -143.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.26 -36.91 6.41 Favored Glycine 0 N--CA 1.478 1.456 0 C-N-CA 120.115 -1.04 . . . . 0.0 111.789 -174.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.531 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 12.9 t -80.68 120.03 24.06 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 175.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.564 ' O ' ' N ' ' C' ' 29' ' ' GLY . 12.9 m120 -88.48 157.96 18.49 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.983 1.475 . . . . 0.0 114.983 -173.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -48.16 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 111.375 -2.648 . . . . 0.0 113.296 177.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -100.51 53.5 0.91 Allowed Glycine 0 CA--C 1.542 1.774 0 O-C-N 121.261 -0.899 . . . . 0.0 115.034 -173.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.529 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -128.21 151.32 49.4 Favored 'General case' 0 C--O 1.244 0.799 0 CA-C-O 122.209 1.004 . . . . 0.0 110.408 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.534 HG23 ' CG2' ' D' ' 31' ' ' ILE . 23.9 mt -112.8 119.23 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.699 -178.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.67 HG23 HD13 ' C' ' 34' ' ' LEU . 2.7 mt -108.81 112.13 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.88 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -127.17 101.37 0.58 Allowed Glycine 0 N--CA 1.471 1.028 0 N-CA-C 107.732 -2.147 . . . . 0.0 107.732 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.88 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.9 mp -141.35 155.01 45.98 Favored 'General case' 0 CA--C 1.501 -0.905 0 CA-C-O 122.507 1.146 . . . . 0.0 112.225 -176.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 72.9 mtp -129.63 116.51 18.96 Favored 'General case' 0 CA--C 1.499 -0.997 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.174 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 17' ' ' LEU . 10.3 m -126.46 113.7 34.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.42 -123.69 1.15 Allowed Glycine 0 C--N 1.302 -1.316 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.22 -67.64 3.01 Favored Glycine 0 CA--C 1.533 1.194 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.414 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.621 ' HA ' HG21 ' D' ' 39' ' ' VAL . 5.9 t -141.42 160.37 22.09 Favored 'Isoleucine or valine' 0 C--N 1.343 0.303 0 C-N-CA 122.698 0.399 . . . . 0.0 110.874 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' C' ' 39' ' ' VAL . 41.8 t . . . . . 0 N--CA 1.472 0.648 0 CA-C-O 117.915 -1.041 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -105.2 130.07 53.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.786 0.326 . . . . 0.0 110.367 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.8 145.94 32.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.369 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.451 ' O ' HG23 ' C' ' 12' ' ' VAL . 75.6 t -123.18 131.39 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.325 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 38.1 t-80 -161.53 112.89 1.73 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.25 -0.58 . . . . 0.0 112.013 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 22.8 m-70 -137.96 161.94 35.37 Favored 'General case' 0 C--O 1.223 -0.316 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.613 HE22 ' C ' ' F' ' 36' ' ' VAL . 93.3 mt-30 -101.03 151.15 22.14 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -113.01 98.69 7.32 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 175.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.561 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.1 mm? -108.02 119.13 38.59 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 120.023 -0.671 . . . . 0.0 110.631 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -123.93 103.22 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 120.983 0.421 . . . . 0.0 109.886 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 6.3 m-30 -106.43 119.38 39.12 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 20.1 t80 -132.54 127.33 34.89 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -176.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.92 117.96 10.05 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.505 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 79.0 tt0 -118.66 145.06 45.77 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.565 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 46.7 t0 41.59 50.51 3.81 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.638 HG11 ' HG2' ' E' ' 28' ' ' LYS . 18.3 m -47.93 164.02 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -174.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.609 ' N ' ' OD1' ' C' ' 23' ' ' ASP . . . -176.09 20.59 0.05 OUTLIER Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' O ' ' E' ' 28' ' ' LYS . 74.5 p -63.82 120.33 11.69 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-O 121.221 0.534 . . . . 0.0 111.943 -177.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' D' ' 29' ' ' GLY . 78.2 m-20 -142.17 -156.8 0.71 Allowed 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.56 -178.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 28.47 -48.9 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -164.73 54.26 0.27 Allowed Glycine 0 CA--C 1.544 1.853 0 CA-C-N 120.919 1.691 . . . . 0.0 115.994 -178.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.88 86.88 6.75 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 119.478 1.639 . . . . 0.0 111.958 178.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.534 ' CG2' HG23 ' C' ' 31' ' ' ILE . 12.4 tt -139.18 125.53 23.61 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 118.57 -1.252 . . . . 0.0 114.202 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' D' ' 32' ' ' ILE . 66.8 mt -112.39 110.51 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.71 105.29 1.49 Allowed Glycine 0 N--CA 1.464 0.531 0 N-CA-C 106.538 -2.625 . . . . 0.0 106.538 177.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.401 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 94.2 mt -132.88 136.64 46.31 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 -175.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.2 tpp -107.4 106.26 16.59 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.708 HG11 HD21 ' B' ' 17' ' ' LEU . 15.4 t -124.98 123.25 65.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -176.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.94 -113.61 0.95 Allowed Glycine 0 C--N 1.316 -0.57 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.422 ' O ' ' CG2' ' E' ' 39' ' ' VAL . . . 71.8 -72.45 0.86 Allowed Glycine 0 CA--C 1.538 1.485 0 N-CA-C 111.935 -0.466 . . . . 0.0 111.935 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.625 HG12 HG23 ' D' ' 40' ' ' VAL . 2.7 t -128.24 128.37 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 123.234 0.613 . . . . 0.0 110.05 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.625 HG23 HG12 ' D' ' 39' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.72 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -115.31 139.82 49.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.665 0.269 . . . . 0.0 110.357 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -142.03 146.04 35.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.916 0.389 . . . . 0.0 110.763 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.38 103.13 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.414 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -146.69 104.46 3.74 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.82 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.674 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 24.9 m-70 -136.69 162.77 32.24 Favored 'General case' 0 N--CA 1.464 0.248 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 tt0 -100.87 150.52 22.75 Favored 'General case' 0 C--O 1.225 -0.186 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.16 101.28 8.82 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 174.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.9 mt -108.77 120.72 43.31 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 121.062 -0.255 . . . . 0.0 110.693 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.35 121.21 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.148 0.499 . . . . 0.0 110.686 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' HB3' ' E' ' 21' ' ' ALA . 57.5 t80 -126.22 118.8 25.92 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.207 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 41.9 t80 -123.73 118.16 26.58 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.515 ' HB3' ' CE1' ' E' ' 19' ' ' PHE . . . -164.6 161.15 20.83 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -178.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -83.17 147.91 27.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.206 176.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.3 t70 -133.97 47.48 2.43 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -176.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 4.3 m -63.38 -160.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.452 -178.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -90.04 -31.03 11.39 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 5.7 p -84.97 139.83 31.51 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.485 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 4.7 t-20 -72.54 147.28 46.1 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.85 -177.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.638 ' HG2' HG11 ' D' ' 24' ' ' VAL . 79.0 mttt -53.83 -48.42 69.94 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.56 -178.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.25 55.25 1.2 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.197 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.18 146.34 17.16 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-N 118.748 1.274 . . . . 0.0 110.562 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.436 ' O ' HG23 ' E' ' 31' ' ' ILE . 11.7 tt -137.78 129.68 40.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 120.084 -0.646 . . . . 0.0 112.708 -176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -112.2 109.83 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 176.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 96.94 1.0 Allowed Glycine 0 CA--C 1.508 -0.349 0 N-CA-C 104.979 -3.248 . . . . 0.0 104.979 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.408 ' O ' HD12 ' F' ' 34' ' ' LEU . 11.6 tp -131.0 135.29 47.49 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 122.549 1.166 . . . . 0.0 113.134 -174.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 96.4 mmm -108.95 102.56 11.55 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.643 HG12 HD11 ' F' ' 34' ' ' LEU . 5.4 p -119.82 123.58 71.18 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 128.78 -114.11 1.71 Allowed Glycine 0 C--N 1.317 -0.514 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.75 -72.3 1.29 Allowed Glycine 0 CA--C 1.533 1.2 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.535 HG12 ' N ' ' E' ' 40' ' ' VAL . 77.5 t -125.74 161.48 30.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.535 ' N ' HG12 ' E' ' 39' ' ' VAL . 70.6 t . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.936 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -109.39 137.33 47.41 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.771 0.319 . . . . 0.0 110.497 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.502 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.4 mp0 -78.67 160.56 27.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.39 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t -108.58 94.29 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 121.039 0.447 . . . . 0.0 110.221 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 51.8 p-80 -149.65 119.21 6.95 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.0 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.674 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 99.1 m-70 -152.49 166.6 31.47 Favored 'General case' 0 N--CA 1.465 0.283 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -89.78 158.83 17.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.101 0.476 . . . . 0.0 110.489 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -139.67 108.49 5.97 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 47.9 tp -120.18 125.94 49.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.945 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -129.69 120.94 51.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 51.1 p90 -133.69 132.52 40.76 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.029 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -129.98 125.4 35.29 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.42 155.6 41.42 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.393 -179.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -98.73 141.16 31.89 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.046 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 23' ' ' ASP . 91.8 m-20 59.96 46.71 10.69 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.648 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.698 HG12 ' H ' ' F' ' 25' ' ' GLY . 29.3 t -72.8 177.65 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.698 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 102.07 -32.83 7.07 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -178.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 35.1 m -81.34 -129.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.415 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 98.8 m-20 -99.8 160.85 14.0 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.695 0.76 . . . . 0.0 112.795 -177.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -43.84 -40.05 4.23 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 114.466 -1.243 . . . . 0.0 113.412 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' E' ' 28' ' ' LYS . . . 101.27 -63.46 0.54 Allowed Glycine 0 CA--C 1.544 1.884 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -177.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.89 169.23 18.17 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.801 HD12 HG22 ' R' ' 39' ' ' VAL . 85.5 mt -124.06 121.71 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-O 122.143 0.973 . . . . 0.0 111.762 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.43 HD13 HG21 ' F' ' 32' ' ' ILE . 59.6 mt -105.86 109.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-N 114.413 -1.267 . . . . 0.0 107.942 178.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.24 88.13 0.62 Allowed Glycine 0 CA--C 1.503 -0.657 0 N-CA-C 103.773 -3.731 . . . . 0.0 103.773 175.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.643 HD11 HG12 ' E' ' 36' ' ' VAL . 15.4 tp -124.0 129.36 50.8 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -174.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.534 ' N ' HD12 ' F' ' 34' ' ' LEU . 96.8 mmm -104.07 108.11 19.31 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.613 ' C ' HE22 ' D' ' 15' ' ' GLN . 0.2 OUTLIER -112.07 123.18 67.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.811 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 145.47 -113.33 0.69 Allowed Glycine 0 N--CA 1.459 0.233 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.331 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.424 ' O ' HD13 ' L' ' 31' ' ' ILE . . . 87.97 -73.16 2.34 Favored Glycine 0 CA--C 1.538 1.492 0 CA-C-N 114.962 -0.619 . . . . 0.0 111.848 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.15 147.06 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.709 0.755 . . . . 0.0 109.603 177.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.47 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 18.2 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.516 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -109.51 135.56 50.32 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -102.42 113.51 26.9 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 110.702 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 12' ' ' VAL . 33.8 m -124.09 127.28 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.504 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CG ' ' H' ' 13' ' ' HIS . 2.0 m-70 -92.39 109.61 21.01 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -149.76 165.12 33.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.235 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.421 HE22 HG13 ' J' ' 36' ' ' VAL . 40.7 tt0 -84.36 154.18 23.02 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.32 108.46 1.65 Allowed 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.875 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 97.4 mt -131.59 114.99 15.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 122.046 0.927 . . . . 0.0 110.851 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 97.9 t -106.58 109.42 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -101.68 104.43 15.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.544 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 43.8 p90 -111.4 116.19 30.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.01 114.24 27.39 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.207 0.527 . . . . 0.0 110.716 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -142.87 176.03 9.38 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.423 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.7 t0 -71.65 48.92 0.16 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.92 -178.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.81 HG12 ' H ' ' G' ' 25' ' ' GLY . 33.1 t -143.89 -178.95 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.459 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.81 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 68.14 -39.2 0.26 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.442 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.426 ' H ' ' C ' ' G' ' 24' ' ' VAL . 36.4 m -67.52 111.22 4.01 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 122.653 -0.322 . . . . 0.0 111.318 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 p-10 -149.09 161.59 41.65 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.825 0.822 . . . . 0.0 112.68 178.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.766 ' H ' ' NZ ' ' H' ' 28' ' ' LYS . 99.1 mttt 29.77 40.62 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 114.135 -1.393 . . . . 0.0 113.293 178.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.43 78.42 0.53 Allowed Glycine 0 N--CA 1.476 1.344 0 C-N-CA 120.087 -1.054 . . . . 0.0 111.534 179.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -81.5 64.44 6.22 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 119.439 1.619 . . . . 0.0 113.863 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.432 HD13 ' O ' ' A' ' 39' ' ' VAL . 81.7 mt -142.25 120.2 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 mm -123.8 129.31 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 120.907 0.384 . . . . 0.0 111.67 -178.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.6 106.57 0.56 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 107.55 -2.22 . . . . 0.0 107.55 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -141.47 158.03 44.38 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.622 0.725 . . . . 0.0 111.541 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 48.3 mtp -141.47 147.51 37.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.663 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' G' ' 37' ' ' GLY . 52.9 t -120.73 131.87 71.72 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -45.21 -111.77 0.0 OUTLIER Glycine 0 CA--C 1.529 0.916 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.451 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.75 -71.5 0.55 Allowed Glycine 0 CA--C 1.538 1.511 0 CA-C-N 115.566 -0.317 . . . . 0.0 112.651 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.535 ' H ' ' CD1' ' M' ' 31' ' ' ILE . 80.8 t -96.82 130.56 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.921 0.361 . . . . 0.0 111.164 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.521 179.701 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.74 137.33 46.85 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.735 0.302 . . . . 0.0 110.373 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 22.5 pt-20 -85.5 138.98 31.84 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.962 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' I' ' 12' ' ' VAL . 67.6 t -113.17 100.83 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.253 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.492 ' HB2' ' HD1' ' I' ' 13' ' ' HIS . 11.6 m170 -98.22 111.15 23.58 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -146.72 163.39 36.08 Favored 'General case' 0 C--O 1.225 -0.188 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 179.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.949 HE22 HG13 ' K' ' 36' ' ' VAL . 50.3 tt0 -85.57 153.5 22.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -161.22 111.65 1.7 Allowed 'General case' 0 C--N 1.317 -0.841 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.798 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.465 ' N ' HD12 ' H' ' 17' ' ' LEU . 4.2 mp -135.85 125.31 25.02 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.587 0.708 . . . . 0.0 111.143 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.59 108.42 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -105.47 103.72 13.3 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -118.2 127.07 53.39 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.57 123.1 24.53 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 98.3 mt-10 -87.25 -177.29 5.94 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 176.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.537 ' O ' ' O ' ' H' ' 24' ' ' VAL . 88.4 m-20 -131.04 51.8 2.11 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' H' ' 23' ' ' ASP . 8.5 t -64.93 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 101.966 -3.346 . . . . 0.0 101.966 168.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 157.13 -36.95 0.56 Allowed Glycine 0 N--CA 1.465 0.592 0 C-N-CA 117.252 -2.404 . . . . 0.0 118.532 170.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 42.7 t -66.53 111.6 3.68 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 122.752 3.276 . . . . 0.0 107.81 177.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' H' ' 29' ' ' GLY . 40.2 t30 -149.28 142.13 24.69 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 118.215 -1.394 . . . . 0.0 112.161 172.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.766 ' NZ ' ' H ' ' G' ' 28' ' ' LYS . 98.5 mttt -11.97 -44.68 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 115.474 1.657 . . . . 0.0 115.474 172.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 141.62 62.9 0.03 OUTLIER Glycine 0 CA--C 1.557 2.674 0 CA-C-O 118.862 -0.966 . . . . 0.0 110.913 -176.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.9 98.49 0.13 Allowed 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 116.055 1.872 . . . . 0.0 116.055 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.903 HD13 ' O ' ' B' ' 39' ' ' VAL . 73.2 mt -125.67 123.36 64.36 Favored 'Isoleucine or valine' 0 C--N 1.342 0.26 0 CA-C-N 112.97 -1.923 . . . . 0.0 108.654 178.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.431 HG22 HD11 ' I' ' 34' ' ' LEU . 77.2 mt -123.29 127.83 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.394 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -132.85 119.98 2.54 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.571 HD23 ' H ' ' H' ' 35' ' ' MET . 0.5 OUTLIER -143.15 138.69 29.95 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.043 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.571 ' H ' HD23 ' H' ' 34' ' ' LEU . 90.5 mmm -127.03 133.25 50.55 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 113.214 0.82 . . . . 0.0 113.214 -178.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 17.8 t -125.76 160.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 174.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.76 92.89 0.1 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 118.287 -1.911 . . . . 0.0 112.772 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.625 ' H ' ' HA2' ' I' ' 38' ' ' GLY . . . 149.08 -81.69 0.19 Allowed Glycine 0 N--CA 1.469 0.893 0 C-N-CA 120.138 -1.029 . . . . 0.0 114.454 175.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.495 HG23 ' O ' ' H' ' 38' ' ' GLY . 44.7 t -156.6 156.0 4.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 87.4 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.555 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.513 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 96.5 m-85 -106.35 134.78 48.96 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.687 0.279 . . . . 0.0 110.283 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' OE2' ' H' ' 11' ' ' GLU . 96.8 mt-10 -138.69 150.67 46.45 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.529 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.512 HG13 HG13 ' H' ' 12' ' ' VAL . 0.6 OUTLIER -119.51 126.48 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.093 0.473 . . . . 0.0 110.125 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 4.7 m-70 -130.83 126.71 36.98 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.411 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -153.11 163.13 40.43 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.887 179.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.569 ' NE2' HG12 ' K' ' 36' ' ' VAL . 67.4 mt-30 -84.61 156.4 21.59 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.302 0.573 . . . . 0.0 109.771 177.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -159.92 99.54 1.38 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.945 HD11 HG11 ' K' ' 36' ' ' VAL . 18.7 mt -121.91 119.67 32.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 120.686 -0.405 . . . . 0.0 111.179 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.2 t -113.17 103.5 15.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -103.64 103.36 13.28 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -115.4 123.54 48.9 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.37 -0.206 . . . . 0.0 111.342 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 130.9 27.03 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.292 0.567 . . . . 0.0 112.082 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' H' ' 23' ' ' ASP . 97.2 mt-10 -85.15 -172.21 4.05 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.219 -0.901 . . . . 0.0 112.242 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.535 ' HB2' HG22 ' J' ' 24' ' ' VAL . 20.2 p-10 -149.21 47.37 0.98 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 113.99 1.108 . . . . 0.0 113.99 -177.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 1.028 HG12 ' H ' ' I' ' 25' ' ' GLY . 63.4 t -63.53 -160.87 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 1.028 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -90.17 -35.41 7.59 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 -178.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.524 ' O ' ' O ' ' H' ' 23' ' ' ASP . 69.6 m -93.69 123.71 37.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' I' ' 28' ' ' LYS . 1.1 t-20 -73.08 149.09 43.4 Favored 'General case' 0 CA--C 1.513 -0.444 0 C-N-CA 118.835 -1.146 . . . . 0.0 108.26 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.68 ' N ' ' ND2' ' I' ' 27' ' ' ASN . 6.7 tmtt? -52.75 -48.97 66.38 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.445 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 90.43 50.91 2.84 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.33 135.92 48.58 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.587 1.184 . . . . 0.0 112.599 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.578 ' CD1' HG13 ' C' ' 39' ' ' VAL . 59.8 mt -125.57 125.39 68.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-N 112.894 -1.957 . . . . 0.0 111.059 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.66 HG23 HD13 ' I' ' 34' ' ' LEU . 72.7 mt -109.25 114.65 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.682 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -121.97 96.01 0.57 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 106.722 -2.551 . . . . 0.0 106.722 177.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.682 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.6 mp -137.52 157.38 46.66 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 123.262 1.506 . . . . 0.0 114.232 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.5 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 97.6 mmm -122.9 100.81 7.09 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 105.668 -1.975 . . . . 0.0 105.668 176.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.47 ' CG2' HD21 ' J' ' 34' ' ' LEU . 80.9 t -104.99 142.63 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.251 -178.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.42 -102.23 0.19 Allowed Glycine 0 C--N 1.292 -1.871 0 C-N-CA 120.268 -0.967 . . . . 0.0 110.982 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.625 ' HA2' ' H ' ' H' ' 38' ' ' GLY . . . 43.36 71.96 0.37 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.183 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.594 ' CG2' HD12 ' P' ' 31' ' ' ILE . 24.1 t -17.24 142.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.585 ' O ' HG13 ' I' ' 40' ' ' VAL . 5.0 p . . . . . 0 C--O 1.217 -0.658 0 CA-C-O 118.816 -0.611 . . . . 0.0 110.228 177.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.513 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -114.75 145.41 42.12 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.648 0.261 . . . . 0.0 110.373 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -69.36 115.75 8.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.013 0.435 . . . . 0.0 110.415 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.51 134.06 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.674 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' O ' ' I' ' 13' ' ' HIS . 7.5 t-80 -139.27 99.81 3.84 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' ND1' ' O ' ' K' ' 14' ' ' HIS . 64.4 t60 -112.27 160.44 17.64 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.517 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 33.6 tt0 -85.76 156.7 20.5 Favored 'General case' 0 C--O 1.226 -0.133 0 O-C-N 122.366 -0.209 . . . . 0.0 111.174 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -159.63 95.73 1.22 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.598 HD22 HD12 ' I' ' 17' ' ' LEU . 7.5 mt -119.66 112.0 18.76 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.81 110.93 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -109.02 105.71 15.34 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 34.6 t80 -111.7 117.5 33.05 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' K' ' 21' ' ' ALA . . . -155.99 148.6 23.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 117.771 -1.572 . . . . 0.0 114.416 -178.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' OD1' ' I' ' 23' ' ' ASP . 37.7 tt0 -110.77 116.66 31.67 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 113.35 -1.75 . . . . 0.0 106.688 177.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' L' ' 30' ' ' ALA . 77.5 m-20 -105.86 47.07 0.89 Allowed 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 -173.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.539 HG23 ' H ' ' J' ' 26' ' ' SER . 3.0 m -70.08 -168.86 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 118.557 -1.257 . . . . 0.0 110.541 -177.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.87 28.46 15.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.683 -0.69 . . . . 0.0 114.32 -174.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.539 ' H ' HG23 ' J' ' 24' ' ' VAL . 40.7 m -83.39 -119.79 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.368 1.084 . . . . 0.0 110.755 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.561 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 58.9 m-80 -92.37 -178.13 4.83 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.594 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.467 ' NZ ' HG22 ' D' ' 40' ' ' VAL . 92.6 mttt -49.88 -38.9 37.65 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -175.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.618 ' O ' ' ND2' ' I' ' 27' ' ' ASN . . . 99.44 -68.0 0.58 Allowed Glycine 0 CA--C 1.547 2.047 0 C-N-CA 121.477 -0.392 . . . . 0.0 113.412 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.47 149.9 0.31 Allowed 'General case' 0 C--O 1.244 0.81 0 CA-C-N 117.568 0.684 . . . . 0.0 111.136 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.561 ' CD1' HG22 ' D' ' 39' ' ' VAL . 51.5 mt -127.79 116.81 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.194 -0.602 . . . . 0.0 110.321 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.777 HG22 HD11 ' K' ' 34' ' ' LEU . 58.0 mt -115.36 124.12 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 177.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.98 106.72 0.74 Allowed Glycine 0 CA--C 1.519 0.341 0 N-CA-C 106.426 -2.67 . . . . 0.0 106.426 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.665 HD23 ' N ' ' J' ' 35' ' ' MET . 3.9 tt -150.37 142.24 23.81 Favored 'General case' 0 N--CA 1.465 0.306 0 C-N-CA 118.366 -1.334 . . . . 0.0 113.758 -175.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.665 ' N ' HD23 ' J' ' 34' ' ' LEU . 1.5 ttm -99.79 108.91 21.33 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.583 HG22 HD22 ' J' ' 34' ' ' LEU . 11.8 t -93.16 103.45 14.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 111.425 -177.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.512 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -2.49 144.15 0.0 OUTLIER Glycine 0 N--CA 1.475 1.24 0 C-N-CA 126.067 1.794 . . . . 0.0 117.536 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' K' ' 39' ' ' VAL . . . -75.18 -57.28 4.4 Favored Glycine 0 CA--C 1.546 1.975 0 CA-C-N 113.827 -1.186 . . . . 0.0 111.95 176.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.471 ' CG2' HD11 ' P' ' 31' ' ' ILE . 83.6 t -109.17 128.79 64.81 Favored 'Isoleucine or valine' 0 C--N 1.357 0.91 0 CA-C-N 118.008 0.904 . . . . 0.0 110.551 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.615 ' H ' HG23 ' K' ' 40' ' ' VAL . 87.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.769 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.96 159.75 43.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.79 0.329 . . . . 0.0 110.408 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.437 ' O ' ' OE1' ' L' ' 11' ' ' GLU . 96.6 mt-10 -140.63 160.21 40.52 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.12 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.525 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 69.1 t -129.08 125.15 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.433 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.525 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 30.0 m-70 -145.48 99.65 3.33 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.997 -0.281 . . . . 0.0 110.473 178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.569 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 16.0 t-80 -115.82 160.68 19.82 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -85.73 156.97 20.41 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.838 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -160.55 96.98 1.18 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.812 176.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.415 HD21 ' CE1' ' L' ' 19' ' ' PHE . 1.4 tt -120.59 120.06 34.69 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -127.16 126.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.3 t80 -123.53 111.56 16.43 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.988 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.528 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.4 t80 -114.72 116.21 28.3 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' J' ' 21' ' ' ALA . . . -171.34 -178.16 2.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 117.149 -1.82 . . . . 0.0 115.367 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.413 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 80.7 mt-10 -92.8 112.8 24.88 Favored 'General case' 0 C--O 1.228 -0.071 0 CA-C-N 113.112 -1.858 . . . . 0.0 106.029 175.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' L' ' 27' ' ' ASN . 5.2 t0 -91.4 47.77 1.42 Allowed 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 -175.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.59 HG13 ' N ' ' K' ' 25' ' ' GLY . 1.5 p -81.24 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.59 ' N ' HG13 ' K' ' 24' ' ' VAL . . . -79.43 -28.61 51.99 Favored Glycine 0 N--CA 1.465 0.57 0 C-N-CA 118.619 -1.753 . . . . 0.0 112.996 -170.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.579 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 9.6 m 144.07 128.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 118.558 1.179 . . . . 0.0 113.603 175.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 25.1 t-20 -54.55 170.21 0.17 Allowed 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 113.66 -1.609 . . . . 0.0 107.488 175.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -58.96 -40.63 85.3 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 118.5 -1.28 . . . . 0.0 109.932 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.401 ' H ' ' HA ' ' J' ' 28' ' ' LYS . . . -162.56 62.58 0.27 Allowed Glycine 0 CA--C 1.547 2.079 0 C-N-CA 119.372 -1.394 . . . . 0.0 115.452 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.27 104.9 15.53 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 174.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.462 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.4 tt -137.81 126.45 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 118.447 -1.301 . . . . 0.0 113.6 -175.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.688 HG23 HD13 ' K' ' 34' ' ' LEU . 55.0 mt -110.42 115.37 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 177.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.836 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -123.32 94.96 0.52 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.836 HD12 ' C ' ' K' ' 33' ' ' GLY . 7.5 mp -138.96 149.8 45.15 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.538 1.161 . . . . 0.0 113.711 -176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -106.05 111.61 24.31 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 113.771 -1.558 . . . . 0.0 108.365 177.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.949 HG13 HE22 ' H' ' 15' ' ' GLN . 21.0 t -128.18 123.13 59.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 CA-C-O 121.206 0.527 . . . . 0.0 110.165 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.71 -113.52 0.83 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.72 -72.16 0.26 Allowed Glycine 0 CA--C 1.53 0.995 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.457 HG12 HG13 ' K' ' 40' ' ' VAL . 65.9 t -152.39 142.63 15.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 178.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.615 HG23 ' H ' ' J' ' 40' ' ' VAL . 9.2 m . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 118.047 -0.977 . . . . 0.0 112.103 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -117.26 142.12 47.45 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.949 0.404 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.437 ' OE1' ' O ' ' K' ' 11' ' ' GLU . 69.6 mm-40 -82.64 131.69 35.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.771 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.528 HG23 ' O ' ' L' ' 12' ' ' VAL . 6.3 m -125.75 123.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-O 121.524 0.678 . . . . 0.0 111.67 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 p-80 -155.6 126.91 7.19 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.28 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -152.59 170.82 19.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.277 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -83.83 153.71 23.9 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 121.047 0.451 . . . . 0.0 111.752 -178.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -159.99 102.84 1.47 Allowed 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.481 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -125.21 124.67 42.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.299 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -125.45 118.2 51.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-O 121.031 0.443 . . . . 0.0 110.426 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.415 ' CE1' HD21 ' K' ' 17' ' ' LEU . 89.7 m-85 -113.27 113.78 25.78 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.381 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -128.36 131.56 48.57 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.65 0.738 . . . . 0.0 110.775 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.4 159.2 35.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.608 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' L' ' 23' ' ' ASP . 97.0 mt-10 -101.37 112.97 25.64 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.211 -179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.863 ' O ' HG13 ' L' ' 24' ' ' VAL . 0.6 OUTLIER 165.27 -55.21 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.956 0.724 . . . . 0.0 112.956 179.473 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.863 HG13 ' O ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER -179.89 -159.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -176.548 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.546 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -51.32 -31.79 28.38 Favored Glycine 0 C--N 1.343 0.93 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -178.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.546 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 12.5 p 101.69 110.79 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 116.172 1.916 . . . . 0.0 116.172 174.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.597 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 74.6 m-20 -71.47 -173.06 0.85 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 112.926 -1.943 . . . . 0.0 109.986 174.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -56.48 -38.89 72.34 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.228 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.85 -69.0 3.45 Favored Glycine 0 CA--C 1.546 2.03 0 CA-C-N 116.176 -0.465 . . . . 0.0 113.91 178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.433 ' HB2' ' OD2' ' J' ' 23' ' ' ASP . . . -131.15 -174.76 3.48 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.424 HD13 ' O ' ' F' ' 38' ' ' GLY . 94.5 mt -120.78 102.74 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 121.355 1.888 . . . . 0.0 110.334 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 91.0 mt -105.53 115.79 48.03 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.66 83.39 0.34 Allowed Glycine 0 CA--C 1.509 -0.298 0 N-CA-C 103.876 -3.69 . . . . 0.0 103.876 176.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.564 HD12 ' O ' ' K' ' 34' ' ' LEU . 36.1 tp -125.14 132.86 53.01 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-N 114.746 -0.727 . . . . 0.0 112.545 -175.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.507 ' O ' ' O ' ' K' ' 36' ' ' VAL . 0.1 OUTLIER -99.13 113.87 26.32 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.46 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.508 HG13 ' HG ' ' L' ' 34' ' ' LEU . 0.6 OUTLIER -125.07 153.72 32.55 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.69 -101.96 2.42 Favored Glycine 0 CA--C 1.528 0.89 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.344 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.73 -80.2 0.06 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 42.4 t -145.57 134.62 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.929 0.395 . . . . 0.0 110.086 178.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.534 ' OXT' ' N ' ' K' ' 40' ' ' VAL . 10.5 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.004 -0.998 . . . . 0.0 111.275 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -106.3 135.81 47.13 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.827 0.346 . . . . 0.0 110.122 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -99.24 144.1 28.75 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.911 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -108.3 99.6 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . 0.474 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 34.4 m170 -78.46 99.13 6.31 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -177.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.62 ' HD1' ' CD2' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -160.47 168.68 24.59 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.268 178.434 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.452 ' OE1' HD11 ' M' ' 17' ' ' LEU . 52.1 tt0 -128.66 149.58 50.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.75 111.92 24.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 118.348 -0.834 . . . . 0.0 110.845 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.455 ' HB3' ' CE2' ' M' ' 19' ' ' PHE . 85.1 mt -125.89 111.81 15.24 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 119.935 1.243 . . . . 0.0 111.61 178.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 13.4 t -108.85 104.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 64.4 m-85 -108.42 114.22 27.89 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -143.41 146.89 33.85 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.101 -0.64 . . . . 0.0 112.156 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.71 120.08 29.7 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.26 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' M' ' 23' ' ' ASP . 96.7 mt-10 -146.46 -160.59 1.17 Allowed 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' M' ' 22' ' ' GLU . 64.6 t0 -36.72 -62.45 0.47 Allowed 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.255 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 83.4 t -60.62 141.89 16.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.07 29.44 0.59 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t 63.03 -120.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -111.34 169.87 8.5 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.285 0.564 . . . . 0.0 111.168 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -38.74 -39.84 0.55 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.209 -0.905 . . . . 0.0 112.84 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.44 65.17 0.24 Allowed Glycine 0 CA--C 1.535 1.327 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.871 -177.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.46 135.52 35.12 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 122.015 0.912 . . . . 0.0 112.042 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' H ' ' G' ' 39' ' ' VAL . 80.4 mt -116.58 130.73 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 113.717 -1.583 . . . . 0.0 110.282 -179.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -124.37 123.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-O 120.801 0.334 . . . . 0.0 110.651 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.77 117.15 2.95 Favored Glycine 0 N--CA 1.469 0.88 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 78.0 mt -138.92 139.15 37.93 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.594 0.712 . . . . 0.0 111.845 -178.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -128.99 130.13 46.26 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.43 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 44.8 t -129.06 146.53 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.32 102.39 0.4 Allowed Glycine 0 C--N 1.318 -0.446 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.17 78.1 0.84 Allowed Glycine 0 N--CA 1.48 1.608 0 CA-C-N 117.712 0.756 . . . . 0.0 113.325 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.499 ' O ' ' CD1' ' A' ' 31' ' ' ILE . 14.9 t -76.09 129.31 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 121.13 0.49 . . . . 0.0 110.956 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.384 179.554 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -106.23 131.39 53.52 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -141.38 163.09 33.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.031 0.443 . . . . 0.0 110.503 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' N' ' 13' ' ' HIS . 67.2 t -132.23 167.46 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.9 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.731 ' H ' ' CD2' ' N' ' 13' ' ' HIS . 0.2 OUTLIER -48.25 119.45 2.97 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 -176.566 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' HD1' ' M' ' 14' ' ' HIS . 1.7 p80 -150.04 161.92 41.4 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.572 177.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.576 HE21 HG22 ' P' ' 36' ' ' VAL . 78.2 mt-30 -90.48 152.31 21.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.634 -0.257 . . . . 0.0 111.543 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -150.3 99.23 2.77 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.176 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.412 HD11 HG21 ' P' ' 36' ' ' VAL . 4.8 mp -135.56 126.94 28.48 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.661 0.743 . . . . 0.0 112.248 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.36 107.36 22.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.495 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.634 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.3 m-85 -106.22 108.37 19.85 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.633 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -132.8 129.33 38.41 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 120.489 -0.484 . . . . 0.0 111.966 -177.449 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.66 120.93 33.28 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' N' ' 24' ' ' VAL . 71.8 tt0 -155.89 165.49 36.32 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-O 121.542 0.686 . . . . 0.0 112.336 -178.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.464 ' N ' ' CG ' ' N' ' 22' ' ' GLU . 52.2 p30 6.69 55.18 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.628 ' H ' ' CB ' ' O' ' 26' ' ' SER . 57.5 t -65.65 135.09 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 175.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.86 -30.88 1.87 Allowed Glycine 0 N--CA 1.471 1.005 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.31 -177.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 35.3 m -72.31 -128.45 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.075 -178.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.435 ' O ' ' C ' ' N' ' 28' ' ' LYS . 66.0 m-80 -119.93 -151.82 0.49 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.894 -178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' N' ' 27' ' ' ASN . 99.0 mttt -35.41 -41.31 0.18 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.166 0.508 . . . . 0.0 109.762 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.8 -64.62 2.42 Favored Glycine 0 CA--C 1.533 1.189 0 CA-C-N 115.322 -0.854 . . . . 0.0 113.62 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.16 140.78 1.99 Allowed 'General case' 0 C--O 1.237 0.414 0 CA-C-N 118.849 1.325 . . . . 0.0 113.642 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 93.5 mt -118.79 115.51 48.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.9 mt -125.52 129.81 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 119.741 -0.784 . . . . 0.0 113.098 -177.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.69 112.16 1.53 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 10.1 tt -143.58 138.21 28.92 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 121.78 -0.835 . . . . 0.0 110.796 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 81.8 mtp -138.2 144.23 40.55 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -178.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 44.9 t -121.59 147.65 25.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.275 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.52 102.22 0.41 Allowed Glycine 0 N--CA 1.463 0.493 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.973 -178.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.86 78.57 1.11 Allowed Glycine 0 N--CA 1.477 1.414 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.241 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.512 ' O ' HD12 ' B' ' 31' ' ' ILE . 11.3 t -67.67 129.95 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.357 0.598 . . . . 0.0 112.306 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.468 HG22 ' O ' ' N' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.976 -1.011 . . . . 0.0 110.534 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -113.38 136.92 52.24 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.735 0.302 . . . . 0.0 110.45 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -113.32 117.77 32.74 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.65 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' N' ' 12' ' ' VAL . 35.0 m -137.4 161.11 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.205 0.526 . . . . 0.0 110.705 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -142.23 141.73 32.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.574 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -151.25 166.44 30.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.336 0.589 . . . . 0.0 111.081 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.422 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 84.0 mt-30 -138.85 150.92 46.55 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -149.17 105.49 3.51 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.701 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.863 HD21 HG21 ' Q' ' 36' ' ' VAL . 4.1 mp -128.56 118.03 22.3 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.41 0.624 . . . . 0.0 110.236 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 63.4 t -107.75 107.15 22.09 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.296 -0.866 . . . . 0.0 109.725 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.547 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 53.5 m-85 -106.17 105.71 15.88 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.633 ' CD1' ' CZ ' ' N' ' 20' ' ' PHE . 3.3 t80 -124.23 126.15 45.61 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -178.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.47 121.56 21.23 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.437 0.637 . . . . 0.0 111.946 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -105.56 132.13 52.09 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.574 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.548 ' H ' ' HB2' ' P' ' 22' ' ' GLU . 1.3 m-20 -82.3 46.87 1.08 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 122.673 1.225 . . . . 0.0 112.44 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.624 HG12 ' H ' ' O' ' 25' ' ' GLY . 1.0 OUTLIER -71.83 -165.01 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 112.772 -2.013 . . . . 0.0 107.704 177.12 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.624 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -98.17 28.29 15.34 Favored Glycine 0 C--N 1.319 -0.379 0 N-CA-C 105.16 -3.176 . . . . 0.0 105.16 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.628 ' CB ' ' H ' ' N' ' 24' ' ' VAL . 39.1 t -80.59 116.91 20.86 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 108.739 -3.731 . . . . 0.0 107.129 176.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 p30 -88.28 -152.65 0.22 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.857 -173.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.7 mttt -49.56 -40.64 39.04 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.226 -171.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' N' ' 28' ' ' LYS . . . 80.98 -68.45 3.43 Favored Glycine 0 N--CA 1.464 0.545 0 C-N-CA 118.575 -1.774 . . . . 0.0 111.108 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.77 160.11 0.89 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 123.258 1.504 . . . . 0.0 112.273 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.504 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 92.5 mt -121.12 120.9 63.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 111.597 -2.547 . . . . 0.0 107.348 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.1 mt -114.88 111.22 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 121.137 0.494 . . . . 0.0 111.82 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.527 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -110.33 99.06 1.14 Allowed Glycine 0 N--CA 1.46 0.273 0 N-CA-C 105.433 -3.067 . . . . 0.0 105.433 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.527 HD12 ' O ' ' O' ' 33' ' ' GLY . 1.0 OUTLIER -134.46 140.24 46.09 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 122.544 1.164 . . . . 0.0 112.905 -175.51 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 25.4 mtp -122.73 101.64 7.57 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 175.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.575 ' O ' HG23 ' O' ' 36' ' ' VAL . 35.6 m -124.39 112.17 31.31 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.842 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 179.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.86 132.62 11.2 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.288 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.93 58.54 0.7 Allowed Glycine 0 CA--C 1.534 1.266 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 175.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.696 ' CG1' ' H ' ' P' ' 39' ' ' VAL . 21.1 m -137.8 129.48 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.356 0 CA-C-N 118.57 1.185 . . . . 0.0 111.318 -177.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.348 -179.921 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -110.04 138.95 45.71 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 56.8 mp0 -137.65 144.57 41.92 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.048 0.452 . . . . 0.0 111.007 -179.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.48 128.84 75.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' Q' ' 13' ' ' HIS . 34.8 m-70 -117.0 127.25 53.99 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 120.621 0.248 . . . . 0.0 111.063 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.424 ' HA ' ' O ' ' Q' ' 14' ' ' HIS . 32.1 m80 -150.91 165.06 34.8 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.244 178.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.424 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 6.6 tt0 -158.31 148.64 20.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -123.6 111.83 16.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.764 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.551 HD11 ' NE2' ' Q' ' 15' ' ' GLN . 9.4 mt -119.47 112.83 19.88 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.58 106.14 20.17 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.451 -0.499 . . . . 0.0 110.312 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.547 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 44.7 m-85 -107.76 105.01 14.64 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 178.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CZ ' ' O' ' 20' ' ' PHE . 44.9 t80 -120.84 125.28 47.11 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.35 133.07 27.22 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.548 ' HB2' ' H ' ' O' ' 23' ' ' ASP . 97.4 mt-10 -87.06 -172.5 4.0 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 175.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' Q' ' 26' ' ' SER . 52.1 t0 -162.36 49.36 0.18 Allowed 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 19.9 t -155.06 160.29 2.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 173.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 64.74 31.27 80.35 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 105.928 -2.869 . . . . 0.0 105.928 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' Q' ' 28' ' ' LYS . 3.4 t -92.25 105.01 17.31 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 116.964 2.209 . . . . 0.0 116.964 -171.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -81.0 -170.22 2.6 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 173.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' Q' ' 29' ' ' GLY . 99.4 mttt -56.09 -39.17 71.72 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 120.206 -0.597 . . . . 0.0 109.559 178.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . 81.34 -69.18 3.32 Favored Glycine 0 CA--C 1.543 1.809 0 N-CA-C 116.503 1.361 . . . . 0.0 116.503 175.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . 179.93 150.57 0.37 Allowed 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.979 1.39 . . . . 0.0 111.955 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.594 HD12 ' CG2' ' I' ' 39' ' ' VAL . 7.0 mt -130.12 125.48 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.977 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.634 HD13 ' CD1' ' N' ' 19' ' ' PHE . 96.9 mt -124.21 114.27 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-O 121.034 0.445 . . . . 0.0 111.707 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.13 109.57 2.46 Favored Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.636 -2.985 . . . . 0.0 105.636 176.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.74 HD23 ' N ' ' P' ' 35' ' ' MET . 1.0 OUTLIER -148.51 146.92 28.56 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 115.048 1.499 . . . . 0.0 115.048 -174.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.74 ' N ' HD23 ' P' ' 34' ' ' LEU . 92.1 mmm -118.49 117.7 29.74 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 113.44 -1.709 . . . . 0.0 106.396 176.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.576 HG22 HE21 ' N' ' 15' ' ' GLN . 1.4 p -143.95 102.59 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.517 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 -161.47 12.8 Favored Glycine 0 N--CA 1.468 0.819 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.531 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.1 -55.54 0.5 Allowed Glycine 0 CA--C 1.548 2.132 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.696 ' H ' ' CG1' ' O' ' 39' ' ' VAL . 8.8 p -154.91 135.73 4.82 Favored 'Isoleucine or valine' 0 C--N 1.337 0.049 0 CA-C-O 121.267 0.556 . . . . 0.0 110.042 175.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.564 ' CG1' ' ND1' ' N' ' 13' ' ' HIS . 94.7 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.308 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -129.93 123.23 30.2 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.873 0.368 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -144.28 126.39 15.55 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.863 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.41 139.77 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.335 0.588 . . . . 0.0 111.48 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.563 ' CD2' ' CD2' ' P' ' 13' ' ' HIS . 80.8 m80 -135.44 101.24 4.75 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.938 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 15.8 m-70 -146.35 175.62 10.39 Favored 'General case' 0 C--O 1.218 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.551 ' NE2' HD11 ' P' ' 17' ' ' LEU . 33.9 tt0 -154.43 140.54 18.44 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.078 0.466 . . . . 0.0 109.811 177.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -91.53 102.72 15.38 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.382 -0.826 . . . . 0.0 111.204 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.613 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.4 tt -115.79 112.65 22.31 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.574 ' CG2' ' CZ ' ' Q' ' 20' ' ' PHE . 9.6 p -125.98 125.22 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-O 121.046 0.45 . . . . 0.0 111.619 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -129.57 117.69 20.83 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.63 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CG2' ' Q' ' 18' ' ' VAL . 24.9 m-85 -124.39 130.98 53.46 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.912 0.387 . . . . 0.0 110.412 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.404 ' CB ' ' NZ ' ' Q' ' 28' ' ' LYS . . . -135.33 131.88 36.97 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.701 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -120.85 147.7 45.03 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.755 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' P' ' 23' ' ' ASP . 10.5 m-20 66.76 46.72 1.66 Allowed 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 178.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' Q' ' 25' ' ' GLY . 49.4 t -72.31 179.18 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 99.86 -29.21 12.56 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -173.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.447 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 70.5 m -127.32 150.82 49.41 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -52.34 130.98 32.55 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.529 ' O ' ' OD2' ' O' ' 23' ' ' ASP . 89.9 mttt -66.61 -51.44 56.35 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.067 175.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 28' ' ' LYS . . . 95.87 51.72 1.75 Allowed Glycine 0 CA--C 1.55 2.223 0 CA-C-N 116.023 -0.535 . . . . 0.0 113.356 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -162.4 134.85 5.66 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 118.274 1.037 . . . . 0.0 110.217 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.416 HG23 HG23 ' P' ' 31' ' ' ILE . 3.9 tt -135.1 122.43 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 119.995 -0.682 . . . . 0.0 111.79 -179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.7 mt -119.83 113.1 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.255 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.21 108.65 2.86 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 104.402 -3.479 . . . . 0.0 104.402 175.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' R' ' 34' ' ' LEU . 7.1 tt -151.39 148.13 27.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 118.267 -1.373 . . . . 0.0 114.317 -173.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.5 mtp -118.35 121.74 41.14 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.781 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.863 HG21 HD21 ' O' ' 17' ' ' LEU . 4.8 p -139.68 112.19 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.394 0.616 . . . . 0.0 111.952 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.7 -131.89 10.79 Favored Glycine 0 N--CA 1.462 0.417 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.853 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.64 -61.34 0.41 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.623 HG12 ' N ' ' Q' ' 40' ' ' VAL . 62.1 t -130.64 162.96 37.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 122.936 0.494 . . . . 0.0 110.527 177.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.623 ' N ' HG12 ' Q' ' 39' ' ' VAL . 61.0 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.355 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -109.59 132.96 53.65 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.728 0.299 . . . . 0.0 110.401 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -120.42 126.29 50.08 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.202 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -138.12 150.35 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-O 120.999 0.428 . . . . 0.0 111.039 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.404 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 39.7 p-80 -145.4 94.51 2.52 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.061 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 77.7 m80 -151.97 167.57 27.96 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -99.96 151.53 21.22 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.389 0.614 . . . . 0.0 112.385 -178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -110.99 104.41 12.98 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 114.926 -1.034 . . . . 0.0 108.377 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.56 121.55 40.5 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.593 -178.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -137.23 134.57 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.259 0.552 . . . . 0.0 110.285 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.37 151.88 30.45 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.179 -0.608 . . . . 0.0 111.639 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -144.76 131.45 20.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.469 ' HB3' ' CG1' ' R' ' 24' ' ' VAL . . . -131.89 132.48 43.65 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.49 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -96.09 140.18 31.19 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 t0 64.28 46.65 3.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.054 0.455 . . . . 0.0 110.542 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.469 ' CG1' ' HB3' ' R' ' 21' ' ' ALA . 11.4 m -72.83 178.68 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.695 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.77 -33.09 6.85 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.865 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.0 t -81.39 -129.73 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.69 1.245 . . . . 0.0 110.233 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -99.98 160.43 14.32 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.357 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -44.94 -40.5 6.42 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.328 177.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.0 -62.53 0.57 Allowed Glycine 0 CA--C 1.548 2.152 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.785 -178.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.96 171.17 7.63 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.435 ' O ' HG23 ' R' ' 31' ' ' ILE . 11.8 tt -132.1 122.51 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 118.918 -1.113 . . . . 0.0 111.239 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.2 mt -114.6 107.71 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.554 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.37 96.7 1.79 Allowed Glycine 0 CA--C 1.504 -0.656 0 N-CA-C 103.334 -3.907 . . . . 0.0 103.334 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' Q' ' 34' ' ' LEU . 15.8 tp -134.03 136.33 43.97 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -110.74 114.35 27.65 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 175.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.632 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 1.3 m -122.85 102.51 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 117.971 0.35 . . . . 0.0 111.941 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.3 -163.96 28.0 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.584 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' F' ' 31' ' ' ILE . . . 155.25 -54.59 0.42 Allowed Glycine 0 CA--C 1.545 1.941 0 CA-C-N 115.094 -0.553 . . . . 0.0 112.448 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.801 HG22 HD12 ' F' ' 31' ' ' ILE . 45.9 t -123.24 131.13 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 CA-C-N 118.263 1.032 . . . . 0.0 109.686 178.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.606 -179.881 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -93.06 135.04 34.59 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.618 0.247 . . . . 0.0 110.395 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -72.52 140.86 48.42 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.257 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.582 HG11 ' HA ' ' B' ' 12' ' ' VAL . 2.6 m -111.24 97.49 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.762 0.791 . . . . 0.0 110.238 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.457 ' O ' ' CB ' ' B' ' 13' ' ' HIS . 12.9 m80 -68.81 122.3 18.31 Favored 'General case' 0 C--O 1.224 -0.248 0 CA-C-N 114.509 -1.223 . . . . 0.0 111.162 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.481 ' NE2' ' O ' ' A' ' 12' ' ' VAL . 9.7 m-70 -98.84 174.72 6.24 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.693 0.758 . . . . 0.0 111.901 -179.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -160.48 140.61 11.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.401 -1.272 . . . . 0.0 107.584 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -159.5 144.55 15.53 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 17' ' ' LEU . 70.0 mt -137.84 129.29 27.98 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 122.569 1.176 . . . . 0.0 111.553 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.5 t -109.38 109.07 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 113.723 -1.581 . . . . 0.0 107.675 178.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.52 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 61.0 m-85 -103.5 102.22 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.632 ' CZ ' ' CD1' ' B' ' 20' ' ' PHE . 4.1 t80 -123.01 131.74 53.83 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.6 -176.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.794 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -122.99 113.14 18.67 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.811 ' O ' HG13 ' B' ' 24' ' ' VAL . 18.7 pt-20 -109.49 -165.74 1.04 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -70.2 54.45 0.14 Allowed 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.193 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.459 ' H ' HG13 ' B' ' 24' ' ' VAL . 57.5 t -68.02 135.81 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.507 -0.77 . . . . 0.0 108.977 177.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.61 -33.68 2.03 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.6 m -80.55 120.99 25.23 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 175.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.564 ' OD1' ' N ' ' A' ' 28' ' ' LYS . 2.9 t30 -87.36 151.52 23.03 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.526 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.564 ' N ' ' OD1' ' A' ' 27' ' ' ASN . 98.6 mttt -50.51 -47.27 57.39 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 122.079 0.942 . . . . 0.0 108.524 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.08 52.17 4.42 Favored Glycine 0 CA--C 1.537 1.456 0 CA-C-N 113.773 -1.558 . . . . 0.0 112.445 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.97 -179.16 0.46 Allowed 'General case' 0 C--O 1.241 0.612 0 CA-C-N 120.617 2.209 . . . . 0.0 115.383 -178.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.7 pt -121.29 131.81 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-N 109.975 -3.284 . . . . 0.0 105.667 177.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.52 137.2 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.4 110.79 0.73 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 94.3 mt -146.24 162.55 37.83 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-N 117.935 0.868 . . . . 0.0 112.273 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 48.9 ttm -144.84 144.76 31.29 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.35 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.8 t -137.72 112.05 9.11 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.55 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.63 132.11 19.8 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.1 -59.06 11.07 Favored Glycine 0 CA--C 1.539 1.553 0 C-N-CA 119.673 -1.251 . . . . 0.0 111.146 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.453 HG12 ' H ' ' A' ' 40' ' ' VAL . 4.3 t -149.63 166.5 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.453 ' H ' HG12 ' A' ' 39' ' ' VAL . 18.9 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.338 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.2 136.24 47.36 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.459 ' O ' HG21 ' A' ' 12' ' ' VAL . 9.4 pt-20 -144.78 152.75 40.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.389 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.582 ' HA ' HG11 ' A' ' 12' ' ' VAL . 9.3 t -131.35 162.45 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.679 ' HE2' ' HZ2' ' J' ' 28' ' ' LYS . 4.5 p-80 -100.48 135.76 41.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.462 0.648 . . . . 0.0 112.731 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 33.0 p80 -150.91 162.89 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.302 176.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' D' ' 37' ' ' GLY . 96.1 mt-30 -90.09 157.99 17.51 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.627 0.727 . . . . 0.0 111.859 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.541 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 64.2 tttm -140.94 123.1 15.67 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.57 -1.195 . . . . 0.0 108.23 177.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.768 HD11 HG11 ' D' ' 36' ' ' VAL . 17.7 mt -125.49 124.92 42.42 Favored 'General case' 0 CA--C 1.503 -0.845 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.613 178.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.541 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 60.1 t -116.47 103.64 15.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.52 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 70.9 m-85 -103.6 104.87 14.97 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CZ ' ' A' ' 20' ' ' PHE . 31.7 t80 -123.92 123.62 40.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.361 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 123.21 32.57 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.235 -0.438 . . . . 0.0 109.938 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' B' ' 24' ' ' VAL . 82.3 tt0 -131.89 111.11 11.29 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' B' ' 22' ' ' GLU . 35.5 m-20 15.54 47.24 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 177.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.993 HG12 ' H ' ' B' ' 25' ' ' GLY . 21.4 t -63.63 -161.56 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.113 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.993 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -90.38 -29.69 13.8 Favored Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.902 -1.142 . . . . 0.0 111.434 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' B' ' 25' ' ' GLY . 3.0 t 92.2 116.62 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' CG ' ' OD1' ' A' ' 27' ' ' ASN . 98.3 m-20 -72.76 162.02 30.01 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 118.579 -1.248 . . . . 0.0 109.957 -179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.31 -40.11 24.05 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-O 121.586 0.708 . . . . 0.0 110.415 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.84 65.67 0.04 OUTLIER Glycine 0 CA--C 1.536 1.365 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.124 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -72.69 126.43 29.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 118.355 1.078 . . . . 0.0 112.085 -177.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.599 HD11 HG13 ' N' ' 39' ' ' VAL . 77.1 mt -123.29 123.63 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 tt -128.03 128.57 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.665 -178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -126.2 117.26 2.79 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -136.34 139.69 42.75 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.895 0.855 . . . . 0.0 112.079 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 1.2 mtp -118.47 107.83 14.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.107 -1.406 . . . . 0.0 109.274 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.48 163.26 9.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . 81.4 102.51 0.36 Allowed Glycine 0 C--O 1.229 -0.166 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.648 ' HA2' ' H ' ' C' ' 39' ' ' VAL . . . 140.97 74.14 0.04 OUTLIER Glycine 0 CA--C 1.526 0.769 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.506 -178.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.505 ' O ' HG13 ' B' ' 40' ' ' VAL . 13.5 t -56.21 131.7 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.505 HG13 ' O ' ' B' ' 39' ' ' VAL . 16.4 m . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.825 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.405 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -107.17 136.6 46.73 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.673 0.273 . . . . 0.0 110.375 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -136.69 155.65 49.59 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 110.65 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.496 HG23 ' ND1' ' C' ' 14' ' ' HIS . 16.7 m -133.2 161.57 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.0 t-80 -85.48 111.94 20.44 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.099 -0.64 . . . . 0.0 111.134 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' HG23 ' C' ' 12' ' ' VAL . 31.3 p-80 -149.75 161.21 42.67 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.372 178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.503 ' OE1' HG13 ' F' ' 36' ' ' VAL . 15.4 tt0 -85.66 155.68 21.0 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.714 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.476 ' O ' HD23 ' C' ' 17' ' ' LEU . 77.8 tttt -160.8 102.43 1.32 Allowed 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.949 178.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.782 HD11 HG11 ' E' ' 36' ' ' VAL . 3.7 mt -127.68 120.5 28.16 Favored 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 121.205 0.526 . . . . 0.0 109.733 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 90.1 t -114.46 109.2 27.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.539 ' CE2' ' CE1' ' D' ' 19' ' ' PHE . 19.8 m-85 -107.49 103.52 12.87 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.53 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 62.1 t80 -115.65 119.95 37.78 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.31 128.28 33.43 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.9 mt-10 -143.57 131.76 21.92 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 102.273 -3.232 . . . . 0.0 102.273 175.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 54.8 m-20 -155.14 47.32 0.53 Allowed 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 -172.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.541 HG22 ' CA ' ' D' ' 25' ' ' GLY . 18.1 t -99.59 162.0 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.65 0 C-N-CA 117.049 -1.86 . . . . 0.0 107.079 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.455 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 71.08 28.59 70.09 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 104.791 -3.323 . . . . 0.0 104.791 -177.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.475 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 24.4 m -143.48 113.12 7.0 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -172.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.446 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 63.3 t30 -61.72 -161.97 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 66.9 mttm -57.71 -39.72 77.89 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 120.168 -0.613 . . . . 0.0 111.551 -175.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.477 ' O ' ' HB2' ' C' ' 30' ' ' ALA . . . 81.51 -68.7 3.42 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.971 177.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' C' ' 29' ' ' GLY . . . 179.99 174.35 0.89 Allowed 'General case' 0 C--O 1.243 0.76 0 CA-C-O 123.84 1.781 . . . . 0.0 114.657 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -133.61 127.94 53.74 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 CA-C-N 110.979 -2.828 . . . . 0.0 110.317 178.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' C' ' 32' ' ' ILE . 55.1 mt -106.7 117.62 52.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.243 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.483 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -114.29 94.23 0.68 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 106.334 -2.706 . . . . 0.0 106.334 176.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.416 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.6 mp -124.67 145.74 49.5 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.817 1.294 . . . . 0.0 114.073 -175.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 97.8 mmm -124.62 99.51 6.21 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 104.365 -2.458 . . . . 0.0 104.365 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.613 ' HB ' HG22 ' D' ' 36' ' ' VAL . 1.5 t -111.7 101.87 13.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.128 -176.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 112.89 -172.29 14.43 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -178.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.747 ' O ' HG21 ' D' ' 39' ' ' VAL . . . 138.42 -54.26 0.7 Allowed Glycine 0 CA--C 1.542 1.729 0 C-N-CA 121.063 -0.589 . . . . 0.0 112.694 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.648 ' H ' ' HA2' ' B' ' 38' ' ' GLY . 2.3 t -129.13 128.39 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 CA-C-N 117.472 0.636 . . . . 0.0 110.983 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.574 ' H ' ' CD1' ' I' ' 31' ' ' ILE . 1.7 p . . . . . 0 N--CA 1.473 0.713 0 CA-C-O 117.735 -1.126 . . . . 0.0 111.768 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -114.89 139.22 49.96 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.713 0.292 . . . . 0.0 110.328 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.519 ' OE1' ' N ' ' D' ' 11' ' ' GLU . 56.5 mp0 -82.89 127.79 33.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.657 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.63 126.72 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-O 121.193 0.52 . . . . 0.0 110.769 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' C' ' 13' ' ' HIS . 28.9 m170 -112.57 122.43 47.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.664 179.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 43.6 t60 -140.44 157.8 44.98 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 120.289 -0.564 . . . . 0.0 110.275 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.61 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 28.3 tt0 -86.06 157.36 20.09 Favored 'General case' 0 C--O 1.222 -0.374 0 O-C-N 122.143 -0.348 . . . . 0.0 110.759 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -159.93 101.87 1.46 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.596 177.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.79 HD11 HG11 ' F' ' 36' ' ' VAL . 5.5 mt -122.81 116.21 23.3 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 92.7 t -111.75 105.59 19.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.657 ' CE2' ' CZ ' ' E' ' 19' ' ' PHE . 56.2 m-85 -103.71 103.28 13.17 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 60.5 t80 -115.54 116.17 27.72 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.92 129.14 15.68 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 122.305 1.05 . . . . 0.0 113.654 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' D' ' 24' ' ' VAL . 67.5 mm-40 -93.67 111.05 22.66 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.559 ' OD2' ' ND2' ' F' ' 27' ' ' ASN . 8.2 m-20 -72.88 46.54 0.17 Allowed 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 118.57 -1.252 . . . . 0.0 111.448 -176.13 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' D' ' 22' ' ' GLU . 3.6 t -120.56 171.0 9.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 103.515 -2.772 . . . . 0.0 103.515 174.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.541 ' CA ' HG22 ' C' ' 24' ' ' VAL . . . 64.65 27.77 72.37 Favored Glycine 0 C--N 1.311 -0.843 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.112 176.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.516 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 2.4 p -81.19 115.88 20.82 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.475 ' ND2' ' O ' ' C' ' 26' ' ' SER . 3.4 m120 -90.5 163.24 14.7 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.342 0.591 . . . . 0.0 110.666 -175.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -42.95 -39.92 2.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.575 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.86 63.88 0.24 Allowed Glycine 0 CA--C 1.545 1.946 0 C-N-CA 119.095 -1.526 . . . . 0.0 115.787 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.446 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . -84.99 124.51 31.77 Favored 'General case' 0 C--O 1.247 0.921 0 CA-C-N 118.735 1.267 . . . . 0.0 109.29 176.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.716 HD11 HG23 ' P' ' 39' ' ' VAL . 96.5 mt -139.04 130.11 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 N-CA-C 114.764 1.394 . . . . 0.0 114.764 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.412 HD13 ' CD1' ' B' ' 19' ' ' PHE . 65.1 mt -106.44 112.66 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 173.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.93 118.31 2.83 Favored Glycine 0 N--CA 1.464 0.566 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.59 ' N ' HD23 ' D' ' 34' ' ' LEU . 2.1 pt? -169.2 169.87 9.01 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 123.166 1.46 . . . . 0.0 112.885 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 32.1 mtp -120.86 116.66 25.6 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 112.655 -2.066 . . . . 0.0 108.687 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.768 HG11 HD11 ' B' ' 17' ' ' LEU . 45.3 t -129.73 111.83 22.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 119.35 -132.24 9.45 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 108.494 -1.842 . . . . 0.0 108.494 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.11 -63.63 4.34 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.454 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.905 HG13 HD12 ' J' ' 31' ' ' ILE . 66.5 t -127.23 128.08 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.325 0 C-N-CA 123.494 0.718 . . . . 0.0 111.318 -178.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.438 ' H ' HG11 ' E' ' 39' ' ' VAL . 89.0 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 118.002 -0.999 . . . . 0.0 111.891 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.19 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -116.04 141.66 47.84 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -138.55 150.15 46.05 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.663 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.435 ' O ' ' CD2' ' E' ' 13' ' ' HIS . 55.1 t -123.78 134.01 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' E' ' 12' ' ' VAL . 18.0 m80 -139.15 103.82 4.86 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.713 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 70.1 m80 -125.63 175.41 7.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 177.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -126.38 141.9 51.73 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.128 177.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.516 ' C ' HD12 ' E' ' 17' ' ' LEU . 38.2 mttm -115.17 104.22 11.63 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.599 HD11 ' OE1' ' D' ' 15' ' ' GLN . 9.9 mp -113.51 110.24 19.95 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -121.67 119.14 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.56 0.219 . . . . 0.0 110.998 -178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.657 ' CZ ' ' CE2' ' D' ' 19' ' ' PHE . 69.9 m-85 -116.19 113.84 23.62 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.853 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.476 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 51.5 t80 -120.07 110.1 16.26 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.446 ' HB1' HD21 ' F' ' 27' ' ' ASN . . . -152.0 141.5 21.66 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 118.59 -1.244 . . . . 0.0 114.225 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.465 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 94.5 mt-10 -86.56 -178.25 6.36 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.271 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -147.83 49.17 1.07 Allowed 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.555 0.946 . . . . 0.0 113.555 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.653 HG12 ' N ' ' E' ' 25' ' ' GLY . 70.5 t -149.17 175.14 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 176.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.653 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 65.01 28.25 73.29 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 108.461 -1.855 . . . . 0.0 108.461 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -81.9 112.57 19.13 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -176.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' D' ' 26' ' ' SER . 0.8 OUTLIER -93.18 -161.16 0.82 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.542 177.655 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -45.09 -38.85 5.36 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 117.385 -1.293 . . . . 0.0 114.3 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.642 ' O ' HG13 ' Q' ' 39' ' ' VAL . . . 121.68 76.6 0.41 Allowed Glycine 0 N--CA 1.492 2.41 0 CA-C-N 121.778 2.081 . . . . 0.0 117.44 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . -81.09 160.29 24.5 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.154 0.977 . . . . 0.0 109.21 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.509 HG22 ' H ' ' F' ' 31' ' ' ILE . 38.1 pt -153.76 164.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 115.755 1.761 . . . . 0.0 115.755 -175.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -120.17 121.04 64.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-N 115.056 -0.974 . . . . 0.0 108.956 173.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.73 101.52 1.65 Allowed Glycine 0 N--CA 1.462 0.428 0 N-CA-C 105.91 -2.876 . . . . 0.0 105.91 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.484 HD12 ' N ' ' E' ' 35' ' ' MET . 24.0 tp -134.77 126.67 29.39 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -174.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.484 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.0 ttm -99.26 110.16 22.73 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.072 -1.422 . . . . 0.0 107.572 176.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.782 HG11 HD11 ' C' ' 17' ' ' LEU . 13.4 t -132.91 113.8 20.75 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.26 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.8 -125.02 1.94 Allowed Glycine 0 C--N 1.314 -0.673 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.532 ' O ' ' CD1' ' K' ' 31' ' ' ILE . . . 71.17 -66.73 0.91 Allowed Glycine 0 CA--C 1.536 1.395 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.84 HG21 HD11 ' J' ' 31' ' ' ILE . 25.2 t -137.81 134.06 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 176.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.554 ' OXT' ' NZ ' ' K' ' 28' ' ' LYS . 5.8 t . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 117.95 -1.024 . . . . 0.0 111.207 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 77.1 t80 -71.3 135.05 47.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.692 0.282 . . . . 0.0 110.509 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.485 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 96.9 mt-10 -72.26 152.39 42.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.522 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -114.27 129.39 70.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.175 0.512 . . . . 0.0 110.293 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.432 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -153.51 117.17 4.7 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.485 -179.574 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.713 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 97.2 m-70 -149.91 163.65 37.5 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -89.93 159.05 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.683 0.754 . . . . 0.0 112.09 -178.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.642 ' C ' HD12 ' F' ' 17' ' ' LEU . 51.4 tttp -139.92 109.98 6.48 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.616 -1.174 . . . . 0.0 107.982 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.642 HD12 ' C ' ' F' ' 16' ' ' LYS . 10.8 mp -117.38 120.98 39.82 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.571 0.224 . . . . 0.0 111.035 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -125.44 111.62 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' E' ' 19' ' ' PHE . 47.1 m-85 -115.2 115.84 27.37 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 111.406 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -126.39 105.94 9.13 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.71 157.61 32.09 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.802 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.569 ' OE1' ' N ' ' F' ' 22' ' ' GLU . 46.4 mp0 -93.35 132.4 37.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.301 178.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 56.99 59.87 3.27 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.33 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' F' ' 25' ' ' GLY . 12.0 t 71.76 -170.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -81.76 -35.45 22.08 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 119.977 -1.106 . . . . 0.0 111.033 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 30.8 t -81.44 119.87 24.28 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.606 ' O ' ' N ' ' F' ' 29' ' ' GLY . 51.4 m-80 -88.91 155.83 19.28 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.264 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -47.01 47.31 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 115.275 1.583 . . . . 0.0 115.275 177.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.606 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . 160.65 -58.28 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 CA-C-N 121.008 1.731 . . . . 0.0 114.593 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.04 150.02 22.28 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 117.985 0.892 . . . . 0.0 110.208 -177.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' R' ' 39' ' ' VAL . 82.5 mt -143.78 149.4 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -177.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' D' ' 19' ' ' PHE . 85.7 mt -111.25 111.33 35.7 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 CA-C-N 113.317 -1.765 . . . . 0.0 107.067 175.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 96.4 0.81 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.703 HD21 ' CG2' ' F' ' 36' ' ' VAL . 0.2 OUTLIER -139.77 145.78 38.67 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.693 0.759 . . . . 0.0 112.168 -175.346 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.1 mtp -109.36 116.1 31.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.398 -1.273 . . . . 0.0 109.427 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.79 HG11 HD11 ' D' ' 17' ' ' LEU . 12.6 t -143.5 132.36 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.007 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.14 111.97 3.67 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.255 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.9 -66.27 0.07 OUTLIER Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.795 HG23 HD12 ' L' ' 31' ' ' ILE . 55.1 t -128.38 128.95 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 CA-C-N 117.888 0.844 . . . . 0.0 109.894 176.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.533 HG22 ' O ' ' F' ' 40' ' ' VAL . 9.1 p . . . . . 0 C--O 1.218 -0.553 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.938 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -82.03 98.97 8.89 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.002 0.429 . . . . 0.0 110.55 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -159.21 117.59 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.122 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.573 HG21 ' H ' ' H' ' 12' ' ' VAL . 2.7 t -110.57 102.93 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.354 0.597 . . . . 0.0 110.064 -179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.504 ' O ' ' CE1' ' H' ' 13' ' ' HIS . 0.1 OUTLIER -69.55 169.08 13.32 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.607 -1.179 . . . . 0.0 112.856 -176.839 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.586 ' CE1' ' H ' ' H' ' 14' ' ' HIS . 58.8 m-70 -142.42 160.61 39.93 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.288 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -90.21 159.1 16.89 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.43 102.73 4.4 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.366 -0.534 . . . . 0.0 110.031 178.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.6 HD21 HG11 ' I' ' 36' ' ' VAL . 91.2 mt -122.59 115.97 23.06 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 120.449 -0.501 . . . . 0.0 110.237 178.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.522 HG13 ' O ' ' G' ' 18' ' ' VAL . 3.7 p -124.15 103.73 13.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.458 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 13.5 m-85 -112.22 106.93 15.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.56 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 5.3 m-85 -123.8 134.59 53.6 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.318 0.58 . . . . 0.0 112.361 -177.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.76 109.65 14.96 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' G' ' 24' ' ' VAL . 98.3 mt-10 -137.86 -178.41 5.24 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.7 0.629 . . . . 0.0 112.7 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.451 ' C ' ' O ' ' G' ' 22' ' ' GLU . 67.9 t0 4.71 60.53 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.299 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.607 ' H ' HG21 ' H' ' 24' ' ' VAL . 11.8 t -70.95 123.33 24.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.351 178.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.82 -34.24 4.42 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.174 -1.571 . . . . 0.0 109.174 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' G' ' 27' ' ' ASN . 56.2 p -151.04 123.91 8.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.683 HD21 ' N ' ' H' ' 29' ' ' GLY . 25.4 t-20 -41.68 150.8 0.1 Allowed 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.864 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -74.71 -50.33 17.91 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.654 -179.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' H' ' 29' ' ' GLY . . . 89.31 50.35 3.23 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.039 -0.867 . . . . 0.0 110.965 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.61 137.79 49.81 Favored 'General case' 0 C--N 1.349 0.559 0 CA-C-N 119.041 1.421 . . . . 0.0 114.727 -176.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.43 HD11 ' N ' ' A' ' 40' ' ' VAL . 28.8 pt -135.75 126.3 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 113.221 -1.809 . . . . 0.0 106.65 176.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 89.0 mt -136.82 143.26 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.573 0.953 . . . . 0.0 113.573 -176.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.52 115.63 1.32 Allowed Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.931 -2.068 . . . . 0.0 107.931 177.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.3 tp -150.82 148.51 28.57 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 118.904 1.352 . . . . 0.0 113.909 -177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -116.39 126.7 53.83 Favored 'General case' 0 C--O 1.232 0.145 0 CA-C-N 114.081 -1.418 . . . . 0.0 109.287 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 53.9 t -124.14 132.26 71.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.211 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.92 111.91 3.35 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.564 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . -77.01 73.53 1.95 Allowed Glycine 0 CA--C 1.535 1.282 0 C-N-CA 121.473 -0.394 . . . . 0.0 113.019 -178.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 t -91.86 135.06 28.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 O-C-N 122.79 -0.241 . . . . 0.0 110.398 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.039 -0.981 . . . . 0.0 111.4 179.839 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -112.75 139.76 48.09 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.681 0.276 . . . . 0.0 110.604 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -87.5 130.54 34.67 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.816 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.603 HG23 ' O ' ' H' ' 12' ' ' VAL . 34.2 m -113.56 89.08 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.159 0.504 . . . . 0.0 110.504 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.506 ' C ' ' ND1' ' H' ' 14' ' ' HIS . 2.5 t60 -113.58 124.44 52.34 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.955 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.586 ' H ' ' CE1' ' G' ' 14' ' ' HIS . 0.5 OUTLIER -138.15 174.38 10.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.03 140.3 17.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 119.659 -0.816 . . . . 0.0 109.376 177.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -94.42 108.42 20.35 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.51 HD11 HG13 ' K' ' 36' ' ' VAL . 12.3 mt -107.07 103.09 12.41 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 105.098 -2.186 . . . . 0.0 105.098 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.463 HG13 ' CG1' ' I' ' 18' ' ' VAL . 2.0 t -116.86 103.09 14.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.458 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 6.9 m-85 -116.61 116.42 27.54 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.56 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 10.0 m-85 -125.66 136.0 52.75 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.681 0.277 . . . . 0.0 110.695 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.696 ' HB1' ' HZ1' ' H' ' 28' ' ' LYS . . . -134.87 121.2 20.27 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 122.041 0.924 . . . . 0.0 113.147 -179.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.22 -164.74 1.2 Allowed 'General case' 0 C--N 1.349 0.548 0 CA-C-N 113.647 -1.615 . . . . 0.0 107.959 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.619 ' CB ' ' H ' ' I' ' 25' ' ' GLY . 6.7 m-20 -157.15 47.64 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.065 0.765 . . . . 0.0 113.065 -175.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.607 HG21 ' H ' ' G' ' 24' ' ' VAL . 0.7 OUTLIER -62.59 -166.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 120.435 -0.506 . . . . 0.0 109.93 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -91.31 27.67 9.11 Favored Glycine 0 N--CA 1.468 0.818 0 CA-C-N 116.733 -0.212 . . . . 0.0 113.243 -173.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.466 ' O ' ' O ' ' H' ' 27' ' ' ASN . 60.5 p -153.44 120.45 5.74 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.528 ' C ' HD22 ' G' ' 27' ' ' ASN . 99.8 m-20 -40.74 167.01 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.817 -177.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.696 ' HZ1' ' HB1' ' H' ' 21' ' ' ALA . 98.7 mttt -79.46 -49.31 12.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.14 -178.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.683 ' N ' HD21 ' G' ' 27' ' ' ASN . . . 90.16 53.17 2.4 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 119.282 -1.437 . . . . 0.0 112.3 179.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.78 110.15 0.95 Allowed 'General case' 0 C--O 1.238 0.483 0 CA-C-N 119.55 1.675 . . . . 0.0 114.283 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' B' ' 39' ' ' VAL . 1.4 pt -124.66 112.83 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 104.19 -2.522 . . . . 0.0 104.19 174.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -127.62 140.64 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 -174.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 104.21 0.65 Allowed Glycine 0 CA--C 1.527 0.784 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.64 139.8 33.12 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 118.59 1.195 . . . . 0.0 111.037 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 82.8 mtp -134.92 147.44 49.81 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 113.758 1.022 . . . . 0.0 113.758 -178.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' H' ' 37' ' ' GLY . 42.2 t -119.45 145.26 25.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.564 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -40.48 -103.66 0.01 OUTLIER Glycine 0 N--CA 1.469 0.893 0 C-N-CA 121.292 -0.48 . . . . 0.0 112.429 -178.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.584 ' HA3' HD13 ' N' ' 31' ' ' ILE . . . -145.9 -72.57 0.02 OUTLIER Glycine 0 CA--C 1.536 1.372 0 N-CA-C 112.12 -0.392 . . . . 0.0 112.12 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.507 ' H ' ' CD1' ' N' ' 31' ' ' ILE . 12.6 p -69.46 131.0 34.4 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 CA-C-O 120.74 0.305 . . . . 0.0 111.286 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 95.2 t . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.772 -179.751 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.466 ' CE2' ' O ' ' I' ' 11' ' ' GLU . 87.8 t80 -71.86 135.02 46.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.921 0.391 . . . . 0.0 110.471 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 57.5 mp0 -78.35 156.91 29.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.782 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 19.2 m -134.37 159.41 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.562 ' NE2' ' O ' ' K' ' 40' ' ' VAL . 8.5 t-80 -69.99 115.49 9.27 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 0.0 OUTLIER -151.54 160.0 43.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.647 176.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.518 ' CG ' HD11 ' I' ' 17' ' ' LEU . 21.2 tp60 -90.14 159.78 16.6 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.016 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.439 ' C ' HD12 ' I' ' 17' ' ' LEU . 98.5 mttt -139.99 100.51 3.94 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.856 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.2 OUTLIER -122.44 121.02 35.63 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.294 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.463 ' CG1' HG13 ' H' ' 18' ' ' VAL . 6.1 p -132.36 107.91 12.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 9.2 m-85 -110.66 123.0 49.18 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.781 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -130.4 127.86 40.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 -177.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.481 ' HB1' ' HE3' ' I' ' 28' ' ' LYS . . . -142.03 116.82 9.82 Favored 'General case' 0 C--O 1.239 0.533 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.515 ' CG ' ' N ' ' I' ' 23' ' ' ASP . 69.5 tt0 -164.56 164.07 21.76 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 116.544 2.053 . . . . 0.0 116.544 -177.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.55 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 54.4 t0 65.52 61.55 0.69 Allowed 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.408 178.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.448 ' HA ' ' CB ' ' H' ' 23' ' ' ASP . 54.0 t -65.83 123.12 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 117.601 -1.64 . . . . 0.0 113.069 -176.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' H' ' 23' ' ' ASP . . . -108.38 -34.81 2.6 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.413 ' O ' ' O ' ' I' ' 27' ' ' ASN . 8.4 t -161.96 120.63 2.31 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 112.513 -1.844 . . . . 0.0 107.586 -177.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.413 ' O ' ' O ' ' I' ' 26' ' ' SER . 2.0 m-20 -23.54 148.76 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.836 ' O ' ' O ' ' J' ' 29' ' ' GLY . 68.6 mttm -84.39 50.21 1.83 Allowed 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 111.673 -2.512 . . . . 0.0 110.074 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.39 53.14 1.13 Allowed Glycine 0 N--CA 1.481 1.673 0 N-CA-C 117.0 1.56 . . . . 0.0 117.0 -170.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.82 150.61 52.1 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-O 122.586 1.184 . . . . 0.0 110.322 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.574 ' CD1' ' H ' ' C' ' 40' ' ' VAL . 80.3 mt -128.45 130.96 69.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 113.785 -1.552 . . . . 0.0 112.08 -177.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.594 HG23 HD13 ' I' ' 34' ' ' LEU . 92.6 mt -114.0 110.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.813 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -119.58 95.72 0.61 Allowed Glycine 0 N--CA 1.473 1.117 0 N-CA-C 107.502 -2.239 . . . . 0.0 107.502 178.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.813 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.8 mp -142.51 155.8 45.07 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 115.78 1.771 . . . . 0.0 115.78 -175.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 46.7 tpp -120.1 104.08 9.81 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-N 112.535 -2.12 . . . . 0.0 105.726 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.6 HG11 HD21 ' G' ' 17' ' ' LEU . 16.2 t -120.18 102.67 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.398 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.15 -162.39 12.43 Favored Glycine 0 N--CA 1.464 0.563 0 C-N-CA 119.855 -1.164 . . . . 0.0 112.188 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.626 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . 158.0 -53.61 0.39 Allowed Glycine 0 CA--C 1.543 1.817 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -177.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -146.3 153.51 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 118.33 1.065 . . . . 0.0 108.997 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 78.1 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.138 -0.934 . . . . 0.0 111.011 -179.792 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . 0.511 ' CE2' ' O ' ' K' ' 10' ' ' TYR . 49.0 t80 -73.14 144.71 46.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.487 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -64.49 141.36 58.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.681 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.411 ' H ' ' CG1' ' I' ' 12' ' ' VAL . 48.4 t -116.67 129.53 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-O 121.08 0.467 . . . . 0.0 110.511 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CB ' HG13 ' L' ' 40' ' ' VAL . 95.4 m-70 -93.37 130.84 39.0 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.478 179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.672 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 1.0 OUTLIER -157.59 166.1 33.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.324 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.672 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 85.3 mt-30 -138.13 150.21 46.62 Favored 'General case' 0 CA--C 1.516 -0.35 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.544 ' C ' HD12 ' J' ' 17' ' ' LEU . 83.9 tttt -116.4 104.29 11.31 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 176.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.854 HD21 HG21 ' L' ' 36' ' ' VAL . 7.0 mp -110.17 109.92 20.59 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.609 0.641 . . . . 0.0 109.535 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.83 99.35 7.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.424 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 9.7 m-30 -112.69 112.03 23.24 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -115.19 122.55 46.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.01 131.64 18.87 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.996 1.109 . . . . 0.0 113.996 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.55 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 76.3 tt0 -86.47 159.81 19.2 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.061 177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.456 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 62.0 t0 -125.14 46.89 2.26 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.906 HG12 ' H ' ' J' ' 25' ' ' GLY . 16.1 t -70.13 -169.15 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.906 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -100.24 28.38 16.02 Favored Glycine 0 CA--C 1.523 0.592 0 C-N-CA 119.141 -1.504 . . . . 0.0 114.08 -176.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 2.6 t -81.35 113.54 19.52 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -90.18 175.57 7.09 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 119.197 -1.001 . . . . 0.0 109.561 179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.679 ' HZ2' ' HE2' ' B' ' 13' ' ' HIS . 68.7 mttm 49.08 39.06 14.19 Favored 'General case' 0 CA--C 1.519 -0.223 0 C-N-CA 119.784 -0.766 . . . . 0.0 109.022 177.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.836 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -81.84 -68.13 1.47 Allowed Glycine 0 C--O 1.207 -1.541 0 C-N-CA 117.513 -2.28 . . . . 0.0 117.147 -173.058 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -150.98 148.15 28.03 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 121.947 2.873 . . . . 0.0 113.673 -177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.905 HD12 HG13 ' D' ' 39' ' ' VAL . 92.0 mt -131.87 122.39 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.113 -0.948 . . . . 0.0 111.941 178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.588 ' CG2' HD21 ' K' ' 34' ' ' LEU . 7.8 mt -108.77 107.81 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.18 113.89 2.84 Favored Glycine 0 CA--C 1.507 -0.417 0 N-CA-C 105.932 -2.867 . . . . 0.0 105.932 177.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.534 HD12 ' O ' ' I' ' 34' ' ' LEU . 1.7 tp -165.44 146.89 7.37 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 116.929 -1.908 . . . . 0.0 112.449 -175.196 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.452 ' H ' HD12 ' J' ' 34' ' ' LEU . 37.7 ttm -118.87 115.21 23.94 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 112.978 -1.919 . . . . 0.0 107.752 178.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 t -108.71 112.51 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 121.897 0.856 . . . . 0.0 108.923 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 132.25 0.01 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 114.045 -1.434 . . . . 0.0 113.494 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.626 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . -79.19 -58.02 3.05 Favored Glycine 0 CA--C 1.538 1.47 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -123.4 131.18 73.59 Favored 'Isoleucine or valine' 0 C--N 1.343 0.319 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.424 ' CG1' ' CD2' ' H' ' 13' ' ' HIS . 3.2 t . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.248 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.511 ' O ' ' CE2' ' J' ' 10' ' ' TYR . 95.4 m-85 -104.5 133.31 49.59 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' L' ' 11' ' ' GLU . 98.0 mt-10 -133.46 115.3 14.63 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 49.8 t -112.14 127.03 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 44.8 p-80 -144.88 121.04 10.8 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.661 ' HD1' ' CE1' ' L' ' 13' ' ' HIS . 1.4 m-70 -114.18 170.72 8.08 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.544 ' HG3' ' H ' ' J' ' 15' ' ' GLN . 40.5 tt0 -159.14 140.16 12.79 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 118.297 -1.361 . . . . 0.0 111.679 178.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -103.85 107.06 17.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.192 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.416 ' CD2' HD13 ' J' ' 17' ' ' LEU . 20.3 mt -114.78 111.93 22.01 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 177.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -118.72 117.5 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.071 0.462 . . . . 0.0 111.155 -178.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.91 109.06 16.57 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.959 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.2 t80 -114.8 118.0 32.34 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.431 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -162.77 155.09 18.75 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 116.085 1.883 . . . . 0.0 116.085 -178.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -81.53 -171.73 3.46 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 113.35 -1.75 . . . . 0.0 107.703 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.434 ' HB3' HG22 ' L' ' 24' ' ' VAL . 2.2 t0 -171.25 48.06 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 -175.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 1.038 HG12 ' H ' ' K' ' 25' ' ' GLY . 21.4 t -62.63 -160.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 C-N-CA 119.439 -0.904 . . . . 0.0 109.037 -176.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 1.038 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.36 -31.46 11.66 Favored Glycine 0 N--CA 1.468 0.826 0 CA-C-O 118.34 -1.256 . . . . 0.0 115.887 -171.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' K' ' 27' ' ' ASN . 47.9 p -142.19 -129.79 0.09 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.274 2.037 . . . . 0.0 112.53 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' K' ' 26' ' ' SER . 62.5 m-20 53.23 152.13 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.232 0 O-C-N 123.501 0.501 . . . . 0.0 109.785 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.554 ' NZ ' ' OXT' ' E' ' 40' ' ' VAL . 88.0 mttt -74.39 -46.68 38.75 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.794 -178.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.94 -66.17 3.82 Favored Glycine 0 CA--C 1.544 1.845 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.743 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.7 148.6 0.28 Allowed 'General case' 0 C--O 1.24 0.554 0 CA-C-N 117.099 0.449 . . . . 0.0 110.601 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.665 HD11 HG21 ' F' ' 39' ' ' VAL . 25.3 mt -128.55 120.39 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.168 177.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -108.2 112.15 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.05 94.09 0.7 Allowed Glycine 0 CA--C 1.522 0.485 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' J' ' 32' ' ' ILE . 97.4 mt -128.38 138.95 52.58 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 114.641 1.349 . . . . 0.0 114.641 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.3 ttm -115.55 107.85 15.68 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 175.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.51 HG13 HD11 ' H' ' 17' ' ' LEU . 15.1 t -111.11 123.03 66.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.679 0.752 . . . . 0.0 110.657 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 39.67 115.04 0.0 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 114.256 -1.338 . . . . 0.0 113.708 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -67.43 -62.25 4.51 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 121.213 -0.518 . . . . 0.0 112.52 177.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.59 135.1 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 O-C-N 122.343 -0.504 . . . . 0.0 109.937 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.562 ' O ' ' NE2' ' I' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 118.203 -0.903 . . . . 0.0 109.553 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -110.46 134.95 51.86 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.694 0.283 . . . . 0.0 110.45 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' K' ' 11' ' ' GLU . 97.4 mt-10 -80.93 119.52 23.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.615 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.548 HG22 ' N ' ' L' ' 13' ' ' HIS . 10.4 p -141.04 164.65 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.73 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CE1' ' HD1' ' K' ' 14' ' ' HIS . 56.7 t-80 -143.71 146.47 33.21 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 111.031 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 95.9 m-70 -84.02 173.77 10.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.96 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -99.23 152.06 20.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.974 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -109.18 113.85 27.05 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 2.4 mp -112.08 119.22 37.7 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.868 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -128.96 129.77 68.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 51.2 p90 -140.07 125.27 18.75 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.575 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -120.08 111.86 18.4 Favored 'General case' 0 CA--C 1.52 -0.191 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -153.65 173.25 16.05 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.75 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.474 ' O ' HG23 ' L' ' 24' ' ' VAL . 93.7 mt-10 -60.53 155.02 19.49 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.411 -0.916 . . . . 0.0 111.17 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.592 ' C ' HG23 ' L' ' 24' ' ' VAL . 99.8 m-20 -59.51 -47.91 83.69 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.644 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.592 HG23 ' C ' ' L' ' 23' ' ' ASP . 0.1 OUTLIER 56.4 -175.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.776 1.274 . . . . 0.0 112.602 178.939 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.462 ' H ' HG12 ' L' ' 24' ' ' VAL . . . -176.1 -25.19 0.03 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 107.287 -2.325 . . . . 0.0 107.287 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 83.3 p -83.17 -138.37 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 114.447 -0.876 . . . . 0.0 110.409 177.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -92.99 160.16 15.0 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.158 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 53.7 mtmt -47.08 -40.68 15.64 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.04 -62.23 0.58 Allowed Glycine 0 CA--C 1.547 2.051 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.76 163.07 14.14 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.795 HD12 HG23 ' F' ' 39' ' ' VAL . 65.1 mt -133.19 128.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 114.161 1.171 . . . . 0.0 114.161 -178.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -109.52 112.79 42.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 175.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.39 117.21 3.14 Favored Glycine 0 N--CA 1.461 0.34 0 N-CA-C 107.686 -2.166 . . . . 0.0 107.686 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.492 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -167.99 173.59 8.0 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 118.153 -1.419 . . . . 0.0 111.986 -177.59 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.7 mtp -130.29 116.62 18.61 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.624 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.854 HG21 HD21 ' J' ' 17' ' ' LEU . 2.6 t -102.7 112.5 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . 55.45 131.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.269 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.859 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' K' ' 38' ' ' GLY . . . -79.3 -57.99 3.04 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 177.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.538 ' HB ' HD11 ' R' ' 31' ' ' ILE . 2.5 p -129.01 133.6 65.73 Favored 'Isoleucine or valine' 0 C--N 1.343 0.326 0 CA-C-O 121.769 0.795 . . . . 0.0 109.998 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.46 HG13 ' CB ' ' J' ' 13' ' ' HIS . 2.4 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-N 114.293 -1.321 . . . . 0.0 109.175 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . 0.509 ' CD2' ' O ' ' N' ' 10' ' ' TYR . 44.1 t80 -74.09 139.17 44.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.73 0.3 . . . . 0.0 110.561 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -70.11 136.75 50.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.11 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' N' ' 12' ' ' VAL . 44.4 t -108.49 88.65 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -72.46 124.71 25.74 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' M' ' 12' ' ' VAL . 39.8 p-80 -155.86 169.19 24.97 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.276 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.659 ' NE2' HG12 ' O' ' 36' ' ' VAL . 53.8 tt0 -89.44 151.01 22.25 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -150.64 113.88 4.85 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 120.009 -0.677 . . . . 0.0 110.476 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' N' ' 17' ' ' LEU . 90.4 mt -122.39 114.26 20.49 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.184 0.516 . . . . 0.0 110.035 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -110.23 102.53 14.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -110.41 106.39 15.71 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -127.46 130.88 50.06 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 121.118 0.485 . . . . 0.0 111.675 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.25 117.08 31.55 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -131.72 -173.0 3.01 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.912 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -55.39 -58.17 8.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.466 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' M' ' 25' ' ' GLY . 36.6 t -148.16 178.55 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 63.56 28.63 72.77 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.771 -0.649 . . . . 0.0 113.158 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 90.0 p -108.15 -120.26 0.26 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 117.806 0.803 . . . . 0.0 110.046 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -80.17 171.18 15.43 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.921 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -54.73 -38.85 67.61 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.682 0.753 . . . . 0.0 110.847 177.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.96 1.48 Allowed Glycine 0 CA--C 1.543 1.836 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.394 -177.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.51 -160.0 1.11 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.942 0.877 . . . . 0.0 111.277 -178.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 88.3 mt -110.59 114.21 46.44 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 175.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.37 132.33 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -177.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.81 106.99 0.7 Allowed Glycine 0 CA--C 1.529 0.908 0 N-CA-C 108.404 -1.879 . . . . 0.0 108.404 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.97 132.64 52.01 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 121.931 0.872 . . . . 0.0 111.753 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . 0.428 ' CE ' ' SD ' ' N' ' 35' ' ' MET . 38.3 tpp -119.42 113.89 21.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.569 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' M' ' 37' ' ' GLY . 61.1 t -127.03 132.23 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.158 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' N' ' 37' ' ' GLY . . . -43.79 -111.5 0.0 OUTLIER Glycine 0 CA--C 1.528 0.878 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.904 178.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.58 67.5 0.26 Allowed Glycine 0 CA--C 1.535 1.331 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.408 ' O ' HG23 ' M' ' 39' ' ' VAL . 19.4 m -96.97 134.58 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.152 0.501 . . . . 0.0 111.498 -178.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.296 179.446 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . 0.509 ' O ' ' CD2' ' M' ' 10' ' ' TYR . 99.4 m-85 -103.95 129.75 51.52 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . 0.411 ' H ' ' HG3' ' O' ' 11' ' ' GLU . 16.8 pt-20 -156.22 143.88 19.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.058 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.508 ' O ' ' CG1' ' M' ' 12' ' ' VAL . 69.1 t -125.22 92.71 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.318 0.58 . . . . 0.0 110.868 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 8.7 m170 -91.13 125.88 36.05 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.319 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.421 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 12.2 p-80 -153.54 163.65 39.59 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 111.38 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -83.91 156.7 22.25 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 176.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.67 103.17 1.54 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.405 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.49 ' CD2' HD12 ' M' ' 17' ' ' LEU . 5.2 mp -133.81 124.95 27.43 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.444 0.64 . . . . 0.0 110.632 179.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -109.57 107.44 22.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.51 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 58.7 m-85 -102.6 104.28 14.65 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' N' ' 20' ' ' PHE . 19.9 t80 -121.48 128.0 51.64 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 117.83 15.12 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.721 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.408 ' O ' ' OD1' ' N' ' 23' ' ' ASP . 81.9 tt0 -164.8 147.29 8.39 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.963 179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.6 p-10 40.45 50.35 2.75 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.091 179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 4.6 t -49.55 164.94 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.197 0.522 . . . . 0.0 109.755 -179.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.494 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . -174.49 19.6 0.05 OUTLIER Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.569 ' O ' ' NZ ' ' O' ' 28' ' ' LYS . 89.5 p -80.36 -129.84 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -100.6 163.89 12.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.539 0.685 . . . . 0.0 111.697 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -37.99 -38.73 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.769 -1.105 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.02 70.5 0.12 Allowed Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -176.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 136.93 45.77 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.533 1.158 . . . . 0.0 112.073 -177.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.584 HD13 ' HA3' ' H' ' 38' ' ' GLY . 52.2 mt -125.91 127.39 71.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 113.027 -1.897 . . . . 0.0 109.752 -178.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -116.23 116.78 53.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.002 0.429 . . . . 0.0 110.786 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.93 107.2 1.55 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 178.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 mt -129.75 140.56 51.05 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 117.752 0.776 . . . . 0.0 111.715 -177.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.538 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 9.7 ttm -141.15 125.39 17.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.892 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 24.2 m -129.36 156.99 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.084 176.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' M' ' 37' ' ' GLY . . . -63.01 -103.32 0.01 OUTLIER Glycine 0 N--CA 1.463 0.49 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.692 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -123.73 -75.89 0.31 Allowed Glycine 0 CA--C 1.534 1.241 0 CA-C-N 115.203 -0.498 . . . . 0.0 112.156 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.599 HG13 HD11 ' B' ' 31' ' ' ILE . 15.5 m -62.09 124.22 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.801 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.505 179.872 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.11 147.68 35.56 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 120.849 0.356 . . . . 0.0 110.789 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.414 ' OE1' ' N ' ' O' ' 11' ' ' GLU . 57.0 mp0 -71.14 136.31 48.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.133 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 m -134.14 160.04 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 121.356 0.598 . . . . 0.0 111.227 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' P' ' 13' ' ' HIS . 49.0 m80 -142.35 127.1 18.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.383 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.14 161.56 41.19 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.06 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.427 ' OE1' ' CG2' ' R' ' 36' ' ' VAL . 40.0 tt0 -85.54 157.66 20.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 177.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -159.35 101.57 1.55 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.99 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 15.8 mt -129.89 120.14 24.41 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.191 178.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -111.75 109.83 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.28 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 42.3 m-85 -107.14 104.67 14.37 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 56.9 t80 -115.35 120.45 39.66 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.38 136.45 26.23 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -139.92 142.17 36.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 104.903 -2.258 . . . . 0.0 104.903 176.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.464 ' OD2' ' OD1' ' O' ' 27' ' ' ASN . 1.2 t70 -164.3 47.62 0.11 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 117.36 -1.736 . . . . 0.0 115.245 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.566 HG22 ' N ' ' O' ' 25' ' ' GLY . 7.7 p -78.91 162.43 3.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 116.473 -2.091 . . . . 0.0 108.537 178.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.566 ' N ' HG22 ' O' ' 24' ' ' VAL . . . 100.21 -29.95 11.16 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.523 -1.831 . . . . 0.0 108.523 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.434 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 4.5 t 92.45 113.27 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 112.336 -1.932 . . . . 0.0 107.437 -177.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.593 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 1.0 OUTLIER -74.4 173.7 9.93 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 119.521 -0.872 . . . . 0.0 112.751 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' O ' ' N' ' 26' ' ' SER . 99.2 mttt -54.53 -40.45 68.64 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.899 177.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.21 62.64 0.51 Allowed Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.844 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 149.01 22.34 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 122.26 1.029 . . . . 0.0 113.436 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 95.6 mt -130.31 126.18 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.506 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 35.1 mt -111.09 115.58 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.49 115.78 2.23 Favored Glycine 0 N--CA 1.468 0.809 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.697 HD23 ' N ' ' O' ' 34' ' ' LEU . 0.8 OUTLIER -169.09 168.86 9.79 Favored 'General case' 0 CA--C 1.506 -0.729 0 C-N-CA 117.24 -1.784 . . . . 0.0 114.282 -177.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.538 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 41.9 mtp -129.65 109.48 11.02 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 111.951 -2.386 . . . . 0.0 109.442 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.659 HG12 ' NE2' ' M' ' 15' ' ' GLN . 61.4 t -130.86 104.61 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-N 114.444 -1.253 . . . . 0.0 107.798 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.546 ' HA3' ' H ' ' P' ' 37' ' ' GLY . . . -178.07 -134.35 2.05 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 117.776 -2.154 . . . . 0.0 112.441 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.419 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . 76.06 -62.94 2.89 Favored Glycine 0 CA--C 1.536 1.345 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.577 HG22 ' N ' ' O' ' 40' ' ' VAL . 3.6 p -167.11 164.69 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.577 ' N ' HG22 ' O' ' 39' ' ' VAL . 12.1 p . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.844 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -113.69 141.04 47.73 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.733 0.302 . . . . 0.0 110.41 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -126.88 147.0 50.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.888 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -124.08 134.36 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 73.9 m-70 -143.57 142.68 31.19 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.492 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.728 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 56.3 m-70 -149.09 162.25 40.33 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.66 177.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.459 ' NE2' HD11 ' P' ' 17' ' ' LEU . 19.9 tt0 -90.46 152.47 20.94 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 175.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 55.9 tttm -149.62 99.31 2.87 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 109.794 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.459 HD11 ' NE2' ' P' ' 15' ' ' GLN . 7.2 mt -119.0 116.05 25.62 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.965 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 77.0 t -112.16 103.63 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 64.9 m-85 -104.93 104.8 14.62 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 29.5 t80 -122.46 127.12 49.21 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -160.39 144.98 14.4 Favored 'General case' 0 N--CA 1.461 0.112 0 N-CA-C 115.369 1.618 . . . . 0.0 115.369 -178.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -86.08 97.89 10.56 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 102.093 -3.299 . . . . 0.0 102.093 173.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.623 ' O ' ' O ' ' P' ' 24' ' ' VAL . 41.4 t0 -67.49 51.31 0.05 Allowed 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -172.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.623 ' O ' ' O ' ' P' ' 23' ' ' ASP . 3.7 t -57.76 -133.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 171.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.493 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 168.28 -38.4 0.22 Allowed Glycine 0 C--O 1.224 -0.497 0 C-N-CA 116.936 -2.554 . . . . 0.0 116.562 171.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 6.0 m -65.76 111.06 3.05 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 121.838 2.819 . . . . 0.0 110.292 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.683 ' O ' ' N ' ' P' ' 29' ' ' GLY . 2.1 t-20 -149.8 141.34 23.44 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 119.214 -0.994 . . . . 0.0 110.322 171.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.494 ' N ' ' ND2' ' P' ' 27' ' ' ASN . 57.0 mmtt -11.14 -45.5 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 172.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.683 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.56 60.83 0.1 OUTLIER Glycine 0 CA--C 1.562 3.012 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.941 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 134.81 47.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.813 1.806 . . . . 0.0 112.605 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -139.59 134.68 39.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 56.2 mt -112.12 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 175.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.44 101.29 1.02 Allowed Glycine 0 N--CA 1.47 0.919 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.653 HD12 ' H ' ' P' ' 35' ' ' MET . 13.6 tp -140.09 145.46 37.66 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 114.405 1.261 . . . . 0.0 114.405 -174.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.653 ' H ' HD12 ' P' ' 34' ' ' LEU . 88.3 mmm -115.45 112.63 22.57 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 113.295 -1.775 . . . . 0.0 108.503 177.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' N' ' 17' ' ' LEU . 2.1 t -107.71 102.78 14.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.546 ' H ' ' HA3' ' O' ' 37' ' ' GLY . . . -39.43 153.6 0.04 OUTLIER Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.91 -0.586 . . . . 0.0 114.054 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' Q' ' 39' ' ' VAL . . . -71.84 -56.67 6.36 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 177.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.716 HG23 HD11 ' D' ' 31' ' ' ILE . 53.7 t -68.55 130.16 33.49 Favored 'Isoleucine or valine' 0 C--N 1.347 0.492 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 177.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.437 ' H ' HG23 ' P' ' 40' ' ' VAL . 1.5 t . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 117.881 -1.057 . . . . 0.0 110.256 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.3 137.82 51.62 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 110.617 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -98.71 128.34 44.94 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.38 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t -118.52 94.23 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.028 0.442 . . . . 0.0 110.909 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' P' ' 13' ' ' HIS . 86.8 m-70 -150.78 114.53 4.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.266 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.728 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 32.8 m80 -119.46 159.44 24.26 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.149 177.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -90.32 159.55 16.58 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -140.15 101.39 4.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 176.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.569 HD23 ' C ' ' Q' ' 17' ' ' LEU . 6.7 tt -117.65 119.06 33.83 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.46 ' N ' HD23 ' Q' ' 17' ' ' LEU . 56.0 t -124.81 121.23 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-O 121.042 0.449 . . . . 0.0 109.82 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -122.14 118.37 28.51 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.945 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.575 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 48.1 t80 -128.93 122.35 30.04 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.4 142.93 30.67 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.585 -0.846 . . . . 0.0 112.616 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.598 ' O ' ' N ' ' P' ' 23' ' ' ASP . 83.0 tt0 -122.37 155.43 36.04 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.88 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' P' ' 23' ' ' ASP . 96.6 m-20 62.14 48.57 4.92 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.541 HG12 ' N ' ' Q' ' 25' ' ' GLY . 87.7 t -72.18 161.12 4.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.541 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 111.18 -34.9 5.05 Favored Glycine 0 N--CA 1.469 0.849 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' P' ' 24' ' ' VAL . 3.0 p -79.99 119.11 22.38 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.716 0.77 . . . . 0.0 109.936 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' O ' ' C ' ' P' ' 25' ' ' GLY . 79.7 m-20 -92.06 -159.08 0.63 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.284 -1.326 . . . . 0.0 113.58 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' P' ' 25' ' ' GLY . 22.4 mttt 35.67 40.27 0.08 Allowed 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -178.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.63 -65.07 1.2 Allowed Glycine 0 CA--C 1.537 1.444 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.076 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.92 150.05 20.29 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 118.602 1.201 . . . . 0.0 110.845 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 37.8 mt -123.14 124.86 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.964 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -110.64 110.87 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.86 95.47 0.96 Allowed Glycine 0 N--CA 1.463 0.499 0 N-CA-C 103.955 -3.658 . . . . 0.0 103.955 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -128.0 130.43 48.32 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -172.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -108.1 108.79 20.02 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 106.792 -1.558 . . . . 0.0 106.792 176.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.81 102.12 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -176.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.16 -161.64 28.5 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.376 178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 114.21 -54.34 0.57 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -176.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.642 HG13 ' O ' ' E' ' 29' ' ' GLY . 12.6 t -141.87 166.88 16.51 Favored 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.559 ' N ' HG12 ' Q' ' 39' ' ' VAL . 2.4 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.041 -0.98 . . . . 0.0 111.058 -179.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -111.19 134.05 53.07 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.717 0.294 . . . . 0.0 110.404 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -85.29 125.94 33.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.001 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' R' ' 13' ' ' HIS . 46.2 t -134.38 166.27 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.529 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -86.53 120.61 28.03 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 111.577 179.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 m80 -147.73 162.24 39.59 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -90.01 159.1 17.04 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.447 0.641 . . . . 0.0 112.473 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.596 ' C ' HD12 ' R' ' 17' ' ' LEU . 99.4 mttt -140.07 106.29 5.25 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.101 177.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.596 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.9 mp -115.34 123.38 48.57 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.691 -179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -128.65 127.02 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 54.9 p90 -139.47 129.87 25.56 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.045 0.45 . . . . 0.0 111.246 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -133.33 125.08 28.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.76 134.75 33.9 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.991 -0.284 . . . . 0.0 110.83 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -95.34 149.26 21.56 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 56.99 46.56 19.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.375 0.607 . . . . 0.0 109.757 -178.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.718 HG22 ' H ' ' R' ' 25' ' ' GLY . 11.9 p -73.53 178.12 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.776 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.718 ' H ' HG22 ' R' ' 24' ' ' VAL . . . 102.32 -33.13 6.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.859 178.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.531 ' OG ' ' N ' ' R' ' 27' ' ' ASN . 26.3 t -81.19 -129.61 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 118.34 1.07 . . . . 0.0 109.839 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.531 ' N ' ' OG ' ' R' ' 26' ' ' SER . 98.6 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.646 178.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . 0.404 ' O ' ' OD2' ' P' ' 23' ' ' ASP . 98.8 mttt -44.59 -40.42 5.75 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.503 0.668 . . . . 0.0 111.23 177.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.91 -62.55 0.58 Allowed Glycine 0 CA--C 1.541 1.682 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -177.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.99 165.23 12.03 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 176.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' L' ' 39' ' ' VAL . 98.1 mt -114.58 116.22 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-N 119.176 0.898 . . . . 0.0 111.104 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.524 HG22 HD22 ' R' ' 34' ' ' LEU . 57.4 mt -106.36 107.73 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.27 109.54 1.21 Allowed Glycine 0 C--O 1.237 0.303 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.72 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.3 pt? -154.88 150.48 27.5 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 118.985 -1.086 . . . . 0.0 112.413 -176.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 23.8 tpp -96.13 111.91 23.81 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 175.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.427 ' CG2' ' OE1' ' O' ' 15' ' ' GLN . 6.2 p -130.77 144.05 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 110.685 -177.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.4 -102.66 1.55 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.73 -80.56 0.91 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-O 119.948 -0.362 . . . . 0.0 112.214 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.559 ' HB ' HD11 ' F' ' 31' ' ' ILE . 8.7 p -168.31 148.95 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 117.482 0.641 . . . . 0.0 111.608 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.616 178.574 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.6 p90 -149.98 159.87 44.06 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.788 0.328 . . . . 0.0 110.67 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -138.45 154.13 48.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.319 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 1.6 p -127.48 127.34 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.303 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.407 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 30.3 m80 -132.59 127.8 35.8 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.586 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -155.47 166.61 33.01 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 70.2 mt-30 -89.92 158.98 17.17 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.84 106.24 5.3 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.6 mt -135.48 122.45 21.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 122.034 0.921 . . . . 0.0 111.173 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' VAL . 17.0 m -119.0 115.05 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 CA-C-N 114.281 -1.327 . . . . 0.0 107.793 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -107.96 107.68 18.49 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -123.37 131.41 53.64 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.776 0.322 . . . . 0.0 111.505 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.45 121.66 20.26 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.157 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.533 ' O ' ' N ' ' A' ' 24' ' ' VAL . 79.8 tt0 -165.93 119.13 1.12 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 22' ' ' GLU . 80.1 m-20 15.21 46.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 22' ' ' GLU . 5.6 m -80.33 179.5 0.48 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.203 0 C-N-CA 117.729 -1.588 . . . . 0.0 106.937 179.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.73 -35.69 62.11 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 118.917 -1.611 . . . . 0.0 113.9 -177.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.49 ' O ' ' O ' ' A' ' 27' ' ' ASN . 57.7 p -157.61 113.99 2.89 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.146 0.973 . . . . 0.0 112.637 178.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' A' ' 26' ' ' SER . 6.7 m120 -48.84 -178.17 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 175.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -72.91 -40.03 65.84 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 118.127 -1.429 . . . . 0.0 109.722 178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.536 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 80.48 67.58 1.54 Allowed Glycine 0 CA--C 1.536 1.351 0 CA-C-O 118.702 -1.054 . . . . 0.0 113.269 176.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.536 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . -179.69 176.27 0.79 Allowed 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 120.007 1.903 . . . . 0.0 113.329 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.531 HD11 ' H ' ' N' ' 39' ' ' VAL . 56.9 mt -122.48 128.98 75.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 112.576 -2.102 . . . . 0.0 106.632 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 tt -145.26 147.83 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 120.83 2.43 Favored Glycine 0 CA--C 1.532 1.111 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.411 ' O ' HD12 ' B' ' 34' ' ' LEU . 78.9 mt -147.77 160.19 43.0 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.588 0.709 . . . . 0.0 111.509 -178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 51.9 mtp -138.25 144.62 40.64 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.041 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' A' ' 37' ' ' GLY . 11.1 t -110.4 102.62 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.806 0.336 . . . . 0.0 111.783 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -27.26 152.89 0.0 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.412 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -54.04 -54.38 31.76 Favored Glycine 0 CA--C 1.546 2.017 0 CA-C-O 119.449 -0.639 . . . . 0.0 113.582 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 38' ' ' GLY . 17.8 t -29.28 151.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-N 118.118 0.959 . . . . 0.0 112.453 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.419 HG23 ' H ' ' A' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.867 -1.064 . . . . 0.0 110.742 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -111.39 134.01 53.28 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.555 0.216 . . . . 0.0 110.555 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -139.61 157.2 46.19 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.488 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 1.6 p -120.89 93.39 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.296 0.569 . . . . 0.0 110.608 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.531 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 1.1 m80 -133.29 138.83 46.58 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.864 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.3 m80 -134.9 158.6 43.86 Favored 'General case' 0 C--O 1.22 -0.451 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -90.27 158.6 17.1 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.75 ' C ' HD22 ' B' ' 17' ' ' LEU . 88.3 tttt -141.24 96.22 2.96 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.291 176.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.75 HD22 ' C ' ' B' ' 16' ' ' LYS . 2.7 mm? -127.71 118.66 24.22 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.282 0.563 . . . . 0.0 110.181 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.71 106.86 20.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.215 -0.902 . . . . 0.0 108.996 178.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.517 ' CE2' ' HB3' ' B' ' 17' ' ' LEU . 51.1 m-85 -107.37 105.36 15.26 Favored 'General case' 0 CA--C 1.531 0.226 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -120.32 128.8 53.61 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -177.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.34 122.82 20.79 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 177.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.57 ' O ' ' N ' ' B' ' 24' ' ' VAL . 55.0 mp0 -134.49 139.64 45.62 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 52.0 t0 12.6 47.82 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 113.832 -1.531 . . . . 0.0 113.824 179.127 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.57 ' N ' ' O ' ' B' ' 22' ' ' GLU . 19.4 m -53.29 -175.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.74 19.41 0.02 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.212 176.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.404 ' OG ' ' OD1' ' A' ' 27' ' ' ASN . 87.5 p -81.16 -130.2 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.573 0.702 . . . . 0.0 110.535 177.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -99.59 -175.78 3.09 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 114.787 -1.097 . . . . 0.0 108.234 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.438 ' O ' ' O ' ' C' ' 29' ' ' GLY . 98.8 mttt -47.54 -38.86 14.97 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' B' ' 30' ' ' ALA . . . 99.98 -68.11 0.54 Allowed Glycine 0 CA--C 1.537 1.435 0 CA-C-N 114.474 -1.239 . . . . 0.0 115.336 175.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' B' ' 29' ' ' GLY . . . 179.63 161.52 0.86 Allowed 'General case' 0 C--O 1.24 0.567 0 CA-C-N 119.863 1.831 . . . . 0.0 113.961 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -132.06 114.63 24.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 112.877 -1.965 . . . . 0.0 106.477 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -121.44 132.76 69.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 113.291 0.848 . . . . 0.0 113.291 -176.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.94 104.32 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.411 HD12 ' O ' ' A' ' 34' ' ' LEU . 49.1 tp -130.77 133.29 45.87 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 117.796 0.798 . . . . 0.0 110.343 -178.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.408 ' H ' HD12 ' B' ' 34' ' ' LEU . 87.4 mtp -127.53 133.93 49.79 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.318 -0.855 . . . . 0.0 112.654 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' B' ' 37' ' ' GLY . 58.8 t -118.3 131.93 69.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -46.24 -111.67 0.01 OUTLIER Glycine 0 CA--C 1.528 0.868 0 CA-C-O 121.574 0.541 . . . . 0.0 112.32 -179.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.7 -70.41 0.08 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.175 -0.512 . . . . 0.0 112.043 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.408 HG22 HG11 ' C' ' 39' ' ' VAL . 83.5 t -65.65 134.67 29.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 115.325 -0.438 . . . . 0.0 111.182 -178.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 34.5 m . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.142 -0.933 . . . . 0.0 110.1 179.813 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.483 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -104.29 133.33 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.957 0.408 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.2 131.93 56.35 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.983 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -132.4 157.97 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.382 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' B' ' 13' ' ' HIS . 60.9 t-80 -143.51 121.93 12.39 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.917 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.563 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 8.6 p-80 -155.14 160.46 40.95 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.848 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.707 HE22 ' N ' ' F' ' 37' ' ' GLY . 86.8 mt-30 -90.15 159.7 16.63 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' C' ' 17' ' ' LEU . 72.9 tttt -140.01 94.53 2.77 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.933 HD22 ' N ' ' C' ' 17' ' ' LEU . 0.0 OUTLIER -123.8 124.68 43.22 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.252 -179.659 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 5.7 p -127.14 118.05 49.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.772 0.796 . . . . 0.0 109.022 177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' E' ' 32' ' ' ILE . 9.9 m-85 -111.37 106.68 15.69 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.473 -1.24 . . . . 0.0 108.068 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -119.74 125.68 49.22 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.66 136.05 33.88 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -138.43 105.86 5.55 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 103.782 -2.673 . . . . 0.0 103.782 175.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.56 ' O ' ' O ' ' D' ' 26' ' ' SER . 0.6 OUTLIER -95.03 47.09 1.13 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 116.08 1.882 . . . . 0.0 116.08 -172.69 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.52 HG12 ' N ' ' C' ' 25' ' ' GLY . 26.3 t -95.79 160.62 2.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 C-N-CA 117.453 -1.699 . . . . 0.0 110.552 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.548 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 78.09 29.28 54.37 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-N 114.022 -1.444 . . . . 0.0 114.534 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.548 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 6.4 m 108.72 147.65 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 117.79 0.795 . . . . 0.0 111.496 175.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 5.3 m-20 -61.91 136.1 57.83 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.661 176.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.604 ' N ' ' O ' ' D' ' 28' ' ' LYS . 64.7 tttp -57.35 -51.44 69.37 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 118.434 -1.306 . . . . 0.0 111.773 178.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.438 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 89.21 50.0 3.34 Favored Glycine 0 CA--C 1.553 2.444 0 CA-C-N 114.703 -1.135 . . . . 0.0 111.221 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.72 150.04 52.08 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.876 1.838 . . . . 0.0 114.367 -176.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.491 HD11 ' HB ' ' O' ' 39' ' ' VAL . 98.2 mt -130.98 121.65 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.935 177.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.799 HG22 HD11 ' D' ' 34' ' ' LEU . 40.4 mt -109.59 112.99 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.498 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -112.78 98.58 0.96 Allowed Glycine 0 N--CA 1.462 0.391 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.498 HD12 ' O ' ' C' ' 33' ' ' GLY . 1.3 mp -130.42 125.26 34.07 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 122.107 0.956 . . . . 0.0 113.474 -175.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 91.6 mmm -104.22 100.66 10.39 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 174.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.42 HG23 HG22 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -124.22 103.4 12.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -177.123 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.65 -153.41 24.88 Favored Glycine 0 C--N 1.313 -0.72 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 116.48 -56.21 0.53 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' C' ' 40' ' ' VAL . 36.2 t -143.48 158.03 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 117.752 0.776 . . . . 0.0 109.401 176.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 15.4 m . . . . . 0 C--O 1.217 -0.647 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.902 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -80.35 137.98 36.63 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -128.34 127.65 43.08 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.481 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 18.1 t -106.75 110.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 28.6 p-80 -131.72 123.15 27.13 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.574 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.68 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -141.95 161.67 37.4 Favored 'General case' 0 C--O 1.22 -0.47 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 -179.971 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -90.13 159.05 16.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -140.43 95.19 2.83 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 176.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.592 HD12 HD22 ' E' ' 17' ' ' LEU . 74.2 mt -115.07 117.94 31.97 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.954 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -117.1 101.3 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.473 ' CD1' HD13 ' F' ' 32' ' ' ILE . 50.4 m-85 -101.85 109.07 20.73 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -129.81 130.77 45.74 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.96 115.26 10.39 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' D' ' 23' ' ' ASP . 97.3 mt-10 -124.98 168.67 13.0 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 -176.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.54 ' H ' ' CD ' ' E' ' 22' ' ' GLU . 99.6 m-20 15.69 60.81 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.839 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.514 HG12 ' OG ' ' E' ' 26' ' ' SER . 2.7 t -70.67 123.01 23.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.52 -33.95 4.31 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.56 ' O ' ' O ' ' C' ' 23' ' ' ASP . 30.5 t -151.03 124.24 8.82 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 27' ' ' ASN . 0.8 OUTLIER -41.47 151.45 0.08 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 119.169 -1.012 . . . . 0.0 109.14 -177.461 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.604 ' O ' ' N ' ' C' ' 28' ' ' LYS . 74.2 tttt -74.31 -50.13 20.1 Favored 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 119.806 -0.757 . . . . 0.0 110.78 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.06 50.28 3.3 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 139.33 50.26 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 117.705 0.753 . . . . 0.0 111.545 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 90.8 mt -123.27 116.24 47.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.289 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.837 HG23 HD13 ' D' ' 34' ' ' LEU . 26.1 mt -103.92 104.91 17.48 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.143 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.665 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -110.04 94.16 0.79 Allowed Glycine 0 CA--C 1.506 -0.483 0 N-CA-C 104.624 -3.39 . . . . 0.0 104.624 176.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.837 HD13 HG23 ' D' ' 32' ' ' ILE . 7.0 mp -132.65 147.5 52.34 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 123.226 1.489 . . . . 0.0 113.479 -174.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 6.0 mtp -120.82 106.46 11.68 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 112.512 -2.131 . . . . 0.0 105.773 177.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.598 HG11 HD21 ' B' ' 17' ' ' LEU . 30.1 t -123.92 123.19 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.95 -113.77 1.02 Allowed Glycine 0 C--N 1.312 -0.764 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.79 -72.72 2.67 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.663 ' CG2' HD11 ' J' ' 31' ' ' ILE . 1.1 t -152.7 173.88 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 120.887 0.375 . . . . 0.0 110.252 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.524 ' O ' ' CD2' ' B' ' 13' ' ' HIS . 3.9 m . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.78 177.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.419 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -75.01 133.27 41.7 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -73.28 147.67 44.32 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.355 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.5 HG12 ' N ' ' E' ' 13' ' ' HIS . 49.2 t -134.79 164.88 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.782 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.5 ' N ' HG12 ' E' ' 12' ' ' VAL . 10.2 p-80 -65.29 124.37 22.02 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.51 ' O ' ' CB ' ' D' ' 14' ' ' HIS . 39.4 p-80 -151.72 163.88 38.17 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.021 178.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.7 tt0 -89.99 157.83 17.65 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.679 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -141.41 103.16 4.36 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.209 177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.592 HD22 HD12 ' D' ' 17' ' ' LEU . 21.5 mt -118.15 116.77 27.51 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 120.999 -0.281 . . . . 0.0 110.555 179.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.17 122.44 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' E' ' 19' ' ' PHE . 12.4 t80 -130.15 125.46 35.09 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.045 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' F' ' 20' ' ' PHE . 28.3 t80 -132.21 120.97 22.94 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.49 137.46 32.11 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 -178.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.54 ' CD ' ' H ' ' D' ' 23' ' ' ASP . 89.5 mt-10 -97.96 118.99 35.78 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.457 178.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.479 ' OD2' ' O ' ' F' ' 26' ' ' SER . 67.1 t0 -84.3 50.15 1.81 Allowed 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 114.634 -1.166 . . . . 0.0 112.019 -179.227 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.501 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.6 t -76.33 -144.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.328 -176.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.501 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.49 -35.29 7.0 Favored Glycine 0 N--CA 1.467 0.713 0 CA-C-N 116.121 -0.491 . . . . 0.0 112.431 -174.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.514 ' OG ' HG12 ' D' ' 24' ' ' VAL . 2.7 t -71.84 129.38 38.48 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.569 ' O ' ' N ' ' E' ' 29' ' ' GLY . 12.9 m120 -90.34 172.87 8.45 Favored 'General case' 0 C--O 1.226 -0.144 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -174.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.61 ' HZ2' ' C ' ' R' ' 39' ' ' VAL . 28.4 mmtt 48.38 -48.58 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 111.795 -2.457 . . . . 0.0 113.095 -177.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 94.56 -56.96 1.96 Allowed Glycine 0 CA--C 1.538 1.488 0 CA-C-N 118.935 0.789 . . . . 0.0 113.09 176.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . 161.98 163.67 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -178.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.934 HD11 HG13 ' Q' ' 39' ' ' VAL . 86.1 mt -121.42 122.02 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.007 0.367 . . . . 0.0 111.425 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.509 HD13 ' CD2' ' C' ' 19' ' ' PHE . 90.3 mt -113.39 109.6 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 176.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.99 101.04 1.66 Allowed Glycine 0 N--CA 1.46 0.256 0 N-CA-C 103.8 -3.72 . . . . 0.0 103.8 175.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.644 HD12 ' O ' ' D' ' 34' ' ' LEU . 42.5 tp -142.37 134.43 27.36 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -173.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.446 ' H ' HD12 ' E' ' 34' ' ' LEU . 3.5 ttm -105.51 110.93 23.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 113.891 -1.504 . . . . 0.0 107.486 175.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' C' ' 17' ' ' LEU . 2.3 t -104.74 120.44 55.21 Favored 'Isoleucine or valine' 0 C--N 1.34 0.176 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.84 -120.9 5.83 Favored Glycine 0 CA--C 1.527 0.804 0 CA-C-N 116.018 -0.537 . . . . 0.0 114.06 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.28 -63.58 0.35 Allowed Glycine 0 CA--C 1.543 1.799 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' E' ' 40' ' ' VAL . 55.3 t -117.95 125.17 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 176.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' E' ' 39' ' ' VAL . 43.3 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.967 -1.016 . . . . 0.0 111.443 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.46 134.39 48.65 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.569 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -111.29 139.92 46.29 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.315 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.05 99.79 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.275 0.559 . . . . 0.0 110.856 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 44.3 p-80 -126.54 101.86 6.85 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.512 ' ND1' ' N ' ' F' ' 15' ' ' GLN . 61.9 t-80 -151.75 167.69 27.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.608 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.512 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 87.6 mt-30 -89.79 159.14 17.17 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -139.78 109.81 6.45 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mp -120.2 120.85 37.35 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.366 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -128.79 111.25 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -119.99 130.55 54.8 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.067 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 48.9 t80 -135.6 133.2 38.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.284 0.564 . . . . 0.0 110.186 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.84 40.69 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -60.01 139.6 57.33 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.099 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 65.6 t0 -70.43 46.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.697 HG12 ' N ' ' F' ' 25' ' ' GLY . 97.2 t -80.64 -179.81 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.697 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -71.16 -32.5 65.59 Favored Glycine 0 CA--C 1.529 0.969 0 C-N-CA 121.001 -0.619 . . . . 0.0 113.019 -178.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.61 ' O ' ' O ' ' F' ' 27' ' ' ASN . 97.1 p -151.54 124.71 8.74 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 118.624 1.212 . . . . 0.0 113.425 -179.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.61 ' O ' ' O ' ' F' ' 26' ' ' SER . 37.8 t30 -41.29 -149.92 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.796 1.239 . . . . 0.0 113.053 177.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.54 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 95.6 mttt 82.61 50.03 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.451 -1.25 . . . . 0.0 112.976 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.17 -51.42 4.7 Favored Glycine 0 CA--C 1.551 2.333 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.993 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 155.67 44.23 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.629 HD12 HG11 ' Q' ' 39' ' ' VAL . 95.7 mt -110.53 108.65 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-N 119.936 1.244 . . . . 0.0 109.298 178.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.473 HD13 ' CD1' ' D' ' 19' ' ' PHE . 97.0 mt -115.5 112.9 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.46 93.97 0.69 Allowed Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 104.336 -3.505 . . . . 0.0 104.336 175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.706 HD23 ' O ' ' F' ' 34' ' ' LEU . 0.2 OUTLIER -140.16 145.15 37.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 122.346 1.07 . . . . 0.0 112.93 -174.533 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.5 mmm -109.38 119.82 40.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 113.154 -1.839 . . . . 0.0 107.05 177.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.601 ' HB ' HD21 ' F' ' 34' ' ' LEU . 14.5 p -108.05 123.27 63.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 122.03 0.919 . . . . 0.0 111.592 -178.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.707 ' N ' HE22 ' C' ' 15' ' ' GLN . . . 35.31 114.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.79 0 CA-C-N 113.482 -1.69 . . . . 0.0 114.12 -179.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.11 -63.21 4.74 Favored Glycine 0 CA--C 1.54 1.656 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.606 ' HB ' HD11 ' L' ' 31' ' ' ILE . 68.8 t -136.85 136.11 48.02 Favored 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 177.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.175 -0.917 . . . . 0.0 110.25 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -78.59 132.16 37.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.793 0.33 . . . . 0.0 110.402 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -100.72 117.43 34.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.831 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.463 ' O ' HG13 ' G' ' 12' ' ' VAL . 13.2 p -134.82 129.38 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -114.92 100.35 8.14 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.793 0.27 . . . . 0.0 110.344 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.466 ' HD1' ' C ' ' G' ' 14' ' ' HIS . 0.1 OUTLIER -156.63 161.23 39.91 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.0 -0.68 . . . . 0.0 112.618 179.046 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -85.65 156.75 20.56 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.926 176.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.53 ' O ' HD22 ' G' ' 17' ' ' LEU . 63.9 tttp -160.03 94.94 1.14 Allowed 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.53 HD22 ' O ' ' G' ' 16' ' ' LYS . 3.5 mm? -118.22 127.03 53.35 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 121.72 0.771 . . . . 0.0 110.685 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.9 104.76 16.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' G' ' 17' ' ' LEU . 55.1 m-85 -104.86 110.18 22.44 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -146.22 150.59 36.12 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.427 ' HB1' ' N ' ' H' ' 26' ' ' SER . . . -125.91 117.62 23.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.011 177.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -142.85 -174.57 4.21 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.676 0.75 . . . . 0.0 112.877 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.449 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 65.3 t0 -59.45 46.33 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 113.972 -1.467 . . . . 0.0 114.581 -178.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.719 HG12 ' H ' ' G' ' 25' ' ' GLY . 57.4 t -80.38 179.61 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 118.12 -1.432 . . . . 0.0 107.713 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.719 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -71.39 -33.79 64.12 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.249 -179.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.488 ' O ' ' O ' ' G' ' 27' ' ' ASN . 34.9 t -153.14 122.45 6.66 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 117.424 0.612 . . . . 0.0 111.734 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.63 ' ND2' ' H ' ' H' ' 25' ' ' GLY . 6.8 m120 -40.67 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.346 -0.542 . . . . 0.0 109.926 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.525 ' H ' HD21 ' H' ' 27' ' ' ASN . 88.4 tttt -80.13 -47.4 14.83 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.755 ' H ' ' ND2' ' H' ' 27' ' ' ASN . . . 81.61 59.32 2.38 Favored Glycine 0 CA--C 1.543 1.789 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 125.53 53.52 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 116.797 2.147 . . . . 0.0 116.797 -175.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.416 HG23 ' CG2' ' H' ' 31' ' ' ILE . 13.3 mt -129.94 106.24 13.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 173.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' G' ' 33' ' ' GLY . 18.9 tt -158.6 161.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 117.662 -1.615 . . . . 0.0 115.086 -177.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' N ' ' CG1' ' G' ' 32' ' ' ILE . . . -137.44 127.47 3.97 Favored Glycine 0 CA--C 1.538 1.502 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 177.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.691 HD23 ' H ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -171.22 170.09 6.17 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 118.865 1.333 . . . . 0.0 112.767 -178.503 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.691 ' H ' HD23 ' G' ' 34' ' ' LEU . 14.8 ttp -151.44 149.91 29.82 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.005 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 72.5 t -126.24 132.14 70.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.84 112.22 3.49 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 178.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' H' ' 37' ' ' GLY . . . -34.1 -66.6 0.28 Allowed Glycine 0 CA--C 1.535 1.301 0 C-N-CA 121.265 -0.493 . . . . 0.0 112.761 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.755 ' H ' ' H ' ' H' ' 40' ' ' VAL . 42.6 t -147.28 139.26 18.68 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 CA-C-N 117.841 0.821 . . . . 0.0 109.035 177.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.794 -179.323 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.402 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.51 133.47 51.14 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.417 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -154.94 125.76 7.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.668 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.409 ' O ' HG23 ' G' ' 12' ' ' VAL . 49.3 t -130.14 120.47 49.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.428 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.614 ' NE2' ' NZ ' ' Q' ' 28' ' ' LYS . 97.4 m-70 -92.03 147.4 22.98 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.665 ' CG ' ' H ' ' H' ' 15' ' ' GLN . 81.9 t60 -160.19 177.84 10.26 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.255 0.55 . . . . 0.0 111.447 -178.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.688 ' NE2' HG12 ' J' ' 36' ' ' VAL . 55.9 tt0 -160.39 140.64 11.5 Favored 'General case' 0 CA--C 1.517 -0.293 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.27 123.22 3.85 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.911 -178.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.627 HD12 HD22 ' I' ' 17' ' ' LEU . 58.2 mt -124.78 123.35 39.78 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.985 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -114.87 103.73 15.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.472 ' HZ ' HD13 ' H' ' 17' ' ' LEU . 31.5 m-85 -105.04 103.25 12.76 Favored 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 1.4 t80 -127.29 130.4 49.48 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-N 117.929 0.331 . . . . 0.0 110.977 -177.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.731 ' HB1' HG13 ' I' ' 24' ' ' VAL . . . -131.46 120.94 23.71 Favored 'General case' 0 C--O 1.243 0.746 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' I' ' 23' ' ' ASP . 69.9 mm-40 -118.73 -167.31 1.35 Allowed 'General case' 0 C--N 1.352 0.694 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.199 177.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' I' ' 23' ' ' ASP . 29.4 t70 -62.52 -59.99 4.17 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -177.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.603 HG12 ' H ' ' H' ' 25' ' ' GLY . 3.8 t -84.86 172.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.713 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.63 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . 94.67 -34.43 4.75 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.427 ' N ' ' HB1' ' G' ' 21' ' ' ALA . 3.8 m -80.68 120.62 24.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 112.881 -1.66 . . . . 0.0 111.05 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.755 ' ND2' ' H ' ' G' ' 29' ' ' GLY . 8.4 m-80 -88.29 161.93 16.89 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.327 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -44.19 -39.82 4.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.417 -177.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.96 64.8 0.25 Allowed Glycine 0 CA--C 1.533 1.181 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.356 -178.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.72 137.24 34.48 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 118.191 0.996 . . . . 0.0 111.95 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.416 ' CG2' HG23 ' G' ' 31' ' ' ILE . 6.8 tt -130.2 124.86 58.82 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 CA-C-N 114.058 -1.428 . . . . 0.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 92.7 mt -116.98 127.34 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.655 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 101.84 0.82 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 107.26 -2.336 . . . . 0.0 107.26 177.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.46 ' O ' ' CB ' ' I' ' 34' ' ' LEU . 95.1 mt -138.8 149.55 45.09 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 118.255 1.028 . . . . 0.0 113.131 -176.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mtp -140.02 131.56 27.08 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.67 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.6 t -130.45 121.26 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.606 0.717 . . . . 0.0 111.97 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.446 ' O ' ' CA ' ' G' ' 38' ' ' GLY . . . -92.88 121.66 6.61 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 176.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -51.46 -62.03 5.83 Favored Glycine 0 CA--C 1.542 1.738 0 C-N-CA 119.464 -1.35 . . . . 0.0 111.805 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.645 ' O ' HG11 ' I' ' 39' ' ' VAL . 81.0 t -134.64 125.49 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 176.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.755 ' H ' ' H ' ' G' ' 39' ' ' VAL . 6.1 p . . . . . 0 C--O 1.218 -0.561 0 CA-C-O 117.805 -1.093 . . . . 0.0 110.828 -178.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.12 133.29 51.95 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.939 0.399 . . . . 0.0 110.571 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.07 115.82 27.42 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.817 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.3 150.15 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.367 0.604 . . . . 0.0 111.105 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 3.9 t-160 -157.51 111.63 2.62 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.045 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -119.43 162.69 18.41 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -89.96 151.94 21.45 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -151.82 93.42 1.85 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 120.574 -0.45 . . . . 0.0 109.829 177.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.627 HD22 HD12 ' H' ' 17' ' ' LEU . 7.7 mt -122.67 120.51 33.91 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -122.25 115.53 46.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 11.5 m-85 -108.04 107.36 18.01 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 16.2 t80 -120.78 122.49 40.45 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 117.847 0.294 . . . . 0.0 110.72 -178.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 118.74 17.71 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.16 0.505 . . . . 0.0 111.506 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -164.2 138.8 5.68 Favored 'General case' 0 C--N 1.344 0.369 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.762 179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' H' ' 23' ' ' ASP . 98.7 m-20 51.32 48.27 23.29 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.309 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.972 HG12 ' H ' ' I' ' 25' ' ' GLY . 2.2 t -69.36 -151.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 CA-C-O 122.71 1.243 . . . . 0.0 114.257 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.972 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -111.8 35.53 4.65 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 126.971 2.224 . . . . 0.0 112.379 -173.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.411 ' O ' ' OD1' ' I' ' 27' ' ' ASN . 7.1 t -61.93 103.51 0.36 Allowed 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 124.075 1.893 . . . . 0.0 113.303 -171.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.661 ' O ' ' N ' ' I' ' 29' ' ' GLY . 91.6 m-20 -158.02 179.05 9.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 109.708 -3.406 . . . . 0.0 108.391 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 1.27 -43.8 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 118.007 2.595 . . . . 0.0 118.007 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.661 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 140.71 68.84 0.04 OUTLIER Glycine 0 N--CA 1.496 2.695 0 CA-C-N 121.711 2.051 . . . . 0.0 115.138 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 138.98 50.47 Favored 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 119.629 1.715 . . . . 0.0 113.618 -177.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.9 tt -151.3 130.94 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.179 0 CA-C-N 114.552 -1.204 . . . . 0.0 113.264 -177.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.404 HG21 HD13 ' I' ' 32' ' ' ILE . 65.7 mt -105.23 126.01 60.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -130.34 117.83 2.37 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.46 ' CB ' ' O ' ' H' ' 34' ' ' LEU . 0.8 OUTLIER -173.46 178.54 2.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 C-N-CA 117.502 -1.679 . . . . 0.0 113.85 -179.238 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 35.6 mtp -137.73 120.71 16.58 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 113.812 -1.54 . . . . 0.0 109.804 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.04 111.6 36.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.25 -131.64 5.77 Favored Glycine 0 C--N 1.312 -0.77 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.615 ' O ' HG11 ' J' ' 39' ' ' VAL . . . 98.49 -62.97 0.83 Allowed Glycine 0 CA--C 1.539 1.544 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.088 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.645 HG11 ' O ' ' H' ' 39' ' ' VAL . 53.0 t -138.44 162.53 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 122.946 0.498 . . . . 0.0 110.353 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' H' ' 39' ' ' VAL . 2.7 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.048 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -109.58 134.45 51.91 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.63 0.252 . . . . 0.0 110.847 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -139.96 137.4 34.71 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.66 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.48 130.47 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 75.3 m-70 -147.46 115.48 6.51 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.459 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 87.9 m-70 -132.5 160.6 36.02 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.709 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -85.52 156.98 20.54 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -159.61 92.42 1.04 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 176.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.489 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.2 mp -121.95 119.55 31.84 Favored 'General case' 0 CA--C 1.51 -0.559 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.487 -179.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.11 108.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' CE1' ' I' ' 19' ' ' PHE . 36.5 m-85 -103.76 106.91 17.56 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 179.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 55.6 t80 -115.45 117.33 30.09 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 127.63 14.41 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -98.42 137.77 36.63 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.128 177.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.423 ' OD2' ' O ' ' K' ' 22' ' ' GLU . 86.9 m-20 -73.54 49.02 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' J' ' 25' ' ' GLY . 85.1 t -148.12 176.67 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.647 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 65.0 27.39 72.19 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 106.844 -2.502 . . . . 0.0 106.844 -178.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.602 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 15.4 p -81.35 116.14 21.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.24 -0.98 . . . . 0.0 111.985 -175.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.944 HD21 ' H ' ' J' ' 30' ' ' ALA . 0.1 OUTLIER -90.72 163.43 14.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.848 -178.846 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -43.85 -37.07 2.62 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.23 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' D' ' 39' ' ' VAL . . . -177.86 76.9 0.07 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 119.864 -1.16 . . . . 0.0 113.413 -176.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.944 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -80.11 112.5 17.47 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.663 HD11 ' CG2' ' D' ' 39' ' ' VAL . 89.6 mt -123.88 125.04 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.637 -176.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -108.22 111.35 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.405 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -127.63 111.97 1.41 Allowed Glycine 0 N--CA 1.469 0.837 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -178.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.55 HD23 ' N ' ' J' ' 34' ' ' LEU . 2.1 pt? -168.65 169.41 10.18 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 117.493 -1.683 . . . . 0.0 113.562 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 16.3 mtp -120.01 116.2 25.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 112.449 -2.16 . . . . 0.0 109.519 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.688 HG12 ' NE2' ' H' ' 15' ' ' GLN . 42.1 t -127.82 111.59 25.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.35 -131.73 5.8 Favored Glycine 0 C--N 1.313 -0.742 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.449 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 83.28 -63.84 4.41 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.109 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.615 HG11 ' O ' ' I' ' 38' ' ' GLY . 2.6 m -126.33 149.92 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 123.213 0.605 . . . . 0.0 109.513 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.475 HG13 ' ND1' ' H' ' 13' ' ' HIS . 44.6 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.184 -178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -106.02 134.53 49.0 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -100.21 136.3 40.32 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.983 0.42 . . . . 0.0 111.069 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.448 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 41.5 t -129.99 106.53 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' K' ' 12' ' ' VAL . 19.2 m-70 -138.54 139.5 38.71 Favored 'General case' 0 C--O 1.218 -0.554 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 43.6 t-80 -153.02 161.47 42.49 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.154 -0.618 . . . . 0.0 111.348 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 49.1 tt0 -85.8 156.29 20.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.999 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 tttt -160.62 92.05 0.94 Allowed 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.629 HD23 ' N ' ' K' ' 18' ' ' VAL . 4.6 tt -119.49 118.88 32.26 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.17 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.629 ' N ' HD23 ' K' ' 17' ' ' LEU . 61.3 t -123.5 125.89 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-O 120.906 0.384 . . . . 0.0 110.375 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -123.26 121.19 35.25 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.624 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -125.86 120.33 30.2 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -158.29 164.22 36.63 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 118.206 -1.398 . . . . 0.0 114.319 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.423 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 28.4 tt0 -85.47 120.49 27.0 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -81.79 47.47 1.09 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 114.58 1.326 . . . . 0.0 114.58 -176.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.922 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.5 t -82.77 -161.61 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.922 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.52 -28.63 51.52 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 119.313 -1.422 . . . . 0.0 111.747 -174.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 5.1 p 143.58 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 175.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -54.14 170.82 0.12 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.421 176.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.602 ' H ' ' HB2' ' J' ' 26' ' ' SER . 43.3 tttp -59.52 -39.78 84.99 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.3 66.1 0.13 Allowed Glycine 0 CA--C 1.55 2.238 0 C-N-CA 119.903 -1.142 . . . . 0.0 114.667 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.3 110.59 21.89 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.902 0.851 . . . . 0.0 111.116 177.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 20.4 tt -143.72 135.52 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 119.679 1.127 . . . . 0.0 113.36 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -115.81 116.99 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.529 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.95 96.79 0.84 Allowed Glycine 0 N--CA 1.463 0.492 0 N-CA-C 105.474 -3.05 . . . . 0.0 105.474 176.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.992 HD22 HG13 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -137.11 136.7 38.53 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -174.158 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.725 ' N ' HD23 ' K' ' 34' ' ' LEU . 3.4 mtp -106.46 111.4 23.96 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.491 176.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.992 HG13 HD22 ' K' ' 34' ' ' LEU . 2.3 m -131.57 123.29 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.065 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.505 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . 136.42 -113.74 1.09 Allowed Glycine 0 C--N 1.311 -0.806 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.455 ' O ' HD11 ' Q' ' 31' ' ' ILE . . . 59.63 -71.28 0.01 OUTLIER Glycine 0 CA--C 1.534 1.275 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.56 HG23 HD12 ' Q' ' 31' ' ' ILE . 28.7 t -125.6 127.82 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 177.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.408 -179.549 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -80.29 136.7 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 110.553 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.37 126.81 30.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.098 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -129.9 132.53 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.682 0.753 . . . . 0.0 111.239 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.44 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 49.1 p-80 -150.78 105.4 3.27 Favored 'General case' 0 C--N 1.341 0.238 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.505 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -149.75 167.53 26.24 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.184 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -89.76 150.89 22.09 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-O 120.864 0.364 . . . . 0.0 111.071 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 57.9 tttp -150.84 103.58 3.09 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.569 0.699 . . . . 0.0 109.884 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.502 HD21 ' NE2' ' K' ' 15' ' ' GLN . 51.5 mt -120.9 120.88 36.79 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.109 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.1 t -127.68 128.95 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -137.76 130.84 30.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.398 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -136.88 138.42 40.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.435 0.636 . . . . 0.0 109.961 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.4 148.33 31.19 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.013 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -87.28 145.97 26.14 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.121 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 57.66 47.32 15.98 Favored 'General case' 0 C--O 1.231 0.126 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.093 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.402 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.5 m -63.81 -159.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.823 -178.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.7 -36.32 3.69 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 121.056 -0.593 . . . . 0.0 112.494 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 95.8 p -137.15 120.49 16.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 114.841 1.423 . . . . 0.0 114.841 -177.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 72.9 m-20 56.67 160.04 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 113.607 -1.633 . . . . 0.0 115.168 175.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -68.48 -45.98 70.96 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 113.435 -1.711 . . . . 0.0 112.08 177.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.91 -59.29 0.87 Allowed Glycine 0 CA--C 1.554 2.516 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.534 -177.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.9 166.08 11.33 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.606 HD11 ' HB ' ' F' ' 39' ' ' VAL . 88.7 mt -115.73 111.51 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 CA-C-N 119.683 1.129 . . . . 0.0 111.367 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -107.3 110.9 33.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 91.28 0.55 Allowed Glycine 0 CA--C 1.506 -0.515 0 N-CA-C 104.55 -3.42 . . . . 0.0 104.55 176.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.479 HD23 ' C ' ' L' ' 34' ' ' LEU . 9.0 tt -139.93 136.93 34.37 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -175.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' HG23 ' K' ' 36' ' ' VAL . 2.5 ttm -96.12 116.28 28.73 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.512 ' O ' HG13 ' L' ' 36' ' ' VAL . 6.8 p -121.91 102.67 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 110.67 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.24 163.36 19.01 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-O 121.947 0.749 . . . . 0.0 112.224 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.05 -55.91 0.33 Allowed Glycine 0 CA--C 1.544 1.9 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.558 HG11 ' HA2' ' Q' ' 29' ' ' GLY . 17.4 t -135.95 128.99 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 117.493 0.646 . . . . 0.0 109.797 175.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.562 HG12 ' O ' ' L' ' 40' ' ' VAL . 61.2 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.872 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.367 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -108.99 138.14 45.8 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -140.2 132.52 28.32 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.114 0.483 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -129.14 135.3 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.296 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' N' ' 14' ' ' HIS . 36.7 m-70 -129.04 115.86 18.41 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 117.641 0.201 . . . . 0.0 110.697 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -159.58 173.93 15.37 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 112.878 0.695 . . . . 0.0 112.878 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -153.02 140.75 20.0 Favored 'General case' 0 C--N 1.341 0.206 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -89.69 101.53 14.22 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' O' ' 36' ' ' VAL . 60.2 mt -121.49 114.13 20.81 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.101 0.864 . . . . 0.0 110.371 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -124.28 104.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' M' ' 17' ' ' LEU . 54.4 m-85 -104.95 108.81 20.51 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -116.05 122.35 44.9 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.8 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -106.94 112.46 25.43 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.435 ' OE1' ' OE1' ' N' ' 22' ' ' GLU . 15.2 pt-20 -171.23 166.66 7.14 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.552 ' H ' HG21 ' N' ' 24' ' ' VAL . 35.0 t0 -98.35 46.15 1.01 Allowed 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 119.579 1.081 . . . . 0.0 111.104 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.713 HG12 ' N ' ' M' ' 25' ' ' GLY . 87.5 t -78.12 -177.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 177.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.713 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -90.0 24.59 14.99 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 67.8 m -112.58 126.39 55.3 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 113.878 -1.161 . . . . 0.0 109.243 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 66.9 t30 62.42 155.87 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.942 0.401 . . . . 0.0 110.473 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.76 -49.41 58.94 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -177.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.539 ' O ' ' ND2' ' N' ' 27' ' ' ASN . . . 90.21 50.8 2.92 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.76 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.51 -147.97 0.35 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 117.475 0.638 . . . . 0.0 110.989 -177.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.403 ' CD1' ' O ' ' G' ' 39' ' ' VAL . 4.2 pt -119.68 122.32 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.428 HG22 ' N ' ' M' ' 33' ' ' GLY . 97.6 mt -141.21 151.35 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-O 121.631 0.729 . . . . 0.0 112.461 -177.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . 0.428 ' N ' HG22 ' M' ' 32' ' ' ILE . . . -130.38 126.83 5.09 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 108.469 -1.852 . . . . 0.0 108.469 177.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 53.6 tp -133.49 134.08 43.03 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.834 0.817 . . . . 0.0 112.234 -178.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttm -123.71 119.24 29.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.772 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 7.9 p -134.99 132.35 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 120.887 0.375 . . . . 0.0 110.675 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -80.94 111.98 3.38 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -95.82 72.87 0.88 Allowed Glycine 0 N--CA 1.47 0.96 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 32.1 m -62.55 175.07 0.32 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-O 120.952 0.406 . . . . 0.0 110.984 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 32.6 m . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.908 -1.044 . . . . 0.0 111.449 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -114.21 137.51 51.67 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . 0.523 ' OE1' ' N ' ' N' ' 11' ' ' GLU . 56.6 mp0 -112.76 144.31 42.51 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.557 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.422 ' C ' ' ND1' ' N' ' 13' ' ' HIS . 35.0 m -134.52 160.52 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.56 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' O' ' 13' ' ' HIS . 45.7 m80 -144.14 123.27 12.9 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.496 ' O ' ' O ' ' M' ' 13' ' ' HIS . 33.4 m-70 -143.69 166.56 24.52 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-N 116.352 -0.386 . . . . 0.0 109.991 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.494 HE22 HG22 ' P' ' 36' ' ' VAL . 57.9 tt0 -156.82 140.41 15.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 175.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -96.6 97.53 9.46 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 118.489 -0.767 . . . . 0.0 112.616 178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.684 HD22 HD12 ' M' ' 17' ' ' LEU . 23.1 mt -116.76 108.84 16.37 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-N 119.434 1.016 . . . . 0.0 108.388 176.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.91 109.38 27.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.752 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CE2' ' HB3' ' N' ' 17' ' ' LEU . 32.7 m-85 -108.82 114.2 27.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 47.3 t80 -129.04 122.13 29.35 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.089 0.471 . . . . 0.0 111.739 -178.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' O' ' 23' ' ' ASP . . . -113.11 117.56 32.3 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.53 ' CG ' ' H ' ' N' ' 23' ' ' ASP . 49.4 tt0 -99.26 173.48 6.76 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 -175.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.53 ' H ' ' CG ' ' N' ' 22' ' ' GLU . 61.9 t0 -101.63 46.77 0.92 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 112.274 -2.239 . . . . 0.0 111.05 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.905 HG22 ' H ' ' N' ' 25' ' ' GLY . 9.8 p -80.36 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.332 -175.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.905 ' H ' HG22 ' N' ' 24' ' ' VAL . . . -70.97 -29.71 68.76 Favored Glycine 0 CA--C 1.537 1.419 0 N-CA-C 118.737 2.255 . . . . 0.0 118.737 -174.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.455 ' O ' ' O ' ' N' ' 27' ' ' ASN . 7.3 t -159.65 -128.56 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 121.713 2.756 . . . . 0.0 116.745 -176.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' M' ' 29' ' ' GLY . 40.3 t30 49.39 164.79 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 113.866 -1.515 . . . . 0.0 110.721 -175.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 60.5 mttp -79.31 36.47 0.3 Allowed 'General case' 0 C--N 1.344 0.349 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.479 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 73.57 -97.37 0.88 Allowed Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 114.6 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.731 -0.652 . . . . 0.0 110.327 177.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.613 HD13 HG11 ' I' ' 39' ' ' VAL . 42.8 mt -110.43 109.0 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -122.52 124.56 71.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 119.937 -0.705 . . . . 0.0 112.212 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.47 121.03 4.62 Favored Glycine 0 C--N 1.337 0.585 0 N-CA-C 107.477 -2.249 . . . . 0.0 107.477 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 tt -147.54 140.02 24.61 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 118.354 1.077 . . . . 0.0 111.726 -176.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -141.62 138.21 32.41 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' O' ' 37' ' ' GLY . 60.7 t -108.23 145.65 15.06 Favored 'Isoleucine or valine' 0 C--N 1.343 0.323 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.001 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.603 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -40.45 -103.54 0.01 OUTLIER Glycine 0 CA--C 1.535 1.285 0 C-N-CA 121.621 -0.323 . . . . 0.0 113.527 -178.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' O' ' 38' ' ' GLY . . . -144.54 -72.76 0.02 OUTLIER Glycine 0 CA--C 1.545 1.961 0 C-N-CA 120.927 -0.654 . . . . 0.0 114.476 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.531 ' H ' HD11 ' A' ' 31' ' ' ILE . 99.2 t -57.23 143.03 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 O-C-N 121.963 -0.728 . . . . 0.0 111.325 -178.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.015 -0.993 . . . . 0.0 111.061 179.878 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -110.89 131.1 55.33 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.655 0.264 . . . . 0.0 110.876 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -146.99 153.08 39.63 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.36 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.43 ' CG2' ' NE2' ' O' ' 14' ' ' HIS . 14.0 p -136.46 148.57 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.322 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.465 ' CE1' ' CE1' ' N' ' 13' ' ' HIS . 21.9 m-70 -140.92 141.46 34.52 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.916 0.389 . . . . 0.0 111.875 -179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.43 ' NE2' ' CG2' ' O' ' 12' ' ' VAL . 36.7 m-70 -150.63 172.55 15.36 Favored 'General case' 0 C--O 1.222 -0.379 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 177.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.582 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 5.4 tt0 -156.25 140.72 16.78 Favored 'General case' 0 C--N 1.342 0.266 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.309 177.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -94.12 105.48 17.47 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.557 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' O' ' 19' ' ' PHE . 29.3 mt -116.51 113.36 22.68 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-N 118.459 0.572 . . . . 0.0 109.63 177.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.98 102.27 13.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 177.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 64.3 m-85 -107.55 106.17 16.41 Favored 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -119.47 114.99 23.15 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.76 114.33 22.51 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.998 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -154.88 103.7 2.44 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.995 -1.484 . . . . 0.0 106.995 177.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' N' ' 22' ' ' GLU . 5.7 m-20 -141.71 46.37 1.68 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.647 HG12 ' N ' ' O' ' 25' ' ' GLY . 77.3 t -84.26 173.19 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 176.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.668 ' H ' ' HZ2' ' P' ' 28' ' ' LYS . . . 91.46 -29.51 7.16 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 120.828 -0.701 . . . . 0.0 113.174 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 19.9 p -165.62 -130.69 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.574 ' OD1' ' N ' ' O' ' 28' ' ' LYS . 39.4 t-20 45.98 146.93 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.284 1.434 . . . . 0.0 112.625 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.574 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 88.5 tttt -83.53 -49.43 9.25 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.55 58.62 0.04 OUTLIER Glycine 0 CA--C 1.544 1.847 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.481 -172.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.66 133.74 44.77 Favored 'General case' 0 CA--C 1.543 0.681 0 CA-C-O 123.468 1.604 . . . . 0.0 114.199 -174.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 63.0 mt -139.63 139.01 38.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 112.355 -2.202 . . . . 0.0 112.366 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.8 mt -109.63 111.99 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.786 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -120.36 101.01 0.8 Allowed Glycine 0 N--CA 1.467 0.713 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.786 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.1 OUTLIER -145.96 166.17 26.83 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 123.21 1.481 . . . . 0.0 114.898 -177.713 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.41 ' SD ' ' HB2' ' P' ' 35' ' ' MET . 44.5 tpp -125.52 101.67 7.03 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 111.719 -2.491 . . . . 0.0 105.507 176.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' M' ' 17' ' ' LEU . 57.4 t -102.89 102.82 14.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' N' ' 36' ' ' VAL . . . 68.79 163.33 2.97 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 114.267 -1.333 . . . . 0.0 111.368 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' N' ' 38' ' ' GLY . . . -105.06 -56.74 0.69 Allowed Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.93 -0.635 . . . . 0.0 112.14 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' C' ' 31' ' ' ILE . 2.6 p -134.83 157.98 41.25 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.473 ' N ' HG22 ' O' ' 39' ' ' VAL . 47.8 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 118.263 -0.875 . . . . 0.0 109.952 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.16 130.06 55.49 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -143.86 158.62 43.57 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.274 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.474 ' CG1' ' CD2' ' Q' ' 13' ' ' HIS . 47.5 t -126.34 130.88 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.465 ' NE2' HG21 ' R' ' 40' ' ' VAL . 20.7 p-80 -149.88 140.09 22.18 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 120.014 -0.674 . . . . 0.0 112.007 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.657 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 1.1 t60 -157.53 166.84 31.85 Favored 'General case' 0 C--O 1.219 -0.516 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.657 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 45.0 tt0 -156.4 140.79 16.69 Favored 'General case' 0 C--N 1.33 -0.283 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.23 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.64 103.22 15.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.673 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.862 HD21 HG11 ' R' ' 36' ' ' VAL . 1.2 mp -117.76 111.93 19.75 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 119.299 0.954 . . . . 0.0 109.442 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.85 103.89 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.42 105.22 15.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -120.95 122.0 39.23 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 121.823 -0.548 . . . . 0.0 109.538 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.76 140.63 33.12 Favored 'General case' 0 C--O 1.25 1.121 0 CA-C-O 123.152 1.453 . . . . 0.0 114.132 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -74.74 171.23 14.32 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 112.582 -2.099 . . . . 0.0 111.456 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.666 ' O ' HG23 ' Q' ' 24' ' ' VAL . 0.6 OUTLIER -177.13 51.29 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -176.925 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.415 HG23 ' N ' ' P' ' 25' ' ' GLY . 34.6 m -100.42 -140.64 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.049 -173.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.415 ' N ' HG23 ' P' ' 24' ' ' VAL . . . -71.46 -36.86 62.71 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 117.375 -1.791 . . . . 0.0 115.082 -171.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' P' ' 27' ' ' ASN . 46.2 t -162.35 116.52 1.81 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 122.474 3.137 . . . . 0.0 117.906 178.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.706 ' CB ' ' H ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -22.23 -173.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 127.445 2.298 . . . . 0.0 115.288 171.591 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.668 ' HZ2' ' H ' ' O' ' 25' ' ' GLY . 24.7 mttt 164.37 23.03 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 178.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.59 100.41 0.22 Allowed Glycine 0 C--N 1.349 1.286 0 N-CA-C 118.786 2.274 . . . . 0.0 118.786 171.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.74 110.83 1.98 Allowed 'General case' 0 C--O 1.244 0.791 0 CA-C-O 121.87 0.843 . . . . 0.0 110.109 178.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 78.7 mt -136.17 133.38 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.732 -178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -110.25 110.78 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . 0.411 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -113.13 110.74 2.57 Favored Glycine 0 N--CA 1.461 0.31 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.709 HD12 ' O ' ' O' ' 34' ' ' LEU . 28.8 tp -157.75 141.39 15.62 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 116.922 -1.911 . . . . 0.0 113.772 -174.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.537 ' H ' HD12 ' P' ' 34' ' ' LEU . 15.1 mtp -114.51 108.7 17.2 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.197 -1.82 . . . . 0.0 106.587 177.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.605 HG12 HD21 ' Q' ' 34' ' ' LEU . 11.0 p -118.1 112.53 38.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.932 0.872 . . . . 0.0 109.605 -179.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.6 132.5 0.04 OUTLIER Glycine 0 CA--C 1.529 0.964 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.226 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' Q' ' 38' ' ' GLY . . . -76.5 -58.36 3.6 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.719 -0.553 . . . . 0.0 111.719 177.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' H ' ' Q' ' 38' ' ' GLY . 2.6 p -139.47 141.39 35.34 Favored 'Isoleucine or valine' 0 C--N 1.341 0.211 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.511 ' O ' HG12 ' P' ' 40' ' ' VAL . 38.5 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.125 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.61 132.81 52.9 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.919 0.39 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -143.15 164.39 30.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.211 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.402 HG12 ' CE1' ' P' ' 13' ' ' HIS . 5.8 t -104.26 119.26 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.474 ' CD2' ' CG1' ' P' ' 12' ' ' VAL . 5.1 m-70 -69.3 161.03 30.12 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.33 0.586 . . . . 0.0 112.204 -177.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 25.6 p-80 -99.9 170.81 8.26 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.221 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -99.18 151.23 21.23 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -110.64 107.11 16.59 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -109.8 120.47 42.57 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 52.4 t -121.56 123.15 68.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.529 ' CZ ' ' HB3' ' Q' ' 21' ' ' ALA . 85.7 t80 -122.73 110.23 15.23 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.353 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -112.66 114.67 27.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.548 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -160.84 151.25 18.01 Favored 'General case' 0 C--O 1.242 0.695 0 C-N-CA 117.148 -1.821 . . . . 0.0 115.005 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -86.8 170.07 12.03 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.689 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 7.6 m-20 -147.41 51.96 1.06 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 117.953 2.575 . . . . 0.0 117.953 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.689 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 38.5 t -57.09 -130.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 102.639 -3.097 . . . . 0.0 102.639 168.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.615 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 171.42 -40.7 0.18 Allowed Glycine 0 C--O 1.234 0.147 0 C-N-CA 115.327 -3.321 . . . . 0.0 119.363 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 8.3 t -69.28 107.08 3.12 Favored 'General case' 0 CA--C 1.532 0.26 1 CA-C-N 125.386 4.593 . . . . 0.0 106.222 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.553 HD21 ' C ' ' R' ' 29' ' ' GLY . 20.3 p30 -124.04 159.83 29.03 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-N 120.149 1.341 . . . . 0.0 112.052 175.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.706 ' H ' ' CB ' ' P' ' 27' ' ' ASN . 35.7 tttp -34.35 -38.97 0.07 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 122.192 0.996 . . . . 0.0 109.887 170.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.558 ' HA2' HG11 ' L' ' 39' ' ' VAL . . . 121.71 74.57 0.34 Allowed Glycine 0 CA--C 1.552 2.401 0 CA-C-N 113.443 -1.708 . . . . 0.0 113.412 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 129.63 34.88 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.029 0.914 . . . . 0.0 110.48 178.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.56 HD12 HG23 ' K' ' 39' ' ' VAL . 53.9 mt -147.86 138.81 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 -176.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.8 mt -107.65 109.61 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.16 103.01 1.12 Allowed Glycine 0 N--CA 1.465 0.605 0 N-CA-C 106.621 -2.592 . . . . 0.0 106.621 177.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.965 HD23 ' N ' ' Q' ' 35' ' ' MET . 4.4 tt -142.95 144.84 32.53 Favored 'General case' 0 CA--C 1.513 -0.464 0 C-N-CA 118.934 -1.107 . . . . 0.0 113.681 -175.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.965 ' N ' HD23 ' Q' ' 34' ' ' LEU . 7.8 mtp -111.75 108.51 17.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.803 HG22 HD22 ' Q' ' 34' ' ' LEU . 1.5 t -100.82 102.73 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 54.4 163.15 0.01 OUTLIER Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 -179.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' P' ' 38' ' ' GLY . . . -96.22 -58.1 1.1 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 121.314 -0.469 . . . . 0.0 111.958 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.934 HG13 HD11 ' E' ' 31' ' ' ILE . 16.1 m -141.56 161.23 21.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.409 HG13 ' CG ' ' O' ' 13' ' ' HIS . 34.7 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.979 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -102.49 132.61 48.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.0 0.428 . . . . 0.0 110.33 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.477 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 58.6 mp0 -73.28 144.73 46.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.047 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -119.87 133.97 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.899 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.2 OUTLIER -135.77 92.77 2.86 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.637 179.827 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.455 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 70.0 m80 -155.95 169.39 24.56 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.306 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -100.3 151.04 21.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.763 0.316 . . . . 0.0 110.242 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -110.22 113.19 25.67 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' R' ' 17' ' ' LEU . 5.3 mp -120.18 126.0 49.59 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 -179.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -125.35 108.8 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -113.71 123.51 50.07 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.346 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -126.66 106.85 9.68 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 177.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.548 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -169.67 172.73 6.69 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.914 -177.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.463 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 95.4 mt-10 -83.13 132.13 35.11 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 176.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -111.93 -59.8 1.94 Allowed 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' R' ' 25' ' ' GLY . 23.4 t -90.41 -179.17 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.868 -177.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 81.31 -34.62 2.43 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.592 178.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.558 ' O ' ' O ' ' R' ' 27' ' ' ASN . 69.4 m -151.92 122.93 7.59 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -178.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.558 ' O ' ' O ' ' R' ' 26' ' ' SER . 11.7 m120 -41.86 179.97 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 121.1 0.476 . . . . 0.0 111.501 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -73.74 -43.22 59.74 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 120.14 -0.624 . . . . 0.0 112.617 -177.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.553 ' C ' HD21 ' Q' ' 27' ' ' ASN . . . 97.51 -60.59 1.05 Allowed Glycine 0 N--CA 1.478 1.486 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.993 179.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.03 156.63 21.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.1 mt -119.1 130.06 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.528 0.68 . . . . 0.0 111.998 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.55 HG23 ' CD1' ' R' ' 34' ' ' LEU . 4.4 mt -103.62 110.24 29.42 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.36 95.3 0.42 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.55 ' CD1' HG23 ' R' ' 32' ' ' ILE . 5.7 mp -128.21 144.11 51.09 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-O 121.666 0.746 . . . . 0.0 110.88 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 95.8 mmm -105.67 105.3 15.27 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.862 HG11 HD21 ' P' ' 17' ' ' LEU . 2.3 t -106.7 123.25 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.559 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 35.68 114.17 0.0 OUTLIER Glycine 0 CA--C 1.539 1.563 0 O-C-N 123.693 0.621 . . . . 0.0 112.289 -177.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' Q' ' 38' ' ' GLY . . . -58.64 -63.93 4.77 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.629 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.61 ' C ' ' HZ2' ' E' ' 28' ' ' LYS . 37.7 t -133.57 135.02 56.32 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 121.536 0.684 . . . . 0.0 109.74 177.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.492 ' C ' ' NZ ' ' E' ' 28' ' ' LYS . 10.3 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.655 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -149.12 156.76 42.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.728 0.299 . . . . 0.0 110.431 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -154.74 146.53 23.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.963 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 12' ' ' VAL . 4.4 m -123.97 127.98 73.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.588 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -110.56 124.38 51.73 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 121.232 -0.187 . . . . 0.0 111.314 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.517 ' CB ' ' O ' ' B' ' 14' ' ' HIS . 32.4 p-80 -152.88 160.44 43.07 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 120.278 -0.569 . . . . 0.0 112.261 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -90.26 159.56 16.62 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -140.17 107.19 5.44 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.241 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.781 ' CD1' HG21 ' C' ' 36' ' ' VAL . 75.3 mt -129.05 113.99 15.82 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.695 0.76 . . . . 0.0 110.329 178.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -109.62 107.3 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.45 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 80.2 m-85 -107.61 105.42 15.29 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.5 p90 -129.31 124.32 34.05 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 110.913 -178.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -98.66 115.11 27.96 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -133.97 163.61 29.14 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.655 ' N ' ' O ' ' B' ' 23' ' ' ASP . 33.4 t70 -86.24 -59.86 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.641 HG12 ' N ' ' A' ' 25' ' ' GLY . 11.4 t -84.13 172.38 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 CA-C-O 122.425 1.107 . . . . 0.0 112.773 -177.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.641 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.87 -36.09 3.77 Favored Glycine 0 CA--C 1.534 1.276 0 CA-C-N 112.893 -1.958 . . . . 0.0 115.455 176.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.757 ' O ' ' O ' ' A' ' 27' ' ' ASN . 3.7 m -172.84 114.29 0.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 120.697 2.249 . . . . 0.0 114.936 176.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.757 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.6 t30 -7.01 161.67 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 115.052 1.501 . . . . 0.0 115.052 172.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.415 ' NZ ' ' O ' ' A' ' 20' ' ' PHE . 27.5 tttt -175.9 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 O-C-N 120.859 -1.15 . . . . 0.0 111.783 173.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -95.17 79.29 0.85 Allowed Glycine 0 CA--C 1.536 1.386 0 CA-C-O 118.566 -1.13 . . . . 0.0 111.071 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.97 167.8 26.51 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 120.295 2.047 . . . . 0.0 114.824 -177.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.3 mt -120.9 121.84 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 112.573 -2.103 . . . . 0.0 106.757 177.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -130.76 132.28 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.152 0.501 . . . . 0.0 112.207 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.92 112.55 0.91 Allowed Glycine 0 N--CA 1.462 0.422 0 N-CA-C 107.327 -2.309 . . . . 0.0 107.327 177.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' H ' ' A' ' 35' ' ' MET . 1.7 tp -163.69 168.6 19.61 Favored 'General case' 0 C--O 1.24 0.589 0 C-N-CA 118.397 -1.321 . . . . 0.0 113.629 -177.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.427 ' H ' ' HG ' ' A' ' 34' ' ' LEU . 6.1 ttm -120.83 112.87 19.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 113.144 -1.844 . . . . 0.0 110.111 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.418 ' O ' HG22 ' B' ' 36' ' ' VAL . 67.0 t -132.07 113.59 22.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 163.09 -124.01 1.24 Allowed Glycine 0 C--N 1.302 -1.325 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 78.1 -67.43 3.01 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.646 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.575 HG12 ' N ' ' A' ' 40' ' ' VAL . 61.8 t -85.09 163.07 2.8 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-O 120.742 0.306 . . . . 0.0 110.449 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.575 ' N ' HG12 ' A' ' 39' ' ' VAL . 89.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.668 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -77.85 129.95 36.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -158.08 130.12 6.95 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.364 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.6 138.96 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.117 0.484 . . . . 0.0 110.494 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' D' ' 40' ' ' VAL . 19.4 m-70 -107.61 143.57 35.87 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' B' ' 15' ' ' GLN . 38.2 t60 -149.52 168.49 23.33 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.3 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.577 HE22 ' N ' ' D' ' 37' ' ' GLY . 21.4 tt0 -138.99 151.34 46.77 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -148.77 109.91 4.36 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.46 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.626 HD11 HG21 ' D' ' 36' ' ' VAL . 6.0 mt -123.07 116.63 23.81 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.935 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -109.51 105.88 19.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -104.25 103.0 12.7 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 36.7 t80 -126.54 128.12 46.37 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.416 -175.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.83 115.1 21.43 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.24 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 21' ' ' ALA . 77.0 tt0 -166.02 139.74 4.32 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.655 ' O ' ' N ' ' A' ' 23' ' ' ASP . 97.9 m-20 54.54 50.23 16.5 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.436 ' H ' HG22 ' B' ' 24' ' ' VAL . 1.2 m -44.84 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.42 0.629 . . . . 0.0 111.017 -175.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.62 -24.16 0.05 OUTLIER Glycine 0 CA--C 1.52 0.375 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.059 -175.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.488 ' O ' ' CD ' ' C' ' 28' ' ' LYS . 5.9 m -81.78 142.43 32.61 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -72.47 175.62 6.09 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -174.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.46 ' O ' HG21 ' O' ' 39' ' ' VAL . 99.1 mttt -54.85 -39.34 68.51 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-N 113.837 -1.529 . . . . 0.0 108.516 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' N' ' 39' ' ' VAL . . . -101.83 66.93 0.42 Allowed Glycine 0 CA--C 1.535 1.303 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.676 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.79 112.24 18.99 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 121.37 0.605 . . . . 0.0 109.401 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.437 HD12 HG23 ' N' ' 39' ' ' VAL . 87.2 mt -129.42 129.36 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.718 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.563 HG22 HD11 ' C' ' 34' ' ' LEU . 88.2 mt -113.21 116.5 52.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.35 102.78 0.72 Allowed Glycine 0 CA--C 1.52 0.399 0 N-CA-C 108.316 -1.913 . . . . 0.0 108.316 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 34' ' ' LEU . 54.6 tp -140.8 136.07 32.07 Favored 'General case' 0 CA--C 1.507 -0.693 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.901 -177.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.86 145.59 51.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.637 -178.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' B' ' 37' ' ' GLY . 52.9 t -116.58 131.99 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.055 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.15 -111.63 0.0 OUTLIER Glycine 0 CA--C 1.53 1.008 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.891 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.2 -71.46 0.43 Allowed Glycine 0 CA--C 1.537 1.447 0 C-N-CA 121.729 -0.272 . . . . 0.0 112.767 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -85.04 129.09 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.468 0.464 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.567 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -85.07 135.9 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.793 0.33 . . . . 0.0 110.311 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -135.82 141.64 44.73 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.18 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 31.2 m -136.27 160.47 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.512 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.587 ' HB2' ' HD1' ' D' ' 13' ' ' HIS . 77.3 m80 -135.7 138.9 43.23 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.212 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.452 ' CG ' ' C ' ' C' ' 13' ' ' HIS . 45.1 m-70 -153.58 167.77 28.41 Favored 'General case' 0 C--O 1.223 -0.339 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 177.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.551 ' OE1' ' NE2' ' D' ' 15' ' ' GLN . 4.3 tt0 -158.14 140.03 13.94 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.548 177.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.681 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.1 mttt -101.22 111.65 23.92 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 114.794 1.405 . . . . 0.0 114.794 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.973 HD21 HG11 ' E' ' 36' ' ' VAL . 10.8 mp -120.05 114.27 21.75 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 119.159 0.891 . . . . 0.0 108.732 174.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 94.7 t -114.44 109.66 29.27 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.372 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.518 ' HZ ' HD23 ' C' ' 17' ' ' LEU . 29.3 m-85 -108.11 102.2 11.37 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 t80 -122.37 130.65 53.33 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 120.778 0.323 . . . . 0.0 111.043 -177.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.74 123.73 29.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.75 0.785 . . . . 0.0 112.984 -179.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' B' ' 22' ' ' GLU . 82.4 tt0 -145.67 126.6 14.52 Favored 'General case' 0 C--O 1.219 -0.518 0 N-CA-C 104.524 -2.398 . . . . 0.0 104.524 176.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.467 ' CB ' ' OD1' ' C' ' 27' ' ' ASN . 34.2 t0 -173.07 51.33 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.408 -175.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.738 HG22 HG21 ' D' ' 24' ' ' VAL . 5.2 t -63.39 151.99 8.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 117.63 -1.628 . . . . 0.0 109.072 -177.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.93 -28.42 10.56 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 107.21 -2.356 . . . . 0.0 107.21 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 7.2 m 105.9 128.71 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 112.725 -1.738 . . . . 0.0 108.81 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.844 ' H ' HD22 ' C' ' 27' ' ' ASN . 0.3 OUTLIER -67.9 149.03 50.33 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -179.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.488 ' CD ' ' O ' ' B' ' 26' ' ' SER . 98.3 mttt -54.09 -46.37 72.03 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.123 176.192 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.42 60.35 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 N-CA-C 115.091 0.796 . . . . 0.0 115.091 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.54 160.82 15.77 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 122.193 0.997 . . . . 0.0 113.665 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 93.2 mt -131.65 125.8 56.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.133 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.613 HG23 HD13 ' C' ' 34' ' ' LEU . 9.8 mt -109.03 115.15 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.819 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -125.66 102.01 0.65 Allowed Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 178.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.819 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.1 mp -141.31 149.74 41.61 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 123.054 1.407 . . . . 0.0 114.081 -176.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -114.0 104.72 12.43 Favored 'General case' 0 CA--C 1.505 -0.775 0 CA-C-N 112.669 -2.06 . . . . 0.0 106.383 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.781 HG21 ' CD1' ' A' ' 17' ' ' LEU . 21.5 m -136.81 113.74 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 -179.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.6 -124.29 1.39 Allowed Glycine 0 C--N 1.304 -1.247 0 C-N-CA 119.297 -1.43 . . . . 0.0 111.233 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.2 -67.43 2.76 Favored Glycine 0 CA--C 1.533 1.178 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.894 HG23 HD11 ' I' ' 31' ' ' ILE . 33.9 t -142.24 160.42 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.448 ' N ' HG12 ' C' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.083 -0.961 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -109.36 133.53 52.95 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.821 0.344 . . . . 0.0 110.656 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' NE2' ' D' ' 13' ' ' HIS . 8.9 pt-20 -142.05 149.87 40.49 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.212 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.599 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 76.7 t -123.28 135.86 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.93 -179.022 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.587 ' HD1' ' HB2' ' C' ' 13' ' ' HIS . 24.1 m-70 -138.13 135.88 36.16 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.179 0.514 . . . . 0.0 111.701 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.599 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 18.8 m-70 -153.09 177.49 10.74 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.551 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 57.0 tt0 -153.94 140.08 18.42 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.848 176.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -94.67 110.21 22.07 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.612 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.4 mm? -114.32 109.84 18.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 176.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.18 115.77 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.887 0.375 . . . . 0.0 111.049 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.634 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 34.9 m-85 -109.25 110.48 21.69 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.656 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 10.5 t80 -129.44 127.3 40.63 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -175.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.65 128.12 40.29 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 178.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 18.7 tt0 -74.8 174.09 9.66 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.118 0.485 . . . . 0.0 112.182 -177.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.53 ' O ' ' O ' ' D' ' 24' ' ' VAL . 33.4 p-10 -26.38 -69.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.146 -0.934 . . . . 0.0 113.451 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.738 HG21 HG22 ' C' ' 24' ' ' VAL . 4.6 t -56.41 -123.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.302 0.572 . . . . 0.0 109.89 178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 138.41 -34.88 2.07 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.371 178.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 38.6 t -69.65 116.44 10.05 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.568 -178.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' E' ' 28' ' ' LYS . 33.4 m-20 -120.03 154.92 33.88 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 176.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.44 ' C ' ' O ' ' D' ' 27' ' ' ASN . 95.2 mttt -33.45 -41.62 0.09 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.157 0.503 . . . . 0.0 111.742 174.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.46 ' O ' HG22 ' P' ' 39' ' ' VAL . . . 130.84 63.14 0.1 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-N 115.626 -0.716 . . . . 0.0 113.003 -178.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.73 147.83 46.97 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 118.27 1.035 . . . . 0.0 111.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -129.88 127.48 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -177.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.656 HG22 HD11 ' E' ' 34' ' ' LEU . 39.9 mt -115.06 117.46 55.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 175.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.07 118.23 3.91 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 106.324 -2.711 . . . . 0.0 106.324 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.612 ' CD2' HG22 ' C' ' 36' ' ' VAL . 0.3 OUTLIER -154.25 136.71 15.02 Favored 'General case' 0 CA--C 1.517 -0.316 0 C-N-CA 117.18 -1.808 . . . . 0.0 114.577 -175.633 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -101.42 113.55 26.75 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 175.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.85 ' CG1' HG12 ' E' ' 36' ' ' VAL . 9.4 p -141.35 143.71 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.6 -177.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.577 ' N ' HE22 ' B' ' 15' ' ' GLN . . . 110.89 -102.77 1.52 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.53 -80.25 0.78 Allowed Glycine 0 CA--C 1.538 1.507 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.706 HG23 HD11 ' J' ' 31' ' ' ILE . 43.5 t -139.67 137.27 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.483 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.167 -0.92 . . . . 0.0 110.538 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -111.83 134.97 53.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.687 0.279 . . . . 0.0 110.418 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -112.0 132.16 54.96 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.464 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' E' ' 12' ' ' VAL . 16.4 m -120.15 120.1 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 121.104 0.478 . . . . 0.0 109.905 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 11.6 p-80 -148.42 141.42 24.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.581 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.651 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 53.4 m-70 -140.52 159.58 41.88 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.222 179.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -90.22 159.88 16.48 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.99 103.41 4.62 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.431 HD12 ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -116.38 124.96 51.35 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.047 -0.261 . . . . 0.0 110.482 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.27 118.23 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.789 0.328 . . . . 0.0 110.458 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.634 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 87.0 m-85 -111.74 117.11 31.95 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.023 179.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.656 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 65.1 t80 -125.19 117.66 24.36 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.14 128.08 27.49 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-O 121.247 0.546 . . . . 0.0 111.939 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.461 ' O ' ' O ' ' D' ' 23' ' ' ASP . 98.8 mt-10 -107.69 163.22 13.27 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 -179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.475 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 17.6 m-20 18.85 52.18 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 113.95 -1.477 . . . . 0.0 113.785 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 88.1 t -65.42 145.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.58 -23.19 0.91 Allowed Glycine 0 N--CA 1.474 1.189 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' E' ' 27' ' ' ASN . 8.0 p -179.17 -149.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.689 0.245 . . . . 0.0 110.381 177.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.466 HD21 HG13 ' R' ' 40' ' ' VAL . 45.3 m-80 -48.53 129.42 16.17 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.9 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' D' ' 27' ' ' ASN . 98.2 mttt -74.6 -51.57 14.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 122.594 1.187 . . . . 0.0 109.246 175.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.96 49.77 3.24 Favored Glycine 0 CA--C 1.539 1.588 0 CA-C-N 113.681 -1.6 . . . . 0.0 112.598 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.99 121.32 24.87 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 118.557 -0.735 . . . . 0.0 109.496 177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.437 ' CD1' HG23 ' Q' ' 39' ' ' VAL . 69.2 mt -114.08 110.17 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.728 1.149 . . . . 0.0 109.392 177.202 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.729 HG23 HD13 ' E' ' 34' ' ' LEU . 51.8 mt -108.76 108.6 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.686 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -116.2 93.12 0.59 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 105.822 -2.911 . . . . 0.0 105.822 177.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.729 HD13 HG23 ' E' ' 32' ' ' ILE . 8.3 mp -135.36 154.28 51.55 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 122.817 1.294 . . . . 0.0 113.15 -175.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.3 mtp -118.38 107.34 13.73 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 112.898 -1.956 . . . . 0.0 107.796 177.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.973 HG11 HD21 ' C' ' 17' ' ' LEU . 15.3 m -122.98 123.19 67.47 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.187 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.48 -113.71 1.14 Allowed Glycine 0 C--N 1.316 -0.535 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.596 ' O ' HD12 ' L' ' 31' ' ' ILE . . . 84.77 -72.91 2.72 Favored Glycine 0 CA--C 1.537 1.413 0 CA-C-N 114.882 -0.659 . . . . 0.0 112.134 -179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.64 HG23 HD11 ' K' ' 31' ' ' ILE . 30.1 t -148.68 138.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 117.347 0.574 . . . . 0.0 109.821 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.521 HG22 ' O ' ' F' ' 38' ' ' GLY . 30.3 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.817 -1.087 . . . . 0.0 110.525 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -106.77 135.21 48.71 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.485 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -73.3 147.9 44.06 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.185 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.578 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 4.5 m -136.27 167.85 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.419 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.569 ' H ' ' CD2' ' F' ' 13' ' ' HIS . 10.6 p80 -81.97 127.47 33.09 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.361 179.382 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.651 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 53.0 t-80 -149.18 164.47 34.65 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -89.94 158.92 17.18 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 121.117 0.484 . . . . 0.0 111.337 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -140.23 113.46 8.42 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.206 178.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.489 ' C ' HD23 ' F' ' 17' ' ' LEU . 8.7 tt -127.59 124.79 38.95 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.194 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -134.06 135.67 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.896 179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.4 p90 -139.18 129.15 25.03 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.164 0.507 . . . . 0.0 111.592 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -121.78 126.4 48.76 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.0 152.73 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 120.401 -0.52 . . . . 0.0 111.576 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.63 ' CG ' ' H ' ' F' ' 23' ' ' ASP . 37.1 tt0 -71.67 -173.42 0.95 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.63 ' H ' ' CG ' ' F' ' 22' ' ' GLU . 53.5 p30 -62.52 51.88 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.657 HG12 ' H ' ' F' ' 25' ' ' GLY . 7.5 t -60.58 -131.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.657 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 113.08 27.93 3.53 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.517 ' H ' HG12 ' F' ' 24' ' ' VAL . 40.7 t -140.23 112.67 7.88 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.914 0.387 . . . . 0.0 110.494 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -64.15 179.16 0.58 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.637 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt 63.92 39.62 7.99 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.37 -65.51 1.57 Allowed Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.015 -1.088 . . . . 0.0 111.204 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.86 153.75 47.97 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 95.9 mt -113.55 106.01 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 118.906 0.775 . . . . 0.0 109.673 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 81.2 mt -107.13 110.05 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.852 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.88 84.95 0.38 Allowed Glycine 0 N--CA 1.452 -0.274 0 N-CA-C 104.42 -3.472 . . . . 0.0 104.42 175.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.403 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.2 mt -121.53 128.07 51.65 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.536 0.684 . . . . 0.0 111.586 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -98.94 104.7 16.77 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.545 HG11 ' HG ' ' D' ' 17' ' ' LEU . 16.3 m -110.91 134.63 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.73 -104.33 0.25 Allowed Glycine 0 C--N 1.308 -1.02 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 -174.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.521 ' O ' HG22 ' E' ' 40' ' ' VAL . . . 72.62 63.95 2.74 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.036 -178.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' F' ' 38' ' ' GLY . 56.9 t -18.64 144.63 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 114.236 1.199 . . . . 0.0 114.236 -178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.451 HG13 ' NE2' ' D' ' 13' ' ' HIS . 83.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-N 114.014 -1.448 . . . . 0.0 111.459 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.422 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.59 ' CE1' ' N ' ' H' ' 9' ' ' GLY . 96.7 m-85 -105.86 132.71 51.64 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.81 0.338 . . . . 0.0 110.562 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -78.93 158.46 28.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.076 0.465 . . . . 0.0 111.306 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.481 HG23 ' O ' ' G' ' 12' ' ' VAL . 18.9 m -114.78 127.98 72.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.357 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.573 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 24.3 m170 -82.56 125.56 31.28 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.034 -178.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.67 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -162.41 159.94 25.82 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.28 178.266 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.551 HE22 ' CA ' ' I' ' 37' ' ' GLY . 39.0 tt0 -90.2 159.57 16.66 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 177.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -140.41 102.58 4.37 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 119.699 -0.8 . . . . 0.0 112.861 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.699 HD11 HG11 ' I' ' 36' ' ' VAL . 64.7 mt -116.97 107.46 14.58 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.6 HG23 ' O ' ' G' ' 18' ' ' VAL . 28.8 m -116.26 104.78 17.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 178.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.569 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 35.6 m-85 -107.94 103.91 13.25 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -114.1 124.6 52.49 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.492 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.442 ' HB3' HG11 ' H' ' 24' ' ' VAL . . . -125.55 119.84 29.23 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.512 0.673 . . . . 0.0 109.785 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' G' ' 23' ' ' ASP . 75.8 tt0 -159.48 176.9 11.53 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -179.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.431 ' N ' ' HG2' ' G' ' 22' ' ' GLU . 65.6 t0 -46.53 -59.66 2.85 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.789 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.6 m -101.44 174.95 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 176.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 69.29 26.98 74.13 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.866 178.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' G' ' 27' ' ' ASN . 6.1 t -153.21 120.62 5.9 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.724 -0.391 . . . . 0.0 112.021 -176.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.559 ' O ' ' O ' ' G' ' 26' ' ' SER . 67.2 t30 -41.98 -179.33 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.261 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.478 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 63.0 mttp -72.58 -41.14 66.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.229 -0.589 . . . . 0.0 111.824 -178.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.0 66.86 0.86 Allowed Glycine 0 CA--C 1.536 1.374 0 C-N-CA 119.527 -1.321 . . . . 0.0 112.145 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.27 -150.77 0.46 Allowed 'General case' 0 C--O 1.234 0.265 0 CA-C-N 117.422 0.611 . . . . 0.0 110.47 -177.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tp -105.8 117.62 51.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -129.41 130.66 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.14 114.85 1.3 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 177.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 45.5 tp -155.11 155.55 34.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 112.437 -177.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 53.6 ttm -133.39 142.73 48.51 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.999 -1.0 . . . . 0.0 110.562 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -130.04 113.74 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.132 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' G' ' 38' ' ' GLY . . . -39.34 123.97 1.82 Allowed Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' H' ' 38' ' ' GLY . . . -29.59 -61.61 0.17 Allowed Glycine 0 CA--C 1.538 1.522 0 CA-C-O 120.083 -0.287 . . . . 0.0 113.552 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.585 HG23 HD13 ' M' ' 31' ' ' ILE . 49.4 t -45.11 145.05 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 117.893 0.847 . . . . 0.0 111.428 -179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' H' ' 40' ' ' VAL . 16.5 m . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.06 -0.972 . . . . 0.0 111.039 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . 0.59 ' N ' ' CE1' ' G' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -106.94 132.15 53.21 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.765 0.316 . . . . 0.0 110.238 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -133.92 128.12 33.88 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.589 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.22 161.38 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.329 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.605 ' CG ' HG13 ' J' ' 40' ' ' VAL . 8.6 t-80 -143.02 133.1 24.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.535 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 67.1 m-70 -147.44 162.1 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.153 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 14.2 tp60 -89.97 157.9 17.62 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 105.52 -2.03 . . . . 0.0 105.52 175.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.636 ' C ' HD12 ' H' ' 17' ' ' LEU . 97.4 mttt -141.04 98.44 3.38 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.955 -0.698 . . . . 0.0 111.252 178.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.776 ' N ' HD12 ' H' ' 17' ' ' LEU . 1.5 mp -121.02 112.87 19.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -115.95 105.89 19.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.502 ' CE1' ' HB3' ' H' ' 17' ' ' LEU . 34.8 m-85 -104.4 103.34 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -122.18 127.04 49.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 -178.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.475 ' HB1' ' CG1' ' H' ' 24' ' ' VAL . . . -140.65 126.92 19.79 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 -178.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.47 ' O ' ' N ' ' H' ' 24' ' ' VAL . 84.7 tt0 -110.85 122.27 47.42 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 114.977 -1.01 . . . . 0.0 108.441 177.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' H' ' 22' ' ' GLU . 99.7 m-20 23.78 45.9 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.73 0.776 . . . . 0.0 111.077 -176.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.475 ' CG1' ' HB1' ' H' ' 21' ' ' ALA . 2.4 m -75.77 179.42 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 CA-C-N 114.202 -1.363 . . . . 0.0 114.453 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' I' ' 27' ' ' ASN . . . 103.96 -37.22 3.87 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 111.196 -2.729 . . . . 0.0 117.784 169.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.408 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 43.4 m -66.02 111.39 3.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 121.684 2.742 . . . . 0.0 110.058 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.712 ' O ' ' N ' ' H' ' 29' ' ' GLY . 86.0 m-20 -149.77 142.98 25.1 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.154 -0.619 . . . . 0.0 110.796 173.311 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' H' ' 27' ' ' ASN . 98.8 mttt -9.81 -45.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 172.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.712 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 168.21 61.04 0.03 OUTLIER Glycine 0 CA--C 1.553 2.458 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.566 -175.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.81 102.16 3.95 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -173.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -135.17 120.76 30.45 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-N 112.16 -2.291 . . . . 0.0 106.894 176.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.1 mt -122.94 131.45 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 114.57 2.07 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 177.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.542 ' HB3' HD22 ' I' ' 34' ' ' LEU . 43.4 tp -137.13 137.8 39.62 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 117.39 0.595 . . . . 0.0 110.916 -177.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 74.1 mtp -134.98 138.16 43.74 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' H' ' 37' ' ' GLY . 53.3 t -123.75 131.99 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 177.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -44.44 -111.75 0.0 OUTLIER Glycine 0 CA--C 1.532 1.107 0 CA-C-O 121.61 0.561 . . . . 0.0 112.977 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' G' ' 38' ' ' GLY . . . -125.54 -70.92 0.19 Allowed Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.516 HG12 ' N ' ' H' ' 40' ' ' VAL . 97.7 t -55.18 159.78 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.28 0 CA-C-O 120.579 0.228 . . . . 0.0 110.807 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' G' ' 40' ' ' VAL . 3.9 t . . . . . 0 C--O 1.218 -0.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.65 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -106.28 132.57 52.17 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.861 0.363 . . . . 0.0 110.427 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -139.17 132.17 29.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.508 ' CG1' ' NE2' ' I' ' 14' ' ' HIS . 44.8 t -125.11 131.12 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 89.1 m-70 -124.65 125.19 43.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.618 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 27.6 m-70 -143.89 159.53 42.38 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.224 -0.591 . . . . 0.0 109.75 176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.873 HE22 ' H ' ' L' ' 37' ' ' GLY . 9.5 mt-30 -90.29 157.98 17.39 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 175.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -141.84 97.27 3.11 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.494 ' CD2' HG21 ' K' ' 36' ' ' VAL . 4.3 mp -130.69 120.65 24.2 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 121.643 0.735 . . . . 0.0 111.853 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -118.44 106.66 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.475 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.193 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' CD2' ' CD1' ' H' ' 19' ' ' PHE . 35.0 m-85 -104.76 103.64 13.29 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -121.11 124.72 45.44 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.52 146.79 27.56 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -177.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -141.89 134.44 28.25 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 112.081 -2.327 . . . . 0.0 106.765 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -163.54 48.65 0.14 Allowed 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.478 ' CG1' ' O ' ' J' ' 24' ' ' VAL . 3.2 m -73.26 160.65 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.932 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.78 -30.72 8.73 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 178.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.7 t 92.97 112.39 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 113.056 -1.572 . . . . 0.0 108.429 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.504 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 49.6 t30 -74.41 173.39 10.36 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 118.595 -1.242 . . . . 0.0 111.623 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.504 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 88.4 tttt -54.75 -37.04 65.46 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 122.483 1.135 . . . . 0.0 108.35 172.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.01 76.54 0.44 Allowed Glycine 0 CA--C 1.543 1.838 0 CA-C-N 112.764 -2.016 . . . . 0.0 109.417 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.77 147.22 29.53 Favored 'General case' 0 C--N 1.356 0.884 0 C-N-CA 122.763 0.425 . . . . 0.0 112.021 -178.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.894 HD11 HG23 ' C' ' 39' ' ' VAL . 55.2 mt -141.13 133.79 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 57.4 mt -108.4 119.5 58.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 174.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.903 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -128.01 103.92 0.65 Allowed Glycine 0 N--CA 1.47 0.924 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.903 HD23 ' O ' ' I' ' 33' ' ' GLY . 0.4 OUTLIER -141.99 154.15 44.81 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 123.097 1.427 . . . . 0.0 113.827 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 mtp -115.13 99.46 7.44 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 105.357 -2.09 . . . . 0.0 105.357 175.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.699 HG11 HD11 ' G' ' 17' ' ' LEU . 2.6 t -131.93 111.53 18.59 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -177.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.551 ' CA ' HE22 ' G' ' 15' ' ' GLN . . . 139.84 -131.61 5.2 Favored Glycine 0 C--N 1.316 -0.549 0 C-N-CA 120.614 -0.803 . . . . 0.0 111.357 178.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.77 -63.84 2.85 Favored Glycine 0 CA--C 1.539 1.572 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 -177.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.52 HG11 HD13 ' N' ' 31' ' ' ILE . 1.8 p -151.08 139.85 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 178.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.459 ' O ' ' CG2' ' H' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.472 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . 0.453 ' CE2' ' O ' ' K' ' 9' ' ' GLY . 92.4 m-85 -108.69 135.04 50.58 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.726 0.298 . . . . 0.0 110.483 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.0 tt0 -148.18 128.54 13.9 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.484 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -117.04 130.33 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.46 ' CD2' HG11 ' L' ' 40' ' ' VAL . 82.0 t60 -122.04 140.52 52.39 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.94 0.4 . . . . 0.0 111.609 -179.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.661 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 3.8 t-80 -150.69 152.92 34.65 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.685 178.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.661 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 1.2 mp0 -98.76 169.49 9.44 Favored 'General case' 0 C--N 1.338 0.091 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 176.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -158.82 91.89 1.08 Allowed 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 175.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.63 119.68 26.44 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 120.161 -0.616 . . . . 0.0 110.879 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -117.72 109.3 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.002 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 18.1 m-85 -104.17 107.89 19.01 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -127.22 129.95 48.75 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.074 0.464 . . . . 0.0 110.902 -177.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.405 ' HB1' ' OD2' ' J' ' 23' ' ' ASP . . . -150.18 137.18 19.4 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.734 1.013 . . . . 0.0 113.734 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -131.16 124.06 29.88 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 176.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.484 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 0.1 OUTLIER -174.49 52.29 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 116.318 -2.153 . . . . 0.0 115.988 -173.233 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' I' ' 24' ' ' VAL . 99.5 t -74.87 142.19 14.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 C-N-CA 117.71 -1.596 . . . . 0.0 106.84 178.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 106.19 -38.36 3.35 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 -175.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.565 ' O ' ' O ' ' K' ' 28' ' ' LYS . 1.5 m -65.44 112.41 3.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 112.107 -2.046 . . . . 0.0 113.064 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.507 ' OD1' ' N ' ' J' ' 27' ' ' ASN . 8.5 p-10 -149.19 162.25 40.37 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.479 ' C ' ' O ' ' J' ' 27' ' ' ASN . 67.0 mmtt 31.49 42.16 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.23 0.538 . . . . 0.0 110.47 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -90.56 -62.47 1.26 Allowed Glycine 0 CA--C 1.552 2.377 0 N-CA-C 116.701 1.44 . . . . 0.0 116.701 -175.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.82 157.4 33.22 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 121.423 2.612 . . . . 0.0 115.376 -176.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.706 HD11 HG23 ' D' ' 39' ' ' VAL . 76.1 mt -132.21 129.69 60.05 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 112.999 -1.909 . . . . 0.0 111.823 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.824 HG22 HD11 ' K' ' 34' ' ' LEU . 36.2 mt -108.6 120.02 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.874 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -133.97 112.94 1.12 Allowed Glycine 0 N--CA 1.479 1.555 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.874 HD12 ' C ' ' J' ' 33' ' ' GLY . 4.6 mp -153.4 160.68 42.68 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 123.203 1.478 . . . . 0.0 114.231 -177.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -110.34 108.58 18.69 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 174.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.771 HG11 HD21 ' H' ' 17' ' ' LEU . 9.4 t -129.24 102.46 7.69 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 CA-C-O 121.071 0.462 . . . . 0.0 111.127 -176.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.48 164.24 22.66 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.91 178.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.3 -56.15 0.24 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-N 114.991 -0.604 . . . . 0.0 111.771 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.665 HG23 HD12 ' P' ' 31' ' ' ILE . 18.1 t -121.38 135.74 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 118.087 0.944 . . . . 0.0 108.924 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.605 HG13 ' CG ' ' H' ' 13' ' ' HIS . 4.2 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.735 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . 0.453 ' O ' ' CE2' ' J' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.76 134.02 50.53 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.86 0.362 . . . . 0.0 110.405 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' J' ' 11' ' ' GLU . 80.5 mm-40 -124.95 127.88 47.74 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.105 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.401 HG21 HD21 ' Q' ' 27' ' ' ASN . 54.1 t -123.08 133.28 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.41 ' CG ' ' CG1' ' J' ' 12' ' ' VAL . 0.3 OUTLIER -85.71 160.73 19.47 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.795 0.331 . . . . 0.0 110.421 -179.958 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.566 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 1.5 m80 -84.63 164.84 18.41 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.529 -178.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.431 ' HA ' ' H ' ' J' ' 15' ' ' GLN . 10.5 pt20 -89.9 158.99 17.17 Favored 'General case' 0 C--N 1.338 0.073 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.323 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -140.23 113.33 8.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.95 177.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.1 122.36 36.93 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -125.25 127.48 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 121.136 -0.225 . . . . 0.0 111.178 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.651 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 44.6 m-85 -120.36 118.4 30.26 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 178.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.521 ' CE1' ' CD1' ' L' ' 20' ' ' PHE . 61.4 t80 -126.94 119.9 27.85 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.0 140.12 36.18 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.15 109.87 9.77 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 176.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.526 ' OD2' ' N ' ' K' ' 28' ' ' LYS . 29.9 t70 -167.18 46.36 0.06 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.047 -176.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.706 HG12 ' H ' ' K' ' 25' ' ' GLY . 4.7 t -90.12 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 C-N-CA 118.935 -1.106 . . . . 0.0 110.815 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.706 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 81.68 -35.25 2.49 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' K' ' 27' ' ' ASN . 85.0 p -153.1 121.64 6.34 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.539 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 45.7 t30 -40.91 163.64 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.462 178.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.565 ' O ' ' O ' ' J' ' 26' ' ' SER . 87.3 tttt -80.28 -50.26 10.44 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.008 0.909 . . . . 0.0 110.504 177.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.6 50.11 3.45 Favored Glycine 0 CA--C 1.534 1.257 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 134.95 47.26 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 117.88 0.84 . . . . 0.0 111.395 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.64 HD11 HG23 ' E' ' 39' ' ' VAL . 94.6 mt -129.12 119.82 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.457 178.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.581 HG23 HD13 ' K' ' 34' ' ' LEU . 40.7 mt -105.26 111.89 36.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.697 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -122.35 93.48 0.5 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 107.51 -2.236 . . . . 0.0 107.51 178.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.824 HD11 HG22 ' J' ' 32' ' ' ILE . 7.1 mp -137.02 152.63 50.33 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.673 1.225 . . . . 0.0 112.733 -177.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -106.55 110.92 23.26 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.246 177.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.494 HG21 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.64 123.85 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.422 ' HA2' HE21 ' I' ' 15' ' ' GLN . . . 121.3 -114.56 2.61 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.91 -72.37 2.8 Favored Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.487 ' CG2' HD11 ' P' ' 31' ' ' ILE . 2.8 t -149.48 127.12 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 117.367 0.583 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.329 178.238 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.64 132.51 51.69 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.83 0.348 . . . . 0.0 110.125 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -84.93 117.7 24.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.785 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -128.64 129.08 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.017 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -151.75 145.57 25.1 Favored 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.95 -179.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -152.6 170.47 20.12 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.26 179.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -89.52 150.93 22.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.875 0.369 . . . . 0.0 110.486 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -148.66 103.85 3.43 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.401 HD23 ' C ' ' L' ' 17' ' ' LEU . 10.3 tt -136.65 130.55 32.38 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.27 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.76 132.43 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.11 0.481 . . . . 0.0 109.753 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 t80 -119.79 124.84 47.12 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.661 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' CE1' ' K' ' 20' ' ' PHE . 53.1 t80 -133.43 124.55 27.29 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 121.195 0.521 . . . . 0.0 110.541 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 141.16 46.68 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 178.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -90.28 133.47 34.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 120.306 -0.558 . . . . 0.0 112.307 -178.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 39.14 61.06 1.36 Allowed 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.543 177.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 m -67.4 123.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.459 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.46 -33.24 4.26 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.788 -177.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.4 t -173.37 127.87 0.43 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.854 0.835 . . . . 0.0 112.542 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 8.6 m120 56.87 -169.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.131 -1.395 . . . . 0.0 112.429 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -77.37 -41.76 38.99 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 114.857 -1.065 . . . . 0.0 111.653 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.478 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . 97.81 -61.23 0.98 Allowed Glycine 0 CA--C 1.543 1.787 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.95 163.74 13.51 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 178.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.596 HD12 ' O ' ' E' ' 38' ' ' GLY . 94.5 mt -129.65 126.91 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.274 -178.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.8 mt -111.34 114.7 47.84 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.533 178.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.77 86.47 0.42 Allowed Glycine 0 C--O 1.237 0.325 0 N-CA-C 104.751 -3.34 . . . . 0.0 104.751 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 19.4 tp -120.3 122.96 42.0 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 115.146 -0.527 . . . . 0.0 111.266 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.49 ' O ' ' O ' ' K' ' 36' ' ' VAL . 28.6 tpp -88.33 112.15 22.53 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 104.284 -2.487 . . . . 0.0 104.284 175.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 38.7 t -114.42 131.61 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -176.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.873 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 80.03 -111.36 3.26 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.309 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.3 -73.37 0.93 Allowed Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.5 HG23 HD12 ' R' ' 31' ' ' ILE . 51.7 t -130.93 132.29 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' Q' ' 28' ' ' LYS . 13.6 m . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.639 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.409 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -106.01 134.52 49.0 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.77 0.319 . . . . 0.0 110.372 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -125.05 131.21 53.39 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.373 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.5 m -136.96 155.91 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.83 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . 0.494 ' C ' ' CD2' ' M' ' 14' ' ' HIS . 61.1 t60 -143.88 111.69 6.12 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.088 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.494 ' CD2' ' C ' ' M' ' 13' ' ' HIS . 3.4 m-70 -153.32 170.27 21.05 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-O 121.284 0.564 . . . . 0.0 111.499 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 57.2 tt0 -155.15 140.61 17.8 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -92.83 106.57 18.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 118.664 -0.684 . . . . 0.0 111.529 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.581 ' CD1' HG21 ' O' ' 36' ' ' VAL . 82.9 mt -125.0 109.1 12.54 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-N 119.512 1.051 . . . . 0.0 110.689 177.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -119.3 107.55 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -107.06 112.55 25.54 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 55.4 p90 -125.49 125.54 43.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.996 0.427 . . . . 0.0 111.01 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.99 114.98 28.94 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -141.68 127.93 19.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -54.48 -61.52 2.26 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.151 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -84.83 150.09 4.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.772 0.796 . . . . 0.0 111.401 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 38.68 5.35 Favored Glycine 0 CA--C 1.532 1.102 0 CA-C-N 114.061 -1.427 . . . . 0.0 115.78 175.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 61.98 111.58 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 116.688 2.107 . . . . 0.0 116.688 170.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.544 ' H ' ' HD2' ' N' ' 28' ' ' LYS . 64.9 t30 -128.81 159.73 34.81 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 105.901 -1.888 . . . . 0.0 105.901 172.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.464 ' C ' ' O ' ' M' ' 27' ' ' ASN . 98.9 mttt -31.09 -40.2 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 113.207 0.817 . . . . 0.0 113.207 -175.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.655 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 82.55 66.98 1.51 Allowed Glycine 0 CA--C 1.538 1.51 0 CA-C-O 117.006 -1.997 . . . . 0.0 110.51 176.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.91 179.77 0.51 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 122.995 3.398 . . . . 0.0 116.633 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.585 HD13 HG23 ' G' ' 39' ' ' VAL . 6.2 tt -123.71 121.45 62.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 109.647 -3.433 . . . . 0.0 103.631 174.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 82.9 mt -132.53 142.61 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 114.787 1.403 . . . . 0.0 114.787 -175.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -137.9 107.83 0.6 Allowed Glycine 0 CA--C 1.532 1.104 0 N-CA-C 106.342 -2.703 . . . . 0.0 106.342 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' M' ' 35' ' ' MET . 27.2 tp -169.52 171.98 7.3 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.136 -176.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . 0.47 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 41.8 ttm -141.33 149.74 41.58 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.073 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' M' ' 37' ' ' GLY . 4.6 p -135.08 122.98 38.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.16 0.505 . . . . 0.0 111.186 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' M' ' 36' ' ' VAL . . . 8.04 -113.28 0.01 OUTLIER Glycine 0 N--CA 1.474 1.193 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.462 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.23 62.21 4.08 Favored Glycine 0 CA--C 1.54 1.631 0 CA-C-N 114.993 -0.603 . . . . 0.0 112.437 -177.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 21.2 m -121.56 164.76 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.39 0.676 . . . . 0.0 109.396 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.753 179.563 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -106.42 133.83 50.5 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . 0.426 ' H ' ' HG2' ' O' ' 11' ' ' GLU . 97.1 mt-10 -143.73 111.98 6.31 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.932 0.396 . . . . 0.0 110.571 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 54.0 t -124.29 131.43 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.667 179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -133.29 117.39 17.3 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.914 0.388 . . . . 0.0 111.339 -179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 7.5 t60 -156.14 170.23 22.68 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.626 179.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.577 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 65.2 tt0 -155.27 141.04 18.1 Favored 'General case' 0 C--N 1.342 0.259 0 C-N-CA 120.431 -0.508 . . . . 0.0 111.126 178.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -92.58 111.37 22.94 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.564 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.542 HD23 ' HB2' ' M' ' 17' ' ' LEU . 10.7 mt -124.34 117.91 25.56 Favored 'General case' 0 N--CA 1.481 1.11 0 CA-C-N 118.602 0.637 . . . . 0.0 110.345 177.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.23 114.46 40.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' N' ' 17' ' ' LEU . 22.6 m-85 -112.13 115.64 29.19 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.561 ' CE2' ' CD1' ' O' ' 20' ' ' PHE . 38.8 t80 -124.47 119.58 29.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.497 0.189 . . . . 0.0 110.797 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.99 127.05 53.45 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.413 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 10.0 tt0 -84.71 -168.96 2.4 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.813 0.339 . . . . 0.0 110.908 -178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.806 ' OD2' HG23 ' O' ' 24' ' ' VAL . 17.8 p30 -147.29 47.2 1.14 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.724 -178.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.427 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.0 OUTLIER -83.15 -160.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 -179.008 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.427 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -80.46 -35.57 25.73 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 119.725 -1.226 . . . . 0.0 110.448 -177.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 34.4 t -155.74 112.67 3.21 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 119.956 -0.697 . . . . 0.0 110.827 176.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.879 ' H ' ' H ' ' O' ' 28' ' ' LYS . 27.7 t-20 -53.07 172.58 0.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 177.195 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.544 ' HD2' ' H ' ' M' ' 27' ' ' ASN . 48.2 tttm -60.76 -38.53 85.52 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.35 70.06 0.68 Allowed Glycine 0 N--CA 1.471 1.003 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.522 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.779 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . -108.08 121.89 45.76 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 122.721 1.248 . . . . 0.0 112.899 -178.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.52 HD13 HG11 ' I' ' 39' ' ' VAL . 87.4 mt -125.98 110.2 23.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 176.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.416 HG21 HD11 ' O' ' 34' ' ' LEU . 87.7 mt -117.53 129.04 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -175.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.03 94.05 0.4 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 105.444 -3.062 . . . . 0.0 105.444 176.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.43 HD12 ' O ' ' M' ' 34' ' ' LEU . 64.7 tp -134.22 138.87 45.4 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.529 0.68 . . . . 0.0 111.186 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 84.2 mtp -127.11 134.93 50.15 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.965 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.01 123.32 63.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.551 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.0 113.59 1.48 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' N' ' 39' ' ' VAL . . . -38.0 -65.43 0.68 Allowed Glycine 0 CA--C 1.537 1.434 0 C-N-CA 121.816 -0.23 . . . . 0.0 112.671 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.454 HG13 ' HA3' ' B' ' 29' ' ' GLY . 72.3 t -28.88 149.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.51 179.717 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -107.88 136.23 47.95 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.722 0.296 . . . . 0.0 110.39 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.426 ' HG2' ' H ' ' N' ' 11' ' ' GLU . 97.2 mt-10 -139.47 120.25 14.34 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 35.8 m -139.38 160.26 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 121.007 0.432 . . . . 0.0 111.178 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.428 ' CD2' ' N ' ' O' ' 13' ' ' HIS . 4.5 m-70 -133.89 123.44 24.72 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . . . . . . . . . 49.4 t60 -120.52 163.83 17.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.104 0.478 . . . . 0.0 110.666 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -139.04 151.62 46.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.717 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -148.66 98.34 2.86 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' Q' ' 36' ' ' VAL . 6.4 mt -117.53 115.43 25.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.251 179.002 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -108.4 103.54 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.419 ' CZ ' ' HB3' ' O' ' 17' ' ' LEU . 59.7 m-85 -101.08 102.47 13.44 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.561 ' CD1' ' CE2' ' N' ' 20' ' ' PHE . 33.3 t80 -114.96 120.96 41.69 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.591 0.234 . . . . 0.0 110.804 -178.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.92 124.49 35.28 Favored 'General case' 0 C--O 1.244 0.777 0 CA-C-O 121.993 0.902 . . . . 0.0 112.519 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.465 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 1.3 tt0 -89.6 163.99 14.94 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.48 ' CB ' ' O ' ' P' ' 23' ' ' ASP . 46.6 m-20 -160.27 55.17 0.34 Allowed 'General case' 0 CA--C 1.541 0.598 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 -174.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.806 HG23 ' OD2' ' N' ' 23' ' ' ASP . 95.7 t -90.86 -123.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 -178.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.744 ' N ' HG12 ' O' ' 24' ' ' VAL . . . -73.22 -36.34 56.09 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-O 116.442 -2.31 . . . . 0.0 111.632 -171.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 13.3 t 139.55 111.85 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 172.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' N' ' 22' ' ' GLU . 11.5 m-20 -56.95 171.41 0.35 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.06 172.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.879 ' H ' ' H ' ' N' ' 27' ' ' ASN . 74.0 tttt -58.96 -40.9 86.13 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.537 177.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.99 62.72 0.49 Allowed Glycine 0 CA--C 1.54 1.637 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.526 -176.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.779 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -90.02 165.51 14.0 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.727 1.251 . . . . 0.0 112.809 -176.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 69.1 mt -132.76 133.5 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 112.886 -1.961 . . . . 0.0 112.631 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.404 HD13 HG21 ' O' ' 32' ' ' ILE . 62.1 mt -104.3 110.63 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 101.33 1.03 Allowed Glycine 0 N--CA 1.462 0.426 0 N-CA-C 106.667 -2.573 . . . . 0.0 106.667 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.561 ' O ' HD12 ' P' ' 34' ' ' LEU . 0.2 OUTLIER -142.24 150.53 41.05 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 122.803 1.287 . . . . 0.0 114.151 -175.626 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.2 mmm -126.22 104.85 8.44 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 176.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.639 ' CG2' HG12 ' P' ' 36' ' ' VAL . 18.8 m -133.69 101.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.426 -178.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 175.39 23.34 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.579 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 166.25 -55.1 0.25 Allowed Glycine 0 CA--C 1.539 1.534 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.548 HG22 ' N ' ' O' ' 40' ' ' VAL . 10.1 p -140.11 159.78 26.11 Favored 'Isoleucine or valine' 0 C--N 1.341 0.223 0 CA-C-N 117.427 0.613 . . . . 0.0 110.42 177.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.548 ' N ' HG22 ' O' ' 39' ' ' VAL . 4.8 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.46 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.17 137.14 46.66 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' CE1' ' P' ' 13' ' ' HIS . 83.7 tt0 -116.66 125.65 52.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.22 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.48 133.27 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.816 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.425 ' CE1' ' OE2' ' P' ' 11' ' ' GLU . 67.7 m80 -117.79 134.06 55.3 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.509 ' CD2' ' N ' ' P' ' 15' ' ' GLN . 9.3 t60 -157.47 167.1 31.2 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.115 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.509 ' N ' ' CD2' ' P' ' 14' ' ' HIS . 4.6 pt20 -156.85 140.26 15.74 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.576 176.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -98.07 106.58 18.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.99 176.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.571 HD22 HD12 ' O' ' 17' ' ' LEU . 10.1 mt -115.07 108.3 16.48 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . 0.423 HG13 ' O ' ' P' ' 18' ' ' VAL . 9.1 p -119.86 116.07 49.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-O 121.872 0.844 . . . . 0.0 109.534 179.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.652 ' CD1' ' CE2' ' Q' ' 19' ' ' PHE . 19.6 m-85 -108.38 108.71 19.79 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.332 -1.303 . . . . 0.0 108.867 -179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.555 ' CE2' ' CD2' ' Q' ' 20' ' ' PHE . 45.2 t80 -118.79 118.23 31.03 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.827 0.346 . . . . 0.0 110.375 -179.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.82 125.57 25.55 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.61 138.14 52.15 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.48 ' O ' ' CB ' ' O' ' 23' ' ' ASP . 98.7 m-20 53.41 46.85 25.43 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.848 178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.728 HG12 ' H ' ' P' ' 25' ' ' GLY . 43.5 t -72.31 177.31 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.624 0 O-C-N 124.255 0.972 . . . . 0.0 112.258 -175.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.728 ' H ' HG12 ' P' ' 24' ' ' VAL . . . 101.73 -28.64 15.07 Favored Glycine 0 CA--C 1.531 1.031 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.738 -175.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -91.44 -171.98 3.11 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.063 0.935 . . . . 0.0 113.383 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t-20 81.53 133.55 0.06 Allowed 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 126.312 1.845 . . . . 0.0 111.828 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -48.28 -51.4 26.0 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 116.584 2.068 . . . . 0.0 116.584 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.508 ' HA3' HG13 ' J' ' 39' ' ' VAL . . . -170.51 51.74 0.19 Allowed Glycine 0 CA--C 1.544 1.894 0 C-N-CA 119.341 -1.409 . . . . 0.0 116.319 -176.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.63 113.23 8.44 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-N 121.433 2.617 . . . . 0.0 111.674 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.665 HD12 HG23 ' J' ' 39' ' ' VAL . 52.9 mt -131.07 133.11 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 32.6 mt -110.21 110.23 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.92 106.76 1.88 Allowed Glycine 0 N--CA 1.465 0.572 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 176.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.703 HD12 ' H ' ' P' ' 35' ' ' MET . 15.1 tp -156.06 150.07 25.32 Favored 'General case' 0 CA--C 1.511 -0.547 0 C-N-CA 117.526 -1.67 . . . . 0.0 113.846 -174.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.703 ' H ' HD12 ' P' ' 34' ' ' LEU . 19.9 mtp -122.59 113.71 19.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 113.583 -1.644 . . . . 0.0 108.244 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.779 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 27.1 m -125.3 102.54 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.633 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.56 -163.81 17.68 Favored Glycine 0 N--CA 1.461 0.322 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.301 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.544 ' CA ' ' H ' ' Q' ' 38' ' ' GLY . . . 155.35 -54.64 0.42 Allowed Glycine 0 CA--C 1.544 1.856 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' O' ' 38' ' ' GLY . 43.7 t -131.23 130.99 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 117.608 0.704 . . . . 0.0 109.368 177.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.436 HG13 ' O ' ' P' ' 39' ' ' VAL . 14.7 m . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.005 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . 0.431 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 94.5 m-85 -106.9 133.96 50.77 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.8 158.13 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.775 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 47.6 t -119.61 129.73 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.259 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -137.72 106.24 5.84 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.17 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.427 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 75.2 m80 -127.64 169.59 13.6 Favored 'General case' 0 C--O 1.221 -0.44 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.499 ' CD ' HE21 ' R' ' 15' ' ' GLN . 1.6 pt20 -154.17 141.02 19.16 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.089 178.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -90.96 107.45 19.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.523 178.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -115.15 111.36 20.89 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.88 124.03 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-O 121.046 0.451 . . . . 0.0 111.089 -179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.652 ' CE2' ' CD1' ' P' ' 19' ' ' PHE . 93.4 m-85 -117.64 111.25 18.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.931 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.555 ' CD2' ' CE2' ' P' ' 20' ' ' PHE . 70.0 t80 -115.85 113.58 23.56 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.61 141.53 24.75 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -177.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -117.69 139.18 51.38 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 176.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -171.88 53.27 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.541 -177.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.579 HG23 ' O ' ' Q' ' 24' ' ' VAL . 30.9 m -92.79 131.62 39.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.683 -177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.39 31.58 68.5 Favored Glycine 0 CA--C 1.536 1.365 0 CA-C-N 112.823 -1.99 . . . . 0.0 117.552 172.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 14.9 t -156.83 109.57 2.54 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 122.109 2.954 . . . . 0.0 115.31 175.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.44 ' OD1' ' OD1' ' R' ' 27' ' ' ASN . 14.0 m-20 -53.78 169.97 0.13 Allowed 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 171.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' L' ' 40' ' ' VAL . 55.6 tttt 78.04 42.26 0.11 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 116.327 1.973 . . . . 0.0 116.327 172.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' Q' ' 30' ' ' ALA . . . -80.59 -61.59 2.16 Favored Glycine 0 CA--C 1.55 2.246 0 C-N-CA 118.598 -1.763 . . . . 0.0 114.076 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . 0.516 ' HB2' ' O ' ' Q' ' 29' ' ' GLY . . . 170.84 165.59 0.07 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 118.547 1.174 . . . . 0.0 108.719 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.449 ' CG2' HG21 ' L' ' 39' ' ' VAL . 38.4 pt -145.27 133.58 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 118.659 -1.216 . . . . 0.0 113.995 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -108.27 114.71 47.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.324 179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.9 92.12 0.61 Allowed Glycine 0 N--CA 1.463 0.473 0 N-CA-C 105.211 -3.156 . . . . 0.0 105.211 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.682 HD12 ' O ' ' P' ' 34' ' ' LEU . 24.5 tp -134.98 141.86 46.33 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 122.368 1.08 . . . . 0.0 112.985 -174.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.522 ' H ' HD12 ' Q' ' 34' ' ' LEU . 4.0 mtp -114.45 111.54 21.57 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 113.73 -1.577 . . . . 0.0 107.87 177.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.779 HG22 ' CG2' ' P' ' 36' ' ' VAL . 35.1 t -113.26 123.65 69.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-O 121.96 0.886 . . . . 0.0 109.986 -178.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . 40.27 114.22 0.0 OUTLIER Glycine 0 CA--C 1.533 1.174 0 CA-C-N 113.709 -1.587 . . . . 0.0 113.079 -177.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.544 ' H ' ' CA ' ' P' ' 38' ' ' GLY . . . -70.62 -62.04 3.83 Favored Glycine 0 CA--C 1.539 1.541 0 CA-C-N 115.385 -0.407 . . . . 0.0 113.066 177.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' E' ' 31' ' ' ILE . 55.1 t -119.75 130.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.489 ' O ' HG12 ' Q' ' 40' ' ' VAL . 63.1 t . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.547 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.68 133.73 49.94 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.809 0.338 . . . . 0.0 110.508 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.431 ' OE1' ' O ' ' Q' ' 10' ' ' TYR . 98.4 mt-10 -126.05 111.74 15.06 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.374 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.33 166.26 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.007 0.432 . . . . 0.0 110.721 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.483 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 46.1 p-80 -138.21 102.0 4.55 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.309 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -143.67 168.91 18.79 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.499 HE21 ' CD ' ' Q' ' 15' ' ' GLN . 86.1 mt-30 -100.17 151.11 21.8 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.115 0.484 . . . . 0.0 111.785 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.31 107.85 17.27 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 176.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 59.6 tp -116.11 119.72 36.75 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.935 0.398 . . . . 0.0 111.607 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -121.24 108.86 23.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB3' ' R' ' 21' ' ' ALA . 66.8 t80 -111.58 114.86 28.2 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.82 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -125.18 113.83 18.19 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.438 ' HB3' ' CE2' ' R' ' 19' ' ' PHE . . . -154.64 149.91 27.11 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 119.698 -0.801 . . . . 0.0 112.269 -178.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -131.35 107.2 8.78 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.464 ' HA ' HG12 ' Q' ' 24' ' ' VAL . 46.2 p-10 -170.7 49.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -82.16 150.38 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 177.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.31 -36.46 4.26 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 107.386 -2.286 . . . . 0.0 107.386 -179.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 8.6 t -80.27 118.56 22.05 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-N 112.671 -1.765 . . . . 0.0 112.023 -178.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' R' ' 29' ' ' GLY . 54.9 p30 -91.37 -160.08 0.69 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.424 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -45.59 49.51 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.768 1.627 . . . . 0.0 114.845 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.617 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -82.02 -51.28 4.53 Favored Glycine 0 CA--C 1.55 2.264 0 CA-C-O 119.33 -0.706 . . . . 0.0 113.316 -178.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.98 139.79 53.14 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 119.04 1.42 . . . . 0.0 108.748 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.5 HD12 HG23 ' L' ' 39' ' ' VAL . 59.1 mt -134.57 130.97 53.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -176.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -102.21 108.94 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.35 85.96 0.42 Allowed Glycine 0 CA--C 1.508 -0.35 0 N-CA-C 105.091 -3.203 . . . . 0.0 105.091 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 23.4 tp -126.93 132.05 50.96 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-O 121.56 0.695 . . . . 0.0 112.348 -175.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.6 tpp -105.04 110.14 22.41 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 175.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.543 HG11 HD13 ' P' ' 17' ' ' LEU . 0.2 OUTLIER -104.83 134.52 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.069 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.599 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 24.84 104.24 0.0 OUTLIER Glycine 0 CA--C 1.534 1.246 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.626 -176.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.66 -68.95 1.38 Allowed Glycine 0 CA--C 1.533 1.188 0 CA-C-N 115.548 -0.326 . . . . 0.0 112.405 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.45 137.96 54.19 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 CA-C-O 121.278 0.561 . . . . 0.0 110.232 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.466 HG13 HD21 ' E' ' 27' ' ' ASN . 9.9 p . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.9 -1.048 . . . . 0.0 111.281 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -74.62 126.34 30.61 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -158.34 141.59 15.01 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 121.028 0.442 . . . . 0.0 110.865 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' O ' ' B' ' 12' ' ' VAL . 1.4 p -128.86 131.33 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.744 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.567 ' O ' ' CE1' ' B' ' 13' ' ' HIS . 85.5 m-70 -128.12 116.39 19.89 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 111.632 0.234 . . . . 0.0 111.632 -178.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.761 ' CE1' ' HZ1' ' A' ' 16' ' ' LYS . 26.3 p-80 -157.1 164.81 37.47 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.227 0.537 . . . . 0.0 111.781 178.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -89.84 159.0 17.22 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.507 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.761 ' HZ1' ' CE1' ' A' ' 14' ' ' HIS . 64.8 mttp -139.82 121.36 15.18 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.434 ' HB3' ' CE2' ' A' ' 19' ' ' PHE . 20.5 mt -129.93 121.43 26.59 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 121.71 0.766 . . . . 0.0 110.431 178.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.0 t -112.54 106.06 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.8 -1.091 . . . . 0.0 108.366 178.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 86.6 m-85 -109.29 115.5 30.11 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -141.23 143.18 34.01 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.06 118.09 30.97 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.423 ' HG2' ' N ' ' A' ' 23' ' ' ASP . 78.4 tt0 -101.8 164.8 11.54 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.507 0.67 . . . . 0.0 112.262 -177.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.423 ' N ' ' HG2' ' A' ' 22' ' ' GLU . 54.9 t0 -94.64 46.48 1.14 Allowed 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.34 -178.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.3 t -80.33 179.77 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.168 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.82 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 -35.71 63.18 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.792 -177.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 48.5 t -155.04 112.17 3.32 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 117.762 0.781 . . . . 0.0 111.873 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 64.6 t30 -52.67 -179.4 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.978 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' H ' ' CG ' ' A' ' 27' ' ' ASN . 98.8 mttt -66.84 -38.91 87.31 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.15 68.22 1.46 Allowed Glycine 0 CA--C 1.533 1.2 0 CA-C-O 119.087 -0.841 . . . . 0.0 111.645 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.93 159.3 44.49 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-O 123.91 1.814 . . . . 0.0 115.209 -177.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.599 HG12 HD12 ' B' ' 31' ' ' ILE . 97.1 mt -122.43 123.11 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 110.82 -2.9 . . . . 0.0 107.156 178.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -131.86 133.45 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.81 109.51 0.64 Allowed Glycine 0 CA--C 1.529 0.954 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 81.8 mt -150.87 159.24 44.68 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-O 122.014 0.912 . . . . 0.0 111.895 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 21.5 mtm -145.35 150.89 37.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.856 -1.066 . . . . 0.0 109.092 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 37' ' ' GLY . 56.2 t -118.76 131.97 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.983 0.42 . . . . 0.0 110.27 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -41.11 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.613 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 39' ' ' VAL . . . -103.48 -71.44 0.87 Allowed Glycine 0 CA--C 1.535 1.327 0 CA-C-N 115.343 -0.429 . . . . 0.0 112.348 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.531 HG22 ' N ' ' A' ' 40' ' ' VAL . 6.5 p -32.68 159.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.531 ' N ' HG22 ' A' ' 39' ' ' VAL . 26.6 m . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.69 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.99 139.66 32.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.834 0.35 . . . . 0.0 110.667 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -146.0 143.87 29.74 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.037 0.446 . . . . 0.0 110.411 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 12' ' ' VAL . 57.5 t -125.86 130.76 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.437 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.567 ' CE1' ' O ' ' A' ' 13' ' ' HIS . 1.4 t-80 -150.48 103.83 3.17 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.661 -0.416 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.555 ' O ' ' CD2' ' A' ' 14' ' ' HIS . 4.2 m-70 -134.03 154.5 51.1 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.779 177.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.534 ' OE1' ' NE2' ' C' ' 15' ' ' GLN . 6.3 mt-30 -90.42 161.49 15.53 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.31 105.42 5.23 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.842 HD11 HG11 ' D' ' 36' ' ' VAL . 16.5 mt -119.59 119.09 32.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.378 0.608 . . . . 0.0 110.175 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.45 103.76 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.34 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.678 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 36.8 m-85 -107.73 105.09 14.77 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.594 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 3.4 t80 -124.38 121.46 35.0 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.713 0.292 . . . . 0.0 110.719 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.448 ' HB3' ' HZ1' ' D' ' 28' ' ' LYS . . . -117.35 114.34 23.42 Favored 'General case' 0 C--O 1.247 0.932 0 CA-C-O 121.012 0.434 . . . . 0.0 110.884 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -90.33 91.94 8.7 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 122.026 0.917 . . . . 0.0 108.606 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.647 ' HB3' ' H ' ' C' ' 24' ' ' VAL . 0.3 OUTLIER -88.05 55.06 3.3 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 113.989 -1.459 . . . . 0.0 108.046 179.638 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.421 HG12 ' N ' ' B' ' 25' ' ' GLY . 11.7 t -92.13 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.192 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -73.93 -39.23 47.2 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.092 -1.051 . . . . 0.0 111.109 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.427 ' O ' ' O ' ' B' ' 27' ' ' ASN . 28.0 m -155.2 112.52 3.33 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 119.451 1.626 . . . . 0.0 112.679 177.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' N ' ' B' ' 28' ' ' LYS . 25.1 t-20 -47.7 179.12 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 114.963 -1.017 . . . . 0.0 109.206 176.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 55.0 mttt -77.35 -48.64 16.81 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 118.677 -1.209 . . . . 0.0 109.646 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.4 51.01 3.03 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 120.527 -0.845 . . . . 0.0 112.246 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.65 149.63 52.22 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-N 118.694 1.247 . . . . 0.0 112.038 -177.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.828 HD13 ' O ' ' N' ' 38' ' ' GLY . 6.1 mt -118.64 115.37 47.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.405 ' O ' HG23 ' B' ' 32' ' ' ILE . 19.1 tt -129.23 130.08 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.823 0.82 . . . . 0.0 112.846 -177.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.1 114.1 1.59 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 177.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.441 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 35.8 tp -139.85 130.48 25.76 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.785 -178.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.445 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 60.0 mtp -132.21 137.53 47.61 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 54.1 t -126.05 135.37 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.151 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 176.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.05 103.12 0.35 Allowed Glycine 0 CA--C 1.504 -0.609 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.35 -73.25 0.24 Allowed Glycine 0 CA--C 1.526 0.767 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.13 177.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 40' ' ' VAL . 2.7 p -140.48 154.98 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 110.483 -0.191 . . . . 0.0 110.483 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.527 ' OXT' HG22 ' B' ' 40' ' ' VAL . 14.6 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 117.855 -1.069 . . . . 0.0 110.444 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -109.74 131.06 55.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.93 0.395 . . . . 0.0 110.772 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -144.1 146.65 32.94 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.248 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 37.3 t -119.64 129.52 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.56 ' CD2' ' NZ ' ' K' ' 28' ' ' LYS . 90.1 m-70 -133.23 134.86 44.56 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.941 0.401 . . . . 0.0 110.847 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.637 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 25.3 t60 -164.31 174.79 10.7 Favored 'General case' 0 C--O 1.22 -0.499 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.637 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.8 tt0 -156.2 139.93 16.09 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.024 175.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -97.77 112.5 24.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.673 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.685 ' CD2' HD12 ' B' ' 17' ' ' LEU . 5.4 mt -122.01 110.04 15.32 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-N 119.359 0.981 . . . . 0.0 108.354 176.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -121.28 112.8 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.943 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.678 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 56.3 m-85 -110.59 107.25 16.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.397 179.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.594 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 60.9 t80 -115.46 128.13 55.81 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.8 123.61 14.26 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.533 ' HB3' ' H ' ' B' ' 23' ' ' ASP . 73.8 tt0 -90.51 -178.39 5.31 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 175.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.541 ' OD2' ' N ' ' D' ' 23' ' ' ASP . 14.7 p30 -138.18 49.04 1.94 Allowed 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 115.042 1.497 . . . . 0.0 115.042 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.666 HG12 ' N ' ' C' ' 25' ' ' GLY . 75.6 t -148.41 176.61 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 176.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.666 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 65.28 28.02 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 118.079 -2.01 . . . . 0.0 109.5 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' D' ' 27' ' ' ASN . 15.3 m -81.51 113.55 19.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.682 0.753 . . . . 0.0 111.241 -176.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.534 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 5.7 t-20 -92.13 -162.5 0.93 Allowed 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.604 -1.18 . . . . 0.0 111.134 -178.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 99.0 mttt -42.77 -39.52 2.49 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.73 74.32 0.04 OUTLIER Glycine 0 N--CA 1.48 1.578 0 C-N-CA 119.428 -1.368 . . . . 0.0 113.175 -177.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.43 133.05 46.49 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 118.432 1.116 . . . . 0.0 112.145 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.572 HD11 HG23 ' P' ' 39' ' ' VAL . 78.7 mt -134.55 133.28 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.26 -177.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' C' ' 34' ' ' LEU . 22.2 mt -110.54 109.8 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 176.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.823 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -120.64 96.93 0.62 Allowed Glycine 0 N--CA 1.472 1.047 0 N-CA-C 107.784 -2.126 . . . . 0.0 107.784 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.823 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.9 mp -135.59 151.0 49.84 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.111 1.434 . . . . 0.0 114.855 -175.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.44 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 9.0 ttm -119.15 109.65 16.12 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-N 112.239 -2.255 . . . . 0.0 106.927 176.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.45 104.58 7.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -177.52 -134.59 2.06 Favored Glycine 0 C--N 1.31 -0.894 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.647 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.577 ' O ' HD12 ' J' ' 31' ' ' ILE . . . 86.47 -62.94 4.22 Favored Glycine 0 CA--C 1.547 2.042 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.565 HG12 ' N ' ' C' ' 40' ' ' VAL . 56.9 t -132.02 160.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.565 ' N ' HG12 ' C' ' 39' ' ' VAL . 49.7 t . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.966 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -105.53 133.46 50.24 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.874 0.368 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.29 133.18 39.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.457 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 27.0 m -120.95 130.48 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.516 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.593 ' CD2' ' N ' ' D' ' 14' ' ' HIS . 8.4 t60 -148.09 149.84 32.78 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' N ' ' CD2' ' D' ' 13' ' ' HIS . 19.1 t60 -145.71 153.78 41.35 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.984 178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 25.9 tp60 -98.83 169.83 9.19 Favored 'General case' 0 N--CA 1.457 -0.119 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -158.61 96.66 1.4 Allowed 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.046 176.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.587 HD12 ' N ' ' D' ' 17' ' ' LEU . 1.2 mp -116.98 115.67 25.89 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.864 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.3 t -115.14 103.24 14.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 177.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 79.3 m-85 -106.61 109.0 20.79 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -118.15 125.43 50.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.79 143.72 23.79 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -178.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.1 mt-10 -99.18 166.65 11.13 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.664 177.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.541 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 76.4 m-20 -143.99 47.33 1.43 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' D' ' 26' ' ' SER . 15.7 m -62.81 -166.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 118.118 0.417 . . . . 0.0 110.42 -178.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.39 27.65 9.22 Favored Glycine 0 CA--C 1.529 0.91 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.827 -175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.479 ' H ' HG23 ' D' ' 24' ' ' VAL . 67.5 m -153.18 120.48 5.86 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.457 ' O ' ' OG ' ' C' ' 26' ' ' SER . 55.7 p30 -41.51 155.22 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.328 -178.02 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' B' ' 21' ' ' ALA . 78.9 tttt -75.09 -49.81 18.43 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.201 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.76 51.9 2.56 Favored Glycine 0 CA--C 1.542 1.736 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.994 -177.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.17 141.49 3.82 Favored 'General case' 0 C--O 1.245 0.847 0 CA-C-N 119.112 1.456 . . . . 0.0 113.66 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -137.87 131.09 42.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 CA-C-N 113.313 -1.767 . . . . 0.0 112.144 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 90.0 mt -108.85 110.92 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.37 107.36 2.49 Favored Glycine 0 N--CA 1.464 0.542 0 N-CA-C 105.093 -3.203 . . . . 0.0 105.093 175.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 16.2 tp -141.38 137.32 32.22 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 11.6 mtp -115.47 103.92 11.24 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 113.136 -1.847 . . . . 0.0 106.467 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.842 HG11 HD11 ' B' ' 17' ' ' LEU . 1.2 t -122.15 104.23 14.5 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.634 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.64 -144.95 9.5 Favored Glycine 0 C--N 1.307 -1.042 0 C-N-CA 118.585 -1.769 . . . . 0.0 111.978 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.2 -59.27 0.73 Allowed Glycine 0 CA--C 1.542 1.77 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -177.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.551 HG13 ' O ' ' D' ' 39' ' ' VAL . 9.9 p -161.02 116.59 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 177.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.469 ' C ' ' NE2' ' B' ' 13' ' ' HIS . 2.7 m . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.146 -0.93 . . . . 0.0 110.134 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -106.05 133.37 50.86 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.637 0.256 . . . . 0.0 110.37 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -73.63 142.65 46.5 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -112.15 97.72 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.456 ' H ' ' HB3' ' F' ' 13' ' ' HIS . 39.7 p-80 -151.79 149.39 28.97 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.317 179.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.73 ' CD2' ' H ' ' F' ' 14' ' ' HIS . 28.7 m80 -142.13 160.56 39.99 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.697 178.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -90.13 159.19 16.91 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.5 95.51 2.88 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.45 120.1 41.24 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.143 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 69.5 t -126.35 117.17 47.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -122.01 121.16 36.37 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -124.46 124.1 41.58 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -157.29 155.36 30.6 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 117.75 -1.58 . . . . 0.0 115.25 -178.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD2' ' D' ' 23' ' ' ASP . 97.1 mt-10 -99.09 123.98 43.78 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 104.63 -2.359 . . . . 0.0 104.63 175.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.437 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 20.3 t70 -121.6 54.05 1.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -175.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' D' ' 23' ' ' ASP . 87.0 t -102.38 125.14 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.62 39.02 67.93 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.555 ' OG ' ' N ' ' F' ' 29' ' ' GLY . 0.0 OUTLIER -64.02 101.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -176.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -158.19 163.92 37.05 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.506 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.413 ' H ' HG12 ' R' ' 39' ' ' VAL . 89.4 mttt 30.07 41.53 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 114.005 1.113 . . . . 0.0 114.005 173.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.422 ' O ' ' HB3' ' D' ' 28' ' ' LYS . . . -91.02 -65.21 1.18 Allowed Glycine 0 CA--C 1.545 1.918 0 C-N-CA 117.065 -2.493 . . . . 0.0 116.918 -175.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.33 159.8 31.68 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 120.434 2.117 . . . . 0.0 110.589 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 92.5 mt -131.61 125.0 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.04 -1.064 . . . . 0.0 113.302 178.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' E' ' 34' ' ' LEU . 40.4 mt -106.99 108.67 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.02 115.63 3.03 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 108.579 -1.809 . . . . 0.0 108.579 179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.538 ' O ' ' CB ' ' F' ' 34' ' ' LEU . 1.6 pp -176.06 173.65 2.2 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 117.539 -1.664 . . . . 0.0 113.625 -176.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 16.1 mtm -139.27 126.09 20.85 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 113.369 -1.742 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' D' ' 36' ' ' VAL . 13.4 m -122.38 102.47 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.407 -1.269 . . . . 0.0 110.813 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.18 -163.19 13.4 Favored Glycine 0 CA--C 1.521 0.461 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.994 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' L' ' 31' ' ' ILE . . . 142.42 -55.63 0.58 Allowed Glycine 0 CA--C 1.543 1.833 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.558 HG23 HD12 ' K' ' 31' ' ' ILE . 34.4 t -130.8 129.65 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 175.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.8 t . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 117.727 -1.13 . . . . 0.0 110.531 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.86 131.77 54.68 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.808 0.337 . . . . 0.0 110.372 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -76.71 145.1 38.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.754 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 32.5 m -137.82 169.45 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.443 -179.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.512 ' H ' ' CD2' ' F' ' 13' ' ' HIS . 6.6 p80 -113.17 121.5 44.71 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.055 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.73 ' H ' ' CD2' ' E' ' 14' ' ' HIS . 68.7 m80 -145.13 165.13 29.16 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.088 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -89.84 159.27 17.08 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-O 121.123 0.487 . . . . 0.0 111.416 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.74 113.34 8.53 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -114.68 124.33 51.54 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.943 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -129.76 110.59 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -119.99 128.85 53.94 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.415 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -139.81 121.15 14.96 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 110.846 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.12 141.7 50.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.091 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -106.23 136.97 45.0 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 54.9 60.76 3.29 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.891 177.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.493 ' O ' HG23 ' F' ' 24' ' ' VAL . 10.2 m -66.05 124.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.21 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.18 -31.96 3.91 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 16.0 p -179.01 -117.36 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.981 0.39 . . . . 0.0 111.374 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -54.54 -179.81 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.5 0.667 . . . . 0.0 112.643 -178.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -67.79 -41.05 83.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.735 -1.12 . . . . 0.0 112.378 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.555 ' N ' ' OG ' ' E' ' 26' ' ' SER . . . 98.92 -61.67 0.8 Allowed Glycine 0 CA--C 1.537 1.413 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -176.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.98 150.34 29.4 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.785 HD12 HG22 ' R' ' 39' ' ' VAL . 96.1 mt -118.2 126.15 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 121.699 0.761 . . . . 0.0 111.527 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -112.74 111.44 36.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.784 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.5 104.05 0.87 Allowed Glycine 0 N--CA 1.464 0.526 0 N-CA-C 107.71 -2.156 . . . . 0.0 107.71 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.538 ' CB ' ' O ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -163.87 172.9 13.39 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.26 -176.213 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.5 mtm -131.74 132.22 43.66 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 113.885 -1.507 . . . . 0.0 108.247 177.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.525 HG21 HD23 ' D' ' 17' ' ' LEU . 90.9 t -121.91 102.31 11.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 114.593 -1.185 . . . . 0.0 110.812 -176.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.51 -165.06 22.29 Favored Glycine 0 CA--C 1.521 0.468 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.595 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.35 -54.88 0.43 Allowed Glycine 0 CA--C 1.543 1.807 0 CA-C-N 114.45 -0.875 . . . . 0.0 111.173 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.574 ' HB ' HD11 ' L' ' 31' ' ' ILE . 54.8 t -135.38 129.65 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-N 118.202 1.001 . . . . 0.0 109.379 176.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.401 -179.464 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -83.78 140.81 31.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.755 0.312 . . . . 0.0 110.636 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -138.0 147.06 43.84 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.172 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.512 HG13 ' H ' ' H' ' 12' ' ' VAL . 94.5 t -114.6 93.39 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.363 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' G' ' 14' ' ' HIS . 0.8 OUTLIER -80.23 125.49 29.93 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.852 -178.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.646 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 40.5 t60 -147.79 159.21 44.07 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.641 HE22 HG23 ' J' ' 36' ' ' VAL . 43.5 tt0 -85.54 156.62 20.68 Favored 'General case' 0 CA--C 1.511 -0.54 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.25 97.77 1.26 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.906 -0.718 . . . . 0.0 110.223 178.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.5 mt -130.91 110.4 11.25 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 121.738 0.78 . . . . 0.0 109.665 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.8 p -110.17 108.15 24.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.693 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -106.02 99.3 8.89 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.538 -2.023 . . . . 0.0 105.538 177.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -115.06 118.21 32.74 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.633 ' HB1' ' HD3' ' H' ' 28' ' ' LYS . . . -108.08 114.69 28.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.445 ' C ' ' H ' ' G' ' 24' ' ' VAL . 21.7 pt-20 -157.57 -150.5 0.27 Allowed 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -179.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 67.4 t0 -70.0 46.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.412 . . . . 0.0 110.652 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.467 HG23 ' H ' ' G' ' 26' ' ' SER . 10.6 m -71.46 -168.54 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.17 28.47 15.56 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.467 ' H ' HG23 ' G' ' 24' ' ' VAL . 35.4 t -80.77 113.83 19.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.493 -0.854 . . . . 0.0 109.373 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -92.03 -176.15 4.31 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.878 -178.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -48.74 -40.35 28.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.338 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.28 63.19 0.28 Allowed Glycine 0 CA--C 1.536 1.384 0 CA-C-O 119.519 -0.6 . . . . 0.0 114.201 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.954 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -107.1 101.15 10.58 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.35 1.071 . . . . 0.0 110.297 178.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 79.8 mt -123.77 124.11 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 113.459 -1.7 . . . . 0.0 108.296 179.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -136.97 145.18 30.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.716 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.444 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -166.7 155.36 26.47 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.581 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -147.86 154.57 40.6 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.029 0.443 . . . . 0.0 110.316 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 96.0 mmm -135.57 119.32 17.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.4 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.13 146.32 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 120.379 -0.528 . . . . 0.0 109.922 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.91 102.19 0.38 Allowed Glycine 0 C--N 1.321 -0.256 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.609 ' O ' HD11 ' M' ' 31' ' ' ILE . . . 157.78 -73.98 0.22 Allowed Glycine 0 CA--C 1.533 1.21 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.939 177.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 p -160.17 150.65 5.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-O 120.663 0.268 . . . . 0.0 110.278 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.309 179.487 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -103.63 132.87 49.5 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -74.12 118.49 17.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.55 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.621 HG22 HG12 ' I' ' 12' ' ' VAL . 76.6 t -126.91 130.45 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.983 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 79.2 m80 -129.13 119.25 23.8 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 122.248 -0.283 . . . . 0.0 111.182 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.646 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 1.5 p-80 -149.9 165.39 32.73 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.231 0.538 . . . . 0.0 111.621 178.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.845 HE22 ' H ' ' K' ' 37' ' ' GLY . 99.1 mt-30 -85.25 155.71 21.27 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.047 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -160.1 99.23 1.35 Allowed 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 120.227 -0.589 . . . . 0.0 110.35 178.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.711 HD21 HG21 ' J' ' 36' ' ' VAL . 5.0 mp -133.38 124.96 28.11 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 122.053 0.93 . . . . 0.0 111.604 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -115.24 107.04 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 114.084 -1.416 . . . . 0.0 109.771 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' H' ' 17' ' ' LEU . 43.6 m-85 -107.6 108.07 19.18 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.89 131.61 47.63 Favored 'General case' 0 N--CA 1.48 1.058 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.4 ' CA ' ' NZ ' ' H' ' 28' ' ' LYS . . . -126.96 122.87 35.76 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.459 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.748 ' H ' ' HZ3' ' H' ' 28' ' ' LYS . 47.4 tt0 -93.24 178.15 5.82 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.343 0.592 . . . . 0.0 112.404 -178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.535 ' H ' ' CG ' ' H' ' 22' ' ' GLU . 35.6 t0 -117.01 46.95 1.57 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 31.2 m -73.81 176.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.407 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.21 27.3 7.7 Favored Glycine 0 N--CA 1.471 0.991 0 N-CA-C 114.131 0.412 . . . . 0.0 114.131 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.449 ' O ' ' C ' ' H' ' 27' ' ' ASN . 42.8 t -153.78 120.86 5.71 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 117.823 0.811 . . . . 0.0 109.08 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 47.8 m-80 -41.33 150.26 0.09 Allowed 'General case' 0 CA--C 1.52 -0.209 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.619 -178.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.748 ' HZ3' ' H ' ' H' ' 22' ' ' GLU . 90.4 mttt -75.78 -50.57 14.85 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 119.452 -0.899 . . . . 0.0 112.024 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.954 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 89.07 50.32 3.29 Favored Glycine 0 CA--C 1.544 1.852 0 CA-C-O 118.037 -1.424 . . . . 0.0 112.321 178.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.571 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -130.51 111.46 12.29 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 120.853 2.327 . . . . 0.0 115.893 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 51.6 mt -116.11 117.12 54.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 173.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 68.6 mt -120.98 127.51 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -176.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' G' ' 33' ' ' GLY . . . -132.64 93.79 0.28 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.442 ' O ' HD23 ' I' ' 34' ' ' LEU . 4.4 mp -128.06 140.15 52.12 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 117.806 0.803 . . . . 0.0 111.145 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 83.2 mtp -142.5 137.62 30.36 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.31 146.5 30.89 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 102.36 0.41 Allowed Glycine 0 CA--C 1.508 -0.391 0 C-N-CA 119.978 -1.106 . . . . 0.0 111.858 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.554 ' O ' HG23 ' I' ' 39' ' ' VAL . . . 139.54 -73.02 0.41 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 121.403 -0.427 . . . . 0.0 113.159 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p -156.78 146.71 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.439 0 O-C-N 122.727 -0.278 . . . . 0.0 110.361 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.299 -179.922 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.531 ' CG ' ' O ' ' J' ' 9' ' ' GLY . 94.7 m-85 -108.14 136.34 47.97 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.774 0.321 . . . . 0.0 110.43 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -113.44 126.52 55.43 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.571 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.621 HG12 HG22 ' H' ' 12' ' ' VAL . 11.4 p -127.27 134.7 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.134 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.487 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 75.9 m80 -123.57 155.24 38.01 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.596 ' ND1' ' O ' ' J' ' 14' ' ' HIS . 84.9 t60 -163.31 155.17 17.59 Favored 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.224 176.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.585 ' OE1' HD21 ' J' ' 17' ' ' LEU . 79.8 mt-30 -87.92 159.03 18.52 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 176.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 66.3 tttm -164.49 89.36 0.52 Allowed 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.51 176.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.886 HD11 HG21 ' K' ' 36' ' ' VAL . 10.7 mt -128.89 123.9 33.84 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.22 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 31.4 m -122.89 112.25 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -107.69 106.2 16.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -121.23 124.16 44.0 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 110.77 13.61 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' I' ' 23' ' ' ASP . 97.4 mt-10 -109.11 128.09 54.7 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.163 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OE1' ' J' ' 22' ' ' GLU . 76.7 m-20 22.04 50.01 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.741 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.442 HG23 ' H ' ' I' ' 24' ' ' VAL . 2.2 t -49.98 166.23 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.535 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.64 14.95 0.04 OUTLIER Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.572 ' O ' ' ND2' ' J' ' 27' ' ' ASN . 45.2 t -82.47 142.41 31.92 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.773 ' O ' ' N ' ' I' ' 29' ' ' GLY . 12.9 m120 -72.87 -151.66 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 178.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.639 ' HZ2' ' HZ3' ' J' ' 28' ' ' LYS . 53.4 mttp -52.91 50.75 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 118.391 0.541 . . . . 0.0 110.416 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.773 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . -99.86 -51.15 1.3 Allowed Glycine 0 CA--C 1.536 1.362 0 N-CA-C 116.679 1.432 . . . . 0.0 116.679 -175.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.98 89.17 3.36 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.407 HD13 ' O ' ' C' ' 38' ' ' GLY . 73.4 mt -139.7 111.34 4.89 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 59.6 mt -108.71 125.38 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.026 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.346 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.58 111.21 1.71 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 106.426 -2.669 . . . . 0.0 106.426 176.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.456 HD22 HG13 ' I' ' 36' ' ' VAL . 0.2 OUTLIER -150.32 147.13 27.25 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 117.47 -1.692 . . . . 0.0 114.919 -176.107 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 4.2 ttm -122.69 103.3 8.58 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 113.046 -1.888 . . . . 0.0 107.404 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.573 ' CG2' HD21 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -125.81 123.02 63.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.775 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.63 -112.88 0.54 Allowed Glycine 0 C--N 1.301 -1.413 0 C-N-CA 119.186 -1.483 . . . . 0.0 112.135 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 70.83 -72.93 0.67 Allowed Glycine 0 C--O 1.217 -0.964 0 N-CA-C 107.711 -2.155 . . . . 0.0 107.711 -175.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.554 HG23 ' O ' ' H' ' 38' ' ' GLY . 73.9 t -132.17 131.36 61.06 Favored 'Isoleucine or valine' 0 C--N 1.342 0.256 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 174.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.598 ' OXT' HG13 ' I' ' 40' ' ' VAL . 7.3 p . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.967 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CG ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.2 141.76 51.13 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -73.12 109.46 6.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.726 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.477 ' H ' HG23 ' I' ' 12' ' ' VAL . 60.6 t -135.55 136.92 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.579 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.484 ' CD2' HG21 ' K' ' 40' ' ' VAL . 16.5 t-80 -136.05 97.88 3.73 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.735 -0.211 . . . . 0.0 111.241 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.596 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 67.8 t60 -117.31 157.57 25.86 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.106 0.479 . . . . 0.0 110.445 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.555 ' CD ' HD21 ' K' ' 17' ' ' LEU . 47.3 tt0 -87.22 158.87 19.02 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.513 178.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.724 ' O ' HD23 ' J' ' 17' ' ' LEU . 87.6 tttt -162.77 90.62 0.71 Allowed 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.538 176.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.863 HD22 HD12 ' I' ' 17' ' ' LEU . 8.4 mt -126.79 121.91 33.29 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.259 178.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.63 114.31 46.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.455 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.594 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 28.1 m-85 -110.4 106.92 16.44 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.63 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.3 t80 -117.06 122.11 43.24 Favored 'General case' 0 N--CA 1.476 0.85 0 O-C-N 122.305 -0.247 . . . . 0.0 111.602 -178.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.23 141.73 26.48 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.481 ' OE1' ' N ' ' I' ' 23' ' ' ASP . 92.6 mt-10 -90.96 -168.3 2.04 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 114.833 -1.076 . . . . 0.0 111.503 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.56 ' OD2' ' O ' ' K' ' 24' ' ' VAL . 32.9 t0 -136.53 50.87 2.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 117.099 2.259 . . . . 0.0 117.099 -174.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' J' ' 25' ' ' GLY . 2.5 t -64.25 -139.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 119.642 1.11 . . . . 0.0 108.558 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -119.34 38.16 2.92 Favored Glycine 0 N--CA 1.466 0.662 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.08 120.23 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 113.71 -1.245 . . . . 0.0 111.287 178.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' I' ' 26' ' ' SER . 65.0 t30 -83.19 162.01 21.37 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.639 ' HZ3' ' HZ2' ' I' ' 28' ' ' LYS . 76.2 tttt -46.54 -38.9 10.05 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.29 69.91 0.09 OUTLIER Glycine 0 CA--C 1.542 1.722 0 C-N-CA 119.353 -1.403 . . . . 0.0 115.163 -178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.17 97.82 10.97 Favored 'General case' 0 N--CA 1.484 1.251 0 CA-C-N 119.2 1.5 . . . . 0.0 109.211 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.577 HD12 ' O ' ' C' ' 38' ' ' GLY . 68.8 mt -133.14 132.2 58.57 Favored 'Isoleucine or valine' 0 C--N 1.355 0.821 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -175.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 56.0 mt -115.43 113.09 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 174.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.09 108.19 1.51 Allowed Glycine 0 N--CA 1.464 0.548 0 N-CA-C 106.306 -2.718 . . . . 0.0 106.306 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.958 HD23 ' N ' ' J' ' 35' ' ' MET . 2.8 tt -153.33 150.55 29.02 Favored 'General case' 0 CA--C 1.516 -0.356 0 C-N-CA 117.51 -1.676 . . . . 0.0 114.424 -174.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.958 ' N ' HD23 ' J' ' 34' ' ' LEU . 96.8 mmm -118.99 108.23 14.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 113.325 -1.761 . . . . 0.0 107.445 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.711 HG21 HD21 ' H' ' 17' ' ' LEU . 4.0 p -128.28 123.03 59.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.559 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.2 -113.46 0.77 Allowed Glycine 0 C--N 1.319 -0.363 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.497 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.34 -73.14 2.44 Favored Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 40' ' ' VAL . 3.8 p -144.65 147.24 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.268 0.556 . . . . 0.0 109.579 177.137 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' J' ' 39' ' ' VAL . 32.8 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.043 -179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -79.91 126.49 31.08 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.267 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -155.39 110.61 3.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.326 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -142.88 147.41 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.16 0.505 . . . . 0.0 111.459 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 1.4 m80 -146.96 107.67 4.13 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.521 178.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.58 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 48.5 m80 -127.24 163.12 24.6 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.802 0.81 . . . . 0.0 112.666 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.406 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tt0 -85.19 157.02 20.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.961 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -160.81 94.29 1.03 Allowed 'General case' 0 C--N 1.311 -1.09 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.396 177.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.555 HD21 ' CD ' ' J' ' 15' ' ' GLN . 79.4 mt -121.63 115.8 23.42 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.454 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.6 p -122.64 118.09 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.653 0.74 . . . . 0.0 110.403 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 75.2 m-85 -110.88 113.03 25.29 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.649 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.63 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 44.3 t80 -114.66 111.28 21.06 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -152.43 134.2 14.71 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 118.275 -1.37 . . . . 0.0 113.159 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -96.94 148.76 22.63 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.491 -1.231 . . . . 0.0 107.992 177.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.485 ' C ' ' OD2' ' J' ' 23' ' ' ASP . 49.7 t0 -139.16 46.62 1.93 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 119.617 -0.833 . . . . 0.0 112.446 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.56 ' O ' ' OD2' ' J' ' 23' ' ' ASP . 6.0 p -100.66 160.81 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 118.582 -1.247 . . . . 0.0 108.499 175.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.554 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 72.33 31.75 63.21 Favored Glycine 0 CA--C 1.536 1.394 0 CA-C-O 118.3 -1.278 . . . . 0.0 114.005 174.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.554 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 7.0 t 105.37 130.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 118.4 1.1 . . . . 0.0 113.45 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -68.28 -157.76 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.163 176.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.56 ' NZ ' ' CD2' ' C' ' 13' ' ' HIS . 85.7 mttt 60.83 45.21 10.06 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 114.484 1.29 . . . . 0.0 114.484 176.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.3 -58.03 2.52 Favored Glycine 0 CA--C 1.554 2.48 0 C-N-CA 119.625 -1.274 . . . . 0.0 114.452 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.62 159.0 44.81 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 119.313 1.556 . . . . 0.0 110.147 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.558 HD12 HG23 ' E' ' 39' ' ' VAL . 16.9 tt -137.47 123.03 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 121.649 0.737 . . . . 0.0 112.113 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.444 HG21 HD13 ' K' ' 32' ' ' ILE . 66.8 mt -112.07 122.03 65.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.885 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.3 102.79 0.89 Allowed Glycine 0 N--CA 1.465 0.631 0 N-CA-C 105.379 -3.088 . . . . 0.0 105.379 176.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.46 ' O ' HD12 ' L' ' 34' ' ' LEU . 7.6 tt -148.6 147.1 28.61 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 122.73 1.252 . . . . 0.0 113.846 -173.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 93.8 mmm -112.9 113.27 25.26 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.847 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.886 HG21 HD11 ' I' ' 17' ' ' LEU . 9.3 p -134.21 151.67 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.363 0.601 . . . . 0.0 111.13 -178.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.845 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 98.66 -101.65 2.49 Favored Glycine 0 C--N 1.319 -0.392 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.292 178.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 76.72 -80.9 1.16 Allowed Glycine 0 CA--C 1.535 1.321 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 -178.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 7.4 p -149.76 155.08 8.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 117.091 0.445 . . . . 0.0 110.303 177.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.49 ' N ' HG22 ' K' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.046 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -100.02 133.44 44.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 110.547 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -110.0 122.24 47.1 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.42 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.453 HG12 ' NE2' ' K' ' 14' ' ' HIS . 28.6 t -126.77 127.22 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.993 0.425 . . . . 0.0 110.194 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.476 ' CD2' ' O ' ' K' ' 13' ' ' HIS . 11.0 t-80 -150.86 137.34 18.7 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.774 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.413 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.9 m-70 -154.67 169.91 22.79 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -89.68 150.27 22.41 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.614 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.406 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 68.5 mttm -150.49 101.89 2.99 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.399 0.618 . . . . 0.0 109.507 178.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.607 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -122.58 117.5 26.01 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.271 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . 0.524 ' N ' HD23 ' L' ' 17' ' ' LEU . 53.0 t -124.13 131.36 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 45.7 p90 -136.38 119.23 16.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.042 0.449 . . . . 0.0 110.818 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -116.47 110.09 18.15 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -163.47 165.63 23.57 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 118.702 -1.199 . . . . 0.0 113.255 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 97.5 mt-10 -109.13 139.7 43.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 113.425 -1.716 . . . . 0.0 106.784 176.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 11.1 p30 -158.1 46.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.156 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.785 HG22 ' H ' ' L' ' 25' ' ' GLY . 11.1 p -90.88 -178.62 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 118.521 -1.271 . . . . 0.0 109.787 179.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.785 ' H ' HG22 ' L' ' 24' ' ' VAL . . . 80.7 -31.51 2.47 Favored Glycine 0 CA--C 1.528 0.846 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.775 177.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.529 ' OG ' ' O ' ' L' ' 25' ' ' GLY . 35.6 m 179.66 -119.43 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.791 0 CA-C-O 121.714 0.769 . . . . 0.0 110.999 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 30.2 m120 -57.36 171.24 0.43 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.46 -1.245 . . . . 0.0 114.188 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.84 -39.02 80.02 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.89 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.19 -65.67 0.25 Allowed Glycine 0 CA--C 1.544 1.891 0 CA-C-N 115.143 -0.935 . . . . 0.0 112.292 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.31 159.8 15.11 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.574 HD11 ' HB ' ' F' ' 39' ' ' VAL . 92.3 mt -125.88 120.51 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 CA-C-N 119.403 1.001 . . . . 0.0 111.803 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -113.13 111.84 37.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 176.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.3 87.62 0.47 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 104.141 -3.583 . . . . 0.0 104.141 176.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.786 HD11 HG12 ' K' ' 36' ' ' VAL . 22.7 tp -129.99 138.18 50.68 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.68 0.752 . . . . 0.0 112.499 -174.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.542 ' H ' HD12 ' L' ' 34' ' ' LEU . 92.5 mmm -109.19 115.97 31.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.06 178.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.801 HG11 ' CD1' ' J' ' 17' ' ' LEU . 21.7 m -126.11 152.82 33.77 Favored 'Isoleucine or valine' 0 C--N 1.341 0.231 0 CA-C-O 121.08 0.466 . . . . 0.0 110.905 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.42 -101.89 2.82 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.594 179.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.39 -80.76 0.99 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -178.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.681 HG22 HD12 ' R' ' 31' ' ' ILE . 39.9 t -126.54 131.52 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.943 -179.826 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -87.48 133.35 33.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.871 0.367 . . . . 0.0 110.488 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -93.08 123.77 36.58 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.229 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.487 HG11 ' N ' ' N' ' 13' ' ' HIS . 42.8 t -120.82 133.1 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.293 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m170 -66.13 145.04 56.28 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.592 -177.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -149.88 162.14 40.89 Favored 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.461 178.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.671 HE21 HD11 ' M' ' 17' ' ' LEU . 38.6 tt0 -90.09 158.67 17.19 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.62 100.31 3.83 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.085 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.671 HD11 HE21 ' M' ' 15' ' ' GLN . 76.7 mt -135.46 123.73 23.15 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.846 0.831 . . . . 0.0 110.926 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . 0.415 HG13 ' O ' ' M' ' 18' ' ' VAL . 2.6 p -124.02 111.12 27.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.999 -1.001 . . . . 0.0 108.814 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . 0.483 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 57.1 m-85 -111.08 108.02 17.58 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -126.52 127.51 45.45 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.746 0.308 . . . . 0.0 110.799 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.46 120.64 42.33 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -159.4 -170.17 2.86 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.885 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -47.81 -59.88 2.99 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.67 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 m -84.15 172.16 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.73 -34.42 4.77 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.405 ' C ' ' OD1' ' N' ' 27' ' ' ASN . 2.0 m -80.47 120.19 24.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.602 -0.799 . . . . 0.0 111.189 -179.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.447 ' O ' ' OD1' ' N' ' 27' ' ' ASN . 97.3 m-20 -90.26 164.27 14.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.835 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -42.78 -38.01 1.97 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.56 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.59 74.85 0.07 OUTLIER Glycine 0 CA--C 1.531 1.083 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.568 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.7 109.05 15.75 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -178.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.609 HD11 ' O ' ' G' ' 38' ' ' GLY . 1.4 tt -130.6 116.39 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 tt -157.4 154.7 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 118.37 -1.332 . . . . 0.0 114.01 -178.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.89 125.11 5.05 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -121.55 135.3 55.02 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.022 0.439 . . . . 0.0 110.738 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 7.5 ttm -130.87 122.71 27.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.948 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.2 t -123.92 131.48 72.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.529 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -30.94 -111.24 0.0 OUTLIER Glycine 0 CA--C 1.533 1.209 0 O-C-N 123.631 0.582 . . . . 0.0 113.573 -179.554 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.47 -71.29 0.2 Allowed Glycine 0 N--CA 1.475 1.283 0 C-N-CA 121.522 -0.37 . . . . 0.0 112.91 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.609 HG12 ' N ' ' M' ' 40' ' ' VAL . 88.8 t -55.25 163.92 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.908 0.385 . . . . 0.0 111.738 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.609 ' N ' HG12 ' M' ' 39' ' ' VAL . 76.6 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.298 179.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -107.84 132.15 53.74 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.758 0.313 . . . . 0.0 110.705 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' M' ' 12' ' ' VAL . 81.7 tt0 -74.69 135.48 41.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.286 -0.416 . . . . 0.0 109.971 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.518 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 32.1 m -137.19 159.18 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.487 ' N ' HG11 ' M' ' 12' ' ' VAL . 5.6 t60 -67.55 119.83 12.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -176.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.518 ' CE1' ' O ' ' N' ' 12' ' ' VAL . 3.3 p-80 -153.92 156.32 37.31 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.132 176.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.589 ' NE2' HG12 ' P' ' 36' ' ' VAL . 2.9 mt-30 -90.48 159.95 16.26 Favored 'General case' 0 CA--C 1.522 -0.127 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 176.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -140.35 99.88 3.76 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.293 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.737 HD21 HG11 ' P' ' 36' ' ' VAL . 6.4 mt -124.49 117.52 24.56 Favored 'General case' 0 C--O 1.24 0.59 0 CA-C-O 121.24 0.543 . . . . 0.0 110.836 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 97.0 t -112.23 103.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 177.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 73.1 m-85 -107.27 106.02 16.27 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.628 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 0.8 OUTLIER -131.48 125.25 31.98 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.969 -177.024 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.8 108.07 15.86 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 177.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -158.38 154.55 27.15 Favored 'General case' 0 C--O 1.223 -0.335 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.45 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 52.48 51.65 15.72 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 91.3 t -65.5 146.29 13.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.189 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.2 -24.33 0.79 Allowed Glycine 0 N--CA 1.46 0.25 0 N-CA-C 107.06 -2.416 . . . . 0.0 107.06 178.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.8 p 61.92 119.43 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 114.445 -0.878 . . . . 0.0 112.752 174.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.447 ' OD1' ' O ' ' M' ' 27' ' ' ASN . 3.3 m120 -110.84 169.6 8.66 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 121.03 0.443 . . . . 0.0 110.452 178.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -39.43 -38.48 0.57 Allowed 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 115.705 1.743 . . . . 0.0 115.705 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.92 75.55 0.07 OUTLIER Glycine 0 CA--C 1.534 1.232 0 C-N-CA 118.788 -1.672 . . . . 0.0 114.151 -176.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.21 97.15 6.81 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 118.371 1.086 . . . . 0.0 113.123 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.41 HD13 HG21 ' N' ' 31' ' ' ILE . 75.9 mt -123.81 109.48 23.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 113.961 -1.472 . . . . 0.0 107.916 178.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -111.23 120.08 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.243 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.74 126.09 5.92 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.438 ' H ' ' HB3' ' O' ' 34' ' ' LEU . 6.8 tt -144.98 142.53 29.89 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 117.843 0.822 . . . . 0.0 110.76 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.42 ' CE ' ' SD ' ' O' ' 35' ' ' MET . 10.2 ttm -146.61 130.01 16.75 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -176.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -139.58 144.35 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.24 102.19 0.36 Allowed Glycine 0 CA--C 1.503 -0.701 0 C-N-CA 119.88 -1.152 . . . . 0.0 112.239 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.828 ' O ' HD13 ' B' ' 31' ' ' ILE . . . 167.17 -74.11 0.15 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 119.576 -1.297 . . . . 0.0 114.125 175.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 p -163.07 144.45 2.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.714 0.757 . . . . 0.0 111.218 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 t . . . . . 0 C--O 1.222 -0.373 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.23 179.72 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.09 137.92 51.69 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.846 0.355 . . . . 0.0 110.539 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -95.74 148.68 22.31 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.29 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.48 ' O ' HG21 ' N' ' 12' ' ' VAL . 15.7 m -120.54 132.49 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.432 0.634 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.756 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 88.5 m-70 -82.09 138.73 34.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.448 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' N' ' 14' ' ' HIS . 57.7 t60 -147.56 172.85 13.36 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.553 ' NE2' HG12 ' Q' ' 36' ' ' VAL . 51.9 tt0 -159.86 139.77 11.54 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.15 177.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -105.92 101.29 10.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 118.505 -0.76 . . . . 0.0 112.196 177.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.614 ' N ' HD12 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -115.52 106.38 13.88 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 120.006 1.275 . . . . 0.0 108.52 177.26 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.23 102.96 14.75 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.422 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 65.9 m-85 -107.49 104.26 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.628 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 23.4 t80 -123.05 129.62 51.72 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.81 118.07 20.27 Favored 'General case' 0 C--O 1.252 1.191 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -133.75 98.35 4.16 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 122.881 1.324 . . . . 0.0 108.195 175.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.71 ' H ' HG11 ' P' ' 24' ' ' VAL . 18.7 t0 -75.16 60.93 1.09 Allowed 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 128.386 2.674 . . . . 0.0 113.009 -179.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.8 t -64.08 -111.22 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-O 116.311 -1.804 . . . . 0.0 114.465 -168.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.18 -42.23 10.96 Favored Glycine 0 N--CA 1.482 1.739 0 C-N-CA 115.721 -3.133 . . . . 0.0 120.164 -166.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.47 ' O ' ' O ' ' O' ' 27' ' ' ASN . 90.8 p -162.52 114.5 1.62 Allowed 'General case' 0 N--CA 1.487 1.409 1 CA-C-N 125.275 4.537 . . . . 0.0 117.54 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.1 t-20 -22.73 152.53 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.658 170.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 80.4 mttt -166.13 30.18 0.05 OUTLIER 'General case' 0 N--CA 1.468 0.453 0 O-C-N 122.116 -0.365 . . . . 0.0 110.453 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.21 86.37 0.74 Allowed Glycine 0 CA--C 1.529 0.947 0 C-N-CA 119.214 -1.47 . . . . 0.0 111.211 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.97 101.57 5.9 Favored 'General case' 0 C--O 1.24 0.578 0 CA-C-O 121.748 0.785 . . . . 0.0 109.398 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.573 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 3.2 mt -136.93 131.52 46.66 Favored 'Isoleucine or valine' 0 C--N 1.349 0.57 0 CA-C-N 114.495 -1.23 . . . . 0.0 113.81 -177.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.54 HG23 HD21 ' O' ' 34' ' ' LEU . 47.9 mt -111.3 107.68 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.564 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -121.82 101.97 0.79 Allowed Glycine 0 N--CA 1.469 0.858 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.793 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -157.23 159.72 37.94 Favored 'General case' 0 CA--C 1.515 -0.373 0 C-N-CA 116.971 -1.892 . . . . 0.0 114.103 -178.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.42 ' SD ' ' CE ' ' N' ' 35' ' ' MET . 23.0 mtp -119.77 108.65 14.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 112.028 -2.351 . . . . 0.0 107.349 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -125.92 102.53 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.776 -178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.84 -162.57 13.38 Favored Glycine 0 N--CA 1.46 0.282 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.946 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.59 -55.58 0.54 Allowed Glycine 0 CA--C 1.544 1.89 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -177.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.48 HG23 HD12 ' C' ' 31' ' ' ILE . 42.2 t -120.64 132.79 69.27 Favored 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 177.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' O' ' 39' ' ' VAL . 57.6 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.25 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -83.62 139.98 32.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.982 0.42 . . . . 0.0 110.76 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -140.14 165.37 27.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.785 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.47 HG23 ' O ' ' Q' ' 12' ' ' VAL . 1.3 p -106.68 114.54 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-O 121.403 0.62 . . . . 0.0 110.064 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.756 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 83.5 t60 -101.8 144.44 30.47 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.978 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.634 ' NE2' ' N ' ' Q' ' 16' ' ' LYS . 7.7 t60 -155.12 169.95 22.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.234 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.483 ' H ' ' CD2' ' P' ' 14' ' ' HIS . 71.5 mt-30 -155.6 140.6 17.34 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.012 176.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . 0.493 ' C ' HD12 ' P' ' 17' ' ' LEU . 98.6 mttt -94.54 102.26 14.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 119.003 -0.523 . . . . 0.0 110.225 176.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.855 ' N ' HD12 ' P' ' 17' ' ' LEU . 1.2 mp -109.08 107.61 17.99 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 119.153 0.888 . . . . 0.0 108.965 178.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -109.29 103.8 16.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.618 ' CD1' HD13 ' R' ' 32' ' ' ILE . 57.7 m-85 -104.48 107.39 18.3 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.564 ' CZ ' ' CD1' ' Q' ' 20' ' ' PHE . 5.9 t80 -123.71 117.18 24.38 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-N 117.903 0.32 . . . . 0.0 110.599 -179.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 120.48 26.21 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 120.873 0.368 . . . . 0.0 110.741 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' P' ' 24' ' ' VAL . 98.0 mt-10 -98.1 147.96 24.03 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.682 ' CG ' ' H ' ' Q' ' 24' ' ' VAL . 0.5 OUTLIER -79.36 50.48 1.1 Allowed 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 123.976 1.845 . . . . 0.0 108.032 176.7 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.776 HG13 ' N ' ' P' ' 25' ' ' GLY . 4.2 p -79.04 -140.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 110.33 -3.123 . . . . 0.0 110.768 -177.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.776 ' N ' HG13 ' P' ' 24' ' ' VAL . . . -94.82 37.67 3.35 Favored Glycine 0 C--N 1.306 -1.114 0 C-N-CA 126.813 2.149 . . . . 0.0 108.913 -173.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.48 105.24 2.56 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 112.176 -2.012 . . . . 0.0 108.167 -176.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.595 ' O ' ' O ' ' Q' ' 28' ' ' LYS . 0.1 OUTLIER -117.88 -151.13 0.47 Allowed 'General case' 0 C--O 1.218 -0.576 0 CA-C-N 108.794 -3.821 . . . . 0.0 111.248 -171.537 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -37.08 -40.28 0.29 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 117.124 2.268 . . . . 0.0 117.124 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.69 73.65 0.04 OUTLIER Glycine 0 N--CA 1.501 2.997 0 CA-C-N 125.165 3.62 . . . . 0.0 119.24 178.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 141.25 52.36 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 119.938 1.869 . . . . 0.0 108.215 176.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 10.6 tt -144.23 137.52 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.9 118.96 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.291 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.39 108.26 1.67 Allowed Glycine 0 N--CA 1.464 0.545 0 N-CA-C 107.055 -2.418 . . . . 0.0 107.055 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.793 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.1 mt -145.41 148.89 33.82 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 115.179 1.548 . . . . 0.0 115.179 -175.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.3 mtp -122.13 111.74 17.36 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 113.023 -1.899 . . . . 0.0 106.301 176.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.737 HG11 HD21 ' N' ' 17' ' ' LEU . 2.9 t -124.75 101.92 9.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.858 -177.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.405 ' HA3' HE22 ' N' ' 15' ' ' GLN . . . 98.12 -172.43 26.73 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.068 -1.063 . . . . 0.0 113.063 178.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.404 ' N ' ' HA2' ' Q' ' 37' ' ' GLY . . . 166.92 -53.29 0.24 Allowed Glycine 0 CA--C 1.545 1.943 0 CA-C-N 114.387 -0.907 . . . . 0.0 111.466 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.572 HG23 HD11 ' C' ' 31' ' ' ILE . 46.6 t -121.58 131.07 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 118.465 1.132 . . . . 0.0 108.615 176.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.434 HG13 ' CD2' ' N' ' 13' ' ' HIS . 32.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.989 -1.005 . . . . 0.0 111.056 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -106.55 130.97 54.23 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.845 0.355 . . . . 0.0 110.57 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.401 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 79.5 mm-40 -126.53 133.42 51.13 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.47 ' O ' HG23 ' P' ' 12' ' ' VAL . 34.8 m -136.9 160.4 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.56 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.472 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 38.1 t60 -123.66 118.3 26.95 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.343 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 47.3 m-70 -150.92 172.26 15.95 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.135 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -154.07 140.67 18.91 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . 0.634 ' N ' ' NE2' ' P' ' 14' ' ' HIS . 38.1 mtmt -92.55 103.39 15.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.077 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' Q' ' 17' ' ' LEU . 5.0 tt -115.11 110.63 19.83 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.479 ' N ' HD23 ' Q' ' 17' ' ' LEU . 40.9 t -114.18 112.94 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -116.12 110.67 19.16 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.235 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.564 ' CD1' ' CZ ' ' P' ' 20' ' ' PHE . 56.6 t80 -118.51 116.77 27.36 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.58 133.64 21.47 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 122.138 0.971 . . . . 0.0 113.243 -178.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.417 ' C ' ' OD2' ' P' ' 23' ' ' ASP . 69.8 mm-40 -88.41 156.03 19.36 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.255 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.61 ' CG ' HG22 ' R' ' 24' ' ' VAL . 11.8 p-10 -134.42 49.93 2.21 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.086 0.469 . . . . 0.0 111.021 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.817 HG12 ' H ' ' Q' ' 25' ' ' GLY . 6.7 t -80.48 -143.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.817 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -90.86 -37.21 6.46 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 115.537 0.975 . . . . 0.0 115.537 -174.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 13.0 t -80.65 117.53 21.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.805 1.803 . . . . 0.0 112.454 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -90.48 -151.14 0.24 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 113.86 -1.518 . . . . 0.0 111.15 178.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' P' ' 27' ' ' ASN . 83.1 mttt 46.36 44.57 12.82 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 177.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.47 -58.84 2.64 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 119.813 -1.184 . . . . 0.0 113.141 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . 0.406 ' H ' ' CB ' ' R' ' 30' ' ' ALA . . . -170.14 158.79 7.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 119.823 1.812 . . . . 0.0 111.656 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' K' ' 39' ' ' VAL . 95.7 mt -125.99 120.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.796 178.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 65.5 mt -108.72 107.68 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.93 102.7 1.25 Allowed Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 105.644 -2.983 . . . . 0.0 105.644 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.984 HD23 ' N ' ' Q' ' 35' ' ' MET . 3.3 tt -146.68 149.55 33.68 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 118.66 -1.216 . . . . 0.0 113.064 -174.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.984 ' N ' HD23 ' Q' ' 34' ' ' LEU . 5.3 ttm -118.08 112.13 19.81 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 113.163 -1.835 . . . . 0.0 108.146 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.553 HG12 ' NE2' ' O' ' 15' ' ' GLN . 0.0 OUTLIER -104.26 102.95 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-O 121.787 0.803 . . . . 0.0 108.928 179.545 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.404 ' HA2' ' N ' ' P' ' 38' ' ' GLY . . . 55.32 161.08 0.01 OUTLIER Glycine 0 CA--C 1.524 0.654 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.252 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.49 -55.39 0.59 Allowed Glycine 0 CA--C 1.542 1.751 0 CA-C-N 115.142 -0.529 . . . . 0.0 112.229 177.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.37 133.43 67.95 Favored 'Isoleucine or valine' 0 C--N 1.344 0.365 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.539 ' CG1' ' CG ' ' O' ' 13' ' ' HIS . 93.1 t . . . . . 0 C--N 1.321 -0.649 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.365 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -110.92 136.1 50.45 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.819 0.343 . . . . 0.0 110.547 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 80.2 mm-40 -73.03 154.29 40.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.974 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.31 130.82 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.911 0.386 . . . . 0.0 110.429 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -140.66 95.61 2.89 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.418 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 96.5 m-70 -150.54 172.91 14.73 Favored 'General case' 0 C--O 1.22 -0.46 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 178.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -128.12 150.71 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.533 0.683 . . . . 0.0 112.066 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -97.03 103.23 15.14 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 114.897 -1.047 . . . . 0.0 109.418 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 33.7 mt -118.93 114.85 23.21 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.163 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . 0.418 ' O ' HG13 ' R' ' 18' ' ' VAL . 11.0 p -126.18 128.1 71.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 53.0 p90 -140.27 127.12 20.6 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.194 0.521 . . . . 0.0 111.557 -178.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -119.79 109.91 16.16 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 177.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.63 148.3 45.68 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.122 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.411 ' O ' ' OD2' ' Q' ' 23' ' ' ASP . 80.1 mm-40 -81.68 133.23 35.34 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.256 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -111.79 47.31 1.05 Allowed 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -177.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.723 HG23 ' H ' ' R' ' 26' ' ' SER . 2.5 m -83.54 -158.76 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.534 ' N ' HG23 ' R' ' 24' ' ' VAL . . . -82.74 -34.66 21.46 Favored Glycine 0 N--CA 1.474 1.22 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 -177.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.723 ' H ' HG23 ' R' ' 24' ' ' VAL . 15.4 m -91.55 121.81 33.57 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -74.48 -179.4 4.0 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -172.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -50.99 -40.18 57.4 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 113.133 -1.848 . . . . 0.0 114.953 -174.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 -61.78 0.59 Allowed Glycine 0 CA--C 1.536 1.392 0 C-N-CA 118.473 -1.822 . . . . 0.0 112.984 -178.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' H ' ' Q' ' 30' ' ' ALA . . . -109.88 163.92 13.08 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -175.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.681 HD12 HG22 ' L' ' 39' ' ' VAL . 96.1 mt -135.96 147.18 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 122.067 0.937 . . . . 0.0 112.924 -176.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.618 HD13 ' CD1' ' P' ' 19' ' ' PHE . 96.5 mt -120.54 117.03 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.162 0 CA-C-N 114.2 -1.364 . . . . 0.0 110.388 178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.18 95.64 0.84 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 105.976 -2.85 . . . . 0.0 105.976 176.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.451 HD11 ' CG2' ' Q' ' 36' ' ' VAL . 27.3 tp -124.57 135.49 53.19 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -176.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 94.9 mmm -114.14 104.4 12.07 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 174.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' R' ' 37' ' ' GLY . 0.0 OUTLIER -99.15 123.3 51.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -179.809 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . 36.82 114.31 0.0 OUTLIER Glycine 0 CA--C 1.532 1.142 0 CA-C-N 114.622 -1.172 . . . . 0.0 113.275 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.79 -63.16 4.84 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 121.663 -0.303 . . . . 0.0 112.407 178.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.785 HG22 HD12 ' F' ' 31' ' ' ILE . 21.8 t -110.69 130.05 64.76 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 66.4 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.498 179.72 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -114.69 136.28 53.24 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.72 0.295 . . . . 0.0 110.307 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -141.63 142.96 33.41 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.003 0.43 . . . . 0.0 111.09 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.495 ' CG1' ' NE2' ' A' ' 14' ' ' HIS . 86.2 t -125.29 97.79 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.467 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.422 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 65.3 m170 -112.13 143.47 43.11 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.906 0.321 . . . . 0.0 110.868 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.827 ' HD1' ' H ' ' B' ' 14' ' ' HIS . 64.9 m-70 -145.83 157.01 43.94 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.817 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.534 HE21 HD21 ' A' ' 17' ' ' LEU . 46.8 tt0 -90.47 160.43 16.02 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.759 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.7 pttt -140.09 103.32 4.59 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.434 177.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.534 HD21 HE21 ' A' ' 15' ' ' GLN . 60.0 mt -120.54 118.12 29.38 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-O 120.958 0.409 . . . . 0.0 110.263 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.654 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.4 m -123.69 108.15 20.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 9.5 m-85 -127.12 124.69 39.74 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -157.53 159.17 36.89 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 118.5 -1.28 . . . . 0.0 113.866 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -109.0 117.99 35.65 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 114.502 -1.226 . . . . 0.0 108.549 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.49 ' O ' HG23 ' A' ' 24' ' ' VAL . 69.7 mt-10 -147.91 -163.78 1.85 Allowed 'General case' 0 N--CA 1.462 0.17 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' A' ' 24' ' ' VAL . 68.3 t0 -21.09 -48.16 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 O-C-N 123.765 0.666 . . . . 0.0 112.342 179.026 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.543 ' O ' ' O ' ' A' ' 23' ' ' ASP . 24.6 t 44.91 169.58 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-O 121.387 0.613 . . . . 0.0 111.425 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -178.72 19.47 0.04 OUTLIER Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 8.7 t -80.4 -130.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -100.54 162.15 13.13 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 121.9 0.857 . . . . 0.0 112.675 -178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -38.82 -38.96 0.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 114.205 -1.361 . . . . 0.0 113.784 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.5 70.5 0.11 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.686 -0.565 . . . . 0.0 111.686 -176.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.97 140.67 47.54 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 122.915 1.341 . . . . 0.0 113.682 -176.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.476 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.2 tt -128.04 123.87 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 112.492 -2.14 . . . . 0.0 107.438 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -121.65 131.02 74.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.814 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 104.56 0.6 Allowed Glycine 0 CA--C 1.53 1.019 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 74.9 mt -126.13 131.82 51.98 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-O 121.373 0.606 . . . . 0.0 110.613 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -117.36 124.6 49.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.23 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.59 HG12 ' N ' ' A' ' 37' ' ' GLY . 33.7 t -140.04 170.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.59 ' N ' HG12 ' A' ' 36' ' ' VAL . . . -168.21 94.17 0.11 Allowed Glycine 0 C--N 1.302 -1.336 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.532 ' O ' HD13 ' H' ' 31' ' ' ILE . . . 166.25 -81.3 0.11 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 119.954 -1.117 . . . . 0.0 112.974 178.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.484 HG23 HD12 ' G' ' 31' ' ' ILE . 51.3 t -133.05 133.8 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.107 0.453 . . . . 0.0 110.532 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.508 HG12 ' O ' ' A' ' 40' ' ' VAL . 66.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.568 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -107.62 139.92 41.43 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.669 0.271 . . . . 0.0 110.468 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -70.54 130.98 43.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.914 0.388 . . . . 0.0 110.322 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 12' ' ' VAL . 58.2 t -130.82 131.93 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.082 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -121.97 120.71 35.22 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.761 0.315 . . . . 0.0 110.379 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.827 ' H ' ' HD1' ' A' ' 14' ' ' HIS . 0.4 OUTLIER -156.98 169.28 25.19 Favored 'General case' 0 C--O 1.225 -0.218 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.417 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.642 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 0.0 OUTLIER -155.72 140.62 17.24 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.333 0.587 . . . . 0.0 109.74 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.521 ' C ' HD12 ' B' ' 17' ' ' LEU . 82.2 tttt -94.42 115.0 27.11 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 114.308 1.225 . . . . 0.0 114.308 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.761 HD21 HG21 ' D' ' 36' ' ' VAL . 11.1 mp -118.51 110.84 17.87 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 174.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -125.7 109.47 21.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.621 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 177.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.482 ' CE1' ' CD2' ' A' ' 19' ' ' PHE . 8.8 m-85 -122.83 125.65 45.84 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 114.463 -1.244 . . . . 0.0 108.626 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -152.04 151.71 31.49 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 117.836 -1.545 . . . . 0.0 113.736 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.83 126.03 50.9 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 114.376 -1.284 . . . . 0.0 111.372 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -113.59 161.49 17.36 Favored 'General case' 0 CA--C 1.541 0.618 0 CA-C-O 121.603 0.716 . . . . 0.0 111.73 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.93 -60.92 2.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.503 1.298 . . . . 0.0 114.503 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 34.3 m -80.04 152.88 4.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.734 0.778 . . . . 0.0 112.335 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.98 36.3 5.03 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-N 114.278 -1.328 . . . . 0.0 110.725 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' C' ' 26' ' ' SER . 12.8 t -71.44 103.29 2.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.337 -0.931 . . . . 0.0 112.249 179.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -115.9 169.68 9.05 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 120.131 -0.627 . . . . 0.0 110.61 178.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -37.87 -39.07 0.34 Allowed 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 114.281 1.215 . . . . 0.0 114.281 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.14 74.15 0.04 OUTLIER Glycine 0 CA--C 1.539 1.532 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.236 -177.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.74 146.56 49.77 Favored 'General case' 0 C--O 1.242 0.676 0 CA-C-O 122.122 0.963 . . . . 0.0 113.404 -177.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.436 HD11 HD12 ' A' ' 31' ' ' ILE . 41.6 pt -136.54 139.2 45.55 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.196 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.62 119.78 62.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.457 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.81 103.78 0.98 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 107.871 -2.092 . . . . 0.0 107.871 178.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.732 ' HB2' HD13 ' C' ' 34' ' ' LEU . 41.3 mt -131.93 141.94 49.49 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.342 -177.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 18.2 ttm -139.48 123.67 17.95 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 53.4 t -130.83 143.71 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 174.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.73 102.45 0.38 Allowed Glycine 0 N--CA 1.461 0.317 0 C-N-CA 119.862 -1.161 . . . . 0.0 112.736 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 146.68 -73.55 0.3 Allowed Glycine 0 N--CA 1.472 1.068 0 C-N-CA 120.46 -0.876 . . . . 0.0 114.37 175.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.433 HG23 HD11 ' H' ' 31' ' ' ILE . 25.1 t -133.96 131.45 56.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 O-C-N 122.341 -0.505 . . . . 0.0 110.273 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 90.3 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.455 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . 0.531 ' CD1' ' O ' ' D' ' 9' ' ' GLY . 95.8 m-85 -101.68 132.42 47.38 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.01 145.65 38.05 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 121.077 0.465 . . . . 0.0 111.351 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.8 t -120.97 129.41 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 74.1 m-70 -144.15 115.82 8.19 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.646 ' CE1' ' H ' ' D' ' 14' ' ' HIS . 18.8 m-70 -154.59 168.97 24.97 Favored 'General case' 0 C--O 1.218 -0.586 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.664 HE21 ' NE2' ' D' ' 15' ' ' GLN . 0.0 OUTLIER -155.17 140.97 18.12 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 120.121 -0.632 . . . . 0.0 109.351 177.714 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.536 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.3 mttt -93.24 112.61 24.59 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 114.859 1.429 . . . . 0.0 114.859 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.536 HD12 ' C ' ' C' ' 16' ' ' LYS . 9.8 mp -113.51 111.21 21.54 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 174.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.42 HG13 ' HA ' ' B' ' 18' ' ' VAL . 4.0 p -123.31 106.19 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.551 0 CA-C-O 122.214 1.006 . . . . 0.0 108.957 178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' CD2' ' E' ' 34' ' ' LEU . 9.3 m-85 -110.62 111.87 23.38 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.866 -1.901 . . . . 0.0 105.866 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -121.88 130.33 53.27 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.85 0.357 . . . . 0.0 111.549 -176.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.04 127.48 34.17 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 115.132 1.53 . . . . 0.0 115.132 -178.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -156.62 82.37 0.96 Allowed 'General case' 0 C--O 1.224 -0.261 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.407 ' OD1' ' CA ' ' D' ' 25' ' ' GLY . 41.6 p-10 -125.94 53.52 1.59 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 -172.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' D' ' 24' ' ' VAL . 24.4 m -91.22 132.02 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.898 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.02 30.42 65.54 Favored Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.883 -178.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' B' ' 26' ' ' SER . 7.5 t -99.92 -120.44 0.15 Allowed 'General case' 0 C--N 1.359 0.992 0 CA-C-N 119.036 1.418 . . . . 0.0 111.403 -179.22 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.467 ' O ' ' ND2' ' D' ' 27' ' ' ASN . 28.9 p30 -85.73 157.64 20.23 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 117.748 -1.581 . . . . 0.0 111.588 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.51 -40.77 27.88 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 174.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.78 66.75 0.04 OUTLIER Glycine 0 CA--C 1.552 2.395 0 CA-C-O 118.758 -1.023 . . . . 0.0 112.623 -175.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.0 150.69 45.4 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 120.266 2.033 . . . . 0.0 113.519 -176.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.576 HD12 ' HB ' ' O' ' 39' ' ' VAL . 67.1 mt -133.84 134.77 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -177.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.512 ' CG2' HD21 ' D' ' 34' ' ' LEU . 70.1 mt -109.4 112.3 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 175.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.46 100.93 0.79 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 105.346 -3.102 . . . . 0.0 105.346 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.761 HD12 ' N ' ' C' ' 35' ' ' MET . 1.5 tp -149.25 141.55 24.13 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.769 1.271 . . . . 0.0 112.596 -174.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.761 ' N ' HD12 ' C' ' 34' ' ' LEU . 80.1 mtp -121.28 108.89 14.28 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 113.273 -1.785 . . . . 0.0 107.841 179.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -95.9 102.43 13.53 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 C-N-CA 119.13 -1.028 . . . . 0.0 109.747 -177.78 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . 29.17 -162.03 0.0 OUTLIER Glycine 0 N--CA 1.476 1.33 0 CA-C-N 114.41 -1.268 . . . . 0.0 114.778 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' D' ' 38' ' ' GLY . . . -116.56 -60.65 0.32 Allowed Glycine 0 CA--C 1.544 1.859 0 CA-C-N 114.878 -0.661 . . . . 0.0 112.119 178.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' I' ' 31' ' ' ILE . 2.9 t -77.18 166.08 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 O-C-N 122.205 -0.585 . . . . 0.0 109.668 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.48 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 5.7 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.466 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -113.16 134.64 54.46 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.784 0.325 . . . . 0.0 110.427 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' E' ' 11' ' ' GLU . 84.5 tt0 -80.39 112.75 18.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.141 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.15 131.72 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.842 0.353 . . . . 0.0 111.62 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' E' ' 13' ' ' HIS . 99.0 m-70 -122.13 95.57 4.7 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.646 ' H ' ' CE1' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -137.38 171.91 13.77 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 -178.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.664 ' NE2' HE21 ' C' ' 15' ' ' GLN . 49.9 tt0 -155.48 140.67 17.52 Favored 'General case' 0 C--O 1.231 0.088 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.273 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 61.9 tttt -92.44 109.14 20.53 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 113.4 0.889 . . . . 0.0 113.4 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.849 HD21 HG21 ' F' ' 36' ' ' VAL . 10.9 mp -110.78 112.14 23.79 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 77.5 t -124.8 106.22 16.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.61 0.719 . . . . 0.0 110.678 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' E' ' 19' ' ' PHE . 2.3 m-85 -113.66 109.97 19.45 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.99 121.84 39.84 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 121.982 -0.449 . . . . 0.0 111.566 -176.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.61 116.7 20.02 Favored 'General case' 0 C--O 1.242 0.678 0 CA-C-O 122.182 0.991 . . . . 0.0 111.085 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.481 ' O ' ' C ' ' D' ' 23' ' ' ASP . 93.8 mt-10 -133.81 162.51 31.81 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.373 179.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.552 ' H ' ' CB ' ' E' ' 23' ' ' ASP . 93.5 m-20 35.45 53.75 0.79 Allowed 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 65.8 t -41.48 150.86 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.832 -175.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.407 ' CA ' ' OD1' ' C' ' 23' ' ' ASP . . . -160.04 19.15 0.24 Allowed Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.122 -176.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' E' ' 29' ' ' GLY . 6.8 t -71.5 129.55 39.06 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 117.984 -1.486 . . . . 0.0 108.931 -175.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.467 ' ND2' ' O ' ' C' ' 27' ' ' ASN . 58.2 m-80 -91.21 -160.19 0.7 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 112.789 -2.005 . . . . 0.0 112.242 -176.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.88 -41.08 4.93 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 113.73 -1.577 . . . . 0.0 112.451 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.541 ' HA2' HG21 ' P' ' 39' ' ' VAL . . . -161.19 63.47 0.28 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 117.894 -2.098 . . . . 0.0 118.188 -175.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.96 108.05 16.0 Favored 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 175.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.615 HD11 ' HB ' ' P' ' 39' ' ' VAL . 43.3 mt -132.71 131.61 59.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.518 HG22 HD11 ' E' ' 34' ' ' LEU . 91.0 mt -109.9 109.43 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 174.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.38 100.27 0.95 Allowed Glycine 0 N--CA 1.464 0.55 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' C' ' 32' ' ' ILE . 92.2 mt -131.3 138.02 49.07 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 114.65 1.352 . . . . 0.0 114.65 -175.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mmm -112.89 102.2 10.22 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 103.978 -2.601 . . . . 0.0 103.978 174.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.761 HG21 HD21 ' B' ' 17' ' ' LEU . 15.8 t -99.37 102.77 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 C-N-CA 119.542 -0.863 . . . . 0.0 112.34 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 43.78 162.82 0.01 OUTLIER Glycine 0 CA--C 1.526 0.774 0 CA-C-N 113.606 -1.633 . . . . 0.0 114.446 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.477 ' N ' ' O ' ' C' ' 38' ' ' GLY . . . -97.04 -57.87 1.06 Allowed Glycine 0 CA--C 1.54 1.648 0 CA-C-N 114.04 -1.08 . . . . 0.0 111.903 178.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.517 ' CG2' HD11 ' J' ' 31' ' ' ILE . 48.8 t -110.36 133.78 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 O-C-N 122.222 -0.575 . . . . 0.0 111.169 -179.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.412 ' O ' HG12 ' D' ' 39' ' ' VAL . 34.4 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.518 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -108.09 135.29 49.69 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 120.742 0.306 . . . . 0.0 110.224 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.442 ' O ' ' O ' ' D' ' 11' ' ' GLU . 80.2 mm-40 -85.33 118.59 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.419 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -122.64 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' O ' ' O ' ' D' ' 13' ' ' HIS . 45.3 m-70 -84.04 167.36 16.92 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 111.478 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.535 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 6.8 m170 -106.41 173.43 6.32 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.419 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 88.5 mt-30 -91.89 148.88 21.88 Favored 'General case' 0 CA--C 1.517 -0.314 0 CA-C-O 121.276 0.56 . . . . 0.0 110.725 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -101.59 114.58 28.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.965 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -97.89 109.25 22.04 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -127.65 116.05 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.167 0 CA-C-O 121.488 0.661 . . . . 0.0 111.075 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.611 ' CE2' HD12 ' F' ' 32' ' ' ILE . 1.0 OUTLIER -136.6 115.62 12.37 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.68 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -123.43 128.65 50.15 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 118.527 0.603 . . . . 0.0 111.204 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.692 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -136.18 132.24 35.68 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 115.032 1.493 . . . . 0.0 115.032 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 74.6 tt0 -159.0 169.86 23.37 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 113.698 -1.592 . . . . 0.0 109.802 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.552 ' CB ' ' H ' ' D' ' 23' ' ' ASP . 5.2 m-20 87.03 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 CA-C-O 120.95 0.405 . . . . 0.0 110.471 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -63.48 -159.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 122.017 0.913 . . . . 0.0 112.015 -176.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.46 -36.95 3.52 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -176.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 3.3 m -94.88 121.81 36.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 172.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.419 ' O ' ' N ' ' E' ' 29' ' ' GLY . 96.7 m-20 -72.81 148.2 44.76 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 116.791 -1.964 . . . . 0.0 113.652 -176.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.5 ' HB3' ' N ' ' F' ' 30' ' ' ALA . 24.0 mttt -56.34 49.16 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.97 0 CA-C-N 112.72 -2.037 . . . . 0.0 113.126 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . -82.42 50.84 4.41 Favored Glycine 0 CA--C 1.548 2.152 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.079 -175.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.524 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -120.93 137.69 54.49 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 117.453 0.627 . . . . 0.0 110.838 177.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.714 HD11 HG11 ' Q' ' 39' ' ' VAL . 67.0 mt -119.4 116.82 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.188 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.923 HG23 HD13 ' E' ' 34' ' ' LEU . 3.6 mt -108.26 109.72 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.709 ' C ' HD12 ' E' ' 34' ' ' LEU . . . -118.23 93.28 0.56 Allowed Glycine 0 N--CA 1.469 0.839 0 N-CA-C 105.597 -3.001 . . . . 0.0 105.597 177.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.923 HD13 HG23 ' E' ' 32' ' ' ILE . 10.9 mp -122.1 131.44 53.97 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -173.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 mtp -114.26 101.42 9.17 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 175.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.511 ' CG1' HE21 ' B' ' 15' ' ' GLN . 2.2 t -119.77 123.09 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.48 -113.85 1.05 Allowed Glycine 0 C--N 1.315 -0.629 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.063 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.73 -71.96 0.92 Allowed Glycine 0 CA--C 1.537 1.44 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.602 HG22 HD12 ' L' ' 31' ' ' ILE . 39.8 t -132.54 134.49 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.487 ' OXT' HG12 ' E' ' 40' ' ' VAL . 70.3 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.28 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.41 135.37 54.17 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.841 0.353 . . . . 0.0 110.423 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -136.92 158.04 45.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.446 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.418 ' O ' ' CD2' ' F' ' 13' ' ' HIS . 59.1 t -106.6 109.33 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.023 0.439 . . . . 0.0 110.968 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.418 ' CD2' ' O ' ' F' ' 12' ' ' VAL . 30.1 m-70 -149.18 104.8 3.44 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.834 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.535 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 74.6 m80 -148.92 162.92 38.91 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -90.04 158.97 17.08 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.352 0.596 . . . . 0.0 111.347 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.23 95.16 2.84 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.8 mt -124.28 120.54 32.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -177.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -131.75 109.02 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.488 ' O ' ' O ' ' F' ' 20' ' ' PHE . 61.8 m-85 -102.81 141.39 35.69 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -176.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.601 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 20.1 p90 -22.3 -149.79 0.0 OUTLIER 'General case' 0 C--O 1.199 -1.587 0 N-CA-C 118.937 2.94 . . . . 0.0 118.937 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 173.26 -175.0 0.06 Allowed 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.768 -173.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.478 ' CB ' ' O ' ' F' ' 21' ' ' ALA . 60.8 mt-10 133.87 -174.15 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.723 1.609 . . . . 0.0 107.446 -177.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -120.94 54.89 1.07 Allowed 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 176.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.406 ' O ' HG13 ' F' ' 24' ' ' VAL . 10.7 p -66.59 134.83 29.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 114.964 -1.016 . . . . 0.0 111.746 -178.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.93 -31.66 2.04 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 108.501 -1.839 . . . . 0.0 108.501 177.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.3 t -81.26 -129.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.628 -0.786 . . . . 0.0 110.012 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -99.91 161.02 13.87 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -43.27 -40.38 3.45 Favored 'General case' 0 C--O 1.232 0.156 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.985 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' E' ' 28' ' ' LYS . . . 100.62 -62.42 0.61 Allowed Glycine 0 CA--C 1.542 1.752 0 C-N-CA 121.463 -0.398 . . . . 0.0 113.25 177.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.524 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -110.86 157.48 19.79 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -178.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.831 HD11 HG23 ' R' ' 39' ' ' VAL . 97.5 mt -134.19 128.88 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.611 HD12 ' CE2' ' E' ' 19' ' ' PHE . 72.8 mt -104.85 105.49 18.7 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.56 86.75 0.5 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 103.344 -3.902 . . . . 0.0 103.344 175.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -120.32 134.04 55.34 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -173.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.429 ' O ' ' O ' ' E' ' 36' ' ' VAL . 95.7 mmm -115.75 110.31 18.92 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 176.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.849 HG21 HD21 ' D' ' 17' ' ' LEU . 0.0 OUTLIER -105.76 123.82 60.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 121.447 0.642 . . . . 0.0 110.233 -178.877 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 115.91 0.01 OUTLIER Glycine 0 CA--C 1.527 0.822 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.966 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.74 -62.52 4.95 Favored Glycine 0 CA--C 1.537 1.434 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.921 HG12 HD11 ' L' ' 31' ' ' ILE . 5.1 p -141.97 137.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.345 0.377 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.471 ' CG2' ' CG ' ' D' ' 13' ' ' HIS . 12.7 p . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.5 ' CE2' ' O ' ' G' ' 11' ' ' GLU . 88.5 t80 -72.12 135.05 46.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.998 0.428 . . . . 0.0 110.827 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.5 ' O ' ' CE2' ' G' ' 10' ' ' TYR . 83.3 tt0 -71.78 146.28 48.18 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.637 HG23 ' O ' ' G' ' 12' ' ' VAL . 10.4 m -110.04 109.29 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.073 0.464 . . . . 0.0 110.229 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.534 ' CE1' ' OE2' ' H' ' 11' ' ' GLU . 6.1 p80 -73.12 137.8 45.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.598 -177.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -150.71 162.98 39.65 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.491 178.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -84.89 154.8 22.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -160.46 105.24 1.45 Allowed 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.498 ' CD1' HG21 ' I' ' 36' ' ' VAL . 27.7 mt -131.47 121.05 23.86 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.634 0.73 . . . . 0.0 111.572 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 67.7 t -117.3 110.53 31.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.293 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.447 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 65.2 m-85 -109.69 106.92 16.77 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.421 ' CZ ' ' CD1' ' H' ' 20' ' ' PHE . 2.6 t80 -113.51 120.03 39.6 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.25 112.77 25.42 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 121.199 0.523 . . . . 0.0 111.328 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.436 ' O ' ' ND2' ' H' ' 27' ' ' ASN . 67.0 tt0 -143.82 167.17 22.94 Favored 'General case' 0 CA--C 1.529 0.157 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -73.52 49.59 0.29 Allowed 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 119.029 -1.068 . . . . 0.0 111.372 -179.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.721 HG12 ' N ' ' G' ' 25' ' ' GLY . 95.1 t -156.36 178.74 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.721 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 61.39 28.92 70.23 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 120.774 -0.727 . . . . 0.0 113.449 177.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 43.7 t -154.15 111.37 3.41 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 118.42 1.11 . . . . 0.0 112.122 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.541 ' C ' ' HZ2' ' H' ' 28' ' ' LYS . 98.8 m-20 -53.22 172.49 0.06 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.067 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.404 ' N ' ' HZ3' ' H' ' 28' ' ' LYS . 66.0 tttm -60.46 -39.22 86.79 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.35 0.595 . . . . 0.0 110.555 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -104.55 70.23 0.25 Allowed Glycine 0 CA--C 1.538 1.481 0 CA-C-N 115.034 -0.985 . . . . 0.0 112.404 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.61 85.34 2.91 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 122.916 1.341 . . . . 0.0 113.181 -177.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.508 HG23 ' O ' ' G' ' 31' ' ' ILE . 9.5 tt -141.16 121.31 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 CA-C-N 112.875 -1.966 . . . . 0.0 105.881 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -127.53 134.15 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -176.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.41 110.09 0.68 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 106.695 -2.562 . . . . 0.0 106.695 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' G' ' 35' ' ' MET . 32.8 tp -163.97 163.83 23.36 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 118.037 -1.465 . . . . 0.0 114.136 -177.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.461 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 78.8 mmm -115.35 130.68 56.97 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.111 178.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.85 142.25 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 118.158 0.435 . . . . 0.0 110.829 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.64 -101.47 0.36 Allowed Glycine 0 C--N 1.314 -0.689 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.23 -80.68 1.75 Allowed Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.529 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.7 p -137.09 161.06 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.818 0.342 . . . . 0.0 110.388 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.529 ' N ' HG22 ' G' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.019 -0.991 . . . . 0.0 111.0 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -82.81 138.24 34.05 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.923 0.392 . . . . 0.0 110.36 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.534 ' OE2' ' CE1' ' G' ' 13' ' ' HIS . 84.2 tt0 -94.54 146.32 24.19 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.67 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.2 t -113.05 98.94 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.607 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 1.6 t-80 -123.07 141.31 52.11 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.761 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.649 ' N ' ' ND1' ' H' ' 13' ' ' HIS . 5.9 p-80 -151.15 158.58 44.17 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.223 178.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.663 HE21 HD11 ' H' ' 17' ' ' LEU . 45.7 tt0 -86.63 156.76 19.89 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.996 177.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -160.59 107.28 1.52 Allowed 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.588 178.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.718 HD21 HG11 ' J' ' 36' ' ' VAL . 9.1 mt -127.32 123.42 36.3 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.36 0.6 . . . . 0.0 111.21 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.81 108.06 23.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 177.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 88.5 m-85 -108.08 110.34 21.99 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.421 ' CD1' ' CZ ' ' G' ' 20' ' ' PHE . 5.6 t80 -120.02 125.22 47.82 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 122.56 -0.087 . . . . 0.0 111.083 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 128.65 44.52 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 120.792 0.33 . . . . 0.0 111.379 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.413 ' OE2' ' OE1' ' G' ' 22' ' ' GLU . 85.7 mt-10 -87.52 -172.67 4.0 Favored 'General case' 0 C--N 1.349 0.552 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.46 ' CB ' ' H ' ' I' ' 24' ' ' VAL . 1.6 m-20 -149.88 51.29 0.92 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.956 -1.474 . . . . 0.0 111.084 -175.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.441 HG12 ' H ' ' H' ' 25' ' ' GLY . 2.2 t -100.15 -141.06 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -174.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.569 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -71.07 -34.14 64.94 Favored Glycine 0 N--CA 1.461 0.308 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.955 -172.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.569 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 12.0 t 139.59 113.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 174.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' G' ' 22' ' ' GLU . 28.3 t-20 -57.01 170.57 0.43 Allowed 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.878 -1.51 . . . . 0.0 108.938 175.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.541 ' HZ2' ' C ' ' G' ' 27' ' ' ASN . 98.6 mttt -58.97 -41.36 87.33 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.353 178.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.6 62.27 0.5 Allowed Glycine 0 N--CA 1.474 1.222 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -177.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.15 150.98 21.8 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-O 122.811 1.291 . . . . 0.0 113.638 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.532 HD13 ' O ' ' A' ' 38' ' ' GLY . 94.0 mt -126.06 124.94 67.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 112.509 -2.132 . . . . 0.0 108.712 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.594 HG22 HD11 ' I' ' 34' ' ' LEU . 64.2 mt -113.97 127.12 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 121.068 0.461 . . . . 0.0 111.366 -179.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.37 101.83 0.51 Allowed Glycine 0 CA--C 1.531 1.036 0 N-CA-C 108.076 -2.009 . . . . 0.0 108.076 178.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 19.1 tp -142.31 143.25 32.7 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.999 -177.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 89.8 mtp -135.02 147.83 49.77 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.178 -0.609 . . . . 0.0 112.583 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.7 t -107.55 133.81 51.2 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.31 102.99 0.32 Allowed Glycine 0 C--N 1.316 -0.571 0 CA-C-O 118.526 -1.152 . . . . 0.0 110.684 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.472 ' O ' ' C ' ' H' ' 39' ' ' VAL . . . 124.73 76.35 0.29 Allowed Glycine 0 N--CA 1.484 1.891 0 CA-C-N 119.8 1.8 . . . . 0.0 114.365 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.472 ' C ' ' O ' ' H' ' 38' ' ' GLY . 3.9 p -6.23 122.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.409 ' H ' HG22 ' H' ' 40' ' ' VAL . 8.2 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.457 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.344 -1.503 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -130.79 140.61 50.3 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.3 109.11 19.29 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.6 ' CG1' ' HE2' ' I' ' 14' ' ' HIS . 71.1 t -130.02 132.08 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.315 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.61 ' CD2' HG12 ' K' ' 40' ' ' VAL . 12.5 t-80 -145.65 137.25 25.14 Favored 'General case' 0 C--O 1.22 -0.454 0 CA-C-O 120.685 0.279 . . . . 0.0 110.607 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.6 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 73.7 m-70 -146.26 176.36 9.81 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.627 HE21 ' NE2' ' H' ' 15' ' ' GLN . 26.1 tt0 -137.94 140.71 40.41 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' O ' HD23 ' I' ' 17' ' ' LEU . 60.2 mttp -130.47 109.52 10.76 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 119.139 -0.458 . . . . 0.0 110.257 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.497 HD22 HD12 ' H' ' 17' ' ' LEU . 10.5 mt -117.83 115.09 24.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 119.017 0.826 . . . . 0.0 109.573 178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -115.75 109.62 28.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.503 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 77.9 m-85 -108.48 105.62 15.35 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.624 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.1 t80 -117.54 121.02 39.85 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.714 0.292 . . . . 0.0 110.874 -178.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.775 ' HB3' ' HZ1' ' K' ' 28' ' ' LYS . . . -136.54 128.26 28.98 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 122.312 1.053 . . . . 0.0 111.597 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.549 ' HG2' HG23 ' I' ' 24' ' ' VAL . 73.5 tt0 -81.08 170.9 15.61 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.117 -1.401 . . . . 0.0 108.561 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' J' ' 24' ' ' VAL . 1.0 OUTLIER -150.48 54.85 0.91 Allowed 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -176.188 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.549 HG23 ' HG2' ' I' ' 22' ' ' GLU . 5.3 t -91.63 -124.59 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.593 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -73.9 -34.2 56.35 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 117.459 -1.745 . . . . 0.0 111.567 -172.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.593 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.9 p 102.0 110.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 119.766 1.783 . . . . 0.0 114.535 175.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 37.9 p30 -70.85 177.99 3.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.86 -1.064 . . . . 0.0 111.735 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -53.47 -36.97 62.21 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.97 77.29 0.47 Allowed Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.549 -1.31 . . . . 0.0 113.647 -179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.77 29.68 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.886 0.851 . . . . 0.0 111.278 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.553 HD11 ' CG2' ' C' ' 39' ' ' VAL . 52.8 mt -127.89 129.16 69.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.453 -1.249 . . . . 0.0 112.201 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.516 HG23 HD13 ' I' ' 34' ' ' LEU . 60.2 mt -109.7 119.18 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 177.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.831 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -129.61 99.04 0.45 Allowed Glycine 0 N--CA 1.47 0.922 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.831 HD12 ' C ' ' I' ' 33' ' ' GLY . 6.9 mp -142.01 149.62 40.25 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 122.846 1.308 . . . . 0.0 114.077 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 85.3 mmm -116.29 102.74 9.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 113.126 -1.852 . . . . 0.0 106.148 177.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.513 HG23 ' O ' ' I' ' 36' ' ' VAL . 19.4 m -124.35 103.62 12.76 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.35 -152.52 24.14 Favored Glycine 0 C--N 1.308 -1.004 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.47 ' O ' HD13 ' O' ' 31' ' ' ILE . . . 88.39 -57.29 4.21 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 35.3 m -110.45 135.29 49.97 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 C-N-CA 123.288 0.635 . . . . 0.0 110.279 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.542 HG12 ' O ' ' I' ' 40' ' ' VAL . 95.0 t . . . . . 0 N--CA 1.471 0.597 0 CA-C-O 117.889 -1.053 . . . . 0.0 112.046 -178.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 42.7 p90 -146.59 160.56 42.01 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.721 0.296 . . . . 0.0 110.732 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -100.23 125.18 46.37 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.957 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' J' ' 13' ' ' HIS . 3.1 p -133.48 134.91 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.863 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CG ' ' J' ' 14' ' ' HIS . 5.6 m80 -142.36 159.66 41.8 Favored 'General case' 0 C--O 1.222 -0.385 0 CA-C-O 121.073 0.463 . . . . 0.0 111.209 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' O ' ' J' ' 13' ' ' HIS . 59.5 m80 -162.6 172.65 15.07 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' OE1' ' I' ' 15' ' ' GLN . 7.6 tt0 -159.63 139.48 11.61 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 119.135 -1.026 . . . . 0.0 111.135 177.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -106.34 113.81 27.56 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.558 -1.201 . . . . 0.0 111.82 177.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.466 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 1.5 mm? -111.52 105.8 14.48 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 119.909 1.231 . . . . 0.0 107.788 176.222 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -111.55 111.3 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.363 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.318 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.579 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 46.4 m-85 -108.6 104.77 14.15 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.624 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 31.0 t80 -114.77 121.55 43.66 Favored 'General case' 0 N--CA 1.476 0.829 0 O-C-N 122.302 -0.249 . . . . 0.0 111.003 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.16 136.47 13.02 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 114.093 1.146 . . . . 0.0 114.093 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -92.54 175.11 6.95 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.155 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.546 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 46.1 t0 -148.33 49.67 1.03 Allowed 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.606 ' N ' ' OD2' ' I' ' 23' ' ' ASP . 52.0 t -105.52 140.8 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 172.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.69 37.58 67.24 Favored Glycine 0 N--CA 1.474 1.17 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.759 174.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.565 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 18.4 p -63.82 102.06 0.43 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -175.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' J' ' 28' ' ' LYS . 20.5 t-20 -160.86 152.05 18.95 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.526 -0.47 . . . . 0.0 111.536 173.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' J' ' 27' ' ' ASN . 64.7 mttp 30.22 42.2 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 172.153 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.76 -63.0 1.22 Allowed Glycine 0 CA--C 1.547 2.071 0 C-N-CA 118.525 -1.798 . . . . 0.0 116.654 -174.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.13 141.21 13.67 Favored 'General case' 0 C--O 1.245 0.854 0 CA-C-N 121.725 2.762 . . . . 0.0 114.736 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.522 HD12 HG23 ' C' ' 39' ' ' VAL . 89.3 mt -130.41 125.39 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.915 177.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.737 HG22 HD11 ' K' ' 34' ' ' LEU . 51.2 mt -122.86 122.51 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.93 113.83 2.05 Favored Glycine 0 C--O 1.237 0.331 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.644 HD23 ' O ' ' I' ' 34' ' ' LEU . 0.3 OUTLIER -154.58 141.74 19.42 Favored 'General case' 0 CA--C 1.507 -0.699 0 C-N-CA 117.483 -1.687 . . . . 0.0 113.19 -175.076 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 19.0 mtp -111.46 106.9 15.93 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 113.912 -1.494 . . . . 0.0 107.719 177.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.718 HG11 HD21 ' H' ' 17' ' ' LEU . 1.6 t -120.04 123.16 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 108.39 -0.966 . . . . 0.0 108.39 -179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.64 -113.86 1.14 Allowed Glycine 0 C--N 1.315 -0.589 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.44 ' O ' ' CG2' ' K' ' 39' ' ' VAL . . . 72.85 -72.33 1.07 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-N 115.157 -0.522 . . . . 0.0 111.929 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' I' ' 40' ' ' VAL . 1.9 p -137.76 164.81 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 117.338 0.569 . . . . 0.0 109.782 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.408 ' H ' HG22 ' J' ' 39' ' ' VAL . 96.5 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.205 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 99.8 m-85 -112.47 136.1 52.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.67 0.271 . . . . 0.0 110.392 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -116.86 113.45 22.5 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.747 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -120.88 95.37 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.971 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.504 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 4.0 p80 -153.06 148.43 27.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.414 ' HB3' ' H ' ' L' ' 14' ' ' HIS . 9.0 p-80 -145.98 161.9 39.05 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.454 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -90.1 159.43 16.8 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.757 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -140.27 107.49 5.5 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -115.62 119.91 37.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.662 -179.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' K' ' 18' ' ' VAL . 14.5 p -130.42 121.92 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-O 121.143 0.497 . . . . 0.0 111.052 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' L' ' 19' ' ' PHE . 64.3 m-85 -112.33 116.29 30.12 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.696 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.533 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 38.6 t80 -115.61 108.37 16.32 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.401 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -158.46 169.34 24.67 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 117.542 -1.663 . . . . 0.0 114.924 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -89.14 119.28 29.5 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.994 179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' L' ' 27' ' ' ASN . 11.5 t70 -103.6 47.26 0.89 Allowed 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.458 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.455 ' O ' ' OG ' ' L' ' 26' ' ' SER . 15.4 m -63.77 -160.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 120.843 0.354 . . . . 0.0 110.63 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.16 -34.84 7.89 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p -92.81 124.79 37.06 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.565 ' O ' ' CB ' ' J' ' 26' ' ' SER . 2.7 t-20 -72.91 148.51 44.28 Favored 'General case' 0 C--O 1.215 -0.76 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.097 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.775 ' HZ1' ' HB3' ' I' ' 21' ' ' ALA . 70.2 tttt -53.0 -49.38 66.31 Favored 'General case' 0 N--CA 1.472 0.654 0 O-C-N 124.419 1.075 . . . . 0.0 113.211 -177.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.534 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . 90.04 50.37 3.07 Favored Glycine 0 CA--C 1.544 1.878 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.999 -178.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.8 139.18 50.18 Favored 'General case' 0 CA--C 1.504 -0.814 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.515 HG23 ' O ' ' K' ' 31' ' ' ILE . 13.9 tt -131.86 119.95 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.891 -179.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.626 HG23 HD13 ' K' ' 34' ' ' LEU . 87.8 mt -106.83 114.66 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.541 177.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -125.11 93.39 0.44 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 106.687 -2.565 . . . . 0.0 106.687 178.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' K' ' 33' ' ' GLY . 8.3 mp -138.2 150.57 46.87 Favored 'General case' 0 CA--C 1.507 -0.678 0 CA-C-O 123.237 1.494 . . . . 0.0 112.802 -177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 93.1 mmm -107.4 105.83 15.95 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 112.296 -2.229 . . . . 0.0 106.017 176.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' L' ' 35' ' ' MET . 4.1 m -121.12 123.87 70.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.27 -114.53 2.71 Favored Glycine 0 C--N 1.316 -0.557 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.482 ' O ' ' CG1' ' L' ' 39' ' ' VAL . . . 73.38 -72.16 1.21 Allowed Glycine 0 C--O 1.216 -0.986 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.443 ' O ' ' O ' ' K' ' 40' ' ' VAL . 25.5 t -120.01 123.68 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.61 HG12 ' CD2' ' I' ' 13' ' ' HIS . 3.9 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.291 -176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -149.49 159.51 44.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.706 0.289 . . . . 0.0 110.296 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.526 ' OE1' ' N ' ' L' ' 11' ' ' GLU . 57.6 mp0 -139.99 157.61 45.39 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.93 0.395 . . . . 0.0 110.493 -179.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.557 HG22 ' N ' ' L' ' 13' ' ' HIS . 2.7 p -140.53 166.2 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.916 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.557 ' N ' HG22 ' L' ' 12' ' ' VAL . 81.4 t60 -96.51 108.23 20.77 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.428 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.414 ' H ' ' HB3' ' K' ' 14' ' ' HIS . 42.3 m-70 -151.8 169.19 22.83 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.07 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -89.77 151.02 22.02 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 120.565 0.221 . . . . 0.0 110.737 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -149.33 107.23 3.7 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 53.6 mt -120.94 124.55 45.19 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 78.3 t -127.28 117.29 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 120.963 0.411 . . . . 0.0 110.339 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 77.8 m-85 -113.24 114.47 26.77 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -128.86 126.81 40.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.616 0.722 . . . . 0.0 110.031 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -158.14 156.85 31.65 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.329 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -91.53 149.1 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.209 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.488 ' O ' ' O ' ' K' ' 23' ' ' ASP . 96.2 m-20 58.76 48.47 11.35 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 110.109 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.432 HG12 ' N ' ' L' ' 25' ' ' GLY . 6.6 t -72.12 161.31 4.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.316 -178.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.04 -33.1 6.06 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -178.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' K' ' 24' ' ' VAL . 94.1 p -81.19 -129.15 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 117.24 0.52 . . . . 0.0 110.577 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.497 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 21.7 t-20 -99.93 160.64 14.15 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 121.306 0.574 . . . . 0.0 112.071 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -43.88 -40.24 4.41 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 114.943 -1.026 . . . . 0.0 113.493 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.437 ' O ' ' CG ' ' K' ' 27' ' ' ASN . . . 101.35 -62.59 0.55 Allowed Glycine 0 CA--C 1.544 1.901 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.1 169.29 8.88 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.921 HD11 HG12 ' F' ' 39' ' ' VAL . 97.2 mt -115.33 112.64 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 119.365 0.984 . . . . 0.0 109.801 177.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 80.0 mt -108.54 114.68 47.34 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.745 178.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 90.41 0.45 Allowed Glycine 0 C--N 1.331 0.304 0 N-CA-C 105.643 -2.983 . . . . 0.0 105.643 177.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.593 HD21 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -129.2 141.52 51.13 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -175.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.51 ' O ' ' O ' ' K' ' 36' ' ' VAL . 93.9 mmm -108.22 103.83 13.1 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 28.8 t -117.57 102.5 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 123.77 0.669 . . . . 0.0 110.844 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.62 163.85 22.5 Favored Glycine 0 N--CA 1.463 0.463 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.037 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.56 -55.9 0.34 Allowed Glycine 0 CA--C 1.542 1.741 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.421 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.482 ' CG1' ' O ' ' K' ' 38' ' ' GLY . 2.7 p -148.19 138.74 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 117.614 0.707 . . . . 0.0 109.956 177.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.784 -1.103 . . . . 0.0 109.837 179.833 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -113.92 139.46 49.18 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -82.29 115.33 21.31 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.927 0.394 . . . . 0.0 110.821 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -127.93 130.33 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.054 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -84.52 114.31 21.85 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.955 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.587 ' CG ' ' N ' ' M' ' 15' ' ' GLN . 3.8 t60 -160.58 172.23 17.53 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.351 -178.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.587 ' N ' ' CG ' ' M' ' 14' ' ' HIS . 43.0 tt0 -153.8 140.18 18.66 Favored 'General case' 0 C--N 1.342 0.252 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -93.72 115.77 28.22 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.667 HD11 HG21 ' O' ' 36' ' ' VAL . 87.2 mt -122.97 112.64 18.05 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 118.739 0.7 . . . . 0.0 109.799 176.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . 0.573 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.0 m -120.6 106.53 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.242 178.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' O' ' 32' ' ' ILE . 9.8 m-85 -110.56 109.7 20.13 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -138.08 151.4 47.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.335 -0.546 . . . . 0.0 111.79 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . 0.641 ' HB1' ' H ' ' N' ' 28' ' ' LYS . . . -126.82 128.29 46.33 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.478 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -141.88 -170.55 3.16 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' M' ' 23' ' ' ASP . 68.5 t0 -76.82 46.76 0.47 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.654 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.44 ' H ' HG22 ' M' ' 24' ' ' VAL . 3.9 m -71.24 -168.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.94 28.13 17.08 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' N' ' 28' ' ' LYS . 29.2 t -81.09 114.93 20.27 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.66 -179.15 5.97 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 122.052 0.93 . . . . 0.0 113.033 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -55.77 -39.17 70.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.867 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.21 68.47 0.44 Allowed Glycine 0 CA--C 1.534 1.262 0 C-N-CA 121.076 -0.583 . . . . 0.0 113.636 -176.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.8 106.8 11.62 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.341 0.591 . . . . 0.0 110.128 178.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 38.3 pt -125.65 134.66 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.623 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.34 127.68 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.844 -178.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.61 115.31 2.58 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 89.1 mt -137.84 142.96 40.76 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 117.818 0.809 . . . . 0.0 111.496 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mtp -143.38 127.62 17.66 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.699 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -136.58 123.41 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.149 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -48.65 113.62 1.64 Allowed Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' N' ' 37' ' ' GLY . . . -71.28 72.32 0.77 Allowed Glycine 0 N--CA 1.471 1.029 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.89 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 12.8 p -127.45 144.37 37.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.732 179.659 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -111.61 134.98 52.81 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.73 0.3 . . . . 0.0 110.264 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -138.85 109.98 6.85 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 121.075 0.464 . . . . 0.0 110.774 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -126.96 132.01 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.115 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.57 123.59 20.27 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 120.217 -0.593 . . . . 0.0 111.569 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.581 ' O ' ' ND1' ' M' ' 14' ' ' HIS . 23.3 p-80 -152.49 154.1 34.81 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.503 175.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' M' ' 15' ' ' GLN . 43.8 tp60 -96.55 161.81 13.74 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -128.75 101.37 6.09 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 175.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.772 HD11 HG11 ' P' ' 36' ' ' VAL . 64.4 mt -108.43 110.51 22.06 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 t -112.39 98.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.53 ' CD2' ' CE1' ' O' ' 19' ' ' PHE . 8.5 m-30 -103.98 107.34 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 105.517 -2.031 . . . . 0.0 105.517 177.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -135.64 127.28 28.98 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -175.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.11 118.89 34.62 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 176.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -95.0 162.56 13.68 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 67.3 t0 -88.59 47.13 1.46 Allowed 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 114.413 -1.267 . . . . 0.0 111.212 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.28 -161.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.97 -33.56 32.87 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.014 -177.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' N' ' 27' ' ' ASN . 92.5 p -153.22 120.96 6.01 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 118.753 1.276 . . . . 0.0 112.304 176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' N' ' 26' ' ' SER . 96.4 m-20 -42.32 -178.84 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.802 175.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.641 ' H ' ' HB1' ' M' ' 21' ' ' ALA . 88.6 tttt -74.74 -41.07 60.8 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.701 178.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.42 66.77 1.58 Allowed Glycine 0 CA--C 1.539 1.59 0 CA-C-O 118.722 -1.044 . . . . 0.0 111.33 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.27 150.01 30.93 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 120.313 2.056 . . . . 0.0 114.343 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 90.2 mt -112.73 118.27 57.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 175.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -120.41 126.85 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.94 106.53 1.46 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 177.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.5 tt -131.73 142.21 49.73 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-N 118.249 1.024 . . . . 0.0 111.749 -177.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 78.0 mtp -143.96 131.49 21.08 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' N' ' 37' ' ' GLY . 77.5 t -125.56 131.68 71.82 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.518 ' H ' ' H ' ' M' ' 38' ' ' GLY . . . -35.89 -111.48 0.0 OUTLIER Glycine 0 CA--C 1.535 1.31 0 N-CA-C 114.229 0.452 . . . . 0.0 114.229 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.84 -70.14 0.06 OUTLIER Glycine 0 CA--C 1.538 1.475 0 O-C-N 122.648 -0.325 . . . . 0.0 112.991 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.596 HG22 ' CG1' ' O' ' 39' ' ' VAL . 94.9 t -60.73 133.05 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 C-N-CA 122.387 0.275 . . . . 0.0 111.133 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.812 -1.09 . . . . 0.0 110.396 179.73 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' P' ' 9' ' ' GLY . 53.2 p90 -148.76 162.3 40.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.74 0.305 . . . . 0.0 110.282 179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.416 ' H ' ' HG2' ' P' ' 11' ' ' GLU . 98.3 mt-10 -138.69 111.76 7.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.122 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.556 HG12 ' H ' ' P' ' 12' ' ' VAL . 30.9 m -127.74 135.47 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.837 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.536 ' O ' ' CG ' ' P' ' 13' ' ' HIS . 0.0 OUTLIER -137.3 123.06 19.96 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.629 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 52.2 m-70 -136.9 158.77 43.7 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.519 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' P' ' 15' ' ' GLN . 96.9 mt-30 -90.5 159.61 16.42 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.607 ' C ' HD12 ' O' ' 17' ' ' LEU . 99.2 mttt -140.41 95.58 2.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.618 ' HG ' HD12 ' N' ' 17' ' ' LEU . 10.0 mp -112.3 112.78 24.61 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -115.01 100.93 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' N' ' 19' ' ' PHE . 8.1 m-30 -109.18 112.27 24.34 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CD1' ' P' ' 20' ' ' PHE . 2.3 t80 -131.22 128.59 40.25 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.134 0.492 . . . . 0.0 112.015 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.72 119.18 27.28 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.531 ' O ' ' N ' ' O' ' 24' ' ' VAL . 76.5 tt0 -110.09 127.24 54.75 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' P' ' 22' ' ' GLU . 40.4 m-20 11.6 51.96 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 177.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.531 ' N ' ' O ' ' O' ' 22' ' ' GLU . 86.3 t -50.75 152.69 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 119.403 -0.919 . . . . 0.0 109.59 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.01 -27.69 0.14 Allowed Glycine 0 N--CA 1.464 0.557 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -80.2 -130.47 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -177.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.509 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 26.9 m120 -100.83 167.41 10.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.378 0.609 . . . . 0.0 111.487 -177.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.593 ' N ' ' HB3' ' P' ' 28' ' ' LYS . 25.7 pttm -35.16 -39.86 0.12 Allowed 'General case' 0 CA--C 1.503 -0.854 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.537 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' O' ' 28' ' ' LYS . . . 91.35 -65.71 2.46 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -169.85 164.47 9.78 Favored 'General case' 0 N--CA 1.432 -1.371 0 CA-C-O 124.09 1.9 . . . . 0.0 114.821 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.47 HD13 ' O ' ' I' ' 38' ' ' GLY . 96.7 mt -122.59 112.76 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 109.981 -3.281 . . . . 0.0 106.465 176.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.441 HD13 ' CD2' ' M' ' 19' ' ' PHE . 28.5 mt -100.91 110.03 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' P' ' 33' ' ' GLY . . . -115.29 107.56 1.77 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 pp -166.63 166.47 16.03 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 116.474 -2.09 . . . . 0.0 114.733 -178.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 23.8 mtp -125.16 121.19 33.5 Favored 'General case' 0 N--CA 1.439 -1.02 0 CA-C-N 111.99 -2.368 . . . . 0.0 108.162 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.694 HG13 ' O ' ' O' ' 36' ' ' VAL . 6.3 p -140.41 102.58 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 109.946 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.1 -162.45 12.79 Favored Glycine 0 N--CA 1.467 0.742 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.446 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.431 ' H ' ' HA2' ' P' ' 37' ' ' GLY . . . 147.69 -55.43 0.51 Allowed Glycine 0 CA--C 1.545 1.959 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.596 ' CG1' HG22 ' N' ' 39' ' ' VAL . 4.8 p -141.25 168.66 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.463 ' H ' HG22 ' O' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.602 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' O' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.93 151.07 43.98 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.416 ' HG2' ' H ' ' O' ' 11' ' ' GLU . 97.9 mt-10 -77.51 110.02 11.94 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.378 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.556 ' H ' HG12 ' O' ' 12' ' ' VAL . 2.3 p -141.04 136.96 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.948 0.404 . . . . 0.0 111.386 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.536 ' CG ' ' O ' ' O' ' 13' ' ' HIS . 2.1 t-80 -129.42 125.88 37.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.476 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.629 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 4.4 p80 -146.59 161.08 41.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.032 0.444 . . . . 0.0 110.466 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.558 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 3.0 tt0 -90.34 159.56 16.56 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.3 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -140.16 99.86 3.77 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 176.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.495 HD22 HD22 ' O' ' 17' ' ' LEU . 12.0 mt -120.96 121.3 37.71 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.641 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . 0.497 HG13 ' O ' ' P' ' 18' ' ' VAL . 8.0 p -127.57 109.81 20.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.445 ' CD2' HD13 ' R' ' 32' ' ' ILE . 4.5 m-30 -112.45 119.92 39.86 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.709 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CD1' ' CE1' ' O' ' 20' ' ' PHE . 29.5 t80 -122.14 125.77 46.88 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.14 123.79 29.32 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' O' ' 23' ' ' ASP . 81.2 tt0 -146.87 99.44 3.19 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' P' ' 22' ' ' GLU . 99.7 m-20 -144.34 50.83 1.29 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.741 -176.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.739 HG22 ' HA ' ' Q' ' 23' ' ' ASP . 2.4 t -81.42 146.28 7.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-O 123.101 1.429 . . . . 0.0 113.13 -173.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.53 38.99 5.14 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-N 111.611 -2.54 . . . . 0.0 113.2 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.2 t 61.7 111.23 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 172.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.56 ' CG ' HD21 ' Q' ' 27' ' ' ASN . 44.6 p-10 -129.18 158.44 38.99 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.099 173.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.593 ' HB3' ' N ' ' O' ' 28' ' ' LYS . 76.0 tttt -29.52 -41.97 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 118.228 2.677 . . . . 0.0 118.228 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 129.77 62.81 0.1 Allowed Glycine 0 CA--C 1.559 2.804 0 C-N-CA 119.467 -1.349 . . . . 0.0 114.661 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.46 137.01 47.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 120.907 2.354 . . . . 0.0 111.956 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -138.94 138.39 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 -176.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.471 ' CG2' HD21 ' P' ' 34' ' ' LEU . 52.8 mt -121.13 113.5 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 175.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' O' ' 33' ' ' GLY . . . -123.28 113.91 2.25 Favored Glycine 0 N--CA 1.471 1.017 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.493 ' O ' HD12 ' Q' ' 34' ' ' LEU . 0.6 OUTLIER -172.42 175.38 3.59 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 116.827 -1.949 . . . . 0.0 114.311 -178.401 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 17.1 mtp -122.19 125.77 46.83 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 112.217 -2.265 . . . . 0.0 109.428 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.772 HG11 HD11 ' N' ' 17' ' ' LEU . 99.2 t -126.25 112.24 29.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 121.937 0.875 . . . . 0.0 109.694 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 45.97 131.82 0.0 OUTLIER Glycine 0 CA--C 1.524 0.623 0 CA-C-N 113.609 -1.632 . . . . 0.0 114.576 178.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.416 ' H ' ' CA ' ' O' ' 38' ' ' GLY . . . -79.17 -58.13 3.03 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-N 114.7 -0.75 . . . . 0.0 111.709 176.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.623 HG23 ' O ' ' Q' ' 39' ' ' VAL . 2.7 p -143.1 142.94 25.48 Favored 'Isoleucine or valine' 0 C--N 1.342 0.24 0 C-N-CA 123.208 0.603 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.536 ' O ' HG22 ' P' ' 39' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.452 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -104.16 133.12 49.63 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.58 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -93.54 142.21 27.6 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.58 HG12 ' N ' ' Q' ' 13' ' ' HIS . 58.9 t -134.36 167.75 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.266 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.58 ' N ' HG12 ' Q' ' 12' ' ' VAL . 37.4 m80 -138.42 155.7 48.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.609 0.641 . . . . 0.0 111.697 179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . . . . . . . . . 56.2 m-70 -87.9 -170.47 3.0 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.28 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.558 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 13.7 pt20 -82.6 150.32 26.93 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-O 121.119 0.485 . . . . 0.0 110.342 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -121.34 119.21 31.5 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.014 -177.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 52.3 tp -119.25 120.8 38.08 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.552 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -133.03 131.72 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' CB ' ' R' ' 19' ' ' PHE . 53.1 p90 -153.76 147.63 25.43 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.598 -1.241 . . . . 0.0 114.092 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -126.06 133.97 51.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.963 -1.471 . . . . 0.0 108.695 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.3 131.8 25.36 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.617 0.969 . . . . 0.0 113.617 -178.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 65.6 tt0 -140.51 110.17 6.37 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.739 ' HA ' HG22 ' P' ' 24' ' ' VAL . 52.8 p-10 -173.02 48.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.439 -0.505 . . . . 0.0 112.077 -176.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.533 HG22 ' N ' ' Q' ' 25' ' ' GLY . 8.3 p -72.36 160.88 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.738 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.533 ' N ' HG22 ' Q' ' 24' ' ' VAL . . . 108.36 -29.81 9.62 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 -178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.466 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 2.7 t 92.52 115.12 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 113.386 -1.407 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.56 HD21 ' CG ' ' P' ' 27' ' ' ASN . 57.7 t-20 -73.46 160.91 31.02 Favored 'General case' 0 C--N 1.342 0.264 0 C-N-CA 118.041 -1.464 . . . . 0.0 108.28 178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' N ' ' OD1' ' Q' ' 27' ' ' ASN . 71.3 tttt -48.74 -41.25 31.54 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 118.879 -1.129 . . . . 0.0 111.233 177.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.68 62.33 0.04 OUTLIER Glycine 0 CA--C 1.55 2.253 0 CA-C-O 118.731 -1.038 . . . . 0.0 114.591 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.9 115.66 17.81 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.339 2.07 . . . . 0.0 109.664 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.441 HD12 HG23 ' K' ' 39' ' ' VAL . 6.3 mt -138.77 132.77 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -176.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -110.88 108.6 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 174.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.9 104.1 2.41 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 105.584 -3.006 . . . . 0.0 105.584 176.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.493 HD12 ' O ' ' P' ' 34' ' ' LEU . 44.8 tp -135.83 131.48 35.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-O 122.705 1.241 . . . . 0.0 114.348 -174.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' R' ' 35' ' ' MET . 99.5 mmm -111.91 101.19 9.52 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 174.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.616 HG13 ' O ' ' Q' ' 36' ' ' VAL . 12.2 p -122.91 112.2 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 107.049 -1.464 . . . . 0.0 107.049 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.473 ' O ' ' NE2' ' O' ' 15' ' ' GLN . . . -78.19 132.31 11.67 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 119.664 -1.255 . . . . 0.0 111.388 -178.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' R' ' 37' ' ' GLY . . . -129.57 57.95 0.71 Allowed Glycine 0 CA--C 1.537 1.431 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.572 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.714 HG11 HD11 ' E' ' 31' ' ' ILE . 45.9 t -121.54 130.3 74.74 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 CA-C-N 118.981 1.39 . . . . 0.0 108.335 177.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.413 ' OXT' ' O ' ' Q' ' 39' ' ' VAL . 23.8 m . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 118.048 -0.977 . . . . 0.0 112.225 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -148.99 158.52 44.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.783 0.325 . . . . 0.0 110.531 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -140.85 127.6 20.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.698 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.19 131.46 71.56 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.953 0.406 . . . . 0.0 110.879 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 1.7 p80 -151.81 115.36 4.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.078 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -146.93 162.57 38.44 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.896 0.379 . . . . 0.0 110.776 179.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.9 OUTLIER -89.87 159.83 16.77 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.377 0.608 . . . . 0.0 110.542 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -139.49 109.6 6.45 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.276 -0.875 . . . . 0.0 109.108 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.563 HD23 ' C ' ' R' ' 17' ' ' LEU . 6.8 tt -123.99 119.45 29.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.068 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . 0.438 ' N ' HD23 ' R' ' 17' ' ' LEU . 62.9 t -125.52 127.05 71.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 47.7 p90 -130.75 126.81 37.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.142 -179.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.62 109.36 10.94 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.55 146.56 50.09 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.604 0.24 . . . . 0.0 110.531 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.21 173.44 11.36 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.522 -179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.416 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.6 t0 -68.15 55.43 0.07 Allowed 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.835 0.679 . . . . 0.0 112.835 -177.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.86 134.12 30.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.11 -32.29 2.24 Favored Glycine 0 N--CA 1.469 0.89 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.462 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 39.8 t -112.49 128.14 56.25 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 117.669 0.735 . . . . 0.0 111.306 178.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 9.5 m120 62.16 159.3 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.952 177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -66.51 -45.79 78.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.767 0.794 . . . . 0.0 109.5 175.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.01 -59.82 1.0 Allowed Glycine 0 N--CA 1.475 1.262 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.605 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 130.1 55.87 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 175.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.86 115.21 47.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.294 0.952 . . . . 0.0 111.698 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.847 HG22 HD22 ' R' ' 34' ' ' LEU . 60.8 mt -107.79 107.42 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 176.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.95 109.71 2.63 Favored Glycine 0 CA--C 1.504 -0.649 0 N-CA-C 106.284 -2.726 . . . . 0.0 106.284 178.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.847 HD22 HG22 ' R' ' 32' ' ' ILE . 0.6 OUTLIER -155.69 162.65 40.53 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 118.248 -1.381 . . . . 0.0 113.584 -176.156 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.482 ' CG ' ' SD ' ' Q' ' 35' ' ' MET . 96.4 mmm -120.01 113.09 19.99 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 112.731 -2.031 . . . . 0.0 106.871 178.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.586 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 0.7 OUTLIER -117.49 122.61 70.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.318 0.58 . . . . 0.0 109.942 -178.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 9.88 113.32 0.0 OUTLIER Glycine 0 N--CA 1.475 1.253 0 CA-C-N 114.715 -1.13 . . . . 0.0 115.413 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.62 -63.81 4.78 Favored Glycine 0 CA--C 1.54 1.614 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 176.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.831 HG23 HD11 ' F' ' 31' ' ' ILE . 52.9 t -131.42 128.57 61.32 Favored 'Isoleucine or valine' 0 C--N 1.351 0.64 0 CA-C-O 121.131 0.491 . . . . 0.0 111.212 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.418 HG22 ' H ' ' R' ' 40' ' ' VAL . 16.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.492 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -110.52 136.25 49.94 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' CE1' ' A' ' 13' ' ' HIS . 82.0 tt0 -111.32 113.62 26.22 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.5 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.579 HG13 ' O ' ' B' ' 12' ' ' VAL . 20.6 t -121.8 91.21 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.817 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.717 ' H ' ' CD2' ' B' ' 13' ' ' HIS . 45.3 m170 -97.67 136.24 38.32 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.668 0.27 . . . . 0.0 110.868 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 -149.41 162.68 39.63 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.358 0.599 . . . . 0.0 111.541 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -84.85 156.15 21.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.869 177.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -160.26 106.12 1.53 Allowed 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.42 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.469 ' CD1' HG11 ' C' ' 36' ' ' VAL . 18.5 mt -128.21 127.54 43.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.6 108.62 24.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CE2' ' HB3' ' A' ' 17' ' ' LEU . 69.5 m-85 -113.53 115.91 28.72 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.415 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 10.9 p90 -151.54 162.98 40.04 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.449 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -127.49 110.27 12.58 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.31 -1.314 . . . . 0.0 107.994 178.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -178.27 154.88 0.87 Allowed 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 43.82 61.13 2.4 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.389 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.3 m -66.08 124.07 20.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.782 0.801 . . . . 0.0 110.607 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.82 -34.04 3.13 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 114.225 -1.352 . . . . 0.0 110.276 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.9 p -162.41 120.37 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 16.5 t-20 -21.8 154.59 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.613 0 O-C-N 124.371 1.044 . . . . 0.0 113.78 -177.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -144.18 -28.22 0.51 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.366 -1.288 . . . . 0.0 109.649 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -70.88 97.86 0.67 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.8 -167.51 2.85 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.783 HD13 ' O ' ' M' ' 38' ' ' GLY . 77.6 mt -108.28 112.6 40.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -124.62 126.57 71.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.893 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.45 119.72 1.83 Allowed Glycine 0 CA--C 1.531 1.056 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 178.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -163.14 154.91 17.71 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 118.848 1.324 . . . . 0.0 112.577 -178.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.3 ttm -131.63 144.78 51.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 113.88 -1.509 . . . . 0.0 111.932 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 55.1 t -117.1 132.66 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 176.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 39' ' ' VAL . . . -91.1 112.37 4.12 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.101 -179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.486 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 50.71 -70.03 0.0 OUTLIER Glycine 0 CA--C 1.539 1.58 0 N-CA-C 114.699 0.639 . . . . 0.0 114.699 177.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 37' ' ' GLY . 9.9 p -51.85 147.89 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 117.172 0.486 . . . . 0.0 112.04 -178.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.838 -1.077 . . . . 0.0 110.609 179.862 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -102.74 133.73 47.3 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -79.89 131.49 35.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.67 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.13 108.34 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.67 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.717 ' CD2' ' H ' ' A' ' 13' ' ' HIS . 30.4 m170 -123.7 142.6 50.92 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.957 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.507 ' CD2' ' CE1' ' C' ' 14' ' ' HIS . 3.7 m80 -136.16 162.05 34.02 Favored 'General case' 0 C--O 1.224 -0.27 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.767 ' NE2' HG23 ' E' ' 36' ' ' VAL . 31.6 tt0 -90.34 152.78 20.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -148.51 101.44 3.23 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 119.522 -0.871 . . . . 0.0 111.16 178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.601 ' CD1' HG21 ' D' ' 36' ' ' VAL . 30.5 mt -120.24 122.84 41.8 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 76.8 t -115.59 106.83 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.135 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.418 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 89.7 m-85 -107.29 104.22 13.78 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 177.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 12.4 t80 -126.17 123.07 37.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -175.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.36 122.9 40.85 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-O 121.068 0.461 . . . . 0.0 111.672 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.449 ' O ' ' O ' ' A' ' 21' ' ' ALA . 83.3 tt0 -164.8 139.76 5.38 Favored 'General case' 0 C--N 1.338 0.088 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.417 179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 t0 53.89 49.45 19.01 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.467 -0.493 . . . . 0.0 109.702 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.668 HG21 ' H ' ' C' ' 25' ' ' GLY . 25.6 t -49.97 169.42 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.68 0.752 . . . . 0.0 111.785 -179.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.643 ' N ' HG12 ' B' ' 24' ' ' VAL . . . -173.84 8.94 0.03 OUTLIER Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.518 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 85.0 p -64.08 158.98 21.3 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-N 115.208 -0.496 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.631 ' ND2' ' ND2' ' A' ' 27' ' ' ASN . 99.3 m-20 -100.43 160.73 14.1 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.042 0.925 . . . . 0.0 112.36 -177.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -40.1 -39.55 0.91 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.345 -1.298 . . . . 0.0 113.449 -178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.84 67.29 0.23 Allowed Glycine 0 N--CA 1.477 1.4 0 C-N-CA 120.871 -0.68 . . . . 0.0 113.598 -177.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.14 94.57 5.82 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.28 0.562 . . . . 0.0 110.302 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 88.8 mt -130.06 127.28 63.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.345 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.167 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.7 mt -120.0 117.86 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.433 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.12 92.75 0.51 Allowed Glycine 0 N--CA 1.462 0.403 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' C' ' 34' ' ' LEU . 84.5 mt -127.42 144.28 51.08 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.462 0.648 . . . . 0.0 112.109 -176.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.5 ptm -152.91 148.12 26.77 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.995 -1.082 . . . . 0.0 112.692 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.444 HG21 HG11 ' B' ' 40' ' ' VAL . 23.2 m -120.34 157.71 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.691 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.486 ' HA3' ' H ' ' A' ' 38' ' ' GLY . . . -63.11 -103.15 0.01 OUTLIER Glycine 0 CA--C 1.522 0.528 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.567 178.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -122.69 -76.15 0.35 Allowed Glycine 0 CA--C 1.534 1.276 0 CA-C-N 115.598 -0.301 . . . . 0.0 112.381 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.683 HG23 HD11 ' H' ' 31' ' ' ILE . 16.6 t -50.2 134.28 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 122.419 0.287 . . . . 0.0 111.115 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.514 HG13 ' O ' ' B' ' 39' ' ' VAL . 15.9 m . . . . . 0 C--O 1.224 -0.279 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.652 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -115.66 139.1 50.44 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.799 0.333 . . . . 0.0 110.57 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -87.22 117.15 25.78 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 64.1 t -124.14 129.56 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.099 0.476 . . . . 0.0 110.438 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 67.1 m-70 -153.14 115.97 4.53 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.361 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.507 ' CE1' ' CD2' ' B' ' 14' ' ' HIS . 9.3 p-80 -152.35 162.23 41.46 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.172 178.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.777 HE22 ' H ' ' F' ' 37' ' ' GLY . 75.7 mt-30 -90.08 159.03 17.03 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.458 ' O ' HD23 ' C' ' 17' ' ' LEU . 6.4 tmtt? -140.84 103.06 4.42 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.684 HD11 HG11 ' E' ' 36' ' ' VAL . 2.9 mt -125.52 130.11 51.09 Favored 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 119.829 -0.748 . . . . 0.0 111.232 179.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.441 ' HA ' HG13 ' D' ' 18' ' ' VAL . 2.3 p -126.22 113.75 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.21 176.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 44.0 m-85 -108.91 105.13 14.54 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 178.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 32.5 t80 -122.32 129.25 51.98 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -176.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.642 ' HB1' HG21 ' C' ' 24' ' ' VAL . . . -131.25 122.32 26.3 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.5 ' O ' ' C ' ' C' ' 23' ' ' ASP . 84.2 tt0 -136.47 146.25 46.09 Favored 'General case' 0 CA--C 1.521 -0.156 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.5 ' C ' ' O ' ' C' ' 22' ' ' GLU . 65.8 t0 24.8 47.78 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.661 0.743 . . . . 0.0 110.98 -178.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.642 HG21 ' HB1' ' C' ' 21' ' ' ALA . 60.3 t -66.57 167.81 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.053 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.668 ' H ' HG21 ' B' ' 24' ' ' VAL . . . -151.22 -24.65 0.05 OUTLIER Glycine 0 CA--C 1.518 0.274 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 20.8 m 63.77 -111.36 0.32 Allowed 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 121.653 0.74 . . . . 0.0 110.091 176.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.518 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 8.0 p30 150.69 -179.95 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 113.787 -1.552 . . . . 0.0 108.45 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -36.96 -40.17 0.27 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.596 ' HA3' HG13 ' O' ' 39' ' ' VAL . . . -176.98 72.98 0.08 OUTLIER Glycine 0 CA--C 1.535 1.329 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.345 -177.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.464 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -80.65 120.01 24.01 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 118.851 1.325 . . . . 0.0 110.332 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.498 HD12 HG23 ' O' ' 39' ' ' VAL . 79.2 mt -132.15 129.95 60.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 N-CA-C 113.121 0.785 . . . . 0.0 113.121 -178.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 62.5 mt -105.61 112.69 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.94 103.79 1.46 Allowed Glycine 0 C--O 1.239 0.448 0 N-CA-C 105.667 -2.973 . . . . 0.0 105.667 177.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' B' ' 34' ' ' LEU . 45.1 tp -136.49 135.27 38.43 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.417 1.265 . . . . 0.0 114.417 -174.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.454 ' H ' HD12 ' C' ' 34' ' ' LEU . 0.9 OUTLIER -117.77 96.29 5.31 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 175.673 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.49 ' O ' HG13 ' C' ' 36' ' ' VAL . 11.9 p -130.32 122.98 54.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 109.566 -176.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' C' ' 39' ' ' VAL . . . 160.3 -112.97 0.55 Allowed Glycine 0 C--N 1.31 -0.895 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.95 -71.86 0.07 OUTLIER Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.826 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.594 HG12 ' N ' ' C' ' 40' ' ' VAL . 62.1 t -126.49 164.6 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.749 0.309 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.594 ' N ' HG12 ' C' ' 39' ' ' VAL . 4.2 m . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.437 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.07 132.31 54.23 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.656 0.265 . . . . 0.0 110.439 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 -118.84 116.74 27.15 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.134 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -113.15 101.96 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.421 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 63.7 t60 -144.76 102.41 3.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.618 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.752 ' HE2' HG12 ' E' ' 12' ' ' VAL . 0.8 OUTLIER -124.38 162.0 24.76 Favored 'General case' 0 C--O 1.221 -0.406 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.501 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.564 ' CD ' HG22 ' F' ' 36' ' ' VAL . 9.5 tt0 -90.29 158.27 17.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -141.47 99.71 3.62 Favored 'General case' 0 C--O 1.241 0.639 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.424 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.715 HD11 HG21 ' F' ' 36' ' ' VAL . 75.1 mt -123.51 123.13 39.94 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 120.534 -0.467 . . . . 0.0 111.7 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' C' ' 18' ' ' VAL . 3.0 p -124.78 108.62 20.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' D' ' 17' ' ' LEU . 47.1 m-85 -105.21 110.57 22.99 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.477 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 26.4 t80 -127.48 134.77 49.8 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -176.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.29 135.65 30.81 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.607 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 80.7 tt0 -153.9 154.07 33.2 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.634 0.254 . . . . 0.0 111.156 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 41.62 49.78 3.75 Favored 'General case' 0 N--CA 1.463 0.184 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.762 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' D' ' 25' ' ' GLY . 6.4 t -49.7 168.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.689 0.757 . . . . 0.0 111.032 -177.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.532 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . -173.34 9.18 0.03 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.2 p -64.45 158.83 22.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -177.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' C' ' 25' ' ' GLY . 91.1 m-20 -98.78 -162.01 0.92 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.582 -177.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -46.35 -39.49 10.35 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 117.46 2.393 . . . . 0.0 117.46 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.487 ' O ' HG22 ' P' ' 39' ' ' VAL . . . -178.29 74.43 0.07 OUTLIER Glycine 0 CA--C 1.538 1.531 0 C-N-CA 116.735 -2.65 . . . . 0.0 117.047 -175.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.2 140.35 36.34 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 119.044 1.422 . . . . 0.0 108.544 177.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 54.5 mt -134.96 132.02 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.7 mt -107.29 112.73 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 174.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.16 115.85 2.41 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.505 HD12 HG22 ' D' ' 36' ' ' VAL . 2.6 pp -168.96 161.95 10.91 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 117.265 -1.774 . . . . 0.0 114.077 -177.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.1 mtp -111.24 113.62 26.24 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 112.782 -2.008 . . . . 0.0 109.718 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.601 HG21 ' CD1' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -125.17 122.99 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 178.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.02 -113.46 0.72 Allowed Glycine 0 C--N 1.31 -0.9 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.789 ' O ' HD12 ' K' ' 31' ' ' ILE . . . 72.25 -72.56 0.94 Allowed Glycine 0 CA--C 1.531 1.09 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -179.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.71 132.98 57.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 C--O 1.224 -0.288 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.834 -179.891 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -105.73 134.2 49.24 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.909 0.385 . . . . 0.0 110.629 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.38 131.79 25.23 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.752 HG12 ' HE2' ' D' ' 14' ' ' HIS . 2.7 t -118.9 123.95 72.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.903 0.382 . . . . 0.0 110.422 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' CE1' ' F' ' 13' ' ' HIS . 7.1 t-160 -158.91 112.08 2.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.818 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' F' ' 14' ' ' HIS . 35.6 m-70 -138.8 159.93 40.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.646 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -90.05 158.88 17.12 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -140.69 104.71 4.78 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.504 -0.478 . . . . 0.0 109.757 176.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -111.07 118.34 35.76 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.99 117.29 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 120.921 0.391 . . . . 0.0 110.15 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 t80 -121.24 112.58 18.8 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.881 179.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -121.56 116.91 25.51 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.854 0.359 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.4 113.69 20.22 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.417 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 96.0 mt-10 -100.5 141.65 33.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.329 0.585 . . . . 0.0 112.139 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.406 ' C ' ' O ' ' E' ' 22' ' ' GLU . 90.3 m-20 28.06 60.62 0.11 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 114.725 -1.125 . . . . 0.0 112.329 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -70.79 123.17 24.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.997 178.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.18 -34.3 4.29 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.5 ' O ' ' O ' ' E' ' 27' ' ' ASN . 89.6 p -151.64 123.03 7.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.018 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.532 ' ND2' ' H ' ' F' ' 29' ' ' GLY . 14.9 t-20 -40.95 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 120.663 -0.415 . . . . 0.0 109.956 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 88.3 tttt -79.62 -50.14 11.11 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 119.159 -1.016 . . . . 0.0 111.817 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.02 50.33 3.3 Favored Glycine 0 CA--C 1.536 1.404 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.67 160.31 34.65 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 87.5 mt -129.83 127.45 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 120.072 -0.651 . . . . 0.0 111.403 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -109.93 107.67 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.38 85.99 0.42 Allowed Glycine 0 N--CA 1.468 0.796 1 N-CA-C 102.725 -4.15 . . . . 0.0 102.725 175.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.512 HD21 ' CG2' ' D' ' 36' ' ' VAL . 6.8 tt -129.93 132.67 46.44 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 122.346 1.069 . . . . 0.0 112.835 -171.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.4 mmm -103.46 110.56 22.64 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 114.046 -1.434 . . . . 0.0 107.275 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.767 HG23 ' NE2' ' B' ' 15' ' ' GLN . 12.2 p -124.18 131.81 72.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.996 0.903 . . . . 0.0 111.797 -178.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.91 112.0 0.59 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.744 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -63.26 0.46 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 176.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.904 HG23 HD11 ' K' ' 31' ' ' ILE . 50.3 t -142.47 143.01 26.48 Favored 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.428 ' OXT' ' CG ' ' C' ' 13' ' ' HIS . 15.8 m . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.655 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.461 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -107.32 134.88 49.74 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.11 141.56 48.67 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.521 HG13 ' O ' ' F' ' 12' ' ' VAL . 9.0 p -117.35 119.17 61.01 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.428 0.632 . . . . 0.0 110.349 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.577 ' CE1' ' ND1' ' E' ' 13' ' ' HIS . 5.6 t-160 -149.4 107.95 3.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.708 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' E' ' 14' ' ' HIS . 98.5 m-70 -152.92 164.51 37.77 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.251 177.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -89.84 159.19 17.11 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.016 0.436 . . . . 0.0 110.798 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -140.07 114.31 9.11 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -119.9 122.96 42.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.775 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -129.14 129.3 67.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.6 p90 -145.6 129.75 17.55 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.146 0.498 . . . . 0.0 111.493 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -131.06 136.88 48.83 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.842 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.08 135.2 33.89 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.965 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -113.5 152.58 30.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.405 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 43.6 t0 66.64 50.38 1.2 Allowed 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 120.766 -0.373 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.436 HG12 ' N ' ' F' ' 25' ' ' GLY . 17.5 t -55.73 160.46 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . 130.39 -36.92 2.22 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -176.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.0 m -79.94 118.05 21.33 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.552 ' O ' ' N ' ' F' ' 29' ' ' GLY . 81.9 m-20 -91.99 -161.31 0.81 Allowed 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.817 -176.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -47.99 48.63 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 -177.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -97.36 54.58 1.29 Allowed Glycine 0 CA--C 1.547 2.059 0 C-N-CA 119.689 -1.244 . . . . 0.0 111.185 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' F' ' 29' ' ' GLY . . . 169.59 136.68 0.02 OUTLIER 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -130.94 127.37 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-N 118.527 0.603 . . . . 0.0 112.48 -178.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -105.92 108.58 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.03 86.63 0.46 Allowed Glycine 0 C--O 1.239 0.425 0 N-CA-C 104.527 -3.429 . . . . 0.0 104.527 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.5 tp -117.84 123.66 46.46 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.567 -0.817 . . . . 0.0 112.241 -174.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -99.95 101.7 12.87 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 104.379 -2.452 . . . . 0.0 104.379 174.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.715 HG21 HD11 ' D' ' 17' ' ' LEU . 14.9 p -118.75 131.96 70.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 121.322 0.582 . . . . 0.0 110.947 -176.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.777 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 87.29 112.28 0.97 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.351 178.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -120.61 -64.01 0.25 Allowed Glycine 0 CA--C 1.545 1.919 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.477 ' CG2' HG22 ' E' ' 39' ' ' VAL . 27.5 m -157.24 156.44 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 117.352 0.576 . . . . 0.0 110.307 176.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.424 ' O ' ' N ' ' E' ' 40' ' ' VAL . 16.8 t . . . . . 0 C--O 1.219 -0.548 0 CA-C-O 117.644 -1.169 . . . . 0.0 109.791 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.1 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -106.82 136.88 45.88 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -95.05 109.67 21.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.615 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.509 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.5 p -130.39 127.85 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.637 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 0.0 OUTLIER -149.4 109.06 4.01 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.633 -179.75 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 27.9 p-80 -155.47 162.01 40.82 Favored 'General case' 0 N--CA 1.461 0.104 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.195 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -89.95 159.32 16.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.956 0.408 . . . . 0.0 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 pttt -139.85 137.89 35.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.897 HD11 HG11 ' I' ' 36' ' ' VAL . 84.4 mt -128.66 134.25 48.47 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.355 0.598 . . . . 0.0 111.876 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.551 HG23 ' O ' ' G' ' 18' ' ' VAL . 29.8 m -126.97 105.74 14.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 178.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' CE1' ' H' ' 19' ' ' PHE . 48.9 m-85 -108.01 106.5 16.76 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.492 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 52.2 p90 -128.08 130.84 48.84 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.114 0.483 . . . . 0.0 111.953 -177.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.39 115.67 30.08 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.282 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.444 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 82.5 tt0 -156.66 114.34 3.21 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.454 ' OD2' ' O ' ' G' ' 23' ' ' ASP . 2.5 p-10 47.54 47.62 17.36 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 111.542 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.801 HG12 ' H ' ' G' ' 25' ' ' GLY . 16.9 t -52.91 -175.6 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.801 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 165.0 19.73 0.02 OUTLIER Glycine 0 CA--C 1.534 1.24 0 C-N-CA 119.316 -1.421 . . . . 0.0 113.568 -179.024 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.428 ' O ' ' O ' ' G' ' 27' ' ' ASN . 35.1 t -102.23 120.67 40.86 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 118.229 1.014 . . . . 0.0 112.132 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' CE ' ' H' ' 28' ' ' LYS . 11.6 m120 53.47 151.68 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.16 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.41 -48.26 35.32 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.632 0.729 . . . . 0.0 111.948 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.95 58.11 0.4 Allowed Glycine 0 N--CA 1.476 1.351 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.842 -177.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.37 109.53 17.37 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-O 123.016 1.388 . . . . 0.0 112.85 -175.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 pt -130.43 131.52 65.22 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 112.329 -2.214 . . . . 0.0 106.828 178.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 94.7 mt -120.97 131.85 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.969 0.414 . . . . 0.0 112.087 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.0 106.08 0.7 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -123.8 135.41 53.77 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.167 0.508 . . . . 0.0 111.877 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.5 mtp -127.57 129.01 46.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' G' ' 37' ' ' GLY . 54.7 t -114.3 131.96 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.5 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -40.46 -111.65 0.0 OUTLIER Glycine 0 CA--C 1.525 0.705 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.899 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.14 -71.42 0.44 Allowed Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.475 -0.362 . . . . 0.0 112.674 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m -58.91 172.63 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.66 0.267 . . . . 0.0 111.52 -179.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.47 0.526 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.432 -179.898 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -106.32 132.21 52.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.898 0.38 . . . . 0.0 110.414 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -141.21 104.45 4.63 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.557 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB2' ' I' ' 11' ' ' GLU . 36.7 t -134.11 131.74 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.525 ' CD2' ' CE1' ' I' ' 13' ' ' HIS . 85.1 m-70 -154.81 157.08 37.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.493 0.663 . . . . 0.0 112.195 -179.103 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.551 ' O ' ' CG ' ' G' ' 14' ' ' HIS . 93.1 m-70 -159.01 165.43 34.04 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.153 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.441 HE22 HG13 ' K' ' 36' ' ' VAL . 21.0 tt0 -138.56 151.06 46.97 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.66 104.27 3.46 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.921 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.556 HD12 HD22 ' I' ' 17' ' ' LEU . 14.0 mt -117.08 111.84 20.08 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 48.5 t -113.77 107.38 22.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.924 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.471 ' CE1' ' CD2' ' G' ' 19' ' ' PHE . 51.6 m-85 -107.31 109.34 21.08 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 11.9 t80 -132.2 127.43 35.82 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -175.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.47 ' HB1' ' OD2' ' I' ' 23' ' ' ASP . . . -118.28 115.87 25.6 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 176.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.479 ' CG ' ' N ' ' H' ' 23' ' ' ASP . 59.4 tt0 -89.66 163.65 15.04 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -175.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.479 ' N ' ' CG ' ' H' ' 22' ' ' GLU . 48.2 p-10 -74.69 46.41 0.28 Allowed 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.585 -1.643 . . . . 0.0 111.869 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.41 HG11 ' H ' ' G' ' 23' ' ' ASP . 6.8 m -80.36 -179.37 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . -70.87 -28.77 70.11 Favored Glycine 0 N--CA 1.466 0.673 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -175.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 0.2 OUTLIER 160.79 125.84 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.807 0.813 . . . . 0.0 112.23 175.086 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.401 HD22 ' HA ' ' I' ' 28' ' ' LYS . 96.6 m-20 -49.23 158.13 0.4 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.32 176.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' O ' ' G' ' 27' ' ' ASN . 26.9 tttp -70.26 -48.1 58.38 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 174.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.33 59.81 0.5 Allowed Glycine 0 CA--C 1.542 1.752 0 CA-C-N 114.305 -1.316 . . . . 0.0 112.386 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.67 159.28 16.47 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.683 HD11 HG23 ' B' ' 39' ' ' VAL . 97.2 mt -120.97 121.25 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.796 177.163 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -113.35 121.82 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-O 121.013 0.435 . . . . 0.0 111.197 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.27 109.07 1.03 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.566 ' H ' ' HB3' ' I' ' 34' ' ' LEU . 20.1 mt -128.22 142.25 51.22 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 121.204 0.526 . . . . 0.0 110.958 -178.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 94.3 mmm -138.66 120.98 15.93 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -178.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.6 t -125.27 136.51 60.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -139.42 103.16 0.37 Allowed Glycine 0 CA--C 1.504 -0.642 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.259 -178.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.498 ' O ' ' CG1' ' I' ' 39' ' ' VAL . . . 150.11 -73.3 0.28 Allowed Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.884 175.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.46 HG12 ' CD1' ' M' ' 31' ' ' ILE . 12.9 p -167.02 140.62 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 117.951 0.875 . . . . 0.0 110.602 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.319 -179.692 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -112.97 136.23 52.87 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.968 0.413 . . . . 0.0 110.074 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.539 ' HB2' HG22 ' H' ' 12' ' ' VAL . 78.8 mm-40 -71.03 162.87 28.69 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.235 0.54 . . . . 0.0 110.657 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.798 HG21 ' C ' ' J' ' 12' ' ' VAL . 33.9 m -130.46 170.93 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.75 -178.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.525 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 2.3 m-70 -80.66 141.55 34.81 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -176.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.632 ' CE1' HG23 ' I' ' 12' ' ' VAL . 0.1 OUTLIER -149.96 162.28 40.66 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.395 174.652 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.921 HE21 HG12 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -108.13 150.67 26.91 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 176.603 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.607 ' C ' HD23 ' I' ' 17' ' ' LEU . 99.4 mttt -140.23 101.72 4.2 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 175.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.729 HD11 HG11 ' K' ' 36' ' ' VAL . 0.9 OUTLIER -122.37 123.73 42.03 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.449 0.568 . . . . 0.0 110.662 -179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -117.13 108.23 24.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -107.76 104.07 13.49 Favored 'General case' 0 N--CA 1.462 0.135 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.591 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 20.1 t80 -122.71 124.21 42.87 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.656 0.265 . . . . 0.0 111.099 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.416 ' HB1' ' NZ ' ' I' ' 28' ' ' LYS . . . -132.59 116.13 16.31 Favored 'General case' 0 C--O 1.243 0.757 0 CA-C-O 121.699 0.761 . . . . 0.0 112.72 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' I' ' 23' ' ' ASP . 76.2 tt0 -136.46 112.67 9.8 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 176.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.47 ' OD2' ' HB1' ' H' ' 21' ' ' ALA . 6.9 m-20 -162.8 53.16 0.19 Allowed 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -176.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -92.7 132.45 36.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.63 30.52 68.55 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 108.609 -1.796 . . . . 0.0 108.609 -177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t -162.65 115.11 1.63 Allowed 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.861 -0.17 . . . . 0.0 110.888 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' I' ' 26' ' ' SER . 93.3 m-20 -21.87 153.24 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 178.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.453 ' H ' ' CB ' ' J' ' 28' ' ' LYS . 29.3 tttt -165.32 29.84 0.06 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.665 0.745 . . . . 0.0 109.296 178.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 77.22 2.04 Favored Glycine 0 CA--C 1.525 0.688 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.402 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.13 139.22 45.75 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 122.542 1.163 . . . . 0.0 110.642 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.679 HD13 ' CG2' ' J' ' 31' ' ' ILE . 1.5 mm -116.08 116.93 53.87 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 112.948 -1.933 . . . . 0.0 112.034 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.406 HG21 HD13 ' I' ' 32' ' ' ILE . 18.8 mt -108.37 109.53 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -132.54 117.3 1.97 Allowed Glycine 0 N--CA 1.464 0.552 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.566 ' HB3' ' H ' ' H' ' 34' ' ' LEU . 0.4 OUTLIER -173.63 174.93 3.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 C-N-CA 117.391 -1.724 . . . . 0.0 113.76 -179.229 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 54.9 mtp -130.26 109.37 10.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 112.171 -2.286 . . . . 0.0 108.721 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.897 HG11 HD11 ' G' ' 17' ' ' LEU . 13.2 t -135.29 103.15 3.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.25 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.408 ' HA3' ' H ' ' J' ' 37' ' ' GLY . . . 139.87 -154.45 23.8 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 178.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' J' ' 39' ' ' VAL . . . 111.89 -55.94 0.49 Allowed Glycine 0 CA--C 1.54 1.644 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' H' ' 38' ' ' GLY . 5.9 p -152.97 148.58 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.111 0 CA-C-N 117.484 0.642 . . . . 0.0 109.937 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.467 HG11 HG23 ' J' ' 40' ' ' VAL . 30.3 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.135 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.034 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 51.3 p90 -146.92 154.59 41.47 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.899 0.381 . . . . 0.0 110.45 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' OE2' ' I' ' 11' ' ' GLU . 98.6 mt-10 -139.27 110.69 7.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.642 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.798 ' C ' HG21 ' I' ' 12' ' ' VAL . 27.9 m -138.02 165.3 26.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.626 -178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -63.19 133.24 54.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.053 0.454 . . . . 0.0 111.107 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 25.6 m-70 -153.32 175.38 13.17 Favored 'General case' 0 C--O 1.221 -0.404 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.58 HE22 ' NE2' ' I' ' 15' ' ' GLN . 7.9 tt0 -157.98 147.87 20.12 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.808 ' C ' HD12 ' J' ' 17' ' ' LEU . 59.9 tttm -124.43 120.85 33.25 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.808 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.1 mp -128.16 117.56 21.8 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 118.767 0.712 . . . . 0.0 110.709 176.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -112.24 109.86 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.206 178.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' L' ' 32' ' ' ILE . 33.8 m-85 -104.73 108.01 19.26 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.562 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 35.4 t80 -119.75 122.75 42.11 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.138 0.426 . . . . 0.0 110.344 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.05 145.67 24.24 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 mt-10 -82.93 179.84 7.65 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.245 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' K' ' 24' ' ' VAL . 6.4 t0 -166.44 52.87 0.09 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.237 -176.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.15 -132.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -175.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.72 -35.18 62.32 Favored Glycine 0 C--N 1.32 -0.31 0 C-N-CA 118.789 -1.672 . . . . 0.0 109.096 -172.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.583 ' CB ' ' O ' ' J' ' 25' ' ' GLY . 12.4 p 139.37 112.1 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 173.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' I' ' 23' ' ' ASP . 6.6 m120 -56.58 -178.66 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 175.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.453 ' CB ' ' H ' ' I' ' 28' ' ' LYS . 68.1 tttt -64.88 -37.04 86.3 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 120.206 -0.598 . . . . 0.0 110.135 177.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.45 76.33 0.45 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 121.451 -0.404 . . . . 0.0 113.982 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' K' ' 29' ' ' GLY . . . -82.14 147.05 29.25 Favored 'General case' 0 C--O 1.244 0.772 0 CA-C-O 121.135 0.493 . . . . 0.0 111.532 178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.679 ' CG2' HD13 ' I' ' 31' ' ' ILE . 13.4 tt -144.1 133.86 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.752 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.455 HG22 HD21 ' K' ' 34' ' ' LEU . 53.4 mt -115.23 126.43 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.781 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.408 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -130.43 113.35 1.42 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 177.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.411 HD12 ' N ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -161.88 152.12 17.09 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 116.819 -1.952 . . . . 0.0 114.883 -176.179 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.447 ' SD ' ' CG ' ' K' ' 35' ' ' MET . 37.6 tpp -105.22 109.2 21.1 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-N 111.998 -2.365 . . . . 0.0 106.385 175.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.635 ' O ' HG13 ' J' ' 36' ' ' VAL . 7.7 p -128.74 102.03 7.52 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.184 0 CA-C-O 121.493 0.663 . . . . 0.0 111.378 -176.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' I' ' 37' ' ' GLY . . . 101.26 174.2 28.73 Favored Glycine 0 N--CA 1.461 0.356 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.35 -55.55 0.26 Allowed Glycine 0 CA--C 1.542 1.738 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 38' ' ' GLY . 55.6 t -128.13 139.27 52.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-N 117.717 0.759 . . . . 0.0 109.758 177.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.467 HG23 HG11 ' I' ' 40' ' ' VAL . 7.1 p . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.595 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -106.14 133.19 51.23 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.991 0.424 . . . . 0.0 110.719 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -99.43 112.17 24.41 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.125 0.488 . . . . 0.0 111.186 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 54.1 t -128.0 128.58 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -141.6 127.69 19.6 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 121.259 0.552 . . . . 0.0 111.943 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.652 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 22.4 m-70 -143.93 160.7 40.35 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.339 177.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.639 ' N ' HE21 ' K' ' 15' ' ' GLN . 0.0 OUTLIER -90.43 159.96 16.29 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.295 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' K' ' 17' ' ' LEU . 67.6 mttm -139.8 99.9 3.81 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.518 HD12 ' C ' ' K' ' 16' ' ' LYS . 10.5 mp -114.17 121.05 42.58 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.071 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.03 124.0 71.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CE2' ' L' ' 19' ' ' PHE . 46.8 t80 -124.0 109.78 13.97 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.114 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -114.8 113.58 24.43 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.514 ' HB3' ' CE1' ' K' ' 19' ' ' PHE . . . -158.69 167.9 28.31 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 117.53 -1.668 . . . . 0.0 114.451 -178.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -89.3 140.07 29.86 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OG ' ' L' ' 26' ' ' SER . 84.5 m-20 -100.8 47.15 0.93 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 116.218 1.933 . . . . 0.0 116.218 -174.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 1.057 HG12 ' H ' ' K' ' 25' ' ' GLY . 71.0 t -83.83 -162.75 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 1.057 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -79.43 -28.55 52.15 Favored Glycine 0 C--N 1.336 0.58 0 CA-C-O 118.183 -1.343 . . . . 0.0 113.332 -174.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.573 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 8.1 t 143.97 128.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 114.398 1.258 . . . . 0.0 114.398 176.22 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -54.35 171.19 0.12 Allowed 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 114.137 -1.392 . . . . 0.0 109.962 176.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -59.12 -39.94 83.85 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 120.421 -0.511 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -166.45 64.36 0.21 Allowed Glycine 0 CA--C 1.546 2.015 0 C-N-CA 119.636 -1.268 . . . . 0.0 114.387 177.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.87 100.93 13.7 Favored 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 117.841 0.821 . . . . 0.0 110.85 176.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.904 HD11 HG23 ' E' ' 39' ' ' VAL . 25.2 mt -144.57 138.28 23.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 118.401 -1.319 . . . . 0.0 113.656 -178.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -119.24 121.8 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.357 177.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.63 101.48 0.77 Allowed Glycine 0 N--CA 1.469 0.844 0 N-CA-C 106.874 -2.49 . . . . 0.0 106.874 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.455 HD21 HG22 ' J' ' 32' ' ' ILE . 88.2 mt -139.23 144.79 38.62 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -175.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.447 ' CG ' ' SD ' ' J' ' 35' ' ' MET . 23.7 tpp -109.02 105.85 15.54 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 174.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.921 HG12 HE21 ' I' ' 15' ' ' GLN . 2.0 t -116.19 131.92 67.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.843 0.354 . . . . 0.0 111.851 -176.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.99 -111.1 3.34 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.961 178.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.11 -72.55 0.62 Allowed Glycine 0 CA--C 1.538 1.492 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.423 HG23 ' CD1' ' Q' ' 31' ' ' ILE . 75.5 t -128.83 136.14 60.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 177.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.515 HG23 ' O ' ' K' ' 40' ' ' VAL . 13.4 m . . . . . 0 C--O 1.216 -0.674 0 CA-C-O 117.643 -1.17 . . . . 0.0 110.341 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -105.81 134.0 49.63 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.838 0.351 . . . . 0.0 110.581 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.32 127.1 56.03 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.088 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.06 127.95 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-O 121.044 0.45 . . . . 0.0 109.941 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 19.3 t-160 -149.46 122.47 8.82 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.341 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.652 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 76.0 m-70 -152.82 166.16 33.13 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -89.73 154.1 20.19 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.622 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 56.1 mtmt -144.53 105.54 4.19 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.315 0.579 . . . . 0.0 110.086 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 34.9 mt -121.16 116.95 25.93 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.33 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -112.93 113.64 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.57 ' CE2' ' CE1' ' K' ' 19' ' ' PHE . 36.9 t80 -119.25 118.82 32.32 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.948 0.404 . . . . 0.0 111.11 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -137.58 134.04 35.12 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.506 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -155.98 155.03 32.04 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 119.761 -0.776 . . . . 0.0 112.537 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -94.36 147.7 22.96 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.729 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 61.43 48.44 5.95 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 121.482 0.658 . . . . 0.0 109.34 -178.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' L' ' 21' ' ' ALA . 5.9 t -72.03 161.79 4.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.033 -178.361 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.444 ' N ' HG12 ' L' ' 24' ' ' VAL . . . 111.37 -33.12 6.0 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.752 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' L' ' 27' ' ' ASN . 13.8 p -81.17 -129.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 118.713 1.257 . . . . 0.0 110.155 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' N ' ' OG ' ' L' ' 26' ' ' SER . 13.7 m120 -100.15 160.85 14.0 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.969 0.414 . . . . 0.0 111.45 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -44.18 -40.3 4.97 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.445 0.641 . . . . 0.0 110.752 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.08 -62.8 0.56 Allowed Glycine 0 CA--C 1.547 2.063 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.588 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.62 167.66 10.06 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -123.1 117.02 50.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.162 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.43 HG22 HD22 ' L' ' 34' ' ' LEU . 38.8 mt -106.7 116.09 49.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 176.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.75 107.27 1.05 Allowed Glycine 0 CA--C 1.508 -0.367 0 N-CA-C 107.31 -2.316 . . . . 0.0 107.31 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.43 HD22 HG22 ' L' ' 32' ' ' ILE . 0.8 OUTLIER -156.26 167.11 31.44 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 118.395 -1.322 . . . . 0.0 112.311 -177.017 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -118.9 114.85 23.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.369 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.427 HG12 ' OE1' ' J' ' 15' ' ' GLN . 10.5 t -103.7 115.13 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.821 -178.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.0 -124.81 7.95 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.904 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.13 -62.77 0.4 Allowed Glycine 0 CA--C 1.539 1.585 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -178.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.565 HG23 HD12 ' R' ' 31' ' ' ILE . 79.2 t -121.98 127.16 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 87.3 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.147 -0.93 . . . . 0.0 110.44 -179.081 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -108.52 130.84 55.27 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.63 0.252 . . . . 0.0 110.488 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.31 135.34 30.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.864 0.364 . . . . 0.0 110.432 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t -126.23 131.28 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.661 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -114.92 131.0 57.02 Favored 'General case' 0 N--CA 1.48 1.033 0 O-C-N 122.195 -0.316 . . . . 0.0 110.993 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.468 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 56.4 p-80 -152.84 161.94 41.91 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.35 178.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.746 HE21 HE21 ' N' ' 15' ' ' GLN . 6.5 tt0 -101.17 152.85 20.15 Favored 'General case' 0 C--N 1.342 0.267 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 176.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -111.62 93.77 4.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 119.027 -0.511 . . . . 0.0 111.08 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.421 HD11 ' NE2' ' M' ' 15' ' ' GLN . 41.4 mt -132.93 114.8 14.45 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 119.26 0.936 . . . . 0.0 110.632 178.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . 0.564 HG23 ' O ' ' M' ' 18' ' ' VAL . 27.4 m -117.88 107.77 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-N 114.27 -1.332 . . . . 0.0 108.053 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -105.01 107.1 17.9 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 54.7 p90 -136.01 129.86 32.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.048 0.451 . . . . 0.0 111.568 -177.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.96 119.49 38.68 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.47 ' HG2' ' H ' ' M' ' 23' ' ' ASP . 72.0 tt0 -144.01 -179.67 6.64 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.551 ' N ' HG23 ' N' ' 24' ' ' VAL . 64.5 t0 -43.65 -60.57 1.72 Allowed 'General case' 0 N--CA 1.463 0.196 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.712 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 6.5 t -73.34 160.45 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 118.958 -1.097 . . . . 0.0 108.866 177.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.93 -35.1 5.06 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 177.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t -80.35 118.96 22.45 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.334 -0.433 . . . . 0.0 111.818 -178.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.47 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 98.3 m-20 -90.37 -179.26 5.57 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.809 178.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.58 -37.66 18.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.397 179.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.49 76.3 0.07 OUTLIER Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -177.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.24 108.82 14.16 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 122.961 1.362 . . . . 0.0 113.905 -176.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.577 HG23 ' O ' ' M' ' 31' ' ' ILE . 18.1 tt -135.75 117.78 20.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 112.891 -1.959 . . . . 0.0 106.484 178.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 10.4 tp -153.51 150.45 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 118.515 -1.274 . . . . 0.0 114.272 -176.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.8 120.31 2.78 Favored Glycine 0 CA--C 1.536 1.357 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 80.2 mt -131.73 148.61 52.59 Favored 'General case' 0 N--CA 1.472 0.651 0 O-C-N 122.304 -0.527 . . . . 0.0 110.66 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 80.8 mtp -143.61 144.41 31.9 Favored 'General case' 0 N--CA 1.462 0.142 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' M' ' 37' ' ' GLY . 40.3 t -136.69 155.82 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 114.357 -1.292 . . . . 0.0 107.614 177.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -52.79 -102.31 0.01 OUTLIER Glycine 0 CA--C 1.528 0.897 0 C-N-CA 120.298 -0.953 . . . . 0.0 111.668 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.783 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -178.59 73.12 0.07 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 121.047 -0.597 . . . . 0.0 111.846 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -137.38 151.3 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 117.176 0.488 . . . . 0.0 110.924 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.363 179.76 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.564 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.48 141.22 45.33 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 120.762 0.315 . . . . 0.0 110.347 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -115.86 136.43 53.05 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.129 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -120.93 128.85 76.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.897 0.38 . . . . 0.0 110.065 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.463 ' H ' ' HA ' ' O' ' 13' ' ' HIS . 15.7 t-80 -127.8 131.03 49.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.303 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.468 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 34.3 p80 -150.75 169.3 21.97 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.562 179.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.746 HE21 HE21 ' M' ' 15' ' ' GLN . 42.1 tt0 -128.87 149.67 50.67 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 177.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -99.39 94.47 6.45 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.152 177.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.84 110.39 16.7 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 118.753 0.706 . . . . 0.0 109.625 178.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.44 105.4 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.901 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -106.27 108.64 20.26 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.09 134.4 45.44 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 122.376 -0.203 . . . . 0.0 111.033 -177.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . 0.674 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . . . -137.57 119.57 15.41 Favored 'General case' 0 C--O 1.24 0.568 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.87 -179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.659 ' N ' ' NZ ' ' O' ' 28' ' ' LYS . 93.6 mt-10 -99.34 -168.74 1.66 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 177.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' N' ' 23' ' ' ASP . 56.2 t0 -102.13 49.06 0.86 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.75 0.705 . . . . 0.0 112.152 -179.462 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.551 HG23 ' N ' ' M' ' 23' ' ' ASP . 15.8 m -151.86 172.25 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 176.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.23 28.52 73.73 Favored Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.448 177.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 8.1 t -97.68 110.23 22.83 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 117.777 0.788 . . . . 0.0 111.105 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' M' ' 27' ' ' ASN . 14.6 m120 -78.15 176.24 9.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.912 177.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -49.91 -37.17 30.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.452 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.408 ' O ' HD12 ' N' ' 31' ' ' ILE . . . -178.7 76.93 0.07 OUTLIER Glycine 0 CA--C 1.538 1.516 0 CA-C-O 119.414 -0.659 . . . . 0.0 111.778 -177.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.63 132.94 35.66 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.408 HD12 ' O ' ' N' ' 29' ' ' GLY . 4.3 mp -135.49 129.76 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-N 114.852 -1.067 . . . . 0.0 111.373 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.5 mt -115.21 119.37 61.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.357 178.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.02 122.4 4.81 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.438 ' CD2' HG12 ' N' ' 36' ' ' VAL . 5.0 tt -152.61 137.16 16.82 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.162 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.426 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 41.6 mtp -121.48 114.87 21.86 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.43 -1.259 . . . . 0.0 111.12 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.533 HG13 ' O ' ' N' ' 36' ' ' VAL . 13.4 p -165.79 122.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.467 177.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' O' ' 37' ' ' GLY . . . 166.03 -113.13 0.53 Allowed Glycine 0 C--N 1.302 -1.348 0 C-N-CA 118.699 -1.715 . . . . 0.0 111.29 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.75 -73.19 2.65 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 -177.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.58 147.7 28.61 Favored 'Isoleucine or valine' 0 C--N 1.345 0.401 0 CA-C-N 116.93 0.365 . . . . 0.0 110.435 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.051 -0.975 . . . . 0.0 110.543 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -149.14 152.5 36.22 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.878 0.37 . . . . 0.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -162.29 143.67 10.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.137 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.762 HG12 ' H ' ' O' ' 13' ' ' HIS . 38.2 t -137.32 176.94 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.013 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.762 ' H ' HG12 ' O' ' 12' ' ' VAL . 8.1 m80 -55.41 126.59 25.77 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.498 ' CB ' ' O ' ' P' ' 14' ' ' HIS . 56.4 p-80 -150.61 168.21 24.97 Favored 'General case' 0 C--O 1.215 -0.718 0 CA-C-N 114.51 -1.223 . . . . 0.0 107.909 178.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.499 ' NE2' HG13 ' Q' ' 36' ' ' VAL . 41.9 tt0 -129.14 150.14 50.65 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-N 119.672 1.124 . . . . 0.0 111.692 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -99.28 101.78 13.19 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.564 179.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.865 HD12 HD22 ' P' ' 17' ' ' LEU . 21.9 mt -118.79 115.72 25.04 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 120.533 -0.467 . . . . 0.0 109.93 177.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -115.16 101.6 12.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' O' ' 17' ' ' LEU . 60.6 m-85 -104.2 107.01 17.71 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -127.48 128.73 46.21 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.16 137.52 25.94 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 119.708 -0.797 . . . . 0.0 113.093 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -111.83 116.96 31.54 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 177.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' Q' ' 28' ' ' LYS . 0.7 OUTLIER -95.71 47.49 1.11 Allowed 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.668 0.787 . . . . 0.0 110.715 -178.413 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 1.055 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.5 t -62.63 -164.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.762 -1.108 . . . . 0.0 112.873 -176.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 1.055 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -91.26 29.36 7.16 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.86 1.219 . . . . 0.0 114.893 -171.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.409 ' O ' ' O ' ' O' ' 27' ' ' ASN . 33.2 t -162.09 115.52 1.8 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.94 1.352 . . . . 0.0 109.988 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' O' ' 26' ' ' SER . 30.1 p30 -22.1 153.56 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 111.71 -2.496 . . . . 0.0 115.821 -175.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.674 ' HZ3' ' HA ' ' N' ' 21' ' ' ALA . 76.9 tttt -168.94 28.86 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.361 0 CA-C-N 112.652 -2.067 . . . . 0.0 108.9 178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' P' ' 28' ' ' LYS . . . -70.9 80.51 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.737 -0.665 . . . . 0.0 113.397 -175.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.78 157.76 30.33 Favored 'General case' 0 C--O 1.245 0.846 0 CA-C-O 122.17 0.986 . . . . 0.0 109.988 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 64.1 mt -130.54 134.9 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 113.844 -1.526 . . . . 0.0 113.608 -175.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.641 HG23 HD13 ' O' ' 34' ' ' LEU . 23.4 mt -110.14 112.1 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.742 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -119.69 97.41 0.67 Allowed Glycine 0 N--CA 1.472 1.058 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.831 ' O ' HD12 ' P' ' 34' ' ' LEU . 7.2 mp -138.8 149.78 45.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.417 1.58 . . . . 0.0 114.531 -176.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.426 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 6.8 mtp -118.06 108.51 15.32 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 112.303 -2.226 . . . . 0.0 106.383 177.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.637 ' CG2' HD11 ' P' ' 34' ' ' LEU . 0.1 OUTLIER -140.31 101.67 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.761 -177.123 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.436 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 109.63 172.99 20.7 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.825 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -55.19 0.27 Allowed Glycine 0 CA--C 1.545 1.951 0 CA-C-N 114.97 -0.615 . . . . 0.0 112.126 -179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.596 HG13 ' HA3' ' C' ' 29' ' ' GLY . 27.8 t -111.72 133.31 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.732 0.766 . . . . 0.0 110.564 179.145 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.522 HG23 ' O ' ' O' ' 39' ' ' VAL . 55.8 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.895 178.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.054 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -109.57 133.01 53.61 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.617 0.246 . . . . 0.0 110.827 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -140.71 142.73 34.82 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.718 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.613 ' H ' ' CG2' ' O' ' 12' ' ' VAL . 6.5 t -141.34 92.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.532 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.514 ' CD2' HG23 ' R' ' 40' ' ' VAL . 87.2 m-70 -82.52 107.42 15.15 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' O' ' 14' ' ' HIS . 51.8 p-80 -147.69 167.51 24.44 Favored 'General case' 0 C--O 1.22 -0.45 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.03 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.597 HE22 ' H ' ' R' ' 37' ' ' GLY . 79.5 mt-30 -128.99 150.07 50.56 Favored 'General case' 0 C--N 1.339 0.119 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . 0.537 ' O ' HD23 ' P' ' 17' ' ' LEU . 99.1 mttt -98.72 102.2 13.86 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.227 178.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.865 HD22 HD12 ' O' ' 17' ' ' LEU . 4.6 mt -121.79 116.12 23.89 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.717 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.18 110.99 33.94 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.739 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -109.12 114.23 27.77 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.45 ' C ' ' CD1' ' P' ' 20' ' ' PHE . 11.4 t80 -131.75 127.87 37.69 Favored 'General case' 0 N--CA 1.476 0.847 0 O-C-N 121.762 -0.586 . . . . 0.0 110.915 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.2 129.65 12.13 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 113.683 0.994 . . . . 0.0 113.683 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -98.06 150.48 21.37 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 177.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.508 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.2 t70 -135.17 53.92 1.96 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 -177.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' O' ' 23' ' ' ASP . 57.7 t -102.72 125.23 57.09 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 N-CA-C 105.676 -1.972 . . . . 0.0 105.676 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' O' ' 24' ' ' VAL . . . 70.51 38.93 69.09 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 105.993 -2.843 . . . . 0.0 105.993 -179.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.42 ' OG ' ' OD2' ' P' ' 23' ' ' ASP . 0.7 OUTLIER -63.97 101.74 0.42 Allowed 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -174.799 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 55.9 p30 -158.64 167.66 28.96 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.499 177.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' O' ' 29' ' ' GLY . 51.9 mtpt 30.6 41.27 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 172.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' P' ' 30' ' ' ALA . . . -89.83 -67.99 1.22 Allowed Glycine 0 CA--C 1.545 1.95 0 CA-C-O 116.961 -2.022 . . . . 0.0 115.2 -173.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.609 ' HB2' ' O ' ' P' ' 29' ' ' GLY . . . -179.25 152.98 0.57 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 123.933 3.866 . . . . 0.0 115.206 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.479 HD12 HG23 ' J' ' 39' ' ' VAL . 35.7 mt -132.12 126.74 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 114.139 -1.392 . . . . 0.0 110.295 176.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.402 HG21 HD13 ' P' ' 32' ' ' ILE . 70.8 mt -111.78 111.82 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.88 109.45 2.7 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 176.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.831 HD12 ' O ' ' O' ' 34' ' ' LEU . 47.7 tp -147.98 151.07 35.16 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 115.061 1.504 . . . . 0.0 115.061 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 96.9 mmm -125.3 111.36 15.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 177.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.595 HG23 HG22 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -133.53 102.66 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.111 -177.81 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.08 -162.42 14.55 Favored Glycine 0 N--CA 1.461 0.35 0 C-N-CA 121.065 -0.588 . . . . 0.0 111.715 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 -55.57 0.51 Allowed Glycine 0 CA--C 1.54 1.62 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.487 HG22 ' O ' ' D' ' 29' ' ' GLY . 80.8 t -119.26 131.55 71.63 Favored 'Isoleucine or valine' 0 C--N 1.344 0.359 0 CA-C-N 117.326 0.563 . . . . 0.0 109.775 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 74.8 t . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.028 -179.66 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -104.86 134.39 48.06 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.047 0.451 . . . . 0.0 110.511 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.36 137.07 36.97 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.623 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 77.6 t -126.3 130.94 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.113 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.536 ' C ' ' ND1' ' Q' ' 14' ' ' HIS . 68.2 m80 -133.05 94.27 3.33 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.909 0.385 . . . . 0.0 110.851 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.61 ' CG ' ' O ' ' R' ' 14' ' ' HIS . 2.0 m80 -143.09 169.9 16.72 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -128.62 150.1 50.37 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -97.89 104.81 16.87 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.987 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.408 HD12 ' O ' ' R' ' 16' ' ' LYS . 2.0 mp -120.9 117.55 27.64 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.31 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 10.1 p -125.92 127.13 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-O 121.565 0.697 . . . . 0.0 109.904 178.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' Q' ' 21' ' ' ALA . 30.8 t80 -124.71 125.12 43.56 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.642 -178.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -130.15 121.91 27.2 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.461 ' HB3' ' CE1' ' Q' ' 19' ' ' PHE . . . -162.18 174.33 13.06 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' P' ' 23' ' ' ASP . 22.6 tt0 -78.79 -178.64 6.09 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 114.538 -1.21 . . . . 0.0 109.965 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.504 ' H ' ' HG2' ' Q' ' 22' ' ' GLU . 56.0 m-20 -169.18 54.95 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 122.476 0.311 . . . . 0.0 111.541 -174.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 t -91.04 -124.22 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 121.424 -0.798 . . . . 0.0 111.71 -173.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.64 -38.91 36.05 Favored Glycine 0 N--CA 1.47 0.902 0 C-N-CA 118.903 -1.618 . . . . 0.0 114.025 -172.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.444 ' O ' ' O ' ' Q' ' 27' ' ' ASN . 23.3 t -162.26 115.93 1.79 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 119.227 1.514 . . . . 0.0 110.997 176.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.523 ' OD1' ' N ' ' Q' ' 27' ' ' ASN . 0.5 OUTLIER -23.72 149.66 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.305 -0.861 . . . . 0.0 112.688 178.3 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.495 ' CE ' ' O ' ' K' ' 40' ' ' VAL . 11.3 mttt -178.85 38.24 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 172.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.447 ' O ' ' OD2' ' O' ' 23' ' ' ASP . . . -71.94 -62.41 3.38 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 120.314 -0.945 . . . . 0.0 113.572 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.06 169.1 0.95 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.423 ' CD1' HG23 ' K' ' 39' ' ' VAL . 23.0 mt -116.77 111.91 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 176.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 69.9 mt -105.16 113.21 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.67 114.85 2.09 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.679 HD23 ' N ' ' Q' ' 34' ' ' LEU . 1.6 pt? -166.21 152.81 9.29 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-O 122.979 1.371 . . . . 0.0 113.672 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -96.13 116.07 28.41 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 112.544 -2.116 . . . . 0.0 107.678 178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.824 HG11 HD11 ' O' ' 17' ' ' LEU . 47.8 t -127.6 102.49 9.03 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.76 -162.85 39.73 Favored Glycine 0 N--CA 1.462 0.382 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.571 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.88 -54.34 0.41 Allowed Glycine 0 CA--C 1.536 1.39 0 CA-C-O 119.668 -0.518 . . . . 0.0 111.904 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.2 p -138.35 133.79 43.38 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 CA-C-N 117.989 0.894 . . . . 0.0 109.59 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.443 HG23 ' O ' ' R' ' 40' ' ' VAL . 34.9 m . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.083 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.75 135.06 49.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.842 0.353 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.533 ' CG ' ' NE2' ' R' ' 13' ' ' HIS . 83.8 tt0 -115.39 126.22 54.12 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.055 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.54 ' O ' ' ND1' ' R' ' 13' ' ' HIS . 14.0 p -127.92 128.88 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.147 0.498 . . . . 0.0 111.17 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 47.8 m-70 -146.91 104.59 3.72 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.4 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.61 ' O ' ' CG ' ' Q' ' 14' ' ' HIS . 80.2 m80 -151.92 171.59 17.54 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -100.09 150.66 22.25 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 118.638 0.654 . . . . 0.0 110.498 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.408 ' O ' HD12 ' Q' ' 17' ' ' LEU . 98.5 mttt -111.34 101.64 10.09 Favored 'General case' 0 C--O 1.237 0.397 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 55.7 tp -118.55 124.5 47.67 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.133 -179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.89 128.79 71.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 52.3 p90 -137.65 128.22 26.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.947 0.403 . . . . 0.0 111.115 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.4 146.8 42.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.609 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -156.35 154.51 30.67 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.554 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -87.95 132.02 34.39 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.595 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.452 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 98.8 m-20 59.01 53.37 5.62 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 p -59.75 142.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.885 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' R' ' 26' ' ' SER . . . -153.66 27.81 0.75 Allowed Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' R' ' 25' ' ' GLY . 1.1 m 91.53 136.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.453 0.644 . . . . 0.0 112.57 178.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t30 83.01 141.98 0.07 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.344 -1.298 . . . . 0.0 111.394 178.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -47.08 -49.15 22.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.323 0.582 . . . . 0.0 110.987 178.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.05 -51.37 0.86 Allowed Glycine 0 CA--C 1.551 2.3 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.037 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.56 172.6 8.58 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.565 HD12 HG23 ' L' ' 39' ' ' VAL . 10.5 mt -111.84 108.28 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 41.8 mt -112.62 113.67 44.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.239 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.52 86.73 0.46 Allowed Glycine 0 N--CA 1.463 0.45 0 N-CA-C 103.6 -3.8 . . . . 0.0 103.6 174.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.467 HD11 HG13 ' R' ' 36' ' ' VAL . 16.2 tp -123.42 128.72 50.25 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.401 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 1.6 mtp -101.08 113.83 27.2 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 177.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.467 HG13 HD11 ' R' ' 34' ' ' LEU . 0.9 OUTLIER -130.36 131.69 65.26 Favored 'Isoleucine or valine' 0 C--N 1.342 0.279 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.473 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' P' ' 15' ' ' GLN . . . 82.04 -111.25 3.31 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.96 -72.63 0.63 Allowed Glycine 0 CA--C 1.541 1.662 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -143.3 137.73 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 117.754 0.777 . . . . 0.0 111.144 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.522 HG22 ' O ' ' R' ' 40' ' ' VAL . 7.7 p . . . . . 0 C--O 1.221 -0.423 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -105.92 136.38 45.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.767 0.318 . . . . 0.0 110.539 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -99.97 121.36 41.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.069 0.461 . . . . 0.0 110.579 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG13 ' O ' ' B' ' 12' ' ' VAL . 2.5 t -118.24 99.29 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.715 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m170 -94.28 116.64 29.06 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -155.43 161.95 40.87 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.574 HE22 ' C ' ' C' ' 36' ' ' VAL . 88.1 mt-30 -90.01 159.74 16.71 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.367 177.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.0 110.26 6.58 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.968 HD11 HG11 ' C' ' 36' ' ' VAL . 21.0 mt -127.9 128.33 44.95 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-O 122.137 0.97 . . . . 0.0 111.66 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.97 100.98 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.559 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD2' ' CE1' ' B' ' 19' ' ' PHE . 63.2 m-85 -105.39 108.23 19.63 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 105.195 -2.15 . . . . 0.0 105.195 177.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.489 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 1.6 t80 -137.72 127.62 25.61 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -176.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' B' ' 22' ' ' GLU . . . -108.69 107.42 17.87 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 174.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.593 ' CG ' ' H ' ' A' ' 23' ' ' ASP . 22.5 tt0 -121.35 179.53 4.4 Favored 'General case' 0 N--CA 1.471 0.599 0 O-C-N 123.793 0.683 . . . . 0.0 111.987 -176.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.593 ' H ' ' CG ' ' A' ' 22' ' ' GLU . 58.0 t0 -60.66 46.36 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.335 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.779 HG12 ' H ' ' A' ' 25' ' ' GLY . 48.9 t -80.46 -179.66 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.305 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.779 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.14 -28.06 70.88 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 120.114 -1.041 . . . . 0.0 111.35 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 8.5 m 143.59 128.68 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.417 0.687 . . . . 0.0 109.959 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -53.82 172.26 0.08 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -61.86 -39.46 91.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.486 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.02 67.82 1.48 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.18 -171.17 3.84 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.674 0.749 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 4.8 mp -113.63 121.3 65.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 95.8 mt -120.72 129.05 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 121.037 0.446 . . . . 0.0 111.73 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.13 107.17 0.83 Allowed Glycine 0 CA--C 1.521 0.455 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.5 tp -133.25 130.55 39.16 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 121.555 0.693 . . . . 0.0 110.657 -178.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.0 mtp -136.71 136.89 39.39 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.74 ' CG2' ' H ' ' B' ' 37' ' ' GLY . 11.7 m -98.03 143.12 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.817 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -30.65 -102.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.754 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.53 72.74 0.08 OUTLIER Glycine 0 CA--C 1.536 1.361 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -138.18 152.38 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.843 179.663 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -115.03 136.6 52.95 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.764 0.316 . . . . 0.0 110.312 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -134.35 127.75 32.3 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.674 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 12' ' ' VAL . 62.0 t -116.0 97.63 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.504 ' CE1' ' OXT' ' D' ' 40' ' ' VAL . 3.2 t-160 -85.52 128.63 34.8 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.655 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 35.8 t60 -154.95 174.58 14.94 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.614 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 33.8 tt0 -158.38 139.81 13.45 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.36 176.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -102.65 105.36 15.82 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.942 -1.026 . . . . 0.0 112.141 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.597 HD21 HG11 ' D' ' 36' ' ' VAL . 8.9 mt -128.55 115.83 18.72 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.932 0.787 . . . . 0.0 109.85 177.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -123.6 112.82 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-O 121.948 0.88 . . . . 0.0 109.423 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.558 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 35.9 m-85 -109.89 112.39 24.38 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 114.238 -1.346 . . . . 0.0 108.262 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.495 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 5.4 t80 -126.58 135.65 51.52 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' OD1' ' C' ' 23' ' ' ASP . . . -130.66 117.14 19.05 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 21' ' ' ALA . 80.9 tt0 173.97 113.95 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.934 ' O ' HG13 ' B' ' 24' ' ' VAL . 43.9 p30 -151.54 -50.9 0.12 Allowed 'General case' 0 C--O 1.204 -1.305 0 N-CA-C 121.159 3.763 . . . . 0.0 121.159 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.934 HG13 ' O ' ' B' ' 23' ' ' ASP . 0.1 OUTLIER 158.95 -142.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 CA-C-N 122.249 2.295 . . . . 0.0 108.813 -173.507 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.448 ' H ' ' HB ' ' B' ' 24' ' ' VAL . . . -71.39 38.88 0.58 Allowed Glycine 0 C--N 1.344 0.986 0 C-N-CA 125.982 1.753 . . . . 0.0 112.673 -174.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.516 ' OG ' ' ND2' ' C' ' 27' ' ' ASN . 14.4 t -74.05 102.55 4.22 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.408 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 29.1 m-20 -93.15 -160.11 0.73 Allowed 'General case' 0 CA--C 1.54 0.568 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 -168.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -42.16 -41.21 2.59 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 118.282 2.697 . . . . 0.0 118.282 -170.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.48 ' HA3' HG22 ' N' ' 39' ' ' VAL . . . -161.46 64.07 0.27 Allowed Glycine 0 N--CA 1.475 1.276 0 C-N-CA 116.332 -2.842 . . . . 0.0 118.182 -174.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.58 117.8 22.82 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' O' ' 39' ' ' VAL . 83.1 mt -122.0 130.96 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.436 -177.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -119.54 120.42 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.71 178.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.24 116.68 3.22 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -139.13 138.44 37.01 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 119.851 -0.739 . . . . 0.0 112.088 -177.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.45 126.55 31.42 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 121.395 0.617 . . . . 0.0 111.525 179.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' C' ' 37' ' ' GLY . 71.6 t -105.32 122.85 59.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.372 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.74 ' H ' ' CG2' ' A' ' 36' ' ' VAL . . . -36.17 113.16 0.15 Allowed Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.799 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' C' ' 38' ' ' GLY . . . -24.87 -66.29 0.05 OUTLIER Glycine 0 CA--C 1.546 2.027 0 CA-C-N 114.789 -0.705 . . . . 0.0 114.596 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.73 HG22 HD11 ' H' ' 31' ' ' ILE . 8.2 m -65.15 133.5 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-N 118.646 1.223 . . . . 0.0 111.142 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.94 -1.028 . . . . 0.0 110.446 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 54.0 p90 -151.25 162.71 40.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.889 0.376 . . . . 0.0 110.498 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -134.78 150.0 50.48 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.279 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -126.34 138.21 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.595 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.531 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 6.2 p80 -152.36 131.59 12.78 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.462 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.7 p80 -149.73 157.51 43.29 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 120.11 -0.636 . . . . 0.0 111.631 178.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.599 ' HB3' HD11 ' C' ' 17' ' ' LEU . 99.4 mm-40 -90.4 160.58 15.99 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.279 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -139.7 101.76 4.28 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.833 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.1 OUTLIER -125.68 125.16 42.61 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.212 -178.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.3 t -117.62 103.7 15.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.561 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 73.9 m-85 -106.2 107.12 17.97 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 179.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.529 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 30.5 t80 -121.25 117.03 26.02 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.96 123.52 43.73 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-O 122.246 1.022 . . . . 0.0 112.901 -178.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 82.9 tt0 -154.62 85.96 1.13 Allowed 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 176.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.59 ' OD1' ' HB1' ' B' ' 21' ' ' ALA . 80.1 m-20 -121.13 46.75 1.97 Allowed 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -175.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.561 ' CG1' ' H ' ' D' ' 26' ' ' SER . 3.1 t -100.95 161.49 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 175.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 69.82 28.41 72.01 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.534 -2.226 . . . . 0.0 107.534 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.0 m -170.14 -135.0 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 -174.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.516 ' ND2' ' OG ' ' B' ' 26' ' ' SER . 4.4 m120 -32.37 129.15 0.21 Allowed 'General case' 0 C--N 1.348 0.505 0 CA-C-O 121.938 0.875 . . . . 0.0 112.88 -175.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' D' ' 28' ' ' LYS . 37.6 tttm -91.21 -44.82 8.99 Favored 'General case' 0 C--O 1.225 -0.227 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.79 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.35 60.77 0.29 Allowed Glycine 0 CA--C 1.547 2.036 0 CA-C-N 115.677 -0.692 . . . . 0.0 113.989 -176.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.34 133.6 35.23 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 118.263 1.031 . . . . 0.0 111.001 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.521 HG12 HD12 ' D' ' 31' ' ' ILE . 72.5 mt -127.6 127.17 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.114 0.783 . . . . 0.0 113.114 -177.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.638 HG22 HD21 ' D' ' 34' ' ' LEU . 52.6 mt -109.19 114.34 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 175.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.36 122.92 5.54 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 107.712 -2.155 . . . . 0.0 107.712 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.694 ' N ' HD23 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -168.8 149.67 4.56 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 116.111 -2.235 . . . . 0.0 114.493 -176.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.409 ' N ' HD12 ' C' ' 34' ' ' LEU . 5.4 ttm -109.59 110.12 21.1 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 112.454 -2.157 . . . . 0.0 108.224 177.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.968 HG11 HD11 ' A' ' 17' ' ' LEU . 0.2 OUTLIER -96.59 102.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.573 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' B' ' 36' ' ' VAL . . . 45.14 170.69 0.01 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 114.643 -1.162 . . . . 0.0 113.108 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -118.29 -54.77 0.28 Allowed Glycine 0 CA--C 1.538 1.516 0 CA-C-N 114.783 -0.709 . . . . 0.0 111.921 179.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -117.4 134.9 59.54 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 O-C-N 122.308 -0.524 . . . . 0.0 109.974 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.358 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.371 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -86.46 137.05 32.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.835 0.35 . . . . 0.0 110.291 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.531 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.1 tt0 -158.76 130.98 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.11 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.526 ' CG1' ' CG ' ' E' ' 13' ' ' HIS . 48.2 t -108.27 132.18 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 9.6 p-80 -142.19 143.4 32.92 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.611 0.72 . . . . 0.0 112.743 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.498 ' O ' ' CB ' ' C' ' 14' ' ' HIS . 52.5 p-80 -160.18 175.88 12.4 Favored 'General case' 0 C--O 1.224 -0.24 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.557 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.456 ' NE2' HD11 ' D' ' 17' ' ' LEU . 13.4 pt20 -154.87 140.36 17.83 Favored 'General case' 0 CA--C 1.52 -0.207 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.461 177.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -93.67 99.1 11.58 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.556 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.549 ' CD2' HD13 ' C' ' 17' ' ' LEU . 2.5 mt -107.83 110.33 22.09 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -113.29 103.2 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 84.0 m-85 -105.05 109.64 21.72 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.593 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 16.1 t80 -125.98 132.61 52.01 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -177.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.552 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . . . -141.0 135.49 31.18 Favored 'General case' 0 C--O 1.246 0.898 0 CA-C-O 121.952 0.882 . . . . 0.0 112.279 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.473 ' OE1' ' CG2' ' D' ' 24' ' ' VAL . 9.4 tt0 -81.87 -154.73 0.12 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 114.664 -1.153 . . . . 0.0 112.439 -178.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.453 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 3.2 t70 -169.01 55.15 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 -174.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.473 ' CG2' ' OE1' ' D' ' 22' ' ' GLU . 5.9 t -90.88 -123.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -176.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.553 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -75.05 -39.16 38.35 Favored Glycine 0 N--CA 1.467 0.766 0 C-N-CA 117.153 -2.451 . . . . 0.0 110.187 -175.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.561 ' H ' ' CG1' ' C' ' 24' ' ' VAL . 1.7 p 152.96 103.47 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 173.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' C' ' 23' ' ' ASP . 91.1 m-20 -40.74 166.97 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 173.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.511 ' O ' ' O ' ' C' ' 28' ' ' LYS . 51.3 pttt -179.28 28.72 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 118.703 -1.199 . . . . 0.0 112.259 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 78.91 0.06 OUTLIER Glycine 0 CA--C 1.528 0.864 0 C-N-CA 119.89 -1.147 . . . . 0.0 113.11 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.22 100.68 2.92 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 119.005 -0.522 . . . . 0.0 109.684 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' P' ' 39' ' ' VAL . 90.0 mt -123.26 119.22 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 CA-C-N 119.236 0.925 . . . . 0.0 111.653 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.405 HG21 HD13 ' D' ' 32' ' ' ILE . 76.2 mt -108.09 107.23 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.45 90.41 0.52 Allowed Glycine 0 N--CA 1.469 0.863 0 N-CA-C 107.311 -2.316 . . . . 0.0 107.311 178.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.694 HD23 ' N ' ' C' ' 34' ' ' LEU . 14.4 mt -137.16 157.07 47.49 Favored 'General case' 0 CA--C 1.509 -0.614 0 CA-C-O 123.225 1.488 . . . . 0.0 114.482 -176.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -117.9 105.04 11.5 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 111.744 -2.48 . . . . 0.0 105.122 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.597 HG11 HD21 ' B' ' 17' ' ' LEU . 1.7 t -93.81 112.34 26.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 119.366 -0.934 . . . . 0.0 109.109 -178.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . 51.87 131.98 0.0 OUTLIER Glycine 0 CA--C 1.528 0.891 0 CA-C-N 114.633 -1.167 . . . . 0.0 112.282 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.453 ' CA ' ' O ' ' C' ' 38' ' ' GLY . . . -74.78 -58.57 4.05 Favored Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.996 178.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' C' ' 38' ' ' GLY . 50.2 t -130.64 123.37 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 117.494 0.647 . . . . 0.0 110.0 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.504 ' OXT' ' CE1' ' B' ' 13' ' ' HIS . 13.2 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -106.79 134.38 50.02 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 120.847 0.356 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' D' ' 11' ' ' GLU . 98.2 mt-10 -86.09 114.45 22.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.333 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.537 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 27.1 m -131.45 162.44 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.526 ' CG ' ' CG1' ' D' ' 12' ' ' VAL . 0.2 OUTLIER -112.28 162.63 15.3 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.138 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 73.0 m-70 -74.87 164.81 26.15 Favored 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.282 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -100.28 151.96 20.86 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -110.48 104.6 13.36 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.428 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.3 tp -114.57 115.65 27.52 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.8 t -126.36 127.95 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 121.268 0.556 . . . . 0.0 111.359 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -125.33 120.36 30.92 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.704 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.593 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 32.5 t80 -125.46 125.75 43.82 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.409 ' CB ' ' HZ3' ' E' ' 28' ' ' LYS . . . -146.98 136.35 22.74 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 120.121 -0.631 . . . . 0.0 112.004 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -100.81 149.32 23.97 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.74 -179.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' F' ' 22' ' ' GLU . 8.1 m-20 42.26 48.89 4.37 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.471 0.653 . . . . 0.0 112.475 177.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.586 HG22 ' O ' ' F' ' 22' ' ' GLU . 8.0 m -71.6 162.22 4.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-O 121.99 0.9 . . . . 0.0 111.715 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.67 -30.79 7.55 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 113.807 -1.542 . . . . 0.0 111.516 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -83.3 143.32 30.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 102.702 -3.073 . . . . 0.0 102.702 171.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.462 ' OD1' ' O ' ' F' ' 29' ' ' GLY . 51.4 t30 -72.31 125.36 27.15 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 114.747 -2.781 . . . . 0.0 109.58 -178.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.552 ' HZ3' ' HB3' ' D' ' 21' ' ' ALA . 98.5 mttt -50.5 -52.82 34.91 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 122.968 1.366 . . . . 0.0 111.64 175.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.72 49.36 3.18 Favored Glycine 0 CA--C 1.554 2.513 0 CA-C-N 112.002 -2.363 . . . . 0.0 111.057 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.89 133.99 46.38 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 82.4 mt -123.6 118.05 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 CA-C-N 119.461 1.028 . . . . 0.0 112.209 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.3 104.96 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.19 97.37 1.32 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 104.707 -3.357 . . . . 0.0 104.707 176.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.485 HD11 ' CG2' ' D' ' 36' ' ' VAL . 30.8 tp -137.12 135.36 37.35 Favored 'General case' 0 CA--C 1.509 -0.619 0 N-CA-C 114.481 1.289 . . . . 0.0 114.481 -173.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.7 mtp -114.54 107.14 15.11 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' C' ' 17' ' ' LEU . 0.2 OUTLIER -96.64 112.28 28.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 51.72 132.03 0.0 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.977 179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.81 -58.84 5.5 Favored Glycine 0 CA--C 1.536 1.396 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.597 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 p -139.27 137.59 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 111.205 -179.215 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -112.55 136.15 52.43 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -110.2 113.88 26.91 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.882 0.373 . . . . 0.0 110.65 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.542 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.6 p -141.69 163.59 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.89 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.542 ' N ' HG22 ' F' ' 12' ' ' VAL . 4.4 m80 -134.89 131.27 37.14 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.973 0.416 . . . . 0.0 110.768 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 56.6 t-80 -86.43 174.02 9.26 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.487 -178.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.559 ' N ' ' ND1' ' F' ' 14' ' ' HIS . 53.3 tt0 -84.0 150.2 25.78 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.851 0.358 . . . . 0.0 110.519 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -122.16 112.78 18.62 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.725 0.774 . . . . 0.0 110.13 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 tp -112.08 121.66 45.59 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.316 179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.9 t -126.65 126.89 69.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.56 125.44 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.15 0.5 . . . . 0.0 110.946 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -124.4 111.16 15.43 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.404 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -136.69 138.87 41.5 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.017 -178.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.586 ' O ' HG22 ' E' ' 24' ' ' VAL . 94.1 mt-10 -95.26 117.65 30.64 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.26 179.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' F' ' 22' ' ' GLU . 14.4 t0 89.33 48.45 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.268 0.556 . . . . 0.0 109.581 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 6.4 m -72.04 161.5 4.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.129 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.13 -33.09 6.05 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.366 -0.693 . . . . 0.0 111.366 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.533 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 26.4 t -81.12 -129.42 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 117.58 0.69 . . . . 0.0 110.48 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.533 ' N ' ' OG ' ' F' ' 26' ' ' SER . 63.3 t30 -100.19 160.6 14.2 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -44.29 -40.37 5.2 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.896 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.462 ' O ' ' OD1' ' E' ' 27' ' ' ASN . . . 101.24 -62.4 0.56 Allowed Glycine 0 CA--C 1.545 1.958 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.44 -177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.469 ' HB2' ' HD2' ' E' ' 28' ' ' LYS . . . -110.95 166.42 11.05 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.545 HD12 HG21 ' Q' ' 39' ' ' VAL . 97.3 mt -112.36 107.75 23.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 118.95 0.796 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -104.56 107.5 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.11 108.79 1.5 Allowed Glycine 0 C--N 1.332 0.334 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.502 ' O ' HD12 ' F' ' 34' ' ' LEU . 0.3 OUTLIER -167.89 173.13 8.45 Favored 'General case' 0 N--CA 1.434 -1.226 0 C-N-CA 118.408 -1.317 . . . . 0.0 111.643 -176.278 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 32.6 mtp -135.5 117.47 15.27 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 113.453 -1.703 . . . . 0.0 107.918 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.537 HG11 ' CD2' ' D' ' 17' ' ' LEU . 1.8 t -89.8 103.06 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.23 161.31 2.58 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 -176.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -108.19 -55.45 0.6 Allowed Glycine 0 N--CA 1.477 1.4 0 CA-C-N 117.251 0.526 . . . . 0.0 112.022 178.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 48.3 t -126.74 131.82 70.74 Favored 'Isoleucine or valine' 0 C--N 1.343 0.322 0 CA-C-O 121.329 0.585 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.22 -0.496 0 CA-C-N 114.99 -1.005 . . . . 0.0 111.172 -179.236 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.454 ' CD2' ' O ' ' H' ' 10' ' ' TYR . 49.3 p90 -149.85 158.72 44.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.836 0.351 . . . . 0.0 110.521 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -143.04 164.03 31.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 121.048 0.451 . . . . 0.0 110.747 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.493 HG23 ' O ' ' G' ' 12' ' ' VAL . 15.2 m -113.3 128.34 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.26 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 7.0 m80 -119.51 141.74 48.93 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 120.712 0.291 . . . . 0.0 111.304 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 47.1 m-70 -148.28 161.12 42.15 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.595 178.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.691 HE21 ' CD1' ' G' ' 17' ' ' LEU . 51.5 tt0 -90.14 159.03 16.99 Favored 'General case' 0 CA--C 1.518 -0.271 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 176.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -140.68 101.48 4.09 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.147 -0.621 . . . . 0.0 111.602 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.691 ' CD1' HE21 ' G' ' 15' ' ' GLN . 95.8 mt -126.6 111.81 14.77 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 118.667 0.667 . . . . 0.0 110.234 177.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 53.0 t -117.36 104.58 16.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -108.06 108.55 19.7 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.9 p90 -116.71 124.24 49.18 Favored 'General case' 0 CA--C 1.521 -0.171 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.67 117.09 30.58 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.761 0.315 . . . . 0.0 111.582 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.445 ' O ' ' OD1' ' G' ' 23' ' ' ASP . 4.1 pt-20 -167.65 104.93 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' G' ' 22' ' ' GLU . 63.5 m-20 -160.71 46.81 0.22 Allowed 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -175.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.688 HG12 ' N ' ' G' ' 25' ' ' GLY . 51.3 t -82.42 173.7 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.284 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.688 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 91.21 -33.35 4.76 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 36.7 t -151.69 123.64 8.09 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.511 ' OD1' ' N ' ' H' ' 27' ' ' ASN . 16.3 t30 -41.52 150.95 0.09 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.837 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.434 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 88.8 tttt -75.22 -50.5 15.97 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.502 177.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.37 50.32 3.22 Favored Glycine 0 CA--C 1.545 1.931 0 CA-C-O 118.417 -1.213 . . . . 0.0 111.596 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -130.64 105.28 7.71 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 116.848 2.166 . . . . 0.0 116.848 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.454 HD11 ' HA3' ' H' ' 29' ' ' GLY . 86.0 mt -125.64 105.49 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 172.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.78 133.23 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.85 1.056 . . . . 0.0 113.85 -176.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.67 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -134.72 105.76 0.57 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 106.77 -2.532 . . . . 0.0 106.77 176.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.67 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.1 mm? -132.74 149.01 52.33 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.651 0.739 . . . . 0.0 111.732 -177.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.9 ttm -131.71 129.68 41.0 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 114.904 -1.044 . . . . 0.0 111.521 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' G' ' 37' ' ' GLY . 53.0 t -123.16 131.53 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.087 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -35.1 -111.56 0.0 OUTLIER Glycine 0 CA--C 1.53 0.999 0 CA-C-O 121.776 0.654 . . . . 0.0 112.849 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.93 67.78 0.08 OUTLIER Glycine 0 CA--C 1.533 1.178 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.434 ' O ' ' C ' ' G' ' 40' ' ' VAL . 7.9 p -136.12 137.78 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 117.797 0.799 . . . . 0.0 110.722 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' G' ' 39' ' ' VAL . 27.5 m . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.72 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . 0.454 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 94.1 m-85 -107.62 138.33 44.05 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.696 0.284 . . . . 0.0 110.428 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.548 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.8 mp0 -134.08 146.9 50.73 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.844 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.439 ' H ' HG12 ' G' ' 12' ' ' VAL . 74.1 t -125.2 128.47 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' I' ' 13' ' ' HIS . 6.6 t60 -138.32 131.71 30.48 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 121.059 -0.256 . . . . 0.0 111.517 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 0.0 OUTLIER -153.26 161.52 42.3 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.703 -179.999 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.449 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 70.6 mm-40 -90.13 159.26 16.87 Favored 'General case' 0 C--N 1.344 0.362 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -140.49 96.16 2.99 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.545 HD21 HG11 ' J' ' 36' ' ' VAL . 87.5 mt -117.58 111.17 18.85 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.416 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -115.71 99.26 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -108.11 108.52 19.63 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -126.97 126.08 42.59 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 111.754 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.34 114.91 25.76 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -128.34 120.23 26.63 Favored 'General case' 0 N--CA 1.461 0.104 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.532 ' H ' ' CD ' ' I' ' 22' ' ' GLU . 19.6 m-20 42.86 50.16 5.17 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.568 HG12 ' N ' ' H' ' 25' ' ' GLY . 42.9 t -49.73 164.56 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.343 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.568 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -174.8 21.58 0.06 OUTLIER Glycine 0 C--O 1.224 -0.496 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.284 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 33.4 t -68.66 115.7 8.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 176.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.511 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 3.4 m120 -118.33 -158.76 0.73 Allowed 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 121.63 0.729 . . . . 0.0 112.612 -178.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 61.2 tttt 29.51 40.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.205 -1.361 . . . . 0.0 112.34 -178.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 30' ' ' ALA . . . 111.31 73.96 0.72 Allowed Glycine 0 CA--C 1.537 1.411 0 C-N-CA 120.29 -0.957 . . . . 0.0 114.747 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 84.15 2.38 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 118.87 1.335 . . . . 0.0 111.47 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.73 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -140.42 130.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.346 0.441 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.675 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.521 HG22 HD21 ' I' ' 34' ' ' LEU . 36.2 mm -114.49 117.75 56.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.2 114.18 2.1 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.649 ' HB3' HD22 ' I' ' 34' ' ' LEU . 52.9 tp -141.28 135.64 30.81 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.335 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -119.58 110.14 16.52 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.532 177.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.21 142.99 9.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.908 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 156.71 -101.95 0.21 Allowed Glycine 0 C--N 1.307 -1.081 0 N-CA-C 109.774 -1.331 . . . . 0.0 109.774 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.405 ' O ' ' CG2' ' I' ' 39' ' ' VAL . . . 61.9 -79.49 0.02 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.422 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.444 ' N ' ' O ' ' H' ' 37' ' ' GLY . 71.1 t -111.17 135.8 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 122.719 0.408 . . . . 0.0 110.419 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.44 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 70.0 t . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 118.106 -0.949 . . . . 0.0 110.132 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . 0.441 ' O ' ' CD2' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -108.3 131.99 54.15 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.787 0.327 . . . . 0.0 110.834 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -74.3 119.11 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.989 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.597 ' CG2' ' NE2' ' I' ' 14' ' ' HIS . 11.8 p -138.63 143.96 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.795 0.331 . . . . 0.0 111.158 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 2.9 t60 -148.77 131.11 15.61 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.229 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 30.9 m-70 -145.63 159.93 42.41 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.642 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.79 ' OE1' HG23 ' L' ' 36' ' ' VAL . 85.1 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -140.74 100.56 3.88 Favored 'General case' 0 C--N 1.313 -0.993 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.906 176.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.674 ' N ' HD12 ' I' ' 17' ' ' LEU . 7.3 mp -110.71 104.83 13.53 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.7 t -110.96 94.82 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 176.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD13 ' K' ' 32' ' ' ILE . 7.5 m-30 -109.35 105.53 14.96 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.498 ' CD2' ' CD1' ' J' ' 20' ' ' PHE . 9.0 m-85 -119.56 138.2 53.35 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 -179.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.33 139.02 31.66 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' H' ' 23' ' ' ASP . 5.8 mt-10 -69.05 -165.38 0.07 Allowed 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.769 ' OD1' HG13 ' J' ' 24' ' ' VAL . 3.2 t0 -170.21 50.38 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 118.162 -1.415 . . . . 0.0 113.227 -174.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.673 HG13 ' N ' ' I' ' 25' ' ' GLY . 6.9 p -76.41 -142.6 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -176.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.673 ' N ' HG13 ' I' ' 24' ' ' VAL . . . -89.19 -38.74 6.65 Favored Glycine 0 N--CA 1.469 0.893 0 C-N-CA 117.373 -2.346 . . . . 0.0 111.696 -174.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 39.8 m -155.61 111.34 3.06 Favored 'General case' 0 C--N 1.32 -0.717 0 C-N-CA 118.123 -1.431 . . . . 0.0 111.583 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.611 HD21 ' C ' ' J' ' 29' ' ' GLY . 25.9 p30 -53.31 170.91 0.08 Allowed 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 173.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? -61.12 -41.78 97.33 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' J' ' 29' ' ' GLY . . . 111.11 62.14 0.49 Allowed Glycine 0 CA--C 1.538 1.482 0 CA-C-N 114.331 -1.304 . . . . 0.0 112.165 -178.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.38 155.54 18.88 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 122.353 1.073 . . . . 0.0 112.252 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -134.8 129.27 51.42 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.382 -178.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -109.75 124.78 66.75 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 177.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.789 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -131.81 104.33 0.57 Allowed Glycine 0 N--CA 1.471 1.023 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 178.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.789 HD23 ' O ' ' I' ' 33' ' ' GLY . 6.0 mt -139.59 146.95 40.46 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 114.338 1.236 . . . . 0.0 114.338 -177.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.443 ' CE ' ' SD ' ' J' ' 35' ' ' MET . 1.7 ttm -109.17 103.63 12.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 103.706 -2.702 . . . . 0.0 103.706 173.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.36 102.52 11.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.819 0.342 . . . . 0.0 111.435 -175.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.61 -163.81 12.69 Favored Glycine 0 CA--C 1.522 0.524 0 CA-C-O 121.869 0.705 . . . . 0.0 112.975 177.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.456 ' N ' ' HA2' ' J' ' 37' ' ' GLY . . . 156.1 -54.3 0.41 Allowed Glycine 0 CA--C 1.544 1.857 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.87 HG13 HD11 ' O' ' 31' ' ' ILE . 0.0 OUTLIER -127.9 132.67 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.786 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.44 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 71.7 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.385 -178.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -106.73 135.77 47.7 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -137.04 143.78 42.87 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.049 0.452 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -126.4 127.4 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.862 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.7 OUTLIER -115.38 153.87 30.23 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.64 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.645 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 7.2 t60 -167.89 168.96 11.84 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -137.69 150.03 47.01 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.504 177.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.582 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.3 mttt -117.27 97.59 5.99 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.149 175.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.829 HD21 HG21 ' L' ' 36' ' ' VAL . 8.6 mp -112.74 112.53 24.1 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 120.263 1.392 . . . . 0.0 110.489 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 t -122.82 106.71 18.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 121.365 0.602 . . . . 0.0 109.511 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -108.45 112.38 24.76 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' CD2' ' I' ' 20' ' ' PHE . 6.3 t80 -131.23 134.45 46.46 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -175.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.22 133.82 33.68 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.473 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -136.15 150.9 49.26 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 115.844 1.794 . . . . 0.0 115.844 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.582 ' O ' ' O ' ' I' ' 23' ' ' ASP . 44.1 t0 61.9 51.73 3.66 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 113.859 -1.519 . . . . 0.0 113.277 177.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.82 HG12 ' OG ' ' K' ' 26' ' ' SER . 1.5 t -66.93 145.0 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.033 0.444 . . . . 0.0 112.104 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.72 -22.82 0.92 Allowed Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.63 ' N ' ' OG ' ' K' ' 26' ' ' SER . 3.4 p 178.9 179.22 0.41 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -45.27 127.72 7.2 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.179 177.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.431 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 49.8 mtmt -73.14 -51.87 16.31 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.467 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.611 ' C ' HD21 ' I' ' 27' ' ' ASN . . . 89.92 49.87 3.23 Favored Glycine 0 CA--C 1.546 2.018 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.483 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.53 149.44 52.2 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 119.588 1.694 . . . . 0.0 109.871 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.416 HD11 HG23 ' D' ' 39' ' ' VAL . 84.7 mt -135.03 129.39 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -112.87 118.67 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 175.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.642 ' O ' HD12 ' J' ' 34' ' ' LEU . . . -117.17 114.96 3.11 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.642 HD12 ' O ' ' J' ' 33' ' ' GLY . 0.9 OUTLIER -148.61 143.88 26.86 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.662 -175.693 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.443 ' SD ' ' CE ' ' I' ' 35' ' ' MET . 4.1 mtp -118.99 101.65 8.18 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 105.173 -2.158 . . . . 0.0 105.173 174.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.545 HG11 HD21 ' H' ' 17' ' ' LEU . 2.0 t -102.32 103.16 14.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 CA-C-O 122.013 0.911 . . . . 0.0 111.197 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.456 ' HA2' ' N ' ' I' ' 38' ' ' GLY . . . 64.23 161.07 0.44 Allowed Glycine 0 CA--C 1.523 0.577 0 CA-C-N 113.779 -1.555 . . . . 0.0 113.903 178.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' K' ' 38' ' ' GLY . . . -108.1 -55.45 0.6 Allowed Glycine 0 CA--C 1.536 1.361 0 CA-C-N 114.408 -0.896 . . . . 0.0 111.189 177.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.555 ' HB ' HD11 ' P' ' 31' ' ' ILE . 2.7 p -136.6 149.53 26.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.416 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.419 ' O ' ' O ' ' J' ' 39' ' ' VAL . 7.0 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.456 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -107.95 138.43 44.22 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.748 0.309 . . . . 0.0 110.597 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -114.06 132.51 56.0 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.225 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.434 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.9 m -116.33 130.47 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.82 0.343 . . . . 0.0 110.326 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.511 ' CB ' ' O ' ' J' ' 13' ' ' HIS . 14.1 p80 -153.42 146.06 24.21 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.91 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' K' ' 14' ' ' HIS . 4.4 m-70 -143.49 156.61 44.68 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.082 177.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -90.5 160.12 16.16 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.185 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -140.37 105.23 4.95 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -112.87 122.34 47.36 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.421 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -123.41 115.52 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.219 0.533 . . . . 0.0 111.588 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -107.81 114.25 28.07 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -123.13 118.87 28.67 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 117.948 0.34 . . . . 0.0 111.663 -177.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.54 118.8 11.41 Favored 'General case' 0 C--O 1.244 0.786 0 CA-C-O 121.605 0.717 . . . . 0.0 111.649 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -114.53 168.11 10.15 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.617 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 60.6 46.58 9.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.919 0.866 . . . . 0.0 110.707 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' K' ' 25' ' ' GLY . 25.0 t -73.04 179.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 113.998 -1.456 . . . . 0.0 111.103 -179.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 102.75 -34.11 6.02 Favored Glycine 0 N--CA 1.466 0.678 0 N-CA-C 106.611 -2.596 . . . . 0.0 106.611 -175.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.82 ' OG ' HG12 ' J' ' 24' ' ' VAL . 1.2 t -93.37 123.54 36.74 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 169.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -73.5 148.77 42.81 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 117.068 2.248 . . . . 0.0 117.068 -173.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 22.6 mttm -55.33 46.65 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 110.598 -3.001 . . . . 0.0 112.288 171.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.54 60.98 4.82 Favored Glycine 0 CA--C 1.551 2.311 0 N-CA-C 117.469 1.747 . . . . 0.0 117.469 -168.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.461 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -138.8 162.34 35.0 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 46.2 mt -140.47 143.09 29.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -174.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.478 HD13 ' CD2' ' I' ' 19' ' ' PHE . 15.1 tt -132.16 123.37 50.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.847 175.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.46 109.61 1.99 Allowed Glycine 0 C--N 1.33 0.244 0 N-CA-C 105.326 -3.11 . . . . 0.0 105.326 177.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.514 HD23 ' N ' ' K' ' 35' ' ' MET . 10.3 tt -149.28 152.66 36.29 Favored 'General case' 0 CA--C 1.5 -0.965 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.44 -174.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.514 ' N ' HD23 ' K' ' 34' ' ' LEU . 60.7 mtp -129.9 114.11 15.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-N 114.222 -1.353 . . . . 0.0 108.638 178.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.614 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -97.14 112.27 28.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.664 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . 51.24 132.01 0.0 OUTLIER Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.086 -1.415 . . . . 0.0 113.204 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' J' ' 38' ' ' GLY . . . -73.78 -58.68 4.36 Favored Glycine 0 CA--C 1.538 1.499 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 176.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.442 ' O ' ' OXT' ' K' ' 40' ' ' VAL . 90.8 t -105.4 118.72 53.38 Favored 'Isoleucine or valine' 0 C--N 1.343 0.315 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.442 ' OXT' ' O ' ' K' ' 39' ' ' VAL . 73.0 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.709 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . 0.433 ' CE2' ' O ' ' L' ' 11' ' ' GLU . 92.6 t80 -70.08 138.02 51.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.865 0.364 . . . . 0.0 110.773 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.433 ' O ' ' CE2' ' L' ' 10' ' ' TYR . 83.8 tt0 -70.34 123.73 22.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.376 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' K' ' 12' ' ' VAL . 2.1 t -114.09 108.98 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 121.118 0.485 . . . . 0.0 110.509 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.443 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 0.4 OUTLIER -151.71 121.64 7.09 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 179.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.578 ' CE1' ' NZ ' ' L' ' 16' ' ' LYS . 3.9 p80 -150.54 165.0 34.59 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.605 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 49.7 tt0 -89.81 159.08 17.2 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-O 120.88 0.372 . . . . 0.0 110.917 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.578 ' NZ ' ' CE1' ' L' ' 14' ' ' HIS . 64.7 mttp -139.97 113.66 8.68 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -116.37 117.43 29.94 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.887 0.375 . . . . 0.0 110.417 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 52.8 t -126.44 130.44 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 52.7 p90 -138.78 123.15 18.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.041 0.448 . . . . 0.0 111.025 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -115.61 111.3 20.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' L' ' 24' ' ' VAL . . . -144.59 145.91 32.05 Favored 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.845 -178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -85.82 155.78 20.84 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.398 -0.921 . . . . 0.0 109.997 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 56.23 48.5 17.17 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.981 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' L' ' 21' ' ' ALA . 6.9 m -71.86 161.62 4.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.764 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.51 -32.84 6.15 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 119.234 -0.759 . . . . 0.0 113.789 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 29.2 m -81.02 -129.72 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.339 1.57 . . . . 0.0 111.095 -178.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -100.05 160.5 14.27 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 120.32 -0.552 . . . . 0.0 111.795 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -44.57 -40.74 5.97 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.35 179.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.58 -62.24 0.62 Allowed Glycine 0 CA--C 1.551 2.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 112.518 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -110.81 176.37 5.06 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 90.9 mt -126.9 121.66 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 118.855 -1.138 . . . . 0.0 111.503 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -109.74 108.07 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 177.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.32 82.56 0.34 Allowed Glycine 0 CA--C 1.499 -0.96 1 N-CA-C 102.894 -4.083 . . . . 0.0 102.894 175.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.443 HD12 ' O ' ' K' ' 34' ' ' LEU . 54.8 tp -114.88 129.61 56.73 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.433 -0.884 . . . . 0.0 113.297 -174.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 96.5 mmm -108.41 103.26 12.37 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 175.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.829 HG21 HD21 ' J' ' 17' ' ' LEU . 11.8 p -122.52 124.06 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.597 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 111.43 -115.2 3.84 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.2 -71.44 0.87 Allowed Glycine 0 CA--C 1.536 1.377 0 N-CA-C 112.133 -0.387 . . . . 0.0 112.133 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.614 HG22 HD12 ' R' ' 31' ' ' ILE . 43.7 t -124.37 130.16 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.449 HG23 ' OXT' ' L' ' 40' ' ' VAL . 13.3 m . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.648 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.404 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -104.48 133.72 48.87 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -115.79 116.47 28.09 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.002 0.429 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.45 ' O ' HG23 ' M' ' 12' ' ' VAL . 32.9 m -127.7 132.85 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.61 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -137.66 127.36 25.31 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.506 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 1.9 p80 -151.78 159.94 43.75 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 51.9 tp60 -90.2 160.25 16.31 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 176.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -139.68 99.47 3.72 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.778 178.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.588 HD11 HG11 ' O' ' 36' ' ' VAL . 14.6 mt -130.69 114.56 15.54 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.909 0.862 . . . . 0.0 109.956 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 85.8 t -110.43 106.66 21.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.895 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . 0.472 ' CD2' ' CE1' ' N' ' 19' ' ' PHE . 82.1 m-85 -104.1 101.07 10.83 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.41 119.34 30.73 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.736 -176.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.97 113.73 26.21 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -172.42 131.07 0.58 Allowed 'General case' 0 C--O 1.231 0.115 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 53.87 50.33 17.11 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.012 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.58 HG12 ' N ' ' M' ' 25' ' ' GLY . 96.8 t -49.15 164.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.409 -178.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.58 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -174.45 19.52 0.05 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 41.7 m -80.54 -130.23 0.02 OUTLIER 'General case' 0 C--O 1.232 0.135 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.462 HD21 ' CA ' ' M' ' 30' ' ' ALA . 17.0 p-10 -100.59 162.41 12.94 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.343 0.592 . . . . 0.0 110.879 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' N' ' 27' ' ' ASN . 64.3 mttp -40.0 -37.99 0.66 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.11 -0.95 . . . . 0.0 113.067 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -177.94 76.17 0.07 OUTLIER Glycine 0 N--CA 1.471 1.001 0 C-N-CA 120.423 -0.894 . . . . 0.0 112.743 -176.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.462 ' CA ' HD21 ' M' ' 27' ' ' ASN . . . -80.1 142.74 34.57 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 122.932 1.349 . . . . 0.0 113.249 -177.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 37.3 pt -126.14 135.42 63.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.483 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tp -152.52 139.51 13.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 119.205 -0.998 . . . . 0.0 112.655 -178.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.84 122.23 2.98 Favored Glycine 0 N--CA 1.459 0.22 0 N-CA-C 107.16 -2.376 . . . . 0.0 107.16 177.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.45 148.7 33.57 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 122.217 1.008 . . . . 0.0 112.404 -177.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 48.5 ttm -138.73 136.02 35.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.201 179.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 56.0 t -129.05 123.39 58.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.935 177.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -46.34 113.45 1.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.455 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . -63.9 71.91 0.05 OUTLIER Glycine 0 CA--C 1.531 1.089 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.406 -178.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' M' ' 40' ' ' VAL . 54.9 t -113.12 137.61 45.53 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' M' ' 39' ' ' VAL . 51.8 t . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.414 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -111.4 136.29 50.75 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -107.04 109.38 21.24 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.865 0.364 . . . . 0.0 110.815 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 t -134.3 125.46 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -151.38 134.16 15.68 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 120.324 -0.55 . . . . 0.0 112.217 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 28.2 m-70 -150.25 153.85 36.9 Favored 'General case' 0 C--O 1.211 -0.95 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.206 177.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.727 HE22 ' CA ' ' P' ' 37' ' ' GLY . 7.8 mt-30 -94.47 163.82 13.25 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -133.89 99.06 4.33 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.827 HD11 HG11 ' P' ' 36' ' ' VAL . 2.9 mt -123.19 117.28 24.99 Favored 'General case' 0 C--N 1.356 0.859 0 CA-C-O 121.446 0.641 . . . . 0.0 110.767 179.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -112.49 104.43 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CD2' ' M' ' 19' ' ' PHE . 74.3 m-85 -107.4 107.84 18.92 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.426 ' CZ ' ' CG ' ' O' ' 20' ' ' PHE . 1.5 t80 -131.43 128.81 40.28 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.036 -178.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.23 115.74 26.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.134 178.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' N' ' 24' ' ' VAL . 81.5 tt0 -149.91 158.67 44.4 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.718 ' H ' HG21 ' O' ' 24' ' ' VAL . 38.4 t0 18.68 47.88 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.139 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.514 ' N ' ' O ' ' N' ' 22' ' ' GLU . 2.4 t -66.87 165.43 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 176.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.34 19.9 0.04 OUTLIER Glycine 0 CA--C 1.521 0.432 0 C-N-CA 119.513 -1.327 . . . . 0.0 112.501 178.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 6.7 m -71.27 119.31 15.23 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.521 ' CG ' ' H ' ' N' ' 28' ' ' LYS . 49.6 t30 -103.71 -169.84 1.69 Allowed 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 122.042 0.925 . . . . 0.0 112.801 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.521 ' H ' ' CG ' ' N' ' 27' ' ' ASN . 99.2 mttt 32.22 40.79 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 116.594 2.072 . . . . 0.0 116.594 176.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.02 73.23 0.7 Allowed Glycine 0 N--CA 1.483 1.808 0 C-N-CA 119.145 -1.502 . . . . 0.0 116.76 175.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.62 94.36 5.42 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 118.67 1.235 . . . . 0.0 110.287 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.63 ' CD1' HD12 ' O' ' 31' ' ' ILE . 11.7 mm -126.77 124.65 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.307 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 77.3 mt -120.18 117.93 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -124.75 123.66 5.14 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 54.8 tp -142.59 144.08 32.7 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 119.429 -0.909 . . . . 0.0 111.752 -178.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.408 ' HE1' ' SD ' ' O' ' 35' ' ' MET . 65.2 mtp -143.25 131.05 21.45 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -178.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 16.5 m -137.77 153.83 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.284 176.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' N' ' 39' ' ' VAL . . . -91.57 102.76 2.96 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.471 ' C ' ' O ' ' N' ' 37' ' ' GLY . . . 9.3 -72.62 0.0 OUTLIER Glycine 0 CA--C 1.539 1.575 0 C-N-CA 123.305 0.478 . . . . 0.0 114.077 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' N' ' 37' ' ' GLY . 11.8 t -31.63 133.89 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 CA-C-N 117.321 0.56 . . . . 0.0 111.794 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 N--CA 1.471 0.582 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.325 179.731 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.432 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -108.24 135.02 50.25 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.854 0.359 . . . . 0.0 110.43 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -117.85 126.03 51.63 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.276 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.452 ' O ' ' CD2' ' O' ' 13' ' ' HIS . 63.7 t -125.37 128.31 72.54 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.843 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 18.3 m80 -141.67 118.46 11.1 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.664 0.269 . . . . 0.0 111.463 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 38.7 m-70 -153.88 176.75 11.8 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.152 179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.693 HE22 ' CG2' ' Q' ' 36' ' ' VAL . 64.0 tt0 -154.97 140.44 17.81 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 120.159 -0.616 . . . . 0.0 111.091 178.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.42 ' O ' HD23 ' O' ' 17' ' ' LEU . 98.8 mttt -94.24 98.59 11.04 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.229 -0.896 . . . . 0.0 112.746 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.56 ' CD1' HG11 ' Q' ' 36' ' ' VAL . 29.3 mt -117.01 111.68 19.9 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 119.293 0.951 . . . . 0.0 109.829 177.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -118.2 110.43 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.482 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 23.6 m-85 -111.7 115.71 29.55 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.426 ' CG ' ' CZ ' ' N' ' 20' ' ' PHE . 2.2 t80 -131.66 133.51 44.97 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 118.032 0.378 . . . . 0.0 111.102 -178.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.55 118.94 17.83 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.042 0.449 . . . . 0.0 111.955 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -101.17 -173.41 2.36 Favored 'General case' 0 C--N 1.352 0.714 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.632 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.437 ' CB ' ' HB ' ' P' ' 24' ' ' VAL . 0.0 OUTLIER -124.1 50.22 1.68 Allowed 'General case' 0 N--CA 1.477 0.91 0 CA-C-O 121.654 0.74 . . . . 0.0 112.441 -177.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.718 HG21 ' H ' ' N' ' 23' ' ' ASP . 1.7 t -80.91 -141.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.572 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.444 ' H ' HG12 ' O' ' 24' ' ' VAL . . . -96.71 36.72 3.74 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.271 -2.332 . . . . 0.0 107.271 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 2.9 m -74.55 103.34 4.84 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 111.024 -2.588 . . . . 0.0 112.666 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.458 ' O ' ' O ' ' P' ' 28' ' ' LYS . 9.2 m120 -93.84 -160.78 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 106.239 -1.763 . . . . 0.0 106.239 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' P' ' 29' ' ' GLY . 99.4 mttt -48.12 -40.26 23.04 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 121.026 1.739 . . . . 0.0 108.545 -173.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' O' ' 30' ' ' ALA . . . 80.52 -68.95 3.26 Favored Glycine 0 C--N 1.311 -0.825 0 N-CA-C 115.243 0.857 . . . . 0.0 115.243 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' O' ' 29' ' ' GLY . . . 179.87 153.65 0.5 Allowed 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 123.206 1.479 . . . . 0.0 113.454 -178.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.87 HD11 HG13 ' I' ' 39' ' ' VAL . 91.8 mt -118.1 117.16 53.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 111.523 -2.581 . . . . 0.0 107.158 174.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.745 HG23 HD21 ' O' ' 34' ' ' LEU . 31.5 mt -106.74 111.83 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.616 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 104.83 0.93 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 178.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.807 ' O ' HD23 ' P' ' 34' ' ' LEU . 0.0 OUTLIER -155.91 160.04 39.8 Favored 'General case' 0 CA--C 1.511 -0.54 0 C-N-CA 117.287 -1.765 . . . . 0.0 113.812 -178.557 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.408 ' SD ' ' HE1' ' N' ' 35' ' ' MET . 18.3 mtp -116.24 107.62 15.09 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 111.253 -2.703 . . . . 0.0 106.664 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.588 HG11 HD11 ' M' ' 17' ' ' LEU . 2.0 t -132.93 101.88 4.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.904 -178.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.64 172.53 19.92 Favored Glycine 0 N--CA 1.457 0.086 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.858 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' P' ' 39' ' ' VAL . . . 158.31 -55.31 0.37 Allowed Glycine 0 CA--C 1.538 1.484 0 CA-C-N 114.154 -1.023 . . . . 0.0 110.587 -178.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' B' ' 31' ' ' ILE . 3.0 p -142.86 155.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 117.6 0.7 . . . . 0.0 110.017 177.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.464 ' N ' HG22 ' O' ' 39' ' ' VAL . 9.0 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.397 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -110.72 132.49 54.15 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.947 0.403 . . . . 0.0 110.788 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -140.45 122.48 15.65 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.014 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.43 HG23 ' H ' ' Q' ' 13' ' ' HIS . 12.7 p -126.26 128.12 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-O 120.75 0.31 . . . . 0.0 110.194 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' Q' ' 13' ' ' HIS . 76.1 t60 -135.25 129.39 33.55 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.159 0.504 . . . . 0.0 111.678 -178.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' P' ' 15' ' ' GLN . 0.1 OUTLIER -152.55 172.16 17.01 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.191 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.613 ' N ' ' ND1' ' P' ' 14' ' ' HIS . 52.7 tt0 -155.78 140.18 16.75 Favored 'General case' 0 CA--C 1.518 -0.262 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.382 176.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -96.95 99.99 11.52 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.506 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.422 ' CD1' HG21 ' R' ' 36' ' ' VAL . 35.6 mt -111.79 108.04 17.31 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 119.409 1.004 . . . . 0.0 108.318 176.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 72.2 t -113.73 107.68 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.563 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 58.9 m-85 -110.48 109.55 19.94 Favored 'General case' 0 C--N 1.333 -0.148 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -117.54 123.92 47.45 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.92 124.99 13.58 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 122.137 0.97 . . . . 0.0 112.718 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -88.69 147.8 24.32 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.047 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 20.7 m-20 -115.13 50.3 0.99 Allowed 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.025 0.916 . . . . 0.0 111.959 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.511 HG12 ' H ' ' P' ' 25' ' ' GLY . 2.8 t -84.03 -141.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 104.737 -2.32 . . . . 0.0 104.737 175.089 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.511 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -97.21 35.27 4.55 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 107.647 -2.181 . . . . 0.0 107.647 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 1.6 p -66.84 108.43 2.54 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-N 110.805 -2.698 . . . . 0.0 107.701 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.578 ' OD1' ' N ' ' P' ' 28' ' ' LYS . 15.3 t30 -148.78 163.38 37.55 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.543 -173.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.578 ' N ' ' OD1' ' P' ' 27' ' ' ASN . 98.3 mttt 31.84 42.4 0.02 OUTLIER 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -177.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' O' ' 28' ' ' LYS . . . -90.17 -61.94 1.31 Allowed Glycine 0 CA--C 1.559 2.83 0 CA-C-O 117.596 -1.669 . . . . 0.0 115.617 -175.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.45 151.97 23.21 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 122.432 3.116 . . . . 0.0 114.884 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.555 HD11 ' HB ' ' J' ' 39' ' ' VAL . 96.6 mt -130.35 122.3 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.548 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.8 mt -117.18 120.95 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 CA-C-O 120.909 0.385 . . . . 0.0 111.383 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 107.97 1.25 Allowed Glycine 0 CA--C 1.53 0.973 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 176.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' O' ' 34' ' ' LEU . 1.8 mt -143.74 148.13 35.22 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mmm -116.53 113.9 23.41 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 104.936 -2.246 . . . . 0.0 104.936 175.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.827 HG11 HD11 ' N' ' 17' ' ' LEU . 53.6 t -137.01 101.98 2.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.542 -0.463 . . . . 0.0 112.132 -176.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.727 ' CA ' HE22 ' N' ' 15' ' ' GLN . . . 114.45 168.59 16.14 Favored Glycine 0 N--CA 1.464 0.525 0 CA-C-O 121.672 0.596 . . . . 0.0 112.355 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HA3' ' Q' ' 38' ' ' GLY . . . 176.79 -54.78 0.11 Allowed Glycine 0 CA--C 1.551 2.314 0 CA-C-N 114.367 -0.916 . . . . 0.0 110.972 -179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' D' ' 31' ' ' ILE . 2.6 p -151.12 139.18 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 118.578 1.189 . . . . 0.0 110.025 176.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.461 ' O ' ' O ' ' P' ' 39' ' ' VAL . 56.5 t . . . . . 0 C--O 1.218 -0.593 0 CA-C-O 118.353 -0.832 . . . . 0.0 110.65 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.212 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -82.07 142.8 31.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -137.9 124.75 21.19 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.9 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 t -118.8 101.53 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.791 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' P' ' 13' ' ' HIS . 61.9 m170 -67.44 169.23 9.4 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.016 -178.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.513 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 1.9 t60 -123.86 173.66 8.04 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.871 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.489 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 77.7 mt-30 -82.97 150.33 26.46 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.239 0.542 . . . . 0.0 110.955 -178.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -121.71 126.23 48.47 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.609 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.637 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.2 mp -120.36 124.49 45.67 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.965 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.442 HG22 ' CG1' ' R' ' 18' ' ' VAL . 86.1 t -123.22 118.76 55.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.864 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.563 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 78.8 m-85 -115.74 110.73 19.52 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.297 -0.41 . . . . 0.0 109.9 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -112.76 115.1 27.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -158.76 154.14 25.76 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 115.591 1.7 . . . . 0.0 115.591 -178.197 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.498 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 97.0 mt-10 -92.39 165.06 13.26 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 113.872 -1.513 . . . . 0.0 108.194 177.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.429 ' CG ' ' O ' ' R' ' 22' ' ' GLU . 21.8 p-10 -132.1 46.4 2.65 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 -177.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.958 HG12 ' H ' ' Q' ' 25' ' ' GLY . 18.4 t -71.17 -169.08 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.958 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -100.2 28.65 14.74 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.541 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.6 m -81.41 112.67 18.89 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 121.161 0.505 . . . . 0.0 111.389 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.431 ' OD1' ' OXT' ' L' ' 40' ' ' VAL . 85.3 m-20 -89.84 -174.86 4.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.13 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 49.55 39.18 16.4 Favored 'General case' 0 CA--C 1.535 0.404 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 176.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 -67.02 1.54 Allowed Glycine 0 CA--C 1.542 1.764 0 C-N-CA 120.512 -0.851 . . . . 0.0 114.297 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -178.77 160.6 1.17 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 119.235 1.518 . . . . 0.0 110.157 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.1 mt -134.59 135.68 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -106.81 105.88 19.6 Favored 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.78 99.11 1.41 Allowed Glycine 0 N--CA 1.462 0.383 0 N-CA-C 105.166 -3.174 . . . . 0.0 105.166 176.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.665 HD12 ' O ' ' P' ' 34' ' ' LEU . 45.0 tp -143.7 133.25 23.54 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -173.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.407 ' H ' HD12 ' Q' ' 34' ' ' LEU . 96.2 mmm -104.85 112.55 25.71 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.811 176.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.693 ' CG2' HE22 ' O' ' 15' ' ' GLN . 2.1 p -135.53 142.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.21 -101.94 0.22 Allowed Glycine 0 C--N 1.309 -0.933 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 62.3 67.4 2.11 Favored Glycine 0 CA--C 1.539 1.576 0 N-CA-C 114.629 0.612 . . . . 0.0 114.629 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.902 HG13 ' O ' ' R' ' 39' ' ' VAL . 90.2 t -21.67 141.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.853 0.861 . . . . 0.0 112.895 179.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.463 ' H ' HG12 ' R' ' 40' ' ' VAL . 1.7 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.091 -0.957 . . . . 0.0 109.624 179.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -70.81 132.76 45.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -139.59 143.4 37.27 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.516 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.28 128.48 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.025 0.441 . . . . 0.0 110.38 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -149.0 101.51 3.17 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.817 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.513 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 83.6 t60 -152.99 164.4 38.04 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.462 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 88.3 mt-30 -89.78 159.27 17.12 Favored 'General case' 0 CA--C 1.515 -0.375 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -140.05 102.59 4.43 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.134 0.492 . . . . 0.0 109.79 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.533 ' HG ' HD13 ' Q' ' 17' ' ' LEU . 5.7 mp -123.87 121.16 34.62 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . 0.442 ' CG1' HG22 ' Q' ' 18' ' ' VAL . 4.7 p -126.26 118.2 50.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.65 0.738 . . . . 0.0 109.517 178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -114.78 114.71 25.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.562 -179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -116.86 114.86 24.49 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -158.81 168.7 26.14 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.826 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' R' ' 24' ' ' VAL . 97.8 mt-10 -76.33 111.13 11.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.165 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' R' ' 22' ' ' GLU . 68.0 t0 7.98 54.93 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.373 1.046 . . . . 0.0 113.04 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.58 ' N ' ' O ' ' R' ' 22' ' ' GLU . 12.7 p -67.96 135.16 29.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.01 -34.06 2.25 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 177.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' R' ' 27' ' ' ASN . 40.8 t -162.32 120.6 2.19 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 114.649 -0.775 . . . . 0.0 108.969 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' R' ' 30' ' ' ALA . 47.9 t30 -22.4 150.52 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 -179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -149.66 -39.39 0.15 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.249 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.19 -67.77 1.56 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.362 -178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' R' ' 27' ' ' ASN . . . -130.11 162.05 29.69 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.614 HD12 HG22 ' L' ' 39' ' ' VAL . 94.9 mt -117.62 130.21 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-O 121.529 0.681 . . . . 0.0 110.815 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -103.91 109.89 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.1 -0.955 . . . . 0.0 108.696 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.19 110.31 1.67 Allowed Glycine 0 N--CA 1.459 0.198 0 N-CA-C 107.434 -2.266 . . . . 0.0 107.434 178.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.488 ' O ' HD12 ' R' ' 34' ' ' LEU . 0.3 OUTLIER -163.88 172.66 13.71 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.534 -177.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.471 ' O ' ' O ' ' Q' ' 36' ' ' VAL . 95.9 mmm -127.36 117.89 23.09 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 113.802 -1.544 . . . . 0.0 109.094 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.634 HG12 ' CG1' ' Q' ' 36' ' ' VAL . 17.1 m -125.94 164.77 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.153 0 N-CA-C 106.457 -1.682 . . . . 0.0 106.457 178.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.426 ' HA2' HE22 ' Q' ' 15' ' ' GLN . . . 129.72 -96.17 0.37 Allowed Glycine 0 C--N 1.315 -0.622 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . 50.15 73.05 0.4 Allowed Glycine 0 CA--C 1.536 1.376 0 C-N-CA 121.566 -0.349 . . . . 0.0 112.517 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.902 ' O ' HG13 ' Q' ' 39' ' ' VAL . 17.5 t -33.93 161.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.304 0.642 . . . . 0.0 112.378 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.488 ' N ' HG12 ' R' ' 39' ' ' VAL . 10.4 m . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.643 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.438 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -147.87 158.83 44.23 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.76 0.314 . . . . 0.0 110.344 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -157.83 133.46 9.08 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.143 0.496 . . . . 0.0 111.062 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -125.16 132.29 71.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -138.0 130.89 29.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 118.371 0.532 . . . . 0.0 110.722 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.549 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 8.9 p-80 -154.82 158.53 39.56 Favored 'General case' 0 C--N 1.343 0.306 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.473 ' H ' ' HG3' ' B' ' 15' ' ' GLN . 53.3 tp60 -90.37 160.5 16.06 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 114.721 -1.127 . . . . 0.0 109.091 176.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -139.59 110.65 6.9 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mt -135.72 127.18 28.64 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 122.028 0.918 . . . . 0.0 110.878 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -115.48 111.16 34.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.273 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.73 106.07 13.1 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -139.5 147.2 40.96 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.336 0.589 . . . . 0.0 112.224 -177.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.479 ' HB2' ' HE3' ' C' ' 28' ' ' LYS . . . -110.61 115.63 29.94 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.385 -0.825 . . . . 0.0 108.92 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.419 ' H ' ' CG2' ' A' ' 24' ' ' VAL . 80.3 tt0 -170.53 100.45 0.25 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 39.31 46.45 1.32 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.772 0.32 . . . . 0.0 110.922 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.601 HG12 ' H ' ' A' ' 25' ' ' GLY . 0.8 OUTLIER -71.38 -168.93 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.601 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -100.39 28.69 14.62 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 t -80.37 112.88 18.13 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -93.95 -175.82 3.83 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.264 0.554 . . . . 0.0 111.813 -178.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -47.49 -39.47 16.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.06 -178.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -139.01 67.37 0.51 Allowed Glycine 0 N--CA 1.477 1.393 0 C-N-CA 120.638 -0.791 . . . . 0.0 113.72 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.37 106.67 18.65 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 117.467 0.633 . . . . 0.0 110.802 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.4 pp -129.22 124.48 60.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 110.433 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -134.83 132.09 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.843 0.354 . . . . 0.0 111.476 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.57 112.75 0.85 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 84.4 mt -145.52 157.81 43.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 122.634 1.207 . . . . 0.0 113.826 -178.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 44.4 tpp -119.08 123.54 44.71 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.464 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' B' ' 36' ' ' VAL . 76.0 t -95.67 112.14 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.05 132.5 11.13 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-N 114.746 -1.116 . . . . 0.0 110.833 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.69 63.02 0.55 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 117.488 0.644 . . . . 0.0 112.315 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 ' O ' ' B' ' 37' ' ' GLY . 6.1 t -94.73 126.41 47.16 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 CA-C-N 116.902 0.351 . . . . 0.0 110.723 -179.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 44.6 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.43 -179.297 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.68 132.78 52.27 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.566 0.222 . . . . 0.0 110.433 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.5 mp0 -130.06 126.25 37.18 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.144 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.534 ' CG1' ' NE2' ' B' ' 14' ' ' HIS . 58.0 t -131.22 130.91 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.924 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 41.9 m170 -130.96 140.51 50.17 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.702 ' HD1' ' H ' ' C' ' 14' ' ' HIS . 82.0 m-70 -155.62 178.6 10.06 Favored 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.573 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' A' ' 15' ' ' GLN . 2.1 tt0 -154.99 139.99 17.36 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.96 177.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.422 ' O ' HD23 ' B' ' 17' ' ' LEU . 88.5 tttt -95.59 97.19 9.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.359 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.438 ' HB3' ' CE2' ' B' ' 19' ' ' PHE . 21.3 mt -119.1 113.59 21.15 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 120.095 1.316 . . . . 0.0 109.269 177.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 99.4 t -109.13 109.14 27.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.017 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' D' ' 32' ' ' ILE . 79.3 m-85 -116.7 105.35 12.31 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -155.01 164.42 38.93 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 115.431 1.641 . . . . 0.0 115.431 178.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.0 117.87 24.98 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.227 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -146.35 128.99 16.13 Favored 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 46.71 51.86 11.85 Favored 'General case' 0 CA--C 1.522 -0.107 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -178.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' C' ' 26' ' ' SER . 46.1 t -50.46 153.71 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.782 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.04 -23.63 0.18 Allowed Glycine 0 CA--C 1.534 1.253 0 CA-C-N 115.5 -0.773 . . . . 0.0 113.082 -177.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -64.12 148.77 49.14 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 112.596 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -88.26 -179.77 6.2 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 114.738 -1.119 . . . . 0.0 113.251 -178.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -55.98 -39.27 71.58 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 114.203 -1.362 . . . . 0.0 113.723 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.58 68.01 0.42 Allowed Glycine 0 CA--C 1.539 1.57 0 N-CA-C 114.91 0.724 . . . . 0.0 114.91 -176.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' C' ' 30' ' ' ALA . . . -122.38 105.61 10.34 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 117.572 0.686 . . . . 0.0 110.212 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 tt -132.01 129.76 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 O-C-N 121.73 -0.606 . . . . 0.0 110.917 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.44 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.5 tt -126.28 119.45 54.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.747 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' C' ' 33' ' ' GLY . . . -122.91 113.14 2.09 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 55.5 mt -138.72 136.1 35.44 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 119.154 -1.018 . . . . 0.0 112.512 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 99.7 mmm -112.36 107.16 15.88 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.299 177.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.438 HG22 ' CG2' ' A' ' 36' ' ' VAL . 6.9 t -144.78 103.11 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -177.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.542 ' O ' HG11 ' A' ' 39' ' ' VAL . . . 147.24 -154.79 26.18 Favored Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.038 -1.077 . . . . 0.0 111.413 177.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.475 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 120.57 -55.78 0.62 Allowed Glycine 0 CA--C 1.547 2.035 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -178.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' H' ' 31' ' ' ILE . 27.3 m -132.28 128.4 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 117.575 0.688 . . . . 0.0 109.36 177.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.495 HG13 ' O ' ' B' ' 39' ' ' VAL . 16.2 m . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.436 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.074 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -107.28 134.28 50.6 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.873 0.368 . . . . 0.0 110.23 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -134.08 131.74 39.14 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.269 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -131.44 134.58 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.499 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 6.6 t60 -145.04 139.94 27.76 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-O 121.423 0.63 . . . . 0.0 111.89 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.702 ' H ' ' HD1' ' B' ' 14' ' ' HIS . 28.5 m-70 -147.52 171.48 15.48 Favored 'General case' 0 C--O 1.216 -0.699 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 177.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -149.44 141.24 23.65 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 118.847 -1.141 . . . . 0.0 111.612 178.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -89.23 103.21 15.86 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.792 178.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.718 HD11 HG11 ' E' ' 36' ' ' VAL . 29.0 mt -116.22 112.32 21.46 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.506 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -109.35 107.53 23.09 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.851 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' E' ' 32' ' ' ILE . 50.9 m-85 -110.76 106.96 16.33 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 177.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.46 ' CZ ' ' CG ' ' D' ' 20' ' ' PHE . 1.6 t80 -137.85 133.48 33.96 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -175.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 118.08 21.18 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 120.756 0.313 . . . . 0.0 110.326 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' C' ' 23' ' ' ASP . 12.3 tp10 -164.46 156.93 16.74 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.849 0.833 . . . . 0.0 112.582 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.561 ' H ' ' CD ' ' C' ' 22' ' ' GLU . 58.1 t0 49.12 60.48 3.72 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 114.322 -1.308 . . . . 0.0 114.513 178.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.898 ' H ' HG11 ' D' ' 24' ' ' VAL . 8.1 t -71.42 123.39 25.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.69 -34.1 4.51 Favored Glycine 0 N--CA 1.473 1.154 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.432 ' O ' ' C ' ' C' ' 27' ' ' ASN . 49.7 m -151.06 123.87 8.6 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 178.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' C' ' 26' ' ' SER . 7.3 m120 -41.43 151.04 0.08 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.459 -175.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 85.3 tttt -76.13 -50.15 15.41 Favored 'General case' 0 CA--C 1.509 -0.616 0 C-N-CA 119.716 -0.794 . . . . 0.0 111.487 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.7 50.72 10.67 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 119.139 -1.505 . . . . 0.0 111.211 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' HB3' ' B' ' 30' ' ' ALA . . . -154.52 158.97 40.65 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 120.865 2.332 . . . . 0.0 115.739 -175.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.416 HG23 ' O ' ' C' ' 31' ' ' ILE . 20.3 tt -135.27 129.97 50.58 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-N 111.756 -2.475 . . . . 0.0 110.9 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.673 HG23 HD13 ' C' ' 34' ' ' LEU . 40.6 mt -109.38 113.24 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.703 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -117.59 97.34 0.73 Allowed Glycine 0 C--N 1.345 1.068 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.703 HD12 ' C ' ' C' ' 33' ' ' GLY . 7.5 mp -137.43 151.07 48.12 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -175.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -117.64 105.69 12.3 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.914 -2.254 . . . . 0.0 104.914 175.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -122.29 102.52 11.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.432 ' H ' ' HA3' ' B' ' 37' ' ' GLY . . . 105.83 -163.21 13.94 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.128 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.507 ' CA ' ' H ' ' D' ' 38' ' ' GLY . . . 156.54 -54.37 0.4 Allowed Glycine 0 CA--C 1.545 1.95 0 N-CA-C 111.942 -0.463 . . . . 0.0 111.942 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.599 ' CG2' HD11 ' I' ' 31' ' ' ILE . 45.3 t -133.22 133.91 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 118.308 1.054 . . . . 0.0 109.479 176.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.115 179.326 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -106.73 135.06 48.91 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.714 0.292 . . . . 0.0 110.261 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.663 ' O ' HG22 ' E' ' 12' ' ' VAL . 96.7 mt-10 -138.57 146.58 42.01 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.155 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.436 ' CG1' ' CD2' ' E' ' 13' ' ' HIS . 62.0 t -105.78 127.59 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' E' ' 13' ' ' HIS . 24.9 p-80 -142.93 137.32 29.36 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 121.465 0.65 . . . . 0.0 112.429 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.671 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 3.2 t-80 -152.82 169.32 23.09 Favored 'General case' 0 C--O 1.218 -0.594 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.671 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 53.7 tt0 -155.34 140.99 17.98 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.759 178.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.78 102.83 15.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.206 -0.906 . . . . 0.0 111.175 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.598 ' CD2' HD12 ' C' ' 17' ' ' LEU . 73.7 mt -112.78 112.41 23.89 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 119.935 -0.706 . . . . 0.0 109.739 177.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 t -110.55 106.28 20.44 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.107 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 55.4 m-85 -107.31 111.5 23.89 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 178.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.4 t80 -133.96 131.61 39.2 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -177.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.65 123.72 10.09 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 121.142 -0.223 . . . . 0.0 110.461 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 83.3 mt-10 -99.05 177.49 5.22 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.538 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 53.3 t0 -85.24 47.2 1.38 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 113.767 -1.561 . . . . 0.0 111.881 -178.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.898 HG11 ' H ' ' C' ' 24' ' ' VAL . 2.3 t -82.52 -160.58 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -179.447 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.785 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -82.97 -28.73 36.61 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 119.834 -1.174 . . . . 0.0 112.47 -175.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.535 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 92.34 118.54 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 118.599 1.2 . . . . 0.0 112.129 176.417 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.737 ' ND2' ' H ' ' D' ' 29' ' ' GLY . 0.6 OUTLIER -71.97 161.81 30.38 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.331 179.891 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.43 ' H ' ' HB3' ' C' ' 27' ' ' ASN . 69.8 mmtt -48.09 -39.95 21.84 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.737 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . 170.69 66.55 0.04 OUTLIER Glycine 0 CA--C 1.541 1.683 0 C-N-CA 120.11 -1.043 . . . . 0.0 113.006 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.714 ' H ' HD22 ' D' ' 27' ' ' ASN . . . -71.72 124.17 24.19 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 119.995 1.898 . . . . 0.0 110.042 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.622 HD12 HG22 ' P' ' 39' ' ' VAL . 63.6 mt -127.62 129.49 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' B' ' 19' ' ' PHE . 91.1 mt -107.25 108.81 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 103.9 1.61 Allowed Glycine 0 C--N 1.334 0.435 0 N-CA-C 104.734 -3.346 . . . . 0.0 104.734 176.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.57 ' O ' HD12 ' E' ' 34' ' ' LEU . 6.5 tt -150.26 142.89 24.56 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.493 -174.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.9 ttm -113.57 110.11 19.71 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 113.13 -1.85 . . . . 0.0 106.52 178.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.564 HG11 HG22 ' E' ' 36' ' ' VAL . 10.1 p -111.5 112.47 40.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 122.157 0.979 . . . . 0.0 109.681 -178.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 63.04 132.74 0.01 OUTLIER Glycine 0 CA--C 1.528 0.858 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.069 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.507 ' H ' ' CA ' ' C' ' 38' ' ' GLY . . . -87.63 -56.21 2.16 Favored Glycine 0 CA--C 1.541 1.675 0 CA-C-N 115.668 -0.266 . . . . 0.0 112.954 178.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.489 HG23 HD11 ' J' ' 31' ' ' ILE . 52.0 t -129.13 137.04 58.17 Favored 'Isoleucine or valine' 0 C--N 1.346 0.436 0 CA-C-O 120.923 0.392 . . . . 0.0 110.382 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.968 179.762 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -107.28 134.64 50.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.623 0.249 . . . . 0.0 110.763 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -75.07 157.7 34.35 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.139 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.663 HG22 ' O ' ' D' ' 11' ' ' GLU . 71.1 t -116.3 127.48 73.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.82 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' D' ' 13' ' ' HIS . 5.9 m-70 -77.64 167.93 20.78 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.991 -179.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' F' ' 13' ' ' HIS . 11.6 m-70 -124.13 172.83 8.72 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.215 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.429 ' HA ' ' H ' ' D' ' 15' ' ' GLN . 18.8 pt20 -83.47 150.71 25.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.565 -178.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -121.18 126.84 50.69 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.755 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' E' ' 17' ' ' LEU . 2.4 mp -121.55 133.27 55.01 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.518 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -123.27 117.1 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.635 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 60.3 m-85 -115.38 112.75 22.81 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.64 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 23.5 t80 -117.6 115.12 24.47 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 176.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.456 ' HB1' ' CA ' ' F' ' 29' ' ' GLY . . . -148.12 141.75 25.53 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' D' ' 23' ' ' ASP . 81.5 mt-10 -112.52 95.29 5.35 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.595 176.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.46 ' HB3' HG21 ' F' ' 24' ' ' VAL . 68.1 t0 -80.0 50.34 1.2 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.71 -178.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.522 HG12 ' H ' ' E' ' 25' ' ' GLY . 1.8 t -76.77 -142.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.677 -176.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -91.9 -38.49 5.75 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.776 -173.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -70.32 114.34 8.36 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 122.438 1.113 . . . . 0.0 109.584 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.464 ' O ' ' OG ' ' D' ' 26' ' ' SER . 97.4 m-20 -111.76 -150.96 0.47 Allowed 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 113.051 -1.886 . . . . 0.0 110.73 -176.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' O ' ' O ' ' D' ' 27' ' ' ASN . 53.8 mttt 32.18 41.41 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 121.28 0.562 . . . . 0.0 111.523 -178.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.477 ' CA ' ' OG ' ' D' ' 26' ' ' SER . . . -90.44 -63.3 1.24 Allowed Glycine 0 CA--C 1.538 1.512 0 CA-C-N 115.432 -0.804 . . . . 0.0 113.064 -178.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.508 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -157.79 145.7 18.75 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 119.521 1.66 . . . . 0.0 113.486 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 4.1 mt -128.16 125.07 63.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.716 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD1' ' C' ' 19' ' ' PHE . 88.3 mt -109.15 109.07 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.83 92.54 0.7 Allowed Glycine 0 C--N 1.332 0.344 0 N-CA-C 104.502 -3.439 . . . . 0.0 104.502 175.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.627 ' HG ' HG23 ' E' ' 36' ' ' VAL . 19.3 tp -132.6 132.42 42.49 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 122.26 1.028 . . . . 0.0 113.213 -173.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.439 ' N ' HD12 ' E' ' 34' ' ' LEU . 2.1 mtp -103.83 105.95 16.32 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 113.555 -1.657 . . . . 0.0 107.403 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.718 HG11 HD11 ' C' ' 17' ' ' LEU . 6.5 t -105.72 123.6 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 122.174 0.988 . . . . 0.0 110.003 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . 43.7 114.48 0.0 OUTLIER Glycine 0 CA--C 1.527 0.799 0 CA-C-N 113.184 -1.825 . . . . 0.0 112.196 -178.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.06 -62.53 4.63 Favored Glycine 0 CA--C 1.531 1.094 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.479 HG22 HD12 ' L' ' 31' ' ' ILE . 91.4 t -127.89 132.27 68.92 Favored 'Isoleucine or valine' 0 C--N 1.342 0.255 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.426 HG13 ' CG ' ' C' ' 13' ' ' HIS . 34.3 t . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.685 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.59 133.77 49.78 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.889 0.376 . . . . 0.0 110.282 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -122.4 116.92 24.85 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.959 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 35.4 m -136.2 159.8 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.623 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' E' ' 14' ' ' HIS . 51.0 t-80 -78.56 161.79 26.76 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.812 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' F' ' 13' ' ' HIS . 97.2 m-70 -86.64 169.0 13.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.226 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -89.62 159.67 17.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -139.12 113.12 8.62 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.779 0.8 . . . . 0.0 110.825 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mp -126.18 122.71 36.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.071 178.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.91 126.8 75.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.504 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 53.7 p90 -136.39 126.76 26.64 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 121.25 0.548 . . . . 0.0 111.902 -178.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -127.28 131.93 50.42 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -158.42 165.75 33.91 Favored 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.3 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.441 ' OE1' HG22 ' E' ' 24' ' ' VAL . 93.1 mt-10 -69.02 161.2 29.48 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.262 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -68.31 46.22 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.749 HG12 ' H ' ' F' ' 25' ' ' GLY . 41.9 t -80.57 -179.87 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.749 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -71.39 -34.13 63.94 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 118.571 -1.776 . . . . 0.0 111.22 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.427 ' O ' ' C ' ' F' ' 27' ' ' ASN . 39.1 t -162.22 120.27 2.18 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 119.014 -1.075 . . . . 0.0 113.118 175.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' F' ' 26' ' ' SER . 14.9 m-20 -24.34 149.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.686 174.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -175.85 -48.58 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 120.12 -0.632 . . . . 0.0 112.139 173.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.456 ' CA ' ' HB1' ' E' ' 21' ' ' ALA . . . 70.64 -57.73 0.94 Allowed Glycine 0 CA--C 1.548 2.11 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.653 176.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -160.45 -168.97 2.29 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 105.01 -2.218 . . . . 0.0 105.01 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.459 HD11 ' HB ' ' R' ' 39' ' ' VAL . 96.5 mt -105.56 109.52 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 120.87 1.668 . . . . 0.0 109.743 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' D' ' 19' ' ' PHE . 96.9 mt -106.66 108.83 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.292 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.96 85.91 0.41 Allowed Glycine 0 C--O 1.236 0.262 0 N-CA-C 104.605 -3.398 . . . . 0.0 104.605 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.579 HD12 ' O ' ' E' ' 34' ' ' LEU . 19.6 tp -121.77 127.69 50.91 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.549 0.69 . . . . 0.0 111.805 -175.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' F' ' 34' ' ' LEU . 28.7 tpp -102.62 112.37 25.1 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 176.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -127.25 153.64 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.23 -102.14 1.43 Allowed Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.95 -80.42 1.79 Allowed Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.48 HG23 HD11 ' L' ' 31' ' ' ILE . 50.3 t -132.21 135.88 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 117.269 0.534 . . . . 0.0 109.906 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' D' ' 13' ' ' HIS . 8.2 p . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.459 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.088 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -81.21 134.59 35.64 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.753 0.311 . . . . 0.0 110.375 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -149.17 165.73 30.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.76 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.498 HG11 ' N ' ' H' ' 13' ' ' HIS . 53.6 t -114.29 128.93 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.266 0.555 . . . . 0.0 110.334 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 m80 -96.31 161.49 13.91 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.019 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' NZ ' ' G' ' 16' ' ' LYS . 0.1 OUTLIER -148.28 162.83 38.71 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.379 0.609 . . . . 0.0 111.775 179.129 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.467 ' OE1' ' CG2' ' J' ' 36' ' ' VAL . 41.7 tt0 -90.13 152.82 20.94 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.713 178.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.632 ' NZ ' ' CD2' ' G' ' 14' ' ' HIS . 62.2 mttp -147.67 108.5 4.19 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.474 ' HB3' ' CE2' ' G' ' 19' ' ' PHE . 17.2 mt -126.43 121.0 31.2 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.274 178.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -119.8 106.2 18.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.583 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.5 ' CZ ' ' CD1' ' I' ' 34' ' ' LEU . 63.5 m-85 -108.22 107.53 18.18 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 177.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' G' ' 20' ' ' PHE . 37.9 p90 -124.44 127.36 47.4 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.201 0.524 . . . . 0.0 112.244 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.842 ' HB1' ' CG ' ' H' ' 23' ' ' ASP . . . -114.6 102.02 9.65 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 179.0 157.15 0.51 Allowed 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.26 56.38 7.02 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.027 179.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 85.7 t -65.04 133.42 30.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.64 0.733 . . . . 0.0 110.907 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.34 -29.42 2.74 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.966 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' G' ' 27' ' ' ASN . 22.1 t -160.41 139.5 10.64 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -177.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.436 ' C ' ' O ' ' G' ' 26' ' ' SER . 24.5 t-20 -23.57 142.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 122.03 0.919 . . . . 0.0 113.085 -176.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -127.99 -30.95 2.42 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.455 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.468 ' HA3' ' H ' ' H' ' 29' ' ' GLY . . . -70.27 96.78 0.56 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.019 -0.61 . . . . 0.0 111.947 -177.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -149.74 178.36 8.95 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.533 ' CD1' ' H ' ' A' ' 39' ' ' VAL . 95.8 mt -117.82 119.19 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 93.9 mt -124.87 133.45 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.017 0.437 . . . . 0.0 111.838 -178.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 120.07 2.37 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 36.9 tp -132.48 139.42 47.94 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-N 117.827 0.814 . . . . 0.0 111.973 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.401 ' CE ' ' SD ' ' H' ' 35' ' ' MET . 39.4 tpp -128.72 127.2 41.61 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 114.692 -1.14 . . . . 0.0 108.895 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.4 t -112.64 131.01 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.573 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.99 112.13 2.55 Favored Glycine 0 CA--C 1.519 0.33 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.83 71.26 0.91 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 120.613 -0.803 . . . . 0.0 111.456 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.599 ' O ' HG12 ' H' ' 39' ' ' VAL . 4.0 t -84.31 127.07 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 117.135 0.468 . . . . 0.0 111.348 -178.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.222 -0.363 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.835 -179.371 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.456 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -108.49 135.71 49.31 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.901 0.381 . . . . 0.0 110.459 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' H ' ' G' ' 12' ' ' VAL . 96.9 mt-10 -81.67 164.88 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.472 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -135.76 166.95 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.404 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.553 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 99.2 m-70 -68.39 129.1 38.92 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 121.261 0.553 . . . . 0.0 111.735 -178.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 13.9 m80 -156.55 171.97 19.38 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.24 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.555 HE22 HG22 ' J' ' 36' ' ' VAL . 49.2 tt0 -158.26 147.95 19.72 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.33 104.3 8.39 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.907 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.676 HD12 HD22 ' I' ' 17' ' ' LEU . 15.5 mt -115.44 110.56 19.49 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 120.35 1.432 . . . . 0.0 108.163 176.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 88.0 t -116.71 110.21 30.63 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.41 ' CZ ' ' HB3' ' H' ' 17' ' ' LEU . 41.9 m-85 -111.67 101.84 10.19 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.576 ' CE1' ' CD1' ' I' ' 20' ' ' PHE . 36.7 t80 -112.45 123.25 49.87 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.636 ' HB1' ' HD3' ' I' ' 28' ' ' LYS . . . -122.46 113.4 19.29 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 122.058 0.932 . . . . 0.0 113.406 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' G' ' 21' ' ' ALA . 79.5 tt0 -159.83 90.11 0.91 Allowed 'General case' 0 C--O 1.224 -0.262 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.842 ' CG ' ' HB1' ' G' ' 21' ' ' ALA . 4.7 m-20 -135.82 49.25 2.15 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.179 -175.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.452 ' H ' HG22 ' H' ' 24' ' ' VAL . 14.0 m -71.05 160.85 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 118.28 -1.368 . . . . 0.0 109.697 -174.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.662 ' H ' ' CB ' ' I' ' 26' ' ' SER . . . 109.97 -28.43 10.52 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 105.776 -2.93 . . . . 0.0 105.776 -174.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.409 ' OG ' ' OG ' ' I' ' 26' ' ' SER . 0.7 OUTLIER 74.46 119.49 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.144 -1.528 . . . . 0.0 112.124 178.583 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -83.34 162.36 21.11 Favored 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 177.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.28 -39.74 22.63 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 179.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.468 ' H ' ' HA3' ' G' ' 29' ' ' GLY . . . 170.89 67.06 0.04 OUTLIER Glycine 0 CA--C 1.543 1.839 0 CA-C-O 119.029 -0.873 . . . . 0.0 112.441 -178.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.846 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -71.48 102.38 2.67 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 119.656 1.728 . . . . 0.0 114.261 -176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' B' ' 39' ' ' VAL . 96.7 mt -126.77 121.22 57.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 113.78 -1.555 . . . . 0.0 107.941 177.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -121.77 130.24 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-O 120.882 0.373 . . . . 0.0 111.503 -178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -128.22 118.19 2.76 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 mt -132.9 141.39 48.36 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 117.736 0.768 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.401 ' SD ' ' CE ' ' G' ' 35' ' ' MET . 21.8 ttm -139.29 122.26 16.7 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 54.6 t -124.09 134.58 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -140.56 103.1 0.34 Allowed Glycine 0 N--CA 1.46 0.241 0 CA-C-O 119.043 -0.865 . . . . 0.0 112.787 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.911 ' O ' HG21 ' N' ' 31' ' ' ILE . . . 170.31 -73.14 0.12 Allowed Glycine 0 CA--C 1.54 1.607 0 C-N-CA 118.181 -1.961 . . . . 0.0 116.331 176.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.599 HG12 ' O ' ' G' ' 39' ' ' VAL . 1.4 p -156.87 171.59 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 118.417 1.109 . . . . 0.0 109.871 -177.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.466 0.35 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.43 178.128 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.506 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -106.48 133.99 50.31 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 120.914 0.388 . . . . 0.0 110.358 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -148.27 146.31 28.56 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.111 0.481 . . . . 0.0 111.2 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 48.4 t -121.36 126.58 75.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.098 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.411 ' CE1' HG23 ' J' ' 40' ' ' VAL . 79.7 t60 -115.19 120.69 40.59 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.083 0.468 . . . . 0.0 112.26 -179.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 36.1 t60 -126.66 167.98 14.97 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.523 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 46.2 tt0 -138.47 150.61 46.62 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.541 ' C ' HD23 ' I' ' 17' ' ' LEU . 88.1 tttt -149.24 107.95 3.84 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.396 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.676 HD22 HD12 ' H' ' 17' ' ' LEU . 2.6 mt -121.95 116.52 24.48 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 178.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -111.46 108.05 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 33.4 m-85 -109.04 110.27 21.5 Favored 'General case' 0 CA--C 1.543 0.678 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.576 ' CD1' ' CE1' ' H' ' 20' ' ' PHE . 7.9 t80 -124.61 129.84 51.3 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 122.11 -0.369 . . . . 0.0 111.658 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.572 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . . . -139.02 129.27 25.46 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.639 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 58.8 tt0 -86.6 172.45 10.25 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.322 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.437 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 4.1 m-20 -137.07 47.36 2.13 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -176.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.606 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.3 t -81.82 -160.7 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 118.511 -1.275 . . . . 0.0 109.783 -177.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.606 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -83.6 -32.54 24.43 Favored Glycine 0 CA--C 1.535 1.331 0 N-CA-C 115.258 0.863 . . . . 0.0 115.258 -175.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.662 ' CB ' ' H ' ' H' ' 25' ' ' GLY . 13.3 t -93.78 134.0 36.58 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 117.84 0.82 . . . . 0.0 109.628 179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' N ' ' ND2' ' J' ' 27' ' ' ASN . 56.9 t30 -71.57 146.13 48.61 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 117.843 -1.543 . . . . 0.0 111.043 -177.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.639 ' NZ ' ' N ' ' I' ' 22' ' ' GLU . 95.9 mttt -54.67 -49.95 69.38 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.56 -1.2 . . . . 0.0 111.656 178.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 89.41 50.28 3.23 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.591 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.83 123.42 29.03 Favored 'General case' 0 C--N 1.353 0.757 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -176.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' C' ' 39' ' ' VAL . 74.0 mt -131.08 110.52 18.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 174.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 54.5 mt -107.96 125.54 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-O 120.612 0.244 . . . . 0.0 110.4 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.92 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -130.8 104.89 0.61 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.92 HD23 ' O ' ' I' ' 33' ' ' GLY . 3.4 mt -138.05 145.25 41.57 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-O 122.521 1.153 . . . . 0.0 113.613 -177.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' J' ' 35' ' ' MET . 96.6 mmm -114.69 97.55 6.34 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 103.698 -2.704 . . . . 0.0 103.698 174.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.464 ' C ' HE22 ' G' ' 15' ' ' GLN . 0.5 OUTLIER -135.76 103.06 3.61 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.43 0 CA-C-N 115.294 -0.867 . . . . 0.0 110.507 -175.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 151.47 -153.68 25.09 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.453 ' O ' HG23 ' J' ' 39' ' ' VAL . . . 110.3 -56.01 0.48 Allowed Glycine 0 CA--C 1.538 1.528 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.486 HG22 ' CD1' ' O' ' 31' ' ' ILE . 2.1 t -114.09 135.66 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.849 0.46 . . . . 0.0 110.728 -179.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' I' ' 39' ' ' VAL . 94.9 t . . . . . 0 N--CA 1.472 0.634 0 CA-C-O 117.953 -1.022 . . . . 0.0 111.871 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -112.87 140.22 47.85 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.91 0.386 . . . . 0.0 110.924 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -82.8 116.85 22.31 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.665 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.463 ' C ' ' CD2' ' J' ' 13' ' ' HIS . 2.5 p -141.12 146.03 24.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.372 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.544 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 4.0 m-70 -146.17 149.7 34.46 Favored 'General case' 0 C--O 1.222 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.428 ' CD2' ' O ' ' K' ' 14' ' ' HIS . 0.1 OUTLIER -153.97 172.59 17.2 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.667 178.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -138.54 140.76 39.22 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.173 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -130.42 108.81 10.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.707 -0.224 . . . . 0.0 110.58 178.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.66 HD11 HG21 ' L' ' 36' ' ' VAL . 18.4 mt -114.8 118.5 33.74 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.139 178.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -116.86 106.95 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 178.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.582 ' CD2' ' CE2' ' K' ' 19' ' ' PHE . 81.5 m-85 -105.52 107.12 17.94 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.532 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 32.1 t80 -113.24 119.08 36.51 Favored 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.507 -0.121 . . . . 0.0 110.937 -179.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.57 138.82 32.92 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 119.632 -0.827 . . . . 0.0 112.911 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.487 ' HB3' HG23 ' J' ' 24' ' ' VAL . 92.7 mt-10 -86.77 173.8 9.22 Favored 'General case' 0 CA--C 1.552 1.045 0 N-CA-C 114.352 1.242 . . . . 0.0 114.352 -178.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.533 ' CG ' HD21 ' K' ' 27' ' ' ASN . 1.3 m-20 -151.27 51.49 0.84 Allowed 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 126.367 1.867 . . . . 0.0 109.127 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.838 HG12 ' H ' ' J' ' 25' ' ' GLY . 22.9 t -99.92 -141.13 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 118.387 -0.816 . . . . 0.0 108.855 -171.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.838 ' H ' HG12 ' J' ' 24' ' ' VAL . . . -69.88 -29.85 70.66 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-O 117.24 -1.867 . . . . 0.0 113.759 -167.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.76 ' O ' ' O ' ' J' ' 27' ' ' ASN . 78.1 p 179.1 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 120.871 2.336 . . . . 0.0 114.207 174.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.76 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.5 m-20 10.09 142.5 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -175.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.663 ' HB2' ' H ' ' K' ' 28' ' ' LYS . 3.5 mmtt -171.72 37.9 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.044 -0.98 . . . . 0.0 108.739 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.441 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . -80.78 69.62 3.19 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 115.884 -0.598 . . . . 0.0 114.253 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.33 127.98 36.71 Favored 'General case' 0 C--O 1.241 0.642 0 CA-C-O 121.517 0.675 . . . . 0.0 109.778 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.489 HD11 HG23 ' D' ' 39' ' ' VAL . 91.5 mt -131.68 127.65 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.932 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' J' ' 34' ' ' LEU . 76.3 mt -112.71 117.37 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 105.87 1.39 Allowed Glycine 0 N--CA 1.466 0.692 0 N-CA-C 106.881 -2.488 . . . . 0.0 106.881 177.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.573 ' HB2' HD13 ' K' ' 34' ' ' LEU . 70.9 mt -139.76 148.75 42.7 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -175.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.459 ' HB3' ' SD ' ' I' ' 35' ' ' MET . 26.2 tpp -120.44 105.87 11.28 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 103.127 -2.916 . . . . 0.0 103.127 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.629 HG12 HD11 ' K' ' 34' ' ' LEU . 3.2 p -135.85 143.78 35.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.504 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.49 -102.69 1.46 Allowed Glycine 0 C--N 1.318 -0.435 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.417 ' H ' ' CA ' ' K' ' 37' ' ' GLY . . . 85.19 -80.18 1.84 Allowed Glycine 0 CA--C 1.53 1.025 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.453 HG23 ' O ' ' I' ' 38' ' ' GLY . 42.0 t -112.26 133.23 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.411 HG23 ' CE1' ' I' ' 13' ' ' HIS . 14.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.36 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.3 133.2 52.2 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 120.957 0.408 . . . . 0.0 110.944 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -134.43 114.29 12.75 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.574 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -120.61 124.45 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 10.6 t60 -158.23 137.31 11.52 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-O 120.949 0.404 . . . . 0.0 111.621 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.628 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 38.3 m-70 -144.25 159.43 42.7 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 176.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -90.31 159.42 16.66 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -140.07 102.29 4.36 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.465 HD22 HD12 ' J' ' 17' ' ' LEU . 6.6 mt -109.54 116.04 31.04 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.903 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -116.61 112.66 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.663 0.268 . . . . 0.0 110.983 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.582 ' CE2' ' CD2' ' J' ' 19' ' ' PHE . 79.7 m-85 -109.81 107.68 17.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.532 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 36.4 t80 -110.24 117.69 34.35 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.22 151.27 28.99 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 118.005 -1.478 . . . . 0.0 114.288 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -78.11 -168.9 1.41 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 176.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.584 ' OD2' HG23 ' L' ' 24' ' ' VAL . 0.0 OUTLIER -169.39 50.13 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 121.209 1.822 . . . . 0.0 115.666 -174.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.595 HG12 ' H ' ' K' ' 25' ' ' GLY . 7.3 t -76.95 -142.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 -179.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.595 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -89.42 -39.07 6.44 Favored Glycine 0 N--CA 1.474 1.185 0 C-N-CA 116.663 -2.684 . . . . 0.0 115.763 -173.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 58.2 p -156.31 110.74 2.8 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.681 2.74 . . . . 0.0 114.331 174.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.533 HD21 ' CG ' ' J' ' 23' ' ' ASP . 1.1 m-80 -54.0 -179.99 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 171.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.663 ' H ' ' HB2' ' J' ' 28' ' ' LYS . 88.2 tttt -65.89 -37.64 86.64 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.08 75.97 0.45 Allowed Glycine 0 CA--C 1.541 1.69 0 CA-C-N 113.252 -1.794 . . . . 0.0 112.881 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.12 149.69 27.86 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 118.286 1.043 . . . . 0.0 109.21 178.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 85.5 mt -136.81 129.77 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 119.483 -0.887 . . . . 0.0 113.113 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -110.29 111.74 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.58 94.81 0.72 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 104.787 -3.325 . . . . 0.0 104.787 176.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' K' ' 35' ' ' MET . 4.2 tp -140.04 140.58 36.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 122.674 1.226 . . . . 0.0 113.785 -173.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' K' ' 34' ' ' LEU . 8.8 mtp -113.02 108.92 18.0 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.455 -1.248 . . . . 0.0 108.708 177.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.673 HG11 HD11 ' I' ' 17' ' ' LEU . 0.1 OUTLIER -93.93 113.14 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 105.488 -2.042 . . . . 0.0 105.488 177.832 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.417 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -14.87 123.06 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.663 -176.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.85 -61.43 7.51 Favored Glycine 0 CA--C 1.534 1.27 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.456 HG21 ' O ' ' Q' ' 29' ' ' GLY . 93.0 t -69.32 122.71 21.34 Favored 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' L' ' 40' ' ' VAL . 4.3 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 117.801 -1.095 . . . . 0.0 110.348 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -82.8 138.8 33.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.836 0.351 . . . . 0.0 110.74 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -153.31 132.8 12.91 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.159 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.462 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.6 t -110.66 101.88 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.46 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -146.11 109.95 4.88 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.678 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.628 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 75.5 m80 -154.42 163.57 39.97 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.144 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -89.89 159.21 17.07 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.823 0.344 . . . . 0.0 110.667 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -140.19 112.37 7.71 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -113.92 118.49 34.33 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -129.01 130.19 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.027 0.441 . . . . 0.0 110.405 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.9 125.13 20.21 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.096 0.474 . . . . 0.0 110.648 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 45.9 m-85 -122.17 132.91 54.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.846 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.1 156.63 40.24 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 120.328 -0.549 . . . . 0.0 109.895 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 97.3 mt-10 -53.89 143.52 21.13 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 118.226 -1.39 . . . . 0.0 109.506 -177.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 50.1 p-10 -64.98 46.37 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 115.17 1.545 . . . . 0.0 115.17 -174.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.678 HG12 ' N ' ' L' ' 25' ' ' GLY . 94.2 t -80.58 179.95 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.678 ' N ' HG12 ' L' ' 24' ' ' VAL . . . -71.43 -34.0 63.89 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 119.229 -1.463 . . . . 0.0 113.821 -178.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' L' ' 27' ' ' ASN . 21.0 m -162.51 120.42 2.1 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 118.64 1.22 . . . . 0.0 112.27 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' L' ' 26' ' ' SER . 45.5 p-10 -22.99 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.467 ' CG ' ' O ' ' L' ' 27' ' ' ASN . 87.2 mttt -168.45 31.28 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 122.414 0.286 . . . . 0.0 110.29 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' K' ' 27' ' ' ASN . . . -71.66 -71.96 0.98 Allowed Glycine 0 CA--C 1.536 1.351 0 C-N-CA 121.024 -0.607 . . . . 0.0 113.745 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.21 -173.23 4.44 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.48 HD11 HG23 ' F' ' 39' ' ' VAL . 37.4 mt -116.08 121.18 66.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 121.514 0.673 . . . . 0.0 109.386 177.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -107.4 115.12 47.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.37 111.66 1.3 Allowed Glycine 0 CA--C 1.51 -0.275 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.559 ' O ' HD12 ' L' ' 34' ' ' LEU . 0.3 OUTLIER -163.98 162.07 23.09 Favored 'General case' 0 N--CA 1.443 -0.781 0 C-N-CA 118.74 -1.184 . . . . 0.0 112.482 -177.145 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 1.5 ttm -108.63 112.22 24.43 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.66 HG21 HD11 ' J' ' 17' ' ' LEU . 6.1 p -133.72 112.03 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 121.204 0.526 . . . . 0.0 109.667 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.37 -131.99 9.52 Favored Glycine 0 N--CA 1.461 0.321 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.23 -62.92 0.55 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.444 ' HB ' HD11 ' R' ' 31' ' ' ILE . 12.3 p -158.66 147.93 8.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-O 121.199 0.524 . . . . 0.0 110.883 177.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.53 HG12 ' OXT' ' L' ' 40' ' ' VAL . 47.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.201 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -111.73 140.45 46.35 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.971 0.415 . . . . 0.0 110.561 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -107.16 126.78 52.83 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.049 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.533 HG23 ' O ' ' M' ' 12' ' ' VAL . 12.5 m -120.4 125.94 74.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.739 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 62.9 m170 -114.93 105.17 12.67 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' O ' ' N' ' 14' ' ' HIS . 23.0 p80 -156.12 164.04 38.89 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.801 -0.359 . . . . 0.0 111.276 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.47 ' OE1' HG11 ' N' ' 40' ' ' VAL . 56.5 tp60 -89.85 159.03 17.19 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -140.17 110.47 6.62 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -133.9 124.67 26.83 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 121.641 0.734 . . . . 0.0 110.835 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 t -119.46 104.25 15.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -104.89 112.58 25.76 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.549 ' O ' ' NZ ' ' M' ' 28' ' ' LYS . 18.2 p90 -141.39 126.15 18.03 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -104.56 110.83 23.27 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 176.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 177.57 121.27 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 52.46 52.14 14.76 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.413 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.28 153.67 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.956 0.408 . . . . 0.0 110.298 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.82 -21.37 0.25 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-N 116.106 -0.497 . . . . 0.0 112.054 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 29.8 p -151.15 169.35 22.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.124 0.462 . . . . 0.0 111.162 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -31.36 134.76 0.07 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.673 -177.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' M' ' 20' ' ' PHE . 88.3 tttt 179.92 -50.48 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.881 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' N' ' 29' ' ' GLY . . . -71.14 58.41 1.08 Allowed Glycine 0 CA--C 1.538 1.53 0 CA-C-N 113.675 -1.602 . . . . 0.0 113.929 -178.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.13 -169.43 3.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 117.31 0.555 . . . . 0.0 109.691 -179.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 96.4 mt -104.93 118.01 51.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.455 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -116.5 125.13 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.521 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.38 104.66 0.67 Allowed Glycine 0 N--CA 1.469 0.835 0 N-CA-C 108.199 -1.96 . . . . 0.0 108.199 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.7 tp -146.56 147.94 31.63 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.535 -177.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.3 mmm -114.46 130.46 56.73 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 114.391 -1.277 . . . . 0.0 108.303 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' M' ' 37' ' ' GLY . 93.9 t -124.06 102.71 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -28.23 152.52 0.0 OUTLIER Glycine 0 CA--C 1.537 1.41 0 O-C-N 123.478 0.486 . . . . 0.0 112.969 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' M' ' 39' ' ' VAL . . . -59.79 -55.17 31.91 Favored Glycine 0 CA--C 1.537 1.444 0 CA-C-O 119.395 -0.669 . . . . 0.0 114.162 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.425 ' C ' ' O ' ' M' ' 38' ' ' GLY . 85.9 t -28.85 147.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 117.963 0.881 . . . . 0.0 112.318 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.523 179.77 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 45.8 p90 -146.26 154.82 42.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.981 0.42 . . . . 0.0 110.217 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.36 152.82 44.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.339 -179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.515 ' CG1' ' NE2' ' N' ' 14' ' ' HIS . 73.5 t -127.0 132.85 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.855 -179.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' N ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -157.8 95.01 1.38 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.641 178.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.515 ' NE2' ' CG1' ' N' ' 12' ' ' VAL . 5.5 m-70 -90.84 159.69 16.13 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.812 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -90.15 158.92 17.03 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 176.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -140.73 96.82 3.08 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.152 -0.619 . . . . 0.0 110.434 178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.496 HD12 HD22 ' O' ' 17' ' ' LEU . 22.8 mt -119.92 120.62 36.95 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.849 178.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -122.62 107.96 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.276 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.423 ' CD2' ' CD1' ' O' ' 19' ' ' PHE . 30.5 m-85 -108.07 111.09 22.96 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -132.06 125.44 31.41 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.506 -0.478 . . . . 0.0 112.174 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.31 119.95 35.53 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -93.8 158.84 15.47 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.835 0.826 . . . . 0.0 112.924 -178.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD1' ' O ' ' N' ' 23' ' ' ASP . 66.3 t0 -70.06 46.48 0.08 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 114.335 -1.302 . . . . 0.0 112.576 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.449 HG12 ' H ' ' N' ' 25' ' ' GLY . 1.4 t -80.43 -179.74 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.463 ' O ' ' CB ' ' N' ' 26' ' ' SER . . . -71.09 -28.96 69.44 Favored Glycine 0 CA--C 1.524 0.603 0 C-N-CA 119.271 -1.442 . . . . 0.0 110.425 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' N' ' 25' ' ' GLY . 2.1 p 160.18 126.25 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.455 0.169 . . . . 0.0 111.094 176.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.661 ' CB ' HD21 ' O' ' 27' ' ' ASN . 51.6 t30 -49.14 162.31 0.13 Allowed 'General case' 0 CA--C 1.52 -0.184 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.419 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 68.1 mttm -73.12 37.98 0.09 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.642 177.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' N' ' 27' ' ' ASN . . . 61.39 89.79 0.02 OUTLIER Glycine 0 N--CA 1.477 1.409 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.12 114.69 28.39 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.911 HG21 ' O ' ' H' ' 38' ' ' GLY . 9.6 mt -124.68 115.37 44.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.619 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 175.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.641 HG22 HD11 ' O' ' 34' ' ' LEU . 66.4 mt -116.24 130.56 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 121.398 0.618 . . . . 0.0 112.419 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.38 102.78 0.56 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' N' ' 35' ' ' MET . 6.5 tt -144.49 148.33 34.39 Favored 'General case' 0 N--CA 1.482 1.163 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.962 -177.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' N' ' 34' ' ' LEU . 37.7 ttm -135.4 136.54 41.49 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.545 ' O ' ' O ' ' N' ' 37' ' ' GLY . 59.5 t -124.16 132.03 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' N' ' 36' ' ' VAL . . . -43.08 -111.61 0.0 OUTLIER Glycine 0 CA--C 1.531 1.067 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.688 -178.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . -127.76 -70.85 0.16 Allowed Glycine 0 CA--C 1.534 1.241 0 O-C-N 122.642 -0.328 . . . . 0.0 112.531 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -60.3 133.8 25.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.192 0 CA-C-O 120.688 0.28 . . . . 0.0 110.908 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.47 HG11 ' OE1' ' M' ' 15' ' ' GLN . 7.2 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.632 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -89.65 136.2 33.17 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.873 0.368 . . . . 0.0 110.537 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 89.4 mt-10 -134.95 143.97 47.18 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.475 HG21 ' N ' ' P' ' 13' ' ' HIS . 32.8 m -138.85 166.41 22.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.624 0.726 . . . . 0.0 111.823 -179.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.617 ' HB3' ' H ' ' N' ' 13' ' ' HIS . 0.0 OUTLIER -77.78 164.44 25.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.88 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.505 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 3.8 m-70 -139.75 162.63 34.66 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 177.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.527 ' OE1' HD21 ' P' ' 17' ' ' LEU . 43.8 tt0 -84.91 156.87 21.04 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.797 ' O ' HD23 ' O' ' 17' ' ' LEU . 62.0 tttt -159.93 99.37 1.38 Allowed 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.724 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.797 HD23 ' O ' ' O' ' 16' ' ' LYS . 1.8 mt -131.21 125.43 32.93 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.596 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -113.76 101.9 13.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.44 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 66.6 m-85 -102.85 105.54 15.95 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -122.24 126.42 48.16 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.21 121.44 27.66 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.492 0.663 . . . . 0.0 112.616 -179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -145.67 110.03 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 104.286 -2.486 . . . . 0.0 104.286 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -166.17 48.86 0.08 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.42 -0.912 . . . . 0.0 113.136 -174.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.482 HG12 ' N ' ' O' ' 25' ' ' GLY . 54.4 t -72.05 161.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 118.154 -1.419 . . . . 0.0 108.256 -178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.49 -29.71 9.67 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.684 -2.166 . . . . 0.0 107.684 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.539 ' HA ' ' H ' ' P' ' 28' ' ' LYS . 10.4 p 92.84 115.06 0.02 OUTLIER 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 113.267 -1.467 . . . . 0.0 108.908 -178.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.661 HD21 ' CB ' ' N' ' 27' ' ' ASN . 64.6 t-20 -73.42 158.84 34.22 Favored 'General case' 0 C--N 1.345 0.384 0 C-N-CA 117.512 -1.675 . . . . 0.0 109.726 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.524 ' N ' ' OD1' ' O' ' 27' ' ' ASN . 87.7 tttt -48.74 -41.97 33.82 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 176.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.4 65.74 0.08 OUTLIER Glycine 0 CA--C 1.553 2.445 0 CA-C-O 118.268 -1.295 . . . . 0.0 113.536 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -87.5 95.76 10.15 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 121.03 2.415 . . . . 0.0 115.565 -176.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.486 ' CD1' HG22 ' I' ' 39' ' ' VAL . 98.8 mt -138.15 126.13 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.358 178.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.566 HG23 HD13 ' O' ' 34' ' ' LEU . 58.8 mt -115.1 116.09 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.84 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -125.63 98.22 0.53 Allowed Glycine 0 N--CA 1.473 1.122 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 178.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.84 HD12 ' C ' ' O' ' 33' ' ' GLY . 7.2 mp -143.03 157.78 44.22 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 123.392 1.567 . . . . 0.0 113.939 -177.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 40.3 tpp -121.48 104.31 9.58 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 111.458 -2.61 . . . . 0.0 104.329 176.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 t -128.94 103.66 9.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -177.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.17 -154.66 16.8 Favored Glycine 0 C--N 1.32 -0.344 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.426 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 137.79 -56.16 0.67 Allowed Glycine 0 CA--C 1.536 1.355 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 p -139.88 155.41 24.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.662 179.899 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.2 135.2 49.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.411 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -72.59 130.81 41.44 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.106 0.479 . . . . 0.0 110.663 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.505 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 2.5 p -138.98 161.53 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.53 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.505 ' N ' HG22 ' P' ' 12' ' ' VAL . 46.6 t-80 -73.87 132.38 42.45 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 114.686 1.365 . . . . 0.0 114.686 -177.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.643 ' ND1' ' CD2' ' Q' ' 14' ' ' HIS . 96.0 m-70 -148.45 159.31 44.17 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.646 175.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.745 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 31.0 tt0 -90.45 156.71 18.01 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 119.719 -0.793 . . . . 0.0 109.279 176.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -142.87 98.11 3.22 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.995 175.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.551 HD22 HD12 ' O' ' 17' ' ' LEU . 40.9 mt -122.25 119.57 31.58 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.513 179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 t -114.42 104.71 17.35 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.44 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 58.9 m-85 -107.54 111.76 24.19 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -125.08 122.92 38.58 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.49 134.49 30.75 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 114.665 1.357 . . . . 0.0 114.665 -177.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -142.97 133.67 25.21 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 176.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.404 ' OD1' ' O ' ' P' ' 23' ' ' ASP . 68.1 t0 -170.14 50.84 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.626 -175.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.443 HG22 ' OD1' ' Q' ' 23' ' ' ASP . 58.6 t -81.82 146.72 6.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 122.379 1.085 . . . . 0.0 111.478 -176.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 38.96 5.24 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 113.049 -1.887 . . . . 0.0 113.873 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.07 111.73 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 118.672 -1.211 . . . . 0.0 113.67 173.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.446 ' O ' ' CD ' ' Q' ' 28' ' ' LYS . 0.5 OUTLIER -128.14 158.45 38.02 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 118.477 -1.289 . . . . 0.0 109.412 176.797 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.539 ' H ' ' HA ' ' O' ' 26' ' ' SER . 13.4 tmtt? -32.15 -39.26 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -176.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.96 75.29 0.4 Allowed Glycine 0 CA--C 1.537 1.458 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -177.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.39 126.56 31.77 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.889 1.844 . . . . 0.0 110.716 -176.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -131.57 130.55 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -113.37 108.52 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.72 106.2 2.14 Favored Glycine 0 N--CA 1.463 0.479 0 N-CA-C 105.418 -3.073 . . . . 0.0 105.418 176.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' Q' ' 34' ' ' LEU . 19.4 tp -144.08 138.76 28.49 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -173.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mtp -114.91 108.55 16.87 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.13 101.89 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -175.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.11 -174.16 22.95 Favored Glycine 0 N--CA 1.463 0.438 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.529 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.4 ' HA2' ' H ' ' Q' ' 38' ' ' GLY . . . 165.09 -54.03 0.27 Allowed Glycine 0 CA--C 1.546 1.996 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.411 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.622 HG22 HD12 ' D' ' 31' ' ' ILE . 3.0 t -112.74 127.49 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 117.97 0.885 . . . . 0.0 109.502 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.41 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 91.8 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.914 -1.041 . . . . 0.0 111.028 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.381 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -97.18 135.5 39.04 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.651 0.263 . . . . 0.0 110.427 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' R' ' 11' ' ' GLU . 96.9 mt-10 -113.0 124.09 51.82 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.681 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.566 ' O ' ' CE1' ' P' ' 14' ' ' HIS . 95.6 t -110.11 119.99 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.4 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 71.8 t60 -112.8 124.9 53.64 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.56 0.695 . . . . 0.0 112.614 -178.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.643 ' CD2' ' ND1' ' P' ' 14' ' ' HIS . 3.3 p-80 -153.92 161.61 41.87 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.362 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.94 159.12 17.08 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . 0.633 ' C ' HD12 ' Q' ' 17' ' ' LEU . 24.6 tttt -140.21 97.88 3.32 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 177.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.745 HD11 ' OE1' ' P' ' 15' ' ' GLN . 7.5 mp -125.28 122.98 38.48 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.433 HG13 ' O ' ' Q' ' 18' ' ' VAL . 13.5 p -126.8 121.96 59.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 177.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.445 ' C ' ' CD1' ' Q' ' 19' ' ' PHE . 1.7 t80 -127.1 128.86 46.9 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.446 -178.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -135.68 116.25 13.81 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.427 ' HB2' ' CZ ' ' Q' ' 19' ' ' PHE . . . -129.99 127.68 40.51 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-O 121.452 0.644 . . . . 0.0 111.682 -179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -132.98 109.08 9.31 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' R' ' 27' ' ' ASN . 53.3 t0 -171.39 48.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 119.606 -0.837 . . . . 0.0 112.834 -177.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.557 HG12 ' N ' ' Q' ' 25' ' ' GLY . 69.1 t -72.22 161.01 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 118.511 -1.275 . . . . 0.0 110.56 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.557 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . 108.94 -30.73 8.38 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 107.006 -2.437 . . . . 0.0 107.006 -178.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 1.5 m 94.12 112.3 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.072 -1.564 . . . . 0.0 111.755 177.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -73.87 176.22 6.58 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 176.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' P' ' 27' ' ' ASN . 72.8 tttt -53.29 -36.68 61.47 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.456 ' O ' HG21 ' K' ' 39' ' ' VAL . . . 121.2 77.01 0.45 Allowed Glycine 0 CA--C 1.54 1.612 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.558 -179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.57 152.52 27.19 Favored 'General case' 0 C--N 1.353 0.722 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -148.58 138.22 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -176.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . 0.446 HD13 HG21 ' Q' ' 32' ' ' ILE . 43.0 mt -107.68 115.14 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 176.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.99 111.33 1.7 Allowed Glycine 0 N--CA 1.466 0.675 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.433 HD21 ' CG2' ' Q' ' 32' ' ' ILE . 1.6 pp -165.95 162.17 17.98 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 117.052 -1.859 . . . . 0.0 115.541 -178.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.413 ' SD ' ' HB3' ' R' ' 35' ' ' MET . 30.9 tpp -112.79 117.28 31.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 112.671 -2.059 . . . . 0.0 109.139 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.77 HG11 HD11 ' O' ' 17' ' ' LEU . 1.8 t -110.39 122.74 65.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-O 121.408 0.623 . . . . 0.0 110.295 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 13.09 113.4 0.0 OUTLIER Glycine 0 CA--C 1.535 1.284 0 CA-C-N 114.56 -1.2 . . . . 0.0 115.013 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.4 ' H ' ' HA2' ' P' ' 38' ' ' GLY . . . -62.47 -63.54 4.6 Favored Glycine 0 CA--C 1.542 1.723 0 CA-C-N 115.232 -0.484 . . . . 0.0 112.044 177.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.86 129.38 40.02 Favored 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.438 ' C ' ' NE2' ' O' ' 13' ' ' HIS . 2.6 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.425 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -113.24 142.14 46.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 120.838 0.352 . . . . 0.0 110.581 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 48.6 tp10 -70.58 136.06 48.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.244 0.545 . . . . 0.0 110.337 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.435 HG22 ' N ' ' R' ' 13' ' ' HIS . 3.7 p -143.36 158.52 17.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.526 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.444 ' CG ' ' CG1' ' Q' ' 12' ' ' VAL . 13.6 m170 -116.61 163.52 15.98 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.057 0.456 . . . . 0.0 110.473 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.551 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 85.9 t60 -69.36 175.4 4.0 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 178.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.551 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 88.5 mt-30 -98.33 150.56 21.45 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.374 0.607 . . . . 0.0 110.815 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -111.28 104.6 13.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.781 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.46 115.69 23.34 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.13 110.24 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.826 0.346 . . . . 0.0 110.431 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.87 125.07 52.15 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.798 179.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -130.05 123.36 30.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' R' ' 24' ' ' VAL . . . -134.7 147.81 50.17 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.062 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.413 ' O ' ' N ' ' R' ' 24' ' ' VAL . 82.3 tt0 -73.6 127.65 33.33 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.208 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 61.47 -59.69 0.1 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.699 -1.137 . . . . 0.0 113.083 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.632 ' O ' ' HB3' ' R' ' 21' ' ' ALA . 15.4 m -102.83 -176.72 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 C-N-CA 120.014 -0.674 . . . . 0.0 110.358 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.91 -32.12 69.94 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 97.0 p -151.22 124.54 8.85 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.444 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 25.3 t30 -41.81 151.06 0.1 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.659 0.743 . . . . 0.0 112.383 -177.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -71.4 47.96 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.349 -1.296 . . . . 0.0 111.7 178.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.97 -59.04 0.04 OUTLIER Glycine 0 CA--C 1.542 1.733 0 C-N-CA 118.96 -1.591 . . . . 0.0 114.925 -178.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.12 136.77 35.95 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 118.384 1.092 . . . . 0.0 111.956 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.444 HD11 ' HB ' ' L' ' 39' ' ' VAL . 96.2 mt -127.94 133.62 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 CA-C-O 121.659 0.742 . . . . 0.0 112.281 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.469 HG22 HD22 ' R' ' 34' ' ' LEU . 78.3 mt -108.14 116.79 52.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.177 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.32 116.16 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 109.128 -1.589 . . . . 0.0 109.128 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.661 HD23 ' N ' ' R' ' 34' ' ' LEU . 0.8 OUTLIER -167.8 162.7 13.89 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 118.523 -1.271 . . . . 0.0 112.588 -178.381 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.413 ' HB3' ' SD ' ' Q' ' 35' ' ' MET . 2.2 ttm -109.52 121.47 45.27 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.099 -1.41 . . . . 0.0 107.359 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.459 ' O ' ' NE2' ' P' ' 15' ' ' GLN . 2.4 m -135.94 102.59 3.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.073 0.464 . . . . 0.0 110.69 -178.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.99 -162.72 13.4 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.81 -55.62 0.53 Allowed Glycine 0 CA--C 1.544 1.897 0 CA-C-N 114.996 -0.602 . . . . 0.0 111.646 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.459 ' HB ' HD11 ' F' ' 31' ' ' ILE . 3.3 p -145.1 140.59 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 117.531 0.666 . . . . 0.0 109.877 177.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.481 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -113.9 137.85 51.11 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.889 0.376 . . . . 0.0 110.42 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -73.76 128.4 35.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.492 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.3 t -110.44 100.57 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.186 0.517 . . . . 0.0 109.751 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -79.94 158.54 26.6 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.486 -178.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' B' ' 14' ' ' HIS . 39.6 m170 -117.0 157.08 26.4 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.099 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -90.39 160.23 16.18 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 115.403 -0.817 . . . . 0.0 108.961 176.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.17 108.89 5.93 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.506 -0.477 . . . . 0.0 110.738 178.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.606 HD21 HG21 ' C' ' 36' ' ' VAL . 4.6 mp -133.61 119.95 20.08 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 122.491 1.139 . . . . 0.0 110.591 177.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG13 ' HB ' ' B' ' 18' ' ' VAL . 2.4 t -109.06 106.84 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 CA-C-N 113.957 -1.474 . . . . 0.0 107.772 178.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.504 ' CD1' HD13 ' C' ' 32' ' ' ILE . 82.2 m-85 -107.16 104.8 14.53 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.2 p90 -143.79 149.5 37.15 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.22 109.27 11.65 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.426 ' O ' ' N ' ' A' ' 24' ' ' VAL . 96.1 mt-10 -121.65 172.48 8.09 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.751 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 66.8 t0 -67.5 46.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.648 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 26' ' ' SER . 16.9 m -71.48 -168.81 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CB ' ' A' ' 26' ' ' SER . . . -99.28 32.45 7.14 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.506 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 p 89.67 129.48 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.472 0.177 . . . . 0.0 110.771 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -79.32 -170.93 2.49 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -56.58 -39.4 73.45 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.914 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.77 67.86 1.49 Allowed Glycine 0 CA--C 1.537 1.451 0 CA-C-O 119.321 -0.711 . . . . 0.0 111.337 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.12 -175.79 5.2 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.065 1.433 . . . . 0.0 113.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.482 ' O ' HD12 ' A' ' 31' ' ' ILE . 2.5 pp -120.57 122.48 68.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 112.917 -1.947 . . . . 0.0 107.419 178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -122.88 131.23 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 121.026 0.441 . . . . 0.0 111.867 -177.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.75 106.61 0.65 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 108.161 -1.975 . . . . 0.0 108.161 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.53 ' O ' HD12 ' B' ' 34' ' ' LEU . 72.3 mt -138.77 149.2 44.75 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 121.873 0.844 . . . . 0.0 112.376 -178.217 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 98.0 mmm -117.27 126.08 52.15 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.122 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 37' ' ' GLY . 53.6 t -136.38 161.51 37.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 140.97 93.19 0.21 Allowed Glycine 0 C--N 1.316 -0.571 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.64 -76.87 0.03 OUTLIER Glycine 0 CA--C 1.533 1.189 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.8 p -126.3 160.57 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 117.216 0.508 . . . . 0.0 109.762 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.493 ' N ' HG22 ' A' ' 39' ' ' VAL . 13.5 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.998 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -84.08 139.44 32.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 110.564 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.33 125.08 27.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.369 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 32.0 m -139.25 164.23 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.12 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' D' ' 40' ' ' VAL . 65.7 t60 -106.21 121.97 45.26 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' B' ' 15' ' ' GLN . 26.7 t60 -155.44 168.93 25.5 Favored 'General case' 0 CA--C 1.517 -0.318 0 C-N-CA 120.453 -0.499 . . . . 0.0 111.4 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 60.5 tt0 -156.16 140.97 17.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.951 178.118 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.11 108.44 19.95 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.485 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.565 HD11 HG11 ' D' ' 36' ' ' VAL . 20.0 mt -120.31 109.84 15.85 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 118.831 0.742 . . . . 0.0 109.273 177.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.452 ' HB ' HG13 ' A' ' 18' ' ' VAL . 19.8 t -107.92 104.51 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.529 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.665 ' CD2' ' CE1' ' C' ' 19' ' ' PHE . 72.7 m-85 -106.2 102.3 11.72 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.581 ' CZ ' ' CD1' ' C' ' 20' ' ' PHE . 9.4 t80 -130.19 136.43 49.24 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 120.71 0.291 . . . . 0.0 111.687 -177.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.74 121.65 23.37 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.466 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 73.2 tt0 -118.92 171.03 8.52 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.0 m-20 -33.62 -62.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.55 142.52 15.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.326 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -155.59 28.15 0.61 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.1 t 78.71 -130.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.196 -0.502 . . . . 0.0 110.423 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -109.81 167.88 9.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.352 0.596 . . . . 0.0 111.486 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -39.68 -39.51 0.77 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.068 -0.969 . . . . 0.0 112.692 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.23 67.98 0.22 Allowed Glycine 0 CA--C 1.537 1.456 0 N-CA-C 115.576 0.991 . . . . 0.0 115.576 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' C' ' 29' ' ' GLY . . . -100.5 104.76 16.15 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 118.078 0.939 . . . . 0.0 108.947 177.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.591 HD13 HG21 ' O' ' 39' ' ' VAL . 8.6 mt -132.72 127.02 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.993 -177.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.4 115.68 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.773 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.44 112.37 2.16 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.53 HD12 ' O ' ' A' ' 34' ' ' LEU . 41.1 tp -147.0 135.27 21.69 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 118.858 -1.137 . . . . 0.0 113.581 -176.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.515 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.0 OUTLIER -105.29 112.52 25.67 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.031 177.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' C' ' 35' ' ' MET . 28.2 t -137.55 142.53 36.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.219 0.533 . . . . 0.0 109.956 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' B' ' 39' ' ' VAL . . . 155.0 -101.94 0.21 Allowed Glycine 0 C--N 1.3 -1.433 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.449 ' O ' HG12 ' C' ' 39' ' ' VAL . . . 54.79 -77.75 0.01 OUTLIER Glycine 0 CA--C 1.536 1.35 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.721 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' B' ' 37' ' ' GLY . 68.4 t -135.5 139.71 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.603 HG12 ' O ' ' B' ' 40' ' ' VAL . 86.7 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.301 178.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -105.78 132.74 51.53 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.748 0.309 . . . . 0.0 110.66 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 141.39 49.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.494 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -121.85 130.65 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.231 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.454 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 9.2 m80 -128.42 130.4 47.58 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.094 0.473 . . . . 0.0 110.515 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.61 ' NE2' ' N ' ' D' ' 16' ' ' LYS . 8.4 t60 -151.14 171.35 17.51 Favored 'General case' 0 C--O 1.215 -0.713 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.797 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.55 ' H ' ' CD2' ' C' ' 14' ' ' HIS . 12.2 tt0 -155.16 140.62 17.8 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.199 177.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.484 ' N ' ' CE1' ' B' ' 14' ' ' HIS . 88.7 tttt -94.83 110.46 22.33 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.328 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.63 HD12 ' N ' ' C' ' 17' ' ' LEU . 0.8 OUTLIER -123.21 114.34 20.14 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.878 0.763 . . . . 0.0 109.743 176.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -108.87 105.83 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.665 ' CE1' ' CD2' ' B' ' 19' ' ' PHE . 80.9 m-85 -108.79 104.46 13.74 Favored 'General case' 0 CA--C 1.529 0.148 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.581 ' CD1' ' CZ ' ' B' ' 20' ' ' PHE . 32.5 t80 -126.08 130.02 50.27 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.766 -178.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.61 130.72 40.59 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 84.2 tt0 -162.7 129.84 3.65 Favored 'General case' 0 C--O 1.224 -0.289 0 N-CA-C 104.759 -2.311 . . . . 0.0 104.759 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.481 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 23.0 t70 -170.98 46.71 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -176.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 2.2 t -83.81 171.38 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 C-N-CA 117.404 -1.718 . . . . 0.0 110.124 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.542 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 90.52 -34.29 4.24 Favored Glycine 0 CA--C 1.524 0.608 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.447 178.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.463 ' O ' ' O ' ' C' ' 27' ' ' ASN . 74.4 p -152.88 122.16 6.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.522 -0.339 . . . . 0.0 110.448 179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' H ' ' C' ' 28' ' ' LYS . 8.9 t-20 -40.63 166.79 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.07 178.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.553 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 91.3 mttt -80.76 -49.57 10.97 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 119.64 -0.824 . . . . 0.0 109.521 178.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 73.53 50.96 10.28 Favored Glycine 0 CA--C 1.538 1.512 0 CA-C-O 118.61 -1.105 . . . . 0.0 113.397 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.79 132.85 10.68 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 120.425 2.112 . . . . 0.0 114.484 -178.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.55 HD12 ' HB ' ' O' ' 39' ' ' VAL . 83.8 mt -126.16 117.38 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.582 176.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.586 HG22 HD11 ' D' ' 34' ' ' LEU . 91.7 mt -107.71 116.83 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.53 99.21 0.78 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 104.649 -3.38 . . . . 0.0 104.649 176.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 4.2 tt -142.17 133.99 27.08 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 122.905 1.336 . . . . 0.0 113.295 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.446 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 6.4 mtp -104.57 109.83 21.89 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 113.244 -1.798 . . . . 0.0 107.831 177.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.606 HG21 HD21 ' A' ' 17' ' ' LEU . 9.3 p -125.99 133.67 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.98 -104.68 0.4 Allowed Glycine 0 C--N 1.308 -1.009 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.564 ' O ' HD11 ' J' ' 31' ' ' ILE . . . 80.78 -79.03 1.82 Allowed Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.59 HG22 ' N ' ' C' ' 40' ' ' VAL . 6.9 p -151.16 165.61 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.59 ' N ' HG22 ' C' ' 39' ' ' VAL . 15.6 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.802 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.78 135.65 44.04 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 110.129 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -119.81 139.32 52.52 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.65 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.742 HG12 ' H ' ' D' ' 13' ' ' HIS . 40.3 t -143.06 177.74 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.66 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.742 ' H ' HG12 ' D' ' 12' ' ' VAL . 67.0 t60 -64.39 125.89 26.08 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' D' ' 12' ' ' VAL . 7.8 m80 -147.88 176.54 10.06 Favored 'General case' 0 C--O 1.215 -0.711 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.483 ' CA ' ' CE1' ' C' ' 14' ' ' HIS . 54.3 tt0 -153.55 140.45 19.18 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 120.079 1.309 . . . . 0.0 112.215 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.61 ' N ' ' NE2' ' C' ' 14' ' ' HIS . 72.4 mttt -93.44 104.41 16.55 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.865 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD13 ' C' ' 17' ' ' LEU . 10.5 mt -119.16 112.7 19.85 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 178.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.37 109.89 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-O 121.03 0.443 . . . . 0.0 110.885 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.529 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 36.9 m-85 -108.09 111.69 23.86 Favored 'General case' 0 CA--C 1.528 0.099 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -132.5 126.29 32.6 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.854 -0.338 . . . . 0.0 111.815 -177.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.85 116.44 17.93 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 122.422 1.106 . . . . 0.0 110.45 178.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.555 ' O ' HG23 ' D' ' 24' ' ' VAL . 96.4 mt-10 -99.11 -151.04 0.38 Allowed 'General case' 0 C--N 1.341 0.199 0 CA-C-N 113.752 -1.567 . . . . 0.0 109.678 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.564 ' O ' ' CG2' ' C' ' 24' ' ' VAL . 0.6 OUTLIER -63.39 47.89 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.584 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -179.314 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.555 HG23 ' O ' ' D' ' 22' ' ' GLU . 0.2 OUTLIER -51.76 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.225 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.436 ' H ' HG12 ' D' ' 24' ' ' VAL . . . 166.07 17.6 0.02 OUTLIER Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.422 ' H ' ' H ' ' D' ' 25' ' ' GLY . 8.0 t -71.37 129.81 39.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.711 0.767 . . . . 0.0 113.007 -177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.568 ' O ' ' N ' ' D' ' 29' ' ' GLY . 66.7 m-20 -90.81 -150.41 0.23 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.833 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt 43.09 -47.78 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 116.22 1.934 . . . . 0.0 116.22 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . 130.48 59.97 0.1 OUTLIER Glycine 0 CA--C 1.544 1.875 0 CA-C-N 121.286 1.857 . . . . 0.0 115.896 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 130.98 43.01 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.658 2.229 . . . . 0.0 110.336 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.517 HD12 HG23 ' P' ' 39' ' ' VAL . 54.1 mt -138.76 135.13 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 -176.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.707 HG23 HD13 ' D' ' 34' ' ' LEU . 36.2 mt -105.61 105.95 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 174.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.827 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -115.38 97.39 0.8 Allowed Glycine 0 N--CA 1.47 0.949 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.827 HD12 ' C ' ' D' ' 33' ' ' GLY . 7.2 mp -139.35 153.62 47.72 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-O 123.475 1.607 . . . . 0.0 115.23 -176.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 tpp -114.74 113.89 24.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 112.038 -2.346 . . . . 0.0 105.132 176.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' B' ' 17' ' ' LEU . 63.2 t -112.59 124.49 69.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 CA-C-O 122.048 0.928 . . . . 0.0 112.739 -176.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.81 115.58 0.01 OUTLIER Glycine 0 N--CA 1.472 1.087 0 CA-C-N 113.433 -1.712 . . . . 0.0 113.452 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.94 -62.08 4.23 Favored Glycine 0 CA--C 1.535 1.319 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.598 HG12 HD13 ' J' ' 31' ' ' ILE . 3.6 p -147.46 133.89 12.94 Favored 'Isoleucine or valine' 0 C--N 1.342 0.264 0 CA-C-O 120.937 0.399 . . . . 0.0 109.99 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.597 HG12 ' O ' ' D' ' 40' ' ' VAL . 61.8 t . . . . . 0 C--O 1.218 -0.597 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.45 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -105.38 134.41 48.54 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.738 0.304 . . . . 0.0 110.474 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -122.2 132.59 54.52 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.253 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.575 ' H ' HG21 ' D' ' 12' ' ' VAL . 59.1 t -117.23 129.93 72.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 CA-C-O 121.303 0.573 . . . . 0.0 110.233 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 -146.37 98.01 3.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.865 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.501 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 8.4 p80 -154.74 165.62 36.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.086 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -129.57 150.97 50.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -96.59 107.83 20.33 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.478 ' CD2' HD12 ' D' ' 17' ' ' LEU . 26.4 mt -113.35 114.52 26.76 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.21 110.74 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.618 0.246 . . . . 0.0 110.442 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.529 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 53.1 m-85 -109.48 112.4 24.48 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.827 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 8.6 t80 -121.72 120.3 34.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.66 126.14 8.77 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.378 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.14 150.8 22.57 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -178.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.447 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 67.2 t0 -74.22 46.75 0.26 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.093 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.976 HG12 ' H ' ' E' ' 25' ' ' GLY . 2.2 t -71.65 -167.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.756 0.788 . . . . 0.0 110.95 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.976 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -99.03 28.27 16.06 Favored Glycine 0 N--CA 1.461 0.338 0 N-CA-C 105.458 -3.057 . . . . 0.0 105.458 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.456 ' H ' ' C ' ' E' ' 24' ' ' VAL . 5.0 p -80.53 116.28 20.49 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 110.509 -2.845 . . . . 0.0 109.919 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.416 ' C ' ' O ' ' F' ' 28' ' ' LYS . 55.9 p30 -89.29 -154.82 0.32 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.277 -175.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' F' ' 29' ' ' GLY . 46.8 mttm -49.64 -40.59 40.07 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.099 -1.04 . . . . 0.0 110.508 -172.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.49 -68.74 3.29 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 174.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.86 168.99 1.22 Allowed 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.129 0.966 . . . . 0.0 110.825 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 59.5 mt -124.85 127.07 72.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 114.206 -1.361 . . . . 0.0 110.012 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.629 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.7 mt -107.74 109.2 27.37 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.73 114.52 3.05 Favored Glycine 0 N--CA 1.459 0.221 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.636 ' O ' HD23 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -171.15 146.33 2.38 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 116.465 -2.094 . . . . 0.0 112.552 -176.645 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.488 ' N ' HD12 ' E' ' 34' ' ' LEU . 35.0 mtp -108.02 124.28 49.94 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.003 -1.453 . . . . 0.0 109.449 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.54 102.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.865 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.88 -162.56 30.15 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.712 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.414 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 147.17 -55.48 0.52 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.597 ' HB ' HD11 ' K' ' 31' ' ' ILE . 70.2 t -130.17 132.83 64.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' D' ' 40' ' ' VAL . 11.8 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.669 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -108.56 133.87 52.1 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.876 0.37 . . . . 0.0 110.504 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -80.38 158.17 26.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.095 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 m -109.8 105.75 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 121.366 0.603 . . . . 0.0 110.821 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -145.37 97.07 2.94 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.123 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 99.4 m-70 -150.63 171.72 16.67 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -99.5 151.05 21.57 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.249 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -110.45 109.91 20.46 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 55.6 tp -117.29 118.51 32.47 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.614 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -125.04 129.2 73.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.496 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 49.9 p90 -145.5 133.11 20.92 Favored 'General case' 0 CA--C 1.515 -0.369 0 C-N-CA 120.001 -0.679 . . . . 0.0 112.406 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -123.22 109.79 14.43 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -167.41 173.3 8.9 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 118.069 -1.452 . . . . 0.0 114.07 -176.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.459 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 80.1 tt0 -128.9 131.42 47.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 113.508 -1.678 . . . . 0.0 110.008 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.517 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 2.6 p-10 50.2 46.42 24.83 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.945 -0.571 . . . . 0.0 112.156 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -85.25 -171.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.456 0.646 . . . . 0.0 109.569 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.93 -31.35 3.69 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.078 -0.964 . . . . 0.0 111.112 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' F' ' 27' ' ' ASN . 71.1 p -142.23 -129.66 0.09 Allowed 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 121.077 0.465 . . . . 0.0 111.374 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' F' ' 23' ' ' ASP . 70.1 m-80 53.37 151.86 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.036 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' E' ' 27' ' ' ASN . 99.3 mttt -71.77 46.17 0.12 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 114.886 -1.052 . . . . 0.0 112.388 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . -90.76 -59.43 1.42 Allowed Glycine 0 CA--C 1.543 1.826 0 C-N-CA 119.22 -1.467 . . . . 0.0 113.662 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.25 150.76 20.31 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.521 HD11 ' HB ' ' R' ' 39' ' ' VAL . 97.3 mt -120.1 116.17 49.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 CA-C-N 119.759 1.163 . . . . 0.0 110.353 178.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.487 HD13 ' CD1' ' D' ' 19' ' ' PHE . 95.0 mt -110.49 111.99 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.61 91.29 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.636 HD23 ' O ' ' E' ' 34' ' ' LEU . 67.0 mt -126.46 139.27 53.37 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.6 mtp -108.08 110.15 21.76 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 105.211 -2.144 . . . . 0.0 105.211 175.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.649 HG23 ' O ' ' F' ' 36' ' ' VAL . 29.3 m -119.96 102.61 12.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.072 0.463 . . . . 0.0 110.547 -176.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.39 -162.53 29.48 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.702 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.93 -55.65 0.52 Allowed Glycine 0 CA--C 1.542 1.76 0 CA-C-N 115.121 -0.539 . . . . 0.0 111.852 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.55 ' CG1' ' H ' ' L' ' 29' ' ' GLY . 19.9 t -143.72 134.53 21.96 Favored 'Isoleucine or valine' 0 C--N 1.343 0.284 0 CA-C-N 118.065 0.933 . . . . 0.0 110.056 177.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.538 HG11 ' CD2' ' D' ' 13' ' ' HIS . 3.3 m . . . . . 0 C--O 1.218 -0.573 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.449 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.448 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -108.17 135.17 49.95 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.847 0.356 . . . . 0.0 110.646 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.17 165.13 28.27 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.887 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.639 HG23 ' O ' ' H' ' 12' ' ' VAL . 0.2 OUTLIER -105.28 106.31 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.278 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -141.33 132.14 25.84 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.301 0.572 . . . . 0.0 111.711 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' H' ' 14' ' ' HIS . 12.6 p-80 -153.56 165.54 35.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.928 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.6 HE22 HG13 ' I' ' 36' ' ' VAL . 51.2 tt0 -89.73 158.51 17.51 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -140.15 124.71 18.07 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.509 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 83.7 mt -113.9 111.57 21.92 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 m -116.2 102.7 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.509 ' CZ ' HD22 ' G' ' 17' ' ' LEU . 55.3 m-85 -110.37 102.6 11.22 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.438 ' CE2' ' CB ' ' H' ' 20' ' ' PHE . 2.2 t80 -124.33 123.58 40.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.883 -175.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.89 108.31 16.56 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.612 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 33.9 tt0 -170.38 179.81 3.28 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 121.271 0.557 . . . . 0.0 111.968 -178.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.612 ' H ' ' CG ' ' G' ' 22' ' ' GLU . 66.1 t0 -59.14 47.13 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 114.576 -1.193 . . . . 0.0 113.492 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' G' ' 22' ' ' GLU . 31.9 m -83.36 -161.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -80.8 -35.52 24.8 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 118.637 -1.744 . . . . 0.0 111.344 -177.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.447 ' O ' ' O ' ' G' ' 27' ' ' ASN . 44.1 t -157.47 114.08 2.95 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.763 175.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.447 ' O ' ' O ' ' G' ' 26' ' ' SER . 78.8 m-20 -47.73 179.67 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -77.86 -47.9 17.7 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 118.275 -1.37 . . . . 0.0 108.543 176.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.614 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 80.66 51.84 4.68 Favored Glycine 0 CA--C 1.54 1.647 0 CA-C-O 117.843 -1.532 . . . . 0.0 115.646 174.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 180.0 -178.42 0.42 Allowed 'General case' 0 C--O 1.24 0.599 0 CA-C-N 121.71 2.755 . . . . 0.0 115.358 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -112.0 118.86 58.72 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 CA-C-N 110.872 -2.877 . . . . 0.0 105.633 176.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 50.8 mm -120.89 133.09 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.89 105.26 0.45 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 107.674 -2.171 . . . . 0.0 107.674 177.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -155.25 172.15 18.65 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 117.766 0.783 . . . . 0.0 111.853 -177.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 19.7 mtp -143.52 152.57 41.63 Favored 'General case' 0 N--CA 1.457 -0.118 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.089 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.46 132.47 70.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.437 ' O ' ' N ' ' G' ' 39' ' ' VAL . . . -84.85 112.14 3.6 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 113.297 -179.071 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . 55.61 -70.59 0.01 OUTLIER Glycine 0 CA--C 1.54 1.64 0 N-CA-C 115.012 0.765 . . . . 0.0 115.012 176.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.437 ' N ' ' O ' ' G' ' 37' ' ' GLY . 30.4 m -116.47 161.03 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 CA-C-N 117.393 0.597 . . . . 0.0 110.924 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 78.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.279 179.396 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.41 133.46 51.89 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -89.84 101.56 14.26 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.946 0.403 . . . . 0.0 110.736 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.639 ' O ' HG23 ' G' ' 12' ' ' VAL . 5.3 m -142.22 131.12 22.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.685 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' I' ' 13' ' ' HIS . 19.0 p80 -153.28 140.03 18.99 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.331 -0.548 . . . . 0.0 111.563 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' H' ' 14' ' ' HIS . 0.0 OUTLIER -151.05 160.45 43.9 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.548 178.4 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.493 ' OE1' ' CG1' ' J' ' 36' ' ' VAL . 40.4 tt0 -90.15 158.96 17.01 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -140.59 115.92 9.99 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 178.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.534 HD11 HG11 ' J' ' 36' ' ' VAL . 9.6 mt -118.08 110.86 18.15 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.063 0.392 . . . . 0.0 109.97 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.3 t -110.96 106.55 20.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.568 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 58.1 m-85 -108.82 105.62 15.26 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.478 ' CE1' ' OE1' ' G' ' 22' ' ' GLU . 8.0 t80 -123.88 127.33 47.86 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.106 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.46 116.72 22.98 Favored 'General case' 0 C--O 1.245 0.818 0 CA-C-O 121.753 0.787 . . . . 0.0 111.919 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' N ' ' H' ' 23' ' ' ASP . 50.0 tp10 -87.4 162.61 17.22 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 114.614 -1.175 . . . . 0.0 109.429 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.511 ' HA ' HD21 ' H' ' 27' ' ' ASN . 10.8 t0 -152.69 55.12 0.79 Allowed 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.75 -1.114 . . . . 0.0 108.801 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.894 HG13 ' H ' ' H' ' 25' ' ' GLY . 8.0 p -91.43 -124.17 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -175.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.894 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -75.31 -39.84 35.21 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 116.974 -2.536 . . . . 0.0 112.385 -175.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.6 p -156.9 111.89 2.81 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 119.521 1.66 . . . . 0.0 112.264 174.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.529 ' OD1' ' ND2' ' I' ' 27' ' ' ASN . 13.3 m-80 -49.36 162.4 0.14 Allowed 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -70.56 -47.48 60.09 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 119.124 -1.03 . . . . 0.0 109.785 176.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.49 58.89 0.84 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.95 154.64 34.17 Favored 'General case' 0 C--O 1.244 0.788 0 CA-C-O 123.248 1.499 . . . . 0.0 114.08 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.442 HD11 ' HA2' ' B' ' 38' ' ' GLY . 14.7 tt -136.29 130.85 48.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-N 112.323 -2.217 . . . . 0.0 108.496 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.666 HG12 HD11 ' I' ' 34' ' ' LEU . 12.7 tt -124.38 134.32 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 CA-C-O 121.551 0.691 . . . . 0.0 112.522 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' I' ' 33' ' ' GLY . . . -131.07 107.79 0.77 Allowed Glycine 0 CA--C 1.528 0.896 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.42 ' H ' ' HG ' ' I' ' 34' ' ' LEU . 8.3 tp -137.3 144.51 42.68 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 119.269 -0.972 . . . . 0.0 112.37 -178.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.417 ' SD ' ' CG ' ' I' ' 35' ' ' MET . 95.5 mmm -120.6 124.08 44.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.04 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' H' ' 37' ' ' GLY . 56.1 t -120.8 131.76 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -49.46 -111.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.721 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' I' ' 39' ' ' VAL . . . -117.99 -71.38 0.4 Allowed Glycine 0 CA--C 1.531 1.04 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 178.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.538 HG23 HD11 ' N' ' 31' ' ' ILE . 4.9 t -71.02 133.32 32.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.424 HG11 ' NE2' ' G' ' 15' ' ' GLN . 18.1 m . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.514 -179.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -112.01 137.56 49.86 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.777 0.322 . . . . 0.0 110.583 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -87.57 118.23 26.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.431 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.523 HG23 ' O ' ' J' ' 12' ' ' VAL . 9.8 p -125.9 128.37 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.715 0.769 . . . . 0.0 111.138 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' NE2' ' H' ' 13' ' ' HIS . 37.9 m170 -122.13 157.12 32.19 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.998 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 58.4 t-80 -160.12 173.11 16.28 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.395 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.564 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 59.7 tp60 -138.19 140.68 39.88 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -130.38 112.23 13.08 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.187 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.726 ' N ' HD12 ' I' ' 17' ' ' LEU . 0.3 OUTLIER -116.67 111.21 19.51 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.657 0.662 . . . . 0.0 109.412 178.14 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -116.28 109.94 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.22 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.568 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 31.0 m-85 -112.79 106.35 14.67 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -118.81 129.8 55.43 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 117.834 0.288 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.403 ' HB3' ' HE2' ' K' ' 28' ' ' LYS . . . -142.27 135.13 28.49 Favored 'General case' 0 C--O 1.252 1.214 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -178.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.595 ' HG2' ' H ' ' I' ' 23' ' ' ASP . 70.8 tt0 -81.91 -177.35 6.55 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 113.242 -1.799 . . . . 0.0 108.963 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.595 ' H ' ' HG2' ' I' ' 22' ' ' GLU . 50.6 m-20 -157.44 51.56 0.46 Allowed 'General case' 0 CA--C 1.565 1.533 0 N-CA-C 116.87 2.174 . . . . 0.0 116.87 -172.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.452 HG23 ' N ' ' I' ' 25' ' ' GLY . 27.4 m -99.68 -140.95 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -176.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . -70.46 -30.92 68.55 Favored Glycine 0 CA--C 1.533 1.194 0 CA-C-N 122.822 2.556 . . . . 0.0 114.093 -168.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.609 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 3.4 p 147.15 125.54 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.999 0 CA-C-N 120.927 2.363 . . . . 0.0 114.446 173.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.629 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 7.9 t-20 -56.45 158.98 3.95 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 175.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.629 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 86.4 tttt -58.98 -45.12 91.37 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 119.495 -0.882 . . . . 0.0 111.788 176.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' I' ' 27' ' ' ASN . . . 170.97 60.46 0.04 OUTLIER Glycine 0 CA--C 1.557 2.709 0 CA-C-O 118.949 -0.917 . . . . 0.0 113.651 -178.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.556 ' HB2' ' ND2' ' I' ' 27' ' ' ASN . . . -78.62 116.84 19.26 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-N 119.882 1.841 . . . . 0.0 113.65 -178.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.62 HD12 HD11 ' J' ' 31' ' ' ILE . 1.4 tt -143.96 128.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-O 121.855 0.836 . . . . 0.0 112.025 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.414 HG23 HD13 ' I' ' 34' ' ' LEU . 76.3 mt -113.59 129.93 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 115.359 -0.837 . . . . 0.0 112.065 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.801 ' C ' HD12 ' I' ' 34' ' ' LEU . . . -137.59 101.0 0.32 Allowed Glycine 0 CA--C 1.539 1.549 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.801 HD12 ' C ' ' I' ' 33' ' ' GLY . 7.2 mp -141.9 151.58 42.77 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.793 1.283 . . . . 0.0 113.74 -178.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.417 ' CG ' ' SD ' ' H' ' 35' ' ' MET . 96.4 mmm -112.49 98.68 7.42 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 105.291 -2.114 . . . . 0.0 105.291 175.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.6 HG13 HE22 ' G' ' 15' ' ' GLN . 10.4 t -133.56 122.96 45.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.688 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' I' ' 39' ' ' VAL . . . 154.52 -113.0 0.55 Allowed Glycine 0 C--N 1.304 -1.23 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.249 178.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.06 -71.82 0.02 OUTLIER Glycine 0 CA--C 1.534 1.259 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -178.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' I' ' 37' ' ' GLY . 2.6 p -159.2 155.99 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.138 0.494 . . . . 0.0 109.978 177.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.418 ' N ' HG22 ' I' ' 39' ' ' VAL . 3.3 p . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . 0.516 ' CG ' ' CD1' ' K' ' 10' ' ' TYR . 41.7 p90 -144.41 150.55 37.89 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.59 0.234 . . . . 0.0 110.527 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' ND1' ' I' ' 13' ' ' HIS . 21.3 pt-20 -165.98 164.59 18.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.977 0.418 . . . . 0.0 111.388 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.523 ' O ' HG23 ' I' ' 12' ' ' VAL . 62.6 t -120.52 125.6 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' CE1' HG13 ' K' ' 12' ' ' VAL . 45.6 p-80 -154.75 146.53 23.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.83 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -142.06 157.68 44.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.545 178.836 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' CA ' ' L' ' 37' ' ' GLY . 84.9 mt-30 -90.41 158.93 16.84 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 120.875 0.369 . . . . 0.0 110.733 177.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.518 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -141.3 97.48 3.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 175.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' K' ' 17' ' ' LEU . 4.0 mp -109.22 113.89 27.12 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 119.126 0.876 . . . . 0.0 110.382 178.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.34 104.8 17.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.5 ' HZ ' HD23 ' J' ' 17' ' ' LEU . 51.4 m-85 -103.58 109.09 20.63 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -120.64 118.18 29.47 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -178.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.22 123.87 16.01 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.431 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 79.8 tt0 -154.25 158.72 40.66 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 117.69 -1.604 . . . . 0.0 114.979 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' I' ' 23' ' ' ASP . 4.7 m-20 88.57 49.57 0.01 OUTLIER 'General case' 0 C--N 1.359 1.022 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.873 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' J' ' 23' ' ' ASP . 30.6 m -42.73 178.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -175.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 112.02 -29.99 8.03 Favored Glycine 0 CA--C 1.544 1.872 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.968 -173.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.417 ' HB3' ' O ' ' I' ' 24' ' ' VAL . 35.2 p -81.21 160.84 24.21 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 118.657 1.229 . . . . 0.0 113.411 -176.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.452 ' O ' ' O ' ' K' ' 28' ' ' LYS . 66.5 m-20 -82.11 -140.44 0.05 OUTLIER 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.464 -179.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.864 ' O ' ' O ' ' K' ' 29' ' ' GLY . 0.8 OUTLIER -50.84 -41.77 57.96 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.968 -175.626 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.51 -68.22 3.38 Favored Glycine 0 CA--C 1.53 0.995 0 C-N-CA 118.436 -1.84 . . . . 0.0 111.341 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.95 158.38 0.73 Allowed 'General case' 0 C--O 1.248 1.006 0 CA-C-O 122.633 1.206 . . . . 0.0 111.968 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.62 HD11 HD12 ' I' ' 31' ' ' ILE . 34.1 pt -144.14 128.85 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-N 114.392 -1.277 . . . . 0.0 111.166 177.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.763 HG22 HD21 ' K' ' 34' ' ' LEU . 55.4 mt -111.4 128.5 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.732 -178.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.52 113.34 1.68 Allowed Glycine 0 CA--C 1.521 0.453 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 176.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.582 ' H ' HD23 ' K' ' 34' ' ' LEU . 0.3 OUTLIER -156.09 144.18 19.78 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 117.498 -1.681 . . . . 0.0 112.812 -175.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 5.0 mtp -108.4 110.58 22.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 CA-C-N 113.161 -1.836 . . . . 0.0 107.855 177.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.534 HG11 HD11 ' H' ' 17' ' ' LEU . 26.7 t -129.71 133.99 64.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.24 -177.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.67 -104.63 0.45 Allowed Glycine 0 C--N 1.318 -0.441 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.529 ' O ' HG12 ' K' ' 39' ' ' VAL . . . 61.86 -77.46 0.02 OUTLIER Glycine 0 CA--C 1.533 1.181 0 N-CA-C 110.839 -0.905 . . . . 0.0 110.839 -178.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.509 HG23 HD12 ' P' ' 31' ' ' ILE . 23.7 t -146.08 139.71 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 177.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.481 HG22 ' OXT' ' J' ' 40' ' ' VAL . 13.1 p . . . . . 0 C--O 1.217 -0.609 0 CA-C-O 117.833 -1.079 . . . . 0.0 110.412 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.516 ' CD1' ' CG ' ' J' ' 10' ' ' TYR . 77.2 m-85 -84.65 138.54 32.62 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.486 ' O ' HG22 ' J' ' 12' ' ' VAL . 14.1 pt-20 -150.43 159.32 44.56 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.898 0.38 . . . . 0.0 110.913 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' J' ' 13' ' ' HIS . 54.4 t -124.99 134.82 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.742 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' K' ' 14' ' ' HIS . 5.1 t-80 -81.69 149.94 28.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.394 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.577 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.3 OUTLIER -86.72 -173.27 4.4 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.029 0.443 . . . . 0.0 111.559 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -89.77 158.86 17.33 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.196 0.522 . . . . 0.0 111.681 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.447 ' HB3' ' HE2' ' J' ' 14' ' ' HIS . 88.8 tttt -139.49 116.44 10.96 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.862 HD22 HD22 ' J' ' 17' ' ' LEU . 15.4 mt -114.61 119.07 35.5 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.404 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 112.41 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -115.66 111.82 21.19 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.902 -178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -117.22 116.81 27.99 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.259 -0.275 . . . . 0.0 110.259 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.34 152.0 21.61 Favored 'General case' 0 C--O 1.242 0.661 0 N-CA-C 116.409 2.004 . . . . 0.0 116.409 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -92.25 152.24 19.93 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 112.66 -2.064 . . . . 0.0 107.591 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.453 ' OD2' ' OD2' ' L' ' 23' ' ' ASP . 18.9 m-20 -156.97 50.29 0.47 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -175.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.518 HG12 ' H ' ' K' ' 25' ' ' GLY . 2.4 t -76.53 -142.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.518 ' H ' HG12 ' K' ' 24' ' ' VAL . . . -90.69 -36.9 6.65 Favored Glycine 0 N--CA 1.468 0.825 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -175.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 43.8 t -80.85 120.28 24.49 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 104.245 -2.502 . . . . 0.0 104.245 174.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 30.5 p30 -87.21 150.24 24.05 Favored 'General case' 0 CA--C 1.513 -0.446 0 C-N-CA 119.043 -1.063 . . . . 0.0 112.326 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' J' ' 27' ' ' ASN . 34.7 tttm -50.06 -49.24 51.92 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-O 122.093 0.949 . . . . 0.0 108.832 177.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.864 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 88.75 50.41 3.33 Favored Glycine 0 C--O 1.199 -2.041 0 CA-C-N 113.189 -1.823 . . . . 0.0 110.988 176.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.439 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -130.81 159.13 38.26 Favored 'General case' 0 CA--C 1.497 -1.095 0 CA-C-N 121.958 2.879 . . . . 0.0 112.323 -177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB ' ' E' ' 39' ' ' VAL . 73.6 mt -137.04 124.07 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.925 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 76.3 mt -113.92 114.3 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.33 98.17 0.74 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.763 HD21 HG22 ' J' ' 32' ' ' ILE . 79.2 mt -137.32 150.15 47.55 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 -174.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.499 ' O ' ' O ' ' J' ' 36' ' ' VAL . 95.8 mmm -115.72 106.01 13.38 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 104.932 -2.248 . . . . 0.0 104.932 174.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.528 HG11 ' CD2' ' I' ' 17' ' ' LEU . 60.1 t -125.77 152.41 32.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.83 -102.05 2.77 Favored Glycine 0 C--N 1.312 -0.768 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . 73.31 -80.57 0.74 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.529 HG12 ' O ' ' J' ' 38' ' ' GLY . 5.3 p -142.16 153.54 18.51 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.47 HG12 ' O ' ' L' ' 40' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.351 -178.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.6 m-85 -107.7 138.72 43.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 110.45 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -128.57 145.8 51.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.333 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -135.04 160.29 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.458 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 36.0 t-80 -76.53 160.38 29.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -85.08 164.28 18.3 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.365 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -89.66 158.82 17.42 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.121 0.486 . . . . 0.0 110.285 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -140.0 111.76 7.4 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.903 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.547 HD23 ' C ' ' L' ' 17' ' ' LEU . 6.1 tt -114.98 110.14 19.16 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -128.87 132.26 67.63 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.209 0.528 . . . . 0.0 110.444 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.541 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.0 p90 -138.46 120.37 15.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.349 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -111.55 109.81 19.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.38 156.49 36.94 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.524 -0.87 . . . . 0.0 111.045 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -117.12 108.71 16.04 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.551 ' OD1' ' N ' ' L' ' 23' ' ' ASP . 0.0 OUTLIER -140.63 46.62 1.78 Allowed 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -179.222 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.2 m -92.61 162.14 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 C-N-CA 117.433 -1.707 . . . . 0.0 106.605 174.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.53 -35.48 3.02 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 119.571 -1.299 . . . . 0.0 112.04 174.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.654 ' O ' ' O ' ' L' ' 27' ' ' ASN . 20.5 p -151.23 124.34 8.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 113.652 -1.274 . . . . 0.0 111.898 -173.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.654 ' O ' ' O ' ' L' ' 26' ' ' SER . 92.1 m-20 -41.94 -163.53 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.685 0 O-C-N 124.12 0.887 . . . . 0.0 112.233 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 54.0 mtmt -78.13 -41.7 34.16 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.335 -0.853 . . . . 0.0 113.152 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.55 ' H ' ' CG1' ' F' ' 39' ' ' VAL . . . 97.9 -61.08 0.97 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 119.192 -1.48 . . . . 0.0 114.136 178.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.439 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -110.73 170.34 8.16 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -178.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 99.0 mt -134.13 128.83 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 mt -106.43 116.64 50.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 174.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.09 121.31 3.5 Favored Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.56 HD23 ' N ' ' L' ' 34' ' ' LEU . 0.7 OUTLIER -165.51 171.73 12.89 Favored 'General case' 0 N--CA 1.434 -1.247 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.949 -178.273 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.465 ' O ' ' O ' ' K' ' 36' ' ' VAL . 96.3 mmm -123.44 115.99 22.5 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.091 -1.413 . . . . 0.0 108.639 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.807 HG21 HD21 ' J' ' 17' ' ' LEU . 3.8 m -120.35 131.24 73.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.577 ' CA ' ' NE2' ' J' ' 15' ' ' GLN . . . 98.65 -111.44 4.24 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.31 -74.03 2.56 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' K' ' 38' ' ' GLY . 46.2 t -125.79 134.74 65.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' K' ' 40' ' ' VAL . 15.9 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.798 -1.096 . . . . 0.0 111.293 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -83.14 138.47 33.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.734 0.302 . . . . 0.0 110.574 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -74.32 149.78 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.422 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.469 HG23 ' O ' ' M' ' 12' ' ' VAL . 4.6 m -111.96 124.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' N' ' 13' ' ' HIS . 61.9 m170 -72.08 161.24 31.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.125 0.488 . . . . 0.0 112.204 -177.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 m80 -151.8 168.1 26.17 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 121.361 0.6 . . . . 0.0 111.161 179.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.403 HE22 HG13 ' O' ' 36' ' ' VAL . 50.3 tt0 -152.16 143.32 23.21 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 174.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -119.41 105.66 11.5 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.452 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' O' ' 36' ' ' VAL . 67.5 mt -116.74 106.47 13.54 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 120.436 1.471 . . . . 0.0 109.596 177.333 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 88.6 t -116.61 100.17 9.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -98.11 104.64 16.69 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' CB ' ' N' ' 20' ' ' PHE . 4.0 m-85 -125.05 130.53 52.48 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.284 0.564 . . . . 0.0 112.516 -176.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.05 109.6 18.31 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 175.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -175.13 126.5 0.27 Allowed 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.486 ' H ' HG23 ' N' ' 24' ' ' VAL . 34.0 m-20 56.47 49.62 14.54 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.14 0.495 . . . . 0.0 111.035 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.661 ' H ' ' HA3' ' N' ' 25' ' ' GLY . 56.0 t -50.3 165.84 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.626 176.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' M' ' 24' ' ' VAL . . . -173.86 19.44 0.05 OUTLIER Glycine 0 CA--C 1.518 0.223 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 30.5 m -80.55 -130.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -100.58 161.76 13.39 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.033 0.444 . . . . 0.0 111.149 179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -41.11 -37.62 0.91 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.925 178.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -132.49 79.03 0.35 Allowed Glycine 0 N--CA 1.472 1.083 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.17 109.93 7.07 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 122.443 1.116 . . . . 0.0 113.626 -176.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.417 HD13 HG21 ' M' ' 31' ' ' ILE . 23.2 pt -127.54 126.92 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 113.302 -1.772 . . . . 0.0 107.483 177.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -130.34 132.9 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.41 111.14 1.0 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 90.5 mt -128.1 145.89 50.86 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-O 121.201 0.524 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 32.0 ttm -139.01 136.53 35.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.954 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' M' ' 37' ' ' GLY . 53.0 t -119.41 131.37 72.22 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' M' ' 36' ' ' VAL . . . -31.38 -111.28 0.0 OUTLIER Glycine 0 CA--C 1.531 1.069 0 CA-C-N 115.323 -0.853 . . . . 0.0 113.637 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -71.93 0.72 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.689 -0.291 . . . . 0.0 112.605 -178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 40' ' ' VAL . 27.7 m -75.6 155.01 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 117.106 0.453 . . . . 0.0 110.998 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' M' ' 39' ' ' VAL . 6.8 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.255 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.467 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -109.83 135.72 50.27 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.879 0.371 . . . . 0.0 110.703 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -141.07 159.21 42.7 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.745 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.514 HG23 ' N ' ' O' ' 13' ' ' HIS . 1.0 OUTLIER -138.56 168.77 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 122.103 0.954 . . . . 0.0 111.646 -179.796 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.549 ' CD2' ' O ' ' M' ' 13' ' ' HIS . 5.4 t-160 -68.83 132.91 47.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 113.869 -1.514 . . . . 0.0 113.288 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.527 ' NE2' ' O ' ' O' ' 12' ' ' VAL . 0.2 OUTLIER -116.29 162.27 17.76 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 177.087 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -89.86 157.19 18.01 Favored 'General case' 0 C--O 1.226 -0.154 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -142.06 97.23 3.1 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.787 177.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' N' ' 19' ' ' PHE . 5.0 mp -127.04 116.18 20.33 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.851 0.834 . . . . 0.0 110.601 177.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -115.53 106.82 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.27 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' O' ' 19' ' ' PHE . 5.4 m-85 -102.77 111.91 24.46 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 179.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.418 ' CB ' ' CZ ' ' M' ' 20' ' ' PHE . 43.0 t80 -132.45 125.68 31.26 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 109.86 10.42 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.512 ' CG ' ' N ' ' N' ' 23' ' ' ASP . 69.5 tt0 -177.93 160.76 1.49 Allowed 'General case' 0 C--N 1.354 0.781 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.89 ' H ' ' HZ3' ' O' ' 28' ' ' LYS . 15.8 t0 82.87 -57.64 0.17 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 118.098 2.629 . . . . 0.0 118.098 174.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.492 HG13 ' O ' ' N' ' 23' ' ' ASP . 0.0 OUTLIER -158.09 -178.38 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.31 -1.356 . . . . 0.0 112.237 -175.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.661 ' HA3' ' H ' ' M' ' 24' ' ' VAL . . . 62.11 28.65 70.97 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-N 113.165 -1.834 . . . . 0.0 116.722 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.539 ' CB ' ' O ' ' O' ' 27' ' ' ASN . 23.0 t -81.59 111.68 18.11 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 118.421 1.111 . . . . 0.0 109.354 178.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 40.2 p30 -94.68 -177.1 4.09 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-O 121.832 0.825 . . . . 0.0 112.928 -177.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -46.51 -38.3 9.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.106 -1.407 . . . . 0.0 113.896 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.13 75.92 0.07 OUTLIER Glycine 0 CA--C 1.534 1.231 0 C-N-CA 120.227 -0.987 . . . . 0.0 112.991 -175.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.824 ' H ' ' NZ ' ' P' ' 28' ' ' LYS . . . -80.4 117.09 20.85 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 122.384 1.088 . . . . 0.0 111.116 -179.117 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.538 HD11 HG23 ' H' ' 39' ' ' VAL . 75.4 mt -130.53 123.6 55.44 Favored 'Isoleucine or valine' 0 C--O 1.231 0.116 0 CA-C-N 113.786 -1.552 . . . . 0.0 109.669 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.4 tt -117.79 127.36 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 121.13 0.49 . . . . 0.0 109.981 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' O' ' 33' ' ' GLY . . . -125.29 128.73 6.7 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 6.7 tt -144.08 142.54 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.728 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.507 ' SD ' ' CG ' ' O' ' 35' ' ' MET . 96.0 mmm -132.06 129.02 39.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.041 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.528 ' CG2' ' H ' ' O' ' 37' ' ' GLY . 3.0 m -124.56 165.83 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 176.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.84 -102.85 0.07 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 120.324 -0.941 . . . . 0.0 111.454 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.474 ' O ' HG22 ' O' ' 39' ' ' VAL . . . -130.4 -75.53 0.15 Allowed Glycine 0 CA--C 1.534 1.221 0 C-N-CA 121.497 -0.383 . . . . 0.0 112.356 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.524 HG23 HD12 ' B' ' 31' ' ' ILE . 56.0 t -51.66 131.11 12.75 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 CA-C-O 120.798 0.332 . . . . 0.0 111.599 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 92.6 t . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.529 -179.779 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.21 133.46 53.54 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.707 0.289 . . . . 0.0 110.537 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.449 ' HG2' ' HE2' ' N' ' 14' ' ' HIS . 79.1 tt0 -159.09 158.2 32.5 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.588 HG12 ' H ' ' O' ' 13' ' ' HIS . 3.2 t -124.01 168.98 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 CA-C-O 120.997 0.427 . . . . 0.0 110.636 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.588 ' H ' HG12 ' O' ' 12' ' ' VAL . 0.3 OUTLIER -61.02 116.02 4.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.686 -178.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' P' ' 14' ' ' HIS . 37.6 m170 -121.73 161.66 22.19 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.17 178.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -90.14 155.92 18.71 Favored 'General case' 0 N--CA 1.457 -0.107 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 176.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -143.27 95.86 2.83 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.709 176.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.667 HD12 HD22 ' P' ' 17' ' ' LEU . 10.2 mt -121.34 116.92 25.72 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -118.4 106.6 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.625 ' CE1' ' CE1' ' N' ' 19' ' ' PHE . 40.3 m-85 -107.53 111.36 23.59 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.61 ' CZ ' ' CE1' ' P' ' 20' ' ' PHE . 5.6 t80 -124.26 120.36 31.99 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 130.72 37.59 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.515 0.674 . . . . 0.0 112.773 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' NZ ' ' O' ' 28' ' ' LYS . 40.2 tt0 -91.53 156.67 17.5 Favored 'General case' 0 C--N 1.344 0.37 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.755 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' O' ' 22' ' ' GLU . 93.3 m-20 -145.5 47.52 1.28 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.664 -177.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.514 HG13 ' CG ' ' O' ' 22' ' ' GLU . 19.7 m -81.75 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.31 -30.35 37.58 Favored Glycine 0 C--N 1.317 -0.493 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 31.0 t -93.03 138.13 31.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 176.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.557 ' HB3' ' H ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -61.73 148.8 41.7 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-N 114.865 -1.062 . . . . 0.0 112.169 -175.623 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.89 ' HZ3' ' H ' ' N' ' 23' ' ' ASP . 86.4 mttt -169.45 30.53 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 122.149 0.976 . . . . 0.0 109.031 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.683 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -99.29 80.08 0.53 Allowed Glycine 0 CA--C 1.548 2.098 0 C-N-CA 126.595 2.045 . . . . 0.0 113.771 179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -102.37 179.99 4.14 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 121.024 2.412 . . . . 0.0 110.576 -175.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 93.3 mt -117.88 131.72 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -175.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.747 HG23 HD21 ' O' ' 34' ' ' LEU . 63.5 mt -115.16 111.72 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 176.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.603 ' C ' HD23 ' O' ' 34' ' ' LEU . . . -122.09 105.46 0.98 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.747 HD21 HG23 ' O' ' 32' ' ' ILE . 0.0 OUTLIER -152.81 172.52 16.61 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 123.404 1.573 . . . . 0.0 113.566 -178.109 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.507 ' CG ' ' SD ' ' N' ' 35' ' ' MET . 95.5 mmm -129.67 107.5 9.48 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 111.926 -2.397 . . . . 0.0 107.037 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.447 HG11 ' CD1' ' M' ' 17' ' ' LEU . 24.6 t -113.86 121.19 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.528 ' H ' ' CG2' ' N' ' 36' ' ' VAL . . . -76.07 121.08 6.1 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.241 -178.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.554 ' H ' ' HA3' ' P' ' 37' ' ' GLY . . . -105.38 66.74 0.27 Allowed Glycine 0 CA--C 1.537 1.464 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.591 HG21 HD13 ' B' ' 31' ' ' ILE . 2.3 m -133.59 158.64 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.585 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.141 -0.933 . . . . 0.0 110.425 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -118.96 139.77 51.12 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.682 0.277 . . . . 0.0 110.327 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' Q' ' 11' ' ' GLU . 96.8 mt-10 -76.39 116.78 17.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.376 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' O' ' 12' ' ' VAL . 18.1 m -120.37 132.63 69.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.541 ' NE2' HG11 ' O' ' 12' ' ' VAL . 79.0 m80 -101.65 127.33 48.44 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.128 178.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' O' ' 14' ' ' HIS . 73.9 t60 -135.4 151.77 50.77 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.521 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 28.8 tt0 -99.11 169.92 9.06 Favored 'General case' 0 CA--C 1.52 -0.195 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -159.27 92.56 1.08 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.295 176.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.667 HD22 HD12 ' O' ' 17' ' ' LEU . 4.3 mt -122.77 115.07 21.41 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.12 104.53 16.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.558 ' CE1' ' CE2' ' O' ' 19' ' ' PHE . 75.9 m-85 -104.13 111.85 24.61 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.61 ' CE1' ' CZ ' ' O' ' 20' ' ' PHE . 29.4 t80 -127.58 130.14 48.53 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 122.1 -0.375 . . . . 0.0 111.691 -178.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.12 145.98 21.19 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.532 ' HG2' ' H ' ' P' ' 23' ' ' ASP . 63.7 tt0 -93.66 -174.62 3.52 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 113.693 -1.594 . . . . 0.0 106.793 177.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.532 ' H ' ' HG2' ' P' ' 22' ' ' GLU . 47.3 t0 -166.34 47.34 0.07 Allowed 'General case' 0 C--N 1.35 0.595 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.987 HG12 ' H ' ' P' ' 25' ' ' GLY . 48.2 t -63.84 -163.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 115.615 -2.434 . . . . 0.0 106.036 177.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.987 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -92.17 -39.48 5.41 Favored Glycine 0 C--N 1.351 1.384 0 C-N-CA 116.26 -2.876 . . . . 0.0 115.1 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.5 m -68.19 111.26 4.42 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 116.227 1.936 . . . . 0.0 116.227 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.683 HD21 ' N ' ' O' ' 29' ' ' GLY . 8.7 t-20 -148.5 133.0 17.66 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 121.976 2.171 . . . . 0.0 112.128 166.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.824 ' NZ ' ' H ' ' N' ' 30' ' ' ALA . 85.5 tttt -14.28 -47.9 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 115.33 1.604 . . . . 0.0 115.33 170.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . 130.78 60.03 0.09 OUTLIER Glycine 0 CA--C 1.574 3.736 0 CA-C-N 113.521 -1.672 . . . . 0.0 110.109 -174.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.646 ' HB2' ' HA2' ' O' ' 29' ' ' GLY . . . -70.88 109.79 5.24 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 116.259 1.948 . . . . 0.0 116.259 -174.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 3.9 mt -143.5 129.61 16.49 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-N 115.272 -0.876 . . . . 0.0 112.873 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.857 HG22 HD11 ' Q' ' 34' ' ' LEU . 90.6 mt -111.75 126.46 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 176.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.35 107.65 0.9 Allowed Glycine 0 CA--C 1.523 0.573 0 N-CA-C 107.341 -2.303 . . . . 0.0 107.341 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.658 HD12 ' O ' ' O' ' 34' ' ' LEU . 45.2 tp -152.36 140.42 20.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 123.053 1.406 . . . . 0.0 114.147 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.449 ' H ' HD12 ' P' ' 34' ' ' LEU . 2.2 ttm -100.89 111.31 23.49 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 113.404 -1.725 . . . . 0.0 108.379 177.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.474 ' HB ' HG13 ' Q' ' 36' ' ' VAL . 2.4 t -113.32 102.82 14.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 178.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.554 ' HA3' ' H ' ' O' ' 38' ' ' GLY . . . -37.21 152.82 0.02 OUTLIER Glycine 0 N--CA 1.47 0.922 0 CA-C-O 121.437 0.465 . . . . 0.0 113.076 -177.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.23 -57.3 3.01 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-N 115.008 -0.596 . . . . 0.0 112.354 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.685 HG12 ' N ' ' P' ' 40' ' ' VAL . 83.3 t -48.38 170.83 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 117.233 0.517 . . . . 0.0 111.148 179.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.685 ' N ' HG12 ' P' ' 39' ' ' VAL . 39.5 t . . . . . 0 C--O 1.218 -0.558 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.858 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . 0.526 ' N ' ' OE2' ' R' ' 11' ' ' GLU . 95.2 m-85 -104.48 133.3 49.58 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.811 0.339 . . . . 0.0 110.11 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' P' ' 11' ' ' GLU . 96.0 mt-10 -79.82 147.1 31.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.569 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 55.9 t -124.52 132.85 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -79.7 163.66 24.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.485 0.66 . . . . 0.0 111.016 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.573 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 98.5 m-70 -79.49 172.17 14.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.193 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -89.51 158.44 17.68 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 178.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . 0.494 ' H ' ' HB3' ' P' ' 15' ' ' GLN . 89.0 tttt -139.91 100.13 3.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.286 0.565 . . . . 0.0 110.437 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -116.32 114.08 23.85 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 65.3 t -122.77 121.65 63.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.891 0.377 . . . . 0.0 110.694 -179.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -124.22 110.54 14.78 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.276 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.412 ' O ' ' HA ' ' P' ' 20' ' ' PHE . 6.4 m-85 -118.53 114.86 23.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.44 ' O ' ' HB1' ' R' ' 21' ' ' ALA . . . -157.51 141.97 16.4 Favored 'General case' 0 C--O 1.238 0.496 0 C-N-CA 118.019 -1.472 . . . . 0.0 114.046 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -105.34 104.23 13.91 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 176.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' R' ' 26' ' ' SER . 97.2 m-20 -107.42 46.3 0.95 Allowed 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 119.759 -0.776 . . . . 0.0 113.057 -176.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -85.06 170.19 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 C-N-CA 117.2 -1.8 . . . . 0.0 108.163 176.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.492 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 94.52 -29.18 9.33 Favored Glycine 0 N--CA 1.462 0.392 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 175.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.586 ' OG ' ' N ' ' Q' ' 27' ' ' ASN . 33.2 p 91.28 -110.84 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 -176.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.586 ' N ' ' OG ' ' Q' ' 26' ' ' SER . 27.5 t-20 78.3 -179.2 0.11 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 174.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' R' ' 29' ' ' GLY . 97.9 mttt -62.25 -38.84 90.81 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 104.525 -2.398 . . . . 0.0 104.525 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.593 ' HA3' ' HB2' ' R' ' 30' ' ' ALA . . . 81.05 -69.84 3.18 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 109.746 -3.388 . . . . 0.0 113.108 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.11 129.17 0.07 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 116.966 -1.492 . . . . 0.0 107.777 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' K' ' 39' ' ' VAL . 65.4 mt -122.42 116.03 47.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 CA-C-N 122.04 2.2 . . . . 0.0 110.775 176.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . 0.676 HG23 HD13 ' Q' ' 34' ' ' LEU . 60.2 mt -109.37 113.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . 0.763 ' C ' HD12 ' Q' ' 34' ' ' LEU . . . -117.71 95.07 0.63 Allowed Glycine 0 N--CA 1.468 0.776 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.857 HD11 HG22 ' P' ' 32' ' ' ILE . 7.1 mp -141.33 160.03 40.99 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-O 122.796 1.284 . . . . 0.0 113.991 -176.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 3.3 mtp -121.6 110.17 15.67 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 112.735 -2.03 . . . . 0.0 106.452 176.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.556 HG11 HD21 ' O' ' 17' ' ' LEU . 2.4 t -143.55 102.37 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.001 -177.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.07 -163.4 17.79 Favored Glycine 0 C--N 1.317 -0.515 0 CA-C-O 121.834 0.686 . . . . 0.0 111.883 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.94 -54.69 0.78 Allowed Glycine 0 CA--C 1.541 1.702 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -146.15 136.7 18.43 Favored 'Isoleucine or valine' 0 C--N 1.342 0.247 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 177.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.523 HG12 ' NE2' ' O' ' 13' ' ' HIS . 30.3 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.408 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -146.89 156.96 43.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.033 0.444 . . . . 0.0 110.693 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' OE2' ' N ' ' Q' ' 10' ' ' TYR . 95.7 mt-10 -95.02 141.03 29.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.652 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.53 128.88 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-O 120.95 0.405 . . . . 0.0 110.317 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 52.9 p-80 -149.59 119.8 7.29 Favored 'General case' 0 CA--C 1.528 0.115 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.19 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.56 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 61.6 t-80 -152.89 164.08 38.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.92 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.52 ' O ' ' ND1' ' R' ' 14' ' ' HIS . 88.8 mt-30 -89.97 159.14 17.05 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.8 0.333 . . . . 0.0 111.072 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -139.88 108.25 5.83 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -115.0 118.27 32.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.276 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.95 129.45 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.522 ' O ' ' CD1' ' R' ' 19' ' ' PHE . 38.6 p90 -140.21 127.45 21.13 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -126.34 107.15 10.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' Q' ' 21' ' ' ALA . . . -161.52 171.88 17.36 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.998 -177.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.559 ' N ' ' OE1' ' R' ' 22' ' ' GLU . 10.8 mp0 -86.48 107.09 17.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.167 179.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -83.08 -59.77 2.37 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.03 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.591 HG12 ' H ' ' R' ' 25' ' ' GLY . 20.9 t -83.53 173.59 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.591 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 90.8 -34.98 4.01 Favored Glycine 0 CA--C 1.521 0.412 0 C-N-CA 119.817 -1.182 . . . . 0.0 110.152 -179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' Q' ' 23' ' ' ASP . 0.4 OUTLIER -141.0 116.0 9.82 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 122.375 1.083 . . . . 0.0 112.58 -177.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.526 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.7 m-20 -62.42 -160.54 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 113.153 -1.839 . . . . 0.0 111.34 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.04 50.51 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.231 1.412 . . . . 0.0 112.026 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' Q' ' 28' ' ' LYS . . . -81.47 -50.36 5.07 Favored Glycine 0 CA--C 1.547 2.09 0 CA-C-O 118.494 -1.17 . . . . 0.0 113.253 -176.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . 0.593 ' HB2' ' HA3' ' Q' ' 29' ' ' GLY . . . -124.69 139.54 53.77 Favored 'General case' 0 N--CA 1.479 1.013 0 CA-C-N 120.137 1.968 . . . . 0.0 108.374 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 83.5 mt -137.29 136.59 46.8 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 114.872 1.434 . . . . 0.0 114.872 -175.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.7 mt -103.39 112.69 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 N-CA-C 106.484 -1.672 . . . . 0.0 106.484 174.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' Q' ' 32' ' ' ILE . . . -118.38 94.26 0.59 Allowed Glycine 0 CA--C 1.508 -0.353 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 178.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.2 tt -142.25 134.79 28.08 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.448 0.642 . . . . 0.0 109.842 -177.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -100.28 115.62 30.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.685 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.405 HG11 HD13 ' P' ' 17' ' ' LEU . 4.8 p -152.67 141.94 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.44 -101.89 0.54 Allowed Glycine 0 C--N 1.321 -0.286 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 178.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.32 -80.28 0.11 Allowed Glycine 0 CA--C 1.533 1.215 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.521 ' HB ' HD11 ' F' ' 31' ' ' ILE . 13.2 p -160.55 142.01 4.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 177.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.445 ' H ' HG22 ' R' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.125 -0.94 . . . . 0.0 109.612 179.872 . . . . . . . . 2 2 . 1 stop_ save_